data_1nmf_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1nmf _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.662 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.957 0 CA-C-O 121.063 0.458 . . . . 0.0 110.348 . . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.483 ' OE2' ' N ' ' A' ' 47' ' ' VAL . 0.3 OUTLIER -114.51 154.5 28.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.076 -1.015 . . . . 0.0 110.096 -179.552 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.24 158.0 20.27 Favored Glycine 0 N--CA 1.484 1.858 0 N-CA-C 109.064 -1.615 . . . . 0.0 109.064 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.443 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.3 mttt -130.73 115.85 17.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.446 -1.032 . . . . 0.0 110.195 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.504 HG12 ' N ' ' A' ' 8' ' ' TRP . 3.6 t -35.42 143.52 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 CA-C-O 123.045 1.402 . . . . 0.0 112.925 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.409 ' CG ' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -102.5 -30.63 10.87 Favored 'General case' 0 C--N 1.288 -2.068 0 N-CA-C 102.996 -2.964 . . . . 0.0 102.996 171.94 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 17.9 p-90 177.31 147.5 0.13 Allowed 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 105.77 -1.937 . . . . 0.0 105.77 177.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.61 ' CZ ' HG22 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -114.19 145.01 42.27 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 120.37 -1.456 . . . . 0.0 110.142 179.944 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.55 ' HB2' ' O ' ' A' ' 15' ' ' PHE . 4.7 m-20 -131.91 32.96 4.0 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.351 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.1 OUTLIER -38.4 -46.95 1.19 Allowed 'General case' 0 N--CA 1.494 1.727 0 CA-C-O 121.486 0.66 . . . . 0.0 109.787 -178.765 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -60.15 -46.82 88.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.363 -0.836 . . . . 0.0 110.044 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.535 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -73.01 4.84 3.81 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.299 -0.876 . . . . 0.0 110.781 -179.317 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.552 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 110.71 -3.78 29.13 Favored Glycine 0 N--CA 1.494 2.545 0 C-N-CA 119.731 -1.223 . . . . 0.0 113.008 177.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.55 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 5.7 p90 176.68 174.77 0.37 Allowed 'General case' 0 N--CA 1.5 2.058 0 CA-C-N 120.614 2.207 . . . . 0.0 111.972 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.499 ' O ' HG12 ' A' ' 28' ' ' VAL . . . -140.03 151.96 22.45 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 107.432 -2.267 . . . . 0.0 107.432 179.32 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.36 141.33 40.34 Favored 'General case' 0 N--CA 1.485 1.323 0 O-C-N 120.058 -1.848 . . . . 0.0 109.498 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.597 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.9 OUTLIER -107.48 160.72 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 178.656 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.549 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 4.3 tt0 -137.74 130.52 29.97 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.071 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.532 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 14.5 p -134.76 140.32 45.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 C-N-CA 117.855 -1.538 . . . . 0.0 111.593 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.45 140.55 58.88 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-N 115.371 -0.832 . . . . 0.0 109.15 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 81.51 -10.7 49.11 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.532 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 2.7 mp0 -139.42 -174.89 4.0 Favored 'General case' 0 C--N 1.308 -1.203 0 O-C-N 121.137 -1.213 . . . . 0.0 108.814 179.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.42 -165.78 1.25 Allowed 'General case' 0 C--N 1.295 -1.782 0 CA-C-O 122.005 0.907 . . . . 0.0 110.368 -179.3 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.597 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 7.5 m-20 -71.12 120.11 16.21 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 115.861 -0.608 . . . . 0.0 109.701 179.214 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.616 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.5 t -83.83 115.29 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 120.482 -1.386 . . . . 0.0 110.722 178.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.413 ' CB ' ' CD ' ' A' ' 59' ' ' GLN . 23.4 t80 -53.71 138.12 35.99 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.61 HG22 ' CZ ' ' A' ' 9' ' ' PHE . 0.6 OUTLIER -129.27 146.48 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 O-C-N 120.712 -1.242 . . . . 0.0 109.381 -179.681 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.552 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 3.7 t60 -147.7 143.85 27.9 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.424 ' CZ ' ' NE2' ' A' ' 29' ' ' HIS . 22.6 p90 -63.85 2.79 0.45 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.043 -1.036 . . . . 0.0 111.611 -179.348 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.3 t -93.75 -51.07 5.07 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.21 -1.556 . . . . 0.0 109.574 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -93.31 -44.25 8.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.177 -0.952 . . . . 0.0 108.919 179.364 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.618 ' CD1' ' N ' ' A' ' 33' ' ' ILE . 1.1 mp . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.529 ' CG2' HD12 ' A' ' 18' ' ' ILE . 21.3 m -136.18 166.06 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 120.535 -1.353 . . . . 0.0 110.551 -179.151 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.9 t -116.66 135.39 53.82 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.09 -1.006 . . . . 0.0 108.6 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.662 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 7.2 p90 -164.1 -178.11 5.39 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.951 -1.093 . . . . 0.0 109.695 -179.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -127.05 94.95 4.16 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.305 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.63 HG13 ' CE1' ' A' ' 49' ' ' PHE . 12.3 mt -62.17 133.11 28.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.915 -1.116 . . . . 0.0 110.339 -179.409 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.516 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.1 m -116.04 -173.48 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 178.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -123.03 116.03 22.84 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.005 -1.059 . . . . 0.0 109.531 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.94 174.26 17.22 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -38.93 -52.67 1.77 Allowed 'General case' 0 N--CA 1.505 2.298 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -178.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 27.0 mmm180 -80.77 22.37 0.6 Allowed 'General case' 0 N--CA 1.498 1.967 0 O-C-N 119.676 -1.89 . . . . 0.0 112.247 -177.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.39 -177.7 26.14 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.278 -1.439 . . . . 0.0 110.488 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.516 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 0.9 OUTLIER -65.56 152.24 82.38 Favored 'Trans proline' 0 C--N 1.32 -0.948 0 C-N-CA 122.109 1.873 . . . . 0.0 110.426 179.114 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.413 ' CD ' ' CB ' ' A' ' 27' ' ' PHE . 0.0 OUTLIER -166.04 146.91 6.65 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.19 -0.944 . . . . 0.0 111.322 -179.653 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.566 ' CB ' ' CG2' ' A' ' 63' ' ' VAL . . . -79.4 159.23 27.16 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 177.174 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.532 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.67 -42.6 0.76 Allowed 'General case' 0 N--CA 1.508 2.439 0 O-C-N 120.366 -1.459 . . . . 0.0 111.886 -176.456 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -119.66 53.19 1.06 Allowed 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.579 ' CG2' ' HB3' ' A' ' 49' ' ' PHE . 25.0 t -70.85 168.77 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.887 -178.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.414 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 1.4 m -152.69 173.84 14.74 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 178.4 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 O-C-N 121.002 -1.061 . . . . 0.0 109.458 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.597 ' C ' ' CD1' ' A' ' 2' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.785 0 CA-C-O 120.974 0.416 . . . . 0.0 110.214 . . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.539 ' O ' ' CD2' ' A' ' 2' ' ' LEU . 0.3 OUTLIER -112.13 168.03 9.93 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.105 -0.997 . . . . 0.0 109.553 -179.202 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.497 ' O ' ' HA ' ' A' ' 46' ' ' ALA . . . -151.78 167.9 31.08 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.379 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.5 mtpp -134.75 118.38 17.01 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.146 -1.208 . . . . 0.0 110.094 -179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.52 ' CG1' ' N ' ' A' ' 8' ' ' TRP . 3.8 t -43.23 142.54 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 122.78 1.276 . . . . 0.0 112.366 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.41 -29.65 13.38 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 103.179 -2.897 . . . . 0.0 103.179 172.587 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.702 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 21.1 p-90 177.79 144.78 0.11 Allowed 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 105.957 -1.868 . . . . 0.0 105.957 177.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.5 ' CD1' HG23 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -118.84 141.0 49.05 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.487 -1.383 . . . . 0.0 109.541 179.493 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.517 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 0.2 OUTLIER -131.5 37.78 3.65 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 179.4 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' ASN . 1.2 p -37.94 -48.49 1.17 Allowed 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.44 0.638 . . . . 0.0 109.332 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -61.9 -44.76 96.14 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.412 -0.805 . . . . 0.0 109.761 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.505 ' CB ' ' OD1' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -69.05 -0.88 6.33 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.359 -0.838 . . . . 0.0 110.132 -179.796 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.484 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 108.35 -0.44 32.95 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.874 -1.155 . . . . 0.0 112.523 178.547 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.436 ' O ' ' C ' ' A' ' 10' ' ' ASN . 6.3 p90 -179.21 169.97 1.44 Allowed 'General case' 0 N--CA 1.498 1.929 0 CA-C-N 120.456 2.128 . . . . 0.0 111.991 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.52 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -143.64 143.08 11.86 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 107.755 -2.138 . . . . 0.0 107.755 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.702 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.87 141.95 40.17 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 120.205 -1.762 . . . . 0.0 110.162 -178.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.613 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.9 OUTLIER -107.58 163.83 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.475 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.585 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 28.6 tt0 -139.2 130.54 26.91 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.515 ' CG1' ' CB ' ' A' ' 23' ' ' GLN . 9.0 p -134.39 140.66 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 C-N-CA 117.594 -1.642 . . . . 0.0 111.984 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.419 ' N ' HG21 ' A' ' 20' ' ' VAL . 35.6 mt-10 -64.05 139.36 58.76 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.242 179.794 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.12 -13.65 43.5 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.515 ' CB ' ' CG1' ' A' ' 20' ' ' VAL . 1.5 mt-30 -138.0 -175.98 4.28 Favored 'General case' 0 C--N 1.308 -1.212 0 O-C-N 121.254 -1.145 . . . . 0.0 108.804 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.39 -165.89 1.26 Allowed 'General case' 0 C--N 1.295 -1.773 0 CA-C-O 121.987 0.899 . . . . 0.0 110.3 -179.429 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.613 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.6 m-20 -72.08 126.51 29.97 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.011 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.602 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -91.82 118.72 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.034 0 O-C-N 120.625 -1.297 . . . . 0.0 111.125 178.539 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.472 ' CB ' ' HG2' ' A' ' 59' ' ' GLN . 4.7 t80 -65.05 134.12 53.15 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.419 -0.8 . . . . 0.0 109.256 178.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.551 HG12 HG11 ' A' ' 26' ' ' VAL . 2.0 m -142.27 131.95 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.674 -1.266 . . . . 0.0 111.14 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.615 ' NE2' ' CZ ' ' A' ' 30' ' ' PHE . 2.5 t-160 -115.68 132.26 56.69 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.615 ' CZ ' ' NE2' ' A' ' 29' ' ' HIS . 7.4 p90 -43.96 -22.12 0.05 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.701 -1.25 . . . . 0.0 111.128 -178.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.441 ' N ' ' O ' ' A' ' 29' ' ' HIS . 1.5 m -66.24 -42.59 88.4 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.755 -1.215 . . . . 0.0 111.218 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.57 -41.33 10.85 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.95 -1.094 . . . . 0.0 108.802 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.546 HG12 ' HB ' ' A' ' 28' ' ' VAL . 1.5 mp . . . . . 0 C--N 1.305 -1.349 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.497 ' HA ' ' O ' ' A' ' 4' ' ' GLY . . . . . . . . 0 N--CA 1.486 1.374 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.531 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 35.0 m -119.29 159.68 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 120.868 -1.145 . . . . 0.0 110.281 -179.478 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.47 ' O ' HG11 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -114.19 136.01 53.42 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.116 -0.99 . . . . 0.0 108.57 179.59 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.594 ' CD1' HD13 ' A' ' 2' ' ' LEU . 19.9 p90 -163.04 -176.05 4.67 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.072 -1.018 . . . . 0.0 109.87 -179.247 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -129.07 96.6 4.38 Favored 'General case' 0 C--N 1.295 -1.771 0 O-C-N 121.542 -0.724 . . . . 0.0 109.185 179.129 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.602 ' CD1' ' CG2' ' A' ' 26' ' ' VAL . 1.5 mm -61.57 139.6 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 CA-C-O 122.452 1.12 . . . . 0.0 111.137 -179.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.503 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 3.1 m -126.72 -174.25 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -123.39 115.99 22.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.966 -1.083 . . . . 0.0 109.933 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.12 171.89 15.86 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 10.6 p-10 -39.1 -52.69 1.86 Allowed 'General case' 0 N--CA 1.505 2.309 0 O-C-N 121.283 -1.128 . . . . 0.0 113.956 -178.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 11.1 ttm180 -78.8 21.96 0.39 Allowed 'General case' 0 N--CA 1.5 2.054 0 O-C-N 119.601 -1.937 . . . . 0.0 112.224 -177.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.0 -179.27 26.07 Favored Glycine 0 N--CA 1.492 2.404 0 C-N-CA 119.339 -1.41 . . . . 0.0 110.667 179.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.503 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -66.78 150.16 83.4 Favored 'Trans proline' 0 C--N 1.321 -0.915 0 C-N-CA 122.238 1.959 . . . . 0.0 110.484 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.488 ' C ' ' CD1' ' A' ' 51' ' ' ILE . 2.5 mt-30 -165.71 152.69 10.09 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.245 -0.91 . . . . 0.0 111.03 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.593 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -82.15 161.43 22.81 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 177.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.548 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -135.0 -41.71 0.74 Allowed 'General case' 0 N--CA 1.51 2.526 0 O-C-N 120.273 -1.517 . . . . 0.0 111.725 -176.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 9.3 m-20 -120.1 52.28 1.14 Allowed 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.571 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 12.5 t -68.74 170.6 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 121.819 0.818 . . . . 0.0 109.69 -179.254 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.2 OUTLIER -152.74 171.75 17.74 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 178.553 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.598 0 O-C-N 121.003 -1.06 . . . . 0.0 109.584 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.652 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.77 0 CA-C-O 121.082 0.467 . . . . 0.0 110.154 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.486 ' O ' ' CD2' ' A' ' 2' ' ' LEU . 0.2 OUTLIER -111.82 161.56 16.22 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.169 -0.957 . . . . 0.0 110.151 -178.527 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.02 157.89 24.51 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.432 ' HD3' ' OE1' ' A' ' 3' ' ' GLU . 10.2 mmtp -130.27 114.55 15.78 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.318 -1.107 . . . . 0.0 109.645 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.459 HG12 ' N ' ' A' ' 8' ' ' TRP . 3.4 t -41.29 140.24 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 CA-C-O 122.8 1.286 . . . . 0.0 112.443 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.01 -30.33 12.4 Favored 'General case' 0 C--N 1.289 -2.041 0 N-CA-C 103.126 -2.916 . . . . 0.0 103.126 172.579 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.697 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 17.3 p-90 176.96 146.27 0.1 Allowed 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 106.228 -1.768 . . . . 0.0 106.228 177.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.641 ' CE1' ' CG2' ' A' ' 28' ' ' VAL . 1.5 t80 -113.66 143.23 44.94 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 120.576 -1.327 . . . . 0.0 109.433 179.394 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.56 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 90.6 m-20 -131.24 39.01 3.59 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -39.08 -47.82 1.58 Allowed 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.436 0.636 . . . . 0.0 109.525 -179.087 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -61.8 -44.52 96.7 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.393 -0.817 . . . . 0.0 109.706 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.54 ' CG ' ' HB3' ' A' ' 10' ' ' ASN . 12.6 mmmt -70.55 2.3 4.17 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.429 -0.794 . . . . 0.0 110.45 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.409 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 113.27 -10.57 24.38 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 119.564 -1.303 . . . . 0.0 112.063 178.675 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.55 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 3.9 p90 175.32 179.1 0.15 Allowed 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.03 -1.865 . . . . 0.0 111.302 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.523 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -136.34 149.38 20.1 Favored Glycine 0 N--CA 1.498 2.803 0 N-CA-C 107.482 -2.247 . . . . 0.0 107.482 179.279 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.697 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.2 m-85 -105.31 140.68 38.07 Favored 'General case' 0 N--CA 1.484 1.252 0 O-C-N 120.272 -1.722 . . . . 0.0 109.792 -178.816 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.586 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 1.2 mt -106.91 162.03 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 178.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.572 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 13.2 tt0 -140.07 130.28 25.12 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 177.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.543 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 14.1 p -135.49 140.96 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 C-N-CA 117.526 -1.67 . . . . 0.0 111.953 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.427 ' N ' HG21 ' A' ' 20' ' ' VAL . 1.2 mp0 -65.33 140.67 58.7 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.123 179.695 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.71 -10.48 45.47 Favored Glycine 0 N--CA 1.486 2.011 0 N-CA-C 108.662 -1.775 . . . . 0.0 108.662 -178.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.543 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 0.9 OUTLIER -140.33 -177.71 5.15 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 121.323 -1.104 . . . . 0.0 108.439 179.619 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 69.7 m-20 -100.84 -166.28 1.3 Allowed 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 121.913 0.863 . . . . 0.0 110.655 -179.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.586 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 0.9 OUTLIER -72.54 126.55 30.15 Favored 'General case' 0 N--CA 1.487 1.421 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.741 179.146 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.612 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -92.84 114.74 30.19 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 120.494 -1.379 . . . . 0.0 111.059 178.479 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.454 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 11.1 t80 -56.5 135.64 54.38 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.641 ' CG2' ' CE1' ' A' ' 9' ' ' PHE . 0.6 OUTLIER -129.5 142.55 43.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 120.6 -1.313 . . . . 0.0 110.393 -178.118 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.517 ' N ' HD13 ' A' ' 33' ' ' ILE . 1.8 t-160 -117.48 155.13 30.24 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.318 -0.994 . . . . 0.0 108.318 179.522 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.517 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 41.1 p90 -84.03 33.05 0.48 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.964 -1.085 . . . . 0.0 109.82 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -135.7 -31.1 0.96 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.046 -1.034 . . . . 0.0 109.732 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.504 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.13 -40.82 11.37 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.021 -1.049 . . . . 0.0 108.649 179.646 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.562 ' CD1' ' HB ' ' A' ' 28' ' ' VAL . 2.8 mt . . . . . 0 N--CA 1.485 1.321 0 O-C-N 121.388 -0.82 . . . . 0.0 109.178 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.486 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.57 ' CG2' HD12 ' A' ' 18' ' ' ILE . 28.6 m -111.49 159.48 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.823 -1.173 . . . . 0.0 109.911 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.6 p -115.72 123.55 48.58 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.076 -1.015 . . . . 0.0 108.429 179.448 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.652 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 8.8 p90 -151.92 -178.7 6.91 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.959 -1.088 . . . . 0.0 109.905 -179.429 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -125.36 94.02 4.03 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.483 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.624 HG13 ' CE1' ' A' ' 49' ' ' PHE . 10.5 mt -60.63 140.0 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 O-C-N 120.92 -1.112 . . . . 0.0 110.032 -179.381 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.546 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.9 m -124.52 -173.01 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 106.384 -1.71 . . . . 0.0 106.384 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -122.53 110.75 15.97 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 120.877 -1.139 . . . . 0.0 109.502 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.4 171.13 16.55 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -37.95 -52.25 1.36 Allowed 'General case' 0 N--CA 1.505 2.288 0 O-C-N 121.426 -1.044 . . . . 0.0 113.571 -178.664 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.21 22.53 0.16 Allowed 'General case' 0 N--CA 1.5 2.049 0 O-C-N 119.66 -1.9 . . . . 0.0 112.252 -178.084 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.405 ' O ' ' HG2' ' A' ' 59' ' ' GLN . . . 97.43 -175.52 30.58 Favored Glycine 0 N--CA 1.492 2.432 0 O-C-N 120.399 -1.438 . . . . 0.0 110.266 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.546 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.3 Cg_endo -65.22 131.36 28.19 Favored 'Trans proline' 0 C--N 1.32 -0.936 0 C-N-CA 121.858 1.706 . . . . 0.0 109.839 178.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.463 ' OE1' ' O ' ' A' ' 58' ' ' PRO . 10.4 mm100 -143.25 148.15 35.95 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.93 -1.106 . . . . 0.0 111.916 -178.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.551 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -82.1 158.2 23.8 Favored 'General case' 0 N--CA 1.496 1.872 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 176.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.504 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -135.29 -42.54 0.71 Allowed 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.219 -1.551 . . . . 0.0 111.876 -176.454 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 43.1 t30 -119.76 54.3 1.02 Allowed 'General case' 0 C--N 1.285 -2.238 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.561 ' CG2' ' HB3' ' A' ' 49' ' ' PHE . 18.4 t -68.62 164.94 2.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.596 -179.193 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.3 -175.8 5.32 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 178.804 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.425 ' HE3' ' O ' ' A' ' 33' ' ' ILE . 25.1 mmtp . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.035 -1.041 . . . . 0.0 109.653 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.587 ' C ' ' CD1' ' A' ' 2' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.776 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 . . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.452 ' OE2' ' HB3' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -113.74 153.48 28.95 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 120.931 -1.106 . . . . 0.0 109.92 -179.716 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.427 ' C ' ' HG3' ' A' ' 5' ' ' LYS . . . -136.37 169.7 23.62 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.427 ' HG3' ' C ' ' A' ' 4' ' ' GLY . 7.6 mttm -138.01 123.58 19.69 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.943 -1.327 . . . . 0.0 109.991 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.576 ' CG1' ' N ' ' A' ' 8' ' ' TRP . 4.5 t -47.09 143.53 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 CA-C-O 122.857 1.313 . . . . 0.0 112.221 -179.538 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.74 -28.23 13.6 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 103.282 -2.859 . . . . 0.0 103.282 172.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.713 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 23.1 p-90 177.92 145.71 0.12 Allowed 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.637 ' CE1' ' CG2' ' A' ' 28' ' ' VAL . 0.8 OUTLIER -112.72 148.8 33.97 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 120.528 -1.357 . . . . 0.0 109.902 179.821 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.574 ' OD1' ' CZ3' ' A' ' 8' ' ' TRP . 2.2 m120 -129.25 36.87 4.11 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 178.471 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.6 p -38.74 -50.95 1.69 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.9 -0.5 . . . . 0.0 110.41 -178.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.431 ' OE2' ' O ' ' A' ' 12' ' ' GLU . 6.7 tp10 -63.96 -37.69 88.34 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.04 -1.038 . . . . 0.0 110.151 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.556 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 1.1 mptt -75.23 2.38 11.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.962 -1.086 . . . . 0.0 110.057 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.475 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 100.63 8.56 48.77 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.983 -1.103 . . . . 0.0 112.828 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.549 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 7.0 p90 177.08 172.6 0.48 Allowed 'General case' 0 N--CA 1.501 2.11 0 CA-C-N 120.213 2.007 . . . . 0.0 111.492 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.504 ' O ' HG21 ' A' ' 28' ' ' VAL . . . -145.49 153.1 25.07 Favored Glycine 0 N--CA 1.501 3.012 0 N-CA-C 107.152 -2.379 . . . . 0.0 107.152 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.713 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.1 m-85 -112.32 139.7 47.66 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 119.72 -2.047 . . . . 0.0 110.095 -179.112 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.59 ' CD1' ' CG1' ' A' ' 28' ' ' VAL . 1.2 mt -107.29 162.16 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.576 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 4.4 tt0 -140.42 133.81 29.9 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.138 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.474 HG12 ' HB2' ' A' ' 23' ' ' GLN . 7.6 p -137.9 140.67 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 C-N-CA 117.936 -1.505 . . . . 0.0 111.804 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -63.92 140.6 58.89 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.302 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.86 -13.8 46.46 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.474 ' HB2' HG12 ' A' ' 20' ' ' VAL . 1.2 mt-30 -138.48 -175.48 4.14 Favored 'General case' 0 C--N 1.309 -1.166 0 O-C-N 121.326 -1.102 . . . . 0.0 108.746 179.612 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.31 -165.37 1.21 Allowed 'General case' 0 C--N 1.295 -1.783 0 CA-C-O 122.044 0.926 . . . . 0.0 110.324 -179.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.57 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 38.1 p-10 -71.34 120.69 17.28 Favored 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.833 179.393 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.606 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.5 t -83.26 114.06 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 120.512 -1.367 . . . . 0.0 110.523 178.428 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.428 ' CB ' ' HG2' ' A' ' 59' ' ' GLN . 3.2 t80 -54.24 140.65 32.17 Favored 'General case' 0 C--N 1.296 -1.761 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 178.511 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.637 ' CG2' ' CE1' ' A' ' 9' ' ' PHE . 0.6 OUTLIER -132.51 148.3 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 120.699 -1.251 . . . . 0.0 110.537 -178.583 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.443 ' N ' HD13 ' A' ' 33' ' ' ILE . 24.5 t-80 -144.61 137.6 26.82 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 13.4 p90 -65.78 5.91 0.41 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.789 -1.194 . . . . 0.0 111.52 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.12 -35.57 11.84 Favored 'General case' 0 N--CA 1.484 1.267 0 O-C-N 120.345 -1.472 . . . . 0.0 108.744 179.307 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.516 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.82 -41.52 10.6 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.246 -0.909 . . . . 0.0 108.666 179.38 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.514 HG12 ' HB ' ' A' ' 63' ' ' VAL . 7.0 mt . . . . . 0 N--CA 1.49 1.534 0 C-N-CA 119.5 -0.88 . . . . 0.0 109.027 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.452 ' HB3' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.576 ' CG2' HD12 ' A' ' 18' ' ' ILE . 33.5 m -123.52 163.61 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 120.77 -1.206 . . . . 0.0 110.525 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.425 ' O ' HG11 ' A' ' 63' ' ' VAL . 3.2 p -117.52 131.9 56.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.147 -0.971 . . . . 0.0 108.951 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.586 ' CE1' HD13 ' A' ' 2' ' ' LEU . 23.0 p90 -161.74 -179.3 7.12 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.865 -1.147 . . . . 0.0 109.966 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -127.5 95.45 4.25 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.668 -0.645 . . . . 0.0 109.484 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.606 ' CD1' ' CG2' ' A' ' 26' ' ' VAL . 1.2 mm -61.49 136.14 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 CA-C-O 122.469 1.128 . . . . 0.0 110.857 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 4.0 m -121.88 -175.01 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 179.364 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.73 114.58 20.13 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.977 -1.077 . . . . 0.0 109.413 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.34 172.68 18.68 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.126 -1.589 . . . . 0.0 109.126 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -37.8 -52.14 1.29 Allowed 'General case' 0 N--CA 1.504 2.252 0 O-C-N 121.426 -1.043 . . . . 0.0 113.411 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 7.2 mtm180 -75.8 22.72 0.14 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 119.609 -1.932 . . . . 0.0 112.162 -178.216 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.32 -177.05 34.65 Favored Glycine 0 N--CA 1.49 2.276 0 O-C-N 120.48 -1.388 . . . . 0.0 109.9 179.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.498 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -66.65 148.9 83.89 Favored 'Trans proline' 0 C--N 1.317 -1.088 0 C-N-CA 121.911 1.741 . . . . 0.0 109.781 178.736 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.48 ' C ' ' CD1' ' A' ' 51' ' ' ILE . 2.6 mt-30 -165.59 151.25 9.24 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.067 -1.021 . . . . 0.0 111.468 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.559 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -81.7 158.79 24.11 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 177.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.516 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -135.4 -42.45 0.7 Allowed 'General case' 0 N--CA 1.507 2.41 0 O-C-N 120.336 -1.477 . . . . 0.0 111.358 -176.788 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -119.43 61.72 0.82 Allowed 'General case' 0 C--N 1.282 -2.357 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.567 ' CG2' ' HB3' ' A' ' 49' ' ' PHE . 18.9 t -79.66 172.48 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.036 -178.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -153.93 171.08 19.56 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.501 0 O-C-N 120.931 -1.106 . . . . 0.0 109.407 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.598 HD13 ' CD1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.822 0 CA-C-O 121.042 0.448 . . . . 0.0 110.036 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.512 ' O ' ' CD2' ' A' ' 2' ' ' LEU . 0.4 OUTLIER -112.04 160.89 17.05 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.194 -0.941 . . . . 0.0 110.155 -178.994 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.23 168.32 28.36 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 6' ' ' VAL . 5.2 mttt -139.86 120.18 13.92 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.026 -1.279 . . . . 0.0 110.086 -179.694 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.542 HG21 ' CD1' ' A' ' 9' ' ' PHE . 3.7 t -41.55 140.51 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 CA-C-O 122.736 1.255 . . . . 0.0 112.073 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.483 ' HG3' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -98.09 -28.1 13.91 Favored 'General case' 0 C--N 1.289 -2.054 0 N-CA-C 103.536 -2.765 . . . . 0.0 103.536 173.008 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 26.1 p-90 177.55 141.74 0.09 Allowed 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 178.17 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.542 ' CD1' HG21 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -120.5 139.71 52.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.511 -1.368 . . . . 0.0 110.162 -179.893 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.501 ' ND2' ' HB2' ' A' ' 13' ' ' LYS . 2.0 t30 -132.05 32.88 3.97 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 179.245 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.457 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -37.45 -48.26 0.95 Allowed 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 121.634 0.73 . . . . 0.0 109.192 -179.404 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -59.99 -47.52 85.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.565 -0.709 . . . . 0.0 109.898 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.501 ' HB2' ' ND2' ' A' ' 10' ' ' ASN . 5.1 mptt -69.52 0.36 5.42 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.428 -0.795 . . . . 0.0 110.64 -179.409 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.455 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 109.9 4.38 29.68 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 119.67 -1.253 . . . . 0.0 113.063 178.386 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.466 ' O ' ' C ' ' A' ' 10' ' ' ASN . 5.0 p90 179.6 166.36 1.12 Allowed 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 120.975 2.387 . . . . 0.0 112.163 179.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.53 ' O ' ' CG2' ' A' ' 28' ' ' VAL . . . -147.4 143.25 11.05 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 107.668 -2.173 . . . . 0.0 107.668 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.0 m-85 -115.07 138.95 50.29 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.196 -1.767 . . . . 0.0 110.231 -178.631 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.563 HD11 ' CG1' ' A' ' 28' ' ' VAL . 1.1 mt -106.74 152.71 8.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 177.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.52 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 1.7 tt0 -129.23 136.29 49.92 Favored 'General case' 0 C--N 1.286 -2.175 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.325 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.499 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 6.6 p -138.88 139.43 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 117.592 -1.643 . . . . 0.0 111.861 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -62.41 140.78 58.57 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.112 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.76 -18.15 36.44 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.51 -1.836 . . . . 0.0 108.51 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.499 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 0.1 OUTLIER -136.44 -175.92 4.16 Favored 'General case' 0 N--CA 1.484 1.226 0 O-C-N 121.423 -1.045 . . . . 0.0 108.334 179.336 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.91 -166.38 1.3 Allowed 'General case' 0 C--N 1.296 -1.749 0 CA-C-O 122.143 0.973 . . . . 0.0 111.014 -178.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.532 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.9 p-10 -73.21 102.2 3.57 Favored 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.553 178.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.604 HG12 ' CB ' ' A' ' 60' ' ' ALA . 2.7 t -66.65 128.38 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 120.422 -1.424 . . . . 0.0 111.04 179.326 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.55 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 3.8 t80 -71.1 135.99 47.98 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.563 ' CG1' HD11 ' A' ' 18' ' ' ILE . 11.2 m -149.88 128.21 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 120.406 -1.434 . . . . 0.0 110.721 -179.574 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.634 ' NE2' ' CE2' ' A' ' 30' ' ' PHE . 10.9 t-80 -99.21 166.31 11.29 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.634 ' CE2' ' NE2' ' A' ' 29' ' ' HIS . 48.5 p90 -82.35 31.61 0.4 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.806 -1.184 . . . . 0.0 110.062 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 32.5 p -116.81 -38.2 3.49 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.976 -1.078 . . . . 0.0 109.11 179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.517 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -92.56 -41.92 9.96 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 108.508 179.356 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.54 ' CD1' ' N ' ' A' ' 33' ' ' ILE . 1.5 mp . . . . . 0 N--CA 1.486 1.344 0 O-C-N 121.535 -0.728 . . . . 0.0 109.083 179.729 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.362 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.477 HG22 HD12 ' A' ' 18' ' ' ILE . 29.9 m -135.92 162.98 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.852 -1.155 . . . . 0.0 109.851 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.3 p -116.0 137.1 52.42 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.036 -1.04 . . . . 0.0 108.442 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.598 ' CD1' HD13 ' A' ' 2' ' ' LEU . 10.4 p90 -162.43 -175.74 4.68 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.884 -1.135 . . . . 0.0 109.852 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -127.35 98.5 5.28 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.555 -0.716 . . . . 0.0 109.586 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.586 HG12 HG23 ' A' ' 26' ' ' VAL . 5.6 mt -61.89 143.69 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 CA-C-O 122.529 1.157 . . . . 0.0 111.309 -179.482 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.501 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 13.9 m -129.51 -176.76 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.27 116.78 23.92 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.728 -1.232 . . . . 0.0 110.369 -179.681 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -116.32 165.03 12.24 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.523 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.431 ' C ' ' O ' ' A' ' 54' ' ' GLY . 4.6 m-20 -38.31 -54.67 1.41 Allowed 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.072 -1.252 . . . . 0.0 112.914 -178.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.1 ttm180 -69.7 -21.26 63.51 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 119.564 -1.96 . . . . 0.0 113.069 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.69 179.2 25.33 Favored Glycine 0 N--CA 1.492 2.415 0 O-C-N 120.27 -1.519 . . . . 0.0 110.358 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.501 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -65.81 140.82 62.85 Favored 'Trans proline' 0 C--N 1.317 -1.094 0 C-N-CA 122.007 1.805 . . . . 0.0 110.464 179.206 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.516 ' HG2' ' CB ' ' A' ' 27' ' ' PHE . 30.3 mt-30 -154.83 151.78 29.03 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.347 -0.846 . . . . 0.0 110.71 -179.591 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.604 ' CB ' HG12 ' A' ' 26' ' ' VAL . . . -83.83 167.76 16.76 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 177.328 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.517 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -135.23 -44.07 0.71 Allowed 'General case' 0 N--CA 1.503 2.22 0 O-C-N 120.289 -1.507 . . . . 0.0 111.672 -176.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.41 ' OD1' ' O ' ' A' ' 62' ' ' ASN . 21.3 p30 -120.0 52.16 1.14 Allowed 'General case' 0 C--N 1.287 -2.11 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.576 ' CG2' ' HB2' ' A' ' 60' ' ' ALA . 20.0 t -67.81 164.13 2.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 121.561 0.696 . . . . 0.0 109.681 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.421 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.2 OUTLIER -146.24 164.29 32.76 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 178.672 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.646 0 O-C-N 121.081 -1.012 . . . . 0.0 109.75 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.602 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.889 0 CA-C-O 120.8 0.333 . . . . 0.0 110.196 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.535 ' O ' ' CD2' ' A' ' 2' ' ' LEU . 0.1 OUTLIER -112.66 167.27 10.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.858 -1.151 . . . . 0.0 109.651 -179.284 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -148.54 159.81 28.16 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.7 mttt -133.88 117.96 17.39 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.373 -1.075 . . . . 0.0 110.742 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.497 HG12 ' N ' ' A' ' 8' ' ' TRP . 3.5 t -37.89 146.67 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 123.122 1.439 . . . . 0.0 113.143 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.63 -30.65 9.84 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 103.191 -2.892 . . . . 0.0 103.191 172.137 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.714 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 22.6 p-90 177.66 145.92 0.12 Allowed 'General case' 0 N--CA 1.484 1.267 0 N-CA-C 106.035 -1.839 . . . . 0.0 106.035 177.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.615 ' CE1' HG23 ' A' ' 28' ' ' VAL . 1.4 t80 -119.18 138.45 52.93 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.442 -1.411 . . . . 0.0 109.611 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.497 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.2 t-20 -133.65 36.76 3.32 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.465 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -37.21 -49.59 0.93 Allowed 'General case' 0 N--CA 1.495 1.818 0 CA-C-O 121.443 0.639 . . . . 0.0 109.541 -179.451 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -60.92 -46.22 91.53 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.475 -0.766 . . . . 0.0 109.806 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.498 ' HD2' ' N ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -69.96 1.0 4.96 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.51 -0.744 . . . . 0.0 110.453 -179.606 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.451 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 123.35 -19.52 7.62 Favored Glycine 0 N--CA 1.491 2.355 0 C-N-CA 119.685 -1.245 . . . . 0.0 111.946 178.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.454 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 5.3 p90 173.7 178.4 0.11 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.056 -1.85 . . . . 0.0 111.456 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.581 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -135.52 145.81 17.84 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 107.884 -2.087 . . . . 0.0 107.884 179.505 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.714 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.7 m-30 -104.57 142.18 35.1 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 120.247 -1.737 . . . . 0.0 109.664 -179.245 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.594 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.5 OUTLIER -106.34 164.51 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 178.56 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.568 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 3.1 tm-20 -141.68 129.77 22.08 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.555 ' CG1' ' CB ' ' A' ' 23' ' ' GLN . 10.3 p -135.59 141.65 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 C-N-CA 117.695 -1.602 . . . . 0.0 112.043 -179.657 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -65.65 140.25 58.48 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-N 115.381 -0.827 . . . . 0.0 108.827 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.41 -14.01 42.96 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.555 ' CB ' ' CG1' ' A' ' 20' ' ' VAL . 1.6 mm100 -137.66 -177.37 4.77 Favored 'General case' 0 N--CA 1.483 1.202 0 O-C-N 121.333 -1.098 . . . . 0.0 108.407 179.538 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -100.73 -166.27 1.3 Allowed 'General case' 0 C--N 1.296 -1.748 0 CA-C-O 121.962 0.887 . . . . 0.0 110.378 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.594 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.4 m-20 -72.08 123.46 22.88 Favored 'General case' 0 N--CA 1.486 1.367 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.676 179.149 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.615 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -84.91 110.5 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.02 0 O-C-N 120.589 -1.32 . . . . 0.0 111.454 178.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -55.37 133.73 49.87 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 178.07 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.615 HG23 ' CE1' ' A' ' 9' ' ' PHE . 0.6 OUTLIER -132.75 137.19 54.53 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 C-N-CA 117.891 -1.524 . . . . 0.0 110.661 -178.782 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.473 ' O ' HD13 ' A' ' 33' ' ' ILE . 5.6 t-160 -109.81 159.49 17.15 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.572 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 46.1 p90 -82.67 39.86 0.64 Allowed 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.763 -1.211 . . . . 0.0 109.831 -179.674 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.1 t -137.65 -33.2 0.73 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.816 -1.178 . . . . 0.0 110.518 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.536 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -93.53 -49.91 5.67 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.961 -1.087 . . . . 0.0 109.706 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.614 ' CG1' ' HB ' ' A' ' 63' ' ' VAL . 1.4 mp . . . . . 0 N--CA 1.491 1.575 0 O-C-N 121.677 -0.64 . . . . 0.0 110.359 -178.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.51 ' CG2' HD12 ' A' ' 18' ' ' ILE . 26.2 m -124.13 163.13 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 120.627 -1.296 . . . . 0.0 110.882 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.421 ' O ' HG11 ' A' ' 63' ' ' VAL . 22.7 p -115.87 137.22 52.3 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 108.5 179.362 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.61 ' CE1' HG13 ' A' ' 51' ' ' ILE . 9.4 p90 -163.66 -177.97 5.5 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.816 -1.177 . . . . 0.0 109.941 -179.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -127.15 93.02 3.64 Favored 'General case' 0 C--N 1.295 -1.773 0 O-C-N 121.688 -0.633 . . . . 0.0 109.475 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.615 ' CD1' ' CG2' ' A' ' 26' ' ' VAL . 16.3 mt -62.1 128.92 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.023 -1.048 . . . . 0.0 109.886 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.507 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 16.1 m -108.11 -176.59 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 178.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -123.32 114.66 20.49 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.012 -1.055 . . . . 0.0 109.735 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.405 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -125.89 169.04 17.86 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.591 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' A' ' 54' ' ' GLY . 22.1 m120 -37.44 -51.99 1.13 Allowed 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.227 -1.161 . . . . 0.0 113.412 -178.45 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.9 tpt180 -75.33 22.62 0.12 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 119.718 -1.864 . . . . 0.0 112.352 -178.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.02 -178.32 31.94 Favored Glycine 0 N--CA 1.494 2.551 0 O-C-N 120.414 -1.429 . . . . 0.0 110.269 179.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -67.91 155.01 71.4 Favored 'Trans proline' 0 C--N 1.32 -0.947 0 C-N-CA 122.005 1.803 . . . . 0.0 109.918 178.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.442 ' HG3' ' O ' ' A' ' 58' ' ' PRO . 0.3 OUTLIER -166.07 143.22 5.31 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.982 -1.074 . . . . 0.0 111.398 -179.693 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.552 ' HB3' ' CG2' ' A' ' 63' ' ' VAL . . . -78.09 157.63 29.44 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 177.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.536 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.54 -44.26 0.75 Allowed 'General case' 0 N--CA 1.507 2.395 0 O-C-N 120.498 -1.376 . . . . 0.0 111.933 -176.407 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -119.81 51.78 1.16 Allowed 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.614 ' HB ' ' CG1' ' A' ' 33' ' ' ILE . 21.2 t -68.03 169.2 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-O 121.693 0.758 . . . . 0.0 109.513 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.418 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.2 OUTLIER -154.62 178.14 10.43 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 178.237 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.579 ' N ' ' CD ' ' A' ' 65' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.735 0 O-C-N 121.043 -1.036 . . . . 0.0 109.557 -179.712 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.66 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.808 0 CA-C-O 121.09 0.471 . . . . 0.0 110.011 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.512 ' N ' HD21 ' A' ' 2' ' ' LEU . 0.0 OUTLIER -113.92 149.03 35.8 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 121.213 -0.929 . . . . 0.0 110.389 -179.372 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.512 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -121.33 166.16 14.26 Favored Glycine 0 N--CA 1.483 1.796 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 179.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.47 ' O ' ' C ' ' A' ' 6' ' ' VAL . 2.0 mttm -140.3 119.0 12.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.922 -1.34 . . . . 0.0 109.609 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.522 HG11 ' N ' ' A' ' 8' ' ' TRP . 2.7 t -33.5 136.67 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 CA-C-O 122.913 1.34 . . . . 0.0 113.401 -179.327 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.479 ' CG ' ' HB3' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -101.8 -31.51 10.71 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 103.149 -2.908 . . . . 0.0 103.149 172.61 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.699 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 22.8 p-90 174.25 145.25 0.05 Allowed 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 178.009 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.576 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.2 OUTLIER -114.21 147.04 39.58 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.149 -1.594 . . . . 0.0 109.952 179.333 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.544 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 80.5 m-20 -130.21 38.68 3.75 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 179.013 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' ASN . 24.7 p -40.89 -41.59 1.64 Allowed 'General case' 0 N--CA 1.488 1.47 0 CA-C-O 121.71 0.767 . . . . 0.0 109.103 -179.078 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -59.9 -48.4 81.87 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.537 -0.727 . . . . 0.0 110.414 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.567 ' N ' ' CD ' ' A' ' 13' ' ' LYS . 2.2 mptp? -73.83 4.35 5.36 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.215 -0.928 . . . . 0.0 110.125 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.43 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 92.24 23.55 26.71 Favored Glycine 0 N--CA 1.49 2.242 0 C-N-CA 120.251 -0.976 . . . . 0.0 112.144 178.549 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.496 ' O ' ' C ' ' A' ' 10' ' ' ASN . 26.7 p90 179.44 167.19 1.09 Allowed 'General case' 0 N--CA 1.501 2.076 0 CA-C-N 120.102 1.951 . . . . 0.0 111.631 179.447 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.576 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -149.0 150.89 23.09 Favored Glycine 0 N--CA 1.497 2.752 0 N-CA-C 106.995 -2.442 . . . . 0.0 106.995 179.328 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.699 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 6.1 m-85 -117.24 138.31 51.8 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 120.035 1.917 . . . . 0.0 110.235 -178.648 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.536 ' CD1' HG23 ' A' ' 47' ' ' VAL . 1.7 mt -105.47 146.55 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.809 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.528 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 9.6 pt-20 -121.01 137.02 54.85 Favored 'General case' 0 C--N 1.285 -2.229 0 C-N-CA 119.472 -0.891 . . . . 0.0 108.944 178.45 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.504 HG12 ' HB2' ' A' ' 23' ' ' GLN . 10.0 p -138.73 140.93 38.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 C-N-CA 117.822 -1.551 . . . . 0.0 111.787 179.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.87 140.49 58.28 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.391 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 87.77 -19.1 35.16 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.504 ' HB2' HG12 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -136.4 -175.43 4.0 Favored 'General case' 0 C--N 1.308 -1.219 0 O-C-N 121.416 -1.049 . . . . 0.0 108.693 179.406 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.61 -165.1 1.17 Allowed 'General case' 0 C--N 1.296 -1.756 0 CA-C-O 122.009 0.909 . . . . 0.0 110.588 -179.051 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.528 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 0.9 OUTLIER -71.65 93.24 1.23 Allowed 'General case' 0 N--CA 1.487 1.388 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.037 179.257 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.618 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.7 t -56.27 142.4 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 120.299 -1.501 . . . . 0.0 109.952 178.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.517 ' N ' HG11 ' A' ' 26' ' ' VAL . 5.0 t80 -71.69 146.3 48.3 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 176.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.557 ' HB ' ' CD1' ' A' ' 33' ' ' ILE . 2.0 m -142.06 113.96 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 120.332 -1.48 . . . . 0.0 110.363 -179.299 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.419 ' O ' HD11 ' A' ' 33' ' ' ILE . 7.5 t60 -99.55 148.95 23.74 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 178.296 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -79.86 32.71 0.26 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.747 -1.221 . . . . 0.0 110.163 -179.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.78 -36.93 3.34 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.963 -1.085 . . . . 0.0 108.924 179.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.519 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -92.36 -47.16 7.33 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 179.366 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.557 ' CD1' ' HB ' ' A' ' 28' ' ' VAL . 11.6 mt . . . . . 0 N--CA 1.487 1.397 0 CA-C-O 121.495 0.664 . . . . 0.0 109.44 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.445 ' CB ' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.486 1.374 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.536 HG23 ' CD1' ' A' ' 18' ' ' ILE . 31.3 m -122.32 165.06 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 120.704 -1.247 . . . . 0.0 110.462 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.4 p -117.01 122.55 44.53 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.66 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 6.3 p90 -150.85 -178.45 6.59 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 120.858 -1.151 . . . . 0.0 109.726 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -127.71 95.02 4.1 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.621 HG13 ' CE1' ' A' ' 49' ' ' PHE . 13.3 mt -62.35 136.34 25.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 CA-C-O 122.326 1.06 . . . . 0.0 110.906 -179.165 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 11.5 m -119.53 -176.61 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 179.124 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -123.48 113.66 19.05 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.01 -1.057 . . . . 0.0 109.629 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.23 171.66 16.52 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -37.99 -52.13 1.37 Allowed 'General case' 0 N--CA 1.505 2.292 0 O-C-N 121.367 -1.078 . . . . 0.0 113.735 -178.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.38 22.38 0.23 Allowed 'General case' 0 N--CA 1.5 2.046 0 O-C-N 119.655 -1.903 . . . . 0.0 112.247 -177.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.18 -176.97 29.67 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.451 -1.357 . . . . 0.0 110.257 179.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.489 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -66.94 153.43 77.93 Favored 'Trans proline' 0 C--N 1.32 -0.938 0 C-N-CA 121.915 1.744 . . . . 0.0 109.977 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -165.65 147.04 7.17 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.207 -0.933 . . . . 0.0 111.083 -179.428 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.558 ' HB3' ' CG2' ' A' ' 63' ' ' VAL . . . -81.04 161.7 24.09 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 177.051 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.519 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.27 -44.98 0.77 Allowed 'General case' 0 N--CA 1.508 2.441 0 O-C-N 120.155 -1.59 . . . . 0.0 111.93 -176.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -119.02 50.73 1.18 Allowed 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.558 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 19.9 t -64.63 157.64 4.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.76 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -142.14 173.57 11.4 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.153 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.409 ' O ' ' HG3' ' A' ' 65' ' ' LYS . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.57 0 O-C-N 120.929 -1.107 . . . . 0.0 109.376 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.619 HD13 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.858 0 CA-C-O 121.467 0.651 . . . . 0.0 110.385 . . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.503 ' HG2' ' O ' ' A' ' 47' ' ' VAL . 0.1 OUTLIER -121.26 136.75 54.92 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.473 -0.767 . . . . 0.0 109.498 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -129.59 -164.19 11.35 Favored Glycine 0 N--CA 1.484 1.834 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 20.9 ttpt -151.71 135.9 16.68 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.882 -1.364 . . . . 0.0 111.048 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.483 HG12 ' N ' ' A' ' 8' ' ' TRP . 3.3 t -42.58 140.07 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 122.865 1.317 . . . . 0.0 112.856 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.422 ' CG ' ' OE1' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -97.4 -31.13 12.53 Favored 'General case' 0 C--N 1.29 -2.011 0 N-CA-C 103.009 -2.96 . . . . 0.0 103.009 172.631 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.707 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.2 p-90 177.45 145.85 0.11 Allowed 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 177.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -113.81 146.32 40.12 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 120.591 -1.318 . . . . 0.0 109.61 179.234 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.562 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 31.4 m-20 -130.08 43.03 3.19 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 10' ' ' ASN . 53.4 p -41.33 -41.44 1.94 Allowed 'General case' 0 N--CA 1.489 1.511 0 CA-C-O 121.612 0.72 . . . . 0.0 109.077 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -59.49 -49.37 78.06 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.435 -0.791 . . . . 0.0 110.607 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.51 ' HD2' ' N ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -72.95 4.36 4.3 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.01 -1.056 . . . . 0.0 110.395 -179.429 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.56 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 91.46 23.91 27.62 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 120.051 -1.071 . . . . 0.0 111.933 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.478 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 11.1 p90 178.92 167.63 0.93 Allowed 'General case' 0 N--CA 1.499 1.987 0 CA-C-N 120.122 1.961 . . . . 0.0 111.815 179.306 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.455 ' O ' HG21 ' A' ' 28' ' ' VAL . . . -146.58 144.33 12.59 Favored Glycine 0 N--CA 1.497 2.758 0 N-CA-C 107.271 -2.331 . . . . 0.0 107.271 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.707 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.1 m-85 -110.13 142.68 41.3 Favored 'General case' 0 N--CA 1.482 1.134 0 O-C-N 120.013 -1.874 . . . . 0.0 110.153 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.591 ' CG2' ' N ' ' A' ' 19' ' ' GLU . 0.6 OUTLIER -105.91 165.23 3.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 177.975 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.591 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 6.8 tt0 -133.92 130.17 37.36 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.47 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.571 ' CG1' ' CB ' ' A' ' 23' ' ' GLN . 11.3 p -131.95 139.11 51.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 C-N-CA 117.728 -1.589 . . . . 0.0 111.699 -179.645 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -65.4 140.7 58.66 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.266 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.2 -9.58 46.8 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.571 ' CB ' ' CG1' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -139.78 -175.43 4.21 Favored 'General case' 0 C--N 1.309 -1.158 0 O-C-N 121.125 -1.221 . . . . 0.0 108.871 179.675 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -100.48 -165.68 1.24 Allowed 'General case' 0 C--N 1.295 -1.77 0 CA-C-O 122.208 1.004 . . . . 0.0 110.583 -178.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.58 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.2 m-20 -71.04 119.95 15.9 Favored 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 115.714 -0.676 . . . . 0.0 109.74 179.353 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.6 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.2 t -78.82 114.31 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 120.674 -1.267 . . . . 0.0 111.398 178.632 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.62 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 2.0 t80 -66.26 125.03 24.3 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.38 -0.971 . . . . 0.0 108.38 178.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.515 HG22 ' CD1' ' A' ' 18' ' ' ILE . 2.3 m -143.99 136.82 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 120.593 -1.317 . . . . 0.0 110.26 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.629 ' NE2' ' CE1' ' A' ' 30' ' ' PHE . 35.6 t60 -98.85 166.91 11.07 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 179.273 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.629 ' CE1' ' NE2' ' A' ' 29' ' ' HIS . 42.0 p90 -83.61 38.99 0.65 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.773 -1.204 . . . . 0.0 109.424 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.5 m -132.27 -30.39 1.52 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.091 -1.006 . . . . 0.0 109.527 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.494 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.53 -42.12 10.42 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.108 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.495 ' O ' ' HA ' ' A' ' 64' ' ' THR . 17.1 mt . . . . . 0 N--CA 1.484 1.243 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.503 ' O ' ' HG2' ' A' ' 3' ' ' GLU . 26.8 m -134.09 155.92 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.877 -1.139 . . . . 0.0 109.975 179.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.1 p -117.32 120.39 38.05 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.09 -1.007 . . . . 0.0 108.613 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.619 ' CE1' HD13 ' A' ' 2' ' ' LEU . 10.8 p90 -149.09 -178.45 6.39 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.056 -1.028 . . . . 0.0 109.729 -179.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.503 ' CG ' ' O ' ' A' ' 50' ' ' GLU . 5.1 pt-20 -127.74 96.53 4.54 Favored 'General case' 0 C--N 1.296 -1.732 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.098 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.614 HG13 ' CE1' ' A' ' 49' ' ' PHE . 10.6 mt -62.38 132.26 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.05 -1.031 . . . . 0.0 110.105 -179.427 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 6.3 m -113.63 -176.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 178.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -124.0 116.13 22.35 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.974 -1.079 . . . . 0.0 109.844 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.404 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -129.96 172.08 20.22 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 179.757 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.404 ' C ' ' O ' ' A' ' 54' ' ' GLY . 0.7 OUTLIER -37.71 -52.03 1.25 Allowed 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.378 -1.071 . . . . 0.0 113.394 -178.572 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.26 22.69 0.11 Allowed 'General case' 0 N--CA 1.501 2.12 0 O-C-N 119.717 -1.865 . . . . 0.0 112.262 -178.303 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.37 -178.28 35.43 Favored Glycine 0 N--CA 1.491 2.337 0 O-C-N 120.434 -1.416 . . . . 0.0 110.13 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.506 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.2 Cg_endo -68.81 150.91 74.26 Favored 'Trans proline' 0 C--N 1.32 -0.938 0 C-N-CA 122.046 1.831 . . . . 0.0 109.791 178.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.487 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 2.9 mt-30 -165.99 148.15 7.13 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.018 -1.051 . . . . 0.0 111.65 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.557 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -79.29 157.14 27.79 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 177.279 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.494 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.82 -42.9 0.74 Allowed 'General case' 0 N--CA 1.506 2.351 0 O-C-N 120.354 -1.466 . . . . 0.0 112.027 -176.46 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -119.13 52.17 1.08 Allowed 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.546 ' CG2' ' HB3' ' A' ' 49' ' ' PHE . 15.0 t -66.68 157.41 5.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.668 -179.436 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.495 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.1 OUTLIER -135.8 158.49 44.26 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 178.713 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.403 ' HG3' ' O ' ' A' ' 65' ' ' LYS . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.569 0 O-C-N 120.907 -1.121 . . . . 0.0 109.445 -179.883 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.642 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.961 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 . . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.531 ' O ' ' CD2' ' A' ' 2' ' ' LEU . 0.5 OUTLIER -112.51 168.13 9.89 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.829 -1.17 . . . . 0.0 110.128 -178.857 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.495 ' N ' ' OE1' ' A' ' 3' ' ' GLU . . . -149.95 156.58 26.82 Favored Glycine 0 N--CA 1.486 2.026 0 N-CA-C 109.083 -1.607 . . . . 0.0 109.083 -179.557 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.442 ' HG2' ' C ' ' A' ' 4' ' ' GLY . 0.5 OUTLIER -135.37 120.8 19.2 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.257 -1.143 . . . . 0.0 110.575 -179.44 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.489 HG12 ' N ' ' A' ' 8' ' ' TRP . 2.6 t -39.83 138.62 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 CA-C-O 122.749 1.261 . . . . 0.0 113.112 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.449 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -100.25 -27.59 13.42 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 103.608 -2.738 . . . . 0.0 103.608 172.948 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.705 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.6 p-90 178.41 145.13 0.13 Allowed 'General case' 0 N--CA 1.482 1.166 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 178.233 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.626 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.3 OUTLIER -114.39 146.38 40.65 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 120.445 -1.409 . . . . 0.0 110.391 -179.793 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.53 ' HB2' ' O ' ' A' ' 15' ' ' PHE . 24.1 m-20 -127.88 37.46 4.18 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 107.097 -1.445 . . . . 0.0 107.097 178.119 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.5 p -38.8 -51.21 1.72 Allowed 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.229 -178.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -59.78 -45.76 91.29 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.365 -0.834 . . . . 0.0 110.291 -179.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.524 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -70.47 0.28 6.98 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.34 -0.85 . . . . 0.0 110.735 -179.001 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.497 ' O ' ' NE2' ' A' ' 29' ' ' HIS . . . 111.57 -2.97 27.73 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.61 -1.281 . . . . 0.0 113.199 177.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.53 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 0.3 OUTLIER 177.63 176.99 0.38 Allowed 'General case' 0 N--CA 1.499 2.019 0 CA-C-N 120.562 2.181 . . . . 0.0 111.82 -179.751 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.626 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -141.98 156.73 26.12 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 107.703 -2.159 . . . . 0.0 107.703 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.705 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.8 m-85 -110.45 139.9 45.23 Favored 'General case' 0 N--CA 1.482 1.127 0 O-C-N 119.929 -1.924 . . . . 0.0 109.82 -179.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.581 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 1.3 mt -106.54 152.8 8.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 178.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 0.0 OUTLIER -128.69 135.79 49.73 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 178.333 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.557 ' CG1' ' CB ' ' A' ' 23' ' ' GLN . 11.6 p -136.44 139.87 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 C-N-CA 118.213 -1.395 . . . . 0.0 111.483 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -65.38 140.37 58.64 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 115.485 -0.779 . . . . 0.0 109.424 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.92 -10.27 48.21 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.557 ' CB ' ' CG1' ' A' ' 20' ' ' VAL . 3.8 mm-40 -137.92 -174.12 3.7 Favored 'General case' 0 C--N 1.31 -1.117 0 O-C-N 121.184 -1.186 . . . . 0.0 108.787 179.796 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -100.56 -167.16 1.4 Allowed 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 122.077 0.942 . . . . 0.0 110.715 -178.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.581 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 0.2 OUTLIER -73.21 108.15 5.93 Favored 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.859 179.214 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.64 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.5 t -71.62 116.73 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.046 0 O-C-N 120.17 -1.581 . . . . 0.0 111.074 178.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.462 ' HB2' ' NE2' ' A' ' 59' ' ' GLN . 3.8 t80 -53.46 142.53 21.82 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 177.636 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.571 ' CG1' ' CD1' ' A' ' 18' ' ' ILE . 0.7 OUTLIER -135.06 154.87 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 120.788 -1.195 . . . . 0.0 109.653 -178.857 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.497 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 9.5 t-160 -150.23 152.55 34.76 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -80.05 27.49 0.31 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.936 -1.102 . . . . 0.0 109.956 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.63 -43.84 2.88 Favored 'General case' 0 C--N 1.308 -1.209 0 O-C-N 120.946 -1.096 . . . . 0.0 108.661 179.759 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.5 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -95.67 -49.36 5.4 Favored 'General case' 0 N--CA 1.493 1.721 0 CA-C-O 121.92 0.867 . . . . 0.0 108.973 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.547 ' CD1' ' CG1' ' A' ' 63' ' ' VAL . 6.0 mm . . . . . 0 N--CA 1.488 1.444 0 O-C-N 121.91 -0.494 . . . . 0.0 110.381 -178.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.399 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.506 ' HB ' HG13 ' A' ' 63' ' ' VAL . 10.4 m -129.6 164.06 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 C-N-CA 117.881 -1.527 . . . . 0.0 111.706 -178.036 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.404 ' HA ' ' HA ' ' A' ' 3' ' ' GLU . 2.1 p -116.35 133.78 55.63 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 178.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.642 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 6.5 p90 -153.55 178.31 9.97 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.093 -1.004 . . . . 0.0 109.782 -179.198 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.6 93.52 4.07 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 179.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.64 ' CD1' ' CG2' ' A' ' 26' ' ' VAL . 14.6 mt -61.92 125.49 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.962 -1.086 . . . . 0.0 109.611 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.538 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.4 m -106.58 -176.07 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 178.571 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -124.06 113.57 18.57 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.052 -1.03 . . . . 0.0 109.569 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.36 170.91 16.5 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.786 -1.726 . . . . 0.0 108.786 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -37.83 -52.08 1.3 Allowed 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.331 -1.099 . . . . 0.0 113.386 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 11.3 mtp180 -76.65 22.38 0.18 Allowed 'General case' 0 N--CA 1.501 2.089 0 O-C-N 119.593 -1.942 . . . . 0.0 112.411 -177.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.26 179.43 31.29 Favored Glycine 0 N--CA 1.494 2.536 0 O-C-N 120.471 -1.393 . . . . 0.0 110.65 179.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.538 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.7 Cg_endo -69.09 152.23 72.81 Favored 'Trans proline' 0 C--N 1.32 -0.932 0 C-N-CA 122.135 1.89 . . . . 0.0 110.205 178.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.462 ' NE2' ' HB2' ' A' ' 27' ' ' PHE . 0.8 OUTLIER -166.43 149.44 7.03 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 120.959 -1.088 . . . . 0.0 111.697 -179.772 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.593 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -80.3 154.04 28.07 Favored 'General case' 0 N--CA 1.495 1.783 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 177.06 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.5 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.74 -39.53 0.79 Allowed 'General case' 0 N--CA 1.509 2.514 0 O-C-N 120.41 -1.431 . . . . 0.0 111.687 -176.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -118.89 52.01 1.08 Allowed 'General case' 0 C--N 1.284 -2.265 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.577 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 21.1 t -68.19 158.25 5.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.626 -179.14 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.472 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.2 OUTLIER -148.51 175.45 11.14 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.671 -0.812 . . . . 0.0 109.394 179.36 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 1.2 tttt . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.078 -1.013 . . . . 0.0 109.552 -179.955 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.662 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.94 0 CA-C-O 121.029 0.442 . . . . 0.0 110.001 . . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.454 ' HG3' ' O ' ' A' ' 47' ' ' VAL . 0.1 OUTLIER -114.76 150.87 34.69 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.043 -1.036 . . . . 0.0 110.555 -179.053 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.472 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -129.62 169.85 20.67 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 108.912 -1.675 . . . . 0.0 108.912 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.44 ' O ' ' C ' ' A' ' 6' ' ' VAL . 5.2 ttmt -141.76 125.71 17.19 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.978 -1.307 . . . . 0.0 110.564 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.52 HG11 ' N ' ' A' ' 8' ' ' TRP . 2.8 t -32.01 140.97 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 CA-C-O 123.333 1.54 . . . . 0.0 114.188 -179.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.453 ' HD3' ' O ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -108.51 -31.79 7.66 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 103.184 -2.895 . . . . 0.0 103.184 172.48 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.696 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 15.4 p-90 175.79 146.49 0.08 Allowed 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 105.9 -1.889 . . . . 0.0 105.9 177.656 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.566 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.2 OUTLIER -117.93 145.35 44.74 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.539 -1.351 . . . . 0.0 109.636 179.237 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.488 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.9 t-20 -131.85 41.26 3.29 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 10' ' ' ASN . 2.1 p -39.17 -45.87 1.39 Allowed 'General case' 0 C--N 1.295 -1.768 0 CA-C-O 121.445 0.641 . . . . 0.0 109.378 -179.542 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -61.96 -45.27 94.4 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.322 -0.861 . . . . 0.0 110.015 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.559 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 1.0 OUTLIER -69.9 0.2 6.25 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.361 -0.837 . . . . 0.0 109.866 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.52 ' O ' ' CD2' ' A' ' 29' ' ' HIS . . . 91.15 20.43 38.92 Favored Glycine 0 N--CA 1.488 2.121 0 O-C-N 121.174 -0.954 . . . . 0.0 111.569 179.105 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.559 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 16.6 p90 -176.87 165.27 2.44 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 119.81 1.805 . . . . 0.0 111.532 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.566 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -150.2 141.79 9.09 Favored Glycine 0 N--CA 1.497 2.725 0 N-CA-C 107.172 -2.371 . . . . 0.0 107.172 179.401 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.696 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.3 m-85 -109.12 139.13 44.44 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.088 -1.83 . . . . 0.0 110.885 -178.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.54 HD12 ' CG2' ' A' ' 47' ' ' VAL . 1.0 OUTLIER -106.63 146.9 12.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 N-CA-C 105.665 -1.976 . . . . 0.0 105.665 177.322 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.512 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 15.1 tt0 -121.07 135.13 55.26 Favored 'General case' 0 C--N 1.28 -2.439 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.009 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.418 HG11 ' HB2' ' A' ' 23' ' ' GLN . 7.5 p -138.49 140.81 38.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 C-N-CA 117.567 -1.653 . . . . 0.0 111.891 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.74 140.5 58.74 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.105 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.51 ' O ' ' NE2' ' A' ' 23' ' ' GLN . . . 86.97 -18.86 33.21 Favored Glycine 0 N--CA 1.486 2.013 0 N-CA-C 108.29 -1.924 . . . . 0.0 108.29 -178.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.51 ' NE2' ' O ' ' A' ' 22' ' ' GLY . 0.1 OUTLIER -135.95 -176.9 4.46 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 121.502 -0.999 . . . . 0.0 108.989 179.502 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -100.81 -166.0 1.27 Allowed 'General case' 0 C--N 1.298 -1.663 0 CA-C-O 121.881 0.848 . . . . 0.0 110.841 -178.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.52 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 5.9 p-10 -71.94 90.88 1.16 Allowed 'General case' 0 N--CA 1.489 1.499 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.568 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.613 ' CG1' ' HB1' ' A' ' 60' ' ' ALA . 2.3 t -50.16 125.44 3.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.107 0 O-C-N 120.711 -1.243 . . . . 0.0 111.832 178.681 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.626 ' CD2' ' CZ ' ' A' ' 17' ' ' PHE . 2.9 t80 -72.24 130.36 40.61 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 176.188 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.531 ' CG2' ' O ' ' A' ' 16' ' ' GLY . 2.6 m -146.6 130.75 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 120.248 -1.532 . . . . 0.0 110.703 -179.056 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.55 ' NE2' ' CE2' ' A' ' 30' ' ' PHE . 9.5 t-160 -98.99 166.74 11.13 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 178.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.55 ' CE2' ' NE2' ' A' ' 29' ' ' HIS . 53.0 p90 -83.82 32.44 0.48 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.795 -1.191 . . . . 0.0 110.135 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.1 m -119.12 -37.6 3.18 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.981 -1.075 . . . . 0.0 109.164 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.469 ' O ' ' O ' ' A' ' 63' ' ' VAL . . . -91.38 -37.34 13.28 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.25 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.582 ' CD1' ' N ' ' A' ' 33' ' ' ILE . 1.4 mp . . . . . 0 N--CA 1.486 1.373 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.54 ' CG2' HD12 ' A' ' 18' ' ' ILE . 35.1 m -132.39 164.33 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 120.893 -1.129 . . . . 0.0 110.311 -179.547 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -117.62 126.8 53.18 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.026 -1.046 . . . . 0.0 108.336 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.674 ' CE1' ' CG1' ' A' ' 51' ' ' ILE . 0.3 OUTLIER -149.13 179.66 7.72 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.011 -1.055 . . . . 0.0 110.392 -179.642 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -123.74 81.14 1.87 Allowed 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.674 ' CG1' ' CE1' ' A' ' 49' ' ' PHE . 15.1 mm -61.29 118.81 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 CA-C-O 122.051 0.929 . . . . 0.0 110.772 -178.543 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.519 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 17.5 m -98.42 -175.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 179.232 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.42 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 0.2 OUTLIER -123.66 116.05 22.44 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.9 -1.125 . . . . 0.0 109.64 -179.885 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.27 174.61 16.97 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.929 -1.668 . . . . 0.0 108.929 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -38.67 -52.85 1.66 Allowed 'General case' 0 N--CA 1.505 2.287 0 O-C-N 121.369 -1.077 . . . . 0.0 113.772 -178.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.505 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -77.84 22.56 0.27 Allowed 'General case' 0 N--CA 1.501 2.092 0 O-C-N 119.69 -1.881 . . . . 0.0 112.211 -177.983 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.95 -178.6 30.89 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.283 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.519 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -63.58 157.78 49.43 Favored 'Trans proline' 0 C--N 1.318 -1.051 0 C-N-CA 121.991 1.794 . . . . 0.0 110.188 179.12 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.491 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 1.2 mt-30 -165.07 147.44 8.03 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 120.99 -1.069 . . . . 0.0 110.575 -179.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.617 ' CB ' ' CG2' ' A' ' 63' ' ' VAL . . . -82.89 158.6 22.6 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 177.701 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.446 ' O ' ' HB2' ' A' ' 32' ' ' ALA . . . -132.9 -47.29 0.86 Allowed 'General case' 0 N--CA 1.501 2.098 0 O-C-N 120.436 -1.415 . . . . 0.0 111.07 -177.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -121.27 55.24 1.08 Allowed 'General case' 0 C--N 1.288 -2.099 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 179.219 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.617 ' CG2' ' CB ' ' A' ' 60' ' ' ALA . 22.9 t -67.47 161.44 3.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-O 121.667 0.746 . . . . 0.0 110.111 -178.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.477 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -141.08 160.63 39.68 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 119.76 -0.776 . . . . 0.0 108.93 178.668 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 19.5 ptmt . . . . . 0 N--CA 1.494 1.761 0 O-C-N 120.927 -1.108 . . . . 0.0 109.857 -179.642 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.653 ' CD2' ' CE1' ' A' ' 49' ' ' PHE . 0.3 OUTLIER . . . . . 0 N--CA 1.488 1.444 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 . . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.537 ' N ' HD22 ' A' ' 2' ' ' LEU . 0.2 OUTLIER -113.37 162.02 16.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.18 -0.95 . . . . 0.0 110.045 -179.438 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.404 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -143.22 159.17 27.43 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.384 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.407 ' O ' ' C ' ' A' ' 6' ' ' VAL . 8.0 mtpt -133.66 112.46 11.45 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.304 -1.115 . . . . 0.0 109.111 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.506 HG12 ' N ' ' A' ' 8' ' ' TRP . 3.6 t -42.45 139.36 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 122.796 1.284 . . . . 0.0 112.555 -178.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.444 ' HG3' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -98.43 -31.4 12.02 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 103.266 -2.864 . . . . 0.0 103.266 172.91 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.706 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 21.0 p-90 178.11 143.9 0.11 Allowed 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 177.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.563 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.9 OUTLIER -119.56 140.47 50.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.73 -1.231 . . . . 0.0 109.522 179.566 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.479 ' OD1' ' CE ' ' A' ' 13' ' ' LYS . 1.5 t-20 -131.43 38.13 3.63 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.454 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.2 p -37.36 -49.76 1.01 Allowed 'General case' 0 N--CA 1.492 1.629 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.886 -179.395 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -61.37 -44.66 96.78 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.284 -0.885 . . . . 0.0 109.91 -179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.479 ' CE ' ' OD1' ' A' ' 10' ' ' ASN . 0.4 OUTLIER -69.21 0.08 5.33 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.371 -0.831 . . . . 0.0 110.267 -179.554 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.508 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 102.46 12.09 34.09 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 119.935 -1.126 . . . . 0.0 112.635 178.329 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.649 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.0 OUTLIER 177.03 166.02 0.53 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-N 120.444 2.122 . . . . 0.0 112.215 179.543 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.563 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -146.74 137.03 6.49 Favored Glycine 0 N--CA 1.499 2.854 0 N-CA-C 106.671 -2.572 . . . . 0.0 106.671 179.342 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.706 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.9 m-30 -106.96 139.16 41.8 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.054 -1.85 . . . . 0.0 110.763 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.559 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 2.5 mt -108.21 151.65 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 177.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.486 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 9.1 tt0 -127.22 133.57 50.23 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.719 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.538 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 11.5 p -136.38 140.06 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 C-N-CA 117.792 -1.563 . . . . 0.0 111.772 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.8 140.13 58.38 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.121 179.771 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.42 -17.17 40.37 Favored Glycine 0 N--CA 1.486 1.967 0 N-CA-C 108.469 -1.853 . . . . 0.0 108.469 -178.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.538 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 3.1 mm-40 -136.85 -174.35 3.7 Favored 'General case' 0 N--CA 1.482 1.163 0 O-C-N 121.324 -1.104 . . . . 0.0 108.652 179.604 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.89 -165.93 1.26 Allowed 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.168 0.985 . . . . 0.0 110.657 -179.025 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.559 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 8.1 p-10 -72.09 106.96 4.53 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.011 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.614 ' CG2' ' CG1' ' A' ' 51' ' ' ILE . 2.4 t -71.17 117.36 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 120.483 -1.386 . . . . 0.0 111.298 178.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.613 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 3.8 t80 -67.47 130.6 43.58 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.497 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.549 ' CG1' HD11 ' A' ' 18' ' ' ILE . 2.4 m -139.11 131.8 37.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 120.476 -1.39 . . . . 0.0 110.715 -179.799 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.544 ' CE1' ' CE1' ' A' ' 30' ' ' PHE . 6.7 t60 -99.92 164.25 12.1 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.567 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 46.1 p90 -82.84 40.94 0.71 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.962 -1.086 . . . . 0.0 109.814 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 94.1 p -129.92 -38.56 1.45 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.858 -1.151 . . . . 0.0 109.711 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -92.78 -41.43 10.11 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 179.518 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.535 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.7 mp . . . . . 0 C--N 1.307 -1.28 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.43 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.532 ' CG2' HD12 ' A' ' 18' ' ' ILE . 33.4 m -116.9 157.72 17.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.886 -1.134 . . . . 0.0 109.909 179.745 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 89.7 p -117.48 122.2 43.09 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.282 -0.887 . . . . 0.0 108.787 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.653 ' CE1' ' CD2' ' A' ' 2' ' ' LEU . 10.4 p90 -153.97 -177.51 6.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.02 -1.05 . . . . 0.0 109.726 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -128.15 102.24 6.62 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.083 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.614 ' CG1' ' CG2' ' A' ' 26' ' ' VAL . 4.9 mt -62.76 144.56 14.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 120.816 -1.177 . . . . 0.0 111.126 -179.385 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.522 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.7 m -131.2 -173.18 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 179.1 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -122.25 114.68 21.15 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.786 -1.196 . . . . 0.0 109.776 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.87 172.66 16.49 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -38.66 -53.72 1.61 Allowed 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.21 -1.171 . . . . 0.0 113.006 -178.659 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.462 ' NH1' ' CG ' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -68.77 -21.24 64.36 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 119.647 -1.908 . . . . 0.0 112.778 -177.85 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 138.46 -170.84 23.73 Favored Glycine 0 N--CA 1.491 2.353 0 O-C-N 120.345 -1.472 . . . . 0.0 109.618 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.8 Cg_endo -62.26 122.88 11.51 Favored 'Trans proline' 0 C--N 1.321 -0.877 0 C-N-CA 121.803 1.668 . . . . 0.0 109.875 178.767 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.454 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 4.5 mt-30 -144.2 148.45 34.97 Favored 'General case' 0 N--CA 1.5 2.07 0 O-C-N 121.189 -0.944 . . . . 0.0 111.097 -179.024 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.588 ' HB3' ' CD1' ' A' ' 49' ' ' PHE . . . -80.48 166.75 20.91 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.531 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.99 -43.32 0.73 Allowed 'General case' 0 N--CA 1.507 2.391 0 O-C-N 120.286 -1.509 . . . . 0.0 112.012 -177.123 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 31.6 t30 -119.66 51.88 1.14 Allowed 'General case' 0 C--N 1.287 -2.129 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.564 ' CG2' ' HB2' ' A' ' 60' ' ' ALA . 17.7 t -66.91 157.31 6.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.53 -179.351 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.7 176.69 9.03 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 178.534 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.035 -1.04 . . . . 0.0 109.318 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.66 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.885 0 CA-C-O 120.972 0.415 . . . . 0.0 109.981 . . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.486 ' HG2' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -112.74 158.79 19.65 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.032 -1.042 . . . . 0.0 110.929 -178.102 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.41 ' HA2' ' HB ' ' A' ' 20' ' ' VAL . . . -136.55 160.36 24.76 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.644 -1.782 . . . . 0.0 108.644 179.492 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.9 mtpt -134.45 116.27 14.94 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.083 -1.245 . . . . 0.0 110.618 -179.42 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.526 HG12 ' N ' ' A' ' 8' ' ' TRP . 2.8 t -32.9 141.17 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 CA-C-O 123.015 1.388 . . . . 0.0 113.635 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 3.0 tmtt? -104.07 -32.18 9.32 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 102.979 -2.971 . . . . 0.0 102.979 172.221 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.696 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.0 p-90 175.56 147.56 0.09 Allowed 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 177.716 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.536 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.6 OUTLIER -114.47 140.09 49.0 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 120.441 -1.412 . . . . 0.0 109.305 178.994 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.565 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 4.9 m120 -122.77 46.78 2.08 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.1 OUTLIER -43.76 -35.34 1.83 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 -179.315 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -59.7 -48.86 79.99 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.467 -0.771 . . . . 0.0 110.009 179.769 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.52 ' O ' ' CE2' ' A' ' 15' ' ' PHE . 13.2 mptt -76.74 11.8 1.56 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.26 -0.9 . . . . 0.0 110.201 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.451 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 84.6 20.81 57.67 Favored Glycine 0 N--CA 1.488 2.118 0 O-C-N 121.093 -1.004 . . . . 0.0 111.661 178.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.52 ' CE2' ' O ' ' A' ' 13' ' ' LYS . 36.1 p90 179.6 167.05 1.15 Allowed 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 119.983 1.892 . . . . 0.0 112.031 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.536 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -142.46 149.31 21.14 Favored Glycine 0 N--CA 1.498 2.784 0 N-CA-C 106.937 -2.465 . . . . 0.0 106.937 178.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.696 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -106.26 143.58 34.18 Favored 'General case' 0 N--CA 1.484 1.269 0 CA-C-N 119.836 1.818 . . . . 0.0 110.302 -178.4 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.597 ' CD1' ' CG1' ' A' ' 28' ' ' VAL . 0.9 OUTLIER -106.61 161.49 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 178.916 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.572 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 2.9 tp10 -142.66 130.02 21.11 Favored 'General case' 0 C--N 1.29 -2.018 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 177.781 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.554 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 13.0 p -135.99 140.56 43.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 117.485 -1.686 . . . . 0.0 111.729 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -65.36 140.62 58.67 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.052 179.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.22 -12.85 48.51 Favored Glycine 0 N--CA 1.487 2.049 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -178.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.554 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 6.1 mm-40 -140.75 -176.57 4.71 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 121.345 -1.091 . . . . 0.0 108.322 179.612 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.49 -165.79 1.25 Allowed 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.18 -0.95 . . . . 0.0 110.806 -179.091 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.579 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 11.6 p-10 -72.57 129.9 39.37 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.05 179.339 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.619 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.5 t -98.55 121.4 49.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 120.802 -1.186 . . . . 0.0 110.81 178.252 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.466 ' HB2' ' HG2' ' A' ' 59' ' ' GLN . 23.0 t80 -58.11 137.28 57.08 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.079 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.597 ' CG1' ' CD1' ' A' ' 18' ' ' ILE . 1.2 m -131.14 115.65 30.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 120.781 -1.199 . . . . 0.0 110.348 -178.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 7.8 t-160 -104.66 148.9 26.05 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.521 ' CD1' ' C ' ' A' ' 30' ' ' PHE . 0.0 OUTLIER -81.16 31.63 0.33 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.816 -1.177 . . . . 0.0 110.486 -179.68 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -125.35 -35.21 2.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.13 -0.981 . . . . 0.0 108.544 178.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.512 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.37 -35.68 14.26 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.817 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.53 HD13 ' CB ' ' A' ' 28' ' ' VAL . 63.0 mt . . . . . 0 N--CA 1.483 1.18 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.473 ' CB ' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.487 1.407 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.581 ' CG2' HD12 ' A' ' 18' ' ' ILE . 28.8 m -119.66 163.9 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.879 -1.138 . . . . 0.0 110.469 -179.165 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.1 p -115.55 126.03 53.73 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.064 -1.023 . . . . 0.0 108.294 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.66 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 8.2 p90 -153.28 -179.41 7.7 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.043 -1.035 . . . . 0.0 109.83 -179.325 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -124.29 92.64 3.71 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.31 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.64 HG13 ' CE1' ' A' ' 49' ' ' PHE . 17.0 mt -61.49 132.79 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 CA-C-O 122.271 1.034 . . . . 0.0 110.338 -179.161 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.51 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.2 m -116.44 -174.46 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 178.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.423 ' CD ' ' N ' ' A' ' 53' ' ' GLU . 0.4 OUTLIER -123.72 114.33 19.81 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.001 -1.062 . . . . 0.0 109.331 179.79 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.72 175.57 18.65 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -37.92 -52.63 1.35 Allowed 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.499 -1.001 . . . . 0.0 113.548 -178.508 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.3 mmm180 -76.07 23.09 0.14 Allowed 'General case' 0 N--CA 1.5 2.036 0 O-C-N 119.807 -1.808 . . . . 0.0 112.137 -178.216 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.28 -174.78 35.62 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.51 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.2 Cg_endo -65.53 150.19 86.91 Favored 'Trans proline' 0 C--N 1.319 -0.997 0 C-N-CA 121.636 1.558 . . . . 0.0 109.791 178.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.466 ' HG2' ' HB2' ' A' ' 27' ' ' PHE . 1.4 mt-30 -165.58 150.31 8.69 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 120.97 -1.082 . . . . 0.0 111.521 -179.433 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.581 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -82.76 157.75 23.12 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 177.613 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.512 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.92 -41.49 0.75 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 120.52 -1.362 . . . . 0.0 111.578 -176.769 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.1 m-20 -119.9 57.18 0.93 Allowed 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 179.618 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.552 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 18.6 t -72.43 166.3 2.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.103 -178.629 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -148.1 176.27 10.34 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.669 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.46 ' O ' ' HG2' ' A' ' 65' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.636 0 O-C-N 121.052 -1.03 . . . . 0.0 109.672 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.626 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.796 0 CA-C-O 121.216 0.531 . . . . 0.0 110.119 . . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.467 ' HG2' ' O ' ' A' ' 47' ' ' VAL . 0.3 OUTLIER -113.24 155.62 24.75 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.207 -0.933 . . . . 0.0 110.007 -179.175 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.411 ' C ' ' HG2' ' A' ' 5' ' ' LYS . . . -133.28 161.95 24.25 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.436 ' O ' ' C ' ' A' ' 6' ' ' VAL . 4.0 mttp -130.24 115.5 17.06 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.209 -1.171 . . . . 0.0 109.887 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.491 HG12 ' N ' ' A' ' 8' ' ' TRP . 3.4 t -36.87 140.44 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 122.869 1.319 . . . . 0.0 112.758 -179.577 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.5 tmtt? -99.41 -31.81 11.47 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 103.042 -2.947 . . . . 0.0 103.042 172.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.701 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 21.5 p-90 176.65 144.14 0.08 Allowed 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 177.741 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.497 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.7 OUTLIER -119.06 141.48 48.7 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.48 -1.387 . . . . 0.0 109.435 179.531 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.478 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 0.1 OUTLIER -130.93 37.72 3.75 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.673 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.45 ' C ' ' O ' ' A' ' 10' ' ' ASN . 15.3 p -37.79 -47.41 1.01 Allowed 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.493 0.663 . . . . 0.0 109.297 -179.682 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -61.12 -46.36 90.92 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.432 -0.792 . . . . 0.0 109.877 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.46 ' HB2' ' CG ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -69.26 0.49 4.84 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.403 -0.811 . . . . 0.0 110.256 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.411 ' O ' ' CB ' ' A' ' 15' ' ' PHE . . . 99.38 15.48 32.33 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 120.001 -1.095 . . . . 0.0 112.399 178.624 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.436 ' O ' ' C ' ' A' ' 10' ' ' ASN . 1.0 OUTLIER 175.53 163.09 0.3 Allowed 'General case' 0 N--CA 1.497 1.917 0 CA-C-N 120.299 2.05 . . . . 0.0 111.849 179.561 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.547 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -146.31 139.99 8.49 Favored Glycine 0 N--CA 1.498 2.832 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.701 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.4 m-85 -108.77 144.11 37.03 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.209 -1.759 . . . . 0.0 110.422 -178.646 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.589 ' CG2' ' N ' ' A' ' 19' ' ' GLU . 0.5 OUTLIER -106.31 165.42 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 178.471 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.589 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 1.9 tt0 -141.8 127.77 19.48 Favored 'General case' 0 C--N 1.291 -1.967 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.155 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.538 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 11.8 p -134.2 141.47 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 C-N-CA 117.446 -1.701 . . . . 0.0 111.851 -179.463 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -63.8 140.14 58.84 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.259 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 82.21 -12.62 43.54 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 -179.118 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.538 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -137.57 -176.33 4.37 Favored 'General case' 0 N--CA 1.484 1.247 0 O-C-N 121.303 -1.116 . . . . 0.0 108.669 179.696 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -100.29 -166.1 1.29 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.271 -0.893 . . . . 0.0 110.505 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.586 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 34.7 p-10 -71.68 122.21 20.2 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.849 179.366 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.61 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.3 t -84.76 104.46 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 120.592 -1.317 . . . . 0.0 111.687 178.733 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.62 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 2.1 t80 -55.44 135.1 50.71 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 178.244 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.576 ' HA ' HD12 ' A' ' 33' ' ' ILE . 2.3 m -150.19 127.26 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 118.067 -1.453 . . . . 0.0 111.641 -179.336 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.624 ' NE2' ' CE1' ' A' ' 30' ' ' PHE . 7.7 t-160 -99.32 162.12 13.22 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 178.659 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.624 ' CE1' ' NE2' ' A' ' 29' ' ' HIS . 52.6 p90 -81.26 39.34 0.51 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.498 -1.376 . . . . 0.0 110.435 -179.432 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.7 t -123.48 -46.5 2.02 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.698 -1.251 . . . . 0.0 109.564 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.585 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.0 -40.56 11.59 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.328 -0.857 . . . . 0.0 108.74 179.57 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.618 ' CG1' ' HB ' ' A' ' 63' ' ' VAL . 2.9 mp . . . . . 0 C--N 1.3 -1.581 0 CA-C-O 121.703 0.763 . . . . 0.0 109.262 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.495 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.467 ' O ' ' HG2' ' A' ' 3' ' ' GLU . 35.9 m -119.32 160.37 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.851 -1.155 . . . . 0.0 109.945 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.441 ' O ' HG11 ' A' ' 63' ' ' VAL . 49.0 p -115.14 132.0 56.74 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 120.968 -1.083 . . . . 0.0 108.495 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.626 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 10.5 p90 -164.28 -176.56 4.49 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.973 -1.079 . . . . 0.0 109.988 -179.439 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.07 98.32 4.89 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.19 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.61 ' CD1' ' CG2' ' A' ' 26' ' ' VAL . 7.2 mt -62.67 141.3 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 120.827 -1.171 . . . . 0.0 110.873 -179.222 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.501 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 8.7 m -124.76 -175.35 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.487 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -123.08 115.26 21.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.935 -1.103 . . . . 0.0 109.772 -179.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.52 168.93 18.53 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 37.4 m-20 -37.84 -52.37 1.31 Allowed 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.329 -1.101 . . . . 0.0 113.634 -178.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.96 22.31 0.19 Allowed 'General case' 0 N--CA 1.5 2.062 0 O-C-N 119.777 -1.827 . . . . 0.0 112.414 -177.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.95 -179.39 28.72 Favored Glycine 0 N--CA 1.494 2.501 0 O-C-N 120.393 -1.442 . . . . 0.0 110.588 179.312 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.501 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.8 Cg_endo -68.77 142.23 51.88 Favored 'Trans proline' 0 C--N 1.321 -0.908 0 C-N-CA 122.225 1.95 . . . . 0.0 110.085 178.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.527 ' HG2' ' CB ' ' A' ' 27' ' ' PHE . 22.5 mt-30 -156.52 149.36 23.87 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.048 -1.032 . . . . 0.0 111.558 -179.568 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.566 ' HB3' ' CG2' ' A' ' 63' ' ' VAL . . . -80.41 161.63 24.86 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.585 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.92 -41.57 0.75 Allowed 'General case' 0 N--CA 1.508 2.426 0 O-C-N 120.458 -1.401 . . . . 0.0 111.972 -176.358 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.432 ' OD1' ' O ' ' A' ' 62' ' ' ASN . 35.1 t-20 -120.57 50.75 1.29 Allowed 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.618 ' HB ' ' CG1' ' A' ' 33' ' ' ILE . 14.9 t -68.18 171.33 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-O 121.814 0.816 . . . . 0.0 109.501 -179.532 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -153.62 172.19 17.61 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 177.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.3 tmtt? . . . . . 0 N--CA 1.491 1.599 0 O-C-N 120.696 -1.252 . . . . 0.0 109.379 179.979 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.674 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.499 1.994 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 . . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.498 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.4 OUTLIER -117.65 135.32 54.07 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 120.817 -1.177 . . . . 0.0 110.794 -179.263 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.403 ' C ' ' HG2' ' A' ' 5' ' ' LYS . . . -103.2 173.68 22.48 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.825 -1.71 . . . . 0.0 108.825 178.789 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.403 ' HG2' ' C ' ' A' ' 4' ' ' GLY . 3.4 mtpp -137.37 112.77 9.31 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 120.781 -1.423 . . . . 0.0 109.955 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.5 t -47.88 131.77 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 CA-C-O 122.688 1.233 . . . . 0.0 112.645 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 2.0 tttt -93.12 -30.39 15.28 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 103.213 -2.884 . . . . 0.0 103.213 173.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.718 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 25.1 p-90 175.28 146.57 0.08 Allowed 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 106.617 -1.624 . . . . 0.0 106.617 178.452 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.598 ' CZ ' HG22 ' A' ' 28' ' ' VAL . 0.5 OUTLIER -112.45 147.27 36.85 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.724 -1.235 . . . . 0.0 108.773 178.517 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.556 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 10.8 m-20 -130.05 42.84 3.22 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.203 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 10' ' ' ASN . 54.1 p -40.89 -40.0 1.27 Allowed 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -179.676 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.0 mm-40 -59.86 -49.33 78.11 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.665 -0.647 . . . . 0.0 110.487 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.504 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 1.4 mptp? -74.5 6.09 4.1 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.097 -1.002 . . . . 0.0 110.038 -179.798 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.529 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 90.76 20.33 40.62 Favored Glycine 0 N--CA 1.49 2.246 0 O-C-N 121.133 -0.979 . . . . 0.0 112.066 178.582 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.517 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 39.8 p90 178.9 170.29 0.88 Allowed 'General case' 0 N--CA 1.499 1.994 0 CA-C-N 120.0 1.9 . . . . 0.0 111.762 179.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.52 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -145.3 152.34 24.42 Favored Glycine 0 N--CA 1.499 2.891 0 N-CA-C 106.864 -2.495 . . . . 0.0 106.864 179.192 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.718 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.6 m-85 -113.14 135.36 53.89 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 120.28 2.04 . . . . 0.0 110.216 -178.786 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.562 ' CD1' ' CG1' ' A' ' 28' ' ' VAL . 2.8 mt -108.61 146.37 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.37 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.514 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 27.6 tt0 -125.52 135.87 52.73 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 177.648 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.48 HG11 ' CB ' ' A' ' 23' ' ' GLN . 10.9 p -137.37 139.64 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 C-N-CA 117.675 -1.61 . . . . 0.0 111.905 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -64.17 140.39 58.86 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.088 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 84.08 -15.06 40.69 Favored Glycine 0 N--CA 1.485 1.953 0 N-CA-C 108.684 -1.767 . . . . 0.0 108.684 -178.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.48 ' CB ' HG11 ' A' ' 20' ' ' VAL . 0.2 OUTLIER -136.95 -174.67 3.79 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 121.299 -1.118 . . . . 0.0 108.682 179.46 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.421 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 4.5 m-20 -100.79 -166.4 1.31 Allowed 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 122.073 0.94 . . . . 0.0 110.71 -179.171 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.522 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 8.1 p-10 -72.3 101.83 2.97 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.92 179.09 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.606 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.6 t -68.15 126.28 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 120.252 -1.53 . . . . 0.0 110.124 178.514 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.408 ' HB3' ' HG2' ' A' ' 59' ' ' GLN . 16.6 t80 -65.46 142.09 58.28 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 177.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.598 HG22 ' CZ ' ' A' ' 9' ' ' PHE . 1.4 m -134.09 156.73 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.735 -1.228 . . . . 0.0 110.345 -178.598 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.529 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 9.1 t60 -138.42 157.92 45.27 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.093 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.453 ' CD1' ' O ' ' A' ' 30' ' ' PHE . 53.1 p90 -85.02 32.74 0.53 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.145 -0.972 . . . . 0.0 109.769 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.4 p -127.91 -35.48 2.07 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.832 -1.168 . . . . 0.0 109.773 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.508 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -93.04 -50.16 5.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.232 -0.917 . . . . 0.0 108.988 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.539 ' CD1' ' HB ' ' A' ' 28' ' ' VAL . 41.0 mt . . . . . 0 C--N 1.305 -1.348 0 CA-C-O 121.819 0.819 . . . . 0.0 109.047 -179.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 121.826 0.822 . . . . 0.0 110.055 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 18.6 m -122.74 165.91 18.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 121.262 -0.899 . . . . 0.0 108.687 179.091 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -117.68 120.23 37.35 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.854 -1.154 . . . . 0.0 109.163 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.674 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 5.6 p90 -149.46 -178.17 6.27 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.165 -0.959 . . . . 0.0 109.978 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.495 ' CG ' ' O ' ' A' ' 50' ' ' GLU . 0.3 OUTLIER -126.47 95.11 4.25 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.376 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.641 HG13 ' CE1' ' A' ' 49' ' ' PHE . 11.3 mt -61.91 140.1 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 CA-C-O 122.513 1.149 . . . . 0.0 111.175 -178.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.468 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 12.0 m -124.57 -177.17 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 106.064 -1.828 . . . . 0.0 106.064 179.166 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -123.32 111.95 17.02 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 118.885 -1.126 . . . . 0.0 109.642 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -116.84 169.86 13.21 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 73.1 m-20 -38.23 -52.68 1.48 Allowed 'General case' 0 N--CA 1.504 2.268 0 O-C-N 121.302 -1.116 . . . . 0.0 113.723 -178.575 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -78.1 22.02 0.32 Allowed 'General case' 0 N--CA 1.5 2.074 0 O-C-N 119.62 -1.925 . . . . 0.0 112.524 -177.564 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.65 -178.02 24.89 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 119.17 -1.491 . . . . 0.0 110.628 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.468 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.3 Cg_endo -66.1 153.02 79.75 Favored 'Trans proline' 0 C--N 1.321 -0.905 0 C-N-CA 122.277 1.984 . . . . 0.0 110.529 179.21 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.408 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 0.2 OUTLIER -165.85 147.52 7.09 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.419 -0.8 . . . . 0.0 110.631 -179.758 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.571 ' CB ' HG12 ' A' ' 26' ' ' VAL . . . -83.07 163.9 20.63 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 177.205 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.508 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.17 -44.05 0.78 Allowed 'General case' 0 N--CA 1.507 2.387 0 O-C-N 120.201 -1.562 . . . . 0.0 111.909 -176.869 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -119.77 52.11 1.13 Allowed 'General case' 0 C--N 1.287 -2.148 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.564 ' CG2' ' HB2' ' A' ' 60' ' ' ALA . 20.8 t -66.09 163.1 2.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-O 121.74 0.781 . . . . 0.0 110.554 -179.035 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.478 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.2 OUTLIER -145.06 179.29 7.46 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 177.9 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.493 1.714 0 O-C-N 120.842 -1.161 . . . . 0.0 109.657 -179.837 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.637 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.883 0 CA-C-O 121.304 0.573 . . . . 0.0 110.301 . . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.483 ' HG2' ' O ' ' A' ' 47' ' ' VAL . 2.2 tt0 -113.74 144.68 42.56 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.303 -0.873 . . . . 0.0 110.174 -179.253 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.457 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -112.7 161.52 12.67 Favored Glycine 0 N--CA 1.483 1.811 0 N-CA-C 108.514 -1.835 . . . . 0.0 108.514 178.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.448 ' O ' ' C ' ' A' ' 6' ' ' VAL . 9.3 mttm -131.74 113.76 13.93 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.187 -1.184 . . . . 0.0 109.754 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.537 HG11 ' N ' ' A' ' 8' ' ' TRP . 2.6 t -33.72 139.62 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 CA-C-O 122.91 1.338 . . . . 0.0 113.636 -179.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.443 ' HG2' ' CB ' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -103.92 -32.07 9.45 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 103.108 -2.923 . . . . 0.0 103.108 172.183 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.704 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 18.9 p-90 174.82 147.38 0.07 Allowed 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 106.315 -1.735 . . . . 0.0 106.315 177.803 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.558 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.4 OUTLIER -113.52 145.32 41.39 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 120.263 -1.523 . . . . 0.0 109.325 178.95 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.557 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 49.7 m-20 -130.11 41.84 3.36 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 178.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.439 ' C ' ' O ' ' A' ' 10' ' ' ASN . 62.0 p -40.98 -43.65 2.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.671 -0.643 . . . . 0.0 109.518 -179.16 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 60.4 mm-40 -61.62 -45.41 94.21 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.307 -0.871 . . . . 0.0 109.718 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.509 ' N ' ' CD ' ' A' ' 13' ' ' LYS . 0.2 OUTLIER -72.39 4.73 3.47 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.531 -0.731 . . . . 0.0 110.469 -179.66 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.486 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 93.34 19.88 34.23 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 120.053 -1.07 . . . . 0.0 112.236 178.372 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.514 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 0.8 OUTLIER 169.87 171.69 0.06 Allowed 'General case' 0 N--CA 1.498 1.958 0 CA-C-N 120.074 1.937 . . . . 0.0 111.641 179.401 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.558 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -143.6 151.85 23.66 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 106.889 -2.484 . . . . 0.0 106.889 178.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.704 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.6 m-85 -112.65 140.6 47.27 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 119.854 -1.968 . . . . 0.0 110.152 -178.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.587 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 1.2 mt -106.86 155.95 7.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 179.385 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.484 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 13.0 tt0 -132.31 133.15 43.71 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.587 ' CG1' ' CB ' ' A' ' 23' ' ' GLN . 14.8 p -132.94 141.04 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 C-N-CA 117.879 -1.528 . . . . 0.0 111.666 -179.606 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -64.52 140.39 58.86 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.4 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.57 -6.22 47.18 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.587 ' CB ' ' CG1' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -140.54 -175.57 4.32 Favored 'General case' 0 C--N 1.309 -1.159 0 O-C-N 121.08 -1.247 . . . . 0.0 108.706 179.789 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.41 -166.97 1.38 Allowed 'General case' 0 C--N 1.297 -1.705 0 CA-C-O 122.151 0.977 . . . . 0.0 110.866 -179.032 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.587 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 5.6 p-10 -71.92 113.02 8.52 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.31 179.486 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.606 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.5 t -79.41 114.82 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 120.463 -1.398 . . . . 0.0 110.742 178.49 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.484 ' HB2' ' HG2' ' A' ' 59' ' ' GLN . 31.5 t80 -49.62 146.24 4.39 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 178.403 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.549 HG22 ' CZ ' ' A' ' 9' ' ' PHE . 1.2 m -139.21 157.57 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 O-C-N 120.801 -1.187 . . . . 0.0 109.24 -179.443 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.486 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 5.5 t60 -158.42 155.15 28.1 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.406 ' N ' ' CD2' ' A' ' 29' ' ' HIS . 33.5 p90 -79.58 26.34 0.31 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.931 -1.106 . . . . 0.0 110.235 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.3 p -116.35 -47.82 2.73 Favored 'General case' 0 N--CA 1.483 1.218 0 O-C-N 120.839 -1.163 . . . . 0.0 108.909 179.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.49 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -92.51 -47.53 7.09 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.531 HD12 ' CB ' ' A' ' 63' ' ' VAL . 10.1 mm . . . . . 0 N--CA 1.486 1.349 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.54 ' CG2' HD12 ' A' ' 18' ' ' ILE . 33.3 m -117.92 162.68 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 120.819 -1.176 . . . . 0.0 111.026 -178.778 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -118.49 117.7 29.71 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.615 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.637 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 6.0 p90 -148.76 -177.73 5.95 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.093 -1.004 . . . . 0.0 110.008 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -128.91 96.87 4.47 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 179.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.62 HG13 ' CE1' ' A' ' 49' ' ' PHE . 10.7 mt -61.63 139.22 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.874 -1.141 . . . . 0.0 110.387 -179.218 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.5 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 2.7 m -127.19 -172.48 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -124.0 118.01 26.04 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.985 -1.072 . . . . 0.0 109.489 179.561 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -129.27 174.67 19.18 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.139 -1.584 . . . . 0.0 109.139 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -38.81 -52.99 1.72 Allowed 'General case' 0 N--CA 1.506 2.329 0 O-C-N 121.414 -1.051 . . . . 0.0 113.67 -178.565 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 29.0 mtp180 -77.91 22.45 0.28 Allowed 'General case' 0 N--CA 1.497 1.924 0 O-C-N 119.688 -1.883 . . . . 0.0 112.217 -177.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.54 -177.72 30.92 Favored Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.364 -1.398 . . . . 0.0 110.285 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.5 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -66.09 146.66 82.65 Favored 'Trans proline' 0 C--N 1.319 -0.981 0 C-N-CA 122.069 1.846 . . . . 0.0 110.065 178.948 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.484 ' HG2' ' HB2' ' A' ' 27' ' ' PHE . 0.4 OUTLIER -165.63 153.8 11.18 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.105 -0.997 . . . . 0.0 111.601 -179.35 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.57 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -82.12 159.45 23.36 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 177.107 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.49 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -135.28 -41.03 0.73 Allowed 'General case' 0 N--CA 1.508 2.432 0 O-C-N 120.288 -1.508 . . . . 0.0 111.97 -176.36 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.0 p30 -119.39 51.89 1.12 Allowed 'General case' 0 C--N 1.283 -2.294 0 N-CA-C 106.689 -1.596 . . . . 0.0 106.689 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.564 ' CG2' ' HB3' ' A' ' 49' ' ' PHE . 19.2 t -69.52 156.49 7.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.556 -179.13 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.442 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.9 OUTLIER -136.32 167.36 21.46 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.684 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 17.4 mttp . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.002 -1.061 . . . . 0.0 109.518 -179.84 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.612 HD13 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.922 0 CA-C-O 121.161 0.505 . . . . 0.0 110.313 . . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.546 ' O ' ' CD2' ' A' ' 2' ' ' LEU . 0.5 OUTLIER -114.07 162.84 15.96 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.057 -1.027 . . . . 0.0 109.386 -179.87 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -158.26 174.64 35.47 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -141.81 130.89 23.27 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.099 -1.236 . . . . 0.0 111.384 -179.293 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' A' ' 18' ' ' ILE . 2.8 t -37.57 138.52 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 122.82 1.295 . . . . 0.0 113.312 179.366 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.426 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -97.09 -29.29 13.7 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 102.992 -2.966 . . . . 0.0 102.992 172.452 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.7 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 19.8 p-90 178.27 145.97 0.14 Allowed 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 106.068 -1.827 . . . . 0.0 106.068 177.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.549 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.6 OUTLIER -120.28 142.54 48.98 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.533 -1.355 . . . . 0.0 109.848 179.767 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.508 ' OD1' ' CD ' ' A' ' 13' ' ' LYS . 0.5 OUTLIER -130.57 38.34 3.74 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 179.004 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 10' ' ' ASN . 11.1 p -39.15 -44.56 1.2 Allowed 'General case' 0 C--N 1.299 -1.595 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.068 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 47.2 mm-40 -61.43 -46.83 88.44 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.437 -0.789 . . . . 0.0 109.847 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.508 ' CD ' ' OD1' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -69.61 1.41 4.17 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.396 -0.815 . . . . 0.0 110.184 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.585 ' O ' ' CD2' ' A' ' 29' ' ' HIS . . . 99.04 12.35 43.12 Favored Glycine 0 N--CA 1.49 2.253 0 C-N-CA 120.152 -1.023 . . . . 0.0 112.325 178.505 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.476 ' HB3' ' O ' ' A' ' 14' ' ' GLY . 38.1 p90 179.95 163.75 1.09 Allowed 'General case' 0 N--CA 1.497 1.889 0 CA-C-N 120.269 2.035 . . . . 0.0 111.678 179.237 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.549 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -145.53 143.22 11.48 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 107.296 -2.322 . . . . 0.0 107.296 179.466 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.7 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.29 143.71 36.78 Favored 'General case' 0 N--CA 1.48 1.045 0 O-C-N 120.24 -1.741 . . . . 0.0 110.19 -178.67 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.61 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.3 OUTLIER -105.45 164.33 4.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 N-CA-C 104.985 -2.228 . . . . 0.0 104.985 177.583 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.554 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 12.1 tp10 -130.3 129.65 43.49 Favored 'General case' 0 C--N 1.285 -2.22 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 178.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.604 ' CG1' ' CB ' ' A' ' 23' ' ' GLN . 14.7 p -132.82 138.93 50.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 118.057 -1.457 . . . . 0.0 111.707 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -66.02 140.37 58.28 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.268 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.32 -8.7 45.14 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 -178.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.604 ' CB ' ' CG1' ' A' ' 20' ' ' VAL . 0.7 OUTLIER -138.45 -175.33 4.08 Favored 'General case' 0 N--CA 1.482 1.136 0 O-C-N 121.197 -1.178 . . . . 0.0 108.503 179.539 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.79 -166.55 1.33 Allowed 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 122.129 0.966 . . . . 0.0 110.923 -178.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.61 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.1 m-20 -72.62 113.8 10.06 Favored 'General case' 0 N--CA 1.485 1.324 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.455 178.861 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.605 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -67.74 114.0 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.112 0 O-C-N 120.432 -1.417 . . . . 0.0 112.105 179.658 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.527 ' CD2' ' CZ ' ' A' ' 17' ' ' PHE . 0.6 OUTLIER -70.11 118.95 13.59 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 177.789 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.499 HG11 ' CG1' ' A' ' 26' ' ' VAL . 2.7 m -147.25 137.5 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 120.552 -1.343 . . . . 0.0 110.394 -179.346 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.585 ' CD2' ' O ' ' A' ' 14' ' ' GLY . 9.7 t-160 -99.19 172.97 7.03 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.384 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.548 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 48.0 p90 -82.64 35.54 0.46 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.044 -1.035 . . . . 0.0 109.758 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 10.8 t -128.15 -28.69 2.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.932 -1.105 . . . . 0.0 109.835 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.448 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.73 -47.89 7.12 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.027 -1.046 . . . . 0.0 108.236 179.293 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.492 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 53.5 mt . . . . . 0 C--N 1.305 -1.337 0 CA-C-O 122.115 0.96 . . . . 0.0 108.516 179.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.431 ' C ' HG11 ' A' ' 47' ' ' VAL . . . . . . . . 0 N--CA 1.488 1.459 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.541 HG23 ' CD1' ' A' ' 18' ' ' ILE . 35.3 m -140.44 161.78 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 120.451 -1.406 . . . . 0.0 111.139 -178.77 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.468 ' HA ' ' O ' ' A' ' 2' ' ' LEU . 9.5 p -115.53 132.86 56.5 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 179.302 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.645 ' CE1' HG13 ' A' ' 51' ' ' ILE . 7.1 p90 -154.88 -179.96 8.54 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.079 -1.013 . . . . 0.0 109.775 -179.005 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -121.16 91.39 3.51 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 178.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.645 HG13 ' CE1' ' A' ' 49' ' ' PHE . 17.9 mt -61.64 126.87 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.845 -1.159 . . . . 0.0 110.004 -179.478 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.522 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 10.4 m -106.09 -171.84 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 106.371 -1.714 . . . . 0.0 106.371 178.581 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.9 mp0 -122.98 114.44 20.41 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.9 -1.125 . . . . 0.0 109.824 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.57 169.07 16.58 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 34.5 m120 -38.07 -52.16 1.4 Allowed 'General case' 0 N--CA 1.504 2.232 0 O-C-N 121.325 -1.103 . . . . 0.0 113.587 -178.561 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.481 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -76.57 22.66 0.17 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 119.677 -1.89 . . . . 0.0 112.355 -178.035 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.07 -177.93 29.13 Favored Glycine 0 N--CA 1.494 2.531 0 O-C-N 120.434 -1.416 . . . . 0.0 110.232 179.565 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -65.66 150.82 86.01 Favored 'Trans proline' 0 C--N 1.32 -0.956 0 C-N-CA 122.025 1.817 . . . . 0.0 109.702 178.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.516 ' N ' HG22 ' A' ' 51' ' ' ILE . 29.5 mt-30 -161.11 144.03 12.69 Favored 'General case' 0 N--CA 1.5 2.043 0 O-C-N 120.991 -1.068 . . . . 0.0 111.567 -179.413 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.582 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -78.68 154.56 30.04 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 177.388 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.448 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -133.89 -41.61 0.83 Allowed 'General case' 0 N--CA 1.506 2.37 0 O-C-N 120.386 -1.446 . . . . 0.0 111.546 -176.534 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 5.6 m-20 -119.94 52.24 1.13 Allowed 'General case' 0 C--N 1.284 -2.255 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 179.618 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.561 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 20.5 t -67.13 163.68 2.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.969 -179.148 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.491 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.2 OUTLIER -147.29 167.88 23.17 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.37 -0.932 . . . . 0.0 108.796 178.608 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.63 0 O-C-N 120.864 -1.147 . . . . 0.0 109.66 -179.77 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.653 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.952 0 CA-C-O 121.003 0.43 . . . . 0.0 109.867 . . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.458 ' O ' HD23 ' A' ' 2' ' ' LEU . 2.3 tt0 -113.77 157.08 22.72 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 120.907 -1.12 . . . . 0.0 110.332 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.415 ' C ' ' HG3' ' A' ' 5' ' ' LYS . . . -133.5 155.44 21.74 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.543 -1.823 . . . . 0.0 108.543 179.54 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.0 OUTLIER -132.2 119.07 20.36 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.284 -1.127 . . . . 0.0 110.201 -179.478 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.514 HG12 ' N ' ' A' ' 8' ' ' TRP . 2.8 t -34.05 143.18 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.182 0 CA-C-O 123.086 1.422 . . . . 0.0 113.701 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.464 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 1.3 tmtm? -104.89 -30.74 9.64 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 103.585 -2.746 . . . . 0.0 103.585 172.733 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.706 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 18.4 p-90 177.51 145.47 0.11 Allowed 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 105.728 -1.953 . . . . 0.0 105.728 178.1 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.639 ' CE1' ' CG2' ' A' ' 28' ' ' VAL . 0.6 OUTLIER -113.23 148.43 35.53 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.457 -1.402 . . . . 0.0 110.655 -179.668 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.595 ' OD1' ' CZ3' ' A' ' 8' ' ' TRP . 3.0 m120 -130.2 36.31 4.01 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.797 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.5 OUTLIER -39.48 -42.78 1.16 Allowed 'General case' 0 N--CA 1.49 1.57 0 CA-C-O 121.42 0.629 . . . . 0.0 109.556 -178.703 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -60.78 -47.37 86.62 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.344 -0.847 . . . . 0.0 110.282 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.526 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -72.94 3.88 4.84 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.178 -0.951 . . . . 0.0 110.068 -179.829 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.476 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 95.25 18.6 33.09 Favored Glycine 0 N--CA 1.49 2.279 0 O-C-N 121.184 -0.948 . . . . 0.0 112.465 178.289 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.512 ' O ' ' C ' ' A' ' 10' ' ' ASN . 37.1 p90 177.77 168.69 0.7 Allowed 'General case' 0 N--CA 1.501 2.075 0 CA-C-N 120.152 1.976 . . . . 0.0 111.644 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.526 ' O ' ' CG2' ' A' ' 28' ' ' VAL . . . -146.34 154.29 25.87 Favored Glycine 0 N--CA 1.497 2.709 0 N-CA-C 107.044 -2.422 . . . . 0.0 107.044 179.133 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.706 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.5 m-85 -109.98 142.33 41.52 Favored 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 120.053 1.927 . . . . 0.0 109.621 -179.201 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.589 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.8 OUTLIER -106.37 163.5 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 179.295 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.578 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 0.8 OUTLIER -140.97 130.79 24.32 Favored 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.897 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.57 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 9.3 p -137.4 139.19 44.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 C-N-CA 117.743 -1.583 . . . . 0.0 111.779 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.86 141.06 58.18 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.428 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.19 -18.88 42.3 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.621 -1.792 . . . . 0.0 108.621 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.57 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 57.3 mt-30 -140.99 -173.15 3.64 Favored 'General case' 0 N--CA 1.484 1.244 0 O-C-N 121.418 -1.048 . . . . 0.0 109.162 179.671 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -98.35 -164.62 1.15 Allowed 'General case' 0 C--N 1.297 -1.688 0 CA-C-O 122.115 0.96 . . . . 0.0 110.822 -178.801 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.589 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 23.5 p-10 -70.91 125.82 27.89 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.239 179.747 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.633 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.3 t -90.49 114.48 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 120.705 -1.247 . . . . 0.0 110.808 178.348 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.438 ' C ' ' O ' ' A' ' 26' ' ' VAL . 18.8 t80 -46.06 143.13 2.41 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.639 ' CG2' ' CE1' ' A' ' 9' ' ' PHE . 1.0 OUTLIER -133.57 148.51 30.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 120.687 -1.258 . . . . 0.0 109.422 -179.176 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.447 ' O ' HG13 ' A' ' 33' ' ' ILE . 10.2 t-160 -151.61 146.84 26.12 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 21.8 p90 -78.8 24.21 0.31 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.018 -1.051 . . . . 0.0 110.714 -179.674 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.3 t -111.6 -45.7 3.34 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 120.637 -1.289 . . . . 0.0 109.212 179.615 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.55 -42.89 9.98 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.284 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.541 HG22 ' CG1' ' A' ' 63' ' ' VAL . 1.3 mt . . . . . 0 N--CA 1.487 1.376 0 CA-C-O 121.496 0.665 . . . . 0.0 109.615 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.408 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.51 ' HB ' HG13 ' A' ' 63' ' ' VAL . 32.9 m -124.56 163.74 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 120.428 -1.42 . . . . 0.0 111.105 -178.755 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -116.58 129.02 55.93 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.1 -1.0 . . . . 0.0 108.517 179.591 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.653 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 6.3 p90 -153.75 -177.97 6.73 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.044 -1.035 . . . . 0.0 109.882 -179.466 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -126.09 93.12 3.73 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.197 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.633 ' CD1' ' CG2' ' A' ' 26' ' ' VAL . 13.7 mt -61.73 128.49 23.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.973 -1.079 . . . . 0.0 109.907 -179.303 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 7.5 m -109.3 -175.99 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 178.707 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.96 116.11 22.34 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.941 -1.099 . . . . 0.0 109.415 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.25 176.16 18.25 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -38.59 -52.59 1.63 Allowed 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.424 -1.044 . . . . 0.0 113.807 -178.504 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.458 ' NH1' ' CG ' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -79.42 22.27 0.45 Allowed 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.665 -1.897 . . . . 0.0 112.134 -177.706 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.56 -177.74 30.9 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.429 -1.367 . . . . 0.0 110.298 179.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.534 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.4 Cg_endo -66.64 153.1 79.18 Favored 'Trans proline' 0 C--N 1.32 -0.921 0 C-N-CA 121.942 1.761 . . . . 0.0 110.186 179.189 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.432 ' HG3' ' O ' ' A' ' 58' ' ' PRO . 2.4 mt-30 -166.31 147.46 6.5 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.069 -1.02 . . . . 0.0 111.278 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.562 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -80.12 155.84 27.3 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 177.239 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.548 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.66 -41.88 0.77 Allowed 'General case' 0 N--CA 1.508 2.445 0 O-C-N 120.308 -1.495 . . . . 0.0 111.695 -176.576 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -120.19 52.03 1.16 Allowed 'General case' 0 C--N 1.283 -2.292 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.613 ' CG2' ' HB3' ' A' ' 49' ' ' PHE . 15.2 t -67.43 167.32 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-O 121.83 0.824 . . . . 0.0 109.562 -179.501 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.437 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.3 OUTLIER -147.17 168.89 20.51 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.994 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.8 mttm . . . . . 0 N--CA 1.49 1.543 0 O-C-N 120.917 -1.114 . . . . 0.0 109.643 -179.797 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.638 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.764 0 CA-C-O 121.3 0.572 . . . . 0.0 110.082 . . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.455 ' O ' HD23 ' A' ' 2' ' ' LEU . 1.9 tt0 -113.95 149.71 34.86 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.165 -0.96 . . . . 0.0 110.423 -178.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.12 165.47 19.29 Favored Glycine 0 N--CA 1.486 1.969 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 179.37 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 6' ' ' VAL . 12.0 mmtt -131.4 115.16 15.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.929 -1.336 . . . . 0.0 109.742 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.524 HG12 ' N ' ' A' ' 8' ' ' TRP . 3.2 t -36.47 139.56 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 CA-C-O 122.914 1.34 . . . . 0.0 112.873 -179.551 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.458 ' HE2' ' OE1' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -99.73 -33.23 10.67 Favored 'General case' 0 C--N 1.288 -2.105 0 N-CA-C 102.876 -3.009 . . . . 0.0 102.876 172.471 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 24.1 p-90 175.16 146.58 0.07 Allowed 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 177.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -112.08 147.41 36.1 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 120.298 -1.501 . . . . 0.0 109.37 178.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.579 ' HB2' ' CD1' ' A' ' 15' ' ' PHE . 1.0 OUTLIER -126.45 41.7 3.47 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.689 -0.632 . . . . 0.0 109.363 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.48 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -39.04 -47.29 1.49 Allowed 'General case' 0 N--CA 1.493 1.712 0 CA-C-O 121.601 0.715 . . . . 0.0 109.569 -179.189 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -58.6 -50.27 74.44 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.45 -0.781 . . . . 0.0 110.939 -179.385 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.528 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -70.85 0.98 6.09 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.014 -1.054 . . . . 0.0 110.429 -179.211 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.579 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 90.47 25.96 24.4 Favored Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.014 -1.054 . . . . 0.0 111.797 178.505 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.579 ' CD1' ' HB2' ' A' ' 10' ' ' ASN . 4.9 p90 -178.58 172.48 1.42 Allowed 'General case' 0 N--CA 1.497 1.914 0 CA-C-N 119.836 1.818 . . . . 0.0 110.866 179.47 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.493 ' O ' HG21 ' A' ' 28' ' ' VAL . . . -154.48 143.94 10.59 Favored Glycine 0 N--CA 1.5 2.911 0 N-CA-C 107.104 -2.399 . . . . 0.0 107.104 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.0 m-85 -111.12 141.33 44.77 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 119.97 -1.9 . . . . 0.0 110.456 -178.465 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.575 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.5 OUTLIER -106.32 162.35 5.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 178.262 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.558 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 14.6 tp10 -141.7 128.47 20.45 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.473 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.56 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 12.4 p -135.53 141.17 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 117.3 -1.76 . . . . 0.0 112.021 -179.213 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.71 140.44 58.46 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-N 115.384 -0.825 . . . . 0.0 108.913 179.596 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.03 -16.23 43.97 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.419 -1.872 . . . . 0.0 108.419 -178.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.56 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 3.1 mm-40 -139.29 -177.11 4.77 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 179.439 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -100.9 -165.95 1.26 Allowed 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.236 -0.915 . . . . 0.0 110.912 -178.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.575 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 3.8 p30 -72.27 124.37 24.92 Favored 'General case' 0 N--CA 1.488 1.46 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.741 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.639 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -88.23 116.01 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 120.647 -1.283 . . . . 0.0 111.264 178.605 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.543 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 1.5 t80 -64.5 127.82 33.16 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 178.191 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.568 ' CG1' HG11 ' A' ' 26' ' ' VAL . 16.1 m -143.32 137.01 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.55 -1.344 . . . . 0.0 111.626 -178.787 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.579 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 4.1 t60 -99.82 162.02 13.25 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 177.327 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.455 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 49.0 p90 -83.99 34.2 0.5 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.467 -1.396 . . . . 0.0 109.993 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.6 m -123.26 -34.27 3.15 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.034 -1.041 . . . . 0.0 108.905 179.305 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.502 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.56 -43.3 9.74 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.571 ' CD1' ' N ' ' A' ' 33' ' ' ILE . 1.2 mp . . . . . 0 C--N 1.305 -1.361 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.46 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.506 ' CG2' HD12 ' A' ' 18' ' ' ILE . 35.7 m -112.59 162.03 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 120.829 -1.17 . . . . 0.0 110.405 -179.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.68 119.15 34.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.06 -1.025 . . . . 0.0 108.729 179.4 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.638 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 10.7 p90 -149.49 -177.6 5.95 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.952 -1.093 . . . . 0.0 110.023 -179.374 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -128.86 93.31 3.58 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.452 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.639 ' CD1' ' CG2' ' A' ' 26' ' ' VAL . 14.1 mt -61.69 132.81 27.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.931 -1.105 . . . . 0.0 109.929 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 17.0 m -113.42 -177.3 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.152 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -123.17 117.19 24.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.999 -1.063 . . . . 0.0 109.299 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.83 175.2 15.63 Favored Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.67 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -39.1 -52.1 1.87 Allowed 'General case' 0 N--CA 1.5 2.071 0 N-CA-C 114.287 1.217 . . . . 0.0 114.287 -178.484 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -93.25 21.09 6.28 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 119.416 -2.053 . . . . 0.0 113.534 -176.616 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 122.68 173.65 14.23 Favored Glycine 0 N--CA 1.495 2.593 0 C-N-CA 118.723 -1.703 . . . . 0.0 111.533 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.505 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 3.0 Cg_endo -69.07 156.51 64.94 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 C-N-CA 122.661 2.241 . . . . 0.0 110.561 179.27 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -166.41 146.11 5.93 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.298 -0.876 . . . . 0.0 110.962 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.585 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -82.19 159.14 23.34 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.502 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.502 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -135.15 -44.53 0.71 Allowed 'General case' 0 N--CA 1.506 2.349 0 O-C-N 120.36 -1.462 . . . . 0.0 112.13 -176.171 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -119.54 51.62 1.15 Allowed 'General case' 0 C--N 1.284 -2.24 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.558 ' CG2' ' HB3' ' A' ' 49' ' ' PHE . 18.1 t -66.06 159.64 4.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.681 -179.431 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.462 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.2 OUTLIER -143.92 -177.86 5.64 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.846 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.533 0 O-C-N 120.931 -1.106 . . . . 0.0 109.354 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.607 HD13 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.813 0 CA-C-O 121.155 0.503 . . . . 0.0 110.264 . . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.526 ' O ' ' CD2' ' A' ' 2' ' ' LEU . 0.2 OUTLIER -112.64 165.2 12.49 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.252 -0.905 . . . . 0.0 109.937 -179.059 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.505 ' O ' ' HA ' ' A' ' 46' ' ' ALA . . . -148.05 169.68 28.76 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 20.0 mttt -134.05 116.14 15.14 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 120.919 -1.342 . . . . 0.0 110.313 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.4 t -49.06 134.98 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 CA-C-O 122.71 1.243 . . . . 0.0 112.998 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.65 -28.36 13.58 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 104.015 -2.587 . . . . 0.0 104.015 174.155 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.681 ' O ' ' CE3' ' A' ' 8' ' ' TRP . 21.6 p-90 176.16 141.88 0.07 Allowed 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 178.274 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.576 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 0.7 OUTLIER -130.02 110.57 11.75 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.537 -1.352 . . . . 0.0 110.096 -179.949 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.567 ' OD1' ' CB ' ' A' ' 13' ' ' LYS . 1.2 p30 -95.15 88.35 5.17 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-O 122.978 1.371 . . . . 0.0 109.031 179.047 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.483 ' HA ' ' CE1' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -67.65 -57.97 5.47 Favored 'General case' 0 C--N 1.29 -2.02 0 O-C-N 120.417 -1.427 . . . . 0.0 108.709 179.741 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -59.7 -45.13 93.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.469 -0.77 . . . . 0.0 111.362 -179.097 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.567 ' CB ' ' OD1' ' A' ' 10' ' ' ASN . 1.4 mptt -68.68 -11.85 60.68 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.05 -1.032 . . . . 0.0 111.134 -177.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.514 ' N ' ' OD1' ' A' ' 10' ' ' ASN . . . 138.73 -37.79 1.75 Allowed Glycine 0 N--CA 1.496 2.636 0 C-N-CA 118.376 -1.869 . . . . 0.0 113.3 178.299 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.532 ' O ' ' ND2' ' A' ' 10' ' ' ASN . 10.9 p90 -175.85 -174.83 0.69 Allowed 'General case' 0 N--CA 1.497 1.882 0 CA-C-N 121.079 2.439 . . . . 0.0 110.424 -179.222 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.596 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -134.49 146.35 18.36 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.626 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 6.0 m-30 -107.0 136.71 46.4 Favored 'General case' 0 N--CA 1.48 1.04 0 O-C-N 120.577 -1.543 . . . . 0.0 109.419 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.61 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 1.0 OUTLIER -107.39 150.53 9.88 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 N-CA-C 105.85 -1.908 . . . . 0.0 105.85 178.049 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.447 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 1.0 OUTLIER -125.92 133.19 51.94 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.396 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.512 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 8.5 p -137.87 140.24 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 C-N-CA 117.635 -1.626 . . . . 0.0 112.221 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -65.28 140.18 58.68 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.056 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.84 -13.76 46.55 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 108.654 -1.778 . . . . 0.0 108.654 -178.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.512 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 3.6 mt-30 -138.56 -175.97 4.31 Favored 'General case' 0 N--CA 1.483 1.195 0 O-C-N 121.257 -1.143 . . . . 0.0 108.632 179.489 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.82 -165.62 1.23 Allowed 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 122.135 0.969 . . . . 0.0 110.627 -179.059 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.61 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.5 m-20 -73.0 104.85 4.24 Favored 'General case' 0 N--CA 1.486 1.355 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.223 179.477 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.598 HG22 ' CZ ' ' A' ' 49' ' ' PHE . 2.4 t -65.72 115.25 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 120.345 -1.472 . . . . 0.0 112.112 179.061 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.44 ' CD1' ' C ' ' A' ' 27' ' ' PHE . 12.7 t80 -70.53 129.84 40.27 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.336 -0.852 . . . . 0.0 109.04 178.236 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.582 ' CG1' ' CD1' ' A' ' 18' ' ' ILE . 23.6 m -135.85 144.83 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.617 -1.302 . . . . 0.0 109.654 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.532 ' O ' ' CD1' ' A' ' 33' ' ' ILE . 0.5 OUTLIER -99.63 165.99 11.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.766 -1.209 . . . . 0.0 108.78 179.678 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.516 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 42.9 p90 -80.28 26.0 0.38 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.949 -1.095 . . . . 0.0 110.937 -179.398 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 43.3 p -136.68 -17.64 1.46 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.701 -1.249 . . . . 0.0 110.209 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.49 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -92.35 -49.6 6.07 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 120.735 -1.228 . . . . 0.0 108.79 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.545 ' CG1' ' HB ' ' A' ' 28' ' ' VAL . 2.5 mt . . . . . 0 N--CA 1.487 1.401 0 CA-C-O 121.933 0.873 . . . . 0.0 108.736 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.505 ' HA ' ' O ' ' A' ' 4' ' ' GLY . . . . . . . . 0 N--CA 1.485 1.301 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.467 HG22 HG12 ' A' ' 63' ' ' VAL . 29.7 m -111.3 162.8 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.18 -0.95 . . . . 0.0 110.247 -179.806 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -115.88 125.38 52.55 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.194 -0.941 . . . . 0.0 108.587 179.503 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.607 ' CE1' HD13 ' A' ' 2' ' ' LEU . 25.0 p90 -153.59 -178.35 6.96 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.019 -1.051 . . . . 0.0 110.035 -179.646 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -126.85 96.14 4.55 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 179.413 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.597 ' CD1' ' CG2' ' A' ' 26' ' ' VAL . 1.3 mm -61.09 141.39 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 122.609 1.195 . . . . 0.0 111.048 -179.393 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.515 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 2.1 m -130.65 -174.96 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 -179.558 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -124.14 116.26 22.46 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.002 -1.062 . . . . 0.0 109.623 179.627 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -129.36 173.32 19.6 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -38.04 -52.26 1.39 Allowed 'General case' 0 N--CA 1.504 2.254 0 O-C-N 121.407 -1.055 . . . . 0.0 113.426 -178.634 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 4.9 mtt180 -75.42 22.74 0.12 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 119.728 -1.858 . . . . 0.0 112.102 -178.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.74 -178.75 36.64 Favored Glycine 0 N--CA 1.492 2.389 0 O-C-N 120.438 -1.414 . . . . 0.0 110.124 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.515 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.4 Cg_endo -68.04 139.59 47.31 Favored 'Trans proline' 0 C--N 1.319 -1.023 0 C-N-CA 122.095 1.863 . . . . 0.0 110.069 178.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.504 ' C ' ' CD1' ' A' ' 51' ' ' ILE . 77.6 mt-30 -159.33 157.92 31.37 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.2 -0.938 . . . . 0.0 111.206 -179.364 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.587 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -83.99 160.56 21.0 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 177.517 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.49 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -135.08 -40.98 0.74 Allowed 'General case' 0 N--CA 1.508 2.433 0 O-C-N 120.294 -1.504 . . . . 0.0 111.812 -176.709 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.438 ' N ' ' OD1' ' A' ' 62' ' ' ASN . 1.6 m-20 -119.62 52.28 1.11 Allowed 'General case' 0 C--N 1.283 -2.283 0 N-CA-C 106.924 -1.509 . . . . 0.0 106.924 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.56 ' CG2' ' HB3' ' A' ' 49' ' ' PHE . 13.4 t -69.17 163.66 3.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.488 -179.308 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.481 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 1.2 m -149.45 -179.08 6.8 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 178.643 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.603 0 O-C-N 120.991 -1.068 . . . . 0.0 109.432 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.641 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.913 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 . . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.528 ' O ' ' CD2' ' A' ' 2' ' ' LEU . 0.3 OUTLIER -113.07 165.94 11.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.87 -1.143 . . . . 0.0 109.858 -179.07 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -151.82 156.27 26.6 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.401 ' O ' ' C ' ' A' ' 6' ' ' VAL . 2.5 ttpt -135.4 126.93 28.77 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.45 -1.03 . . . . 0.0 110.675 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.521 ' CG1' ' N ' ' A' ' 8' ' ' TRP . 5.6 t -35.7 150.01 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.285 0 CA-C-O 123.453 1.597 . . . . 0.0 113.338 -179.634 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.507 ' CG ' ' HB2' ' A' ' 19' ' ' GLU . 1.0 OUTLIER -110.54 -29.21 8.16 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 103.174 -2.899 . . . . 0.0 103.174 172.247 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.711 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 15.4 p-90 178.92 144.61 0.14 Allowed 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 177.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.576 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 1.1 t80 -118.89 127.41 53.47 Favored 'General case' 0 N--CA 1.506 2.361 0 O-C-N 120.527 -1.358 . . . . 0.0 109.756 -178.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.554 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 72.7 m-20 -120.6 56.21 1.0 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.598 -0.689 . . . . 0.0 109.682 -179.426 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -43.74 -38.11 3.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.287 -0.883 . . . . 0.0 108.861 179.933 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -61.03 -47.03 88.32 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.572 -0.705 . . . . 0.0 110.253 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.496 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -71.53 4.42 3.09 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.218 -0.926 . . . . 0.0 109.768 179.853 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.478 ' C ' ' CD2' ' A' ' 15' ' ' PHE . . . 98.53 8.0 55.13 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 120.22 -0.99 . . . . 0.0 111.712 179.045 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.478 ' CD2' ' C ' ' A' ' 14' ' ' GLY . 3.9 p90 173.88 173.78 0.16 Allowed 'General case' 0 N--CA 1.495 1.818 0 CA-C-N 120.391 2.096 . . . . 0.0 112.588 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.576 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -130.33 142.61 13.89 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 106.644 -2.582 . . . . 0.0 106.644 178.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.711 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 4.1 m-30 -99.0 142.27 30.7 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 120.199 -1.765 . . . . 0.0 109.001 -178.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.61 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.6 OUTLIER -105.64 165.88 3.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 179.746 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.586 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 14.4 tm-20 -140.96 132.34 26.75 Favored 'General case' 0 C--N 1.289 -2.063 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 178.425 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.576 ' CG1' ' CB ' ' A' ' 23' ' ' GLN . 11.5 p -136.1 140.87 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 118.068 -1.453 . . . . 0.0 111.641 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -64.05 140.55 58.88 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.363 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.5 -8.88 45.38 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.576 ' CB ' ' CG1' ' A' ' 20' ' ' VAL . 0.3 OUTLIER -139.23 -175.07 4.04 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 121.129 -1.218 . . . . 0.0 108.849 179.608 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -100.66 -166.31 1.3 Allowed 'General case' 0 C--N 1.296 -1.721 0 CA-C-O 122.112 0.958 . . . . 0.0 110.437 -179.208 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.61 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 5.1 p30 -72.12 125.12 26.48 Favored 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.689 179.177 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.614 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.5 t -87.62 108.76 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 120.557 -1.339 . . . . 0.0 111.341 178.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.459 ' CE2' ' CE1' ' A' ' 17' ' ' PHE . 8.8 t80 -51.16 135.13 26.31 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 177.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.563 ' CG1' ' CD1' ' A' ' 18' ' ' ILE . 0.7 OUTLIER -131.74 140.8 47.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 120.48 -1.388 . . . . 0.0 109.615 -178.831 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.509 ' N ' HD13 ' A' ' 33' ' ' ILE . 36.2 t-80 -123.63 155.73 37.17 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.492 ' CE1' ' CE1' ' A' ' 29' ' ' HIS . 55.6 p90 -82.47 32.5 0.4 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.975 -1.078 . . . . 0.0 109.585 179.754 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.7 m -132.04 -33.24 1.36 Allowed 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.075 -1.016 . . . . 0.0 109.358 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.505 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.34 -40.93 11.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.154 -0.966 . . . . 0.0 108.781 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.555 ' CD1' ' HB ' ' A' ' 28' ' ' VAL . 3.1 mt . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.382 -0.823 . . . . 0.0 108.878 178.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.333 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.544 ' CG2' HD12 ' A' ' 18' ' ' ILE . 35.0 m -128.28 164.29 30.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 120.675 -1.266 . . . . 0.0 110.741 -178.292 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -115.36 136.4 53.13 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 179.1 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.641 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 7.0 p90 -156.52 -179.41 8.15 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-O 121.99 0.9 . . . . 0.0 109.522 -178.731 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 20.1 tt0 -123.18 93.45 3.96 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.049 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.635 HG13 ' CE1' ' A' ' 49' ' ' PHE . 16.9 mt -62.14 128.58 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.981 -1.074 . . . . 0.0 110.154 -179.519 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.521 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 11.4 m -108.16 -176.56 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 178.348 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.408 ' CD ' ' N ' ' A' ' 53' ' ' GLU . 2.1 pm0 -123.85 116.62 23.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.967 -1.083 . . . . 0.0 109.729 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.406 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -132.26 172.4 21.14 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.181 -1.567 . . . . 0.0 109.181 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.406 ' C ' ' O ' ' A' ' 54' ' ' GLY . 17.8 m120 -37.37 -51.88 1.1 Allowed 'General case' 0 N--CA 1.505 2.322 0 O-C-N 121.439 -1.036 . . . . 0.0 113.268 -178.639 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.87 23.34 0.1 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 119.65 -1.907 . . . . 0.0 112.14 -178.456 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.77 -177.07 38.46 Favored Glycine 0 N--CA 1.491 2.359 0 O-C-N 120.529 -1.357 . . . . 0.0 109.773 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.521 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -68.28 152.92 75.44 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 C-N-CA 121.832 1.688 . . . . 0.0 109.652 178.768 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.466 ' HG3' ' O ' ' A' ' 58' ' ' PRO . 0.8 OUTLIER -165.82 146.1 6.61 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 120.907 -1.121 . . . . 0.0 111.608 -179.557 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.583 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -78.49 155.75 29.66 Favored 'General case' 0 N--CA 1.494 1.77 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.235 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.505 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.52 -40.57 0.8 Allowed 'General case' 0 N--CA 1.508 2.475 0 O-C-N 120.557 -1.339 . . . . 0.0 111.37 -176.836 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -119.88 57.09 0.93 Allowed 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.556 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 19.9 t -73.14 165.61 3.0 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.184 -178.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.486 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.2 OUTLIER -149.83 157.97 43.71 Favored 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.143 178.952 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.4 ' HA ' HG13 ' A' ' 47' ' ' VAL . 4.2 tmtm? . . . . . 0 N--CA 1.491 1.617 0 O-C-N 120.821 -1.174 . . . . 0.0 109.562 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.46 ' HG3' ' O ' ' A' ' 1' ' ' MET . 1.6 ppp? . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.213 0.53 . . . . 0.0 109.583 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.662 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -141.29 174.13 10.83 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.203 -0.935 . . . . 0.0 110.348 179.661 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.483 ' OE2' ' N ' ' A' ' 47' ' ' VAL . 0.3 OUTLIER -114.51 154.5 28.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.076 -1.015 . . . . 0.0 110.096 -179.552 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.24 158.0 20.27 Favored Glycine 0 N--CA 1.484 1.858 0 N-CA-C 109.064 -1.615 . . . . 0.0 109.064 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.443 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.3 mttt -130.73 115.85 17.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.446 -1.032 . . . . 0.0 110.195 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.537 ' CG2' ' HB3' ' A' ' 45' ' ' GLN . 3.6 t -35.42 143.52 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 CA-C-O 123.045 1.402 . . . . 0.0 112.925 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.409 ' CG ' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -102.5 -30.63 10.87 Favored 'General case' 0 C--N 1.288 -2.068 0 N-CA-C 102.996 -2.964 . . . . 0.0 102.996 171.94 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 17.9 p-90 177.31 147.5 0.13 Allowed 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 105.77 -1.937 . . . . 0.0 105.77 177.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.61 ' CZ ' HG22 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -114.19 145.01 42.27 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 120.37 -1.456 . . . . 0.0 110.142 179.944 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.55 ' HB2' ' O ' ' A' ' 15' ' ' PHE . 4.7 m-20 -131.91 32.96 4.0 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.351 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.1 OUTLIER -38.4 -46.95 1.19 Allowed 'General case' 0 N--CA 1.494 1.727 0 CA-C-O 121.486 0.66 . . . . 0.0 109.787 -178.765 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -60.15 -46.82 88.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.363 -0.836 . . . . 0.0 110.044 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.535 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -73.01 4.84 3.81 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.299 -0.876 . . . . 0.0 110.781 -179.317 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.552 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 110.71 -3.78 29.13 Favored Glycine 0 N--CA 1.494 2.545 0 C-N-CA 119.731 -1.223 . . . . 0.0 113.008 177.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.55 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 5.7 p90 176.68 174.77 0.37 Allowed 'General case' 0 N--CA 1.5 2.058 0 CA-C-N 120.614 2.207 . . . . 0.0 111.972 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.499 ' O ' HG12 ' A' ' 28' ' ' VAL . . . -140.03 151.96 22.45 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 107.432 -2.267 . . . . 0.0 107.432 179.32 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.36 141.33 40.34 Favored 'General case' 0 N--CA 1.485 1.323 0 O-C-N 120.058 -1.848 . . . . 0.0 109.498 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.597 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.9 OUTLIER -107.48 160.72 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 178.656 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.549 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 4.3 tt0 -137.74 130.52 29.97 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.071 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.532 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 14.5 p -134.76 140.32 45.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 C-N-CA 117.855 -1.538 . . . . 0.0 111.593 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.45 140.55 58.88 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-N 115.371 -0.832 . . . . 0.0 109.15 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 81.51 -10.7 49.11 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.532 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 2.7 mp0 -139.42 -174.89 4.0 Favored 'General case' 0 C--N 1.308 -1.203 0 O-C-N 121.137 -1.213 . . . . 0.0 108.814 179.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.42 -165.78 1.25 Allowed 'General case' 0 C--N 1.295 -1.782 0 CA-C-O 122.005 0.907 . . . . 0.0 110.368 -179.3 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.597 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 7.5 m-20 -71.12 120.11 16.21 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 115.861 -0.608 . . . . 0.0 109.701 179.214 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.616 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.5 t -83.83 115.29 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 120.482 -1.386 . . . . 0.0 110.722 178.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.413 ' CB ' ' CD ' ' A' ' 59' ' ' GLN . 23.4 t80 -53.71 138.12 35.99 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.61 HG22 ' CZ ' ' A' ' 9' ' ' PHE . 0.6 OUTLIER -129.27 146.48 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 O-C-N 120.712 -1.242 . . . . 0.0 109.381 -179.681 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.552 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 3.7 t60 -147.7 143.85 27.9 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.457 ' O ' ' HB3' ' A' ' 34' ' ' GLN . 22.6 p90 -63.85 2.79 0.45 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.043 -1.036 . . . . 0.0 111.611 -179.348 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.459 ' O ' ' OE1' ' A' ' 34' ' ' GLN . 23.3 t -93.75 -51.07 5.07 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.21 -1.556 . . . . 0.0 109.574 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -93.31 -44.25 8.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.177 -0.952 . . . . 0.0 108.919 179.364 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.618 ' CD1' ' N ' ' A' ' 33' ' ' ILE . 1.1 mp -76.09 2.14 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.501 ' O ' ' O ' ' A' ' 33' ' ' ILE . 0.6 OUTLIER -47.3 -176.25 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.532 -0.73 . . . . 0.0 110.869 -178.355 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.34 -169.67 22.95 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -48.17 109.61 0.25 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.161 -1.199 . . . . 0.0 109.624 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 69.56 165.54 4.68 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.856 -1.298 . . . . 0.0 109.856 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -84.8 87.3 7.31 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.192 -1.181 . . . . 0.0 109.47 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -110.26 168.02 9.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.219 -0.926 . . . . 0.0 109.382 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.425 ' C ' ' HG ' ' A' ' 41' ' ' LEU . 0.2 OUTLIER -99.43 167.31 10.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.249 -0.907 . . . . 0.0 108.607 179.698 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.458 HD21 ' CD ' ' A' ' 45' ' ' GLN . 1.1 mp -134.69 142.83 46.92 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.543 -1.348 . . . . 0.0 110.043 -179.513 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -108.81 179.94 4.04 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.537 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.465 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 9.9 tm-20 -52.67 152.66 3.59 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.267 -0.895 . . . . 0.0 109.046 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.465 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 92.82 -6.4 76.85 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 -179.211 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.58 ' OE1' ' CE1' ' A' ' 9' ' ' PHE . 36.0 tt0 -62.2 105.94 0.67 Allowed 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.307 -1.113 . . . . 0.0 110.754 -179.482 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.449 ' O ' ' HB2' ' A' ' 66' ' ' GLU . . . -92.37 135.36 34.1 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 177.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.529 ' CG2' HD12 ' A' ' 18' ' ' ILE . 21.3 m -136.18 166.06 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 120.535 -1.353 . . . . 0.0 110.551 -179.151 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.9 t -116.66 135.39 53.82 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.09 -1.006 . . . . 0.0 108.6 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.662 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 7.2 p90 -164.1 -178.11 5.39 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.951 -1.093 . . . . 0.0 109.695 -179.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -127.05 94.95 4.16 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.305 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.63 HG13 ' CE1' ' A' ' 49' ' ' PHE . 12.3 mt -62.17 133.11 28.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.915 -1.116 . . . . 0.0 110.339 -179.409 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.516 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.1 m -116.04 -173.48 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 178.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -123.03 116.03 22.84 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.005 -1.059 . . . . 0.0 109.531 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.94 174.26 17.22 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -38.93 -52.67 1.77 Allowed 'General case' 0 N--CA 1.505 2.298 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -178.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 27.0 mmm180 -80.77 22.37 0.6 Allowed 'General case' 0 N--CA 1.498 1.967 0 O-C-N 119.676 -1.89 . . . . 0.0 112.247 -177.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.39 -177.7 26.14 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.278 -1.439 . . . . 0.0 110.488 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.516 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 0.9 OUTLIER -65.56 152.24 82.38 Favored 'Trans proline' 0 C--N 1.32 -0.948 0 C-N-CA 122.109 1.873 . . . . 0.0 110.426 179.114 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.413 ' CD ' ' CB ' ' A' ' 27' ' ' PHE . 0.0 OUTLIER -166.04 146.91 6.65 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.19 -0.944 . . . . 0.0 111.322 -179.653 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.566 ' CB ' ' CG2' ' A' ' 63' ' ' VAL . . . -79.4 159.23 27.16 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 177.174 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.532 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.67 -42.6 0.76 Allowed 'General case' 0 N--CA 1.508 2.439 0 O-C-N 120.366 -1.459 . . . . 0.0 111.886 -176.456 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -119.66 53.19 1.06 Allowed 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.579 ' CG2' ' HB3' ' A' ' 49' ' ' PHE . 25.0 t -70.85 168.77 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.887 -178.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.414 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 1.4 m -152.69 173.84 14.74 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 178.4 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -79.68 135.7 36.61 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.002 -1.061 . . . . 0.0 109.458 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.449 ' HB2' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -61.72 98.69 0.1 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.298 -0.876 . . . . 0.0 109.505 -179.993 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.49 179.987 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.597 ' C ' ' CD1' ' A' ' 2' ' ' LEU . 0.0 OUTLIER -129.41 175.69 8.56 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.234 -0.916 . . . . 0.0 110.214 179.844 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.539 ' O ' ' CD2' ' A' ' 2' ' ' LEU . 0.3 OUTLIER -112.13 168.03 9.93 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.105 -0.997 . . . . 0.0 109.553 -179.202 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.497 ' O ' ' HA ' ' A' ' 46' ' ' ALA . . . -151.78 167.9 31.08 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.379 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.5 mtpp -134.75 118.38 17.01 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.146 -1.208 . . . . 0.0 110.094 -179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.52 ' CG1' ' N ' ' A' ' 8' ' ' TRP . 3.8 t -43.23 142.54 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 122.78 1.276 . . . . 0.0 112.366 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.41 -29.65 13.38 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 103.179 -2.897 . . . . 0.0 103.179 172.587 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.702 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 21.1 p-90 177.79 144.78 0.11 Allowed 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 105.957 -1.868 . . . . 0.0 105.957 177.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.573 ' CE1' HD13 ' A' ' 41' ' ' LEU . 0.1 OUTLIER -118.84 141.0 49.05 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.487 -1.383 . . . . 0.0 109.541 179.493 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.517 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 0.2 OUTLIER -131.5 37.78 3.65 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 179.4 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' ASN . 1.2 p -37.94 -48.49 1.17 Allowed 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.44 0.638 . . . . 0.0 109.332 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -61.9 -44.76 96.14 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.412 -0.805 . . . . 0.0 109.761 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.505 ' CB ' ' OD1' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -69.05 -0.88 6.33 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.359 -0.838 . . . . 0.0 110.132 -179.796 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.484 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 108.35 -0.44 32.95 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.874 -1.155 . . . . 0.0 112.523 178.547 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.436 ' O ' ' C ' ' A' ' 10' ' ' ASN . 6.3 p90 -179.21 169.97 1.44 Allowed 'General case' 0 N--CA 1.498 1.929 0 CA-C-N 120.456 2.128 . . . . 0.0 111.991 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.52 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -143.64 143.08 11.86 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 107.755 -2.138 . . . . 0.0 107.755 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.702 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.87 141.95 40.17 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 120.205 -1.762 . . . . 0.0 110.162 -178.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.613 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.9 OUTLIER -107.58 163.83 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.475 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.585 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 28.6 tt0 -139.2 130.54 26.91 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.515 ' CG1' ' CB ' ' A' ' 23' ' ' GLN . 9.0 p -134.39 140.66 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 C-N-CA 117.594 -1.642 . . . . 0.0 111.984 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.419 ' N ' HG21 ' A' ' 20' ' ' VAL . 35.6 mt-10 -64.05 139.36 58.76 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.242 179.794 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.12 -13.65 43.5 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.515 ' CB ' ' CG1' ' A' ' 20' ' ' VAL . 1.5 mt-30 -138.0 -175.98 4.28 Favored 'General case' 0 C--N 1.308 -1.212 0 O-C-N 121.254 -1.145 . . . . 0.0 108.804 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.39 -165.89 1.26 Allowed 'General case' 0 C--N 1.295 -1.773 0 CA-C-O 121.987 0.899 . . . . 0.0 110.3 -179.429 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.613 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.6 m-20 -72.08 126.51 29.97 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.011 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.602 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -91.82 118.72 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.034 0 O-C-N 120.625 -1.297 . . . . 0.0 111.125 178.539 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.472 ' CB ' ' HG2' ' A' ' 59' ' ' GLN . 4.7 t80 -65.05 134.12 53.15 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.419 -0.8 . . . . 0.0 109.256 178.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.551 HG12 HG11 ' A' ' 26' ' ' VAL . 2.0 m -142.27 131.95 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.674 -1.266 . . . . 0.0 111.14 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.615 ' NE2' ' CZ ' ' A' ' 30' ' ' PHE . 2.5 t-160 -115.68 132.26 56.69 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.615 ' CZ ' ' NE2' ' A' ' 29' ' ' HIS . 7.4 p90 -43.96 -22.12 0.05 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.701 -1.25 . . . . 0.0 111.128 -178.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.463 ' O ' ' HG2' ' A' ' 34' ' ' GLN . 1.5 m -66.24 -42.59 88.4 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.755 -1.215 . . . . 0.0 111.218 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.57 -41.33 10.85 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.95 -1.094 . . . . 0.0 108.802 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.546 HG12 ' HB ' ' A' ' 28' ' ' VAL . 1.5 mp -57.69 -16.1 5.29 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.484 ' OE1' ' O ' ' A' ' 30' ' ' PHE . 4.7 pt20 -83.77 -174.93 5.56 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 119.306 -0.958 . . . . 0.0 109.47 -179.643 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 174.37 -50.23 0.14 Allowed Glycine 0 N--CA 1.489 2.216 0 N-CA-C 108.429 -1.868 . . . . 0.0 108.429 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -104.12 54.37 0.73 Allowed 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.708 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.43 172.13 22.2 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 108.842 -1.703 . . . . 0.0 108.842 -179.182 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 39.1 t80 -79.81 88.33 5.25 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.094 -1.239 . . . . 0.0 109.581 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 5.6 tptm -110.63 143.67 40.72 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.346 -0.846 . . . . 0.0 109.731 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.9 t -116.51 -169.92 1.72 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.29 -0.881 . . . . 0.0 108.728 179.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.573 HD13 ' CE1' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -146.88 172.49 13.59 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.13 -0.981 . . . . 0.0 109.623 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.423 ' O ' ' HB2' ' A' ' 45' ' ' GLN . 1.2 tt0 -119.6 -175.97 3.06 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.371 -0.83 . . . . 0.0 109.462 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -66.64 143.37 57.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.434 -0.791 . . . . 0.0 109.46 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.54 -8.08 80.36 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 -179.407 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.488 ' NE2' ' CB ' ' A' ' 41' ' ' LEU . 0.0 OUTLIER -77.11 126.05 30.33 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.308 -1.113 . . . . 0.0 110.508 -179.556 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.497 ' HA ' ' O ' ' A' ' 4' ' ' GLY . . . -91.68 135.65 33.72 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.602 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.531 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 35.0 m -119.29 159.68 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 120.868 -1.145 . . . . 0.0 110.281 -179.478 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.47 ' O ' HG11 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -114.19 136.01 53.42 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.116 -0.99 . . . . 0.0 108.57 179.59 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.594 ' CD1' HD13 ' A' ' 2' ' ' LEU . 19.9 p90 -163.04 -176.05 4.67 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.072 -1.018 . . . . 0.0 109.87 -179.247 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -129.07 96.6 4.38 Favored 'General case' 0 C--N 1.295 -1.771 0 O-C-N 121.542 -0.724 . . . . 0.0 109.185 179.129 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.602 ' CD1' ' CG2' ' A' ' 26' ' ' VAL . 1.5 mm -61.57 139.6 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 CA-C-O 122.452 1.12 . . . . 0.0 111.137 -179.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.503 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 3.1 m -126.72 -174.25 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -123.39 115.99 22.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.966 -1.083 . . . . 0.0 109.933 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.12 171.89 15.86 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 10.6 p-10 -39.1 -52.69 1.86 Allowed 'General case' 0 N--CA 1.505 2.309 0 O-C-N 121.283 -1.128 . . . . 0.0 113.956 -178.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 11.1 ttm180 -78.8 21.96 0.39 Allowed 'General case' 0 N--CA 1.5 2.054 0 O-C-N 119.601 -1.937 . . . . 0.0 112.224 -177.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.0 -179.27 26.07 Favored Glycine 0 N--CA 1.492 2.404 0 C-N-CA 119.339 -1.41 . . . . 0.0 110.667 179.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.503 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -66.78 150.16 83.4 Favored 'Trans proline' 0 C--N 1.321 -0.915 0 C-N-CA 122.238 1.959 . . . . 0.0 110.484 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.488 ' C ' ' CD1' ' A' ' 51' ' ' ILE . 2.5 mt-30 -165.71 152.69 10.09 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.245 -0.91 . . . . 0.0 111.03 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.593 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -82.15 161.43 22.81 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 177.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.548 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -135.0 -41.71 0.74 Allowed 'General case' 0 N--CA 1.51 2.526 0 O-C-N 120.273 -1.517 . . . . 0.0 111.725 -176.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 9.3 m-20 -120.1 52.28 1.14 Allowed 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.571 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 12.5 t -68.74 170.6 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 121.819 0.818 . . . . 0.0 109.69 -179.254 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.2 OUTLIER -152.74 171.75 17.74 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 178.553 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.4 132.7 34.86 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.003 -1.06 . . . . 0.0 109.584 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -80.66 148.77 30.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.188 -0.945 . . . . 0.0 109.605 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.474 179.941 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 121.31 0.576 . . . . 0.0 109.476 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.652 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -132.29 176.23 8.59 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.168 -0.957 . . . . 0.0 110.154 179.93 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.486 ' O ' ' CD2' ' A' ' 2' ' ' LEU . 0.2 OUTLIER -111.82 161.56 16.22 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.169 -0.957 . . . . 0.0 110.151 -178.527 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.02 157.89 24.51 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.432 ' HD3' ' OE1' ' A' ' 3' ' ' GLU . 10.2 mmtp -130.27 114.55 15.78 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.318 -1.107 . . . . 0.0 109.645 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.47 HG11 ' OE1' ' A' ' 43' ' ' GLU . 3.4 t -41.29 140.24 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 CA-C-O 122.8 1.286 . . . . 0.0 112.443 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.01 -30.33 12.4 Favored 'General case' 0 C--N 1.289 -2.041 0 N-CA-C 103.126 -2.916 . . . . 0.0 103.126 172.579 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.697 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 17.3 p-90 176.96 146.27 0.1 Allowed 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 106.228 -1.768 . . . . 0.0 106.228 177.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.641 ' CE1' ' CG2' ' A' ' 28' ' ' VAL . 1.5 t80 -113.66 143.23 44.94 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 120.576 -1.327 . . . . 0.0 109.433 179.394 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.56 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 90.6 m-20 -131.24 39.01 3.59 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -39.08 -47.82 1.58 Allowed 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.436 0.636 . . . . 0.0 109.525 -179.087 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -61.8 -44.52 96.7 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.393 -0.817 . . . . 0.0 109.706 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.54 ' CG ' ' HB3' ' A' ' 10' ' ' ASN . 12.6 mmmt -70.55 2.3 4.17 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.429 -0.794 . . . . 0.0 110.45 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.409 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 113.27 -10.57 24.38 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 119.564 -1.303 . . . . 0.0 112.063 178.675 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.55 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 3.9 p90 175.32 179.1 0.15 Allowed 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.03 -1.865 . . . . 0.0 111.302 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.523 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -136.34 149.38 20.1 Favored Glycine 0 N--CA 1.498 2.803 0 N-CA-C 107.482 -2.247 . . . . 0.0 107.482 179.279 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.697 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.2 m-85 -105.31 140.68 38.07 Favored 'General case' 0 N--CA 1.484 1.252 0 O-C-N 120.272 -1.722 . . . . 0.0 109.792 -178.816 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.586 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 1.2 mt -106.91 162.03 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 178.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.572 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 13.2 tt0 -140.07 130.28 25.12 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 177.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.543 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 14.1 p -135.49 140.96 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 C-N-CA 117.526 -1.67 . . . . 0.0 111.953 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.427 ' N ' HG21 ' A' ' 20' ' ' VAL . 1.2 mp0 -65.33 140.67 58.7 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.123 179.695 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.71 -10.48 45.47 Favored Glycine 0 N--CA 1.486 2.011 0 N-CA-C 108.662 -1.775 . . . . 0.0 108.662 -178.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.543 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 0.9 OUTLIER -140.33 -177.71 5.15 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 121.323 -1.104 . . . . 0.0 108.439 179.619 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 69.7 m-20 -100.84 -166.28 1.3 Allowed 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 121.913 0.863 . . . . 0.0 110.655 -179.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.586 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 0.9 OUTLIER -72.54 126.55 30.15 Favored 'General case' 0 N--CA 1.487 1.421 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.741 179.146 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.612 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -92.84 114.74 30.19 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 120.494 -1.379 . . . . 0.0 111.059 178.479 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.454 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 11.1 t80 -56.5 135.64 54.38 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.641 ' CG2' ' CE1' ' A' ' 9' ' ' PHE . 0.6 OUTLIER -129.5 142.55 43.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 120.6 -1.313 . . . . 0.0 110.393 -178.118 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.517 ' N ' HD13 ' A' ' 33' ' ' ILE . 1.8 t-160 -117.48 155.13 30.24 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.318 -0.994 . . . . 0.0 108.318 179.522 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.517 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 41.1 p90 -84.03 33.05 0.48 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.964 -1.085 . . . . 0.0 109.82 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -135.7 -31.1 0.96 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.046 -1.034 . . . . 0.0 109.732 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.504 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.13 -40.82 11.37 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.021 -1.049 . . . . 0.0 108.649 179.646 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.562 ' CD1' ' HB ' ' A' ' 28' ' ' VAL . 2.8 mt -73.8 -4.88 5.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 O-C-N 121.388 -0.82 . . . . 0.0 109.178 179.661 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.27 -168.5 1.32 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.474 -0.766 . . . . 0.0 109.966 -179.048 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.515 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -162.5 -169.58 26.08 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -47.99 91.6 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.274 -1.133 . . . . 0.0 109.811 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' A' ' 35' ' ' GLY . . . 151.24 154.13 6.43 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 179.536 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 27.4 t80 -86.2 81.54 8.38 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.096 -1.238 . . . . 0.0 109.629 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.68 161.01 16.18 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.095 -1.003 . . . . 0.0 109.894 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.487 ' OG1' ' N ' ' A' ' 41' ' ' LEU . 0.2 OUTLIER -138.36 179.72 6.29 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.391 -0.818 . . . . 0.0 108.984 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.499 ' CD1' HG23 ' A' ' 33' ' ' ILE . 0.1 OUTLIER -114.61 153.19 30.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.062 -1.024 . . . . 0.0 109.622 -179.959 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -121.09 177.09 5.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.352 -0.842 . . . . 0.0 109.445 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.47 ' OE1' HG11 ' A' ' 6' ' ' VAL . 3.4 tp10 -75.16 141.52 43.65 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.237 -0.915 . . . . 0.0 108.957 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 78.29 6.99 87.95 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 -179.438 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.458 ' OE1' ' N ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -75.89 131.93 39.98 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.172 -1.193 . . . . 0.0 110.624 -179.505 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.459 ' O ' ' HB2' ' A' ' 66' ' ' GLU . . . -94.54 118.0 30.99 Favored 'General case' 0 N--CA 1.489 1.486 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.15 178.761 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.57 ' CG2' HD12 ' A' ' 18' ' ' ILE . 28.6 m -111.49 159.48 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.823 -1.173 . . . . 0.0 109.911 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.6 p -115.72 123.55 48.58 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.076 -1.015 . . . . 0.0 108.429 179.448 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.652 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 8.8 p90 -151.92 -178.7 6.91 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.959 -1.088 . . . . 0.0 109.905 -179.429 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -125.36 94.02 4.03 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.483 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.624 HG13 ' CE1' ' A' ' 49' ' ' PHE . 10.5 mt -60.63 140.0 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 O-C-N 120.92 -1.112 . . . . 0.0 110.032 -179.381 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.546 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.9 m -124.52 -173.01 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 106.384 -1.71 . . . . 0.0 106.384 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -122.53 110.75 15.97 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 120.877 -1.139 . . . . 0.0 109.502 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.4 171.13 16.55 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -37.95 -52.25 1.36 Allowed 'General case' 0 N--CA 1.505 2.288 0 O-C-N 121.426 -1.044 . . . . 0.0 113.571 -178.664 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.21 22.53 0.16 Allowed 'General case' 0 N--CA 1.5 2.049 0 O-C-N 119.66 -1.9 . . . . 0.0 112.252 -178.084 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.405 ' O ' ' HG2' ' A' ' 59' ' ' GLN . . . 97.43 -175.52 30.58 Favored Glycine 0 N--CA 1.492 2.432 0 O-C-N 120.399 -1.438 . . . . 0.0 110.266 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.546 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.3 Cg_endo -65.22 131.36 28.19 Favored 'Trans proline' 0 C--N 1.32 -0.936 0 C-N-CA 121.858 1.706 . . . . 0.0 109.839 178.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.463 ' OE1' ' O ' ' A' ' 58' ' ' PRO . 10.4 mm100 -143.25 148.15 35.95 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.93 -1.106 . . . . 0.0 111.916 -178.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.551 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -82.1 158.2 23.8 Favored 'General case' 0 N--CA 1.496 1.872 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 176.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.504 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -135.29 -42.54 0.71 Allowed 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.219 -1.551 . . . . 0.0 111.876 -176.454 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 43.1 t30 -119.76 54.3 1.02 Allowed 'General case' 0 C--N 1.285 -2.238 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.561 ' CG2' ' HB3' ' A' ' 49' ' ' PHE . 18.4 t -68.62 164.94 2.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.596 -179.193 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.3 -175.8 5.32 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 178.804 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.425 ' HE3' ' O ' ' A' ' 33' ' ' ILE . 25.1 mmtp -87.74 131.05 34.62 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.035 -1.041 . . . . 0.0 109.653 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.459 ' HB2' ' O ' ' A' ' 46' ' ' ALA . 0.3 OUTLIER -76.55 110.13 10.86 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.044 -1.035 . . . . 0.0 109.773 -179.881 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.603 0 CA-C-O 117.926 -1.035 . . . . 0.0 109.361 179.876 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 121.201 0.525 . . . . 0.0 109.627 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.587 ' C ' ' CD1' ' A' ' 2' ' ' LEU . 0.0 OUTLIER -100.58 175.62 5.6 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.276 -0.89 . . . . 0.0 109.866 -179.961 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.452 ' OE2' ' HB3' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -113.74 153.48 28.95 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 120.931 -1.106 . . . . 0.0 109.92 -179.716 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.427 ' C ' ' HG3' ' A' ' 5' ' ' LYS . . . -136.37 169.7 23.62 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.427 ' HG3' ' C ' ' A' ' 4' ' ' GLY . 7.6 mttm -138.01 123.58 19.69 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.943 -1.327 . . . . 0.0 109.991 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.576 ' CG1' ' N ' ' A' ' 8' ' ' TRP . 4.5 t -47.09 143.53 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 CA-C-O 122.857 1.313 . . . . 0.0 112.221 -179.538 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.74 -28.23 13.6 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 103.282 -2.859 . . . . 0.0 103.282 172.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.713 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 23.1 p-90 177.92 145.71 0.12 Allowed 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.637 ' CE1' ' CG2' ' A' ' 28' ' ' VAL . 0.8 OUTLIER -112.72 148.8 33.97 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 120.528 -1.357 . . . . 0.0 109.902 179.821 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.574 ' OD1' ' CZ3' ' A' ' 8' ' ' TRP . 2.2 m120 -129.25 36.87 4.11 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 178.471 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.6 p -38.74 -50.95 1.69 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.9 -0.5 . . . . 0.0 110.41 -178.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.431 ' OE2' ' O ' ' A' ' 12' ' ' GLU . 6.7 tp10 -63.96 -37.69 88.34 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.04 -1.038 . . . . 0.0 110.151 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.556 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 1.1 mptt -75.23 2.38 11.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.962 -1.086 . . . . 0.0 110.057 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.475 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 100.63 8.56 48.77 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.983 -1.103 . . . . 0.0 112.828 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.549 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 7.0 p90 177.08 172.6 0.48 Allowed 'General case' 0 N--CA 1.501 2.11 0 CA-C-N 120.213 2.007 . . . . 0.0 111.492 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.504 ' O ' HG21 ' A' ' 28' ' ' VAL . . . -145.49 153.1 25.07 Favored Glycine 0 N--CA 1.501 3.012 0 N-CA-C 107.152 -2.379 . . . . 0.0 107.152 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.713 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.1 m-85 -112.32 139.7 47.66 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 119.72 -2.047 . . . . 0.0 110.095 -179.112 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.59 ' CD1' ' CG1' ' A' ' 28' ' ' VAL . 1.2 mt -107.29 162.16 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.576 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 4.4 tt0 -140.42 133.81 29.9 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.138 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.474 HG12 ' HB2' ' A' ' 23' ' ' GLN . 7.6 p -137.9 140.67 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 C-N-CA 117.936 -1.505 . . . . 0.0 111.804 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -63.92 140.6 58.89 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.302 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.86 -13.8 46.46 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.474 ' HB2' HG12 ' A' ' 20' ' ' VAL . 1.2 mt-30 -138.48 -175.48 4.14 Favored 'General case' 0 C--N 1.309 -1.166 0 O-C-N 121.326 -1.102 . . . . 0.0 108.746 179.612 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.31 -165.37 1.21 Allowed 'General case' 0 C--N 1.295 -1.783 0 CA-C-O 122.044 0.926 . . . . 0.0 110.324 -179.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.57 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 38.1 p-10 -71.34 120.69 17.28 Favored 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.833 179.393 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.606 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.5 t -83.26 114.06 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 120.512 -1.367 . . . . 0.0 110.523 178.428 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.428 ' CB ' ' HG2' ' A' ' 59' ' ' GLN . 3.2 t80 -54.24 140.65 32.17 Favored 'General case' 0 C--N 1.296 -1.761 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 178.511 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.637 ' CG2' ' CE1' ' A' ' 9' ' ' PHE . 0.6 OUTLIER -132.51 148.3 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 120.699 -1.251 . . . . 0.0 110.537 -178.583 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.443 ' N ' HD13 ' A' ' 33' ' ' ILE . 24.5 t-80 -144.61 137.6 26.82 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 13.4 p90 -65.78 5.91 0.41 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.789 -1.194 . . . . 0.0 111.52 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.417 ' O ' ' CG ' ' A' ' 34' ' ' GLN . 0.4 OUTLIER -95.12 -35.57 11.84 Favored 'General case' 0 N--CA 1.484 1.267 0 O-C-N 120.345 -1.472 . . . . 0.0 108.744 179.307 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.516 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.82 -41.52 10.6 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.246 -0.909 . . . . 0.0 108.666 179.38 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.514 HG12 ' HB ' ' A' ' 63' ' ' VAL . 7.0 mt -72.73 -4.44 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 119.5 -0.88 . . . . 0.0 109.027 179.327 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.477 ' O ' ' O ' ' A' ' 37' ' ' GLY . 1.7 pp0? -32.7 -43.44 0.09 Allowed 'General case' 0 N--CA 1.497 1.911 0 CA-C-O 121.017 0.437 . . . . 0.0 111.169 -178.401 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.535 ' HA2' ' CG2' ' A' ' 64' ' ' THR . . . 54.11 -169.68 1.29 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -57.13 92.91 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.297 -1.119 . . . . 0.0 110.328 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 34' ' ' GLN . . . 96.51 157.25 31.3 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 110.173 -1.171 . . . . 0.0 110.173 179.115 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.574 ' O ' ' CD2' ' A' ' 38' ' ' PHE . 20.1 t80 -85.92 90.36 8.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.109 -1.23 . . . . 0.0 109.116 179.652 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.3 mtmp? -110.68 157.17 20.02 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.134 -0.979 . . . . 0.0 109.908 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.462 ' O ' ' HG ' ' A' ' 41' ' ' LEU . 0.2 OUTLIER -99.83 -179.06 4.05 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 179.202 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.525 ' CD1' ' N ' ' A' ' 41' ' ' LEU . 0.5 OUTLIER -145.97 152.07 38.81 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.806 -1.184 . . . . 0.0 110.124 -179.357 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.467 ' O ' ' HB3' ' A' ' 45' ' ' GLN . 1.9 mt-10 -103.75 173.44 6.3 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.392 -0.817 . . . . 0.0 108.867 179.388 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.477 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 8.1 tm-20 -62.8 152.2 36.63 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.117 -0.989 . . . . 0.0 108.945 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.477 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 83.55 4.52 89.13 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.464 -1.455 . . . . 0.0 109.464 -179.616 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.545 ' O ' ' HG2' ' A' ' 45' ' ' GLN . 0.8 OUTLIER -75.9 134.12 40.36 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.201 -1.176 . . . . 0.0 110.746 -179.316 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.452 ' HB3' ' OE2' ' A' ' 3' ' ' GLU . . . -94.16 128.25 40.47 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.219 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.576 ' CG2' HD12 ' A' ' 18' ' ' ILE . 33.5 m -123.52 163.61 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 120.77 -1.206 . . . . 0.0 110.525 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.425 ' O ' HG11 ' A' ' 63' ' ' VAL . 3.2 p -117.52 131.9 56.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.147 -0.971 . . . . 0.0 108.951 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.586 ' CE1' HD13 ' A' ' 2' ' ' LEU . 23.0 p90 -161.74 -179.3 7.12 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.865 -1.147 . . . . 0.0 109.966 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -127.5 95.45 4.25 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.668 -0.645 . . . . 0.0 109.484 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.606 ' CD1' ' CG2' ' A' ' 26' ' ' VAL . 1.2 mm -61.49 136.14 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 CA-C-O 122.469 1.128 . . . . 0.0 110.857 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 4.0 m -121.88 -175.01 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 179.364 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.73 114.58 20.13 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.977 -1.077 . . . . 0.0 109.413 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.34 172.68 18.68 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.126 -1.589 . . . . 0.0 109.126 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -37.8 -52.14 1.29 Allowed 'General case' 0 N--CA 1.504 2.252 0 O-C-N 121.426 -1.043 . . . . 0.0 113.411 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 7.2 mtm180 -75.8 22.72 0.14 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 119.609 -1.932 . . . . 0.0 112.162 -178.216 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.32 -177.05 34.65 Favored Glycine 0 N--CA 1.49 2.276 0 O-C-N 120.48 -1.388 . . . . 0.0 109.9 179.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.498 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -66.65 148.9 83.89 Favored 'Trans proline' 0 C--N 1.317 -1.088 0 C-N-CA 121.911 1.741 . . . . 0.0 109.781 178.736 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.48 ' C ' ' CD1' ' A' ' 51' ' ' ILE . 2.6 mt-30 -165.59 151.25 9.24 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.067 -1.021 . . . . 0.0 111.468 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.559 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -81.7 158.79 24.11 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 177.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.516 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -135.4 -42.45 0.7 Allowed 'General case' 0 N--CA 1.507 2.41 0 O-C-N 120.336 -1.477 . . . . 0.0 111.358 -176.788 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -119.43 61.72 0.82 Allowed 'General case' 0 C--N 1.282 -2.357 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.567 ' CG2' ' HB3' ' A' ' 49' ' ' PHE . 18.9 t -79.66 172.48 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.036 -178.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.535 ' CG2' ' HA2' ' A' ' 35' ' ' GLY . 0.2 OUTLIER -153.93 171.08 19.56 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.764 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.32 130.34 34.55 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.931 -1.106 . . . . 0.0 109.407 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.406 ' OE2' ' N ' ' A' ' 67' ' ' ALA . 0.7 OUTLIER -81.76 154.78 25.8 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.286 -0.884 . . . . 0.0 109.716 -179.727 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . 0.406 ' N ' ' OE2' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.424 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.2 mtt . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 121.243 0.544 . . . . 0.0 109.634 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.598 HD13 ' CD1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -119.77 175.76 5.72 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.353 -0.842 . . . . 0.0 110.036 179.841 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.512 ' O ' ' CD2' ' A' ' 2' ' ' LEU . 0.4 OUTLIER -112.04 160.89 17.05 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.194 -0.941 . . . . 0.0 110.155 -178.994 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.23 168.32 28.36 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 6' ' ' VAL . 5.2 mttt -139.86 120.18 13.92 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.026 -1.279 . . . . 0.0 110.086 -179.694 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.542 HG21 ' CD1' ' A' ' 9' ' ' PHE . 3.7 t -41.55 140.51 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 CA-C-O 122.736 1.255 . . . . 0.0 112.073 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.483 ' HG3' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -98.09 -28.1 13.91 Favored 'General case' 0 C--N 1.289 -2.054 0 N-CA-C 103.536 -2.765 . . . . 0.0 103.536 173.008 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 26.1 p-90 177.55 141.74 0.09 Allowed 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 178.17 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.568 ' CD2' ' HB3' ' A' ' 41' ' ' LEU . 0.1 OUTLIER -120.5 139.71 52.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.511 -1.368 . . . . 0.0 110.162 -179.893 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.501 ' ND2' ' HB2' ' A' ' 13' ' ' LYS . 2.0 t30 -132.05 32.88 3.97 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 179.245 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.457 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -37.45 -48.26 0.95 Allowed 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 121.634 0.73 . . . . 0.0 109.192 -179.404 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -59.99 -47.52 85.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.565 -0.709 . . . . 0.0 109.898 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.501 ' HB2' ' ND2' ' A' ' 10' ' ' ASN . 5.1 mptt -69.52 0.36 5.42 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.428 -0.795 . . . . 0.0 110.64 -179.409 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.455 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 109.9 4.38 29.68 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 119.67 -1.253 . . . . 0.0 113.063 178.386 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.466 ' O ' ' C ' ' A' ' 10' ' ' ASN . 5.0 p90 179.6 166.36 1.12 Allowed 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 120.975 2.387 . . . . 0.0 112.163 179.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.53 ' O ' ' CG2' ' A' ' 28' ' ' VAL . . . -147.4 143.25 11.05 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 107.668 -2.173 . . . . 0.0 107.668 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.0 m-85 -115.07 138.95 50.29 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.196 -1.767 . . . . 0.0 110.231 -178.631 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.563 HD11 ' CG1' ' A' ' 28' ' ' VAL . 1.1 mt -106.74 152.71 8.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 177.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.52 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 1.7 tt0 -129.23 136.29 49.92 Favored 'General case' 0 C--N 1.286 -2.175 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.325 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.499 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 6.6 p -138.88 139.43 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 117.592 -1.643 . . . . 0.0 111.861 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -62.41 140.78 58.57 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.112 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.76 -18.15 36.44 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.51 -1.836 . . . . 0.0 108.51 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.499 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 0.1 OUTLIER -136.44 -175.92 4.16 Favored 'General case' 0 N--CA 1.484 1.226 0 O-C-N 121.423 -1.045 . . . . 0.0 108.334 179.336 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.91 -166.38 1.3 Allowed 'General case' 0 C--N 1.296 -1.749 0 CA-C-O 122.143 0.973 . . . . 0.0 111.014 -178.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.532 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.9 p-10 -73.21 102.2 3.57 Favored 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.553 178.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.604 HG12 ' CB ' ' A' ' 60' ' ' ALA . 2.7 t -66.65 128.38 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 120.422 -1.424 . . . . 0.0 111.04 179.326 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.55 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 3.8 t80 -71.1 135.99 47.98 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.563 ' CG1' HD11 ' A' ' 18' ' ' ILE . 11.2 m -149.88 128.21 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 120.406 -1.434 . . . . 0.0 110.721 -179.574 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.634 ' NE2' ' CE2' ' A' ' 30' ' ' PHE . 10.9 t-80 -99.21 166.31 11.29 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.634 ' CE2' ' NE2' ' A' ' 29' ' ' HIS . 48.5 p90 -82.35 31.61 0.4 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.806 -1.184 . . . . 0.0 110.062 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.49 ' O ' ' OE1' ' A' ' 34' ' ' GLN . 32.5 p -116.81 -38.2 3.49 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.976 -1.078 . . . . 0.0 109.11 179.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.517 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -92.56 -41.92 9.96 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 108.508 179.356 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.54 ' CD1' ' N ' ' A' ' 33' ' ' ILE . 1.5 mp -62.7 -11.77 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.535 -0.728 . . . . 0.0 109.083 179.729 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.49 ' OE1' ' O ' ' A' ' 31' ' ' SER . 1.1 pt20 -83.58 -175.96 6.07 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.195 -0.941 . . . . 0.0 109.663 -179.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -169.56 -48.24 0.03 OUTLIER Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -104.6 78.44 1.46 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.294 -1.121 . . . . 0.0 109.126 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.43 163.68 23.71 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.022 -1.631 . . . . 0.0 109.022 -179.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.61 ' CG ' ' O ' ' A' ' 38' ' ' PHE . 10.2 p90 -47.07 103.65 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.884 -1.362 . . . . 0.0 109.154 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.491 ' HE3' ' CE ' ' A' ' 65' ' ' LYS . 13.7 mmtt -106.15 150.64 25.64 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.198 -0.938 . . . . 0.0 109.695 -179.49 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.511 ' OG1' ' N ' ' A' ' 41' ' ' LEU . 0.6 OUTLIER -115.42 -177.68 3.2 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.542 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.568 ' HB3' ' CD2' ' A' ' 9' ' ' PHE . 2.1 tp -144.05 132.95 22.64 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.002 -1.061 . . . . 0.0 110.024 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -98.66 179.51 4.65 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.416 -0.802 . . . . 0.0 108.91 179.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.513 ' OE1' ' N ' ' A' ' 44' ' ' GLY . 0.0 OUTLIER -75.17 141.84 43.6 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.203 -0.936 . . . . 0.0 109.627 -179.511 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.513 ' N ' ' OE1' ' A' ' 43' ' ' GLU . . . 92.69 -7.92 76.98 Favored Glycine 0 N--CA 1.487 2.067 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.486 ' OE1' ' HG ' ' A' ' 41' ' ' LEU . 1.4 tt0 -77.07 125.16 28.86 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.218 -1.166 . . . . 0.0 110.767 -179.411 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.478 ' O ' ' HB2' ' A' ' 66' ' ' GLU . . . -92.27 146.5 23.66 Favored 'General case' 0 N--CA 1.486 1.362 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 178.391 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.477 HG22 HD12 ' A' ' 18' ' ' ILE . 29.9 m -135.92 162.98 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.852 -1.155 . . . . 0.0 109.851 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.3 p -116.0 137.1 52.42 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.036 -1.04 . . . . 0.0 108.442 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.598 ' CD1' HD13 ' A' ' 2' ' ' LEU . 10.4 p90 -162.43 -175.74 4.68 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.884 -1.135 . . . . 0.0 109.852 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -127.35 98.5 5.28 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.555 -0.716 . . . . 0.0 109.586 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.586 HG12 HG23 ' A' ' 26' ' ' VAL . 5.6 mt -61.89 143.69 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 CA-C-O 122.529 1.157 . . . . 0.0 111.309 -179.482 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.501 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 13.9 m -129.51 -176.76 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.27 116.78 23.92 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.728 -1.232 . . . . 0.0 110.369 -179.681 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -116.32 165.03 12.24 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.523 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.431 ' C ' ' O ' ' A' ' 54' ' ' GLY . 4.6 m-20 -38.31 -54.67 1.41 Allowed 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.072 -1.252 . . . . 0.0 112.914 -178.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.1 ttm180 -69.7 -21.26 63.51 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 119.564 -1.96 . . . . 0.0 113.069 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.69 179.2 25.33 Favored Glycine 0 N--CA 1.492 2.415 0 O-C-N 120.27 -1.519 . . . . 0.0 110.358 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.501 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -65.81 140.82 62.85 Favored 'Trans proline' 0 C--N 1.317 -1.094 0 C-N-CA 122.007 1.805 . . . . 0.0 110.464 179.206 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.516 ' HG2' ' CB ' ' A' ' 27' ' ' PHE . 30.3 mt-30 -154.83 151.78 29.03 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.347 -0.846 . . . . 0.0 110.71 -179.591 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.604 ' CB ' HG12 ' A' ' 26' ' ' VAL . . . -83.83 167.76 16.76 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 177.328 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.517 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -135.23 -44.07 0.71 Allowed 'General case' 0 N--CA 1.503 2.22 0 O-C-N 120.289 -1.507 . . . . 0.0 111.672 -176.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.41 ' OD1' ' O ' ' A' ' 62' ' ' ASN . 21.3 p30 -120.0 52.16 1.14 Allowed 'General case' 0 C--N 1.287 -2.11 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.576 ' CG2' ' HB2' ' A' ' 60' ' ' ALA . 20.0 t -67.81 164.13 2.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 121.561 0.696 . . . . 0.0 109.681 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.421 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.2 OUTLIER -146.24 164.29 32.76 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 178.672 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.491 ' CE ' ' HE3' ' A' ' 39' ' ' LYS . 0.0 OUTLIER -79.62 140.41 37.12 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.081 -1.012 . . . . 0.0 109.75 -179.74 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.478 ' HB2' ' O ' ' A' ' 46' ' ' ALA . 1.3 mm-40 -68.23 140.18 56.05 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.216 -0.927 . . . . 0.0 109.643 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 118.06 -0.971 . . . . 0.0 109.353 179.819 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.8 tpp . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.602 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -110.2 179.19 4.17 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.223 -0.923 . . . . 0.0 110.196 -179.88 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.535 ' O ' ' CD2' ' A' ' 2' ' ' LEU . 0.1 OUTLIER -112.66 167.27 10.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.858 -1.151 . . . . 0.0 109.651 -179.284 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -148.54 159.81 28.16 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.7 mttt -133.88 117.96 17.39 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.373 -1.075 . . . . 0.0 110.742 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.546 ' CG2' ' HB3' ' A' ' 45' ' ' GLN . 3.5 t -37.89 146.67 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 123.122 1.439 . . . . 0.0 113.143 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.63 -30.65 9.84 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 103.191 -2.892 . . . . 0.0 103.191 172.137 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.714 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 22.6 p-90 177.66 145.92 0.12 Allowed 'General case' 0 N--CA 1.484 1.267 0 N-CA-C 106.035 -1.839 . . . . 0.0 106.035 177.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.615 ' CE1' HG23 ' A' ' 28' ' ' VAL . 1.4 t80 -119.18 138.45 52.93 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.442 -1.411 . . . . 0.0 109.611 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.497 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.2 t-20 -133.65 36.76 3.32 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.465 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -37.21 -49.59 0.93 Allowed 'General case' 0 N--CA 1.495 1.818 0 CA-C-O 121.443 0.639 . . . . 0.0 109.541 -179.451 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -60.92 -46.22 91.53 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.475 -0.766 . . . . 0.0 109.806 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.498 ' HD2' ' N ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -69.96 1.0 4.96 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.51 -0.744 . . . . 0.0 110.453 -179.606 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.451 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 123.35 -19.52 7.62 Favored Glycine 0 N--CA 1.491 2.355 0 C-N-CA 119.685 -1.245 . . . . 0.0 111.946 178.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.454 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 5.3 p90 173.7 178.4 0.11 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.056 -1.85 . . . . 0.0 111.456 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.581 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -135.52 145.81 17.84 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 107.884 -2.087 . . . . 0.0 107.884 179.505 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.714 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.7 m-30 -104.57 142.18 35.1 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 120.247 -1.737 . . . . 0.0 109.664 -179.245 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.594 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.5 OUTLIER -106.34 164.51 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 178.56 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.568 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 3.1 tm-20 -141.68 129.77 22.08 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.555 ' CG1' ' CB ' ' A' ' 23' ' ' GLN . 10.3 p -135.59 141.65 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 C-N-CA 117.695 -1.602 . . . . 0.0 112.043 -179.657 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -65.65 140.25 58.48 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-N 115.381 -0.827 . . . . 0.0 108.827 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.41 -14.01 42.96 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.555 ' CB ' ' CG1' ' A' ' 20' ' ' VAL . 1.6 mm100 -137.66 -177.37 4.77 Favored 'General case' 0 N--CA 1.483 1.202 0 O-C-N 121.333 -1.098 . . . . 0.0 108.407 179.538 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -100.73 -166.27 1.3 Allowed 'General case' 0 C--N 1.296 -1.748 0 CA-C-O 121.962 0.887 . . . . 0.0 110.378 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.594 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.4 m-20 -72.08 123.46 22.88 Favored 'General case' 0 N--CA 1.486 1.367 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.676 179.149 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.615 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -84.91 110.5 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.02 0 O-C-N 120.589 -1.32 . . . . 0.0 111.454 178.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -55.37 133.73 49.87 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 178.07 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.615 HG23 ' CE1' ' A' ' 9' ' ' PHE . 0.6 OUTLIER -132.75 137.19 54.53 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 C-N-CA 117.891 -1.524 . . . . 0.0 110.661 -178.782 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.473 ' O ' HD13 ' A' ' 33' ' ' ILE . 5.6 t-160 -109.81 159.49 17.15 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.572 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 46.1 p90 -82.67 39.86 0.64 Allowed 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.763 -1.211 . . . . 0.0 109.831 -179.674 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.51 ' O ' ' HG2' ' A' ' 34' ' ' GLN . 3.1 t -137.65 -33.2 0.73 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.816 -1.178 . . . . 0.0 110.518 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.536 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -93.53 -49.91 5.67 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.961 -1.087 . . . . 0.0 109.706 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.614 ' CG1' ' HB ' ' A' ' 63' ' ' VAL . 1.4 mp -75.93 0.53 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.677 -0.64 . . . . 0.0 110.359 -178.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.51 ' HG2' ' O ' ' A' ' 31' ' ' SER . 9.7 pt20 -77.75 -3.75 42.85 Favored 'General case' 0 C--N 1.293 -1.851 0 O-C-N 121.403 -0.81 . . . . 0.0 109.916 -179.235 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 47.35 -169.7 0.06 OUTLIER Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -50.18 130.91 23.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.35 -1.088 . . . . 0.0 109.955 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 76.12 157.84 7.49 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 179.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -85.6 104.35 15.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.115 -1.226 . . . . 0.0 109.033 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -109.84 157.75 18.87 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.248 -0.908 . . . . 0.0 109.867 -179.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.446 ' C ' ' CD2' ' A' ' 41' ' ' LEU . 0.2 OUTLIER -99.16 169.17 9.58 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.732 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.596 ' HB2' ' CD2' ' A' ' 9' ' ' PHE . 4.0 mm? -122.48 178.37 5.0 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.733 -1.229 . . . . 0.0 109.999 -179.285 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -156.89 -179.82 8.57 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.382 -0.824 . . . . 0.0 109.084 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 21.0 tp10 -70.65 145.51 50.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.197 -0.939 . . . . 0.0 109.056 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 84.94 -2.34 88.33 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -178.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.546 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 3.6 tt0 -55.9 111.66 0.99 Allowed 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.489 -1.007 . . . . 0.0 110.516 -179.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -94.43 116.25 28.57 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 177.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.521 HG12 ' NE2' ' A' ' 45' ' ' GLN . 26.2 m -124.13 163.13 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 120.627 -1.296 . . . . 0.0 110.882 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.421 ' O ' HG11 ' A' ' 63' ' ' VAL . 22.7 p -115.87 137.22 52.3 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 108.5 179.362 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.61 ' CE1' HG13 ' A' ' 51' ' ' ILE . 9.4 p90 -163.66 -177.97 5.5 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.816 -1.177 . . . . 0.0 109.941 -179.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -127.15 93.02 3.64 Favored 'General case' 0 C--N 1.295 -1.773 0 O-C-N 121.688 -0.633 . . . . 0.0 109.475 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.615 ' CD1' ' CG2' ' A' ' 26' ' ' VAL . 16.3 mt -62.1 128.92 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.023 -1.048 . . . . 0.0 109.886 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.507 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 16.1 m -108.11 -176.59 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 178.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -123.32 114.66 20.49 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.012 -1.055 . . . . 0.0 109.735 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.405 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -125.89 169.04 17.86 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.591 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' A' ' 54' ' ' GLY . 22.1 m120 -37.44 -51.99 1.13 Allowed 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.227 -1.161 . . . . 0.0 113.412 -178.45 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.9 tpt180 -75.33 22.62 0.12 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 119.718 -1.864 . . . . 0.0 112.352 -178.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.02 -178.32 31.94 Favored Glycine 0 N--CA 1.494 2.551 0 O-C-N 120.414 -1.429 . . . . 0.0 110.269 179.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -67.91 155.01 71.4 Favored 'Trans proline' 0 C--N 1.32 -0.947 0 C-N-CA 122.005 1.803 . . . . 0.0 109.918 178.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.442 ' HG3' ' O ' ' A' ' 58' ' ' PRO . 0.3 OUTLIER -166.07 143.22 5.31 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.982 -1.074 . . . . 0.0 111.398 -179.693 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.552 ' HB3' ' CG2' ' A' ' 63' ' ' VAL . . . -78.09 157.63 29.44 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 177.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.536 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.54 -44.26 0.75 Allowed 'General case' 0 N--CA 1.507 2.395 0 O-C-N 120.498 -1.376 . . . . 0.0 111.933 -176.407 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -119.81 51.78 1.16 Allowed 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.614 ' HB ' ' CG1' ' A' ' 33' ' ' ILE . 21.2 t -68.03 169.2 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-O 121.693 0.758 . . . . 0.0 109.513 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.418 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.2 OUTLIER -154.62 178.14 10.43 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 178.237 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.579 ' N ' ' CD ' ' A' ' 65' ' ' LYS . 0.0 OUTLIER -84.36 140.89 31.27 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.043 -1.036 . . . . 0.0 109.557 -179.712 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.433 ' O ' ' CB ' ' A' ' 67' ' ' ALA . 1.0 OUTLIER -95.22 139.94 30.84 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.31 -0.869 . . . . 0.0 109.292 179.684 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . 0.433 ' CB ' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 118.071 -0.966 . . . . 0.0 109.383 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 121.235 0.541 . . . . 0.0 109.554 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.66 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.32 172.61 12.49 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.143 -0.973 . . . . 0.0 110.011 179.727 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.512 ' N ' HD21 ' A' ' 2' ' ' LEU . 0.0 OUTLIER -113.92 149.03 35.8 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 121.213 -0.929 . . . . 0.0 110.389 -179.372 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.512 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -121.33 166.16 14.26 Favored Glycine 0 N--CA 1.483 1.796 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 179.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.47 ' O ' ' C ' ' A' ' 6' ' ' VAL . 2.0 mttm -140.3 119.0 12.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.922 -1.34 . . . . 0.0 109.609 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.522 HG11 ' N ' ' A' ' 8' ' ' TRP . 2.7 t -33.5 136.67 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 CA-C-O 122.913 1.34 . . . . 0.0 113.401 -179.327 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.479 ' CG ' ' HB3' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -101.8 -31.51 10.71 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 103.149 -2.908 . . . . 0.0 103.149 172.61 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.699 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 22.8 p-90 174.25 145.25 0.05 Allowed 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 178.009 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.641 ' CG ' ' CB ' ' A' ' 41' ' ' LEU . 0.2 OUTLIER -114.21 147.04 39.58 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.149 -1.594 . . . . 0.0 109.952 179.333 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.544 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 80.5 m-20 -130.21 38.68 3.75 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 179.013 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.522 ' HB3' ' CD2' ' A' ' 41' ' ' LEU . 24.7 p -40.89 -41.59 1.64 Allowed 'General case' 0 N--CA 1.488 1.47 0 CA-C-O 121.71 0.767 . . . . 0.0 109.103 -179.078 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -59.9 -48.4 81.87 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.537 -0.727 . . . . 0.0 110.414 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.567 ' N ' ' CD ' ' A' ' 13' ' ' LYS . 2.2 mptp? -73.83 4.35 5.36 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.215 -0.928 . . . . 0.0 110.125 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.43 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 92.24 23.55 26.71 Favored Glycine 0 N--CA 1.49 2.242 0 C-N-CA 120.251 -0.976 . . . . 0.0 112.144 178.549 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.496 ' O ' ' C ' ' A' ' 10' ' ' ASN . 26.7 p90 179.44 167.19 1.09 Allowed 'General case' 0 N--CA 1.501 2.076 0 CA-C-N 120.102 1.951 . . . . 0.0 111.631 179.447 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.576 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -149.0 150.89 23.09 Favored Glycine 0 N--CA 1.497 2.752 0 N-CA-C 106.995 -2.442 . . . . 0.0 106.995 179.328 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.699 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 6.1 m-85 -117.24 138.31 51.8 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 120.035 1.917 . . . . 0.0 110.235 -178.648 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.536 ' CD1' HG23 ' A' ' 47' ' ' VAL . 1.7 mt -105.47 146.55 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.809 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.528 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 9.6 pt-20 -121.01 137.02 54.85 Favored 'General case' 0 C--N 1.285 -2.229 0 C-N-CA 119.472 -0.891 . . . . 0.0 108.944 178.45 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.504 HG12 ' HB2' ' A' ' 23' ' ' GLN . 10.0 p -138.73 140.93 38.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 C-N-CA 117.822 -1.551 . . . . 0.0 111.787 179.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.87 140.49 58.28 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.391 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 87.77 -19.1 35.16 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.504 ' HB2' HG12 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -136.4 -175.43 4.0 Favored 'General case' 0 C--N 1.308 -1.219 0 O-C-N 121.416 -1.049 . . . . 0.0 108.693 179.406 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.61 -165.1 1.17 Allowed 'General case' 0 C--N 1.296 -1.756 0 CA-C-O 122.009 0.909 . . . . 0.0 110.588 -179.051 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.528 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 0.9 OUTLIER -71.65 93.24 1.23 Allowed 'General case' 0 N--CA 1.487 1.388 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.037 179.257 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.618 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.7 t -56.27 142.4 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 120.299 -1.501 . . . . 0.0 109.952 178.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.517 ' N ' HG11 ' A' ' 26' ' ' VAL . 5.0 t80 -71.69 146.3 48.3 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 176.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.557 ' HB ' ' CD1' ' A' ' 33' ' ' ILE . 2.0 m -142.06 113.96 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 120.332 -1.48 . . . . 0.0 110.363 -179.299 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.419 ' O ' HD11 ' A' ' 33' ' ' ILE . 7.5 t60 -99.55 148.95 23.74 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 178.296 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.422 ' O ' ' HD2' ' A' ' 39' ' ' LYS . 49.8 p90 -79.86 32.71 0.26 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.747 -1.221 . . . . 0.0 110.163 -179.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.78 -36.93 3.34 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.963 -1.085 . . . . 0.0 108.924 179.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.519 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -92.36 -47.16 7.33 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 179.366 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.557 ' CD1' ' HB ' ' A' ' 28' ' ' VAL . 11.6 mt -58.22 -16.22 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 CA-C-O 121.495 0.664 . . . . 0.0 109.44 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.437 ' HG2' ' HA ' ' A' ' 39' ' ' LYS . 0.0 OUTLIER -111.41 -168.84 1.36 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.59 -0.694 . . . . 0.0 109.886 -179.557 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -152.28 -169.97 18.29 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.081 -1.607 . . . . 0.0 109.081 179.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -49.53 92.4 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.105 -1.232 . . . . 0.0 109.339 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 35' ' ' GLY . . . 166.21 -170.05 40.68 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.427 ' O ' ' CD1' ' A' ' 38' ' ' PHE . 45.2 p90 -67.06 139.66 57.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.285 -1.127 . . . . 0.0 109.582 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.437 ' HA ' ' HG2' ' A' ' 34' ' ' GLN . 24.1 mtmt -110.24 137.37 48.07 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -0.891 . . . . 0.0 109.43 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.1 t -169.35 -169.91 1.01 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.058 -1.026 . . . . 0.0 109.761 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.641 ' CB ' ' CG ' ' A' ' 9' ' ' PHE . 0.8 OUTLIER -119.99 179.91 4.12 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.35 -0.844 . . . . 0.0 110.247 -179.511 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.468 ' O ' ' CB ' ' A' ' 45' ' ' GLN . 0.1 OUTLIER -163.92 120.59 1.69 Allowed 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 179.246 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -62.05 140.88 58.35 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.286 -0.884 . . . . 0.0 108.975 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 69.06 16.14 70.37 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.34 -1.904 . . . . 0.0 108.34 -178.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.468 ' CB ' ' O ' ' A' ' 42' ' ' GLU . 44.7 tt0 -72.54 116.11 12.6 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.535 -0.98 . . . . 0.0 110.351 -179.342 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.445 ' CB ' ' OE2' ' A' ' 3' ' ' GLU . . . -92.16 126.05 37.09 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 178.322 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.536 HG23 ' CD1' ' A' ' 18' ' ' ILE . 31.3 m -122.32 165.06 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 120.704 -1.247 . . . . 0.0 110.462 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.4 p -117.01 122.55 44.53 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.66 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 6.3 p90 -150.85 -178.45 6.59 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 120.858 -1.151 . . . . 0.0 109.726 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -127.71 95.02 4.1 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.621 HG13 ' CE1' ' A' ' 49' ' ' PHE . 13.3 mt -62.35 136.34 25.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 CA-C-O 122.326 1.06 . . . . 0.0 110.906 -179.165 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 11.5 m -119.53 -176.61 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 179.124 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -123.48 113.66 19.05 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.01 -1.057 . . . . 0.0 109.629 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.23 171.66 16.52 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -37.99 -52.13 1.37 Allowed 'General case' 0 N--CA 1.505 2.292 0 O-C-N 121.367 -1.078 . . . . 0.0 113.735 -178.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.38 22.38 0.23 Allowed 'General case' 0 N--CA 1.5 2.046 0 O-C-N 119.655 -1.903 . . . . 0.0 112.247 -177.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.18 -176.97 29.67 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.451 -1.357 . . . . 0.0 110.257 179.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.489 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -66.94 153.43 77.93 Favored 'Trans proline' 0 C--N 1.32 -0.938 0 C-N-CA 121.915 1.744 . . . . 0.0 109.977 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -165.65 147.04 7.17 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.207 -0.933 . . . . 0.0 111.083 -179.428 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.558 ' HB3' ' CG2' ' A' ' 63' ' ' VAL . . . -81.04 161.7 24.09 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 177.051 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.519 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.27 -44.98 0.77 Allowed 'General case' 0 N--CA 1.508 2.441 0 O-C-N 120.155 -1.59 . . . . 0.0 111.93 -176.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -119.02 50.73 1.18 Allowed 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.558 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 19.9 t -64.63 157.64 4.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.76 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -142.14 173.57 11.4 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.153 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.409 ' O ' ' HG3' ' A' ' 65' ' ' LYS . 0.4 OUTLIER -79.3 126.0 30.22 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.929 -1.107 . . . . 0.0 109.376 -179.917 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.456 ' HG3' ' CG ' ' A' ' 3' ' ' GLU . 10.1 tm-20 -90.58 97.03 10.94 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.285 -0.884 . . . . 0.0 109.602 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . 0.412 ' C ' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.524 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.6 mtp . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 121.24 0.543 . . . . 0.0 109.63 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.619 HD13 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.84 169.34 17.81 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.205 -0.935 . . . . 0.0 110.385 179.585 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.503 ' HG2' ' O ' ' A' ' 47' ' ' VAL . 0.1 OUTLIER -121.26 136.75 54.92 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.473 -0.767 . . . . 0.0 109.498 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -129.59 -164.19 11.35 Favored Glycine 0 N--CA 1.484 1.834 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 20.9 ttpt -151.71 135.9 16.68 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.882 -1.364 . . . . 0.0 111.048 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.483 HG12 ' N ' ' A' ' 8' ' ' TRP . 3.3 t -42.58 140.07 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 122.865 1.317 . . . . 0.0 112.856 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.422 ' CG ' ' OE1' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -97.4 -31.13 12.53 Favored 'General case' 0 C--N 1.29 -2.011 0 N-CA-C 103.009 -2.96 . . . . 0.0 103.009 172.631 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.707 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.2 p-90 177.45 145.85 0.11 Allowed 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 177.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.519 ' CE1' ' CD1' ' A' ' 41' ' ' LEU . 0.7 OUTLIER -113.81 146.32 40.12 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 120.591 -1.318 . . . . 0.0 109.61 179.234 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.562 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 31.4 m-20 -130.08 43.03 3.19 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 10' ' ' ASN . 53.4 p -41.33 -41.44 1.94 Allowed 'General case' 0 N--CA 1.489 1.511 0 CA-C-O 121.612 0.72 . . . . 0.0 109.077 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -59.49 -49.37 78.06 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.435 -0.791 . . . . 0.0 110.607 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.51 ' HD2' ' N ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -72.95 4.36 4.3 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.01 -1.056 . . . . 0.0 110.395 -179.429 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.56 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 91.46 23.91 27.62 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 120.051 -1.071 . . . . 0.0 111.933 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.478 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 11.1 p90 178.92 167.63 0.93 Allowed 'General case' 0 N--CA 1.499 1.987 0 CA-C-N 120.122 1.961 . . . . 0.0 111.815 179.306 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.455 ' O ' HG21 ' A' ' 28' ' ' VAL . . . -146.58 144.33 12.59 Favored Glycine 0 N--CA 1.497 2.758 0 N-CA-C 107.271 -2.331 . . . . 0.0 107.271 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.707 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.1 m-85 -110.13 142.68 41.3 Favored 'General case' 0 N--CA 1.482 1.134 0 O-C-N 120.013 -1.874 . . . . 0.0 110.153 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.591 ' CG2' ' N ' ' A' ' 19' ' ' GLU . 0.6 OUTLIER -105.91 165.23 3.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 177.975 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.591 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 6.8 tt0 -133.92 130.17 37.36 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.47 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.571 ' CG1' ' CB ' ' A' ' 23' ' ' GLN . 11.3 p -131.95 139.11 51.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 C-N-CA 117.728 -1.589 . . . . 0.0 111.699 -179.645 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -65.4 140.7 58.66 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.266 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.2 -9.58 46.8 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.571 ' CB ' ' CG1' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -139.78 -175.43 4.21 Favored 'General case' 0 C--N 1.309 -1.158 0 O-C-N 121.125 -1.221 . . . . 0.0 108.871 179.675 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -100.48 -165.68 1.24 Allowed 'General case' 0 C--N 1.295 -1.77 0 CA-C-O 122.208 1.004 . . . . 0.0 110.583 -178.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.58 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.2 m-20 -71.04 119.95 15.9 Favored 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 115.714 -0.676 . . . . 0.0 109.74 179.353 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.6 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.2 t -78.82 114.31 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 120.674 -1.267 . . . . 0.0 111.398 178.632 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.62 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 2.0 t80 -66.26 125.03 24.3 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.38 -0.971 . . . . 0.0 108.38 178.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.515 HG22 ' CD1' ' A' ' 18' ' ' ILE . 2.3 m -143.99 136.82 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 120.593 -1.317 . . . . 0.0 110.26 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.629 ' NE2' ' CE1' ' A' ' 30' ' ' PHE . 35.6 t60 -98.85 166.91 11.07 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 179.273 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.629 ' CE1' ' NE2' ' A' ' 29' ' ' HIS . 42.0 p90 -83.61 38.99 0.65 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.773 -1.204 . . . . 0.0 109.424 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.447 ' HA ' ' NE2' ' A' ' 34' ' ' GLN . 2.5 m -132.27 -30.39 1.52 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.091 -1.006 . . . . 0.0 109.527 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.494 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.53 -42.12 10.42 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.108 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.495 ' O ' ' HA ' ' A' ' 64' ' ' THR . 17.1 mt -53.63 -19.74 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.193 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.483 ' NE2' ' O ' ' A' ' 30' ' ' PHE . 2.9 pt20 -110.56 -169.59 1.49 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.33 -0.856 . . . . 0.0 109.312 179.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -154.59 -49.85 0.01 OUTLIER Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.439 ' O ' ' O ' ' A' ' 37' ' ' GLY . 1.0 OUTLIER -103.65 130.88 51.18 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.299 -1.118 . . . . 0.0 109.225 179.791 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.439 ' O ' ' O ' ' A' ' 36' ' ' GLU . . . 56.08 167.61 0.06 OUTLIER Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.154 -1.578 . . . . 0.0 109.154 -179.688 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.582 ' CG ' ' O ' ' A' ' 38' ' ' PHE . 7.0 p90 -82.14 114.72 20.85 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.065 -1.256 . . . . 0.0 109.341 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.401 ' HB2' ' CB ' ' A' ' 34' ' ' GLN . 0.0 OUTLIER -109.3 -174.4 2.5 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.086 -1.009 . . . . 0.0 109.483 -179.749 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.478 ' OG1' ' N ' ' A' ' 41' ' ' LEU . 0.1 OUTLIER -160.58 178.85 9.1 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.278 -0.889 . . . . 0.0 109.234 179.813 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.519 ' CD1' ' CE1' ' A' ' 9' ' ' PHE . 0.2 OUTLIER -145.5 168.34 20.83 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.964 -1.085 . . . . 0.0 109.511 -179.974 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.477 ' O ' ' HB2' ' A' ' 45' ' ' GLN . 0.3 OUTLIER -116.2 -179.1 3.57 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.263 -0.898 . . . . 0.0 109.193 179.833 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.463 ' OE1' HG11 ' A' ' 6' ' ' VAL . 12.4 tp10 -68.88 145.31 53.8 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.191 -0.943 . . . . 0.0 109.035 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 83.85 2.21 89.73 Favored Glycine 0 N--CA 1.486 1.998 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.493 ' NE2' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -76.21 136.97 39.72 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.153 -1.204 . . . . 0.0 110.319 -179.675 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.493 ' O ' ' NE2' ' A' ' 45' ' ' GLN . . . -93.34 140.23 29.78 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.224 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.503 ' O ' ' HG2' ' A' ' 3' ' ' GLU . 26.8 m -134.09 155.92 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.877 -1.139 . . . . 0.0 109.975 179.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.1 p -117.32 120.39 38.05 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.09 -1.007 . . . . 0.0 108.613 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.619 ' CE1' HD13 ' A' ' 2' ' ' LEU . 10.8 p90 -149.09 -178.45 6.39 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.056 -1.028 . . . . 0.0 109.729 -179.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.503 ' CG ' ' O ' ' A' ' 50' ' ' GLU . 5.1 pt-20 -127.74 96.53 4.54 Favored 'General case' 0 C--N 1.296 -1.732 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.098 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.614 HG13 ' CE1' ' A' ' 49' ' ' PHE . 10.6 mt -62.38 132.26 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.05 -1.031 . . . . 0.0 110.105 -179.427 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 6.3 m -113.63 -176.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 178.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -124.0 116.13 22.35 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.974 -1.079 . . . . 0.0 109.844 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.404 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -129.96 172.08 20.22 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 179.757 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.404 ' C ' ' O ' ' A' ' 54' ' ' GLY . 0.7 OUTLIER -37.71 -52.03 1.25 Allowed 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.378 -1.071 . . . . 0.0 113.394 -178.572 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.26 22.69 0.11 Allowed 'General case' 0 N--CA 1.501 2.12 0 O-C-N 119.717 -1.865 . . . . 0.0 112.262 -178.303 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.37 -178.28 35.43 Favored Glycine 0 N--CA 1.491 2.337 0 O-C-N 120.434 -1.416 . . . . 0.0 110.13 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.506 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.2 Cg_endo -68.81 150.91 74.26 Favored 'Trans proline' 0 C--N 1.32 -0.938 0 C-N-CA 122.046 1.831 . . . . 0.0 109.791 178.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.487 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 2.9 mt-30 -165.99 148.15 7.13 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.018 -1.051 . . . . 0.0 111.65 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.557 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -79.29 157.14 27.79 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 177.279 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.494 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.82 -42.9 0.74 Allowed 'General case' 0 N--CA 1.506 2.351 0 O-C-N 120.354 -1.466 . . . . 0.0 112.027 -176.46 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -119.13 52.17 1.08 Allowed 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.546 ' CG2' ' HB3' ' A' ' 49' ' ' PHE . 15.0 t -66.68 157.41 5.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.668 -179.436 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.495 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.1 OUTLIER -135.8 158.49 44.26 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 178.713 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.403 ' HG3' ' O ' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -81.42 126.18 31.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.907 -1.121 . . . . 0.0 109.445 -179.883 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.44 ' OE2' ' HG3' ' A' ' 3' ' ' GLU . 4.3 tt0 -88.06 138.16 31.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.232 -0.918 . . . . 0.0 109.565 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.497 0 CA-C-O 117.936 -1.03 . . . . 0.0 109.47 -179.991 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.1 mmt . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.262 0.553 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.642 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.67 179.1 6.89 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.303 -0.873 . . . . 0.0 110.018 179.746 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.531 ' O ' ' CD2' ' A' ' 2' ' ' LEU . 0.5 OUTLIER -112.51 168.13 9.89 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.829 -1.17 . . . . 0.0 110.128 -178.857 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.495 ' N ' ' OE1' ' A' ' 3' ' ' GLU . . . -149.95 156.58 26.82 Favored Glycine 0 N--CA 1.486 2.026 0 N-CA-C 109.083 -1.607 . . . . 0.0 109.083 -179.557 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.442 ' HG2' ' C ' ' A' ' 4' ' ' GLY . 0.5 OUTLIER -135.37 120.8 19.2 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.257 -1.143 . . . . 0.0 110.575 -179.44 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.489 HG12 ' N ' ' A' ' 8' ' ' TRP . 2.6 t -39.83 138.62 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 CA-C-O 122.749 1.261 . . . . 0.0 113.112 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.449 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -100.25 -27.59 13.42 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 103.608 -2.738 . . . . 0.0 103.608 172.948 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.705 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.6 p-90 178.41 145.13 0.13 Allowed 'General case' 0 N--CA 1.482 1.166 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 178.233 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.626 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.3 OUTLIER -114.39 146.38 40.65 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 120.445 -1.409 . . . . 0.0 110.391 -179.793 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.53 ' HB2' ' O ' ' A' ' 15' ' ' PHE . 24.1 m-20 -127.88 37.46 4.18 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 107.097 -1.445 . . . . 0.0 107.097 178.119 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.5 p -38.8 -51.21 1.72 Allowed 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.229 -178.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -59.78 -45.76 91.29 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.365 -0.834 . . . . 0.0 110.291 -179.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.524 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -70.47 0.28 6.98 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.34 -0.85 . . . . 0.0 110.735 -179.001 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.497 ' O ' ' NE2' ' A' ' 29' ' ' HIS . . . 111.57 -2.97 27.73 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.61 -1.281 . . . . 0.0 113.199 177.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.53 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 0.3 OUTLIER 177.63 176.99 0.38 Allowed 'General case' 0 N--CA 1.499 2.019 0 CA-C-N 120.562 2.181 . . . . 0.0 111.82 -179.751 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.626 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -141.98 156.73 26.12 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 107.703 -2.159 . . . . 0.0 107.703 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.705 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.8 m-85 -110.45 139.9 45.23 Favored 'General case' 0 N--CA 1.482 1.127 0 O-C-N 119.929 -1.924 . . . . 0.0 109.82 -179.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.581 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 1.3 mt -106.54 152.8 8.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 178.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 0.0 OUTLIER -128.69 135.79 49.73 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 178.333 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.557 ' CG1' ' CB ' ' A' ' 23' ' ' GLN . 11.6 p -136.44 139.87 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 C-N-CA 118.213 -1.395 . . . . 0.0 111.483 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -65.38 140.37 58.64 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 115.485 -0.779 . . . . 0.0 109.424 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.92 -10.27 48.21 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.557 ' CB ' ' CG1' ' A' ' 20' ' ' VAL . 3.8 mm-40 -137.92 -174.12 3.7 Favored 'General case' 0 C--N 1.31 -1.117 0 O-C-N 121.184 -1.186 . . . . 0.0 108.787 179.796 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -100.56 -167.16 1.4 Allowed 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 122.077 0.942 . . . . 0.0 110.715 -178.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.581 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 0.2 OUTLIER -73.21 108.15 5.93 Favored 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.859 179.214 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.64 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.5 t -71.62 116.73 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.046 0 O-C-N 120.17 -1.581 . . . . 0.0 111.074 178.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.462 ' HB2' ' NE2' ' A' ' 59' ' ' GLN . 3.8 t80 -53.46 142.53 21.82 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 177.636 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.571 ' CG1' ' CD1' ' A' ' 18' ' ' ILE . 0.7 OUTLIER -135.06 154.87 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 120.788 -1.195 . . . . 0.0 109.653 -178.857 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.497 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 9.5 t-160 -150.23 152.55 34.76 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -80.05 27.49 0.31 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.936 -1.102 . . . . 0.0 109.956 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.63 -43.84 2.88 Favored 'General case' 0 C--N 1.308 -1.209 0 O-C-N 120.946 -1.096 . . . . 0.0 108.661 179.759 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.5 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -95.67 -49.36 5.4 Favored 'General case' 0 N--CA 1.493 1.721 0 CA-C-O 121.92 0.867 . . . . 0.0 108.973 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.547 ' CD1' ' CG1' ' A' ' 63' ' ' VAL . 6.0 mm -48.88 -29.38 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.91 -0.494 . . . . 0.0 110.381 -178.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -112.57 -52.01 2.81 Favored 'General case' 0 N--CA 1.499 1.976 0 C-N-CA 118.867 -1.133 . . . . 0.0 109.854 -179.274 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 141.15 171.07 12.45 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 108.804 -1.719 . . . . 0.0 108.804 -179.146 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -52.01 107.57 0.21 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.104 -1.233 . . . . 0.0 109.704 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 155.34 156.39 7.75 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -86.08 89.02 7.69 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.986 -1.302 . . . . 0.0 109.646 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 24.2 mmtp -110.53 171.68 7.31 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.149 -0.969 . . . . 0.0 109.769 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -160.12 165.08 32.41 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.266 -0.896 . . . . 0.0 109.239 179.609 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.491 HD13 ' CE2' ' A' ' 9' ' ' PHE . 0.3 OUTLIER -151.73 -168.97 3.23 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.722 -1.236 . . . . 0.0 109.411 179.916 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -93.81 174.43 7.18 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 179.24 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.547 ' CG ' ' HA ' ' A' ' 8' ' ' TRP . 27.6 tt0 -77.98 61.49 2.58 Favored 'General case' 0 N--CA 1.503 2.177 0 O-C-N 121.269 -0.895 . . . . 0.0 112.481 -178.608 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -170.71 41.9 0.19 Allowed Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.976 -1.65 . . . . 0.0 108.976 177.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.532 ' HG3' ' CG1' ' A' ' 47' ' ' VAL . 7.6 tp-100 -78.77 130.12 35.4 Favored 'General case' 0 N--CA 1.478 0.932 0 O-C-N 120.837 -1.39 . . . . 0.0 111.676 -178.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -96.44 112.82 24.42 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 176.327 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.532 ' CG1' ' HG3' ' A' ' 45' ' ' GLN . 10.4 m -129.6 164.06 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 C-N-CA 117.881 -1.527 . . . . 0.0 111.706 -178.036 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.404 ' HA ' ' HA ' ' A' ' 3' ' ' GLU . 2.1 p -116.35 133.78 55.63 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 178.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.642 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 6.5 p90 -153.55 178.31 9.97 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.093 -1.004 . . . . 0.0 109.782 -179.198 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.6 93.52 4.07 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 179.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.64 ' CD1' ' CG2' ' A' ' 26' ' ' VAL . 14.6 mt -61.92 125.49 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.962 -1.086 . . . . 0.0 109.611 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.538 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.4 m -106.58 -176.07 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 178.571 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -124.06 113.57 18.57 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.052 -1.03 . . . . 0.0 109.569 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.36 170.91 16.5 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.786 -1.726 . . . . 0.0 108.786 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -37.83 -52.08 1.3 Allowed 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.331 -1.099 . . . . 0.0 113.386 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 11.3 mtp180 -76.65 22.38 0.18 Allowed 'General case' 0 N--CA 1.501 2.089 0 O-C-N 119.593 -1.942 . . . . 0.0 112.411 -177.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.26 179.43 31.29 Favored Glycine 0 N--CA 1.494 2.536 0 O-C-N 120.471 -1.393 . . . . 0.0 110.65 179.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.538 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.7 Cg_endo -69.09 152.23 72.81 Favored 'Trans proline' 0 C--N 1.32 -0.932 0 C-N-CA 122.135 1.89 . . . . 0.0 110.205 178.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.462 ' NE2' ' HB2' ' A' ' 27' ' ' PHE . 0.8 OUTLIER -166.43 149.44 7.03 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 120.959 -1.088 . . . . 0.0 111.697 -179.772 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.593 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -80.3 154.04 28.07 Favored 'General case' 0 N--CA 1.495 1.783 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 177.06 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.5 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.74 -39.53 0.79 Allowed 'General case' 0 N--CA 1.509 2.514 0 O-C-N 120.41 -1.431 . . . . 0.0 111.687 -176.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -118.89 52.01 1.08 Allowed 'General case' 0 C--N 1.284 -2.265 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.577 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 21.1 t -68.19 158.25 5.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.626 -179.14 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.472 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.2 OUTLIER -148.51 175.45 11.14 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.671 -0.812 . . . . 0.0 109.394 179.36 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 1.2 tttt -77.35 137.98 39.06 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.078 -1.013 . . . . 0.0 109.552 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -57.31 113.48 1.77 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.242 -0.911 . . . . 0.0 109.545 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.03 -0.986 . . . . 0.0 109.498 179.78 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.662 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -141.15 173.48 11.45 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.28 -0.887 . . . . 0.0 110.001 179.506 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.454 ' HG3' ' O ' ' A' ' 47' ' ' VAL . 0.1 OUTLIER -114.76 150.87 34.69 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.043 -1.036 . . . . 0.0 110.555 -179.053 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.472 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -129.62 169.85 20.67 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 108.912 -1.675 . . . . 0.0 108.912 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.44 ' O ' ' C ' ' A' ' 6' ' ' VAL . 5.2 ttmt -141.76 125.71 17.19 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.978 -1.307 . . . . 0.0 110.564 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.52 HG11 ' N ' ' A' ' 8' ' ' TRP . 2.8 t -32.01 140.97 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 CA-C-O 123.333 1.54 . . . . 0.0 114.188 -179.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.453 ' HD3' ' O ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -108.51 -31.79 7.66 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 103.184 -2.895 . . . . 0.0 103.184 172.48 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.696 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 15.4 p-90 175.79 146.49 0.08 Allowed 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 105.9 -1.889 . . . . 0.0 105.9 177.656 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.566 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.2 OUTLIER -117.93 145.35 44.74 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.539 -1.351 . . . . 0.0 109.636 179.237 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.488 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.9 t-20 -131.85 41.26 3.29 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.504 ' HB3' ' CD2' ' A' ' 41' ' ' LEU . 2.1 p -39.17 -45.87 1.39 Allowed 'General case' 0 C--N 1.295 -1.768 0 CA-C-O 121.445 0.641 . . . . 0.0 109.378 -179.542 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -61.96 -45.27 94.4 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.322 -0.861 . . . . 0.0 110.015 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.559 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 1.0 OUTLIER -69.9 0.2 6.25 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.361 -0.837 . . . . 0.0 109.866 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.52 ' O ' ' CD2' ' A' ' 29' ' ' HIS . . . 91.15 20.43 38.92 Favored Glycine 0 N--CA 1.488 2.121 0 O-C-N 121.174 -0.954 . . . . 0.0 111.569 179.105 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.559 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 16.6 p90 -176.87 165.27 2.44 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 119.81 1.805 . . . . 0.0 111.532 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.566 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -150.2 141.79 9.09 Favored Glycine 0 N--CA 1.497 2.725 0 N-CA-C 107.172 -2.371 . . . . 0.0 107.172 179.401 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.696 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.3 m-85 -109.12 139.13 44.44 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.088 -1.83 . . . . 0.0 110.885 -178.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.54 HD12 ' CG2' ' A' ' 47' ' ' VAL . 1.0 OUTLIER -106.63 146.9 12.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 N-CA-C 105.665 -1.976 . . . . 0.0 105.665 177.322 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.512 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 15.1 tt0 -121.07 135.13 55.26 Favored 'General case' 0 C--N 1.28 -2.439 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.009 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.418 HG11 ' HB2' ' A' ' 23' ' ' GLN . 7.5 p -138.49 140.81 38.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 C-N-CA 117.567 -1.653 . . . . 0.0 111.891 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.74 140.5 58.74 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.105 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.51 ' O ' ' NE2' ' A' ' 23' ' ' GLN . . . 86.97 -18.86 33.21 Favored Glycine 0 N--CA 1.486 2.013 0 N-CA-C 108.29 -1.924 . . . . 0.0 108.29 -178.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.51 ' NE2' ' O ' ' A' ' 22' ' ' GLY . 0.1 OUTLIER -135.95 -176.9 4.46 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 121.502 -0.999 . . . . 0.0 108.989 179.502 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -100.81 -166.0 1.27 Allowed 'General case' 0 C--N 1.298 -1.663 0 CA-C-O 121.881 0.848 . . . . 0.0 110.841 -178.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.52 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 5.9 p-10 -71.94 90.88 1.16 Allowed 'General case' 0 N--CA 1.489 1.499 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.568 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.613 ' CG1' ' HB1' ' A' ' 60' ' ' ALA . 2.3 t -50.16 125.44 3.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.107 0 O-C-N 120.711 -1.243 . . . . 0.0 111.832 178.681 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.626 ' CD2' ' CZ ' ' A' ' 17' ' ' PHE . 2.9 t80 -72.24 130.36 40.61 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 176.188 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.531 ' CG2' ' O ' ' A' ' 16' ' ' GLY . 2.6 m -146.6 130.75 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 120.248 -1.532 . . . . 0.0 110.703 -179.056 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.55 ' NE2' ' CE2' ' A' ' 30' ' ' PHE . 9.5 t-160 -98.99 166.74 11.13 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 178.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.55 ' CE2' ' NE2' ' A' ' 29' ' ' HIS . 53.0 p90 -83.82 32.44 0.48 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.795 -1.191 . . . . 0.0 110.135 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.1 m -119.12 -37.6 3.18 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.981 -1.075 . . . . 0.0 109.164 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.469 ' O ' ' O ' ' A' ' 63' ' ' VAL . . . -91.38 -37.34 13.28 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.25 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.582 ' CD1' ' N ' ' A' ' 33' ' ' ILE . 1.4 mp -70.11 -4.84 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -51.02 -51.34 54.04 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.537 -0.727 . . . . 0.0 109.989 -179.214 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.545 ' HA3' ' CG2' ' A' ' 64' ' ' THR . . . 48.85 -170.47 0.09 OUTLIER Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -71.23 96.18 1.37 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.181 -1.187 . . . . 0.0 109.368 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 159.15 -170.88 35.58 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.56 ' CD1' ' N ' ' A' ' 39' ' ' LYS . 28.5 t80 -83.23 155.91 23.43 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.268 -1.137 . . . . 0.0 109.472 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.56 ' N ' ' CD1' ' A' ' 38' ' ' PHE . 3.2 pttm -94.0 125.38 38.59 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.203 -0.935 . . . . 0.0 109.282 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.5 t -176.9 -170.23 0.3 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.992 -1.067 . . . . 0.0 109.62 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.537 ' HB2' ' CB ' ' A' ' 9' ' ' PHE . 0.9 OUTLIER -125.85 166.58 16.61 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.34 -0.85 . . . . 0.0 109.919 -179.688 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.423 ' O ' ' HB2' ' A' ' 45' ' ' GLN . 8.7 tt0 -174.8 127.46 0.3 Allowed 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 179.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.463 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 9.3 tm-20 -58.34 145.63 37.38 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.163 -179.65 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.463 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 74.52 3.87 68.04 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -179.103 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.468 ' HB3' HG21 ' A' ' 6' ' ' VAL . 25.4 tt0 -57.18 109.86 0.74 Allowed 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.355 -1.085 . . . . 0.0 110.266 -179.593 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -91.98 128.55 37.87 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.54 ' CG2' HD12 ' A' ' 18' ' ' ILE . 35.1 m -132.39 164.33 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 120.893 -1.129 . . . . 0.0 110.311 -179.547 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -117.62 126.8 53.18 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.026 -1.046 . . . . 0.0 108.336 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.674 ' CE1' ' CG1' ' A' ' 51' ' ' ILE . 0.3 OUTLIER -149.13 179.66 7.72 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.011 -1.055 . . . . 0.0 110.392 -179.642 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -123.74 81.14 1.87 Allowed 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.674 ' CG1' ' CE1' ' A' ' 49' ' ' PHE . 15.1 mm -61.29 118.81 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 CA-C-O 122.051 0.929 . . . . 0.0 110.772 -178.543 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.519 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 17.5 m -98.42 -175.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 179.232 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.42 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 0.2 OUTLIER -123.66 116.05 22.44 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.9 -1.125 . . . . 0.0 109.64 -179.885 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.27 174.61 16.97 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.929 -1.668 . . . . 0.0 108.929 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -38.67 -52.85 1.66 Allowed 'General case' 0 N--CA 1.505 2.287 0 O-C-N 121.369 -1.077 . . . . 0.0 113.772 -178.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.505 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -77.84 22.56 0.27 Allowed 'General case' 0 N--CA 1.501 2.092 0 O-C-N 119.69 -1.881 . . . . 0.0 112.211 -177.983 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.95 -178.6 30.89 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.283 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.519 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -63.58 157.78 49.43 Favored 'Trans proline' 0 C--N 1.318 -1.051 0 C-N-CA 121.991 1.794 . . . . 0.0 110.188 179.12 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.491 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 1.2 mt-30 -165.07 147.44 8.03 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 120.99 -1.069 . . . . 0.0 110.575 -179.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.617 ' CB ' ' CG2' ' A' ' 63' ' ' VAL . . . -82.89 158.6 22.6 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 177.701 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.446 ' O ' ' HB2' ' A' ' 32' ' ' ALA . . . -132.9 -47.29 0.86 Allowed 'General case' 0 N--CA 1.501 2.098 0 O-C-N 120.436 -1.415 . . . . 0.0 111.07 -177.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -121.27 55.24 1.08 Allowed 'General case' 0 C--N 1.288 -2.099 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 179.219 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.617 ' CG2' ' CB ' ' A' ' 60' ' ' ALA . 22.9 t -67.47 161.44 3.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-O 121.667 0.746 . . . . 0.0 110.111 -178.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.545 ' CG2' ' HA3' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -141.08 160.63 39.68 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 119.76 -0.776 . . . . 0.0 108.93 178.668 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 19.5 ptmt -88.35 139.4 30.53 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.927 -1.108 . . . . 0.0 109.857 -179.642 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 59.7 tt0 -80.39 143.22 33.67 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.21 -0.931 . . . . 0.0 109.299 179.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 117.931 -1.033 . . . . 0.0 109.589 -179.968 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 121.29 0.567 . . . . 0.0 109.543 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.653 ' CD2' ' CE1' ' A' ' 49' ' ' PHE . 0.3 OUTLIER -116.69 163.08 16.66 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.264 -0.897 . . . . 0.0 108.712 179.719 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.537 ' N ' HD22 ' A' ' 2' ' ' LEU . 0.2 OUTLIER -113.37 162.02 16.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.18 -0.95 . . . . 0.0 110.045 -179.438 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.404 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -143.22 159.17 27.43 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.384 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.407 ' O ' ' C ' ' A' ' 6' ' ' VAL . 8.0 mtpt -133.66 112.46 11.45 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.304 -1.115 . . . . 0.0 109.111 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.506 HG12 ' N ' ' A' ' 8' ' ' TRP . 3.6 t -42.45 139.36 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 122.796 1.284 . . . . 0.0 112.555 -178.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.444 ' HG3' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -98.43 -31.4 12.02 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 103.266 -2.864 . . . . 0.0 103.266 172.91 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.706 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 21.0 p-90 178.11 143.9 0.11 Allowed 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 177.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.563 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.9 OUTLIER -119.56 140.47 50.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.73 -1.231 . . . . 0.0 109.522 179.566 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.479 ' OD1' ' CE ' ' A' ' 13' ' ' LYS . 1.5 t-20 -131.43 38.13 3.63 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.454 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.2 p -37.36 -49.76 1.01 Allowed 'General case' 0 N--CA 1.492 1.629 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.886 -179.395 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -61.37 -44.66 96.78 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.284 -0.885 . . . . 0.0 109.91 -179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.479 ' CE ' ' OD1' ' A' ' 10' ' ' ASN . 0.4 OUTLIER -69.21 0.08 5.33 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.371 -0.831 . . . . 0.0 110.267 -179.554 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.508 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 102.46 12.09 34.09 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 119.935 -1.126 . . . . 0.0 112.635 178.329 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.649 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.0 OUTLIER 177.03 166.02 0.53 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-N 120.444 2.122 . . . . 0.0 112.215 179.543 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.563 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -146.74 137.03 6.49 Favored Glycine 0 N--CA 1.499 2.854 0 N-CA-C 106.671 -2.572 . . . . 0.0 106.671 179.342 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.706 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.9 m-30 -106.96 139.16 41.8 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.054 -1.85 . . . . 0.0 110.763 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.559 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 2.5 mt -108.21 151.65 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 177.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.486 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 9.1 tt0 -127.22 133.57 50.23 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.719 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.538 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 11.5 p -136.38 140.06 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 C-N-CA 117.792 -1.563 . . . . 0.0 111.772 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.8 140.13 58.38 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.121 179.771 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.42 -17.17 40.37 Favored Glycine 0 N--CA 1.486 1.967 0 N-CA-C 108.469 -1.853 . . . . 0.0 108.469 -178.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.538 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 3.1 mm-40 -136.85 -174.35 3.7 Favored 'General case' 0 N--CA 1.482 1.163 0 O-C-N 121.324 -1.104 . . . . 0.0 108.652 179.604 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.89 -165.93 1.26 Allowed 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.168 0.985 . . . . 0.0 110.657 -179.025 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.559 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 8.1 p-10 -72.09 106.96 4.53 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.011 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.614 ' CG2' ' CG1' ' A' ' 51' ' ' ILE . 2.4 t -71.17 117.36 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 120.483 -1.386 . . . . 0.0 111.298 178.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.613 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 3.8 t80 -67.47 130.6 43.58 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.497 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.549 ' CG1' HD11 ' A' ' 18' ' ' ILE . 2.4 m -139.11 131.8 37.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 120.476 -1.39 . . . . 0.0 110.715 -179.799 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.544 ' CE1' ' CE1' ' A' ' 30' ' ' PHE . 6.7 t60 -99.92 164.25 12.1 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.567 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 46.1 p90 -82.84 40.94 0.71 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.962 -1.086 . . . . 0.0 109.814 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.494 ' HA ' ' NE2' ' A' ' 34' ' ' GLN . 94.1 p -129.92 -38.56 1.45 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.858 -1.151 . . . . 0.0 109.711 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -92.78 -41.43 10.11 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 179.518 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.535 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.7 mp -56.34 -17.28 4.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.709 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.494 ' NE2' ' HA ' ' A' ' 31' ' ' SER . 4.5 pt20 -87.6 -171.8 3.61 Favored 'General case' 0 N--CA 1.493 1.711 0 C-N-CA 119.123 -1.031 . . . . 0.0 109.595 -179.579 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.52 -45.8 0.04 OUTLIER Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -105.04 66.47 0.76 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.273 -1.134 . . . . 0.0 109.448 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.71 -174.7 38.07 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -74.75 97.04 3.16 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.233 -1.157 . . . . 0.0 109.616 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.79 169.94 8.3 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.264 -0.897 . . . . 0.0 109.474 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.517 ' OG1' ' N ' ' A' ' 41' ' ' LEU . 0.5 OUTLIER -128.48 -178.02 4.41 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.24 -0.913 . . . . 0.0 109.168 179.943 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.517 ' N ' ' OG1' ' A' ' 40' ' ' THR . 4.5 mp -141.35 142.46 33.79 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.124 -0.985 . . . . 0.0 109.59 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -105.29 158.88 16.31 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.3 -0.875 . . . . 0.0 109.276 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.485 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 9.6 tm-20 -55.71 148.22 16.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.126 -0.984 . . . . 0.0 109.498 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.485 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 79.66 1.84 87.3 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 108.819 -1.712 . . . . 0.0 108.819 -179.425 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.474 ' HA ' ' OE1' ' A' ' 45' ' ' GLN . 35.7 tp60 -75.72 134.14 40.58 Favored 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.324 -1.103 . . . . 0.0 110.532 -179.502 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -93.84 127.58 39.66 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 178.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.532 ' CG2' HD12 ' A' ' 18' ' ' ILE . 33.4 m -116.9 157.72 17.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.886 -1.134 . . . . 0.0 109.909 179.745 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 89.7 p -117.48 122.2 43.09 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.282 -0.887 . . . . 0.0 108.787 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.653 ' CE1' ' CD2' ' A' ' 2' ' ' LEU . 10.4 p90 -153.97 -177.51 6.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.02 -1.05 . . . . 0.0 109.726 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -128.15 102.24 6.62 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.083 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.614 ' CG1' ' CG2' ' A' ' 26' ' ' VAL . 4.9 mt -62.76 144.56 14.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 120.816 -1.177 . . . . 0.0 111.126 -179.385 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.522 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.7 m -131.2 -173.18 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 179.1 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -122.25 114.68 21.15 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.786 -1.196 . . . . 0.0 109.776 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.87 172.66 16.49 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -38.66 -53.72 1.61 Allowed 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.21 -1.171 . . . . 0.0 113.006 -178.659 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.462 ' NH1' ' CG ' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -68.77 -21.24 64.36 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 119.647 -1.908 . . . . 0.0 112.778 -177.85 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 138.46 -170.84 23.73 Favored Glycine 0 N--CA 1.491 2.353 0 O-C-N 120.345 -1.472 . . . . 0.0 109.618 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.8 Cg_endo -62.26 122.88 11.51 Favored 'Trans proline' 0 C--N 1.321 -0.877 0 C-N-CA 121.803 1.668 . . . . 0.0 109.875 178.767 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.454 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 4.5 mt-30 -144.2 148.45 34.97 Favored 'General case' 0 N--CA 1.5 2.07 0 O-C-N 121.189 -0.944 . . . . 0.0 111.097 -179.024 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.588 ' HB3' ' CD1' ' A' ' 49' ' ' PHE . . . -80.48 166.75 20.91 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.531 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.99 -43.32 0.73 Allowed 'General case' 0 N--CA 1.507 2.391 0 O-C-N 120.286 -1.509 . . . . 0.0 112.012 -177.123 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 31.6 t30 -119.66 51.88 1.14 Allowed 'General case' 0 C--N 1.287 -2.129 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.564 ' CG2' ' HB2' ' A' ' 60' ' ' ALA . 17.7 t -66.91 157.31 6.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.53 -179.351 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.7 176.69 9.03 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 178.534 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -82.68 142.98 31.26 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.035 -1.04 . . . . 0.0 109.318 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -54.69 102.15 0.06 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.202 -0.936 . . . . 0.0 109.536 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.658 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.49 179.999 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 32.5 mtp . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.66 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.53 176.21 8.97 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.365 -0.834 . . . . 0.0 109.981 179.541 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.486 ' HG2' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -112.74 158.79 19.65 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.032 -1.042 . . . . 0.0 110.929 -178.102 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.41 ' HA2' ' HB ' ' A' ' 20' ' ' VAL . . . -136.55 160.36 24.76 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.644 -1.782 . . . . 0.0 108.644 179.492 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.9 mtpt -134.45 116.27 14.94 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.083 -1.245 . . . . 0.0 110.618 -179.42 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.526 HG12 ' N ' ' A' ' 8' ' ' TRP . 2.8 t -32.9 141.17 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 CA-C-O 123.015 1.388 . . . . 0.0 113.635 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 3.0 tmtt? -104.07 -32.18 9.32 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 102.979 -2.971 . . . . 0.0 102.979 172.221 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.696 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.0 p-90 175.56 147.56 0.09 Allowed 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 177.716 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.564 ' CB ' ' HB2' ' A' ' 41' ' ' LEU . 0.6 OUTLIER -114.47 140.09 49.0 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 120.441 -1.412 . . . . 0.0 109.305 178.994 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.565 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 4.9 m120 -122.77 46.78 2.08 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.533 ' OG ' ' CD2' ' A' ' 41' ' ' LEU . 0.1 OUTLIER -43.76 -35.34 1.83 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 -179.315 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -59.7 -48.86 79.99 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.467 -0.771 . . . . 0.0 110.009 179.769 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.52 ' O ' ' CE2' ' A' ' 15' ' ' PHE . 13.2 mptt -76.74 11.8 1.56 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.26 -0.9 . . . . 0.0 110.201 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.451 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 84.6 20.81 57.67 Favored Glycine 0 N--CA 1.488 2.118 0 O-C-N 121.093 -1.004 . . . . 0.0 111.661 178.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.52 ' CE2' ' O ' ' A' ' 13' ' ' LYS . 36.1 p90 179.6 167.05 1.15 Allowed 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 119.983 1.892 . . . . 0.0 112.031 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.536 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -142.46 149.31 21.14 Favored Glycine 0 N--CA 1.498 2.784 0 N-CA-C 106.937 -2.465 . . . . 0.0 106.937 178.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.696 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -106.26 143.58 34.18 Favored 'General case' 0 N--CA 1.484 1.269 0 CA-C-N 119.836 1.818 . . . . 0.0 110.302 -178.4 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.597 ' CD1' ' CG1' ' A' ' 28' ' ' VAL . 0.9 OUTLIER -106.61 161.49 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 178.916 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.572 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 2.9 tp10 -142.66 130.02 21.11 Favored 'General case' 0 C--N 1.29 -2.018 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 177.781 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.554 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 13.0 p -135.99 140.56 43.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 117.485 -1.686 . . . . 0.0 111.729 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -65.36 140.62 58.67 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.052 179.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.22 -12.85 48.51 Favored Glycine 0 N--CA 1.487 2.049 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -178.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.554 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 6.1 mm-40 -140.75 -176.57 4.71 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 121.345 -1.091 . . . . 0.0 108.322 179.612 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.49 -165.79 1.25 Allowed 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.18 -0.95 . . . . 0.0 110.806 -179.091 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.579 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 11.6 p-10 -72.57 129.9 39.37 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.05 179.339 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.619 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.5 t -98.55 121.4 49.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 120.802 -1.186 . . . . 0.0 110.81 178.252 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.466 ' HB2' ' HG2' ' A' ' 59' ' ' GLN . 23.0 t80 -58.11 137.28 57.08 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.079 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.597 ' CG1' ' CD1' ' A' ' 18' ' ' ILE . 1.2 m -131.14 115.65 30.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 120.781 -1.199 . . . . 0.0 110.348 -178.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 7.8 t-160 -104.66 148.9 26.05 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.521 ' CD1' ' C ' ' A' ' 30' ' ' PHE . 0.0 OUTLIER -81.16 31.63 0.33 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.816 -1.177 . . . . 0.0 110.486 -179.68 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -125.35 -35.21 2.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.13 -0.981 . . . . 0.0 108.544 178.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.512 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.37 -35.68 14.26 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.817 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.53 HD13 ' CB ' ' A' ' 28' ' ' VAL . 63.0 mt -68.5 -5.66 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.473 ' O ' ' O ' ' A' ' 33' ' ' ILE . 0.1 OUTLIER -52.57 -167.07 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 CA-C-O 121.562 0.696 . . . . 0.0 110.159 -179.69 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 153.77 -169.72 32.42 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.702 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -81.36 74.24 8.36 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.059 -1.26 . . . . 0.0 109.571 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 176.22 -169.71 42.37 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -78.1 139.76 39.05 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.311 -1.111 . . . . 0.0 109.853 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.467 ' O ' ' HB ' ' A' ' 40' ' ' THR . 0.4 OUTLIER -110.29 136.12 49.97 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.334 -0.854 . . . . 0.0 109.411 179.82 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.467 ' HB ' ' O ' ' A' ' 39' ' ' LYS . 6.6 t 179.92 -170.67 0.15 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.999 -1.063 . . . . 0.0 109.897 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.564 ' HB2' ' CB ' ' A' ' 9' ' ' PHE . 1.3 pt? -109.88 158.28 18.35 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.523 -0.735 . . . . 0.0 109.959 -179.29 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.439 ' OE1' ' N ' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -175.09 138.59 0.44 Allowed 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.491 -0.755 . . . . 0.0 109.116 179.524 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.439 ' N ' ' OE1' ' A' ' 42' ' ' GLU . 9.1 tm-20 -74.33 146.37 43.14 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.284 -0.885 . . . . 0.0 108.961 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 77.14 5.31 85.01 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 108.706 -1.757 . . . . 0.0 108.706 -178.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 47.5 tt0 -68.43 111.77 4.87 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 121.499 -1.001 . . . . 0.0 110.003 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.473 ' CB ' ' OE2' ' A' ' 3' ' ' GLU . . . -91.9 124.92 36.38 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 178.866 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.581 ' CG2' HD12 ' A' ' 18' ' ' ILE . 28.8 m -119.66 163.9 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.879 -1.138 . . . . 0.0 110.469 -179.165 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.1 p -115.55 126.03 53.73 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.064 -1.023 . . . . 0.0 108.294 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.66 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 8.2 p90 -153.28 -179.41 7.7 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.043 -1.035 . . . . 0.0 109.83 -179.325 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -124.29 92.64 3.71 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.31 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.64 HG13 ' CE1' ' A' ' 49' ' ' PHE . 17.0 mt -61.49 132.79 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 CA-C-O 122.271 1.034 . . . . 0.0 110.338 -179.161 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.51 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.2 m -116.44 -174.46 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 178.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.423 ' CD ' ' N ' ' A' ' 53' ' ' GLU . 0.4 OUTLIER -123.72 114.33 19.81 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.001 -1.062 . . . . 0.0 109.331 179.79 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.72 175.57 18.65 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -37.92 -52.63 1.35 Allowed 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.499 -1.001 . . . . 0.0 113.548 -178.508 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.3 mmm180 -76.07 23.09 0.14 Allowed 'General case' 0 N--CA 1.5 2.036 0 O-C-N 119.807 -1.808 . . . . 0.0 112.137 -178.216 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.28 -174.78 35.62 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.51 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.2 Cg_endo -65.53 150.19 86.91 Favored 'Trans proline' 0 C--N 1.319 -0.997 0 C-N-CA 121.636 1.558 . . . . 0.0 109.791 178.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.466 ' HG2' ' HB2' ' A' ' 27' ' ' PHE . 1.4 mt-30 -165.58 150.31 8.69 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 120.97 -1.082 . . . . 0.0 111.521 -179.433 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.581 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -82.76 157.75 23.12 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 177.613 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.512 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.92 -41.49 0.75 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 120.52 -1.362 . . . . 0.0 111.578 -176.769 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.1 m-20 -119.9 57.18 0.93 Allowed 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 179.618 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.552 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 18.6 t -72.43 166.3 2.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.103 -178.629 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -148.1 176.27 10.34 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.669 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.46 ' O ' ' HG2' ' A' ' 65' ' ' LYS . 0.0 OUTLIER -85.54 133.38 34.07 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.052 -1.03 . . . . 0.0 109.672 179.916 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.465 ' HB3' ' O ' ' A' ' 46' ' ' ALA . 13.9 tp10 -82.31 84.67 7.04 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.147 -0.971 . . . . 0.0 109.607 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.452 179.975 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.626 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.61 174.18 10.77 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.257 -0.902 . . . . 0.0 110.119 179.688 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.467 ' HG2' ' O ' ' A' ' 47' ' ' VAL . 0.3 OUTLIER -113.24 155.62 24.75 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.207 -0.933 . . . . 0.0 110.007 -179.175 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.411 ' C ' ' HG2' ' A' ' 5' ' ' LYS . . . -133.28 161.95 24.25 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.436 ' O ' ' C ' ' A' ' 6' ' ' VAL . 4.0 mttp -130.24 115.5 17.06 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.209 -1.171 . . . . 0.0 109.887 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.491 HG12 ' N ' ' A' ' 8' ' ' TRP . 3.4 t -36.87 140.44 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 122.869 1.319 . . . . 0.0 112.758 -179.577 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.5 tmtt? -99.41 -31.81 11.47 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 103.042 -2.947 . . . . 0.0 103.042 172.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.701 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 21.5 p-90 176.65 144.14 0.08 Allowed 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 177.741 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.585 ' CE1' HD21 ' A' ' 41' ' ' LEU . 0.7 OUTLIER -119.06 141.48 48.7 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.48 -1.387 . . . . 0.0 109.435 179.531 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.478 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 0.1 OUTLIER -130.93 37.72 3.75 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.673 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.45 ' C ' ' O ' ' A' ' 10' ' ' ASN . 15.3 p -37.79 -47.41 1.01 Allowed 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.493 0.663 . . . . 0.0 109.297 -179.682 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -61.12 -46.36 90.92 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.432 -0.792 . . . . 0.0 109.877 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.46 ' HB2' ' CG ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -69.26 0.49 4.84 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.403 -0.811 . . . . 0.0 110.256 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.411 ' O ' ' CB ' ' A' ' 15' ' ' PHE . . . 99.38 15.48 32.33 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 120.001 -1.095 . . . . 0.0 112.399 178.624 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.436 ' O ' ' C ' ' A' ' 10' ' ' ASN . 1.0 OUTLIER 175.53 163.09 0.3 Allowed 'General case' 0 N--CA 1.497 1.917 0 CA-C-N 120.299 2.05 . . . . 0.0 111.849 179.561 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.547 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -146.31 139.99 8.49 Favored Glycine 0 N--CA 1.498 2.832 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.701 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.4 m-85 -108.77 144.11 37.03 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.209 -1.759 . . . . 0.0 110.422 -178.646 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.589 ' CG2' ' N ' ' A' ' 19' ' ' GLU . 0.5 OUTLIER -106.31 165.42 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 178.471 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.589 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 1.9 tt0 -141.8 127.77 19.48 Favored 'General case' 0 C--N 1.291 -1.967 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.155 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.538 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 11.8 p -134.2 141.47 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 C-N-CA 117.446 -1.701 . . . . 0.0 111.851 -179.463 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -63.8 140.14 58.84 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.259 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 82.21 -12.62 43.54 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 -179.118 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.538 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -137.57 -176.33 4.37 Favored 'General case' 0 N--CA 1.484 1.247 0 O-C-N 121.303 -1.116 . . . . 0.0 108.669 179.696 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -100.29 -166.1 1.29 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.271 -0.893 . . . . 0.0 110.505 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.586 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 34.7 p-10 -71.68 122.21 20.2 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.849 179.366 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.61 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.3 t -84.76 104.46 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 120.592 -1.317 . . . . 0.0 111.687 178.733 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.62 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 2.1 t80 -55.44 135.1 50.71 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 178.244 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.576 ' HA ' HD12 ' A' ' 33' ' ' ILE . 2.3 m -150.19 127.26 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 118.067 -1.453 . . . . 0.0 111.641 -179.336 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.624 ' NE2' ' CE1' ' A' ' 30' ' ' PHE . 7.7 t-160 -99.32 162.12 13.22 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 178.659 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.624 ' CE1' ' NE2' ' A' ' 29' ' ' HIS . 52.6 p90 -81.26 39.34 0.51 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.498 -1.376 . . . . 0.0 110.435 -179.432 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.7 t -123.48 -46.5 2.02 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.698 -1.251 . . . . 0.0 109.564 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.585 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.0 -40.56 11.59 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.328 -0.857 . . . . 0.0 108.74 179.57 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.618 ' CG1' ' HB ' ' A' ' 63' ' ' VAL . 2.9 mp -81.08 1.78 2.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 CA-C-O 121.703 0.763 . . . . 0.0 109.262 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -78.67 -167.55 1.13 Allowed 'General case' 0 C--N 1.297 -1.698 0 CA-C-O 121.433 0.635 . . . . 0.0 109.961 -179.272 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.69 177.91 32.56 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -68.27 128.63 37.29 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.207 -1.172 . . . . 0.0 109.835 -179.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.86 169.01 28.5 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -75.02 85.16 2.29 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.305 -1.115 . . . . 0.0 109.418 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.5 mttp -104.65 -169.83 1.67 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.298 -0.876 . . . . 0.0 110.011 -179.628 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.8 t -176.41 178.95 1.26 Allowed 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.585 HD21 ' CE1' ' A' ' 9' ' ' PHE . 0.3 OUTLIER -118.6 118.21 31.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.896 -1.128 . . . . 0.0 109.818 -179.755 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 9.9 tt0 -94.84 151.12 19.49 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.374 -0.829 . . . . 0.0 109.051 179.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.437 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 8.6 tm-20 -51.85 145.88 9.08 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.148 -0.97 . . . . 0.0 109.412 -179.797 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.437 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 77.58 3.51 83.24 Favored Glycine 0 N--CA 1.487 2.076 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 -179.597 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.514 ' HA ' ' NE2' ' A' ' 45' ' ' GLN . 5.7 tp-100 -75.98 133.79 40.35 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.274 -1.133 . . . . 0.0 110.732 -179.457 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.404 ' O ' ' OE1' ' A' ' 45' ' ' GLN . . . -94.44 128.65 41.13 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.553 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.467 ' O ' ' HG2' ' A' ' 3' ' ' GLU . 35.9 m -119.32 160.37 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.851 -1.155 . . . . 0.0 109.945 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.441 ' O ' HG11 ' A' ' 63' ' ' VAL . 49.0 p -115.14 132.0 56.74 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 120.968 -1.083 . . . . 0.0 108.495 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.626 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 10.5 p90 -164.28 -176.56 4.49 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.973 -1.079 . . . . 0.0 109.988 -179.439 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.07 98.32 4.89 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.19 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.61 ' CD1' ' CG2' ' A' ' 26' ' ' VAL . 7.2 mt -62.67 141.3 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 120.827 -1.171 . . . . 0.0 110.873 -179.222 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.501 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 8.7 m -124.76 -175.35 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.487 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -123.08 115.26 21.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.935 -1.103 . . . . 0.0 109.772 -179.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.52 168.93 18.53 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 37.4 m-20 -37.84 -52.37 1.31 Allowed 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.329 -1.101 . . . . 0.0 113.634 -178.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.96 22.31 0.19 Allowed 'General case' 0 N--CA 1.5 2.062 0 O-C-N 119.777 -1.827 . . . . 0.0 112.414 -177.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.95 -179.39 28.72 Favored Glycine 0 N--CA 1.494 2.501 0 O-C-N 120.393 -1.442 . . . . 0.0 110.588 179.312 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.501 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.8 Cg_endo -68.77 142.23 51.88 Favored 'Trans proline' 0 C--N 1.321 -0.908 0 C-N-CA 122.225 1.95 . . . . 0.0 110.085 178.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.527 ' HG2' ' CB ' ' A' ' 27' ' ' PHE . 22.5 mt-30 -156.52 149.36 23.87 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.048 -1.032 . . . . 0.0 111.558 -179.568 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.566 ' HB3' ' CG2' ' A' ' 63' ' ' VAL . . . -80.41 161.63 24.86 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.585 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.92 -41.57 0.75 Allowed 'General case' 0 N--CA 1.508 2.426 0 O-C-N 120.458 -1.401 . . . . 0.0 111.972 -176.358 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.432 ' OD1' ' O ' ' A' ' 62' ' ' ASN . 35.1 t-20 -120.57 50.75 1.29 Allowed 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.618 ' HB ' ' CG1' ' A' ' 33' ' ' ILE . 14.9 t -68.18 171.33 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-O 121.814 0.816 . . . . 0.0 109.501 -179.532 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -153.62 172.19 17.61 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 177.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.3 tmtt? -83.75 129.28 34.95 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.696 -1.252 . . . . 0.0 109.379 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -87.93 135.38 33.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.302 -0.874 . . . . 0.0 109.53 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 117.925 -1.036 . . . . 0.0 109.558 -179.988 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 19.9 ttt . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.414 0.626 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.674 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -115.83 174.59 5.95 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.35 -0.844 . . . . 0.0 109.715 179.751 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.498 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.4 OUTLIER -117.65 135.32 54.07 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 120.817 -1.177 . . . . 0.0 110.794 -179.263 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.403 ' C ' ' HG2' ' A' ' 5' ' ' LYS . . . -103.2 173.68 22.48 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.825 -1.71 . . . . 0.0 108.825 178.789 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.403 ' HG2' ' C ' ' A' ' 4' ' ' GLY . 3.4 mtpp -137.37 112.77 9.31 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 120.781 -1.423 . . . . 0.0 109.955 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.858 ' HB ' ' O ' ' A' ' 43' ' ' GLU . 2.5 t -47.88 131.77 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 CA-C-O 122.688 1.233 . . . . 0.0 112.645 -179.811 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 2.0 tttt -93.12 -30.39 15.28 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 103.213 -2.884 . . . . 0.0 103.213 173.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.718 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 25.1 p-90 175.28 146.57 0.08 Allowed 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 106.617 -1.624 . . . . 0.0 106.617 178.452 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.598 ' CZ ' HG22 ' A' ' 28' ' ' VAL . 0.5 OUTLIER -112.45 147.27 36.85 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.724 -1.235 . . . . 0.0 108.773 178.517 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.556 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 10.8 m-20 -130.05 42.84 3.22 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.203 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 10' ' ' ASN . 54.1 p -40.89 -40.0 1.27 Allowed 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -179.676 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.0 mm-40 -59.86 -49.33 78.11 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.665 -0.647 . . . . 0.0 110.487 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.504 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 1.4 mptp? -74.5 6.09 4.1 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.097 -1.002 . . . . 0.0 110.038 -179.798 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.529 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 90.76 20.33 40.62 Favored Glycine 0 N--CA 1.49 2.246 0 O-C-N 121.133 -0.979 . . . . 0.0 112.066 178.582 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.517 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 39.8 p90 178.9 170.29 0.88 Allowed 'General case' 0 N--CA 1.499 1.994 0 CA-C-N 120.0 1.9 . . . . 0.0 111.762 179.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.52 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -145.3 152.34 24.42 Favored Glycine 0 N--CA 1.499 2.891 0 N-CA-C 106.864 -2.495 . . . . 0.0 106.864 179.192 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.718 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.6 m-85 -113.14 135.36 53.89 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 120.28 2.04 . . . . 0.0 110.216 -178.786 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.562 ' CD1' ' CG1' ' A' ' 28' ' ' VAL . 2.8 mt -108.61 146.37 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.37 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.514 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 27.6 tt0 -125.52 135.87 52.73 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 177.648 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.48 HG11 ' CB ' ' A' ' 23' ' ' GLN . 10.9 p -137.37 139.64 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 C-N-CA 117.675 -1.61 . . . . 0.0 111.905 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -64.17 140.39 58.86 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.088 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 84.08 -15.06 40.69 Favored Glycine 0 N--CA 1.485 1.953 0 N-CA-C 108.684 -1.767 . . . . 0.0 108.684 -178.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.48 ' CB ' HG11 ' A' ' 20' ' ' VAL . 0.2 OUTLIER -136.95 -174.67 3.79 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 121.299 -1.118 . . . . 0.0 108.682 179.46 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.421 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 4.5 m-20 -100.79 -166.4 1.31 Allowed 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 122.073 0.94 . . . . 0.0 110.71 -179.171 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.522 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 8.1 p-10 -72.3 101.83 2.97 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.92 179.09 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.606 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.6 t -68.15 126.28 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 120.252 -1.53 . . . . 0.0 110.124 178.514 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.408 ' HB3' ' HG2' ' A' ' 59' ' ' GLN . 16.6 t80 -65.46 142.09 58.28 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 177.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.598 HG22 ' CZ ' ' A' ' 9' ' ' PHE . 1.4 m -134.09 156.73 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.735 -1.228 . . . . 0.0 110.345 -178.598 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.529 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 9.1 t60 -138.42 157.92 45.27 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.093 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.583 ' CE1' ' HB2' ' A' ' 38' ' ' PHE . 53.1 p90 -85.02 32.74 0.53 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.145 -0.972 . . . . 0.0 109.769 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.4 p -127.91 -35.48 2.07 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.832 -1.168 . . . . 0.0 109.773 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.508 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -93.04 -50.16 5.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.232 -0.917 . . . . 0.0 108.988 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.539 ' CD1' ' HB ' ' A' ' 28' ' ' VAL . 41.0 mt -53.09 -22.52 4.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-O 121.819 0.819 . . . . 0.0 109.047 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -112.24 -167.27 1.16 Allowed 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.601 -0.687 . . . . 0.0 109.968 -179.773 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -145.54 -38.04 0.06 OUTLIER Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 179.542 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.465 ' O ' ' O ' ' A' ' 37' ' ' GLY . 5.8 mt-10 -76.84 -170.01 1.47 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.256 -1.143 . . . . 0.0 109.771 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 36' ' ' GLU . . . -43.86 170.55 0.01 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 -179.799 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.583 ' HB2' ' CE1' ' A' ' 30' ' ' PHE . 50.1 p90 -74.5 118.02 16.98 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.397 -1.06 . . . . 0.0 110.124 -179.713 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 5.3 mmmt -111.09 160.38 16.94 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.258 -0.901 . . . . 0.0 109.335 179.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.6 p -119.56 114.23 21.93 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.129 -0.982 . . . . 0.0 109.151 179.679 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -151.9 166.87 30.12 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.177 -1.577 . . . . 0.0 110.016 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.547 ' HA ' ' CB ' ' A' ' 9' ' ' PHE . 3.3 mp0 -101.29 98.85 9.18 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 178.075 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.858 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 1.1 tp10 -76.57 44.3 0.35 Allowed 'General case' 0 N--CA 1.501 2.118 0 N-CA-C 115.233 1.568 . . . . 0.0 115.233 -176.552 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.618 ' HA2' ' CG1' ' A' ' 6' ' ' VAL . . . -45.91 -14.93 0.09 OUTLIER Glycine 0 N--CA 1.505 3.239 0 CA-C-N 119.978 1.263 . . . . 0.0 110.684 177.397 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.526 ' N ' ' O ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -75.41 -177.36 3.54 Favored 'General case' 0 C--N 1.288 -2.071 0 O-C-N 121.564 -0.962 . . . . 0.0 110.033 -179.598 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.459 ' O ' ' HB2' ' A' ' 66' ' ' GLU . . . -91.83 144.67 25.26 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.826 0.822 . . . . 0.0 110.055 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 18.6 m -122.74 165.91 18.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 121.262 -0.899 . . . . 0.0 108.687 179.091 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -117.68 120.23 37.35 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.854 -1.154 . . . . 0.0 109.163 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.674 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 5.6 p90 -149.46 -178.17 6.27 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.165 -0.959 . . . . 0.0 109.978 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.495 ' CG ' ' O ' ' A' ' 50' ' ' GLU . 0.3 OUTLIER -126.47 95.11 4.25 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.376 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.641 HG13 ' CE1' ' A' ' 49' ' ' PHE . 11.3 mt -61.91 140.1 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 CA-C-O 122.513 1.149 . . . . 0.0 111.175 -178.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.468 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 12.0 m -124.57 -177.17 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 106.064 -1.828 . . . . 0.0 106.064 179.166 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -123.32 111.95 17.02 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 118.885 -1.126 . . . . 0.0 109.642 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -116.84 169.86 13.21 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 73.1 m-20 -38.23 -52.68 1.48 Allowed 'General case' 0 N--CA 1.504 2.268 0 O-C-N 121.302 -1.116 . . . . 0.0 113.723 -178.575 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -78.1 22.02 0.32 Allowed 'General case' 0 N--CA 1.5 2.074 0 O-C-N 119.62 -1.925 . . . . 0.0 112.524 -177.564 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.65 -178.02 24.89 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 119.17 -1.491 . . . . 0.0 110.628 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.468 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.3 Cg_endo -66.1 153.02 79.75 Favored 'Trans proline' 0 C--N 1.321 -0.905 0 C-N-CA 122.277 1.984 . . . . 0.0 110.529 179.21 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.408 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 0.2 OUTLIER -165.85 147.52 7.09 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.419 -0.8 . . . . 0.0 110.631 -179.758 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.571 ' CB ' HG12 ' A' ' 26' ' ' VAL . . . -83.07 163.9 20.63 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 177.205 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.508 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.17 -44.05 0.78 Allowed 'General case' 0 N--CA 1.507 2.387 0 O-C-N 120.201 -1.562 . . . . 0.0 111.909 -176.869 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -119.77 52.11 1.13 Allowed 'General case' 0 C--N 1.287 -2.148 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.564 ' CG2' ' HB2' ' A' ' 60' ' ' ALA . 20.8 t -66.09 163.1 2.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-O 121.74 0.781 . . . . 0.0 110.554 -179.035 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.478 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.2 OUTLIER -145.06 179.29 7.46 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 177.9 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -89.11 134.07 34.14 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.842 -1.161 . . . . 0.0 109.657 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.459 ' HB2' ' O ' ' A' ' 46' ' ' ALA . 2.7 tt0 -59.58 148.48 33.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.116 -0.99 . . . . 0.0 109.301 179.84 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . 0.456 ' N ' ' HG2' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.401 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 76.4 mtp . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.637 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.5 172.64 12.44 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.125 -0.984 . . . . 0.0 110.301 179.806 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.483 ' HG2' ' O ' ' A' ' 47' ' ' VAL . 2.2 tt0 -113.74 144.68 42.56 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.303 -0.873 . . . . 0.0 110.174 -179.253 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.457 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -112.7 161.52 12.67 Favored Glycine 0 N--CA 1.483 1.811 0 N-CA-C 108.514 -1.835 . . . . 0.0 108.514 178.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.448 ' O ' ' C ' ' A' ' 6' ' ' VAL . 9.3 mttm -131.74 113.76 13.93 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.187 -1.184 . . . . 0.0 109.754 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.537 HG11 ' N ' ' A' ' 8' ' ' TRP . 2.6 t -33.72 139.62 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 CA-C-O 122.91 1.338 . . . . 0.0 113.636 -179.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.443 ' HG2' ' CB ' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -103.92 -32.07 9.45 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 103.108 -2.923 . . . . 0.0 103.108 172.183 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.704 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 18.9 p-90 174.82 147.38 0.07 Allowed 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 106.315 -1.735 . . . . 0.0 106.315 177.803 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.61 ' CG ' ' CB ' ' A' ' 41' ' ' LEU . 0.4 OUTLIER -113.52 145.32 41.39 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 120.263 -1.523 . . . . 0.0 109.325 178.95 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.557 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 49.7 m-20 -130.11 41.84 3.36 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 178.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.474 ' OG ' HD22 ' A' ' 41' ' ' LEU . 62.0 p -40.98 -43.65 2.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.671 -0.643 . . . . 0.0 109.518 -179.16 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 60.4 mm-40 -61.62 -45.41 94.21 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.307 -0.871 . . . . 0.0 109.718 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.509 ' N ' ' CD ' ' A' ' 13' ' ' LYS . 0.2 OUTLIER -72.39 4.73 3.47 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.531 -0.731 . . . . 0.0 110.469 -179.66 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.486 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 93.34 19.88 34.23 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 120.053 -1.07 . . . . 0.0 112.236 178.372 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.514 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 0.8 OUTLIER 169.87 171.69 0.06 Allowed 'General case' 0 N--CA 1.498 1.958 0 CA-C-N 120.074 1.937 . . . . 0.0 111.641 179.401 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.558 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -143.6 151.85 23.66 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 106.889 -2.484 . . . . 0.0 106.889 178.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.704 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.6 m-85 -112.65 140.6 47.27 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 119.854 -1.968 . . . . 0.0 110.152 -178.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.587 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 1.2 mt -106.86 155.95 7.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 179.385 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.484 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 13.0 tt0 -132.31 133.15 43.71 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.587 ' CG1' ' CB ' ' A' ' 23' ' ' GLN . 14.8 p -132.94 141.04 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 C-N-CA 117.879 -1.528 . . . . 0.0 111.666 -179.606 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -64.52 140.39 58.86 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.4 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.57 -6.22 47.18 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.587 ' CB ' ' CG1' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -140.54 -175.57 4.32 Favored 'General case' 0 C--N 1.309 -1.159 0 O-C-N 121.08 -1.247 . . . . 0.0 108.706 179.789 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.41 -166.97 1.38 Allowed 'General case' 0 C--N 1.297 -1.705 0 CA-C-O 122.151 0.977 . . . . 0.0 110.866 -179.032 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.587 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 5.6 p-10 -71.92 113.02 8.52 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.31 179.486 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.606 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.5 t -79.41 114.82 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 120.463 -1.398 . . . . 0.0 110.742 178.49 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.484 ' HB2' ' HG2' ' A' ' 59' ' ' GLN . 31.5 t80 -49.62 146.24 4.39 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 178.403 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.549 HG22 ' CZ ' ' A' ' 9' ' ' PHE . 1.2 m -139.21 157.57 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 O-C-N 120.801 -1.187 . . . . 0.0 109.24 -179.443 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.486 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 5.5 t60 -158.42 155.15 28.1 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.406 ' N ' ' CD2' ' A' ' 29' ' ' HIS . 33.5 p90 -79.58 26.34 0.31 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.931 -1.106 . . . . 0.0 110.235 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.3 p -116.35 -47.82 2.73 Favored 'General case' 0 N--CA 1.483 1.218 0 O-C-N 120.839 -1.163 . . . . 0.0 108.909 179.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.49 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -92.51 -47.53 7.09 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.531 HD12 ' CB ' ' A' ' 63' ' ' VAL . 10.1 mm -49.56 -25.22 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.52 ' CG ' ' HB2' ' A' ' 39' ' ' LYS . 0.0 OUTLIER -111.15 -167.33 1.17 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.638 -0.664 . . . . 0.0 109.684 -179.777 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 173.91 -45.27 0.15 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 179.826 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -105.35 74.86 1.12 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.213 -1.169 . . . . 0.0 110.264 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.406 ' O ' ' OE1' ' A' ' 34' ' ' GLN . . . 104.72 161.96 24.06 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 179.137 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -85.77 114.74 22.95 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.244 -1.151 . . . . 0.0 109.67 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.52 ' HB2' ' CG ' ' A' ' 34' ' ' GLN . 0.1 OUTLIER -98.55 -169.67 1.83 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.327 179.727 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.524 ' OG1' ' N ' ' A' ' 41' ' ' LEU . 0.5 OUTLIER -135.46 -174.79 3.73 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.241 -0.912 . . . . 0.0 109.32 -179.758 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.61 ' CB ' ' CG ' ' A' ' 9' ' ' PHE . 2.1 pp -110.54 159.62 17.37 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.285 -0.884 . . . . 0.0 110.626 -178.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.474 ' O ' ' HB2' ' A' ' 45' ' ' GLN . 9.3 tt0 -166.98 126.38 1.44 Allowed 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 178.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.408 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 5.5 tm-20 -48.35 146.78 2.64 Favored 'General case' 0 C--N 1.295 -1.803 0 C-N-CA 119.596 -0.841 . . . . 0.0 108.963 -179.357 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.408 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 84.52 -1.05 89.16 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 109.037 -1.625 . . . . 0.0 109.037 -179.142 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.488 ' NE2' ' HE3' ' A' ' 65' ' ' LYS . 18.7 tt0 -58.88 112.13 1.54 Allowed 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.372 -1.075 . . . . 0.0 110.039 -179.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -91.86 122.89 34.81 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 178.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.54 ' CG2' HD12 ' A' ' 18' ' ' ILE . 33.3 m -117.92 162.68 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 120.819 -1.176 . . . . 0.0 111.026 -178.778 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -118.49 117.7 29.71 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.615 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.637 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 6.0 p90 -148.76 -177.73 5.95 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.093 -1.004 . . . . 0.0 110.008 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -128.91 96.87 4.47 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 179.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.62 HG13 ' CE1' ' A' ' 49' ' ' PHE . 10.7 mt -61.63 139.22 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.874 -1.141 . . . . 0.0 110.387 -179.218 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.5 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 2.7 m -127.19 -172.48 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -124.0 118.01 26.04 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.985 -1.072 . . . . 0.0 109.489 179.561 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -129.27 174.67 19.18 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.139 -1.584 . . . . 0.0 109.139 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -38.81 -52.99 1.72 Allowed 'General case' 0 N--CA 1.506 2.329 0 O-C-N 121.414 -1.051 . . . . 0.0 113.67 -178.565 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 29.0 mtp180 -77.91 22.45 0.28 Allowed 'General case' 0 N--CA 1.497 1.924 0 O-C-N 119.688 -1.883 . . . . 0.0 112.217 -177.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.54 -177.72 30.92 Favored Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.364 -1.398 . . . . 0.0 110.285 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.5 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -66.09 146.66 82.65 Favored 'Trans proline' 0 C--N 1.319 -0.981 0 C-N-CA 122.069 1.846 . . . . 0.0 110.065 178.948 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.484 ' HG2' ' HB2' ' A' ' 27' ' ' PHE . 0.4 OUTLIER -165.63 153.8 11.18 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.105 -0.997 . . . . 0.0 111.601 -179.35 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.57 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -82.12 159.45 23.36 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 177.107 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.49 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -135.28 -41.03 0.73 Allowed 'General case' 0 N--CA 1.508 2.432 0 O-C-N 120.288 -1.508 . . . . 0.0 111.97 -176.36 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.0 p30 -119.39 51.89 1.12 Allowed 'General case' 0 C--N 1.283 -2.294 0 N-CA-C 106.689 -1.596 . . . . 0.0 106.689 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.564 ' CG2' ' HB3' ' A' ' 49' ' ' PHE . 19.2 t -69.52 156.49 7.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.556 -179.13 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.442 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.9 OUTLIER -136.32 167.36 21.46 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.684 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.488 ' HE3' ' NE2' ' A' ' 45' ' ' GLN . 17.4 mttp -89.46 127.96 35.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.002 -1.061 . . . . 0.0 109.518 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -71.06 85.01 0.71 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.214 -0.929 . . . . 0.0 109.473 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.488 0 CA-C-O 118.059 -0.972 . . . . 0.0 109.546 -179.974 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.449 ' HE2' ' O ' ' A' ' 1' ' ' MET . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 . . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.612 HD13 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -117.34 173.65 6.57 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.226 -0.921 . . . . 0.0 110.313 -179.853 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.546 ' O ' ' CD2' ' A' ' 2' ' ' LEU . 0.5 OUTLIER -114.07 162.84 15.96 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.057 -1.027 . . . . 0.0 109.386 -179.87 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -158.26 174.64 35.47 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -141.81 130.89 23.27 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.099 -1.236 . . . . 0.0 111.384 -179.293 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' A' ' 18' ' ' ILE . 2.8 t -37.57 138.52 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 122.82 1.295 . . . . 0.0 113.312 179.366 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.426 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -97.09 -29.29 13.7 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 102.992 -2.966 . . . . 0.0 102.992 172.452 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.7 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 19.8 p-90 178.27 145.97 0.14 Allowed 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 106.068 -1.827 . . . . 0.0 106.068 177.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.549 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.6 OUTLIER -120.28 142.54 48.98 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.533 -1.355 . . . . 0.0 109.848 179.767 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.508 ' OD1' ' CD ' ' A' ' 13' ' ' LYS . 0.5 OUTLIER -130.57 38.34 3.74 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 179.004 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 10' ' ' ASN . 11.1 p -39.15 -44.56 1.2 Allowed 'General case' 0 C--N 1.299 -1.595 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.068 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 47.2 mm-40 -61.43 -46.83 88.44 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.437 -0.789 . . . . 0.0 109.847 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.508 ' CD ' ' OD1' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -69.61 1.41 4.17 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.396 -0.815 . . . . 0.0 110.184 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.585 ' O ' ' CD2' ' A' ' 29' ' ' HIS . . . 99.04 12.35 43.12 Favored Glycine 0 N--CA 1.49 2.253 0 C-N-CA 120.152 -1.023 . . . . 0.0 112.325 178.505 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.476 ' HB3' ' O ' ' A' ' 14' ' ' GLY . 38.1 p90 179.95 163.75 1.09 Allowed 'General case' 0 N--CA 1.497 1.889 0 CA-C-N 120.269 2.035 . . . . 0.0 111.678 179.237 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.549 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -145.53 143.22 11.48 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 107.296 -2.322 . . . . 0.0 107.296 179.466 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.7 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.29 143.71 36.78 Favored 'General case' 0 N--CA 1.48 1.045 0 O-C-N 120.24 -1.741 . . . . 0.0 110.19 -178.67 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.61 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.3 OUTLIER -105.45 164.33 4.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 N-CA-C 104.985 -2.228 . . . . 0.0 104.985 177.583 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.554 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 12.1 tp10 -130.3 129.65 43.49 Favored 'General case' 0 C--N 1.285 -2.22 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 178.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.604 ' CG1' ' CB ' ' A' ' 23' ' ' GLN . 14.7 p -132.82 138.93 50.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 118.057 -1.457 . . . . 0.0 111.707 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -66.02 140.37 58.28 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.268 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.32 -8.7 45.14 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 -178.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.604 ' CB ' ' CG1' ' A' ' 20' ' ' VAL . 0.7 OUTLIER -138.45 -175.33 4.08 Favored 'General case' 0 N--CA 1.482 1.136 0 O-C-N 121.197 -1.178 . . . . 0.0 108.503 179.539 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.79 -166.55 1.33 Allowed 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 122.129 0.966 . . . . 0.0 110.923 -178.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.61 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.1 m-20 -72.62 113.8 10.06 Favored 'General case' 0 N--CA 1.485 1.324 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.455 178.861 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.605 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -67.74 114.0 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.112 0 O-C-N 120.432 -1.417 . . . . 0.0 112.105 179.658 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.527 ' CD2' ' CZ ' ' A' ' 17' ' ' PHE . 0.6 OUTLIER -70.11 118.95 13.59 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 177.789 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.499 HG11 ' CG1' ' A' ' 26' ' ' VAL . 2.7 m -147.25 137.5 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 120.552 -1.343 . . . . 0.0 110.394 -179.346 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.585 ' CD2' ' O ' ' A' ' 14' ' ' GLY . 9.7 t-160 -99.19 172.97 7.03 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.384 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.548 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 48.0 p90 -82.64 35.54 0.46 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.044 -1.035 . . . . 0.0 109.758 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 10.8 t -128.15 -28.69 2.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.932 -1.105 . . . . 0.0 109.835 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.448 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.73 -47.89 7.12 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.027 -1.046 . . . . 0.0 108.236 179.293 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.492 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 53.5 mt -56.32 -30.37 30.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-O 122.115 0.96 . . . . 0.0 108.516 179.433 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.96 -168.29 1.3 Allowed 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -93.56 177.0 37.21 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 179.097 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -65.38 102.16 0.65 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.016 -1.285 . . . . 0.0 109.507 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 176.08 174.72 42.85 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 179.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 35.9 t80 -83.92 84.59 7.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.352 -1.087 . . . . 0.0 109.479 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -109.88 174.33 5.91 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.269 -0.894 . . . . 0.0 109.481 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.459 ' O ' ' HG ' ' A' ' 41' ' ' LEU . 0.2 OUTLIER -158.48 167.13 30.46 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.279 -0.888 . . . . 0.0 109.102 179.884 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.544 ' CB ' ' NE2' ' A' ' 45' ' ' GLN . 4.1 mp -146.97 -169.87 3.4 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.735 -1.228 . . . . 0.0 109.146 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -152.53 178.94 9.04 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.207 -0.933 . . . . 0.0 109.738 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -53.61 145.88 14.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.343 -0.848 . . . . 0.0 109.608 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 95.42 -9.5 69.32 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.076 -1.61 . . . . 0.0 109.076 -179.388 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.544 ' NE2' ' CB ' ' A' ' 41' ' ' LEU . 4.3 tt0 -59.72 104.31 0.27 Allowed 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.363 -1.081 . . . . 0.0 110.599 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.431 ' C ' HG11 ' A' ' 47' ' ' VAL . . . -92.23 131.24 37.61 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 177.663 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.541 HG23 ' CD1' ' A' ' 18' ' ' ILE . 35.3 m -140.44 161.78 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 120.451 -1.406 . . . . 0.0 111.139 -178.77 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.468 ' HA ' ' O ' ' A' ' 2' ' ' LEU . 9.5 p -115.53 132.86 56.5 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 179.302 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.645 ' CE1' HG13 ' A' ' 51' ' ' ILE . 7.1 p90 -154.88 -179.96 8.54 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.079 -1.013 . . . . 0.0 109.775 -179.005 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -121.16 91.39 3.51 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 178.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.645 HG13 ' CE1' ' A' ' 49' ' ' PHE . 17.9 mt -61.64 126.87 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.845 -1.159 . . . . 0.0 110.004 -179.478 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.522 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 10.4 m -106.09 -171.84 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 106.371 -1.714 . . . . 0.0 106.371 178.581 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.9 mp0 -122.98 114.44 20.41 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.9 -1.125 . . . . 0.0 109.824 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.57 169.07 16.58 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 34.5 m120 -38.07 -52.16 1.4 Allowed 'General case' 0 N--CA 1.504 2.232 0 O-C-N 121.325 -1.103 . . . . 0.0 113.587 -178.561 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.481 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -76.57 22.66 0.17 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 119.677 -1.89 . . . . 0.0 112.355 -178.035 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.07 -177.93 29.13 Favored Glycine 0 N--CA 1.494 2.531 0 O-C-N 120.434 -1.416 . . . . 0.0 110.232 179.565 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -65.66 150.82 86.01 Favored 'Trans proline' 0 C--N 1.32 -0.956 0 C-N-CA 122.025 1.817 . . . . 0.0 109.702 178.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.516 ' N ' HG22 ' A' ' 51' ' ' ILE . 29.5 mt-30 -161.11 144.03 12.69 Favored 'General case' 0 N--CA 1.5 2.043 0 O-C-N 120.991 -1.068 . . . . 0.0 111.567 -179.413 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.582 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -78.68 154.56 30.04 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 177.388 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.448 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -133.89 -41.61 0.83 Allowed 'General case' 0 N--CA 1.506 2.37 0 O-C-N 120.386 -1.446 . . . . 0.0 111.546 -176.534 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 5.6 m-20 -119.94 52.24 1.13 Allowed 'General case' 0 C--N 1.284 -2.255 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 179.618 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.561 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 20.5 t -67.13 163.68 2.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.969 -179.148 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.491 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.2 OUTLIER -147.29 167.88 23.17 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.37 -0.932 . . . . 0.0 108.796 178.608 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.15 144.77 48.46 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.864 -1.147 . . . . 0.0 109.66 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.45 ' OE2' ' O ' ' A' ' 66' ' ' GLU . 0.9 OUTLIER -56.78 134.3 54.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.346 -0.846 . . . . 0.0 109.522 -179.898 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.491 0 CA-C-O 117.961 -1.019 . . . . 0.0 109.414 179.922 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.6 tpt . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.653 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -134.35 175.2 9.72 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.245 -0.909 . . . . 0.0 109.867 179.595 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.458 ' O ' HD23 ' A' ' 2' ' ' LEU . 2.3 tt0 -113.77 157.08 22.72 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 120.907 -1.12 . . . . 0.0 110.332 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.415 ' C ' ' HG3' ' A' ' 5' ' ' LYS . . . -133.5 155.44 21.74 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.543 -1.823 . . . . 0.0 108.543 179.54 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.0 OUTLIER -132.2 119.07 20.36 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.284 -1.127 . . . . 0.0 110.201 -179.478 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.553 ' CG1' ' HG3' ' A' ' 43' ' ' GLU . 2.8 t -34.05 143.18 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.182 0 CA-C-O 123.086 1.422 . . . . 0.0 113.701 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.464 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 1.3 tmtm? -104.89 -30.74 9.64 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 103.585 -2.746 . . . . 0.0 103.585 172.733 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.706 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 18.4 p-90 177.51 145.47 0.11 Allowed 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 105.728 -1.953 . . . . 0.0 105.728 178.1 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.639 ' CE1' ' CG2' ' A' ' 28' ' ' VAL . 0.6 OUTLIER -113.23 148.43 35.53 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.457 -1.402 . . . . 0.0 110.655 -179.668 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.595 ' OD1' ' CZ3' ' A' ' 8' ' ' TRP . 3.0 m120 -130.2 36.31 4.01 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.797 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.5 OUTLIER -39.48 -42.78 1.16 Allowed 'General case' 0 N--CA 1.49 1.57 0 CA-C-O 121.42 0.629 . . . . 0.0 109.556 -178.703 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -60.78 -47.37 86.62 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.344 -0.847 . . . . 0.0 110.282 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.526 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -72.94 3.88 4.84 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.178 -0.951 . . . . 0.0 110.068 -179.829 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.476 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 95.25 18.6 33.09 Favored Glycine 0 N--CA 1.49 2.279 0 O-C-N 121.184 -0.948 . . . . 0.0 112.465 178.289 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.512 ' O ' ' C ' ' A' ' 10' ' ' ASN . 37.1 p90 177.77 168.69 0.7 Allowed 'General case' 0 N--CA 1.501 2.075 0 CA-C-N 120.152 1.976 . . . . 0.0 111.644 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.526 ' O ' ' CG2' ' A' ' 28' ' ' VAL . . . -146.34 154.29 25.87 Favored Glycine 0 N--CA 1.497 2.709 0 N-CA-C 107.044 -2.422 . . . . 0.0 107.044 179.133 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.706 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.5 m-85 -109.98 142.33 41.52 Favored 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 120.053 1.927 . . . . 0.0 109.621 -179.201 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.589 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.8 OUTLIER -106.37 163.5 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 179.295 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.578 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 0.8 OUTLIER -140.97 130.79 24.32 Favored 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.897 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.57 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 9.3 p -137.4 139.19 44.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 C-N-CA 117.743 -1.583 . . . . 0.0 111.779 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.86 141.06 58.18 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.428 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.19 -18.88 42.3 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.621 -1.792 . . . . 0.0 108.621 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.57 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 57.3 mt-30 -140.99 -173.15 3.64 Favored 'General case' 0 N--CA 1.484 1.244 0 O-C-N 121.418 -1.048 . . . . 0.0 109.162 179.671 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -98.35 -164.62 1.15 Allowed 'General case' 0 C--N 1.297 -1.688 0 CA-C-O 122.115 0.96 . . . . 0.0 110.822 -178.801 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.589 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 23.5 p-10 -70.91 125.82 27.89 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.239 179.747 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.633 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.3 t -90.49 114.48 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 120.705 -1.247 . . . . 0.0 110.808 178.348 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.438 ' C ' ' O ' ' A' ' 26' ' ' VAL . 18.8 t80 -46.06 143.13 2.41 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.639 ' CG2' ' CE1' ' A' ' 9' ' ' PHE . 1.0 OUTLIER -133.57 148.51 30.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 120.687 -1.258 . . . . 0.0 109.422 -179.176 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.447 ' O ' HG13 ' A' ' 33' ' ' ILE . 10.2 t-160 -151.61 146.84 26.12 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 21.8 p90 -78.8 24.21 0.31 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.018 -1.051 . . . . 0.0 110.714 -179.674 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.3 t -111.6 -45.7 3.34 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 120.637 -1.289 . . . . 0.0 109.212 179.615 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.55 -42.89 9.98 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.284 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.541 HG22 ' CG1' ' A' ' 63' ' ' VAL . 1.3 mt -73.83 -1.45 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 CA-C-O 121.496 0.665 . . . . 0.0 109.615 179.647 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.465 ' OE1' ' O ' ' A' ' 37' ' ' GLY . 0.2 OUTLIER -72.02 -167.89 0.34 Allowed 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.494 -0.754 . . . . 0.0 110.28 -178.83 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 143.51 -42.48 1.07 Allowed Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 -179.718 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -105.29 62.34 0.68 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.32 -1.106 . . . . 0.0 109.638 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.465 ' O ' ' OE1' ' A' ' 34' ' ' GLN . . . 61.79 164.29 0.31 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -82.03 90.52 6.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.099 -1.236 . . . . 0.0 109.664 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 10.5 mtpt -110.53 161.37 15.76 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.242 -0.911 . . . . 0.0 109.599 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.24 165.83 11.6 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.286 -0.884 . . . . 0.0 108.763 179.639 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.526 ' CD2' ' HB2' ' A' ' 45' ' ' GLN . 0.4 OUTLIER -151.91 -176.16 5.53 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.595 -1.316 . . . . 0.0 109.731 179.975 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -94.39 -174.91 3.48 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 178.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.553 ' HG3' ' CG1' ' A' ' 6' ' ' VAL . 34.8 tt0 -77.34 65.51 2.92 Favored 'General case' 0 N--CA 1.501 2.105 0 O-C-N 121.363 -0.836 . . . . 0.0 111.668 -179.155 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -162.82 35.01 0.32 Allowed Glycine 0 N--CA 1.49 2.243 0 O-C-N 120.856 -1.152 . . . . 0.0 110.427 178.525 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.526 ' HB2' ' CD2' ' A' ' 41' ' ' LEU . 41.7 tp60 -79.62 127.29 31.99 Favored 'General case' 0 N--CA 1.481 1.088 0 O-C-N 120.353 -1.675 . . . . 0.0 111.167 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -96.98 115.74 27.96 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 176.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.51 ' HB ' HG13 ' A' ' 63' ' ' VAL . 32.9 m -124.56 163.74 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 120.428 -1.42 . . . . 0.0 111.105 -178.755 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -116.58 129.02 55.93 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.1 -1.0 . . . . 0.0 108.517 179.591 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.653 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 6.3 p90 -153.75 -177.97 6.73 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.044 -1.035 . . . . 0.0 109.882 -179.466 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -126.09 93.12 3.73 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.197 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.633 ' CD1' ' CG2' ' A' ' 26' ' ' VAL . 13.7 mt -61.73 128.49 23.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.973 -1.079 . . . . 0.0 109.907 -179.303 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 7.5 m -109.3 -175.99 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 178.707 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.96 116.11 22.34 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.941 -1.099 . . . . 0.0 109.415 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.25 176.16 18.25 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -38.59 -52.59 1.63 Allowed 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.424 -1.044 . . . . 0.0 113.807 -178.504 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.458 ' NH1' ' CG ' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -79.42 22.27 0.45 Allowed 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.665 -1.897 . . . . 0.0 112.134 -177.706 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.56 -177.74 30.9 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.429 -1.367 . . . . 0.0 110.298 179.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.534 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.4 Cg_endo -66.64 153.1 79.18 Favored 'Trans proline' 0 C--N 1.32 -0.921 0 C-N-CA 121.942 1.761 . . . . 0.0 110.186 179.189 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.432 ' HG3' ' O ' ' A' ' 58' ' ' PRO . 2.4 mt-30 -166.31 147.46 6.5 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.069 -1.02 . . . . 0.0 111.278 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.562 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -80.12 155.84 27.3 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 177.239 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.548 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.66 -41.88 0.77 Allowed 'General case' 0 N--CA 1.508 2.445 0 O-C-N 120.308 -1.495 . . . . 0.0 111.695 -176.576 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -120.19 52.03 1.16 Allowed 'General case' 0 C--N 1.283 -2.292 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.613 ' CG2' ' HB3' ' A' ' 49' ' ' PHE . 15.2 t -67.43 167.32 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-O 121.83 0.824 . . . . 0.0 109.562 -179.501 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.437 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.3 OUTLIER -147.17 168.89 20.51 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.994 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.8 mttm -83.85 136.47 34.11 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.917 -1.114 . . . . 0.0 109.643 -179.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -54.68 158.46 2.58 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.198 -0.939 . . . . 0.0 109.605 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.408 179.899 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.638 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.18 172.24 13.04 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.182 -0.949 . . . . 0.0 110.082 179.504 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.455 ' O ' HD23 ' A' ' 2' ' ' LEU . 1.9 tt0 -113.95 149.71 34.86 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.165 -0.96 . . . . 0.0 110.423 -178.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.12 165.47 19.29 Favored Glycine 0 N--CA 1.486 1.969 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 179.37 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 6' ' ' VAL . 12.0 mmtt -131.4 115.16 15.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.929 -1.336 . . . . 0.0 109.742 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.524 HG12 ' N ' ' A' ' 8' ' ' TRP . 3.2 t -36.47 139.56 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 CA-C-O 122.914 1.34 . . . . 0.0 112.873 -179.551 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.458 ' HE2' ' OE1' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -99.73 -33.23 10.67 Favored 'General case' 0 C--N 1.288 -2.105 0 N-CA-C 102.876 -3.009 . . . . 0.0 102.876 172.471 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 24.1 p-90 175.16 146.58 0.07 Allowed 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 177.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.589 ' CG ' ' HG ' ' A' ' 41' ' ' LEU . 0.4 OUTLIER -112.08 147.41 36.1 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 120.298 -1.501 . . . . 0.0 109.37 178.815 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.579 ' HB2' ' CD1' ' A' ' 15' ' ' PHE . 1.0 OUTLIER -126.45 41.7 3.47 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.689 -0.632 . . . . 0.0 109.363 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.48 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -39.04 -47.29 1.49 Allowed 'General case' 0 N--CA 1.493 1.712 0 CA-C-O 121.601 0.715 . . . . 0.0 109.569 -179.189 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -58.6 -50.27 74.44 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.45 -0.781 . . . . 0.0 110.939 -179.385 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.528 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -70.85 0.98 6.09 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.014 -1.054 . . . . 0.0 110.429 -179.211 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.579 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 90.47 25.96 24.4 Favored Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.014 -1.054 . . . . 0.0 111.797 178.505 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.579 ' CD1' ' HB2' ' A' ' 10' ' ' ASN . 4.9 p90 -178.58 172.48 1.42 Allowed 'General case' 0 N--CA 1.497 1.914 0 CA-C-N 119.836 1.818 . . . . 0.0 110.866 179.47 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.493 ' O ' HG21 ' A' ' 28' ' ' VAL . . . -154.48 143.94 10.59 Favored Glycine 0 N--CA 1.5 2.911 0 N-CA-C 107.104 -2.399 . . . . 0.0 107.104 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.0 m-85 -111.12 141.33 44.77 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 119.97 -1.9 . . . . 0.0 110.456 -178.465 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.575 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.5 OUTLIER -106.32 162.35 5.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 178.262 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.558 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 14.6 tp10 -141.7 128.47 20.45 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.473 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.56 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 12.4 p -135.53 141.17 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 117.3 -1.76 . . . . 0.0 112.021 -179.213 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.71 140.44 58.46 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-N 115.384 -0.825 . . . . 0.0 108.913 179.596 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.03 -16.23 43.97 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.419 -1.872 . . . . 0.0 108.419 -178.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.56 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 3.1 mm-40 -139.29 -177.11 4.77 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 179.439 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -100.9 -165.95 1.26 Allowed 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.236 -0.915 . . . . 0.0 110.912 -178.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.575 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 3.8 p30 -72.27 124.37 24.92 Favored 'General case' 0 N--CA 1.488 1.46 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.741 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.639 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -88.23 116.01 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 120.647 -1.283 . . . . 0.0 111.264 178.605 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.543 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 1.5 t80 -64.5 127.82 33.16 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 178.191 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.568 ' CG1' HG11 ' A' ' 26' ' ' VAL . 16.1 m -143.32 137.01 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.55 -1.344 . . . . 0.0 111.626 -178.787 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.579 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 4.1 t60 -99.82 162.02 13.25 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 177.327 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.455 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 49.0 p90 -83.99 34.2 0.5 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.467 -1.396 . . . . 0.0 109.993 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.6 m -123.26 -34.27 3.15 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.034 -1.041 . . . . 0.0 108.905 179.305 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.502 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.56 -43.3 9.74 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.571 ' CD1' ' N ' ' A' ' 33' ' ' ILE . 1.2 mp -59.39 -22.91 23.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.849 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.524 ' HG3' ' HA ' ' A' ' 39' ' ' LYS . 0.5 OUTLIER -112.18 -166.89 1.12 Allowed 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.812 -0.755 . . . . 0.0 110.796 -178.937 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 154.48 -29.52 0.69 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -99.71 119.2 37.75 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.093 -1.239 . . . . 0.0 109.971 -179.497 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.429 ' O ' ' C ' ' A' ' 38' ' ' PHE . . . 59.7 -176.36 3.27 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 179.598 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.429 ' C ' ' O ' ' A' ' 37' ' ' GLY . 0.1 OUTLIER -43.63 156.41 0.06 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.327 -1.102 . . . . 0.0 109.472 179.892 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.524 ' HA ' ' HG3' ' A' ' 34' ' ' GLN . 0.0 OUTLIER -107.89 159.43 16.53 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.154 -0.966 . . . . 0.0 109.984 -179.684 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.468 ' HB ' ' O ' ' A' ' 39' ' ' LYS . 5.9 t 179.3 -169.13 0.1 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.384 -0.823 . . . . 0.0 109.614 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.632 ' CD1' ' N ' ' A' ' 41' ' ' LEU . 0.0 OUTLIER -147.08 -174.4 4.49 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.361 -0.837 . . . . 0.0 110.223 -178.834 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.432 ' O ' ' CB ' ' A' ' 45' ' ' GLN . 1.3 mt-10 -168.75 124.75 0.95 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.541 -0.725 . . . . 0.0 109.166 179.808 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.452 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 11.9 tm-20 -55.85 145.49 24.46 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.181 -0.949 . . . . 0.0 109.471 -179.683 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.452 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 73.31 5.59 67.31 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 -179.563 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.435 ' NE2' ' HA ' ' A' ' 45' ' ' GLN . 6.6 tp-100 -76.24 133.78 40.02 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.269 -1.136 . . . . 0.0 110.815 -179.451 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.534 ' O ' ' CB ' ' A' ' 66' ' ' GLU . . . -94.08 123.24 37.33 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 178.593 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.506 ' CG2' HD12 ' A' ' 18' ' ' ILE . 35.7 m -112.59 162.03 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 120.829 -1.17 . . . . 0.0 110.405 -179.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.68 119.15 34.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.06 -1.025 . . . . 0.0 108.729 179.4 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.638 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 10.7 p90 -149.49 -177.6 5.95 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.952 -1.093 . . . . 0.0 110.023 -179.374 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -128.86 93.31 3.58 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.452 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.639 ' CD1' ' CG2' ' A' ' 26' ' ' VAL . 14.1 mt -61.69 132.81 27.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.931 -1.105 . . . . 0.0 109.929 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 17.0 m -113.42 -177.3 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.152 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -123.17 117.19 24.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.999 -1.063 . . . . 0.0 109.299 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.83 175.2 15.63 Favored Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.67 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -39.1 -52.1 1.87 Allowed 'General case' 0 N--CA 1.5 2.071 0 N-CA-C 114.287 1.217 . . . . 0.0 114.287 -178.484 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -93.25 21.09 6.28 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 119.416 -2.053 . . . . 0.0 113.534 -176.616 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 122.68 173.65 14.23 Favored Glycine 0 N--CA 1.495 2.593 0 C-N-CA 118.723 -1.703 . . . . 0.0 111.533 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.505 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 3.0 Cg_endo -69.07 156.51 64.94 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 C-N-CA 122.661 2.241 . . . . 0.0 110.561 179.27 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -166.41 146.11 5.93 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.298 -0.876 . . . . 0.0 110.962 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.585 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -82.19 159.14 23.34 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.502 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.502 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -135.15 -44.53 0.71 Allowed 'General case' 0 N--CA 1.506 2.349 0 O-C-N 120.36 -1.462 . . . . 0.0 112.13 -176.171 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -119.54 51.62 1.15 Allowed 'General case' 0 C--N 1.284 -2.24 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.558 ' CG2' ' HB3' ' A' ' 49' ' ' PHE . 18.1 t -66.06 159.64 4.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.681 -179.431 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.462 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.2 OUTLIER -143.92 -177.86 5.64 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.846 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -86.39 139.51 30.87 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.931 -1.106 . . . . 0.0 109.354 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.534 ' CB ' ' O ' ' A' ' 46' ' ' ALA . 29.4 tp10 -60.56 115.15 3.39 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.199 -0.938 . . . . 0.0 109.572 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 118.038 -0.982 . . . . 0.0 109.458 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.607 HD13 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.77 174.64 10.32 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.179 -0.951 . . . . 0.0 110.264 179.75 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.526 ' O ' ' CD2' ' A' ' 2' ' ' LEU . 0.2 OUTLIER -112.64 165.2 12.49 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.252 -0.905 . . . . 0.0 109.937 -179.059 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.505 ' O ' ' HA ' ' A' ' 46' ' ' ALA . . . -148.05 169.68 28.76 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 20.0 mttt -134.05 116.14 15.14 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 120.919 -1.342 . . . . 0.0 110.313 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.841 ' HB ' ' O ' ' A' ' 43' ' ' GLU . 2.4 t -49.06 134.98 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 CA-C-O 122.71 1.243 . . . . 0.0 112.998 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.65 -28.36 13.58 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 104.015 -2.587 . . . . 0.0 104.015 174.155 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.681 ' O ' ' CE3' ' A' ' 8' ' ' TRP . 21.6 p-90 176.16 141.88 0.07 Allowed 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 178.274 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.576 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 0.7 OUTLIER -130.02 110.57 11.75 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.537 -1.352 . . . . 0.0 110.096 -179.949 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.567 ' OD1' ' CB ' ' A' ' 13' ' ' LYS . 1.2 p30 -95.15 88.35 5.17 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-O 122.978 1.371 . . . . 0.0 109.031 179.047 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.526 ' CB ' ' HA ' ' A' ' 40' ' ' THR . 0.4 OUTLIER -67.65 -57.97 5.47 Favored 'General case' 0 C--N 1.29 -2.02 0 O-C-N 120.417 -1.427 . . . . 0.0 108.709 179.741 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.518 ' HG2' ' CG2' ' A' ' 40' ' ' THR . 13.9 mt-10 -59.7 -45.13 93.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.469 -0.77 . . . . 0.0 111.362 -179.097 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.567 ' CB ' ' OD1' ' A' ' 10' ' ' ASN . 1.4 mptt -68.68 -11.85 60.68 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.05 -1.032 . . . . 0.0 111.134 -177.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.514 ' N ' ' OD1' ' A' ' 10' ' ' ASN . . . 138.73 -37.79 1.75 Allowed Glycine 0 N--CA 1.496 2.636 0 C-N-CA 118.376 -1.869 . . . . 0.0 113.3 178.299 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.532 ' O ' ' ND2' ' A' ' 10' ' ' ASN . 10.9 p90 -175.85 -174.83 0.69 Allowed 'General case' 0 N--CA 1.497 1.882 0 CA-C-N 121.079 2.439 . . . . 0.0 110.424 -179.222 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.596 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -134.49 146.35 18.36 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.626 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 6.0 m-30 -107.0 136.71 46.4 Favored 'General case' 0 N--CA 1.48 1.04 0 O-C-N 120.577 -1.543 . . . . 0.0 109.419 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.61 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 1.0 OUTLIER -107.39 150.53 9.88 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 N-CA-C 105.85 -1.908 . . . . 0.0 105.85 178.049 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.447 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 1.0 OUTLIER -125.92 133.19 51.94 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.396 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.512 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 8.5 p -137.87 140.24 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 C-N-CA 117.635 -1.626 . . . . 0.0 112.221 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -65.28 140.18 58.68 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.056 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.84 -13.76 46.55 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 108.654 -1.778 . . . . 0.0 108.654 -178.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.512 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 3.6 mt-30 -138.56 -175.97 4.31 Favored 'General case' 0 N--CA 1.483 1.195 0 O-C-N 121.257 -1.143 . . . . 0.0 108.632 179.489 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.82 -165.62 1.23 Allowed 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 122.135 0.969 . . . . 0.0 110.627 -179.059 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.61 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.5 m-20 -73.0 104.85 4.24 Favored 'General case' 0 N--CA 1.486 1.355 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.223 179.477 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.598 HG22 ' CZ ' ' A' ' 49' ' ' PHE . 2.4 t -65.72 115.25 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 120.345 -1.472 . . . . 0.0 112.112 179.061 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.44 ' CD1' ' C ' ' A' ' 27' ' ' PHE . 12.7 t80 -70.53 129.84 40.27 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.336 -0.852 . . . . 0.0 109.04 178.236 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.582 ' CG1' ' CD1' ' A' ' 18' ' ' ILE . 23.6 m -135.85 144.83 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.617 -1.302 . . . . 0.0 109.654 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.532 ' O ' ' CD1' ' A' ' 33' ' ' ILE . 0.5 OUTLIER -99.63 165.99 11.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.766 -1.209 . . . . 0.0 108.78 179.678 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.516 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 42.9 p90 -80.28 26.0 0.38 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.949 -1.095 . . . . 0.0 110.937 -179.398 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 43.3 p -136.68 -17.64 1.46 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.701 -1.249 . . . . 0.0 110.209 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.49 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -92.35 -49.6 6.07 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 120.735 -1.228 . . . . 0.0 108.79 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.545 ' CG1' ' HB ' ' A' ' 28' ' ' VAL . 2.5 mt -55.59 -27.65 21.76 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 CA-C-O 121.933 0.873 . . . . 0.0 108.736 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -112.3 -168.09 1.27 Allowed 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.745 -0.597 . . . . 0.0 109.732 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.27 -42.65 0.03 OUTLIER Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' A' ' 37' ' ' GLY . 0.0 OUTLIER -65.7 -170.09 0.07 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.381 -1.07 . . . . 0.0 109.653 179.871 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.471 ' O ' ' O ' ' A' ' 36' ' ' GLU . . . -44.19 170.0 0.01 OUTLIER Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.584 ' O ' ' CD2' ' A' ' 38' ' ' PHE . 48.0 p90 -73.11 116.11 13.24 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.21 -1.171 . . . . 0.0 110.098 -179.625 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.462 ' HG3' HD22 ' A' ' 41' ' ' LEU . 0.5 OUTLIER -110.68 135.08 51.83 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.273 -0.892 . . . . 0.0 108.881 179.608 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.526 ' HA ' ' CB ' ' A' ' 11' ' ' SER . 25.8 p -99.62 110.95 23.35 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.873 -1.142 . . . . 0.0 109.967 -179.567 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.467 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 0.7 OUTLIER -151.79 -179.19 7.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.419 -1.426 . . . . 0.0 109.706 179.757 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.526 ' HA ' ' HB3' ' A' ' 9' ' ' PHE . 1.8 mp0 -114.13 105.98 13.84 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.385 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.841 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 2.1 tp10 -76.59 45.66 0.41 Allowed 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 115.031 1.493 . . . . 0.0 115.031 -176.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.586 ' HA2' ' CG1' ' A' ' 6' ' ' VAL . . . -45.57 -15.8 0.1 OUTLIER Glycine 0 N--CA 1.507 3.385 0 CA-C-N 119.86 1.209 . . . . 0.0 110.432 177.337 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.532 ' N ' ' O ' ' A' ' 43' ' ' GLU . 0.0 OUTLIER -70.0 177.54 3.13 Favored 'General case' 0 C--N 1.289 -2.024 0 O-C-N 121.699 -0.883 . . . . 0.0 109.779 -179.844 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.51 ' O ' ' CB ' ' A' ' 66' ' ' GLU . . . -90.68 132.54 35.73 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.679 -0.638 . . . . 0.0 109.395 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.545 ' CG1' ' HG2' ' A' ' 43' ' ' GLU . 29.7 m -111.3 162.8 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.18 -0.95 . . . . 0.0 110.247 -179.806 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -115.88 125.38 52.55 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.194 -0.941 . . . . 0.0 108.587 179.503 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.607 ' CE1' HD13 ' A' ' 2' ' ' LEU . 25.0 p90 -153.59 -178.35 6.96 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.019 -1.051 . . . . 0.0 110.035 -179.646 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -126.85 96.14 4.55 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 179.413 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.597 ' CD1' ' CG2' ' A' ' 26' ' ' VAL . 1.3 mm -61.09 141.39 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 122.609 1.195 . . . . 0.0 111.048 -179.393 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.515 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 2.1 m -130.65 -174.96 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 -179.558 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -124.14 116.26 22.46 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.002 -1.062 . . . . 0.0 109.623 179.627 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -129.36 173.32 19.6 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -38.04 -52.26 1.39 Allowed 'General case' 0 N--CA 1.504 2.254 0 O-C-N 121.407 -1.055 . . . . 0.0 113.426 -178.634 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 4.9 mtt180 -75.42 22.74 0.12 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 119.728 -1.858 . . . . 0.0 112.102 -178.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.74 -178.75 36.64 Favored Glycine 0 N--CA 1.492 2.389 0 O-C-N 120.438 -1.414 . . . . 0.0 110.124 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.515 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.4 Cg_endo -68.04 139.59 47.31 Favored 'Trans proline' 0 C--N 1.319 -1.023 0 C-N-CA 122.095 1.863 . . . . 0.0 110.069 178.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.504 ' C ' ' CD1' ' A' ' 51' ' ' ILE . 77.6 mt-30 -159.33 157.92 31.37 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.2 -0.938 . . . . 0.0 111.206 -179.364 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.587 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -83.99 160.56 21.0 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 177.517 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.49 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -135.08 -40.98 0.74 Allowed 'General case' 0 N--CA 1.508 2.433 0 O-C-N 120.294 -1.504 . . . . 0.0 111.812 -176.709 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.438 ' N ' ' OD1' ' A' ' 62' ' ' ASN . 1.6 m-20 -119.62 52.28 1.11 Allowed 'General case' 0 C--N 1.283 -2.283 0 N-CA-C 106.924 -1.509 . . . . 0.0 106.924 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.56 ' CG2' ' HB3' ' A' ' 49' ' ' PHE . 13.4 t -69.17 163.66 3.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.488 -179.308 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.481 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 1.2 m -149.45 -179.08 6.8 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 178.643 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.93 128.58 34.58 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.991 -1.068 . . . . 0.0 109.432 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 46' ' ' ALA . 0.5 OUTLIER -79.89 120.22 23.83 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.233 -0.917 . . . . 0.0 109.454 179.929 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 117.991 -1.004 . . . . 0.0 109.432 -179.964 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.6 ptt? . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.641 ' CD1' ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -113.87 177.75 4.53 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.206 -0.934 . . . . 0.0 110.045 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.528 ' O ' ' CD2' ' A' ' 2' ' ' LEU . 0.3 OUTLIER -113.07 165.94 11.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.87 -1.143 . . . . 0.0 109.858 -179.07 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -151.82 156.27 26.6 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.401 ' O ' ' C ' ' A' ' 6' ' ' VAL . 2.5 ttpt -135.4 126.93 28.77 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.45 -1.03 . . . . 0.0 110.675 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.521 ' CG1' ' N ' ' A' ' 8' ' ' TRP . 5.6 t -35.7 150.01 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.285 0 CA-C-O 123.453 1.597 . . . . 0.0 113.338 -179.634 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.507 ' CG ' ' HB2' ' A' ' 19' ' ' GLU . 1.0 OUTLIER -110.54 -29.21 8.16 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 103.174 -2.899 . . . . 0.0 103.174 172.247 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.711 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 15.4 p-90 178.92 144.61 0.14 Allowed 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 177.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.576 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 1.1 t80 -118.89 127.41 53.47 Favored 'General case' 0 N--CA 1.506 2.361 0 O-C-N 120.527 -1.358 . . . . 0.0 109.756 -178.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.554 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 72.7 m-20 -120.6 56.21 1.0 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.598 -0.689 . . . . 0.0 109.682 -179.426 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.45 ' OG ' ' HG ' ' A' ' 41' ' ' LEU . 0.0 OUTLIER -43.74 -38.11 3.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.287 -0.883 . . . . 0.0 108.861 179.933 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -61.03 -47.03 88.32 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.572 -0.705 . . . . 0.0 110.253 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.496 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -71.53 4.42 3.09 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.218 -0.926 . . . . 0.0 109.768 179.853 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.478 ' C ' ' CD2' ' A' ' 15' ' ' PHE . . . 98.53 8.0 55.13 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 120.22 -0.99 . . . . 0.0 111.712 179.045 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.478 ' CD2' ' C ' ' A' ' 14' ' ' GLY . 3.9 p90 173.88 173.78 0.16 Allowed 'General case' 0 N--CA 1.495 1.818 0 CA-C-N 120.391 2.096 . . . . 0.0 112.588 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.576 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -130.33 142.61 13.89 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 106.644 -2.582 . . . . 0.0 106.644 178.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.711 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 4.1 m-30 -99.0 142.27 30.7 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 120.199 -1.765 . . . . 0.0 109.001 -178.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.61 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.6 OUTLIER -105.64 165.88 3.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 179.746 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.586 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 14.4 tm-20 -140.96 132.34 26.75 Favored 'General case' 0 C--N 1.289 -2.063 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 178.425 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.576 ' CG1' ' CB ' ' A' ' 23' ' ' GLN . 11.5 p -136.1 140.87 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 118.068 -1.453 . . . . 0.0 111.641 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -64.05 140.55 58.88 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.363 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.5 -8.88 45.38 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.576 ' CB ' ' CG1' ' A' ' 20' ' ' VAL . 0.3 OUTLIER -139.23 -175.07 4.04 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 121.129 -1.218 . . . . 0.0 108.849 179.608 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -100.66 -166.31 1.3 Allowed 'General case' 0 C--N 1.296 -1.721 0 CA-C-O 122.112 0.958 . . . . 0.0 110.437 -179.208 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.61 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 5.1 p30 -72.12 125.12 26.48 Favored 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.689 179.177 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.614 ' CG2' ' CD1' ' A' ' 51' ' ' ILE . 2.5 t -87.62 108.76 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 120.557 -1.339 . . . . 0.0 111.341 178.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.459 ' CE2' ' CE1' ' A' ' 17' ' ' PHE . 8.8 t80 -51.16 135.13 26.31 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 177.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.563 ' CG1' ' CD1' ' A' ' 18' ' ' ILE . 0.7 OUTLIER -131.74 140.8 47.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 120.48 -1.388 . . . . 0.0 109.615 -178.831 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.509 ' N ' HD13 ' A' ' 33' ' ' ILE . 36.2 t-80 -123.63 155.73 37.17 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.492 ' CE1' ' CE1' ' A' ' 29' ' ' HIS . 55.6 p90 -82.47 32.5 0.4 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.975 -1.078 . . . . 0.0 109.585 179.754 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.7 m -132.04 -33.24 1.36 Allowed 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.075 -1.016 . . . . 0.0 109.358 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.505 ' CB ' ' O ' ' A' ' 61' ' ' ALA . . . -91.34 -40.93 11.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.154 -0.966 . . . . 0.0 108.781 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.555 ' CD1' ' HB ' ' A' ' 28' ' ' VAL . 3.1 mt -75.16 -0.59 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.382 -0.823 . . . . 0.0 108.878 178.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.591 ' O ' ' C ' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -30.2 -34.8 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.543 -178.876 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.591 ' C ' ' O ' ' A' ' 34' ' ' GLN . . . -10.46 123.96 0.01 OUTLIER Glycine 0 N--CA 1.506 3.361 0 N-CA-C 111.591 -0.604 . . . . 0.0 111.591 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.506 ' C ' ' O ' ' A' ' 35' ' ' GLY . 0.2 OUTLIER -30.37 129.69 0.11 Allowed 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.935 -0.744 . . . . 0.0 110.919 -179.219 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 155.39 162.82 11.58 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.516 ' O ' ' CD1' ' A' ' 38' ' ' PHE . 37.2 p90 -84.96 130.95 34.55 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.018 -1.283 . . . . 0.0 109.458 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.416 ' O ' ' HB ' ' A' ' 40' ' ' THR . 0.8 OUTLIER -97.89 154.07 17.9 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -0.908 . . . . 0.0 109.505 -179.857 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.545 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 9.2 t 179.91 -176.83 0.34 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.265 -0.897 . . . . 0.0 109.327 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.45 ' HG ' ' OG ' ' A' ' 11' ' ' SER . 5.2 mp -108.25 89.3 2.95 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.162 -0.962 . . . . 0.0 109.558 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -146.31 143.92 29.46 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 179.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -77.7 60.9 2.29 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.044 -1.035 . . . . 0.0 112.144 -178.567 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -150.69 33.56 0.98 Allowed Glycine 0 N--CA 1.494 2.566 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 178.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.482 ' HB2' HG22 ' A' ' 6' ' ' VAL . 3.2 tt0 -80.19 96.7 6.64 Favored 'General case' 0 C--N 1.31 -1.15 0 O-C-N 121.077 -1.249 . . . . 0.0 110.452 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.412 ' HB2' ' HG2' ' A' ' 66' ' ' GLU . . . -94.18 105.44 17.43 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 177.555 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.544 ' CG2' HD12 ' A' ' 18' ' ' ILE . 35.0 m -128.28 164.29 30.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 120.675 -1.266 . . . . 0.0 110.741 -178.292 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -115.36 136.4 53.13 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 179.1 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.641 ' CE1' ' CD1' ' A' ' 2' ' ' LEU . 7.0 p90 -156.52 -179.41 8.15 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-O 121.99 0.9 . . . . 0.0 109.522 -178.731 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 20.1 tt0 -123.18 93.45 3.96 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.049 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.635 HG13 ' CE1' ' A' ' 49' ' ' PHE . 16.9 mt -62.14 128.58 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.981 -1.074 . . . . 0.0 110.154 -179.519 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.521 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 11.4 m -108.16 -176.56 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 178.348 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.408 ' CD ' ' N ' ' A' ' 53' ' ' GLU . 2.1 pm0 -123.85 116.62 23.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.967 -1.083 . . . . 0.0 109.729 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.406 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -132.26 172.4 21.14 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.181 -1.567 . . . . 0.0 109.181 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.406 ' C ' ' O ' ' A' ' 54' ' ' GLY . 17.8 m120 -37.37 -51.88 1.1 Allowed 'General case' 0 N--CA 1.505 2.322 0 O-C-N 121.439 -1.036 . . . . 0.0 113.268 -178.639 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.87 23.34 0.1 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 119.65 -1.907 . . . . 0.0 112.14 -178.456 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.77 -177.07 38.46 Favored Glycine 0 N--CA 1.491 2.359 0 O-C-N 120.529 -1.357 . . . . 0.0 109.773 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.521 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -68.28 152.92 75.44 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 C-N-CA 121.832 1.688 . . . . 0.0 109.652 178.768 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.466 ' HG3' ' O ' ' A' ' 58' ' ' PRO . 0.8 OUTLIER -165.82 146.1 6.61 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 120.907 -1.121 . . . . 0.0 111.608 -179.557 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.583 ' CB ' ' CG1' ' A' ' 26' ' ' VAL . . . -78.49 155.75 29.66 Favored 'General case' 0 N--CA 1.494 1.77 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.235 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.505 ' O ' ' CB ' ' A' ' 32' ' ' ALA . . . -134.52 -40.57 0.8 Allowed 'General case' 0 N--CA 1.508 2.475 0 O-C-N 120.557 -1.339 . . . . 0.0 111.37 -176.836 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -119.88 57.09 0.93 Allowed 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.556 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 19.9 t -73.14 165.61 3.0 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.184 -178.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.531 ' CG2' ' HA3' ' A' ' 35' ' ' GLY . 0.2 OUTLIER -149.83 157.97 43.71 Favored 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.143 178.952 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.4 ' HA ' HG13 ' A' ' 47' ' ' VAL . 4.2 tmtm? -70.25 138.07 51.34 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.821 -1.174 . . . . 0.0 109.562 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.412 ' HG2' ' HB2' ' A' ' 46' ' ' ALA . 0.3 OUTLIER -55.4 160.56 2.27 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.27 -0.894 . . . . 0.0 109.419 -179.978 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.607 -179.834 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.158 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.957 0 CA-C-O 121.063 0.458 . . . . 0.0 110.348 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.701 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -114.51 154.5 28.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.076 -1.015 . . . . 0.0 110.096 -179.552 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.24 158.0 20.27 Favored Glycine 0 N--CA 1.484 1.858 0 N-CA-C 109.064 -1.615 . . . . 0.0 109.064 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.443 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.3 mttt -130.73 115.85 17.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.446 -1.032 . . . . 0.0 110.195 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.588 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.6 t -35.42 143.52 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 CA-C-O 123.045 1.402 . . . . 0.0 112.925 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.423 ' CG ' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -102.5 -30.63 10.87 Favored 'General case' 0 C--N 1.288 -2.068 0 N-CA-C 102.996 -2.964 . . . . 0.0 102.996 171.94 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 17.9 p-90 177.31 147.5 0.13 Allowed 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 105.77 -1.937 . . . . 0.0 105.77 177.874 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.977 ' CE1' HG21 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -114.19 145.01 42.27 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 120.37 -1.456 . . . . 0.0 110.142 179.944 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.57 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 4.7 m-20 -131.91 32.96 4.0 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.351 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.1 OUTLIER -38.4 -46.95 1.19 Allowed 'General case' 0 N--CA 1.494 1.727 0 CA-C-O 121.486 0.66 . . . . 0.0 109.787 -178.765 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -60.15 -46.82 88.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.363 -0.836 . . . . 0.0 110.044 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.57 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -73.01 4.84 3.81 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.299 -0.876 . . . . 0.0 110.781 -179.317 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.552 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 110.71 -3.78 29.13 Favored Glycine 0 N--CA 1.494 2.545 0 C-N-CA 119.731 -1.223 . . . . 0.0 113.008 177.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.558 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 5.7 p90 176.68 174.77 0.37 Allowed 'General case' 0 N--CA 1.5 2.058 0 CA-C-N 120.614 2.207 . . . . 0.0 111.972 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.905 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -140.03 151.96 22.45 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 107.432 -2.267 . . . . 0.0 107.432 179.32 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.36 141.33 40.34 Favored 'General case' 0 N--CA 1.485 1.323 0 O-C-N 120.058 -1.848 . . . . 0.0 109.498 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.03 HD12 HG12 ' A' ' 28' ' ' VAL . 0.9 OUTLIER -107.48 160.72 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 178.656 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.549 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 4.3 tt0 -137.74 130.52 29.97 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.071 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.765 HG13 ' HB2' ' A' ' 23' ' ' GLN . 14.5 p -134.76 140.32 45.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 C-N-CA 117.855 -1.538 . . . . 0.0 111.593 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.45 140.55 58.88 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-N 115.371 -0.832 . . . . 0.0 109.15 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 81.51 -10.7 49.11 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.075 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.765 ' HB2' HG13 ' A' ' 20' ' ' VAL . 2.7 mp0 -139.42 -174.89 4.0 Favored 'General case' 0 C--N 1.308 -1.203 0 O-C-N 121.137 -1.213 . . . . 0.0 108.814 179.687 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.42 -165.78 1.25 Allowed 'General case' 0 C--N 1.295 -1.782 0 CA-C-O 122.005 0.907 . . . . 0.0 110.368 -179.3 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.613 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 7.5 m-20 -71.12 120.11 16.21 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 115.861 -0.608 . . . . 0.0 109.701 179.214 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.866 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.5 t -83.83 115.29 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 120.482 -1.386 . . . . 0.0 110.722 178.783 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.413 ' CB ' ' CD ' ' A' ' 59' ' ' GLN . 23.4 t80 -53.71 138.12 35.99 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.659 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.03 HG12 HD12 ' A' ' 18' ' ' ILE . 0.6 OUTLIER -129.27 146.48 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 O-C-N 120.712 -1.242 . . . . 0.0 109.381 -179.681 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.552 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 3.7 t60 -147.7 143.85 27.9 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.424 ' CZ ' ' NE2' ' A' ' 29' ' ' HIS . 22.6 p90 -63.85 2.79 0.45 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.043 -1.036 . . . . 0.0 111.611 -179.348 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.3 t -93.75 -51.07 5.07 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.21 -1.556 . . . . 0.0 109.574 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.745 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -93.31 -44.25 8.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.177 -0.952 . . . . 0.0 108.919 179.364 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.693 ' O ' HG22 ' A' ' 33' ' ' ILE . 1.1 mp . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.698 HG21 HD11 ' A' ' 18' ' ' ILE . 21.3 m -136.18 166.06 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 120.535 -1.353 . . . . 0.0 110.551 -179.151 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.9 t -116.66 135.39 53.82 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.09 -1.006 . . . . 0.0 108.6 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.158 ' CE1' HD11 ' A' ' 2' ' ' LEU . 7.2 p90 -164.1 -178.11 5.39 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.951 -1.093 . . . . 0.0 109.695 -179.662 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -127.05 94.95 4.16 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.305 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.866 HD11 ' CG2' ' A' ' 26' ' ' VAL . 12.3 mt -62.17 133.11 28.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.915 -1.116 . . . . 0.0 110.339 -179.409 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.542 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.1 m -116.04 -173.48 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 178.666 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -123.03 116.03 22.84 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.005 -1.059 . . . . 0.0 109.531 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.94 174.26 17.22 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -38.93 -52.67 1.77 Allowed 'General case' 0 N--CA 1.505 2.298 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -178.513 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 27.0 mmm180 -80.77 22.37 0.6 Allowed 'General case' 0 N--CA 1.498 1.967 0 O-C-N 119.676 -1.89 . . . . 0.0 112.247 -177.402 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.39 -177.7 26.14 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.278 -1.439 . . . . 0.0 110.488 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.542 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 0.9 OUTLIER -65.56 152.24 82.38 Favored 'Trans proline' 0 C--N 1.32 -0.948 0 C-N-CA 122.109 1.873 . . . . 0.0 110.426 179.114 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.413 ' CD ' ' CB ' ' A' ' 27' ' ' PHE . 0.0 OUTLIER -166.04 146.91 6.65 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.19 -0.944 . . . . 0.0 111.322 -179.653 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.794 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -79.4 159.23 27.16 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 177.174 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.745 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.67 -42.6 0.76 Allowed 'General case' 0 N--CA 1.508 2.439 0 O-C-N 120.366 -1.459 . . . . 0.0 111.886 -176.456 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -119.66 53.19 1.06 Allowed 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 1.008 HG22 ' CB ' ' A' ' 49' ' ' PHE . 25.0 t -70.85 168.77 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.887 -178.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.598 ' N ' HG12 ' A' ' 63' ' ' VAL . 1.4 m -152.69 173.84 14.74 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 178.4 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.484 ' H ' HG22 ' A' ' 64' ' ' THR . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 O-C-N 121.002 -1.061 . . . . 0.0 109.458 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.911 HD12 ' O ' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.785 0 CA-C-O 120.974 0.416 . . . . 0.0 110.214 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.861 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -112.13 168.03 9.93 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.105 -0.997 . . . . 0.0 109.553 -179.202 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.514 ' O ' ' HA ' ' A' ' 46' ' ' ALA . . . -151.78 167.9 31.08 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.379 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.5 mtpp -134.75 118.38 17.01 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.146 -1.208 . . . . 0.0 110.094 -179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.556 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.8 t -43.23 142.54 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 122.78 1.276 . . . . 0.0 112.366 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.402 ' HG3' ' OE2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -97.41 -29.65 13.38 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 103.179 -2.897 . . . . 0.0 103.179 172.587 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.702 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 21.1 p-90 177.79 144.78 0.11 Allowed 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 105.957 -1.868 . . . . 0.0 105.957 177.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.492 ' CD1' HG22 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -118.84 141.0 49.05 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.487 -1.383 . . . . 0.0 109.541 179.493 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.535 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 0.2 OUTLIER -131.5 37.78 3.65 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 179.4 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' ASN . 1.2 p -37.94 -48.49 1.17 Allowed 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.44 0.638 . . . . 0.0 109.332 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -61.9 -44.76 96.14 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.412 -0.805 . . . . 0.0 109.761 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.505 ' CB ' ' OD1' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -69.05 -0.88 6.33 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.359 -0.838 . . . . 0.0 110.132 -179.796 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.484 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 108.35 -0.44 32.95 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.874 -1.155 . . . . 0.0 112.523 178.547 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.436 ' O ' ' C ' ' A' ' 10' ' ' ASN . 6.3 p90 -179.21 169.97 1.44 Allowed 'General case' 0 N--CA 1.498 1.929 0 CA-C-N 120.456 2.128 . . . . 0.0 111.991 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.585 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -143.64 143.08 11.86 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 107.755 -2.138 . . . . 0.0 107.755 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.702 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.87 141.95 40.17 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 120.205 -1.762 . . . . 0.0 110.162 -178.851 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.946 HD11 HG21 ' A' ' 47' ' ' VAL . 0.9 OUTLIER -107.58 163.83 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.475 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.585 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 28.6 tt0 -139.2 130.54 26.91 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.609 HG13 ' HB2' ' A' ' 23' ' ' GLN . 9.0 p -134.39 140.66 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 C-N-CA 117.594 -1.642 . . . . 0.0 111.984 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -64.05 139.36 58.76 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.242 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.12 -13.65 43.5 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.609 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.5 OUTLIER -138.0 -175.98 4.28 Favored 'General case' 0 C--N 1.308 -1.212 0 O-C-N 121.254 -1.145 . . . . 0.0 108.804 179.851 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.39 -165.89 1.26 Allowed 'General case' 0 C--N 1.295 -1.773 0 CA-C-O 121.987 0.899 . . . . 0.0 110.3 -179.429 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.627 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.6 m-20 -72.08 126.51 29.97 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.011 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 1.015 HG22 ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -91.82 118.72 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.034 0 O-C-N 120.625 -1.297 . . . . 0.0 111.125 178.539 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.481 ' CB ' ' HG2' ' A' ' 59' ' ' GLN . 4.7 t80 -65.05 134.12 53.15 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.419 -0.8 . . . . 0.0 109.256 178.81 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.788 HG11 ' CD1' ' A' ' 18' ' ' ILE . 2.0 m -142.27 131.95 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.674 -1.266 . . . . 0.0 111.14 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.613 ' NE2' ' CZ ' ' A' ' 30' ' ' PHE . 2.5 t-160 -115.68 132.26 56.69 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.613 ' CZ ' ' NE2' ' A' ' 29' ' ' HIS . 7.4 p90 -43.96 -22.12 0.05 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.701 -1.25 . . . . 0.0 111.128 -178.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.441 ' N ' ' O ' ' A' ' 29' ' ' HIS . 1.5 m -66.24 -42.59 88.4 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.755 -1.215 . . . . 0.0 111.218 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.808 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.57 -41.33 10.85 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.95 -1.094 . . . . 0.0 108.802 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.637 HD11 HG12 ' A' ' 28' ' ' VAL . 1.5 mp . . . . . 0 C--N 1.305 -1.349 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.56 ' HB1' ' CD ' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.486 1.374 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.946 HG21 HD11 ' A' ' 18' ' ' ILE . 35.0 m -119.29 159.68 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 120.868 -1.145 . . . . 0.0 110.281 -179.478 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -114.19 136.01 53.42 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.116 -0.99 . . . . 0.0 108.57 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.915 ' CZ ' HG21 ' A' ' 26' ' ' VAL . 19.9 p90 -163.04 -176.05 4.67 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.072 -1.018 . . . . 0.0 109.87 -179.247 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -129.07 96.6 4.38 Favored 'General case' 0 C--N 1.295 -1.771 0 O-C-N 121.542 -0.724 . . . . 0.0 109.185 179.129 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 1.015 ' CD1' HG22 ' A' ' 26' ' ' VAL . 1.5 mm -61.57 139.6 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 CA-C-O 122.452 1.12 . . . . 0.0 111.137 -179.406 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 3.1 m -126.72 -174.25 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -123.39 115.99 22.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.966 -1.083 . . . . 0.0 109.933 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.12 171.89 15.86 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 10.6 p-10 -39.1 -52.69 1.86 Allowed 'General case' 0 N--CA 1.505 2.309 0 O-C-N 121.283 -1.128 . . . . 0.0 113.956 -178.334 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 11.1 ttm180 -78.8 21.96 0.39 Allowed 'General case' 0 N--CA 1.5 2.054 0 O-C-N 119.601 -1.937 . . . . 0.0 112.224 -177.713 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.0 -179.27 26.07 Favored Glycine 0 N--CA 1.492 2.404 0 C-N-CA 119.339 -1.41 . . . . 0.0 110.667 179.151 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.527 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -66.78 150.16 83.4 Favored 'Trans proline' 0 C--N 1.321 -0.915 0 C-N-CA 122.238 1.959 . . . . 0.0 110.484 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.965 ' C ' HD13 ' A' ' 51' ' ' ILE . 2.5 mt-30 -165.71 152.69 10.09 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.245 -0.91 . . . . 0.0 111.03 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.808 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.15 161.43 22.81 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 177.462 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.808 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.0 -41.71 0.74 Allowed 'General case' 0 N--CA 1.51 2.526 0 O-C-N 120.273 -1.517 . . . . 0.0 111.725 -176.724 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 9.3 m-20 -120.1 52.28 1.14 Allowed 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.9 HG22 ' CB ' ' A' ' 49' ' ' PHE . 12.5 t -68.74 170.6 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 121.819 0.818 . . . . 0.0 109.69 -179.254 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.552 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -152.74 171.75 17.74 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 178.553 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.407 ' O ' ' HG2' ' A' ' 65' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.598 0 O-C-N 121.003 -1.06 . . . . 0.0 109.584 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.191 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.77 0 CA-C-O 121.082 0.467 . . . . 0.0 110.154 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.797 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.2 OUTLIER -111.82 161.56 16.22 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.169 -0.957 . . . . 0.0 110.151 -178.527 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.02 157.89 24.51 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.429 ' HD3' ' OE1' ' A' ' 3' ' ' GLU . 10.2 mmtp -130.27 114.55 15.78 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.318 -1.107 . . . . 0.0 109.645 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.553 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.4 t -41.29 140.24 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 CA-C-O 122.8 1.286 . . . . 0.0 112.443 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.01 -30.33 12.4 Favored 'General case' 0 C--N 1.289 -2.041 0 N-CA-C 103.126 -2.916 . . . . 0.0 103.126 172.579 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.697 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 17.3 p-90 176.96 146.27 0.1 Allowed 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 106.228 -1.768 . . . . 0.0 106.228 177.835 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.881 ' CE1' HG21 ' A' ' 28' ' ' VAL . 1.5 t80 -113.66 143.23 44.94 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 120.576 -1.327 . . . . 0.0 109.433 179.394 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.56 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 90.6 m-20 -131.24 39.01 3.59 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.782 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -39.08 -47.82 1.58 Allowed 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.436 0.636 . . . . 0.0 109.525 -179.087 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -61.8 -44.52 96.7 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.393 -0.817 . . . . 0.0 109.706 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.543 ' CG ' ' HB3' ' A' ' 10' ' ' ASN . 12.6 mmmt -70.55 2.3 4.17 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.429 -0.794 . . . . 0.0 110.45 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 113.27 -10.57 24.38 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 119.564 -1.303 . . . . 0.0 112.063 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.556 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 3.9 p90 175.32 179.1 0.15 Allowed 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.03 -1.865 . . . . 0.0 111.302 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.907 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -136.34 149.38 20.1 Favored Glycine 0 N--CA 1.498 2.803 0 N-CA-C 107.482 -2.247 . . . . 0.0 107.482 179.279 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.697 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.2 m-85 -105.31 140.68 38.07 Favored 'General case' 0 N--CA 1.484 1.252 0 O-C-N 120.272 -1.722 . . . . 0.0 109.792 -178.816 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.049 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.2 mt -106.91 162.03 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 178.845 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.572 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 13.2 tt0 -140.07 130.28 25.12 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 177.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.802 HG13 ' HB2' ' A' ' 23' ' ' GLN . 14.1 p -135.49 140.96 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 C-N-CA 117.526 -1.67 . . . . 0.0 111.953 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -65.33 140.67 58.7 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.123 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.71 -10.48 45.47 Favored Glycine 0 N--CA 1.486 2.011 0 N-CA-C 108.662 -1.775 . . . . 0.0 108.662 -178.723 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.802 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.9 OUTLIER -140.33 -177.71 5.15 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 121.323 -1.104 . . . . 0.0 108.439 179.619 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 69.7 m-20 -100.84 -166.28 1.3 Allowed 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 121.913 0.863 . . . . 0.0 110.655 -179.192 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.599 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 0.9 OUTLIER -72.54 126.55 30.15 Favored 'General case' 0 N--CA 1.487 1.421 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.741 179.146 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.854 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.4 t -92.84 114.74 30.19 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 120.494 -1.379 . . . . 0.0 111.059 178.479 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.454 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 11.1 t80 -56.5 135.64 54.38 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.049 ' CG1' HD12 ' A' ' 18' ' ' ILE . 0.6 OUTLIER -129.5 142.55 43.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 120.6 -1.313 . . . . 0.0 110.393 -178.118 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.809 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.8 t-160 -117.48 155.13 30.24 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.318 -0.994 . . . . 0.0 108.318 179.522 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.517 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 41.1 p90 -84.03 33.05 0.48 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.964 -1.085 . . . . 0.0 109.82 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -135.7 -31.1 0.96 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.046 -1.034 . . . . 0.0 109.732 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.747 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.13 -40.82 11.37 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.021 -1.049 . . . . 0.0 108.649 179.646 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.809 HD12 ' O ' ' A' ' 29' ' ' HIS . 2.8 mt . . . . . 0 N--CA 1.485 1.321 0 O-C-N 121.388 -0.82 . . . . 0.0 109.178 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.689 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.486 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.613 HG21 HD11 ' A' ' 18' ' ' ILE . 28.6 m -111.49 159.48 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.823 -1.173 . . . . 0.0 109.911 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.6 p -115.72 123.55 48.58 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.076 -1.015 . . . . 0.0 108.429 179.448 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.191 ' CE1' HD11 ' A' ' 2' ' ' LEU . 8.8 p90 -151.92 -178.7 6.91 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.959 -1.088 . . . . 0.0 109.905 -179.429 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -125.36 94.02 4.03 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.483 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.854 HD11 ' CG2' ' A' ' 26' ' ' VAL . 10.5 mt -60.63 140.0 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 O-C-N 120.92 -1.112 . . . . 0.0 110.032 -179.381 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.584 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.9 m -124.52 -173.01 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 106.384 -1.71 . . . . 0.0 106.384 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -122.53 110.75 15.97 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 120.877 -1.139 . . . . 0.0 109.502 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.4 171.13 16.55 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -37.95 -52.25 1.36 Allowed 'General case' 0 N--CA 1.505 2.288 0 O-C-N 121.426 -1.044 . . . . 0.0 113.571 -178.664 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.21 22.53 0.16 Allowed 'General case' 0 N--CA 1.5 2.049 0 O-C-N 119.66 -1.9 . . . . 0.0 112.252 -178.084 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.424 ' O ' ' HG2' ' A' ' 59' ' ' GLN . . . 97.43 -175.52 30.58 Favored Glycine 0 N--CA 1.492 2.432 0 O-C-N 120.399 -1.438 . . . . 0.0 110.266 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.584 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.3 Cg_endo -65.22 131.36 28.19 Favored 'Trans proline' 0 C--N 1.32 -0.936 0 C-N-CA 121.858 1.706 . . . . 0.0 109.839 178.821 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.463 ' OE1' ' O ' ' A' ' 58' ' ' PRO . 10.4 mm100 -143.25 148.15 35.95 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.93 -1.106 . . . . 0.0 111.916 -178.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.713 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.1 158.2 23.8 Favored 'General case' 0 N--CA 1.496 1.872 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 176.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.747 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.29 -42.54 0.71 Allowed 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.219 -1.551 . . . . 0.0 111.876 -176.454 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 43.1 t30 -119.76 54.3 1.02 Allowed 'General case' 0 C--N 1.285 -2.238 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.916 HG22 ' CB ' ' A' ' 49' ' ' PHE . 18.4 t -68.62 164.94 2.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.596 -179.193 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.566 HG22 ' H ' ' A' ' 65' ' ' LYS . 0.7 OUTLIER -151.3 -175.8 5.32 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 178.804 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.566 ' H ' HG22 ' A' ' 64' ' ' THR . 25.1 mmtp . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.035 -1.041 . . . . 0.0 109.653 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.026 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.776 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 . . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.91 ' OE2' ' HB1' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -113.74 153.48 28.95 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 120.931 -1.106 . . . . 0.0 109.92 -179.716 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.442 ' C ' ' HG3' ' A' ' 5' ' ' LYS . . . -136.37 169.7 23.62 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.442 ' HG3' ' C ' ' A' ' 4' ' ' GLY . 7.6 mttm -138.01 123.58 19.69 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.943 -1.327 . . . . 0.0 109.991 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.596 HG13 ' H ' ' A' ' 8' ' ' TRP . 4.5 t -47.09 143.53 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 CA-C-O 122.857 1.313 . . . . 0.0 112.221 -179.538 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.74 -28.23 13.6 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 103.282 -2.859 . . . . 0.0 103.282 172.56 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.717 ' CZ3' ' ND2' ' A' ' 10' ' ' ASN . 23.1 p-90 177.92 145.71 0.12 Allowed 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.146 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.976 ' CE1' HG21 ' A' ' 28' ' ' VAL . 0.8 OUTLIER -112.72 148.8 33.97 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 120.528 -1.357 . . . . 0.0 109.902 179.821 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.717 ' ND2' ' CZ3' ' A' ' 8' ' ' TRP . 16.2 m-20 -129.25 36.87 4.11 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 178.471 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.6 p -38.74 -50.95 1.69 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.9 -0.5 . . . . 0.0 110.41 -178.467 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.431 ' OE2' ' O ' ' A' ' 12' ' ' GLU . 6.7 tp10 -63.96 -37.69 88.34 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.04 -1.038 . . . . 0.0 110.151 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.591 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 1.1 mptt -75.23 2.38 11.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.962 -1.086 . . . . 0.0 110.057 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.468 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 100.63 8.56 48.77 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.983 -1.103 . . . . 0.0 112.828 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.556 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 7.0 p90 177.08 172.6 0.48 Allowed 'General case' 0 N--CA 1.501 2.11 0 CA-C-N 120.213 2.007 . . . . 0.0 111.492 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.93 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -145.49 153.1 25.07 Favored Glycine 0 N--CA 1.501 3.012 0 N-CA-C 107.152 -2.379 . . . . 0.0 107.152 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.713 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.1 m-85 -112.32 139.7 47.66 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 119.72 -2.047 . . . . 0.0 110.095 -179.112 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.05 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.2 mt -107.29 162.16 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.684 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.589 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 4.4 tt0 -140.42 133.81 29.9 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.138 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.622 HG13 ' HB2' ' A' ' 23' ' ' GLN . 7.6 p -137.9 140.67 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 C-N-CA 117.936 -1.505 . . . . 0.0 111.804 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -63.92 140.6 58.89 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.302 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.86 -13.8 46.46 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.622 ' HB2' HG13 ' A' ' 20' ' ' VAL . 1.2 mt-30 -138.48 -175.48 4.14 Favored 'General case' 0 C--N 1.309 -1.166 0 O-C-N 121.326 -1.102 . . . . 0.0 108.746 179.612 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.31 -165.37 1.21 Allowed 'General case' 0 C--N 1.295 -1.783 0 CA-C-O 122.044 0.926 . . . . 0.0 110.324 -179.43 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.589 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 38.1 p-10 -71.34 120.69 17.28 Favored 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.833 179.393 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 1.028 HG22 ' CD1' ' A' ' 51' ' ' ILE . 2.5 t -83.26 114.06 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 120.512 -1.367 . . . . 0.0 110.523 178.428 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.434 ' CB ' ' HG2' ' A' ' 59' ' ' GLN . 3.2 t80 -54.24 140.65 32.17 Favored 'General case' 0 C--N 1.296 -1.761 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 178.511 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.05 ' CG1' HD12 ' A' ' 18' ' ' ILE . 0.6 OUTLIER -132.51 148.3 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 120.699 -1.251 . . . . 0.0 110.537 -178.583 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 24.5 t-80 -144.61 137.6 26.82 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.814 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 13.4 p90 -65.78 5.91 0.41 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.789 -1.194 . . . . 0.0 111.52 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.12 -35.57 11.84 Favored 'General case' 0 N--CA 1.484 1.267 0 O-C-N 120.345 -1.472 . . . . 0.0 108.744 179.307 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.748 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.82 -41.52 10.6 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.246 -0.909 . . . . 0.0 108.666 179.38 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.802 HD11 ' HB ' ' A' ' 28' ' ' VAL . 7.0 mt . . . . . 0 N--CA 1.49 1.534 0 C-N-CA 119.5 -0.88 . . . . 0.0 109.027 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.91 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.568 HG21 ' CD1' ' A' ' 18' ' ' ILE . 33.5 m -123.52 163.61 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 120.77 -1.206 . . . . 0.0 110.525 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.2 p -117.52 131.9 56.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.147 -0.971 . . . . 0.0 108.951 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.026 ' CE1' HD11 ' A' ' 2' ' ' LEU . 23.0 p90 -161.74 -179.3 7.12 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.865 -1.147 . . . . 0.0 109.966 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -127.5 95.45 4.25 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.668 -0.645 . . . . 0.0 109.484 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 1.028 ' CD1' HG22 ' A' ' 26' ' ' VAL . 1.2 mm -61.49 136.14 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 CA-C-O 122.469 1.128 . . . . 0.0 110.857 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.528 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 4.0 m -121.88 -175.01 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 179.364 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.73 114.58 20.13 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.977 -1.077 . . . . 0.0 109.413 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.34 172.68 18.68 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.126 -1.589 . . . . 0.0 109.126 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -37.8 -52.14 1.29 Allowed 'General case' 0 N--CA 1.504 2.252 0 O-C-N 121.426 -1.043 . . . . 0.0 113.411 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 7.2 mtm180 -75.8 22.72 0.14 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 119.609 -1.932 . . . . 0.0 112.162 -178.216 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.32 -177.05 34.65 Favored Glycine 0 N--CA 1.49 2.276 0 O-C-N 120.48 -1.388 . . . . 0.0 109.9 179.733 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.528 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -66.65 148.9 83.89 Favored 'Trans proline' 0 C--N 1.317 -1.088 0 C-N-CA 121.911 1.741 . . . . 0.0 109.781 178.736 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.95 ' C ' HD13 ' A' ' 51' ' ' ILE . 2.6 mt-30 -165.59 151.25 9.24 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.067 -1.021 . . . . 0.0 111.468 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.759 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -81.7 158.79 24.11 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 177.367 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.748 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.4 -42.45 0.7 Allowed 'General case' 0 N--CA 1.507 2.41 0 O-C-N 120.336 -1.477 . . . . 0.0 111.358 -176.788 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -119.43 61.72 0.82 Allowed 'General case' 0 C--N 1.282 -2.357 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.96 HG22 ' CB ' ' A' ' 49' ' ' PHE . 18.9 t -79.66 172.48 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.036 -178.755 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.57 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -153.93 171.08 19.56 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.764 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.501 0 O-C-N 120.931 -1.106 . . . . 0.0 109.407 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.089 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.822 0 CA-C-O 121.042 0.448 . . . . 0.0 110.036 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.802 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.4 OUTLIER -112.04 160.89 17.05 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.194 -0.941 . . . . 0.0 110.155 -178.994 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.23 168.32 28.36 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 6' ' ' VAL . 5.2 mttt -139.86 120.18 13.92 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.026 -1.279 . . . . 0.0 110.086 -179.694 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.614 HG22 ' CD1' ' A' ' 9' ' ' PHE . 3.7 t -41.55 140.51 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 CA-C-O 122.736 1.255 . . . . 0.0 112.073 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.499 ' HG3' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -98.09 -28.1 13.91 Favored 'General case' 0 C--N 1.289 -2.054 0 N-CA-C 103.536 -2.765 . . . . 0.0 103.536 173.008 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 26.1 p-90 177.55 141.74 0.09 Allowed 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 178.17 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.614 ' CD1' HG22 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -120.5 139.71 52.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.511 -1.368 . . . . 0.0 110.162 -179.893 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.52 ' ND2' ' HB2' ' A' ' 13' ' ' LYS . 2.0 t30 -132.05 32.88 3.97 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 179.245 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.457 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -37.45 -48.26 0.95 Allowed 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 121.634 0.73 . . . . 0.0 109.192 -179.404 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -59.99 -47.52 85.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.565 -0.709 . . . . 0.0 109.898 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.52 ' HB2' ' ND2' ' A' ' 10' ' ' ASN . 5.1 mptt -69.52 0.36 5.42 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.428 -0.795 . . . . 0.0 110.64 -179.409 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.438 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 109.9 4.38 29.68 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 119.67 -1.253 . . . . 0.0 113.063 178.386 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.466 ' O ' ' C ' ' A' ' 10' ' ' ASN . 5.0 p90 179.6 166.36 1.12 Allowed 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 120.975 2.387 . . . . 0.0 112.163 179.807 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.532 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -147.4 143.25 11.05 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 107.668 -2.173 . . . . 0.0 107.668 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.0 m-85 -115.07 138.95 50.29 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.196 -1.767 . . . . 0.0 110.231 -178.631 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.796 HD11 HG21 ' A' ' 47' ' ' VAL . 1.1 mt -106.74 152.71 8.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 177.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.556 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 1.7 tt0 -129.23 136.29 49.92 Favored 'General case' 0 C--N 1.286 -2.175 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.325 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.571 HG13 ' HB2' ' A' ' 23' ' ' GLN . 6.6 p -138.88 139.43 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 117.592 -1.643 . . . . 0.0 111.861 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -62.41 140.78 58.57 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.112 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.76 -18.15 36.44 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.51 -1.836 . . . . 0.0 108.51 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.571 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.1 OUTLIER -136.44 -175.92 4.16 Favored 'General case' 0 N--CA 1.484 1.226 0 O-C-N 121.423 -1.045 . . . . 0.0 108.334 179.336 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.91 -166.38 1.3 Allowed 'General case' 0 C--N 1.296 -1.749 0 CA-C-O 122.143 0.973 . . . . 0.0 111.014 -178.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.556 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 1.9 p-10 -73.21 102.2 3.57 Favored 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.553 178.796 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.885 HG13 ' H ' ' A' ' 60' ' ' ALA . 2.7 t -66.65 128.38 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 120.422 -1.424 . . . . 0.0 111.04 179.326 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.55 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 3.8 t80 -71.1 135.99 47.98 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.679 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.803 HG13 HG12 ' A' ' 26' ' ' VAL . 11.2 m -149.88 128.21 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 120.406 -1.434 . . . . 0.0 110.721 -179.574 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.634 ' NE2' ' CE2' ' A' ' 30' ' ' PHE . 10.9 t-80 -99.21 166.31 11.29 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.634 ' CE2' ' NE2' ' A' ' 29' ' ' HIS . 48.5 p90 -82.35 31.61 0.4 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.806 -1.184 . . . . 0.0 110.062 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 32.5 p -116.81 -38.2 3.49 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.976 -1.078 . . . . 0.0 109.11 179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.751 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.56 -41.92 9.96 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 108.508 179.356 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.603 ' N ' HD12 ' A' ' 33' ' ' ILE . 1.5 mp . . . . . 0 N--CA 1.486 1.344 0 O-C-N 121.535 -0.728 . . . . 0.0 109.083 179.729 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.68 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.486 1.362 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.796 HG21 HD11 ' A' ' 18' ' ' ILE . 29.9 m -135.92 162.98 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.852 -1.155 . . . . 0.0 109.851 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.3 p -116.0 137.1 52.42 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.036 -1.04 . . . . 0.0 108.442 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.089 ' CE1' HD11 ' A' ' 2' ' ' LEU . 10.4 p90 -162.43 -175.74 4.68 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.884 -1.135 . . . . 0.0 109.852 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -127.35 98.5 5.28 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.555 -0.716 . . . . 0.0 109.586 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.629 HD11 ' CG2' ' A' ' 26' ' ' VAL . 5.6 mt -61.89 143.69 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 CA-C-O 122.529 1.157 . . . . 0.0 111.309 -179.482 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.52 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 13.9 m -129.51 -176.76 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.27 116.78 23.92 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.728 -1.232 . . . . 0.0 110.369 -179.681 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -116.32 165.03 12.24 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.523 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.431 ' C ' ' O ' ' A' ' 54' ' ' GLY . 4.6 m-20 -38.31 -54.67 1.41 Allowed 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.072 -1.252 . . . . 0.0 112.914 -178.462 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.1 ttm180 -69.7 -21.26 63.51 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 119.564 -1.96 . . . . 0.0 113.069 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.69 179.2 25.33 Favored Glycine 0 N--CA 1.492 2.415 0 O-C-N 120.27 -1.519 . . . . 0.0 110.358 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.52 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -65.81 140.82 62.85 Favored 'Trans proline' 0 C--N 1.317 -1.094 0 C-N-CA 122.007 1.805 . . . . 0.0 110.464 179.206 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.522 ' HG2' ' CB ' ' A' ' 27' ' ' PHE . 30.3 mt-30 -154.83 151.78 29.03 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.347 -0.846 . . . . 0.0 110.71 -179.591 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.885 ' H ' HG13 ' A' ' 26' ' ' VAL . . . -83.83 167.76 16.76 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 177.328 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.751 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.23 -44.07 0.71 Allowed 'General case' 0 N--CA 1.503 2.22 0 O-C-N 120.289 -1.507 . . . . 0.0 111.672 -176.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.54 ' O ' ' ND2' ' A' ' 62' ' ' ASN . 0.4 OUTLIER -120.0 52.16 1.14 Allowed 'General case' 0 C--N 1.287 -2.11 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 -179.9 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.973 HG22 ' CB ' ' A' ' 49' ' ' PHE . 20.0 t -67.81 164.13 2.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 121.561 0.696 . . . . 0.0 109.681 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.484 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -146.24 164.29 32.76 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 178.672 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.526 ' HA ' HG12 ' A' ' 47' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.646 0 O-C-N 121.081 -1.012 . . . . 0.0 109.75 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.145 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.889 0 CA-C-O 120.8 0.333 . . . . 0.0 110.196 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.866 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.1 OUTLIER -112.66 167.27 10.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.858 -1.151 . . . . 0.0 109.651 -179.284 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -148.54 159.81 28.16 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.7 mttt -133.88 117.96 17.39 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.373 -1.075 . . . . 0.0 110.742 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.605 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.5 t -37.89 146.67 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 123.122 1.439 . . . . 0.0 113.143 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.63 -30.65 9.84 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 103.191 -2.892 . . . . 0.0 103.191 172.137 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.714 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 22.6 p-90 177.66 145.92 0.12 Allowed 'General case' 0 N--CA 1.484 1.267 0 N-CA-C 106.035 -1.839 . . . . 0.0 106.035 177.84 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.847 ' CE1' HG21 ' A' ' 28' ' ' VAL . 1.4 t80 -119.18 138.45 52.93 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.442 -1.411 . . . . 0.0 109.611 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.516 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.2 t-20 -133.65 36.76 3.32 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.651 ' HG ' ' HD2' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -37.21 -49.59 0.93 Allowed 'General case' 0 N--CA 1.495 1.818 0 CA-C-O 121.443 0.639 . . . . 0.0 109.541 -179.451 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -60.92 -46.22 91.53 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.475 -0.766 . . . . 0.0 109.806 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.501 ' HD2' ' N ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -69.96 1.0 4.96 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.51 -0.744 . . . . 0.0 110.453 -179.606 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.44 ' O ' ' CB ' ' A' ' 15' ' ' PHE . . . 123.35 -19.52 7.62 Favored Glycine 0 N--CA 1.491 2.355 0 C-N-CA 119.685 -1.245 . . . . 0.0 111.946 178.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.471 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 5.3 p90 173.7 178.4 0.11 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.056 -1.85 . . . . 0.0 111.456 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.954 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -135.52 145.81 17.84 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 107.884 -2.087 . . . . 0.0 107.884 179.505 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.714 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.7 m-30 -104.57 142.18 35.1 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 120.247 -1.737 . . . . 0.0 109.664 -179.245 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.005 HD12 HG11 ' A' ' 28' ' ' VAL . 0.5 OUTLIER -106.34 164.51 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 178.56 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.568 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 3.1 tm-20 -141.68 129.77 22.08 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.645 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.693 HG13 ' HB2' ' A' ' 23' ' ' GLN . 10.3 p -135.59 141.65 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 C-N-CA 117.695 -1.602 . . . . 0.0 112.043 -179.657 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -65.65 140.25 58.48 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-N 115.381 -0.827 . . . . 0.0 108.827 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.41 -14.01 42.96 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.693 ' HB2' HG13 ' A' ' 20' ' ' VAL . 1.8 mm-40 -137.66 -177.37 4.77 Favored 'General case' 0 N--CA 1.483 1.202 0 O-C-N 121.333 -1.098 . . . . 0.0 108.407 179.538 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -100.73 -166.27 1.3 Allowed 'General case' 0 C--N 1.296 -1.748 0 CA-C-O 121.962 0.887 . . . . 0.0 110.378 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.612 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.4 m-20 -72.08 123.46 22.88 Favored 'General case' 0 N--CA 1.486 1.367 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.676 179.149 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.88 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.4 t -84.91 110.5 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.02 0 O-C-N 120.589 -1.32 . . . . 0.0 111.454 178.92 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -55.37 133.73 49.87 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 178.07 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.005 HG11 HD12 ' A' ' 18' ' ' ILE . 0.6 OUTLIER -132.75 137.19 54.53 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 C-N-CA 117.891 -1.524 . . . . 0.0 110.661 -178.782 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.714 ' O ' HD12 ' A' ' 33' ' ' ILE . 0.7 OUTLIER -109.81 159.49 17.15 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.757 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.572 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 46.1 p90 -82.67 39.86 0.64 Allowed 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.763 -1.211 . . . . 0.0 109.831 -179.674 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.1 t -137.65 -33.2 0.73 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.816 -1.178 . . . . 0.0 110.518 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.734 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -93.53 -49.91 5.67 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.961 -1.087 . . . . 0.0 109.706 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.823 HG23 ' CG1' ' A' ' 63' ' ' VAL . 1.4 mp . . . . . 0 N--CA 1.491 1.575 0 O-C-N 121.677 -0.64 . . . . 0.0 110.359 -178.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.764 HG21 HD11 ' A' ' 18' ' ' ILE . 26.2 m -124.13 163.13 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 120.627 -1.296 . . . . 0.0 110.882 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 22.7 p -115.87 137.22 52.3 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 108.5 179.362 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.145 ' CE1' HD11 ' A' ' 2' ' ' LEU . 9.4 p90 -163.66 -177.97 5.5 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.816 -1.177 . . . . 0.0 109.941 -179.257 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -127.15 93.02 3.64 Favored 'General case' 0 C--N 1.295 -1.773 0 O-C-N 121.688 -0.633 . . . . 0.0 109.475 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.88 HD11 ' CG2' ' A' ' 26' ' ' VAL . 16.3 mt -62.1 128.92 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.023 -1.048 . . . . 0.0 109.886 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 16.1 m -108.11 -176.59 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 178.786 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -123.32 114.66 20.49 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.012 -1.055 . . . . 0.0 109.735 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.405 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -125.89 169.04 17.86 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.591 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' A' ' 54' ' ' GLY . 22.1 m120 -37.44 -51.99 1.13 Allowed 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.227 -1.161 . . . . 0.0 113.412 -178.45 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.9 tpt180 -75.33 22.62 0.12 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 119.718 -1.864 . . . . 0.0 112.352 -178.14 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.02 -178.32 31.94 Favored Glycine 0 N--CA 1.494 2.551 0 O-C-N 120.414 -1.429 . . . . 0.0 110.269 179.502 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.54 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -67.91 155.01 71.4 Favored 'Trans proline' 0 C--N 1.32 -0.947 0 C-N-CA 122.005 1.803 . . . . 0.0 109.918 178.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.436 ' N ' HG23 ' A' ' 51' ' ' ILE . 1.0 OUTLIER -166.07 143.22 5.31 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.982 -1.074 . . . . 0.0 111.398 -179.693 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.775 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -78.09 157.63 29.44 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 177.405 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.734 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.54 -44.26 0.75 Allowed 'General case' 0 N--CA 1.507 2.395 0 O-C-N 120.498 -1.376 . . . . 0.0 111.933 -176.407 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -119.81 51.78 1.16 Allowed 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.976 HG22 ' CB ' ' A' ' 49' ' ' PHE . 21.2 t -68.03 169.2 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-O 121.693 0.758 . . . . 0.0 109.513 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.592 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -154.62 178.14 10.43 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 178.237 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.579 ' N ' ' CD ' ' A' ' 65' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.735 0 O-C-N 121.043 -1.036 . . . . 0.0 109.557 -179.712 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.192 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.808 0 CA-C-O 121.09 0.471 . . . . 0.0 110.011 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.845 ' OE2' ' HB1' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -113.92 149.03 35.8 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 121.213 -0.929 . . . . 0.0 110.389 -179.372 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.438 ' HA3' HG21 ' A' ' 18' ' ' ILE . . . -121.33 166.16 14.26 Favored Glycine 0 N--CA 1.483 1.796 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 179.429 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.47 ' O ' ' C ' ' A' ' 6' ' ' VAL . 2.0 mttm -140.3 119.0 12.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.922 -1.34 . . . . 0.0 109.609 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.504 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.7 t -33.5 136.67 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 CA-C-O 122.913 1.34 . . . . 0.0 113.401 -179.327 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.489 ' CG ' ' HB3' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -101.8 -31.51 10.71 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 103.149 -2.908 . . . . 0.0 103.149 172.61 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.699 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 22.8 p-90 174.25 145.25 0.05 Allowed 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 178.009 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.595 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.2 OUTLIER -114.21 147.04 39.58 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.149 -1.594 . . . . 0.0 109.952 179.333 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.544 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 80.5 m-20 -130.21 38.68 3.75 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 179.013 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' ASN . 24.7 p -40.89 -41.59 1.64 Allowed 'General case' 0 N--CA 1.488 1.47 0 CA-C-O 121.71 0.767 . . . . 0.0 109.103 -179.078 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -59.9 -48.4 81.87 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.537 -0.727 . . . . 0.0 110.414 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.567 ' N ' ' CD ' ' A' ' 13' ' ' LYS . 2.2 mptp? -73.83 4.35 5.36 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.215 -0.928 . . . . 0.0 110.125 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.414 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 92.24 23.55 26.71 Favored Glycine 0 N--CA 1.49 2.242 0 C-N-CA 120.251 -0.976 . . . . 0.0 112.144 178.549 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.496 ' O ' ' C ' ' A' ' 10' ' ' ASN . 26.7 p90 179.44 167.19 1.09 Allowed 'General case' 0 N--CA 1.501 2.076 0 CA-C-N 120.102 1.951 . . . . 0.0 111.631 179.447 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.595 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -149.0 150.89 23.09 Favored Glycine 0 N--CA 1.497 2.752 0 N-CA-C 106.995 -2.442 . . . . 0.0 106.995 179.328 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.699 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 6.1 m-85 -117.24 138.31 51.8 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 120.035 1.917 . . . . 0.0 110.235 -178.648 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.547 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.7 mt -105.47 146.55 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.809 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.56 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 9.6 pt-20 -121.01 137.02 54.85 Favored 'General case' 0 C--N 1.285 -2.229 0 C-N-CA 119.472 -0.891 . . . . 0.0 108.944 178.45 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.52 HG13 ' HB2' ' A' ' 23' ' ' GLN . 10.0 p -138.73 140.93 38.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 C-N-CA 117.822 -1.551 . . . . 0.0 111.787 179.816 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.87 140.49 58.28 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.391 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 87.77 -19.1 35.16 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.119 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.52 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -136.4 -175.43 4.0 Favored 'General case' 0 C--N 1.308 -1.219 0 O-C-N 121.416 -1.049 . . . . 0.0 108.693 179.406 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.61 -165.1 1.17 Allowed 'General case' 0 C--N 1.296 -1.756 0 CA-C-O 122.009 0.909 . . . . 0.0 110.588 -179.051 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.56 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 0.9 OUTLIER -71.65 93.24 1.23 Allowed 'General case' 0 N--CA 1.487 1.388 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.037 179.257 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.822 HG13 ' H ' ' A' ' 60' ' ' ALA . 2.7 t -56.27 142.4 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 120.299 -1.501 . . . . 0.0 109.952 178.579 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.498 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 5.0 t80 -71.69 146.3 48.3 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 176.817 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.859 ' HB ' HD11 ' A' ' 33' ' ' ILE . 2.0 m -142.06 113.96 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 120.332 -1.48 . . . . 0.0 110.363 -179.299 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.691 ' O ' HD12 ' A' ' 33' ' ' ILE . 5.4 t-160 -99.55 148.95 23.74 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 178.296 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -79.86 32.71 0.26 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.747 -1.221 . . . . 0.0 110.163 -179.73 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.78 -36.93 3.34 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.963 -1.085 . . . . 0.0 108.924 179.579 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.706 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.36 -47.16 7.33 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 179.366 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.859 HD11 ' HB ' ' A' ' 28' ' ' VAL . 11.6 mt . . . . . 0 N--CA 1.487 1.397 0 CA-C-O 121.495 0.664 . . . . 0.0 109.44 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.845 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.486 1.374 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.5 HG21 ' CD1' ' A' ' 18' ' ' ILE . 31.3 m -122.32 165.06 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 120.704 -1.247 . . . . 0.0 110.462 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.4 p -117.01 122.55 44.53 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.26 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.192 ' CE1' HD11 ' A' ' 2' ' ' LEU . 6.3 p90 -150.85 -178.45 6.59 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 120.858 -1.151 . . . . 0.0 109.726 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -127.71 95.02 4.1 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.751 HD11 ' CG2' ' A' ' 26' ' ' VAL . 13.3 mt -62.35 136.34 25.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 CA-C-O 122.326 1.06 . . . . 0.0 110.906 -179.165 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.515 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 11.5 m -119.53 -176.61 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 179.124 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -123.48 113.66 19.05 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.01 -1.057 . . . . 0.0 109.629 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.23 171.66 16.52 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -37.99 -52.13 1.37 Allowed 'General case' 0 N--CA 1.505 2.292 0 O-C-N 121.367 -1.078 . . . . 0.0 113.735 -178.363 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.38 22.38 0.23 Allowed 'General case' 0 N--CA 1.5 2.046 0 O-C-N 119.655 -1.903 . . . . 0.0 112.247 -177.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.18 -176.97 29.67 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.451 -1.357 . . . . 0.0 110.257 179.509 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.515 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -66.94 153.43 77.93 Favored 'Trans proline' 0 C--N 1.32 -0.938 0 C-N-CA 121.915 1.744 . . . . 0.0 109.977 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.412 ' CD ' ' HB2' ' A' ' 27' ' ' PHE . 0.0 OUTLIER -165.65 147.04 7.17 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.207 -0.933 . . . . 0.0 111.083 -179.428 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.822 ' H ' HG13 ' A' ' 26' ' ' VAL . . . -81.04 161.7 24.09 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 177.051 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.706 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.27 -44.98 0.77 Allowed 'General case' 0 N--CA 1.508 2.441 0 O-C-N 120.155 -1.59 . . . . 0.0 111.93 -176.841 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -119.02 50.73 1.18 Allowed 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.953 HG22 ' CB ' ' A' ' 49' ' ' PHE . 19.9 t -64.63 157.64 4.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.76 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.409 HG22 ' H ' ' A' ' 65' ' ' LYS . 0.9 OUTLIER -142.14 173.57 11.4 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.153 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.409 ' H ' HG22 ' A' ' 64' ' ' THR . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.57 0 O-C-N 120.929 -1.107 . . . . 0.0 109.376 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.935 HD13 ' O ' ' A' ' 2' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.858 0 CA-C-O 121.467 0.651 . . . . 0.0 110.385 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.683 ' N ' HD22 ' A' ' 2' ' ' LEU . 0.1 OUTLIER -121.26 136.75 54.92 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.473 -0.767 . . . . 0.0 109.498 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -129.59 -164.19 11.35 Favored Glycine 0 N--CA 1.484 1.834 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 20.9 ttpt -151.71 135.9 16.68 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.882 -1.364 . . . . 0.0 111.048 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.555 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.3 t -42.58 140.07 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 122.865 1.317 . . . . 0.0 112.856 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.438 ' HG3' ' OE1' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -97.4 -31.13 12.53 Favored 'General case' 0 C--N 1.29 -2.011 0 N-CA-C 103.009 -2.96 . . . . 0.0 103.009 172.631 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.707 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.2 p-90 177.45 145.85 0.11 Allowed 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 177.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -113.81 146.32 40.12 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 120.591 -1.318 . . . . 0.0 109.61 179.234 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.562 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 31.4 m-20 -130.08 43.03 3.19 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 10' ' ' ASN . 53.4 p -41.33 -41.44 1.94 Allowed 'General case' 0 N--CA 1.489 1.511 0 CA-C-O 121.612 0.72 . . . . 0.0 109.077 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -59.49 -49.37 78.06 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.435 -0.791 . . . . 0.0 110.607 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.534 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -72.95 4.36 4.3 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.01 -1.056 . . . . 0.0 110.395 -179.429 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.56 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 91.46 23.91 27.62 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 120.051 -1.071 . . . . 0.0 111.933 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.473 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 11.1 p90 178.92 167.63 0.93 Allowed 'General case' 0 N--CA 1.499 1.987 0 CA-C-N 120.122 1.961 . . . . 0.0 111.815 179.306 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -146.58 144.33 12.59 Favored Glycine 0 N--CA 1.497 2.758 0 N-CA-C 107.271 -2.331 . . . . 0.0 107.271 179.404 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.707 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.1 m-85 -110.13 142.68 41.3 Favored 'General case' 0 N--CA 1.482 1.134 0 O-C-N 120.013 -1.874 . . . . 0.0 110.153 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.003 HD12 HG21 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -105.91 165.23 3.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 177.975 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.591 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 6.8 tt0 -133.92 130.17 37.36 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.47 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.781 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.3 p -131.95 139.11 51.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 C-N-CA 117.728 -1.589 . . . . 0.0 111.699 -179.645 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -65.4 140.7 58.66 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.266 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.2 -9.58 46.8 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.781 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -139.78 -175.43 4.21 Favored 'General case' 0 C--N 1.309 -1.158 0 O-C-N 121.125 -1.221 . . . . 0.0 108.871 179.675 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -100.48 -165.68 1.24 Allowed 'General case' 0 C--N 1.295 -1.77 0 CA-C-O 122.208 1.004 . . . . 0.0 110.583 -178.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.594 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.2 m-20 -71.04 119.95 15.9 Favored 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 115.714 -0.676 . . . . 0.0 109.74 179.353 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.861 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.2 t -78.82 114.31 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 120.674 -1.267 . . . . 0.0 111.398 178.632 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.62 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 2.0 t80 -66.26 125.03 24.3 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.38 -0.971 . . . . 0.0 108.38 178.764 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.003 HG21 HD12 ' A' ' 18' ' ' ILE . 2.3 m -143.99 136.82 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 120.593 -1.317 . . . . 0.0 110.26 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.629 ' NE2' ' CE1' ' A' ' 30' ' ' PHE . 35.6 t60 -98.85 166.91 11.07 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 179.273 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.629 ' CE1' ' NE2' ' A' ' 29' ' ' HIS . 42.0 p90 -83.61 38.99 0.65 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.773 -1.204 . . . . 0.0 109.424 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.5 m -132.27 -30.39 1.52 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.091 -1.006 . . . . 0.0 109.527 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.771 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.53 -42.12 10.42 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.108 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.493 ' O ' ' HA ' ' A' ' 64' ' ' THR . 17.1 mt . . . . . 0 N--CA 1.484 1.243 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.193 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.682 HG21 ' CD1' ' A' ' 18' ' ' ILE . 26.8 m -134.09 155.92 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.877 -1.139 . . . . 0.0 109.975 179.658 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.1 p -117.32 120.39 38.05 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.09 -1.007 . . . . 0.0 108.613 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.924 ' CB ' HG22 ' A' ' 63' ' ' VAL . 10.8 p90 -149.09 -178.45 6.39 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.056 -1.028 . . . . 0.0 109.729 -179.264 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.503 ' CG ' ' O ' ' A' ' 50' ' ' GLU . 5.1 pt-20 -127.74 96.53 4.54 Favored 'General case' 0 C--N 1.296 -1.732 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.098 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.861 HD11 ' CG2' ' A' ' 26' ' ' VAL . 10.6 mt -62.38 132.26 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.05 -1.031 . . . . 0.0 110.105 -179.427 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.538 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 6.3 m -113.63 -176.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 178.802 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -124.0 116.13 22.35 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.974 -1.079 . . . . 0.0 109.844 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.404 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -129.96 172.08 20.22 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 179.757 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.404 ' C ' ' O ' ' A' ' 54' ' ' GLY . 0.7 OUTLIER -37.71 -52.03 1.25 Allowed 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.378 -1.071 . . . . 0.0 113.394 -178.572 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.26 22.69 0.11 Allowed 'General case' 0 N--CA 1.501 2.12 0 O-C-N 119.717 -1.865 . . . . 0.0 112.262 -178.303 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.37 -178.28 35.43 Favored Glycine 0 N--CA 1.491 2.337 0 O-C-N 120.434 -1.416 . . . . 0.0 110.13 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.538 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.2 Cg_endo -68.81 150.91 74.26 Favored 'Trans proline' 0 C--N 1.32 -0.938 0 C-N-CA 122.046 1.831 . . . . 0.0 109.791 178.817 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.513 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 2.9 mt-30 -165.99 148.15 7.13 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.018 -1.051 . . . . 0.0 111.65 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.735 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -79.29 157.14 27.79 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 177.279 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.771 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.82 -42.9 0.74 Allowed 'General case' 0 N--CA 1.506 2.351 0 O-C-N 120.354 -1.466 . . . . 0.0 112.027 -176.46 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -119.13 52.17 1.08 Allowed 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.924 HG22 ' CB ' ' A' ' 49' ' ' PHE . 15.0 t -66.68 157.41 5.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.668 -179.436 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.493 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.1 OUTLIER -135.8 158.49 44.26 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 178.713 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.417 ' O ' ' HG3' ' A' ' 65' ' ' LYS . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.569 0 O-C-N 120.907 -1.121 . . . . 0.0 109.445 -179.883 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.189 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.961 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 . . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.844 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.5 OUTLIER -112.51 168.13 9.89 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.829 -1.17 . . . . 0.0 110.128 -178.857 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.495 ' N ' ' OE1' ' A' ' 3' ' ' GLU . . . -149.95 156.58 26.82 Favored Glycine 0 N--CA 1.486 2.026 0 N-CA-C 109.083 -1.607 . . . . 0.0 109.083 -179.557 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.451 ' HG2' ' C ' ' A' ' 4' ' ' GLY . 0.5 OUTLIER -135.37 120.8 19.2 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.257 -1.143 . . . . 0.0 110.575 -179.44 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.545 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.6 t -39.83 138.62 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 CA-C-O 122.749 1.261 . . . . 0.0 113.112 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.449 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -100.25 -27.59 13.42 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 103.608 -2.738 . . . . 0.0 103.608 172.948 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.705 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.6 p-90 178.41 145.13 0.13 Allowed 'General case' 0 N--CA 1.482 1.166 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 178.233 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.641 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.3 OUTLIER -114.39 146.38 40.65 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 120.445 -1.409 . . . . 0.0 110.391 -179.793 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.557 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 24.1 m-20 -127.88 37.46 4.18 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 107.097 -1.445 . . . . 0.0 107.097 178.119 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.5 p -38.8 -51.21 1.72 Allowed 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.229 -178.498 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -59.78 -45.76 91.29 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.365 -0.834 . . . . 0.0 110.291 -179.326 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.557 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -70.47 0.28 6.98 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.34 -0.85 . . . . 0.0 110.735 -179.001 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.497 ' O ' ' NE2' ' A' ' 29' ' ' HIS . . . 111.57 -2.97 27.73 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.61 -1.281 . . . . 0.0 113.199 177.889 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.54 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 0.3 OUTLIER 177.63 176.99 0.38 Allowed 'General case' 0 N--CA 1.499 2.019 0 CA-C-N 120.562 2.181 . . . . 0.0 111.82 -179.751 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.863 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -141.98 156.73 26.12 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 107.703 -2.159 . . . . 0.0 107.703 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.705 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.8 m-85 -110.45 139.9 45.23 Favored 'General case' 0 N--CA 1.482 1.127 0 O-C-N 119.929 -1.924 . . . . 0.0 109.82 -179.461 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.984 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.3 mt -106.54 152.8 8.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 178.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 0.0 OUTLIER -128.69 135.79 49.73 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 178.333 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.771 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.6 p -136.44 139.87 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 C-N-CA 118.213 -1.395 . . . . 0.0 111.483 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -65.38 140.37 58.64 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 115.485 -0.779 . . . . 0.0 109.424 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.92 -10.27 48.21 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.771 ' HB2' HG13 ' A' ' 20' ' ' VAL . 3.8 mm-40 -137.92 -174.12 3.7 Favored 'General case' 0 C--N 1.31 -1.117 0 O-C-N 121.184 -1.186 . . . . 0.0 108.787 179.796 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -100.56 -167.16 1.4 Allowed 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 122.077 0.942 . . . . 0.0 110.715 -178.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.599 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 0.2 OUTLIER -73.21 108.15 5.93 Favored 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.859 179.214 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 1.074 HG21 ' CZ ' ' A' ' 49' ' ' PHE . 2.5 t -71.62 116.73 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.046 0 O-C-N 120.17 -1.581 . . . . 0.0 111.074 178.747 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.454 ' CB ' ' HG2' ' A' ' 59' ' ' GLN . 3.8 t80 -53.46 142.53 21.82 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 177.636 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.984 ' CG1' HD12 ' A' ' 18' ' ' ILE . 0.7 OUTLIER -135.06 154.87 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 120.788 -1.195 . . . . 0.0 109.653 -178.857 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.497 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 9.5 t-160 -150.23 152.55 34.76 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -80.05 27.49 0.31 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.936 -1.102 . . . . 0.0 109.956 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.63 -43.84 2.88 Favored 'General case' 0 C--N 1.308 -1.209 0 O-C-N 120.946 -1.096 . . . . 0.0 108.661 179.759 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.637 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -95.67 -49.36 5.4 Favored 'General case' 0 N--CA 1.493 1.721 0 CA-C-O 121.92 0.867 . . . . 0.0 108.973 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.921 HD13 ' CG1' ' A' ' 63' ' ' VAL . 6.0 mm . . . . . 0 N--CA 1.488 1.444 0 O-C-N 121.91 -0.494 . . . . 0.0 110.381 -178.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.647 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.487 1.399 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.578 ' HB ' HG12 ' A' ' 63' ' ' VAL . 10.4 m -129.6 164.06 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 C-N-CA 117.881 -1.527 . . . . 0.0 111.706 -178.036 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.422 ' HA ' ' HA ' ' A' ' 3' ' ' GLU . 2.1 p -116.35 133.78 55.63 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 178.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.189 ' CE1' HD11 ' A' ' 2' ' ' LEU . 6.5 p90 -153.55 178.31 9.97 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.093 -1.004 . . . . 0.0 109.782 -179.198 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.6 93.52 4.07 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 179.419 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.958 HD11 HG23 ' A' ' 26' ' ' VAL . 14.6 mt -61.92 125.49 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.962 -1.086 . . . . 0.0 109.611 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.4 m -106.58 -176.07 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 178.571 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -124.06 113.57 18.57 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.052 -1.03 . . . . 0.0 109.569 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.36 170.91 16.5 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.786 -1.726 . . . . 0.0 108.786 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -37.83 -52.08 1.3 Allowed 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.331 -1.099 . . . . 0.0 113.386 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 11.3 mtp180 -76.65 22.38 0.18 Allowed 'General case' 0 N--CA 1.501 2.089 0 O-C-N 119.593 -1.942 . . . . 0.0 112.411 -177.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.26 179.43 31.29 Favored Glycine 0 N--CA 1.494 2.536 0 O-C-N 120.471 -1.393 . . . . 0.0 110.65 179.262 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.572 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.7 Cg_endo -69.09 152.23 72.81 Favored 'Trans proline' 0 C--N 1.32 -0.932 0 C-N-CA 122.135 1.89 . . . . 0.0 110.205 178.962 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.454 ' HG2' ' CB ' ' A' ' 27' ' ' PHE . 0.3 OUTLIER -166.43 149.44 7.03 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 120.959 -1.088 . . . . 0.0 111.697 -179.772 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.831 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -80.3 154.04 28.07 Favored 'General case' 0 N--CA 1.495 1.783 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 177.06 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.637 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.74 -39.53 0.79 Allowed 'General case' 0 N--CA 1.509 2.514 0 O-C-N 120.41 -1.431 . . . . 0.0 111.687 -176.642 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -118.89 52.01 1.08 Allowed 'General case' 0 C--N 1.284 -2.265 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.958 HG22 ' CB ' ' A' ' 49' ' ' PHE . 21.1 t -68.19 158.25 5.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.626 -179.14 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.474 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.2 OUTLIER -148.51 175.45 11.14 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.671 -0.812 . . . . 0.0 109.394 179.36 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.556 ' HA ' HG12 ' A' ' 47' ' ' VAL . 1.2 tttt . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.078 -1.013 . . . . 0.0 109.552 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.137 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.94 0 CA-C-O 121.029 0.442 . . . . 0.0 110.001 . . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.612 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.1 OUTLIER -114.76 150.87 34.69 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.043 -1.036 . . . . 0.0 110.555 -179.053 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.418 ' HA3' HG21 ' A' ' 18' ' ' ILE . . . -129.62 169.85 20.67 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 108.912 -1.675 . . . . 0.0 108.912 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.44 ' O ' ' C ' ' A' ' 6' ' ' VAL . 5.2 ttmt -141.76 125.71 17.19 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.978 -1.307 . . . . 0.0 110.564 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.507 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.8 t -32.01 140.97 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 CA-C-O 123.333 1.54 . . . . 0.0 114.188 -179.602 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.465 ' HD3' ' O ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -108.51 -31.79 7.66 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 103.184 -2.895 . . . . 0.0 103.184 172.48 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.696 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 15.4 p-90 175.79 146.49 0.08 Allowed 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 105.9 -1.889 . . . . 0.0 105.9 177.656 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.584 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.2 OUTLIER -117.93 145.35 44.74 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.539 -1.351 . . . . 0.0 109.636 179.237 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.506 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.9 t-20 -131.85 41.26 3.29 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.937 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 10' ' ' ASN . 2.1 p -39.17 -45.87 1.39 Allowed 'General case' 0 C--N 1.295 -1.768 0 CA-C-O 121.445 0.641 . . . . 0.0 109.378 -179.542 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -61.96 -45.27 94.4 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.322 -0.861 . . . . 0.0 110.015 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.58 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 1.0 OUTLIER -69.9 0.2 6.25 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.361 -0.837 . . . . 0.0 109.866 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.52 ' O ' ' CD2' ' A' ' 29' ' ' HIS . . . 91.15 20.43 38.92 Favored Glycine 0 N--CA 1.488 2.121 0 O-C-N 121.174 -0.954 . . . . 0.0 111.569 179.105 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.58 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 16.6 p90 -176.87 165.27 2.44 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 119.81 1.805 . . . . 0.0 111.532 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.71 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -150.2 141.79 9.09 Favored Glycine 0 N--CA 1.497 2.725 0 N-CA-C 107.172 -2.371 . . . . 0.0 107.172 179.401 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.696 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.3 m-85 -109.12 139.13 44.44 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.088 -1.83 . . . . 0.0 110.885 -178.523 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.732 HD11 HG21 ' A' ' 47' ' ' VAL . 1.0 OUTLIER -106.63 146.9 12.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 N-CA-C 105.665 -1.976 . . . . 0.0 105.665 177.322 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 15.1 tt0 -121.07 135.13 55.26 Favored 'General case' 0 C--N 1.28 -2.439 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.009 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.508 HG13 ' HB2' ' A' ' 23' ' ' GLN . 7.5 p -138.49 140.81 38.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 C-N-CA 117.567 -1.653 . . . . 0.0 111.891 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.74 140.5 58.74 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.105 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.97 -18.86 33.21 Favored Glycine 0 N--CA 1.486 2.013 0 N-CA-C 108.29 -1.924 . . . . 0.0 108.29 -178.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.508 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.8 OUTLIER -135.95 -176.9 4.46 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 121.502 -0.999 . . . . 0.0 108.989 179.502 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -100.81 -166.0 1.27 Allowed 'General case' 0 C--N 1.298 -1.663 0 CA-C-O 121.881 0.848 . . . . 0.0 110.841 -178.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.547 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 5.9 p-10 -71.94 90.88 1.16 Allowed 'General case' 0 N--CA 1.489 1.499 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.568 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.917 HG12 HG13 ' A' ' 28' ' ' VAL . 2.3 t -50.16 125.44 3.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.107 0 O-C-N 120.711 -1.243 . . . . 0.0 111.832 178.681 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.626 ' CD2' ' CZ ' ' A' ' 17' ' ' PHE . 2.9 t80 -72.24 130.36 40.61 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 176.188 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.917 HG13 HG12 ' A' ' 26' ' ' VAL . 2.6 m -146.6 130.75 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 120.248 -1.532 . . . . 0.0 110.703 -179.056 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.55 ' NE2' ' CE2' ' A' ' 30' ' ' PHE . 9.5 t-160 -98.99 166.74 11.13 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 178.448 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.55 ' CE2' ' NE2' ' A' ' 29' ' ' HIS . 53.0 p90 -83.82 32.44 0.48 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.795 -1.191 . . . . 0.0 110.135 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.1 m -119.12 -37.6 3.18 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.981 -1.075 . . . . 0.0 109.164 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.659 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.38 -37.34 13.28 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.25 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.672 ' N ' HD12 ' A' ' 33' ' ' ILE . 1.4 mp . . . . . 0 N--CA 1.486 1.373 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.732 HG21 HD11 ' A' ' 18' ' ' ILE . 35.1 m -132.39 164.33 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 120.893 -1.129 . . . . 0.0 110.311 -179.547 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -117.62 126.8 53.18 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.026 -1.046 . . . . 0.0 108.336 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.137 ' CE1' HD11 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -149.13 179.66 7.72 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.011 -1.055 . . . . 0.0 110.392 -179.642 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -123.74 81.14 1.87 Allowed 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.815 ' CD1' ' HB2' ' A' ' 60' ' ' ALA . 15.1 mm -61.29 118.81 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 CA-C-O 122.051 0.929 . . . . 0.0 110.772 -178.543 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.556 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 17.5 m -98.42 -175.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 179.232 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.411 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 0.2 OUTLIER -123.66 116.05 22.44 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.9 -1.125 . . . . 0.0 109.64 -179.885 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.27 174.61 16.97 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.929 -1.668 . . . . 0.0 108.929 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -38.67 -52.85 1.66 Allowed 'General case' 0 N--CA 1.505 2.287 0 O-C-N 121.369 -1.077 . . . . 0.0 113.772 -178.65 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.509 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -77.84 22.56 0.27 Allowed 'General case' 0 N--CA 1.501 2.092 0 O-C-N 119.69 -1.881 . . . . 0.0 112.211 -177.983 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.95 -178.6 30.89 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.283 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.556 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -63.58 157.78 49.43 Favored 'Trans proline' 0 C--N 1.318 -1.051 0 C-N-CA 121.991 1.794 . . . . 0.0 110.188 179.12 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.535 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 1.2 mt-30 -165.07 147.44 8.03 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 120.99 -1.069 . . . . 0.0 110.575 -179.559 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.872 ' HB1' ' CG2' ' A' ' 63' ' ' VAL . . . -82.89 158.6 22.6 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 177.701 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.659 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -132.9 -47.29 0.86 Allowed 'General case' 0 N--CA 1.501 2.098 0 O-C-N 120.436 -1.415 . . . . 0.0 111.07 -177.149 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -121.27 55.24 1.08 Allowed 'General case' 0 C--N 1.288 -2.099 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 179.219 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.888 HG22 ' CB ' ' A' ' 49' ' ' PHE . 22.9 t -67.47 161.44 3.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-O 121.667 0.746 . . . . 0.0 110.111 -178.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.494 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -141.08 160.63 39.68 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 119.76 -0.776 . . . . 0.0 108.93 178.668 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.487 ' HA ' HG12 ' A' ' 47' ' ' VAL . 19.5 ptmt . . . . . 0 N--CA 1.494 1.761 0 O-C-N 120.927 -1.108 . . . . 0.0 109.857 -179.642 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.978 HD22 ' CE1' ' A' ' 49' ' ' PHE . 0.3 OUTLIER . . . . . 0 N--CA 1.488 1.444 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 . . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.543 ' N ' ' HG ' ' A' ' 2' ' ' LEU . 0.2 OUTLIER -113.37 162.02 16.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.18 -0.95 . . . . 0.0 110.045 -179.438 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.22 159.17 27.43 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.384 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.407 ' O ' ' C ' ' A' ' 6' ' ' VAL . 8.0 mtpt -133.66 112.46 11.45 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.304 -1.115 . . . . 0.0 109.111 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.53 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.6 t -42.45 139.36 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 122.796 1.284 . . . . 0.0 112.555 -178.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.483 ' HG3' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -98.43 -31.4 12.02 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 103.266 -2.864 . . . . 0.0 103.266 172.91 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.706 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 21.0 p-90 178.11 143.9 0.11 Allowed 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 177.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.573 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.9 OUTLIER -119.56 140.47 50.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.73 -1.231 . . . . 0.0 109.522 179.566 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.484 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.5 t-20 -131.43 38.13 3.63 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.454 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.2 p -37.36 -49.76 1.01 Allowed 'General case' 0 N--CA 1.492 1.629 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.886 -179.395 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -61.37 -44.66 96.78 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.284 -0.885 . . . . 0.0 109.91 -179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.479 ' CE ' ' OD1' ' A' ' 10' ' ' ASN . 0.4 OUTLIER -69.21 0.08 5.33 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.371 -0.831 . . . . 0.0 110.267 -179.554 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.508 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 102.46 12.09 34.09 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 119.935 -1.126 . . . . 0.0 112.635 178.329 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.649 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.0 OUTLIER 177.03 166.02 0.53 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-N 120.444 2.122 . . . . 0.0 112.215 179.543 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.654 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -146.74 137.03 6.49 Favored Glycine 0 N--CA 1.499 2.854 0 N-CA-C 106.671 -2.572 . . . . 0.0 106.671 179.342 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.706 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.9 m-30 -106.96 139.16 41.8 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.054 -1.85 . . . . 0.0 110.763 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.805 ' CD1' HG21 ' A' ' 47' ' ' VAL . 2.5 mt -108.21 151.65 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 177.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.509 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 9.1 tt0 -127.22 133.57 50.23 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.719 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.72 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.5 p -136.38 140.06 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 C-N-CA 117.792 -1.563 . . . . 0.0 111.772 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.8 140.13 58.38 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.121 179.771 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.42 -17.17 40.37 Favored Glycine 0 N--CA 1.486 1.967 0 N-CA-C 108.469 -1.853 . . . . 0.0 108.469 -178.868 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.72 ' HB2' HG13 ' A' ' 20' ' ' VAL . 3.1 mm-40 -136.85 -174.35 3.7 Favored 'General case' 0 N--CA 1.482 1.163 0 O-C-N 121.324 -1.104 . . . . 0.0 108.652 179.604 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.89 -165.93 1.26 Allowed 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.168 0.985 . . . . 0.0 110.657 -179.025 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.572 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 8.1 p-10 -72.09 106.96 4.53 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.011 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.84 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.4 t -71.17 117.36 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 120.483 -1.386 . . . . 0.0 111.298 178.863 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.613 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 3.8 t80 -67.47 130.6 43.58 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.497 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.699 HG11 HD12 ' A' ' 18' ' ' ILE . 2.4 m -139.11 131.8 37.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 120.476 -1.39 . . . . 0.0 110.715 -179.799 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.544 ' CE1' ' CE1' ' A' ' 30' ' ' PHE . 6.7 t60 -99.92 164.25 12.1 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.567 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 46.1 p90 -82.84 40.94 0.71 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.962 -1.086 . . . . 0.0 109.814 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 94.1 p -129.92 -38.56 1.45 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.858 -1.151 . . . . 0.0 109.711 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.729 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.78 -41.43 10.11 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 179.518 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.622 HD11 HG12 ' A' ' 28' ' ' VAL . 1.7 mp . . . . . 0 C--N 1.307 -1.28 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.43 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.805 HG21 ' CD1' ' A' ' 18' ' ' ILE . 33.4 m -116.9 157.72 17.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.886 -1.134 . . . . 0.0 109.909 179.745 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 89.7 p -117.48 122.2 43.09 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.282 -0.887 . . . . 0.0 108.787 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.978 ' CE1' HD22 ' A' ' 2' ' ' LEU . 10.4 p90 -153.97 -177.51 6.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.02 -1.05 . . . . 0.0 109.726 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -128.15 102.24 6.62 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.083 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.84 HD11 ' CG2' ' A' ' 26' ' ' VAL . 4.9 mt -62.76 144.56 14.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 120.816 -1.177 . . . . 0.0 111.126 -179.385 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.556 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.7 m -131.2 -173.18 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 179.1 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -122.25 114.68 21.15 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.786 -1.196 . . . . 0.0 109.776 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.87 172.66 16.49 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -38.66 -53.72 1.61 Allowed 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.21 -1.171 . . . . 0.0 113.006 -178.659 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.462 ' NH1' ' CG ' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -68.77 -21.24 64.36 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 119.647 -1.908 . . . . 0.0 112.778 -177.85 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 138.46 -170.84 23.73 Favored Glycine 0 N--CA 1.491 2.353 0 O-C-N 120.345 -1.472 . . . . 0.0 109.618 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.556 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.8 Cg_endo -62.26 122.88 11.51 Favored 'Trans proline' 0 C--N 1.321 -0.877 0 C-N-CA 121.803 1.668 . . . . 0.0 109.875 178.767 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.474 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 4.5 mt-30 -144.2 148.45 34.97 Favored 'General case' 0 N--CA 1.5 2.07 0 O-C-N 121.189 -0.944 . . . . 0.0 111.097 -179.024 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.661 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -80.48 166.75 20.91 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.644 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.729 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.99 -43.32 0.73 Allowed 'General case' 0 N--CA 1.507 2.391 0 O-C-N 120.286 -1.509 . . . . 0.0 112.012 -177.123 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 31.6 t30 -119.66 51.88 1.14 Allowed 'General case' 0 C--N 1.287 -2.129 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.959 HG22 ' CB ' ' A' ' 49' ' ' PHE . 17.7 t -66.91 157.31 6.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.53 -179.351 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.413 HG22 ' H ' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -143.7 176.69 9.03 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 178.534 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.413 ' H ' HG22 ' A' ' 64' ' ' THR . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.035 -1.04 . . . . 0.0 109.318 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.158 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.885 0 CA-C-O 120.972 0.415 . . . . 0.0 109.981 . . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.91 ' OE2' ' HB1' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -112.74 158.79 19.65 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.032 -1.042 . . . . 0.0 110.929 -178.102 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.446 ' HA2' ' HB ' ' A' ' 20' ' ' VAL . . . -136.55 160.36 24.76 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.644 -1.782 . . . . 0.0 108.644 179.492 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.9 mtpt -134.45 116.27 14.94 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.083 -1.245 . . . . 0.0 110.618 -179.42 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.54 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.8 t -32.9 141.17 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 CA-C-O 123.015 1.388 . . . . 0.0 113.635 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.473 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 3.0 tmtt? -104.07 -32.18 9.32 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 102.979 -2.971 . . . . 0.0 102.979 172.221 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.696 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.0 p-90 175.56 147.56 0.09 Allowed 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 177.716 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.548 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.6 OUTLIER -114.47 140.09 49.0 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 120.441 -1.412 . . . . 0.0 109.305 178.994 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.565 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 79.5 m-20 -122.77 46.78 2.08 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.605 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.1 OUTLIER -43.76 -35.34 1.83 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 -179.315 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -59.7 -48.86 79.99 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.467 -0.771 . . . . 0.0 110.009 179.769 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.52 ' O ' ' CE2' ' A' ' 15' ' ' PHE . 13.2 mptt -76.74 11.8 1.56 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.26 -0.9 . . . . 0.0 110.201 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.436 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 84.6 20.81 57.67 Favored Glycine 0 N--CA 1.488 2.118 0 O-C-N 121.093 -1.004 . . . . 0.0 111.661 178.751 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.52 ' CE2' ' O ' ' A' ' 13' ' ' LYS . 36.1 p90 179.6 167.05 1.15 Allowed 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 119.983 1.892 . . . . 0.0 112.031 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.548 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -142.46 149.31 21.14 Favored Glycine 0 N--CA 1.498 2.784 0 N-CA-C 106.937 -2.465 . . . . 0.0 106.937 178.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.696 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -106.26 143.58 34.18 Favored 'General case' 0 N--CA 1.484 1.269 0 CA-C-N 119.836 1.818 . . . . 0.0 110.302 -178.4 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.999 HD12 HG12 ' A' ' 28' ' ' VAL . 0.9 OUTLIER -106.61 161.49 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 178.916 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.572 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 2.9 tp10 -142.66 130.02 21.11 Favored 'General case' 0 C--N 1.29 -2.018 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 177.781 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.773 HG13 ' HB2' ' A' ' 23' ' ' GLN . 13.0 p -135.99 140.56 43.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 117.485 -1.686 . . . . 0.0 111.729 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -65.36 140.62 58.67 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.052 179.791 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.22 -12.85 48.51 Favored Glycine 0 N--CA 1.487 2.049 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -178.887 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.773 ' HB2' HG13 ' A' ' 20' ' ' VAL . 6.1 mm-40 -140.75 -176.57 4.71 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 121.345 -1.091 . . . . 0.0 108.322 179.612 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.49 -165.79 1.25 Allowed 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.18 -0.95 . . . . 0.0 110.806 -179.091 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.588 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 11.6 p-10 -72.57 129.9 39.37 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.05 179.339 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.896 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.5 t -98.55 121.4 49.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 120.802 -1.186 . . . . 0.0 110.81 178.252 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.504 ' HB2' ' HG2' ' A' ' 59' ' ' GLN . 23.0 t80 -58.11 137.28 57.08 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.079 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.999 HG12 HD12 ' A' ' 18' ' ' ILE . 1.2 m -131.14 115.65 30.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 120.781 -1.199 . . . . 0.0 110.348 -178.89 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.406 ' O ' HD12 ' A' ' 33' ' ' ILE . 7.8 t-160 -104.66 148.9 26.05 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.442 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.521 ' CD1' ' C ' ' A' ' 30' ' ' PHE . 0.0 OUTLIER -81.16 31.63 0.33 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.816 -1.177 . . . . 0.0 110.486 -179.68 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -125.35 -35.21 2.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.13 -0.981 . . . . 0.0 108.544 178.724 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.763 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.37 -35.68 14.26 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.817 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.942 HD11 ' HB ' ' A' ' 28' ' ' VAL . 63.0 mt . . . . . 0 N--CA 1.483 1.18 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.985 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.91 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.487 1.407 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.726 HG21 HD11 ' A' ' 18' ' ' ILE . 28.8 m -119.66 163.9 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.879 -1.138 . . . . 0.0 110.469 -179.165 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.1 p -115.55 126.03 53.73 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.064 -1.023 . . . . 0.0 108.294 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.158 ' CE1' HD11 ' A' ' 2' ' ' LEU . 8.2 p90 -153.28 -179.41 7.7 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.043 -1.035 . . . . 0.0 109.83 -179.325 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -124.29 92.64 3.71 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.31 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.896 HD11 ' CG2' ' A' ' 26' ' ' VAL . 17.0 mt -61.49 132.79 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 CA-C-O 122.271 1.034 . . . . 0.0 110.338 -179.161 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.547 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.2 m -116.44 -174.46 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 178.853 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.423 ' CD ' ' N ' ' A' ' 53' ' ' GLU . 0.4 OUTLIER -123.72 114.33 19.81 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.001 -1.062 . . . . 0.0 109.331 179.79 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.72 175.57 18.65 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -37.92 -52.63 1.35 Allowed 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.499 -1.001 . . . . 0.0 113.548 -178.508 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.3 mmm180 -76.07 23.09 0.14 Allowed 'General case' 0 N--CA 1.5 2.036 0 O-C-N 119.807 -1.808 . . . . 0.0 112.137 -178.216 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.28 -174.78 35.62 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.547 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.2 Cg_endo -65.53 150.19 86.91 Favored 'Trans proline' 0 C--N 1.319 -0.997 0 C-N-CA 121.636 1.558 . . . . 0.0 109.791 178.871 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.504 ' HG2' ' HB2' ' A' ' 27' ' ' PHE . 1.4 mt-30 -165.58 150.31 8.69 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 120.97 -1.082 . . . . 0.0 111.521 -179.433 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.814 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.76 157.75 23.12 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 177.613 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.763 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.92 -41.49 0.75 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 120.52 -1.362 . . . . 0.0 111.578 -176.769 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.1 m-20 -119.9 57.18 0.93 Allowed 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 179.618 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.88 HG22 ' CB ' ' A' ' 49' ' ' PHE . 18.6 t -72.43 166.3 2.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.103 -178.629 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.534 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -148.1 176.27 10.34 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.669 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.471 ' O ' ' HG2' ' A' ' 65' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.636 0 O-C-N 121.052 -1.03 . . . . 0.0 109.672 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.171 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.796 0 CA-C-O 121.216 0.531 . . . . 0.0 110.119 . . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.744 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -113.24 155.62 24.75 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.207 -0.933 . . . . 0.0 110.007 -179.175 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.415 ' C ' ' HG2' ' A' ' 5' ' ' LYS . . . -133.28 161.95 24.25 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.436 ' O ' ' C ' ' A' ' 6' ' ' VAL . 4.0 mttp -130.24 115.5 17.06 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.209 -1.171 . . . . 0.0 109.887 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.537 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.4 t -36.87 140.44 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 122.869 1.319 . . . . 0.0 112.758 -179.577 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.5 tmtt? -99.41 -31.81 11.47 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 103.042 -2.947 . . . . 0.0 103.042 172.8 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.701 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 21.5 p-90 176.65 144.14 0.08 Allowed 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 177.741 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.5 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.7 OUTLIER -119.06 141.48 48.7 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.48 -1.387 . . . . 0.0 109.435 179.531 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.499 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.2 t-20 -130.93 37.72 3.75 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.45 ' C ' ' O ' ' A' ' 10' ' ' ASN . 15.3 p -37.79 -47.41 1.01 Allowed 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.493 0.663 . . . . 0.0 109.297 -179.682 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -61.12 -46.36 90.92 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.432 -0.792 . . . . 0.0 109.877 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.473 ' HB2' ' CG ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -69.26 0.49 4.84 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.403 -0.811 . . . . 0.0 110.256 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.411 ' O ' ' CB ' ' A' ' 15' ' ' PHE . . . 99.38 15.48 32.33 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 120.001 -1.095 . . . . 0.0 112.399 178.624 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.436 ' O ' ' C ' ' A' ' 10' ' ' ASN . 1.0 OUTLIER 175.53 163.09 0.3 Allowed 'General case' 0 N--CA 1.497 1.917 0 CA-C-N 120.299 2.05 . . . . 0.0 111.849 179.561 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.672 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -146.31 139.99 8.49 Favored Glycine 0 N--CA 1.498 2.832 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.701 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.4 m-85 -108.77 144.11 37.03 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.209 -1.759 . . . . 0.0 110.422 -178.646 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.724 HD12 HG21 ' A' ' 28' ' ' VAL . 0.5 OUTLIER -106.31 165.42 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 178.471 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.589 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 1.9 tt0 -141.8 127.77 19.48 Favored 'General case' 0 C--N 1.291 -1.967 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.155 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.751 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.8 p -134.2 141.47 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 C-N-CA 117.446 -1.701 . . . . 0.0 111.851 -179.463 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -63.8 140.14 58.84 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.259 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 82.21 -12.62 43.54 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 -179.118 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.751 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.1 OUTLIER -137.57 -176.33 4.37 Favored 'General case' 0 N--CA 1.484 1.247 0 O-C-N 121.303 -1.116 . . . . 0.0 108.669 179.696 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -100.29 -166.1 1.29 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.271 -0.893 . . . . 0.0 110.505 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.601 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 34.7 p-10 -71.68 122.21 20.2 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.849 179.366 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.87 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.3 t -84.76 104.46 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 120.592 -1.317 . . . . 0.0 111.687 178.733 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.62 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 2.1 t80 -55.44 135.1 50.71 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 178.244 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.724 HG21 HD12 ' A' ' 18' ' ' ILE . 2.3 m -150.19 127.26 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 118.067 -1.453 . . . . 0.0 111.641 -179.336 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.624 ' NE2' ' CE1' ' A' ' 30' ' ' PHE . 7.7 t-160 -99.32 162.12 13.22 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 178.659 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.624 ' CE1' ' NE2' ' A' ' 29' ' ' HIS . 52.6 p90 -81.26 39.34 0.51 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.498 -1.376 . . . . 0.0 110.435 -179.432 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.7 t -123.48 -46.5 2.02 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.698 -1.251 . . . . 0.0 109.564 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.741 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.0 -40.56 11.59 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.328 -0.857 . . . . 0.0 108.74 179.57 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.714 HG23 ' HB ' ' A' ' 63' ' ' VAL . 2.9 mp . . . . . 0 C--N 1.3 -1.581 0 CA-C-O 121.703 0.763 . . . . 0.0 109.262 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.495 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.713 HG21 HD11 ' A' ' 18' ' ' ILE . 35.9 m -119.32 160.37 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.851 -1.155 . . . . 0.0 109.945 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 49.0 p -115.14 132.0 56.74 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 120.968 -1.083 . . . . 0.0 108.495 179.485 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.171 ' CE1' HD11 ' A' ' 2' ' ' LEU . 10.5 p90 -164.28 -176.56 4.49 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.973 -1.079 . . . . 0.0 109.988 -179.439 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.07 98.32 4.89 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.19 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.87 HD11 ' CG2' ' A' ' 26' ' ' VAL . 7.2 mt -62.67 141.3 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 120.827 -1.171 . . . . 0.0 110.873 -179.222 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.521 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 8.7 m -124.76 -175.35 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.487 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -123.08 115.26 21.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.935 -1.103 . . . . 0.0 109.772 -179.736 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.52 168.93 18.53 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 37.4 m-20 -37.84 -52.37 1.31 Allowed 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.329 -1.101 . . . . 0.0 113.634 -178.541 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.96 22.31 0.19 Allowed 'General case' 0 N--CA 1.5 2.062 0 O-C-N 119.777 -1.827 . . . . 0.0 112.414 -177.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.95 -179.39 28.72 Favored Glycine 0 N--CA 1.494 2.501 0 O-C-N 120.393 -1.442 . . . . 0.0 110.588 179.312 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.521 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.8 Cg_endo -68.77 142.23 51.88 Favored 'Trans proline' 0 C--N 1.321 -0.908 0 C-N-CA 122.225 1.95 . . . . 0.0 110.085 178.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.528 ' HG2' ' CB ' ' A' ' 27' ' ' PHE . 22.5 mt-30 -156.52 149.36 23.87 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.048 -1.032 . . . . 0.0 111.558 -179.568 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.77 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -80.41 161.63 24.86 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.481 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.741 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.92 -41.57 0.75 Allowed 'General case' 0 N--CA 1.508 2.426 0 O-C-N 120.458 -1.401 . . . . 0.0 111.972 -176.358 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.513 ' O ' ' ND2' ' A' ' 62' ' ' ASN . 0.2 OUTLIER -120.57 50.75 1.29 Allowed 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 179.91 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.958 HG22 ' CB ' ' A' ' 49' ' ' PHE . 14.9 t -68.18 171.33 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-O 121.814 0.816 . . . . 0.0 109.501 -179.532 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.578 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -153.62 172.19 17.61 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 177.908 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.3 tmtt? . . . . . 0 N--CA 1.491 1.599 0 O-C-N 120.696 -1.252 . . . . 0.0 109.379 179.979 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.214 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.499 1.994 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 . . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.567 ' N ' HD22 ' A' ' 2' ' ' LEU . 0.4 OUTLIER -117.65 135.32 54.07 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 120.817 -1.177 . . . . 0.0 110.794 -179.263 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.415 ' C ' ' HG2' ' A' ' 5' ' ' LYS . . . -103.2 173.68 22.48 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.825 -1.71 . . . . 0.0 108.825 178.789 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.415 ' HG2' ' C ' ' A' ' 4' ' ' GLY . 3.4 mtpp -137.37 112.77 9.31 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 120.781 -1.423 . . . . 0.0 109.955 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.45 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.5 t -47.88 131.77 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 CA-C-O 122.688 1.233 . . . . 0.0 112.645 -179.811 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 2.0 tttt -93.12 -30.39 15.28 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 103.213 -2.884 . . . . 0.0 103.213 173.496 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.718 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 25.1 p-90 175.28 146.57 0.08 Allowed 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 106.617 -1.624 . . . . 0.0 106.617 178.452 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.522 ' CZ ' HG23 ' A' ' 28' ' ' VAL . 0.5 OUTLIER -112.45 147.27 36.85 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.724 -1.235 . . . . 0.0 108.773 178.517 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.556 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 10.8 m-20 -130.05 42.84 3.22 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.203 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 10' ' ' ASN . 54.1 p -40.89 -40.0 1.27 Allowed 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -179.676 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.0 mm-40 -59.86 -49.33 78.11 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.665 -0.647 . . . . 0.0 110.487 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.529 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 1.4 mptp? -74.5 6.09 4.1 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.097 -1.002 . . . . 0.0 110.038 -179.798 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.468 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 90.76 20.33 40.62 Favored Glycine 0 N--CA 1.49 2.246 0 O-C-N 121.133 -0.979 . . . . 0.0 112.066 178.582 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.516 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 39.8 p90 178.9 170.29 0.88 Allowed 'General case' 0 N--CA 1.499 1.994 0 CA-C-N 120.0 1.9 . . . . 0.0 111.762 179.467 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.572 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -145.3 152.34 24.42 Favored Glycine 0 N--CA 1.499 2.891 0 N-CA-C 106.864 -2.495 . . . . 0.0 106.864 179.192 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.718 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.6 m-85 -113.14 135.36 53.89 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 120.28 2.04 . . . . 0.0 110.216 -178.786 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.963 HD12 ' CG1' ' A' ' 28' ' ' VAL . 2.8 mt -108.61 146.37 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.37 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.546 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 27.6 tt0 -125.52 135.87 52.73 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 177.648 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.602 HG13 ' HB2' ' A' ' 23' ' ' GLN . 10.9 p -137.37 139.64 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 C-N-CA 117.675 -1.61 . . . . 0.0 111.905 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -64.17 140.39 58.86 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.088 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 84.08 -15.06 40.69 Favored Glycine 0 N--CA 1.485 1.953 0 N-CA-C 108.684 -1.767 . . . . 0.0 108.684 -178.924 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.634 ' NE2' HG21 ' A' ' 51' ' ' ILE . 0.2 OUTLIER -136.95 -174.67 3.79 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 121.299 -1.118 . . . . 0.0 108.682 179.46 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.421 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 4.5 m-20 -100.79 -166.4 1.31 Allowed 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 122.073 0.94 . . . . 0.0 110.71 -179.171 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.546 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 8.1 p-10 -72.3 101.83 2.97 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.92 179.09 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.791 HG13 ' H ' ' A' ' 60' ' ' ALA . 2.6 t -68.15 126.28 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 120.252 -1.53 . . . . 0.0 110.124 178.514 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.433 ' HB3' ' HG2' ' A' ' 59' ' ' GLN . 16.6 t80 -65.46 142.09 58.28 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 177.81 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.977 ' HB ' HD11 ' A' ' 33' ' ' ILE . 1.4 m -134.09 156.73 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.735 -1.228 . . . . 0.0 110.345 -178.598 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.524 ' CE1' ' CE2' ' A' ' 30' ' ' PHE . 16.7 t-80 -138.42 157.92 45.27 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.093 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.524 ' CE2' ' CE1' ' A' ' 29' ' ' HIS . 53.1 p90 -85.02 32.74 0.53 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.145 -0.972 . . . . 0.0 109.769 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.4 p -127.91 -35.48 2.07 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.832 -1.168 . . . . 0.0 109.773 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.755 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -93.04 -50.16 5.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.232 -0.917 . . . . 0.0 108.988 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.977 HD11 ' HB ' ' A' ' 28' ' ' VAL . 41.0 mt . . . . . 0 C--N 1.305 -1.348 0 CA-C-O 121.819 0.819 . . . . 0.0 109.047 -179.735 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 121.826 0.822 . . . . 0.0 110.055 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 18.6 m -122.74 165.91 18.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 121.262 -0.899 . . . . 0.0 108.687 179.091 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -117.68 120.23 37.35 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.854 -1.154 . . . . 0.0 109.163 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.214 ' CE1' HD11 ' A' ' 2' ' ' LEU . 5.6 p90 -149.46 -178.17 6.27 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.165 -0.959 . . . . 0.0 109.978 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.495 ' CG ' ' O ' ' A' ' 50' ' ' GLU . 0.3 OUTLIER -126.47 95.11 4.25 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.376 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.784 HD11 ' CG2' ' A' ' 26' ' ' VAL . 11.3 mt -61.91 140.1 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 CA-C-O 122.513 1.149 . . . . 0.0 111.175 -178.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 12.0 m -124.57 -177.17 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 106.064 -1.828 . . . . 0.0 106.064 179.166 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -123.32 111.95 17.02 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 118.885 -1.126 . . . . 0.0 109.642 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -116.84 169.86 13.21 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 73.1 m-20 -38.23 -52.68 1.48 Allowed 'General case' 0 N--CA 1.504 2.268 0 O-C-N 121.302 -1.116 . . . . 0.0 113.723 -178.575 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -78.1 22.02 0.32 Allowed 'General case' 0 N--CA 1.5 2.074 0 O-C-N 119.62 -1.925 . . . . 0.0 112.524 -177.564 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.65 -178.02 24.89 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 119.17 -1.491 . . . . 0.0 110.628 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.489 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.3 Cg_endo -66.1 153.02 79.75 Favored 'Trans proline' 0 C--N 1.321 -0.905 0 C-N-CA 122.277 1.984 . . . . 0.0 110.529 179.21 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.433 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 0.2 OUTLIER -165.85 147.52 7.09 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.419 -0.8 . . . . 0.0 110.631 -179.758 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.791 ' H ' HG13 ' A' ' 26' ' ' VAL . . . -83.07 163.9 20.63 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 177.205 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.755 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.17 -44.05 0.78 Allowed 'General case' 0 N--CA 1.507 2.387 0 O-C-N 120.201 -1.562 . . . . 0.0 111.909 -176.869 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -119.77 52.11 1.13 Allowed 'General case' 0 C--N 1.287 -2.148 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.92 HG22 ' CB ' ' A' ' 49' ' ' PHE . 20.8 t -66.09 163.1 2.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-O 121.74 0.781 . . . . 0.0 110.554 -179.035 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.527 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -145.06 179.29 7.46 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 177.9 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.493 1.714 0 O-C-N 120.842 -1.161 . . . . 0.0 109.657 -179.837 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.182 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.883 0 CA-C-O 121.304 0.573 . . . . 0.0 110.301 . . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.62 ' N ' HD22 ' A' ' 2' ' ' LEU . 2.2 tt0 -113.74 144.68 42.56 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.303 -0.873 . . . . 0.0 110.174 -179.253 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.43 ' HA3' HG21 ' A' ' 18' ' ' ILE . . . -112.7 161.52 12.67 Favored Glycine 0 N--CA 1.483 1.811 0 N-CA-C 108.514 -1.835 . . . . 0.0 108.514 178.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.448 ' O ' ' C ' ' A' ' 6' ' ' VAL . 9.3 mttm -131.74 113.76 13.93 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.187 -1.184 . . . . 0.0 109.754 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.536 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.6 t -33.72 139.62 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 CA-C-O 122.91 1.338 . . . . 0.0 113.636 -179.675 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.461 ' HG2' ' CB ' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -103.92 -32.07 9.45 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 103.108 -2.923 . . . . 0.0 103.108 172.183 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.704 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 18.9 p-90 174.82 147.38 0.07 Allowed 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 106.315 -1.735 . . . . 0.0 106.315 177.803 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.569 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.4 OUTLIER -113.52 145.32 41.39 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 120.263 -1.523 . . . . 0.0 109.325 178.95 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.557 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 49.7 m-20 -130.11 41.84 3.36 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 178.987 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.439 ' C ' ' O ' ' A' ' 10' ' ' ASN . 62.0 p -40.98 -43.65 2.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.671 -0.643 . . . . 0.0 109.518 -179.16 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 60.4 mm-40 -61.62 -45.41 94.21 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.307 -0.871 . . . . 0.0 109.718 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.509 ' N ' ' CD ' ' A' ' 13' ' ' LYS . 0.2 OUTLIER -72.39 4.73 3.47 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.531 -0.731 . . . . 0.0 110.469 -179.66 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.486 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 93.34 19.88 34.23 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 120.053 -1.07 . . . . 0.0 112.236 178.372 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.513 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 0.8 OUTLIER 169.87 171.69 0.06 Allowed 'General case' 0 N--CA 1.498 1.958 0 CA-C-N 120.074 1.937 . . . . 0.0 111.641 179.401 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.848 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -143.6 151.85 23.66 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 106.889 -2.484 . . . . 0.0 106.889 178.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.704 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.6 m-85 -112.65 140.6 47.27 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 119.854 -1.968 . . . . 0.0 110.152 -178.817 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.929 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.2 mt -106.86 155.95 7.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 179.385 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.508 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 13.0 tt0 -132.31 133.15 43.71 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.797 HG13 ' HB2' ' A' ' 23' ' ' GLN . 14.8 p -132.94 141.04 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 C-N-CA 117.879 -1.528 . . . . 0.0 111.666 -179.606 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -64.52 140.39 58.86 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.4 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.57 -6.22 47.18 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.797 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -140.54 -175.57 4.32 Favored 'General case' 0 C--N 1.309 -1.159 0 O-C-N 121.08 -1.247 . . . . 0.0 108.706 179.789 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.41 -166.97 1.38 Allowed 'General case' 0 C--N 1.297 -1.705 0 CA-C-O 122.151 0.977 . . . . 0.0 110.866 -179.032 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.596 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 5.6 p-10 -71.92 113.02 8.52 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.31 179.486 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.972 HG21 ' CZ ' ' A' ' 49' ' ' PHE . 2.5 t -79.41 114.82 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 120.463 -1.398 . . . . 0.0 110.742 178.49 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.526 ' HB2' ' HG2' ' A' ' 59' ' ' GLN . 31.5 t80 -49.62 146.24 4.39 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 178.403 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.929 ' CG1' HD12 ' A' ' 18' ' ' ILE . 1.2 m -139.21 157.57 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 O-C-N 120.801 -1.187 . . . . 0.0 109.24 -179.443 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.486 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 5.5 t60 -158.42 155.15 28.1 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.406 ' N ' ' CD2' ' A' ' 29' ' ' HIS . 33.5 p90 -79.58 26.34 0.31 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.931 -1.106 . . . . 0.0 110.235 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.3 p -116.35 -47.82 2.73 Favored 'General case' 0 N--CA 1.483 1.218 0 O-C-N 120.839 -1.163 . . . . 0.0 108.909 179.686 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.711 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.51 -47.53 7.09 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.948 HD13 ' HB ' ' A' ' 63' ' ' VAL . 10.1 mm . . . . . 0 N--CA 1.486 1.349 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.506 ' O ' ' HG2' ' A' ' 3' ' ' GLU . 33.3 m -117.92 162.68 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 120.819 -1.176 . . . . 0.0 111.026 -178.778 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -118.49 117.7 29.71 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.615 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.182 ' CE1' HD11 ' A' ' 2' ' ' LEU . 6.0 p90 -148.76 -177.73 5.95 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.093 -1.004 . . . . 0.0 110.008 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -128.91 96.87 4.47 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 179.268 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.867 HD11 ' CG2' ' A' ' 26' ' ' VAL . 10.7 mt -61.63 139.22 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.874 -1.141 . . . . 0.0 110.387 -179.218 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 2.7 m -127.19 -172.48 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -124.0 118.01 26.04 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.985 -1.072 . . . . 0.0 109.489 179.561 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -129.27 174.67 19.18 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.139 -1.584 . . . . 0.0 109.139 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -38.81 -52.99 1.72 Allowed 'General case' 0 N--CA 1.506 2.329 0 O-C-N 121.414 -1.051 . . . . 0.0 113.67 -178.565 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 29.0 mtp180 -77.91 22.45 0.28 Allowed 'General case' 0 N--CA 1.497 1.924 0 O-C-N 119.688 -1.883 . . . . 0.0 112.217 -177.886 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.54 -177.72 30.92 Favored Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.364 -1.398 . . . . 0.0 110.285 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.527 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -66.09 146.66 82.65 Favored 'Trans proline' 0 C--N 1.319 -0.981 0 C-N-CA 122.069 1.846 . . . . 0.0 110.065 178.948 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.526 ' HG2' ' HB2' ' A' ' 27' ' ' PHE . 0.4 OUTLIER -165.63 153.8 11.18 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.105 -0.997 . . . . 0.0 111.601 -179.35 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.771 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.12 159.45 23.36 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 177.107 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.711 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.28 -41.03 0.73 Allowed 'General case' 0 N--CA 1.508 2.432 0 O-C-N 120.288 -1.508 . . . . 0.0 111.97 -176.36 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.0 p30 -119.39 51.89 1.12 Allowed 'General case' 0 C--N 1.283 -2.294 0 N-CA-C 106.689 -1.596 . . . . 0.0 106.689 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.96 HG22 ' CB ' ' A' ' 49' ' ' PHE . 19.2 t -69.52 156.49 7.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.556 -179.13 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.436 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.9 OUTLIER -136.32 167.36 21.46 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.684 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 17.4 mttp . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.002 -1.061 . . . . 0.0 109.518 -179.84 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.004 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.922 0 CA-C-O 121.161 0.505 . . . . 0.0 110.313 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.841 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.5 OUTLIER -114.07 162.84 15.96 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.057 -1.027 . . . . 0.0 109.386 -179.87 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -158.26 174.64 35.47 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -141.81 130.89 23.27 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.099 -1.236 . . . . 0.0 111.384 -179.293 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.588 ' HA ' ' HA ' ' A' ' 18' ' ' ILE . 2.8 t -37.57 138.52 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 122.82 1.295 . . . . 0.0 113.312 179.366 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.432 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -97.09 -29.29 13.7 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 102.992 -2.966 . . . . 0.0 102.992 172.452 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.7 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 19.8 p-90 178.27 145.97 0.14 Allowed 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 106.068 -1.827 . . . . 0.0 106.068 177.888 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.559 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.6 OUTLIER -120.28 142.54 48.98 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.533 -1.355 . . . . 0.0 109.848 179.767 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.508 ' OD1' ' CD ' ' A' ' 13' ' ' LYS . 0.5 OUTLIER -130.57 38.34 3.74 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 179.004 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 10' ' ' ASN . 11.1 p -39.15 -44.56 1.2 Allowed 'General case' 0 C--N 1.299 -1.595 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.068 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 47.2 mm-40 -61.43 -46.83 88.44 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.437 -0.789 . . . . 0.0 109.847 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.508 ' CD ' ' OD1' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -69.61 1.41 4.17 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.396 -0.815 . . . . 0.0 110.184 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.585 ' O ' ' CD2' ' A' ' 29' ' ' HIS . . . 99.04 12.35 43.12 Favored Glycine 0 N--CA 1.49 2.253 0 C-N-CA 120.152 -1.023 . . . . 0.0 112.325 178.505 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.462 ' HB3' ' O ' ' A' ' 14' ' ' GLY . 38.1 p90 179.95 163.75 1.09 Allowed 'General case' 0 N--CA 1.497 1.889 0 CA-C-N 120.269 2.035 . . . . 0.0 111.678 179.237 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.559 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -145.53 143.22 11.48 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 107.296 -2.322 . . . . 0.0 107.296 179.466 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.7 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.29 143.71 36.78 Favored 'General case' 0 N--CA 1.48 1.045 0 O-C-N 120.24 -1.741 . . . . 0.0 110.19 -178.67 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.014 HD12 HG21 ' A' ' 28' ' ' VAL . 0.3 OUTLIER -105.45 164.33 4.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 N-CA-C 104.985 -2.228 . . . . 0.0 104.985 177.583 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.554 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 12.1 tp10 -130.3 129.65 43.49 Favored 'General case' 0 C--N 1.285 -2.22 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 178.91 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.756 HG13 ' HB2' ' A' ' 23' ' ' GLN . 14.7 p -132.82 138.93 50.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 118.057 -1.457 . . . . 0.0 111.707 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -66.02 140.37 58.28 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.268 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.32 -8.7 45.14 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 -178.935 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.756 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.7 OUTLIER -138.45 -175.33 4.08 Favored 'General case' 0 N--CA 1.482 1.136 0 O-C-N 121.197 -1.178 . . . . 0.0 108.503 179.539 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.79 -166.55 1.33 Allowed 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 122.129 0.966 . . . . 0.0 110.923 -178.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.625 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.1 m-20 -72.62 113.8 10.06 Favored 'General case' 0 N--CA 1.485 1.324 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.455 178.861 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 1.005 HG21 ' CZ ' ' A' ' 49' ' ' PHE . 2.4 t -67.74 114.0 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.112 0 O-C-N 120.432 -1.417 . . . . 0.0 112.105 179.658 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.527 ' CD2' ' CZ ' ' A' ' 17' ' ' PHE . 0.6 OUTLIER -70.11 118.95 13.59 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 177.789 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.014 HG21 HD12 ' A' ' 18' ' ' ILE . 2.7 m -147.25 137.5 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 120.552 -1.343 . . . . 0.0 110.394 -179.346 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.585 ' CD2' ' O ' ' A' ' 14' ' ' GLY . 9.7 t-160 -99.19 172.97 7.03 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.384 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.548 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 48.0 p90 -82.64 35.54 0.46 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.044 -1.035 . . . . 0.0 109.758 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 10.8 t -128.15 -28.69 2.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.932 -1.105 . . . . 0.0 109.835 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.729 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.73 -47.89 7.12 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.027 -1.046 . . . . 0.0 108.236 179.293 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.66 HD11 ' HB ' ' A' ' 28' ' ' VAL . 53.5 mt . . . . . 0 C--N 1.305 -1.337 0 CA-C-O 122.115 0.96 . . . . 0.0 108.516 179.433 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.459 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.685 HG21 HD11 ' A' ' 18' ' ' ILE . 35.3 m -140.44 161.78 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 120.451 -1.406 . . . . 0.0 111.139 -178.77 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.482 ' HA ' ' O ' ' A' ' 2' ' ' LEU . 9.5 p -115.53 132.86 56.5 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 179.302 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.005 ' CZ ' HG21 ' A' ' 26' ' ' VAL . 7.1 p90 -154.88 -179.96 8.54 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.079 -1.013 . . . . 0.0 109.775 -179.005 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -121.16 91.39 3.51 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 178.936 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.921 HD11 HG23 ' A' ' 26' ' ' VAL . 17.9 mt -61.64 126.87 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.845 -1.159 . . . . 0.0 110.004 -179.478 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.557 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 10.4 m -106.09 -171.84 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 106.371 -1.714 . . . . 0.0 106.371 178.581 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.9 mp0 -122.98 114.44 20.41 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.9 -1.125 . . . . 0.0 109.824 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.57 169.07 16.58 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 34.5 m120 -38.07 -52.16 1.4 Allowed 'General case' 0 N--CA 1.504 2.232 0 O-C-N 121.325 -1.103 . . . . 0.0 113.587 -178.561 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.49 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -76.57 22.66 0.17 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 119.677 -1.89 . . . . 0.0 112.355 -178.035 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.07 -177.93 29.13 Favored Glycine 0 N--CA 1.494 2.531 0 O-C-N 120.434 -1.416 . . . . 0.0 110.232 179.565 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.557 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -65.66 150.82 86.01 Favored 'Trans proline' 0 C--N 1.32 -0.956 0 C-N-CA 122.025 1.817 . . . . 0.0 109.702 178.86 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.525 ' N ' HG23 ' A' ' 51' ' ' ILE . 29.5 mt-30 -161.11 144.03 12.69 Favored 'General case' 0 N--CA 1.5 2.043 0 O-C-N 120.991 -1.068 . . . . 0.0 111.567 -179.413 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.891 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -78.68 154.56 30.04 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 177.388 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.729 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -133.89 -41.61 0.83 Allowed 'General case' 0 N--CA 1.506 2.37 0 O-C-N 120.386 -1.446 . . . . 0.0 111.546 -176.534 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 5.6 m-20 -119.94 52.24 1.13 Allowed 'General case' 0 C--N 1.284 -2.255 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 179.618 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.92 HG22 ' CB ' ' A' ' 49' ' ' PHE . 20.5 t -67.13 163.68 2.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.969 -179.148 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.491 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.2 OUTLIER -147.29 167.88 23.17 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.37 -0.932 . . . . 0.0 108.796 178.608 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.63 0 O-C-N 120.864 -1.147 . . . . 0.0 109.66 -179.77 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.189 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.952 0 CA-C-O 121.003 0.43 . . . . 0.0 109.867 . . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.714 ' O ' HD22 ' A' ' 2' ' ' LEU . 2.3 tt0 -113.77 157.08 22.72 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 120.907 -1.12 . . . . 0.0 110.332 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.425 ' C ' ' HG3' ' A' ' 5' ' ' LYS . . . -133.5 155.44 21.74 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.543 -1.823 . . . . 0.0 108.543 179.54 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.0 OUTLIER -132.2 119.07 20.36 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.284 -1.127 . . . . 0.0 110.201 -179.478 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.544 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.8 t -34.05 143.18 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.182 0 CA-C-O 123.086 1.422 . . . . 0.0 113.701 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.472 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 1.3 tmtm? -104.89 -30.74 9.64 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 103.585 -2.746 . . . . 0.0 103.585 172.733 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.745 ' CZ3' ' ND2' ' A' ' 10' ' ' ASN . 18.4 p-90 177.51 145.47 0.11 Allowed 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 105.728 -1.953 . . . . 0.0 105.728 178.1 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.917 ' CE1' HG21 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -113.23 148.43 35.53 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.457 -1.402 . . . . 0.0 110.655 -179.668 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.745 ' ND2' ' CZ3' ' A' ' 8' ' ' TRP . 36.6 m-20 -130.2 36.31 4.01 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.797 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.5 OUTLIER -39.48 -42.78 1.16 Allowed 'General case' 0 N--CA 1.49 1.57 0 CA-C-O 121.42 0.629 . . . . 0.0 109.556 -178.703 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -60.78 -47.37 86.62 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.344 -0.847 . . . . 0.0 110.282 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.554 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -72.94 3.88 4.84 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.178 -0.951 . . . . 0.0 110.068 -179.829 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.465 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 95.25 18.6 33.09 Favored Glycine 0 N--CA 1.49 2.279 0 O-C-N 121.184 -0.948 . . . . 0.0 112.465 178.289 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.512 ' O ' ' C ' ' A' ' 10' ' ' ASN . 37.1 p90 177.77 168.69 0.7 Allowed 'General case' 0 N--CA 1.501 2.075 0 CA-C-N 120.152 1.976 . . . . 0.0 111.644 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.871 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -146.34 154.29 25.87 Favored Glycine 0 N--CA 1.497 2.709 0 N-CA-C 107.044 -2.422 . . . . 0.0 107.044 179.133 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.706 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.5 m-85 -109.98 142.33 41.52 Favored 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 120.053 1.927 . . . . 0.0 109.621 -179.201 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.662 HD12 HG12 ' A' ' 28' ' ' VAL . 0.8 OUTLIER -106.37 163.5 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 179.295 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.578 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 0.8 OUTLIER -140.97 130.79 24.32 Favored 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.897 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.582 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 9.3 p -137.4 139.19 44.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 C-N-CA 117.743 -1.583 . . . . 0.0 111.779 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.86 141.06 58.18 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.428 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.19 -18.88 42.3 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.621 -1.792 . . . . 0.0 108.621 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.582 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 57.3 mt-30 -140.99 -173.15 3.64 Favored 'General case' 0 N--CA 1.484 1.244 0 O-C-N 121.418 -1.048 . . . . 0.0 109.162 179.671 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -98.35 -164.62 1.15 Allowed 'General case' 0 C--N 1.297 -1.688 0 CA-C-O 122.115 0.96 . . . . 0.0 110.822 -178.801 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.597 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 23.5 p-10 -70.91 125.82 27.89 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.239 179.747 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.873 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.3 t -90.49 114.48 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 120.705 -1.247 . . . . 0.0 110.808 178.348 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.438 ' C ' ' O ' ' A' ' 26' ' ' VAL . 18.8 t80 -46.06 143.13 2.41 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.292 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.917 HG21 ' CE1' ' A' ' 9' ' ' PHE . 1.0 OUTLIER -133.57 148.51 30.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 120.687 -1.258 . . . . 0.0 109.422 -179.176 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.446 ' O ' HG13 ' A' ' 33' ' ' ILE . 10.2 t-160 -151.61 146.84 26.12 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 21.8 p90 -78.8 24.21 0.31 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.018 -1.051 . . . . 0.0 110.714 -179.674 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.3 t -111.6 -45.7 3.34 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 120.637 -1.289 . . . . 0.0 109.212 179.615 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.729 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.55 -42.89 9.98 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.284 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.587 HD11 ' HA ' ' A' ' 28' ' ' VAL . 1.3 mt . . . . . 0 N--CA 1.487 1.376 0 CA-C-O 121.496 0.665 . . . . 0.0 109.615 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.408 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.491 HG21 HD11 ' A' ' 18' ' ' ILE . 32.9 m -124.56 163.74 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 120.428 -1.42 . . . . 0.0 111.105 -178.755 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -116.58 129.02 55.93 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.1 -1.0 . . . . 0.0 108.517 179.591 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.189 ' CE1' HD11 ' A' ' 2' ' ' LEU . 6.3 p90 -153.75 -177.97 6.73 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.044 -1.035 . . . . 0.0 109.882 -179.466 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -126.09 93.12 3.73 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.197 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.873 HD11 ' CG2' ' A' ' 26' ' ' VAL . 13.7 mt -61.73 128.49 23.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.973 -1.079 . . . . 0.0 109.907 -179.303 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.57 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 7.5 m -109.3 -175.99 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 178.707 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.96 116.11 22.34 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.941 -1.099 . . . . 0.0 109.415 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.25 176.16 18.25 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -38.59 -52.59 1.63 Allowed 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.424 -1.044 . . . . 0.0 113.807 -178.504 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.458 ' NH1' ' CG ' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -79.42 22.27 0.45 Allowed 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.665 -1.897 . . . . 0.0 112.134 -177.706 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.56 -177.74 30.9 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.429 -1.367 . . . . 0.0 110.298 179.43 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.57 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.4 Cg_endo -66.64 153.1 79.18 Favored 'Trans proline' 0 C--N 1.32 -0.921 0 C-N-CA 121.942 1.761 . . . . 0.0 110.186 179.189 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.421 ' HG3' ' O ' ' A' ' 58' ' ' PRO . 2.4 mt-30 -166.31 147.46 6.5 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.069 -1.02 . . . . 0.0 111.278 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.767 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -80.12 155.84 27.3 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 177.239 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.729 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.66 -41.88 0.77 Allowed 'General case' 0 N--CA 1.508 2.445 0 O-C-N 120.308 -1.495 . . . . 0.0 111.695 -176.576 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -120.19 52.03 1.16 Allowed 'General case' 0 C--N 1.283 -2.292 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.952 HG22 ' CB ' ' A' ' 49' ' ' PHE . 15.2 t -67.43 167.32 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-O 121.83 0.824 . . . . 0.0 109.562 -179.501 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.586 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.3 OUTLIER -147.17 168.89 20.51 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.994 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.8 mttm . . . . . 0 N--CA 1.49 1.543 0 O-C-N 120.917 -1.114 . . . . 0.0 109.643 -179.797 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.178 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.764 0 CA-C-O 121.3 0.572 . . . . 0.0 110.082 . . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.595 ' O ' HD22 ' A' ' 2' ' ' LEU . 1.9 tt0 -113.95 149.71 34.86 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.165 -0.96 . . . . 0.0 110.423 -178.93 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.12 165.47 19.29 Favored Glycine 0 N--CA 1.486 1.969 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 179.37 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 6' ' ' VAL . 12.0 mmtt -131.4 115.16 15.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.929 -1.336 . . . . 0.0 109.742 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.553 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.2 t -36.47 139.56 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 CA-C-O 122.914 1.34 . . . . 0.0 112.873 -179.551 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.473 ' HE2' ' OE1' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -99.73 -33.23 10.67 Favored 'General case' 0 C--N 1.288 -2.105 0 N-CA-C 102.876 -3.009 . . . . 0.0 102.876 172.471 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 24.1 p-90 175.16 146.58 0.07 Allowed 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 177.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -112.08 147.41 36.1 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 120.298 -1.501 . . . . 0.0 109.37 178.815 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.605 ' HB2' ' CD1' ' A' ' 15' ' ' PHE . 2.6 m-20 -126.45 41.7 3.47 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.689 -0.632 . . . . 0.0 109.363 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.48 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -39.04 -47.29 1.49 Allowed 'General case' 0 N--CA 1.493 1.712 0 CA-C-O 121.601 0.715 . . . . 0.0 109.569 -179.189 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -58.6 -50.27 74.44 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.45 -0.781 . . . . 0.0 110.939 -179.385 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.558 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -70.85 0.98 6.09 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.014 -1.054 . . . . 0.0 110.429 -179.211 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.47 25.96 24.4 Favored Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.014 -1.054 . . . . 0.0 111.797 178.505 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.605 ' CD1' ' HB2' ' A' ' 10' ' ' ASN . 4.9 p90 -178.58 172.48 1.42 Allowed 'General case' 0 N--CA 1.497 1.914 0 CA-C-N 119.836 1.818 . . . . 0.0 110.866 179.47 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.445 ' O ' ' CG2' ' A' ' 28' ' ' VAL . . . -154.48 143.94 10.59 Favored Glycine 0 N--CA 1.5 2.911 0 N-CA-C 107.104 -2.399 . . . . 0.0 107.104 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.0 m-85 -111.12 141.33 44.77 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 119.97 -1.9 . . . . 0.0 110.456 -178.465 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.651 HD11 HG21 ' A' ' 47' ' ' VAL . 0.5 OUTLIER -106.32 162.35 5.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 178.262 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.558 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 14.6 tp10 -141.7 128.47 20.45 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.473 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.744 HG13 ' HB2' ' A' ' 23' ' ' GLN . 12.4 p -135.53 141.17 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 117.3 -1.76 . . . . 0.0 112.021 -179.213 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.71 140.44 58.46 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-N 115.384 -0.825 . . . . 0.0 108.913 179.596 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.03 -16.23 43.97 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.419 -1.872 . . . . 0.0 108.419 -178.63 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.744 ' HB2' HG13 ' A' ' 20' ' ' VAL . 3.1 mm-40 -139.29 -177.11 4.77 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 179.439 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -100.9 -165.95 1.26 Allowed 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.236 -0.915 . . . . 0.0 110.912 -178.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.587 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 3.8 p30 -72.27 124.37 24.92 Favored 'General case' 0 N--CA 1.488 1.46 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.741 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.895 HG12 HG13 ' A' ' 28' ' ' VAL . 2.4 t -88.23 116.01 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 120.647 -1.283 . . . . 0.0 111.264 178.605 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.543 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 1.5 t80 -64.5 127.82 33.16 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 178.191 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.895 HG13 HG12 ' A' ' 26' ' ' VAL . 16.1 m -143.32 137.01 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.55 -1.344 . . . . 0.0 111.626 -178.787 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.519 ' CE1' ' CE1' ' A' ' 30' ' ' PHE . 42.2 t-80 -99.82 162.02 13.25 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 177.327 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.519 ' CE1' ' CE1' ' A' ' 29' ' ' HIS . 49.0 p90 -83.99 34.2 0.5 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.467 -1.396 . . . . 0.0 109.993 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.6 m -123.26 -34.27 3.15 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.034 -1.041 . . . . 0.0 108.905 179.305 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.739 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.56 -43.3 9.74 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.572 ' CD1' ' HB ' ' A' ' 28' ' ' VAL . 1.2 mp . . . . . 0 C--N 1.305 -1.361 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.46 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.651 HG21 HD11 ' A' ' 18' ' ' ILE . 35.7 m -112.59 162.03 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 120.829 -1.17 . . . . 0.0 110.405 -179.882 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.68 119.15 34.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.06 -1.025 . . . . 0.0 108.729 179.4 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.178 ' CE1' HD11 ' A' ' 2' ' ' LEU . 10.7 p90 -149.49 -177.6 5.95 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.952 -1.093 . . . . 0.0 110.023 -179.374 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -128.86 93.31 3.58 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.452 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.877 HD11 ' CG2' ' A' ' 26' ' ' VAL . 14.1 mt -61.69 132.81 27.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.931 -1.105 . . . . 0.0 109.929 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 17.0 m -113.42 -177.3 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.152 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -123.17 117.19 24.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.999 -1.063 . . . . 0.0 109.299 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.83 175.2 15.63 Favored Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.67 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -39.1 -52.1 1.87 Allowed 'General case' 0 N--CA 1.5 2.071 0 N-CA-C 114.287 1.217 . . . . 0.0 114.287 -178.484 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -93.25 21.09 6.28 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 119.416 -2.053 . . . . 0.0 113.534 -176.616 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 122.68 173.65 14.23 Favored Glycine 0 N--CA 1.495 2.593 0 C-N-CA 118.723 -1.703 . . . . 0.0 111.533 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.527 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 3.0 Cg_endo -69.07 156.51 64.94 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 C-N-CA 122.661 2.241 . . . . 0.0 110.561 179.27 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 -166.41 146.11 5.93 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.298 -0.876 . . . . 0.0 110.962 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.715 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.19 159.14 23.34 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.502 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.739 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.15 -44.53 0.71 Allowed 'General case' 0 N--CA 1.506 2.349 0 O-C-N 120.36 -1.462 . . . . 0.0 112.13 -176.171 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -119.54 51.62 1.15 Allowed 'General case' 0 C--N 1.284 -2.24 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.932 HG22 ' CB ' ' A' ' 49' ' ' PHE . 18.1 t -66.06 159.64 4.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.681 -179.431 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.489 HG22 ' H ' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -143.92 -177.86 5.64 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.846 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.489 ' H ' HG22 ' A' ' 64' ' ' THR . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.533 0 O-C-N 120.931 -1.106 . . . . 0.0 109.354 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.069 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.813 0 CA-C-O 121.155 0.503 . . . . 0.0 110.264 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.84 ' CD ' ' HB1' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -112.64 165.2 12.49 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.252 -0.905 . . . . 0.0 109.937 -179.059 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 46' ' ' ALA . . . -148.05 169.68 28.76 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 20.0 mttt -134.05 116.14 15.14 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 120.919 -1.342 . . . . 0.0 110.313 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.406 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.4 t -49.06 134.98 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 CA-C-O 122.71 1.243 . . . . 0.0 112.998 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.65 -28.36 13.58 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 104.015 -2.587 . . . . 0.0 104.015 174.155 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.681 ' O ' ' CE3' ' A' ' 8' ' ' TRP . 21.6 p-90 176.16 141.88 0.07 Allowed 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 178.274 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.576 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 0.7 OUTLIER -130.02 110.57 11.75 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.537 -1.352 . . . . 0.0 110.096 -179.949 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.567 ' OD1' ' CB ' ' A' ' 13' ' ' LYS . 1.2 p30 -95.15 88.35 5.17 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-O 122.978 1.371 . . . . 0.0 109.031 179.047 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.485 ' HA ' ' CE1' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -67.65 -57.97 5.47 Favored 'General case' 0 C--N 1.29 -2.02 0 O-C-N 120.417 -1.427 . . . . 0.0 108.709 179.741 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -59.7 -45.13 93.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.469 -0.77 . . . . 0.0 111.362 -179.097 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.567 ' CB ' ' OD1' ' A' ' 10' ' ' ASN . 1.4 mptt -68.68 -11.85 60.68 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.05 -1.032 . . . . 0.0 111.134 -177.885 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.514 ' N ' ' OD1' ' A' ' 10' ' ' ASN . . . 138.73 -37.79 1.75 Allowed Glycine 0 N--CA 1.496 2.636 0 C-N-CA 118.376 -1.869 . . . . 0.0 113.3 178.299 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.532 ' O ' ' ND2' ' A' ' 10' ' ' ASN . 10.9 p90 -175.85 -174.83 0.69 Allowed 'General case' 0 N--CA 1.497 1.882 0 CA-C-N 121.079 2.439 . . . . 0.0 110.424 -179.222 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.862 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -134.49 146.35 18.36 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.626 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 6.0 m-30 -107.0 136.71 46.4 Favored 'General case' 0 N--CA 1.48 1.04 0 O-C-N 120.577 -1.543 . . . . 0.0 109.419 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.961 ' CD1' HG11 ' A' ' 28' ' ' VAL . 1.0 OUTLIER -107.39 150.53 9.88 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 N-CA-C 105.85 -1.908 . . . . 0.0 105.85 178.049 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.466 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 1.0 OUTLIER -125.92 133.19 51.94 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.396 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.687 HG13 ' HB2' ' A' ' 23' ' ' GLN . 8.5 p -137.87 140.24 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 C-N-CA 117.635 -1.626 . . . . 0.0 112.221 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -65.28 140.18 58.68 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.056 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.84 -13.76 46.55 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 108.654 -1.778 . . . . 0.0 108.654 -178.73 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.687 ' HB2' HG13 ' A' ' 20' ' ' VAL . 3.6 mt-30 -138.56 -175.97 4.31 Favored 'General case' 0 N--CA 1.483 1.195 0 O-C-N 121.257 -1.143 . . . . 0.0 108.632 179.489 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.82 -165.62 1.23 Allowed 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 122.135 0.969 . . . . 0.0 110.627 -179.059 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.626 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.5 m-20 -73.0 104.85 4.24 Favored 'General case' 0 N--CA 1.486 1.355 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.223 179.477 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 1.038 HG22 ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -65.72 115.25 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 120.345 -1.472 . . . . 0.0 112.112 179.061 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.453 ' HB3' ' CD ' ' A' ' 59' ' ' GLN . 12.7 t80 -70.53 129.84 40.27 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.336 -0.852 . . . . 0.0 109.04 178.236 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.961 HG11 ' CD1' ' A' ' 18' ' ' ILE . 23.6 m -135.85 144.83 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.617 -1.302 . . . . 0.0 109.654 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.848 ' O ' HD12 ' A' ' 33' ' ' ILE . 0.5 OUTLIER -99.63 165.99 11.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.766 -1.209 . . . . 0.0 108.78 179.678 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.516 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 42.9 p90 -80.28 26.0 0.38 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.949 -1.095 . . . . 0.0 110.937 -179.398 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 43.3 p -136.68 -17.64 1.46 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.701 -1.249 . . . . 0.0 110.209 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.735 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.35 -49.6 6.07 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 120.735 -1.228 . . . . 0.0 108.79 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.848 HD12 ' O ' ' A' ' 29' ' ' HIS . 2.5 mt . . . . . 0 N--CA 1.487 1.401 0 CA-C-O 121.933 0.873 . . . . 0.0 108.736 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.84 ' HB1' ' CD ' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.485 1.301 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.564 HG21 ' CD1' ' A' ' 18' ' ' ILE . 29.7 m -111.3 162.8 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.18 -0.95 . . . . 0.0 110.247 -179.806 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -115.88 125.38 52.55 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.194 -0.941 . . . . 0.0 108.587 179.503 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.069 ' CE1' HD11 ' A' ' 2' ' ' LEU . 25.0 p90 -153.59 -178.35 6.96 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.019 -1.051 . . . . 0.0 110.035 -179.646 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -126.85 96.14 4.55 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 179.413 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 1.038 ' CD1' HG22 ' A' ' 26' ' ' VAL . 1.3 mm -61.09 141.39 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 122.609 1.195 . . . . 0.0 111.048 -179.393 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.544 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 2.1 m -130.65 -174.96 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 -179.558 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -124.14 116.26 22.46 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.002 -1.062 . . . . 0.0 109.623 179.627 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -129.36 173.32 19.6 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.753 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -38.04 -52.26 1.39 Allowed 'General case' 0 N--CA 1.504 2.254 0 O-C-N 121.407 -1.055 . . . . 0.0 113.426 -178.634 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 4.9 mtt180 -75.42 22.74 0.12 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 119.728 -1.858 . . . . 0.0 112.102 -178.409 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.74 -178.75 36.64 Favored Glycine 0 N--CA 1.492 2.389 0 O-C-N 120.438 -1.414 . . . . 0.0 110.124 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.544 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.4 Cg_endo -68.04 139.59 47.31 Favored 'Trans proline' 0 C--N 1.319 -1.023 0 C-N-CA 122.095 1.863 . . . . 0.0 110.069 178.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.959 ' C ' HD13 ' A' ' 51' ' ' ILE . 77.6 mt-30 -159.33 157.92 31.37 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.2 -0.938 . . . . 0.0 111.206 -179.364 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.799 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -83.99 160.56 21.0 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 177.517 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.735 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.08 -40.98 0.74 Allowed 'General case' 0 N--CA 1.508 2.433 0 O-C-N 120.294 -1.504 . . . . 0.0 111.812 -176.709 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.438 ' N ' ' OD1' ' A' ' 62' ' ' ASN . 1.6 m-20 -119.62 52.28 1.11 Allowed 'General case' 0 C--N 1.283 -2.283 0 N-CA-C 106.924 -1.509 . . . . 0.0 106.924 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.914 HG22 ' CB ' ' A' ' 49' ' ' PHE . 13.4 t -69.17 163.66 3.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.488 -179.308 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.59 HG22 ' H ' ' A' ' 65' ' ' LYS . 1.2 m -149.45 -179.08 6.8 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 178.643 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.59 ' H ' HG22 ' A' ' 64' ' ' THR . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.603 0 O-C-N 120.991 -1.068 . . . . 0.0 109.432 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 1.175 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.913 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 . . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.847 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -113.07 165.94 11.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.87 -1.143 . . . . 0.0 109.858 -179.07 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -151.82 156.27 26.6 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.401 ' O ' ' C ' ' A' ' 6' ' ' VAL . 2.5 ttpt -135.4 126.93 28.77 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.45 -1.03 . . . . 0.0 110.675 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.619 HG13 ' N ' ' A' ' 8' ' ' TRP . 5.6 t -35.7 150.01 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.285 0 CA-C-O 123.453 1.597 . . . . 0.0 113.338 -179.634 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.524 ' CG ' ' HB2' ' A' ' 19' ' ' GLU . 1.0 OUTLIER -110.54 -29.21 8.16 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 103.174 -2.899 . . . . 0.0 103.174 172.247 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.711 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 15.4 p-90 178.92 144.61 0.14 Allowed 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 177.816 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.592 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 1.1 t80 -118.89 127.41 53.47 Favored 'General case' 0 N--CA 1.506 2.361 0 O-C-N 120.527 -1.358 . . . . 0.0 109.756 -178.897 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.554 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 72.7 m-20 -120.6 56.21 1.0 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.598 -0.689 . . . . 0.0 109.682 -179.426 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -43.74 -38.11 3.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.287 -0.883 . . . . 0.0 108.861 179.933 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -61.03 -47.03 88.32 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.572 -0.705 . . . . 0.0 110.253 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.512 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -71.53 4.42 3.09 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.218 -0.926 . . . . 0.0 109.768 179.853 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.478 ' C ' ' CD2' ' A' ' 15' ' ' PHE . . . 98.53 8.0 55.13 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 120.22 -0.99 . . . . 0.0 111.712 179.045 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.478 ' CD2' ' C ' ' A' ' 14' ' ' GLY . 3.9 p90 173.88 173.78 0.16 Allowed 'General case' 0 N--CA 1.495 1.818 0 CA-C-N 120.391 2.096 . . . . 0.0 112.588 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.882 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -130.33 142.61 13.89 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 106.644 -2.582 . . . . 0.0 106.644 178.678 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.711 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 4.1 m-30 -99.0 142.27 30.7 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 120.199 -1.765 . . . . 0.0 109.001 -178.849 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.028 HD12 ' CG1' ' A' ' 28' ' ' VAL . 0.6 OUTLIER -105.64 165.88 3.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 179.746 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.586 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 14.4 tm-20 -140.96 132.34 26.75 Favored 'General case' 0 C--N 1.289 -2.063 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 178.425 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.667 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.5 p -136.1 140.87 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 118.068 -1.453 . . . . 0.0 111.641 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -64.05 140.55 58.88 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.363 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.5 -8.88 45.38 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.667 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.3 OUTLIER -139.23 -175.07 4.04 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 121.129 -1.218 . . . . 0.0 108.849 179.608 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -100.66 -166.31 1.3 Allowed 'General case' 0 C--N 1.296 -1.721 0 CA-C-O 122.112 0.958 . . . . 0.0 110.437 -179.208 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.624 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 5.1 p30 -72.12 125.12 26.48 Favored 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.689 179.177 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 1.003 HG21 ' CZ ' ' A' ' 49' ' ' PHE . 2.5 t -87.62 108.76 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 120.557 -1.339 . . . . 0.0 111.341 178.794 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.459 ' CE2' ' CE1' ' A' ' 17' ' ' PHE . 8.8 t80 -51.16 135.13 26.31 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 177.88 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.028 ' CG1' HD12 ' A' ' 18' ' ' ILE . 0.7 OUTLIER -131.74 140.8 47.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 120.48 -1.388 . . . . 0.0 109.615 -178.831 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.736 ' O ' HD12 ' A' ' 33' ' ' ILE . 36.2 t-80 -123.63 155.73 37.17 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.492 ' CE1' ' CE1' ' A' ' 29' ' ' HIS . 55.6 p90 -82.47 32.5 0.4 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.975 -1.078 . . . . 0.0 109.585 179.754 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.7 m -132.04 -33.24 1.36 Allowed 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.075 -1.016 . . . . 0.0 109.358 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.758 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.34 -40.93 11.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.154 -0.966 . . . . 0.0 108.781 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.79 HD11 ' HB ' ' A' ' 28' ' ' VAL . 3.1 mt . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.382 -0.823 . . . . 0.0 108.878 178.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.333 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.593 HG12 ' HA ' ' A' ' 65' ' ' LYS . 35.0 m -128.28 164.29 30.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 120.675 -1.266 . . . . 0.0 110.741 -178.292 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -115.36 136.4 53.13 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 179.1 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 1.175 ' CE1' HD11 ' A' ' 2' ' ' LEU . 7.0 p90 -156.52 -179.41 8.15 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-O 121.99 0.9 . . . . 0.0 109.522 -178.731 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 20.1 tt0 -123.18 93.45 3.96 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.049 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.908 HD11 ' CG2' ' A' ' 26' ' ' VAL . 16.9 mt -62.14 128.58 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.981 -1.074 . . . . 0.0 110.154 -179.519 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 11.4 m -108.16 -176.56 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 178.348 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.408 ' CD ' ' N ' ' A' ' 53' ' ' GLU . 2.1 pm0 -123.85 116.62 23.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.967 -1.083 . . . . 0.0 109.729 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.406 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -132.26 172.4 21.14 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.181 -1.567 . . . . 0.0 109.181 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.406 ' C ' ' O ' ' A' ' 54' ' ' GLY . 17.8 m120 -37.37 -51.88 1.1 Allowed 'General case' 0 N--CA 1.505 2.322 0 O-C-N 121.439 -1.036 . . . . 0.0 113.268 -178.639 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.87 23.34 0.1 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 119.65 -1.907 . . . . 0.0 112.14 -178.456 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.77 -177.07 38.46 Favored Glycine 0 N--CA 1.491 2.359 0 O-C-N 120.529 -1.357 . . . . 0.0 109.773 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.554 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -68.28 152.92 75.44 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 C-N-CA 121.832 1.688 . . . . 0.0 109.652 178.768 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.468 ' HG3' ' O ' ' A' ' 58' ' ' PRO . 0.8 OUTLIER -165.82 146.1 6.61 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 120.907 -1.121 . . . . 0.0 111.608 -179.557 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.809 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -78.49 155.75 29.66 Favored 'General case' 0 N--CA 1.494 1.77 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.235 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.758 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.52 -40.57 0.8 Allowed 'General case' 0 N--CA 1.508 2.475 0 O-C-N 120.557 -1.339 . . . . 0.0 111.37 -176.836 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -119.88 57.09 0.93 Allowed 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.914 HG22 ' CB ' ' A' ' 49' ' ' PHE . 19.9 t -73.14 165.61 3.0 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.184 -178.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.507 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -149.83 157.97 43.71 Favored 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.143 178.952 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.593 ' HA ' HG12 ' A' ' 47' ' ' VAL . 4.2 tmtm? . . . . . 0 N--CA 1.491 1.617 0 O-C-N 120.821 -1.174 . . . . 0.0 109.562 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.45 ' HG3' ' O ' ' A' ' 1' ' ' MET . 1.6 ppp? . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.213 0.53 . . . . 0.0 109.583 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.158 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -141.29 174.13 10.83 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.203 -0.935 . . . . 0.0 110.348 179.661 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.701 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -114.51 154.5 28.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.076 -1.015 . . . . 0.0 110.096 -179.552 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.24 158.0 20.27 Favored Glycine 0 N--CA 1.484 1.858 0 N-CA-C 109.064 -1.615 . . . . 0.0 109.064 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.443 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.3 mttt -130.73 115.85 17.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.446 -1.032 . . . . 0.0 110.195 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.588 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.6 t -35.42 143.52 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 CA-C-O 123.045 1.402 . . . . 0.0 112.925 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.423 ' CG ' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -102.5 -30.63 10.87 Favored 'General case' 0 C--N 1.288 -2.068 0 N-CA-C 102.996 -2.964 . . . . 0.0 102.996 171.94 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 17.9 p-90 177.31 147.5 0.13 Allowed 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 105.77 -1.937 . . . . 0.0 105.77 177.874 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.977 ' CE1' HG21 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -114.19 145.01 42.27 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 120.37 -1.456 . . . . 0.0 110.142 179.944 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.57 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 4.7 m-20 -131.91 32.96 4.0 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.351 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.1 OUTLIER -38.4 -46.95 1.19 Allowed 'General case' 0 N--CA 1.494 1.727 0 CA-C-O 121.486 0.66 . . . . 0.0 109.787 -178.765 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -60.15 -46.82 88.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.363 -0.836 . . . . 0.0 110.044 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.57 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -73.01 4.84 3.81 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.299 -0.876 . . . . 0.0 110.781 -179.317 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.552 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 110.71 -3.78 29.13 Favored Glycine 0 N--CA 1.494 2.545 0 C-N-CA 119.731 -1.223 . . . . 0.0 113.008 177.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.558 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 5.7 p90 176.68 174.77 0.37 Allowed 'General case' 0 N--CA 1.5 2.058 0 CA-C-N 120.614 2.207 . . . . 0.0 111.972 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.905 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -140.03 151.96 22.45 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 107.432 -2.267 . . . . 0.0 107.432 179.32 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.36 141.33 40.34 Favored 'General case' 0 N--CA 1.485 1.323 0 O-C-N 120.058 -1.848 . . . . 0.0 109.498 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.03 HD12 HG12 ' A' ' 28' ' ' VAL . 0.9 OUTLIER -107.48 160.72 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 178.656 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.549 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 4.3 tt0 -137.74 130.52 29.97 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.071 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.765 HG13 ' HB2' ' A' ' 23' ' ' GLN . 14.5 p -134.76 140.32 45.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 C-N-CA 117.855 -1.538 . . . . 0.0 111.593 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.45 140.55 58.88 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-N 115.371 -0.832 . . . . 0.0 109.15 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 81.51 -10.7 49.11 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.075 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.765 ' HB2' HG13 ' A' ' 20' ' ' VAL . 2.7 mp0 -139.42 -174.89 4.0 Favored 'General case' 0 C--N 1.308 -1.203 0 O-C-N 121.137 -1.213 . . . . 0.0 108.814 179.687 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.42 -165.78 1.25 Allowed 'General case' 0 C--N 1.295 -1.782 0 CA-C-O 122.005 0.907 . . . . 0.0 110.368 -179.3 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.613 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 7.5 m-20 -71.12 120.11 16.21 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 115.861 -0.608 . . . . 0.0 109.701 179.214 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.866 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.5 t -83.83 115.29 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 120.482 -1.386 . . . . 0.0 110.722 178.783 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.413 ' CB ' ' CD ' ' A' ' 59' ' ' GLN . 23.4 t80 -53.71 138.12 35.99 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.03 HG12 HD12 ' A' ' 18' ' ' ILE . 0.6 OUTLIER -129.27 146.48 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 O-C-N 120.712 -1.242 . . . . 0.0 109.381 -179.681 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.552 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 3.7 t60 -147.7 143.85 27.9 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.477 ' O ' ' HB3' ' A' ' 34' ' ' GLN . 22.6 p90 -63.85 2.79 0.45 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.043 -1.036 . . . . 0.0 111.611 -179.348 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.459 ' O ' ' OE1' ' A' ' 34' ' ' GLN . 23.3 t -93.75 -51.07 5.07 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.21 -1.556 . . . . 0.0 109.574 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.745 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -93.31 -44.25 8.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.177 -0.952 . . . . 0.0 108.919 179.364 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.693 ' O ' HG22 ' A' ' 33' ' ' ILE . 1.1 mp -76.09 2.14 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.501 ' O ' ' O ' ' A' ' 33' ' ' ILE . 0.6 OUTLIER -47.3 -176.25 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.532 -0.73 . . . . 0.0 110.869 -178.355 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.34 -169.67 22.95 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -48.17 109.61 0.25 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.161 -1.199 . . . . 0.0 109.624 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 69.56 165.54 4.68 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.856 -1.298 . . . . 0.0 109.856 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -84.8 87.3 7.31 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.192 -1.181 . . . . 0.0 109.47 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -110.26 168.02 9.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.219 -0.926 . . . . 0.0 109.382 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.431 ' C ' ' HG ' ' A' ' 41' ' ' LEU . 0.2 OUTLIER -99.43 167.31 10.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.249 -0.907 . . . . 0.0 108.607 179.698 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.538 HD22 ' CD ' ' A' ' 45' ' ' GLN . 1.1 mp -134.69 142.83 46.92 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.543 -1.348 . . . . 0.0 110.043 -179.513 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -108.81 179.94 4.04 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.537 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.465 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 9.9 tm-20 -52.67 152.66 3.59 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.267 -0.895 . . . . 0.0 109.046 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.465 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 92.82 -6.4 76.85 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 -179.211 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.58 ' OE1' ' CE1' ' A' ' 9' ' ' PHE . 36.0 tt0 -62.2 105.94 0.67 Allowed 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.307 -1.113 . . . . 0.0 110.754 -179.482 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.463 ' O ' ' HB2' ' A' ' 66' ' ' GLU . . . -92.37 135.36 34.1 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 177.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.698 HG21 HD11 ' A' ' 18' ' ' ILE . 21.3 m -136.18 166.06 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 120.535 -1.353 . . . . 0.0 110.551 -179.151 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.9 t -116.66 135.39 53.82 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.09 -1.006 . . . . 0.0 108.6 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.158 ' CE1' HD11 ' A' ' 2' ' ' LEU . 7.2 p90 -164.1 -178.11 5.39 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.951 -1.093 . . . . 0.0 109.695 -179.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -127.05 94.95 4.16 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.305 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.866 HD11 ' CG2' ' A' ' 26' ' ' VAL . 12.3 mt -62.17 133.11 28.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.915 -1.116 . . . . 0.0 110.339 -179.409 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.542 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.1 m -116.04 -173.48 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 178.666 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -123.03 116.03 22.84 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.005 -1.059 . . . . 0.0 109.531 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.94 174.26 17.22 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -38.93 -52.67 1.77 Allowed 'General case' 0 N--CA 1.505 2.298 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -178.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 27.0 mmm180 -80.77 22.37 0.6 Allowed 'General case' 0 N--CA 1.498 1.967 0 O-C-N 119.676 -1.89 . . . . 0.0 112.247 -177.402 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.39 -177.7 26.14 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.278 -1.439 . . . . 0.0 110.488 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.542 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 0.9 OUTLIER -65.56 152.24 82.38 Favored 'Trans proline' 0 C--N 1.32 -0.948 0 C-N-CA 122.109 1.873 . . . . 0.0 110.426 179.114 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.413 ' CD ' ' CB ' ' A' ' 27' ' ' PHE . 0.0 OUTLIER -166.04 146.91 6.65 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.19 -0.944 . . . . 0.0 111.322 -179.653 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.794 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -79.4 159.23 27.16 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 177.174 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.745 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.67 -42.6 0.76 Allowed 'General case' 0 N--CA 1.508 2.439 0 O-C-N 120.366 -1.459 . . . . 0.0 111.886 -176.456 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -119.66 53.19 1.06 Allowed 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 1.008 HG22 ' CB ' ' A' ' 49' ' ' PHE . 25.0 t -70.85 168.77 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.887 -178.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.598 ' N ' HG12 ' A' ' 63' ' ' VAL . 1.4 m -152.69 173.84 14.74 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 178.4 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.484 ' H ' HG22 ' A' ' 64' ' ' THR . 0.2 OUTLIER -79.68 135.7 36.61 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.002 -1.061 . . . . 0.0 109.458 -179.878 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.463 ' HB2' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -61.72 98.69 0.1 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.298 -0.876 . . . . 0.0 109.505 -179.993 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.49 179.987 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.911 HD12 ' O ' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -129.41 175.69 8.56 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.234 -0.916 . . . . 0.0 110.214 179.844 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.861 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -112.13 168.03 9.93 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.105 -0.997 . . . . 0.0 109.553 -179.202 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.514 ' O ' ' HA ' ' A' ' 46' ' ' ALA . . . -151.78 167.9 31.08 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.379 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.5 mtpp -134.75 118.38 17.01 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.146 -1.208 . . . . 0.0 110.094 -179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.556 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.8 t -43.23 142.54 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 122.78 1.276 . . . . 0.0 112.366 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.402 ' HG3' ' OE2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -97.41 -29.65 13.38 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 103.179 -2.897 . . . . 0.0 103.179 172.587 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.702 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 21.1 p-90 177.79 144.78 0.11 Allowed 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 105.957 -1.868 . . . . 0.0 105.957 177.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.731 ' CZ ' HD21 ' A' ' 41' ' ' LEU . 0.1 OUTLIER -118.84 141.0 49.05 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.487 -1.383 . . . . 0.0 109.541 179.493 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.535 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 0.2 OUTLIER -131.5 37.78 3.65 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 179.4 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' ASN . 1.2 p -37.94 -48.49 1.17 Allowed 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.44 0.638 . . . . 0.0 109.332 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -61.9 -44.76 96.14 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.412 -0.805 . . . . 0.0 109.761 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.505 ' CB ' ' OD1' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -69.05 -0.88 6.33 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.359 -0.838 . . . . 0.0 110.132 -179.796 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.484 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 108.35 -0.44 32.95 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.874 -1.155 . . . . 0.0 112.523 178.547 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.436 ' O ' ' C ' ' A' ' 10' ' ' ASN . 6.3 p90 -179.21 169.97 1.44 Allowed 'General case' 0 N--CA 1.498 1.929 0 CA-C-N 120.456 2.128 . . . . 0.0 111.991 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.585 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -143.64 143.08 11.86 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 107.755 -2.138 . . . . 0.0 107.755 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.702 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.87 141.95 40.17 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 120.205 -1.762 . . . . 0.0 110.162 -178.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.946 HD11 HG21 ' A' ' 47' ' ' VAL . 0.9 OUTLIER -107.58 163.83 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.475 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.585 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 28.6 tt0 -139.2 130.54 26.91 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.609 HG13 ' HB2' ' A' ' 23' ' ' GLN . 9.0 p -134.39 140.66 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 C-N-CA 117.594 -1.642 . . . . 0.0 111.984 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -64.05 139.36 58.76 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.242 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.12 -13.65 43.5 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.609 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.5 OUTLIER -138.0 -175.98 4.28 Favored 'General case' 0 C--N 1.308 -1.212 0 O-C-N 121.254 -1.145 . . . . 0.0 108.804 179.851 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.39 -165.89 1.26 Allowed 'General case' 0 C--N 1.295 -1.773 0 CA-C-O 121.987 0.899 . . . . 0.0 110.3 -179.429 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.627 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.6 m-20 -72.08 126.51 29.97 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.011 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 1.015 HG22 ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -91.82 118.72 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.034 0 O-C-N 120.625 -1.297 . . . . 0.0 111.125 178.539 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.481 ' CB ' ' HG2' ' A' ' 59' ' ' GLN . 4.7 t80 -65.05 134.12 53.15 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.419 -0.8 . . . . 0.0 109.256 178.81 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.788 HG11 ' CD1' ' A' ' 18' ' ' ILE . 2.0 m -142.27 131.95 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.674 -1.266 . . . . 0.0 111.14 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.613 ' NE2' ' CZ ' ' A' ' 30' ' ' PHE . 2.5 t-160 -115.68 132.26 56.69 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.613 ' CZ ' ' NE2' ' A' ' 29' ' ' HIS . 7.4 p90 -43.96 -22.12 0.05 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.701 -1.25 . . . . 0.0 111.128 -178.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.465 ' O ' ' HG2' ' A' ' 34' ' ' GLN . 1.5 m -66.24 -42.59 88.4 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.755 -1.215 . . . . 0.0 111.218 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.808 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.57 -41.33 10.85 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.95 -1.094 . . . . 0.0 108.802 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.637 HD11 HG12 ' A' ' 28' ' ' VAL . 1.5 mp -57.69 -16.1 5.29 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.484 ' OE1' ' O ' ' A' ' 30' ' ' PHE . 4.7 pt20 -83.77 -174.93 5.56 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 119.306 -0.958 . . . . 0.0 109.47 -179.643 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 174.37 -50.23 0.14 Allowed Glycine 0 N--CA 1.489 2.216 0 N-CA-C 108.429 -1.868 . . . . 0.0 108.429 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -104.12 54.37 0.73 Allowed 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.708 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.43 172.13 22.2 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 108.842 -1.703 . . . . 0.0 108.842 -179.182 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 39.1 t80 -79.81 88.33 5.25 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.094 -1.239 . . . . 0.0 109.581 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 5.6 tptm -110.63 143.67 40.72 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.346 -0.846 . . . . 0.0 109.731 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.9 t -116.51 -169.92 1.72 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.29 -0.881 . . . . 0.0 108.728 179.497 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.731 HD21 ' CZ ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -146.88 172.49 13.59 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.13 -0.981 . . . . 0.0 109.623 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.483 ' H ' ' NE2' ' A' ' 45' ' ' GLN . 1.2 tt0 -119.6 -175.97 3.06 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.371 -0.83 . . . . 0.0 109.462 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -66.64 143.37 57.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.434 -0.791 . . . . 0.0 109.46 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.54 -8.08 80.36 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 -179.407 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.483 ' NE2' ' H ' ' A' ' 42' ' ' GLU . 0.0 OUTLIER -77.11 126.05 30.33 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.308 -1.113 . . . . 0.0 110.508 -179.556 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.56 ' HB1' ' CD ' ' A' ' 3' ' ' GLU . . . -91.68 135.65 33.72 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.602 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.946 HG21 HD11 ' A' ' 18' ' ' ILE . 35.0 m -119.29 159.68 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 120.868 -1.145 . . . . 0.0 110.281 -179.478 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -114.19 136.01 53.42 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.116 -0.99 . . . . 0.0 108.57 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.915 ' CZ ' HG21 ' A' ' 26' ' ' VAL . 19.9 p90 -163.04 -176.05 4.67 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.072 -1.018 . . . . 0.0 109.87 -179.247 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -129.07 96.6 4.38 Favored 'General case' 0 C--N 1.295 -1.771 0 O-C-N 121.542 -0.724 . . . . 0.0 109.185 179.129 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 1.015 ' CD1' HG22 ' A' ' 26' ' ' VAL . 1.5 mm -61.57 139.6 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 CA-C-O 122.452 1.12 . . . . 0.0 111.137 -179.406 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 3.1 m -126.72 -174.25 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -123.39 115.99 22.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.966 -1.083 . . . . 0.0 109.933 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.12 171.89 15.86 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 10.6 p-10 -39.1 -52.69 1.86 Allowed 'General case' 0 N--CA 1.505 2.309 0 O-C-N 121.283 -1.128 . . . . 0.0 113.956 -178.334 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 11.1 ttm180 -78.8 21.96 0.39 Allowed 'General case' 0 N--CA 1.5 2.054 0 O-C-N 119.601 -1.937 . . . . 0.0 112.224 -177.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.0 -179.27 26.07 Favored Glycine 0 N--CA 1.492 2.404 0 C-N-CA 119.339 -1.41 . . . . 0.0 110.667 179.151 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.527 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -66.78 150.16 83.4 Favored 'Trans proline' 0 C--N 1.321 -0.915 0 C-N-CA 122.238 1.959 . . . . 0.0 110.484 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.965 ' C ' HD13 ' A' ' 51' ' ' ILE . 2.5 mt-30 -165.71 152.69 10.09 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.245 -0.91 . . . . 0.0 111.03 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.808 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.15 161.43 22.81 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 177.462 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.808 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.0 -41.71 0.74 Allowed 'General case' 0 N--CA 1.51 2.526 0 O-C-N 120.273 -1.517 . . . . 0.0 111.725 -176.724 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 9.3 m-20 -120.1 52.28 1.14 Allowed 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.9 HG22 ' CB ' ' A' ' 49' ' ' PHE . 12.5 t -68.74 170.6 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 121.819 0.818 . . . . 0.0 109.69 -179.254 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.552 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -152.74 171.75 17.74 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 178.553 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.407 ' O ' ' HG2' ' A' ' 65' ' ' LYS . 0.0 OUTLIER -89.4 132.7 34.86 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.003 -1.06 . . . . 0.0 109.584 -179.859 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -80.66 148.77 30.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.188 -0.945 . . . . 0.0 109.605 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.474 179.941 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 121.31 0.576 . . . . 0.0 109.476 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.191 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -132.29 176.23 8.59 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.168 -0.957 . . . . 0.0 110.154 179.93 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.797 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.2 OUTLIER -111.82 161.56 16.22 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.169 -0.957 . . . . 0.0 110.151 -178.527 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.02 157.89 24.51 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.429 ' HD3' ' OE1' ' A' ' 3' ' ' GLU . 10.2 mmtp -130.27 114.55 15.78 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.318 -1.107 . . . . 0.0 109.645 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.56 HG12 ' OE1' ' A' ' 43' ' ' GLU . 3.4 t -41.29 140.24 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 CA-C-O 122.8 1.286 . . . . 0.0 112.443 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.01 -30.33 12.4 Favored 'General case' 0 C--N 1.289 -2.041 0 N-CA-C 103.126 -2.916 . . . . 0.0 103.126 172.579 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.697 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 17.3 p-90 176.96 146.27 0.1 Allowed 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 106.228 -1.768 . . . . 0.0 106.228 177.835 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.881 ' CE1' HG21 ' A' ' 28' ' ' VAL . 1.5 t80 -113.66 143.23 44.94 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 120.576 -1.327 . . . . 0.0 109.433 179.394 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.56 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 90.6 m-20 -131.24 39.01 3.59 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.782 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -39.08 -47.82 1.58 Allowed 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.436 0.636 . . . . 0.0 109.525 -179.087 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -61.8 -44.52 96.7 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.393 -0.817 . . . . 0.0 109.706 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.543 ' CG ' ' HB3' ' A' ' 10' ' ' ASN . 12.6 mmmt -70.55 2.3 4.17 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.429 -0.794 . . . . 0.0 110.45 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 113.27 -10.57 24.38 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 119.564 -1.303 . . . . 0.0 112.063 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.556 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 3.9 p90 175.32 179.1 0.15 Allowed 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.03 -1.865 . . . . 0.0 111.302 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.907 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -136.34 149.38 20.1 Favored Glycine 0 N--CA 1.498 2.803 0 N-CA-C 107.482 -2.247 . . . . 0.0 107.482 179.279 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.697 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.2 m-85 -105.31 140.68 38.07 Favored 'General case' 0 N--CA 1.484 1.252 0 O-C-N 120.272 -1.722 . . . . 0.0 109.792 -178.816 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.049 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.2 mt -106.91 162.03 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 178.845 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.572 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 13.2 tt0 -140.07 130.28 25.12 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 177.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.802 HG13 ' HB2' ' A' ' 23' ' ' GLN . 14.1 p -135.49 140.96 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 C-N-CA 117.526 -1.67 . . . . 0.0 111.953 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -65.33 140.67 58.7 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.123 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.71 -10.48 45.47 Favored Glycine 0 N--CA 1.486 2.011 0 N-CA-C 108.662 -1.775 . . . . 0.0 108.662 -178.723 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.802 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.9 OUTLIER -140.33 -177.71 5.15 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 121.323 -1.104 . . . . 0.0 108.439 179.619 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 69.7 m-20 -100.84 -166.28 1.3 Allowed 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 121.913 0.863 . . . . 0.0 110.655 -179.192 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.599 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 0.9 OUTLIER -72.54 126.55 30.15 Favored 'General case' 0 N--CA 1.487 1.421 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.741 179.146 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.854 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.4 t -92.84 114.74 30.19 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 120.494 -1.379 . . . . 0.0 111.059 178.479 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.454 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 11.1 t80 -56.5 135.64 54.38 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.049 ' CG1' HD12 ' A' ' 18' ' ' ILE . 0.6 OUTLIER -129.5 142.55 43.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 120.6 -1.313 . . . . 0.0 110.393 -178.118 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.809 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.8 t-160 -117.48 155.13 30.24 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.318 -0.994 . . . . 0.0 108.318 179.522 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.517 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 41.1 p90 -84.03 33.05 0.48 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.964 -1.085 . . . . 0.0 109.82 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -135.7 -31.1 0.96 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.046 -1.034 . . . . 0.0 109.732 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.747 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.13 -40.82 11.37 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.021 -1.049 . . . . 0.0 108.649 179.646 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.809 HD12 ' O ' ' A' ' 29' ' ' HIS . 2.8 mt -73.8 -4.88 5.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 O-C-N 121.388 -0.82 . . . . 0.0 109.178 179.661 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.27 -168.5 1.32 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.474 -0.766 . . . . 0.0 109.966 -179.048 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.515 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -162.5 -169.58 26.08 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -47.99 91.6 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.274 -1.133 . . . . 0.0 109.811 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' A' ' 35' ' ' GLY . . . 151.24 154.13 6.43 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 179.536 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 27.4 t80 -86.2 81.54 8.38 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.096 -1.238 . . . . 0.0 109.629 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.68 161.01 16.18 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.095 -1.003 . . . . 0.0 109.894 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.487 ' OG1' ' N ' ' A' ' 41' ' ' LEU . 0.2 OUTLIER -138.36 179.72 6.29 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.391 -0.818 . . . . 0.0 108.984 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.487 ' N ' ' OG1' ' A' ' 40' ' ' THR . 0.1 OUTLIER -114.61 153.19 30.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.062 -1.024 . . . . 0.0 109.622 -179.959 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.403 ' O ' ' HB2' ' A' ' 45' ' ' GLN . 5.2 pt-20 -121.09 177.09 5.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.352 -0.842 . . . . 0.0 109.445 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.56 ' OE1' HG12 ' A' ' 6' ' ' VAL . 3.4 tp10 -75.16 141.52 43.65 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.237 -0.915 . . . . 0.0 108.957 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 78.29 6.99 87.95 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 -179.438 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.458 ' OE1' ' N ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -75.89 131.93 39.98 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.172 -1.193 . . . . 0.0 110.624 -179.505 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.689 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . -94.54 118.0 30.99 Favored 'General case' 0 N--CA 1.489 1.486 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.15 178.761 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.613 HG21 HD11 ' A' ' 18' ' ' ILE . 28.6 m -111.49 159.48 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.823 -1.173 . . . . 0.0 109.911 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.6 p -115.72 123.55 48.58 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.076 -1.015 . . . . 0.0 108.429 179.448 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.191 ' CE1' HD11 ' A' ' 2' ' ' LEU . 8.8 p90 -151.92 -178.7 6.91 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.959 -1.088 . . . . 0.0 109.905 -179.429 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -125.36 94.02 4.03 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.483 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.854 HD11 ' CG2' ' A' ' 26' ' ' VAL . 10.5 mt -60.63 140.0 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 O-C-N 120.92 -1.112 . . . . 0.0 110.032 -179.381 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.584 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.9 m -124.52 -173.01 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 106.384 -1.71 . . . . 0.0 106.384 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -122.53 110.75 15.97 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 120.877 -1.139 . . . . 0.0 109.502 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.4 171.13 16.55 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -37.95 -52.25 1.36 Allowed 'General case' 0 N--CA 1.505 2.288 0 O-C-N 121.426 -1.044 . . . . 0.0 113.571 -178.664 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.21 22.53 0.16 Allowed 'General case' 0 N--CA 1.5 2.049 0 O-C-N 119.66 -1.9 . . . . 0.0 112.252 -178.084 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.424 ' O ' ' HG2' ' A' ' 59' ' ' GLN . . . 97.43 -175.52 30.58 Favored Glycine 0 N--CA 1.492 2.432 0 O-C-N 120.399 -1.438 . . . . 0.0 110.266 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.584 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.3 Cg_endo -65.22 131.36 28.19 Favored 'Trans proline' 0 C--N 1.32 -0.936 0 C-N-CA 121.858 1.706 . . . . 0.0 109.839 178.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.463 ' OE1' ' O ' ' A' ' 58' ' ' PRO . 10.4 mm100 -143.25 148.15 35.95 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.93 -1.106 . . . . 0.0 111.916 -178.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.713 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.1 158.2 23.8 Favored 'General case' 0 N--CA 1.496 1.872 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 176.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.747 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.29 -42.54 0.71 Allowed 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.219 -1.551 . . . . 0.0 111.876 -176.454 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 43.1 t30 -119.76 54.3 1.02 Allowed 'General case' 0 C--N 1.285 -2.238 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.916 HG22 ' CB ' ' A' ' 49' ' ' PHE . 18.4 t -68.62 164.94 2.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.596 -179.193 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.566 HG22 ' H ' ' A' ' 65' ' ' LYS . 0.7 OUTLIER -151.3 -175.8 5.32 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 178.804 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.566 ' H ' HG22 ' A' ' 64' ' ' THR . 25.1 mmtp -87.74 131.05 34.62 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.035 -1.041 . . . . 0.0 109.653 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.481 ' HB2' ' O ' ' A' ' 46' ' ' ALA . 0.3 OUTLIER -76.55 110.13 10.86 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.044 -1.035 . . . . 0.0 109.773 -179.881 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.603 0 CA-C-O 117.926 -1.035 . . . . 0.0 109.361 179.876 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 121.201 0.525 . . . . 0.0 109.627 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.026 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -100.58 175.62 5.6 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.276 -0.89 . . . . 0.0 109.866 -179.961 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.91 ' OE2' ' HB1' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -113.74 153.48 28.95 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 120.931 -1.106 . . . . 0.0 109.92 -179.716 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.442 ' C ' ' HG3' ' A' ' 5' ' ' LYS . . . -136.37 169.7 23.62 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.442 ' HG3' ' C ' ' A' ' 4' ' ' GLY . 7.6 mttm -138.01 123.58 19.69 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.943 -1.327 . . . . 0.0 109.991 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.596 HG13 ' H ' ' A' ' 8' ' ' TRP . 4.5 t -47.09 143.53 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 CA-C-O 122.857 1.313 . . . . 0.0 112.221 -179.538 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.74 -28.23 13.6 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 103.282 -2.859 . . . . 0.0 103.282 172.56 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.717 ' CZ3' ' ND2' ' A' ' 10' ' ' ASN . 23.1 p-90 177.92 145.71 0.12 Allowed 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.146 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.976 ' CE1' HG21 ' A' ' 28' ' ' VAL . 0.8 OUTLIER -112.72 148.8 33.97 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 120.528 -1.357 . . . . 0.0 109.902 179.821 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.717 ' ND2' ' CZ3' ' A' ' 8' ' ' TRP . 16.2 m-20 -129.25 36.87 4.11 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 178.471 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.6 p -38.74 -50.95 1.69 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.9 -0.5 . . . . 0.0 110.41 -178.467 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.431 ' OE2' ' O ' ' A' ' 12' ' ' GLU . 6.7 tp10 -63.96 -37.69 88.34 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.04 -1.038 . . . . 0.0 110.151 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.591 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 1.1 mptt -75.23 2.38 11.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.962 -1.086 . . . . 0.0 110.057 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.468 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 100.63 8.56 48.77 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.983 -1.103 . . . . 0.0 112.828 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.556 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 7.0 p90 177.08 172.6 0.48 Allowed 'General case' 0 N--CA 1.501 2.11 0 CA-C-N 120.213 2.007 . . . . 0.0 111.492 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.93 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -145.49 153.1 25.07 Favored Glycine 0 N--CA 1.501 3.012 0 N-CA-C 107.152 -2.379 . . . . 0.0 107.152 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.713 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.1 m-85 -112.32 139.7 47.66 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 119.72 -2.047 . . . . 0.0 110.095 -179.112 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.05 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.2 mt -107.29 162.16 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.684 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.589 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 4.4 tt0 -140.42 133.81 29.9 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.138 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.622 HG13 ' HB2' ' A' ' 23' ' ' GLN . 7.6 p -137.9 140.67 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 C-N-CA 117.936 -1.505 . . . . 0.0 111.804 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -63.92 140.6 58.89 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.302 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.86 -13.8 46.46 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.622 ' HB2' HG13 ' A' ' 20' ' ' VAL . 1.2 mt-30 -138.48 -175.48 4.14 Favored 'General case' 0 C--N 1.309 -1.166 0 O-C-N 121.326 -1.102 . . . . 0.0 108.746 179.612 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.31 -165.37 1.21 Allowed 'General case' 0 C--N 1.295 -1.783 0 CA-C-O 122.044 0.926 . . . . 0.0 110.324 -179.43 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.589 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 38.1 p-10 -71.34 120.69 17.28 Favored 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.833 179.393 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 1.028 HG22 ' CD1' ' A' ' 51' ' ' ILE . 2.5 t -83.26 114.06 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 120.512 -1.367 . . . . 0.0 110.523 178.428 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.434 ' CB ' ' HG2' ' A' ' 59' ' ' GLN . 3.2 t80 -54.24 140.65 32.17 Favored 'General case' 0 C--N 1.296 -1.761 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 178.511 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.05 ' CG1' HD12 ' A' ' 18' ' ' ILE . 0.6 OUTLIER -132.51 148.3 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 120.699 -1.251 . . . . 0.0 110.537 -178.583 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 24.5 t-80 -144.61 137.6 26.82 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.814 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 13.4 p90 -65.78 5.91 0.41 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.789 -1.194 . . . . 0.0 111.52 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.417 ' O ' ' CG ' ' A' ' 34' ' ' GLN . 0.4 OUTLIER -95.12 -35.57 11.84 Favored 'General case' 0 N--CA 1.484 1.267 0 O-C-N 120.345 -1.472 . . . . 0.0 108.744 179.307 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.748 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.82 -41.52 10.6 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.246 -0.909 . . . . 0.0 108.666 179.38 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.802 HD11 ' HB ' ' A' ' 28' ' ' VAL . 7.0 mt -72.73 -4.44 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 119.5 -0.88 . . . . 0.0 109.027 179.327 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.477 ' O ' ' O ' ' A' ' 37' ' ' GLY . 1.7 pp0? -32.7 -43.44 0.09 Allowed 'General case' 0 N--CA 1.497 1.911 0 CA-C-O 121.017 0.437 . . . . 0.0 111.169 -178.401 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.559 ' HA2' ' CG2' ' A' ' 64' ' ' THR . . . 54.11 -169.68 1.29 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -57.13 92.91 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.297 -1.119 . . . . 0.0 110.328 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 34' ' ' GLN . . . 96.51 157.25 31.3 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 110.173 -1.171 . . . . 0.0 110.173 179.115 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.574 ' O ' ' CD2' ' A' ' 38' ' ' PHE . 20.1 t80 -85.92 90.36 8.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.109 -1.23 . . . . 0.0 109.116 179.652 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.3 mtmp? -110.68 157.17 20.02 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.134 -0.979 . . . . 0.0 109.908 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.469 ' O ' ' HG ' ' A' ' 41' ' ' LEU . 0.2 OUTLIER -99.83 -179.06 4.05 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 179.202 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.749 ' N ' HD12 ' A' ' 41' ' ' LEU . 0.5 OUTLIER -145.97 152.07 38.81 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.806 -1.184 . . . . 0.0 110.124 -179.357 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.469 ' O ' ' HB3' ' A' ' 45' ' ' GLN . 1.9 mt-10 -103.75 173.44 6.3 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.392 -0.817 . . . . 0.0 108.867 179.388 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.477 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 8.1 tm-20 -62.8 152.2 36.63 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.117 -0.989 . . . . 0.0 108.945 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.477 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 83.55 4.52 89.13 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.464 -1.455 . . . . 0.0 109.464 -179.616 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.713 ' OE1' HD22 ' A' ' 41' ' ' LEU . 0.0 OUTLIER -75.9 134.12 40.36 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.201 -1.176 . . . . 0.0 110.746 -179.316 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.91 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . -94.16 128.25 40.47 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.219 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.568 HG21 ' CD1' ' A' ' 18' ' ' ILE . 33.5 m -123.52 163.61 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 120.77 -1.206 . . . . 0.0 110.525 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.2 p -117.52 131.9 56.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.147 -0.971 . . . . 0.0 108.951 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.026 ' CE1' HD11 ' A' ' 2' ' ' LEU . 23.0 p90 -161.74 -179.3 7.12 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.865 -1.147 . . . . 0.0 109.966 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -127.5 95.45 4.25 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.668 -0.645 . . . . 0.0 109.484 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 1.028 ' CD1' HG22 ' A' ' 26' ' ' VAL . 1.2 mm -61.49 136.14 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 CA-C-O 122.469 1.128 . . . . 0.0 110.857 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.528 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 4.0 m -121.88 -175.01 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 179.364 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.73 114.58 20.13 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.977 -1.077 . . . . 0.0 109.413 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.34 172.68 18.68 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.126 -1.589 . . . . 0.0 109.126 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -37.8 -52.14 1.29 Allowed 'General case' 0 N--CA 1.504 2.252 0 O-C-N 121.426 -1.043 . . . . 0.0 113.411 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 7.2 mtm180 -75.8 22.72 0.14 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 119.609 -1.932 . . . . 0.0 112.162 -178.216 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.32 -177.05 34.65 Favored Glycine 0 N--CA 1.49 2.276 0 O-C-N 120.48 -1.388 . . . . 0.0 109.9 179.733 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.528 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -66.65 148.9 83.89 Favored 'Trans proline' 0 C--N 1.317 -1.088 0 C-N-CA 121.911 1.741 . . . . 0.0 109.781 178.736 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.95 ' C ' HD13 ' A' ' 51' ' ' ILE . 2.6 mt-30 -165.59 151.25 9.24 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.067 -1.021 . . . . 0.0 111.468 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.759 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -81.7 158.79 24.11 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 177.367 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.748 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.4 -42.45 0.7 Allowed 'General case' 0 N--CA 1.507 2.41 0 O-C-N 120.336 -1.477 . . . . 0.0 111.358 -176.788 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -119.43 61.72 0.82 Allowed 'General case' 0 C--N 1.282 -2.357 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.96 HG22 ' CB ' ' A' ' 49' ' ' PHE . 18.9 t -79.66 172.48 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.036 -178.755 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.57 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -153.93 171.08 19.56 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.764 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.32 130.34 34.55 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.931 -1.106 . . . . 0.0 109.407 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.406 ' OE2' ' N ' ' A' ' 67' ' ' ALA . 0.7 OUTLIER -81.76 154.78 25.8 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.286 -0.884 . . . . 0.0 109.716 -179.727 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.406 ' N ' ' OE2' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.424 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.2 mtt . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 121.243 0.544 . . . . 0.0 109.634 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.089 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -119.77 175.76 5.72 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.353 -0.842 . . . . 0.0 110.036 179.841 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.802 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.4 OUTLIER -112.04 160.89 17.05 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.194 -0.941 . . . . 0.0 110.155 -178.994 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.23 168.32 28.36 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 6' ' ' VAL . 5.2 mttt -139.86 120.18 13.92 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.026 -1.279 . . . . 0.0 110.086 -179.694 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.614 HG22 ' CD1' ' A' ' 9' ' ' PHE . 3.7 t -41.55 140.51 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 CA-C-O 122.736 1.255 . . . . 0.0 112.073 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.499 ' HG3' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -98.09 -28.1 13.91 Favored 'General case' 0 C--N 1.289 -2.054 0 N-CA-C 103.536 -2.765 . . . . 0.0 103.536 173.008 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 26.1 p-90 177.55 141.74 0.09 Allowed 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 178.17 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.614 ' CD1' HG22 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -120.5 139.71 52.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.511 -1.368 . . . . 0.0 110.162 -179.893 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.52 ' ND2' ' HB2' ' A' ' 13' ' ' LYS . 2.0 t30 -132.05 32.88 3.97 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 179.245 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.457 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -37.45 -48.26 0.95 Allowed 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 121.634 0.73 . . . . 0.0 109.192 -179.404 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -59.99 -47.52 85.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.565 -0.709 . . . . 0.0 109.898 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.52 ' HB2' ' ND2' ' A' ' 10' ' ' ASN . 5.1 mptt -69.52 0.36 5.42 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.428 -0.795 . . . . 0.0 110.64 -179.409 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.438 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 109.9 4.38 29.68 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 119.67 -1.253 . . . . 0.0 113.063 178.386 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.466 ' O ' ' C ' ' A' ' 10' ' ' ASN . 5.0 p90 179.6 166.36 1.12 Allowed 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 120.975 2.387 . . . . 0.0 112.163 179.807 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.532 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -147.4 143.25 11.05 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 107.668 -2.173 . . . . 0.0 107.668 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.0 m-85 -115.07 138.95 50.29 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.196 -1.767 . . . . 0.0 110.231 -178.631 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.796 HD11 HG21 ' A' ' 47' ' ' VAL . 1.1 mt -106.74 152.71 8.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 177.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.556 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 1.7 tt0 -129.23 136.29 49.92 Favored 'General case' 0 C--N 1.286 -2.175 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.325 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.571 HG13 ' HB2' ' A' ' 23' ' ' GLN . 6.6 p -138.88 139.43 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 117.592 -1.643 . . . . 0.0 111.861 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -62.41 140.78 58.57 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.112 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.76 -18.15 36.44 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.51 -1.836 . . . . 0.0 108.51 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.571 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.1 OUTLIER -136.44 -175.92 4.16 Favored 'General case' 0 N--CA 1.484 1.226 0 O-C-N 121.423 -1.045 . . . . 0.0 108.334 179.336 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.91 -166.38 1.3 Allowed 'General case' 0 C--N 1.296 -1.749 0 CA-C-O 122.143 0.973 . . . . 0.0 111.014 -178.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.556 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 1.9 p-10 -73.21 102.2 3.57 Favored 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.553 178.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.885 HG13 ' H ' ' A' ' 60' ' ' ALA . 2.7 t -66.65 128.38 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 120.422 -1.424 . . . . 0.0 111.04 179.326 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.55 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 3.8 t80 -71.1 135.99 47.98 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.679 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.803 HG13 HG12 ' A' ' 26' ' ' VAL . 11.2 m -149.88 128.21 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 120.406 -1.434 . . . . 0.0 110.721 -179.574 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.634 ' NE2' ' CE2' ' A' ' 30' ' ' PHE . 10.9 t-80 -99.21 166.31 11.29 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.634 ' CE2' ' NE2' ' A' ' 29' ' ' HIS . 48.5 p90 -82.35 31.61 0.4 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.806 -1.184 . . . . 0.0 110.062 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.628 ' O ' ' NE2' ' A' ' 34' ' ' GLN . 32.5 p -116.81 -38.2 3.49 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.976 -1.078 . . . . 0.0 109.11 179.677 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.751 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.56 -41.92 9.96 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 108.508 179.356 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.603 ' N ' HD12 ' A' ' 33' ' ' ILE . 1.5 mp -62.7 -11.77 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.535 -0.728 . . . . 0.0 109.083 179.729 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.628 ' NE2' ' O ' ' A' ' 31' ' ' SER . 6.9 pt20 -83.58 -175.96 6.07 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.195 -0.941 . . . . 0.0 109.663 -179.526 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -169.56 -48.24 0.03 OUTLIER Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -104.6 78.44 1.46 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.294 -1.121 . . . . 0.0 109.126 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.43 163.68 23.71 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.022 -1.631 . . . . 0.0 109.022 -179.525 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.61 ' CG ' ' O ' ' A' ' 38' ' ' PHE . 10.2 p90 -47.07 103.65 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.884 -1.362 . . . . 0.0 109.154 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.502 ' HE3' ' CE ' ' A' ' 65' ' ' LYS . 13.7 mmtt -106.15 150.64 25.64 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.198 -0.938 . . . . 0.0 109.695 -179.49 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.511 ' OG1' ' N ' ' A' ' 41' ' ' LEU . 0.6 OUTLIER -115.42 -177.68 3.2 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.542 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.594 ' HB3' ' CD2' ' A' ' 9' ' ' PHE . 2.1 tp -144.05 132.95 22.64 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.002 -1.061 . . . . 0.0 110.024 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -98.66 179.51 4.65 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.416 -0.802 . . . . 0.0 108.91 179.524 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.513 ' OE1' ' N ' ' A' ' 44' ' ' GLY . 0.0 OUTLIER -75.17 141.84 43.6 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.203 -0.936 . . . . 0.0 109.627 -179.511 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.513 ' N ' ' OE1' ' A' ' 43' ' ' GLU . . . 92.69 -7.92 76.98 Favored Glycine 0 N--CA 1.487 2.067 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.49 ' OE1' ' HG ' ' A' ' 41' ' ' LEU . 1.4 tt0 -77.07 125.16 28.86 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.218 -1.166 . . . . 0.0 110.767 -179.411 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.68 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . -92.27 146.5 23.66 Favored 'General case' 0 N--CA 1.486 1.362 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 178.391 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.796 HG21 HD11 ' A' ' 18' ' ' ILE . 29.9 m -135.92 162.98 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.852 -1.155 . . . . 0.0 109.851 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.3 p -116.0 137.1 52.42 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.036 -1.04 . . . . 0.0 108.442 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.089 ' CE1' HD11 ' A' ' 2' ' ' LEU . 10.4 p90 -162.43 -175.74 4.68 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.884 -1.135 . . . . 0.0 109.852 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -127.35 98.5 5.28 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.555 -0.716 . . . . 0.0 109.586 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.629 HD11 ' CG2' ' A' ' 26' ' ' VAL . 5.6 mt -61.89 143.69 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 CA-C-O 122.529 1.157 . . . . 0.0 111.309 -179.482 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.52 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 13.9 m -129.51 -176.76 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.27 116.78 23.92 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.728 -1.232 . . . . 0.0 110.369 -179.681 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -116.32 165.03 12.24 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.523 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.431 ' C ' ' O ' ' A' ' 54' ' ' GLY . 4.6 m-20 -38.31 -54.67 1.41 Allowed 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.072 -1.252 . . . . 0.0 112.914 -178.462 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.1 ttm180 -69.7 -21.26 63.51 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 119.564 -1.96 . . . . 0.0 113.069 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.69 179.2 25.33 Favored Glycine 0 N--CA 1.492 2.415 0 O-C-N 120.27 -1.519 . . . . 0.0 110.358 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.52 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -65.81 140.82 62.85 Favored 'Trans proline' 0 C--N 1.317 -1.094 0 C-N-CA 122.007 1.805 . . . . 0.0 110.464 179.206 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.522 ' HG2' ' CB ' ' A' ' 27' ' ' PHE . 30.3 mt-30 -154.83 151.78 29.03 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.347 -0.846 . . . . 0.0 110.71 -179.591 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.885 ' H ' HG13 ' A' ' 26' ' ' VAL . . . -83.83 167.76 16.76 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 177.328 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.751 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.23 -44.07 0.71 Allowed 'General case' 0 N--CA 1.503 2.22 0 O-C-N 120.289 -1.507 . . . . 0.0 111.672 -176.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.54 ' O ' ' ND2' ' A' ' 62' ' ' ASN . 0.4 OUTLIER -120.0 52.16 1.14 Allowed 'General case' 0 C--N 1.287 -2.11 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 -179.9 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.973 HG22 ' CB ' ' A' ' 49' ' ' PHE . 20.0 t -67.81 164.13 2.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 121.561 0.696 . . . . 0.0 109.681 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.484 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -146.24 164.29 32.76 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 178.672 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.526 ' HA ' HG12 ' A' ' 47' ' ' VAL . 0.0 OUTLIER -79.62 140.41 37.12 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.081 -1.012 . . . . 0.0 109.75 -179.74 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.482 ' HB2' ' O ' ' A' ' 46' ' ' ALA . 1.3 mm-40 -68.23 140.18 56.05 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.216 -0.927 . . . . 0.0 109.643 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 118.06 -0.971 . . . . 0.0 109.353 179.819 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.8 tpp . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.145 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -110.2 179.19 4.17 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.223 -0.923 . . . . 0.0 110.196 -179.88 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.866 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.1 OUTLIER -112.66 167.27 10.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.858 -1.151 . . . . 0.0 109.651 -179.284 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -148.54 159.81 28.16 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.7 mttt -133.88 117.96 17.39 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.373 -1.075 . . . . 0.0 110.742 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.605 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.5 t -37.89 146.67 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 123.122 1.439 . . . . 0.0 113.143 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.63 -30.65 9.84 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 103.191 -2.892 . . . . 0.0 103.191 172.137 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.714 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 22.6 p-90 177.66 145.92 0.12 Allowed 'General case' 0 N--CA 1.484 1.267 0 N-CA-C 106.035 -1.839 . . . . 0.0 106.035 177.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.847 ' CE1' HG21 ' A' ' 28' ' ' VAL . 1.4 t80 -119.18 138.45 52.93 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.442 -1.411 . . . . 0.0 109.611 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.516 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.2 t-20 -133.65 36.76 3.32 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.651 ' HG ' ' HD2' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -37.21 -49.59 0.93 Allowed 'General case' 0 N--CA 1.495 1.818 0 CA-C-O 121.443 0.639 . . . . 0.0 109.541 -179.451 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -60.92 -46.22 91.53 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.475 -0.766 . . . . 0.0 109.806 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.501 ' HD2' ' N ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -69.96 1.0 4.96 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.51 -0.744 . . . . 0.0 110.453 -179.606 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.44 ' O ' ' CB ' ' A' ' 15' ' ' PHE . . . 123.35 -19.52 7.62 Favored Glycine 0 N--CA 1.491 2.355 0 C-N-CA 119.685 -1.245 . . . . 0.0 111.946 178.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.471 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 5.3 p90 173.7 178.4 0.11 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.056 -1.85 . . . . 0.0 111.456 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.954 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -135.52 145.81 17.84 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 107.884 -2.087 . . . . 0.0 107.884 179.505 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.714 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.7 m-30 -104.57 142.18 35.1 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 120.247 -1.737 . . . . 0.0 109.664 -179.245 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.005 HD12 HG11 ' A' ' 28' ' ' VAL . 0.5 OUTLIER -106.34 164.51 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 178.56 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.568 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 3.1 tm-20 -141.68 129.77 22.08 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.645 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.693 HG13 ' HB2' ' A' ' 23' ' ' GLN . 10.3 p -135.59 141.65 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 C-N-CA 117.695 -1.602 . . . . 0.0 112.043 -179.657 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -65.65 140.25 58.48 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-N 115.381 -0.827 . . . . 0.0 108.827 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.41 -14.01 42.96 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.693 ' HB2' HG13 ' A' ' 20' ' ' VAL . 1.8 mm-40 -137.66 -177.37 4.77 Favored 'General case' 0 N--CA 1.483 1.202 0 O-C-N 121.333 -1.098 . . . . 0.0 108.407 179.538 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -100.73 -166.27 1.3 Allowed 'General case' 0 C--N 1.296 -1.748 0 CA-C-O 121.962 0.887 . . . . 0.0 110.378 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.612 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.4 m-20 -72.08 123.46 22.88 Favored 'General case' 0 N--CA 1.486 1.367 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.676 179.149 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.88 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.4 t -84.91 110.5 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.02 0 O-C-N 120.589 -1.32 . . . . 0.0 111.454 178.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -55.37 133.73 49.87 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 178.07 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.005 HG11 HD12 ' A' ' 18' ' ' ILE . 0.6 OUTLIER -132.75 137.19 54.53 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 C-N-CA 117.891 -1.524 . . . . 0.0 110.661 -178.782 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.714 ' O ' HD12 ' A' ' 33' ' ' ILE . 0.7 OUTLIER -109.81 159.49 17.15 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.757 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.572 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 46.1 p90 -82.67 39.86 0.64 Allowed 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.763 -1.211 . . . . 0.0 109.831 -179.674 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.524 ' O ' ' HG2' ' A' ' 34' ' ' GLN . 3.1 t -137.65 -33.2 0.73 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.816 -1.178 . . . . 0.0 110.518 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.734 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -93.53 -49.91 5.67 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.961 -1.087 . . . . 0.0 109.706 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.823 HG23 ' CG1' ' A' ' 63' ' ' VAL . 1.4 mp -75.93 0.53 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.677 -0.64 . . . . 0.0 110.359 -178.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.524 ' HG2' ' O ' ' A' ' 31' ' ' SER . 9.7 pt20 -77.75 -3.75 42.85 Favored 'General case' 0 C--N 1.293 -1.851 0 O-C-N 121.403 -0.81 . . . . 0.0 109.916 -179.235 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 47.35 -169.7 0.06 OUTLIER Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -50.18 130.91 23.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.35 -1.088 . . . . 0.0 109.955 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 76.12 157.84 7.49 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 179.452 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -85.6 104.35 15.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.115 -1.226 . . . . 0.0 109.033 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -109.84 157.75 18.87 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.248 -0.908 . . . . 0.0 109.867 -179.63 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.941 ' C ' HD22 ' A' ' 41' ' ' LEU . 0.2 OUTLIER -99.16 169.17 9.58 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.732 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.941 HD22 ' C ' ' A' ' 40' ' ' THR . 4.0 mm? -122.48 178.37 5.0 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.733 -1.229 . . . . 0.0 109.999 -179.285 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -156.89 -179.82 8.57 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.382 -0.824 . . . . 0.0 109.084 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 21.0 tp10 -70.65 145.51 50.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.197 -0.939 . . . . 0.0 109.056 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 84.94 -2.34 88.33 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -178.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.698 ' HG3' HD12 ' A' ' 41' ' ' LEU . 3.6 tt0 -55.9 111.66 0.99 Allowed 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.489 -1.007 . . . . 0.0 110.516 -179.649 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -94.43 116.25 28.57 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 177.361 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.764 HG21 HD11 ' A' ' 18' ' ' ILE . 26.2 m -124.13 163.13 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 120.627 -1.296 . . . . 0.0 110.882 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.444 ' HB3' ' HG2' ' A' ' 66' ' ' GLU . 22.7 p -115.87 137.22 52.3 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 108.5 179.362 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.145 ' CE1' HD11 ' A' ' 2' ' ' LEU . 9.4 p90 -163.66 -177.97 5.5 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.816 -1.177 . . . . 0.0 109.941 -179.257 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -127.15 93.02 3.64 Favored 'General case' 0 C--N 1.295 -1.773 0 O-C-N 121.688 -0.633 . . . . 0.0 109.475 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.88 HD11 ' CG2' ' A' ' 26' ' ' VAL . 16.3 mt -62.1 128.92 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.023 -1.048 . . . . 0.0 109.886 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 16.1 m -108.11 -176.59 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 178.786 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -123.32 114.66 20.49 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.012 -1.055 . . . . 0.0 109.735 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.405 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -125.89 169.04 17.86 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.591 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' A' ' 54' ' ' GLY . 22.1 m120 -37.44 -51.99 1.13 Allowed 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.227 -1.161 . . . . 0.0 113.412 -178.45 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.9 tpt180 -75.33 22.62 0.12 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 119.718 -1.864 . . . . 0.0 112.352 -178.14 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.02 -178.32 31.94 Favored Glycine 0 N--CA 1.494 2.551 0 O-C-N 120.414 -1.429 . . . . 0.0 110.269 179.502 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.54 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -67.91 155.01 71.4 Favored 'Trans proline' 0 C--N 1.32 -0.947 0 C-N-CA 122.005 1.803 . . . . 0.0 109.918 178.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.436 ' N ' HG23 ' A' ' 51' ' ' ILE . 1.0 OUTLIER -166.07 143.22 5.31 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.982 -1.074 . . . . 0.0 111.398 -179.693 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.775 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -78.09 157.63 29.44 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 177.405 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.734 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.54 -44.26 0.75 Allowed 'General case' 0 N--CA 1.507 2.395 0 O-C-N 120.498 -1.376 . . . . 0.0 111.933 -176.407 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -119.81 51.78 1.16 Allowed 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.976 HG22 ' CB ' ' A' ' 49' ' ' PHE . 21.2 t -68.03 169.2 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-O 121.693 0.758 . . . . 0.0 109.513 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.592 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -154.62 178.14 10.43 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 178.237 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.676 ' HZ3' HD11 ' A' ' 41' ' ' LEU . 0.0 OUTLIER -84.36 140.89 31.27 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.043 -1.036 . . . . 0.0 109.557 -179.712 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.622 ' O ' ' HB3' ' A' ' 67' ' ' ALA . 1.0 OUTLIER -95.22 139.94 30.84 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.31 -0.869 . . . . 0.0 109.292 179.684 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.622 ' HB3' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 118.071 -0.966 . . . . 0.0 109.383 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 121.235 0.541 . . . . 0.0 109.554 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.192 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.32 172.61 12.49 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.143 -0.973 . . . . 0.0 110.011 179.727 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.845 ' OE2' ' HB1' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -113.92 149.03 35.8 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 121.213 -0.929 . . . . 0.0 110.389 -179.372 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.438 ' HA3' HG21 ' A' ' 18' ' ' ILE . . . -121.33 166.16 14.26 Favored Glycine 0 N--CA 1.483 1.796 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 179.429 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.47 ' O ' ' C ' ' A' ' 6' ' ' VAL . 2.0 mttm -140.3 119.0 12.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.922 -1.34 . . . . 0.0 109.609 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.504 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.7 t -33.5 136.67 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 CA-C-O 122.913 1.34 . . . . 0.0 113.401 -179.327 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.489 ' CG ' ' HB3' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -101.8 -31.51 10.71 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 103.149 -2.908 . . . . 0.0 103.149 172.61 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.699 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 22.8 p-90 174.25 145.25 0.05 Allowed 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 178.009 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.811 ' HB3' HD13 ' A' ' 41' ' ' LEU . 0.2 OUTLIER -114.21 147.04 39.58 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.149 -1.594 . . . . 0.0 109.952 179.333 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.544 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 80.5 m-20 -130.21 38.68 3.75 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 179.013 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.565 ' HB3' HD23 ' A' ' 41' ' ' LEU . 24.7 p -40.89 -41.59 1.64 Allowed 'General case' 0 N--CA 1.488 1.47 0 CA-C-O 121.71 0.767 . . . . 0.0 109.103 -179.078 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -59.9 -48.4 81.87 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.537 -0.727 . . . . 0.0 110.414 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.567 ' N ' ' CD ' ' A' ' 13' ' ' LYS . 2.2 mptp? -73.83 4.35 5.36 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.215 -0.928 . . . . 0.0 110.125 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.414 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 92.24 23.55 26.71 Favored Glycine 0 N--CA 1.49 2.242 0 C-N-CA 120.251 -0.976 . . . . 0.0 112.144 178.549 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.496 ' O ' ' C ' ' A' ' 10' ' ' ASN . 26.7 p90 179.44 167.19 1.09 Allowed 'General case' 0 N--CA 1.501 2.076 0 CA-C-N 120.102 1.951 . . . . 0.0 111.631 179.447 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.595 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -149.0 150.89 23.09 Favored Glycine 0 N--CA 1.497 2.752 0 N-CA-C 106.995 -2.442 . . . . 0.0 106.995 179.328 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.699 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 6.1 m-85 -117.24 138.31 51.8 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 120.035 1.917 . . . . 0.0 110.235 -178.648 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.547 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.7 mt -105.47 146.55 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.809 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.56 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 9.6 pt-20 -121.01 137.02 54.85 Favored 'General case' 0 C--N 1.285 -2.229 0 C-N-CA 119.472 -0.891 . . . . 0.0 108.944 178.45 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.52 HG13 ' HB2' ' A' ' 23' ' ' GLN . 10.0 p -138.73 140.93 38.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 C-N-CA 117.822 -1.551 . . . . 0.0 111.787 179.816 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.87 140.49 58.28 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.391 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 87.77 -19.1 35.16 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.119 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.52 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -136.4 -175.43 4.0 Favored 'General case' 0 C--N 1.308 -1.219 0 O-C-N 121.416 -1.049 . . . . 0.0 108.693 179.406 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.61 -165.1 1.17 Allowed 'General case' 0 C--N 1.296 -1.756 0 CA-C-O 122.009 0.909 . . . . 0.0 110.588 -179.051 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.56 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 0.9 OUTLIER -71.65 93.24 1.23 Allowed 'General case' 0 N--CA 1.487 1.388 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.037 179.257 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.822 HG13 ' H ' ' A' ' 60' ' ' ALA . 2.7 t -56.27 142.4 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 120.299 -1.501 . . . . 0.0 109.952 178.579 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.498 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 5.0 t80 -71.69 146.3 48.3 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 176.817 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.859 ' HB ' HD11 ' A' ' 33' ' ' ILE . 2.0 m -142.06 113.96 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 120.332 -1.48 . . . . 0.0 110.363 -179.299 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.691 ' O ' HD12 ' A' ' 33' ' ' ILE . 5.4 t-160 -99.55 148.95 23.74 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 178.296 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.431 ' O ' ' HD2' ' A' ' 39' ' ' LYS . 49.8 p90 -79.86 32.71 0.26 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.747 -1.221 . . . . 0.0 110.163 -179.73 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.78 -36.93 3.34 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.963 -1.085 . . . . 0.0 108.924 179.579 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.706 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.36 -47.16 7.33 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 179.366 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.859 HD11 ' HB ' ' A' ' 28' ' ' VAL . 11.6 mt -58.22 -16.22 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 CA-C-O 121.495 0.664 . . . . 0.0 109.44 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.431 ' HG2' ' HA ' ' A' ' 39' ' ' LYS . 0.0 OUTLIER -111.41 -168.84 1.36 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.59 -0.694 . . . . 0.0 109.886 -179.557 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -152.28 -169.97 18.29 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.081 -1.607 . . . . 0.0 109.081 179.726 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -49.53 92.4 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.105 -1.232 . . . . 0.0 109.339 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 35' ' ' GLY . . . 166.21 -170.05 40.68 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.427 ' O ' ' CD1' ' A' ' 38' ' ' PHE . 45.2 p90 -67.06 139.66 57.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.285 -1.127 . . . . 0.0 109.582 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.431 ' HA ' ' HG2' ' A' ' 34' ' ' GLN . 24.1 mtmt -110.24 137.37 48.07 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -0.891 . . . . 0.0 109.43 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.1 t -169.35 -169.91 1.01 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.058 -1.026 . . . . 0.0 109.761 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.811 HD13 ' HB3' ' A' ' 9' ' ' PHE . 0.8 OUTLIER -119.99 179.91 4.12 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.35 -0.844 . . . . 0.0 110.247 -179.511 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.468 ' O ' ' CB ' ' A' ' 45' ' ' GLN . 0.1 OUTLIER -163.92 120.59 1.69 Allowed 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 179.246 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -62.05 140.88 58.35 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.286 -0.884 . . . . 0.0 108.975 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 69.06 16.14 70.37 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.34 -1.904 . . . . 0.0 108.34 -178.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.468 ' CB ' ' O ' ' A' ' 42' ' ' GLU . 44.7 tt0 -72.54 116.11 12.6 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.535 -0.98 . . . . 0.0 110.351 -179.342 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.845 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . -92.16 126.05 37.09 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 178.322 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.5 HG21 ' CD1' ' A' ' 18' ' ' ILE . 31.3 m -122.32 165.06 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 120.704 -1.247 . . . . 0.0 110.462 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.4 p -117.01 122.55 44.53 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.26 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.192 ' CE1' HD11 ' A' ' 2' ' ' LEU . 6.3 p90 -150.85 -178.45 6.59 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 120.858 -1.151 . . . . 0.0 109.726 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -127.71 95.02 4.1 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.751 HD11 ' CG2' ' A' ' 26' ' ' VAL . 13.3 mt -62.35 136.34 25.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 CA-C-O 122.326 1.06 . . . . 0.0 110.906 -179.165 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.515 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 11.5 m -119.53 -176.61 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 179.124 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -123.48 113.66 19.05 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.01 -1.057 . . . . 0.0 109.629 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.23 171.66 16.52 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -37.99 -52.13 1.37 Allowed 'General case' 0 N--CA 1.505 2.292 0 O-C-N 121.367 -1.078 . . . . 0.0 113.735 -178.363 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.38 22.38 0.23 Allowed 'General case' 0 N--CA 1.5 2.046 0 O-C-N 119.655 -1.903 . . . . 0.0 112.247 -177.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.18 -176.97 29.67 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.451 -1.357 . . . . 0.0 110.257 179.509 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.515 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -66.94 153.43 77.93 Favored 'Trans proline' 0 C--N 1.32 -0.938 0 C-N-CA 121.915 1.744 . . . . 0.0 109.977 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.412 ' CD ' ' HB2' ' A' ' 27' ' ' PHE . 0.0 OUTLIER -165.65 147.04 7.17 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.207 -0.933 . . . . 0.0 111.083 -179.428 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.822 ' H ' HG13 ' A' ' 26' ' ' VAL . . . -81.04 161.7 24.09 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 177.051 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.706 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.27 -44.98 0.77 Allowed 'General case' 0 N--CA 1.508 2.441 0 O-C-N 120.155 -1.59 . . . . 0.0 111.93 -176.841 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -119.02 50.73 1.18 Allowed 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.953 HG22 ' CB ' ' A' ' 49' ' ' PHE . 19.9 t -64.63 157.64 4.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.76 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.409 HG22 ' H ' ' A' ' 65' ' ' LYS . 0.9 OUTLIER -142.14 173.57 11.4 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.153 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.409 ' H ' HG22 ' A' ' 64' ' ' THR . 0.4 OUTLIER -79.3 126.0 30.22 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.929 -1.107 . . . . 0.0 109.376 -179.917 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.461 ' HG3' ' CG ' ' A' ' 3' ' ' GLU . 10.1 tm-20 -90.58 97.03 10.94 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.285 -0.884 . . . . 0.0 109.602 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.412 ' C ' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.524 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.6 mtp . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 121.24 0.543 . . . . 0.0 109.63 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.935 HD13 ' O ' ' A' ' 2' ' ' LEU . 0.0 OUTLIER -140.84 169.34 17.81 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.205 -0.935 . . . . 0.0 110.385 179.585 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.683 ' N ' HD22 ' A' ' 2' ' ' LEU . 0.1 OUTLIER -121.26 136.75 54.92 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.473 -0.767 . . . . 0.0 109.498 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -129.59 -164.19 11.35 Favored Glycine 0 N--CA 1.484 1.834 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 20.9 ttpt -151.71 135.9 16.68 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.882 -1.364 . . . . 0.0 111.048 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.555 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.3 t -42.58 140.07 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 122.865 1.317 . . . . 0.0 112.856 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.438 ' HG3' ' OE1' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -97.4 -31.13 12.53 Favored 'General case' 0 C--N 1.29 -2.011 0 N-CA-C 103.009 -2.96 . . . . 0.0 103.009 172.631 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.707 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.2 p-90 177.45 145.85 0.11 Allowed 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 177.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.991 ' CE1' HD11 ' A' ' 41' ' ' LEU . 0.7 OUTLIER -113.81 146.32 40.12 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 120.591 -1.318 . . . . 0.0 109.61 179.234 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.562 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 31.4 m-20 -130.08 43.03 3.19 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 10' ' ' ASN . 53.4 p -41.33 -41.44 1.94 Allowed 'General case' 0 N--CA 1.489 1.511 0 CA-C-O 121.612 0.72 . . . . 0.0 109.077 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -59.49 -49.37 78.06 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.435 -0.791 . . . . 0.0 110.607 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.534 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -72.95 4.36 4.3 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.01 -1.056 . . . . 0.0 110.395 -179.429 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.56 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 91.46 23.91 27.62 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 120.051 -1.071 . . . . 0.0 111.933 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.473 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 11.1 p90 178.92 167.63 0.93 Allowed 'General case' 0 N--CA 1.499 1.987 0 CA-C-N 120.122 1.961 . . . . 0.0 111.815 179.306 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -146.58 144.33 12.59 Favored Glycine 0 N--CA 1.497 2.758 0 N-CA-C 107.271 -2.331 . . . . 0.0 107.271 179.404 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.707 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.1 m-85 -110.13 142.68 41.3 Favored 'General case' 0 N--CA 1.482 1.134 0 O-C-N 120.013 -1.874 . . . . 0.0 110.153 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.003 HD12 HG21 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -105.91 165.23 3.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 177.975 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.591 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 6.8 tt0 -133.92 130.17 37.36 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.47 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.781 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.3 p -131.95 139.11 51.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 C-N-CA 117.728 -1.589 . . . . 0.0 111.699 -179.645 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -65.4 140.7 58.66 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.266 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.2 -9.58 46.8 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.781 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -139.78 -175.43 4.21 Favored 'General case' 0 C--N 1.309 -1.158 0 O-C-N 121.125 -1.221 . . . . 0.0 108.871 179.675 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -100.48 -165.68 1.24 Allowed 'General case' 0 C--N 1.295 -1.77 0 CA-C-O 122.208 1.004 . . . . 0.0 110.583 -178.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.594 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.2 m-20 -71.04 119.95 15.9 Favored 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 115.714 -0.676 . . . . 0.0 109.74 179.353 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.861 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.2 t -78.82 114.31 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 120.674 -1.267 . . . . 0.0 111.398 178.632 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.62 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 2.0 t80 -66.26 125.03 24.3 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.38 -0.971 . . . . 0.0 108.38 178.764 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.003 HG21 HD12 ' A' ' 18' ' ' ILE . 2.3 m -143.99 136.82 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 120.593 -1.317 . . . . 0.0 110.26 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.629 ' NE2' ' CE1' ' A' ' 30' ' ' PHE . 35.6 t60 -98.85 166.91 11.07 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 179.273 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.629 ' CE1' ' NE2' ' A' ' 29' ' ' HIS . 42.0 p90 -83.61 38.99 0.65 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.773 -1.204 . . . . 0.0 109.424 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.457 ' HA ' ' NE2' ' A' ' 34' ' ' GLN . 2.5 m -132.27 -30.39 1.52 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.091 -1.006 . . . . 0.0 109.527 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.771 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.53 -42.12 10.42 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.108 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.493 ' O ' ' HA ' ' A' ' 64' ' ' THR . 17.1 mt -53.63 -19.74 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.193 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.483 ' NE2' ' O ' ' A' ' 30' ' ' PHE . 2.9 pt20 -110.56 -169.59 1.49 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.33 -0.856 . . . . 0.0 109.312 179.799 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -154.59 -49.85 0.01 OUTLIER Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.439 ' O ' ' O ' ' A' ' 37' ' ' GLY . 1.0 OUTLIER -103.65 130.88 51.18 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.299 -1.118 . . . . 0.0 109.225 179.791 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.439 ' O ' ' O ' ' A' ' 36' ' ' GLU . . . 56.08 167.61 0.06 OUTLIER Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.154 -1.578 . . . . 0.0 109.154 -179.688 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.582 ' CG ' ' O ' ' A' ' 38' ' ' PHE . 7.0 p90 -82.14 114.72 20.85 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.065 -1.256 . . . . 0.0 109.341 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.413 ' HB2' ' CB ' ' A' ' 34' ' ' GLN . 0.0 OUTLIER -109.3 -174.4 2.5 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.086 -1.009 . . . . 0.0 109.483 -179.749 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.483 ' C ' HD23 ' A' ' 41' ' ' LEU . 0.1 OUTLIER -160.58 178.85 9.1 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.278 -0.889 . . . . 0.0 109.234 179.813 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.991 HD11 ' CE1' ' A' ' 9' ' ' PHE . 0.2 OUTLIER -145.5 168.34 20.83 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.964 -1.085 . . . . 0.0 109.511 -179.974 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.49 ' O ' ' HB2' ' A' ' 45' ' ' GLN . 0.3 OUTLIER -116.2 -179.1 3.57 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.263 -0.898 . . . . 0.0 109.193 179.833 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.521 ' OE1' HG12 ' A' ' 6' ' ' VAL . 12.4 tp10 -68.88 145.31 53.8 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.191 -0.943 . . . . 0.0 109.035 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 83.85 2.21 89.73 Favored Glycine 0 N--CA 1.486 1.998 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.493 ' NE2' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -76.21 136.97 39.72 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.153 -1.204 . . . . 0.0 110.319 -179.675 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.493 ' O ' ' NE2' ' A' ' 45' ' ' GLN . . . -93.34 140.23 29.78 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.224 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.682 HG21 ' CD1' ' A' ' 18' ' ' ILE . 26.8 m -134.09 155.92 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.877 -1.139 . . . . 0.0 109.975 179.658 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.1 p -117.32 120.39 38.05 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.09 -1.007 . . . . 0.0 108.613 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.924 ' CB ' HG22 ' A' ' 63' ' ' VAL . 10.8 p90 -149.09 -178.45 6.39 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.056 -1.028 . . . . 0.0 109.729 -179.264 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.503 ' CG ' ' O ' ' A' ' 50' ' ' GLU . 5.1 pt-20 -127.74 96.53 4.54 Favored 'General case' 0 C--N 1.296 -1.732 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.098 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.861 HD11 ' CG2' ' A' ' 26' ' ' VAL . 10.6 mt -62.38 132.26 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.05 -1.031 . . . . 0.0 110.105 -179.427 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.538 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 6.3 m -113.63 -176.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 178.802 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -124.0 116.13 22.35 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.974 -1.079 . . . . 0.0 109.844 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.404 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -129.96 172.08 20.22 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 179.757 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.404 ' C ' ' O ' ' A' ' 54' ' ' GLY . 0.7 OUTLIER -37.71 -52.03 1.25 Allowed 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.378 -1.071 . . . . 0.0 113.394 -178.572 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.26 22.69 0.11 Allowed 'General case' 0 N--CA 1.501 2.12 0 O-C-N 119.717 -1.865 . . . . 0.0 112.262 -178.303 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.37 -178.28 35.43 Favored Glycine 0 N--CA 1.491 2.337 0 O-C-N 120.434 -1.416 . . . . 0.0 110.13 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.538 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.2 Cg_endo -68.81 150.91 74.26 Favored 'Trans proline' 0 C--N 1.32 -0.938 0 C-N-CA 122.046 1.831 . . . . 0.0 109.791 178.817 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.513 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 2.9 mt-30 -165.99 148.15 7.13 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.018 -1.051 . . . . 0.0 111.65 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.735 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -79.29 157.14 27.79 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 177.279 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.771 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.82 -42.9 0.74 Allowed 'General case' 0 N--CA 1.506 2.351 0 O-C-N 120.354 -1.466 . . . . 0.0 112.027 -176.46 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -119.13 52.17 1.08 Allowed 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.924 HG22 ' CB ' ' A' ' 49' ' ' PHE . 15.0 t -66.68 157.41 5.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.668 -179.436 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.493 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.1 OUTLIER -135.8 158.49 44.26 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 178.713 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.417 ' O ' ' HG3' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -81.42 126.18 31.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.907 -1.121 . . . . 0.0 109.445 -179.883 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.515 ' O ' ' HB2' ' A' ' 67' ' ' ALA . 4.3 tt0 -88.06 138.16 31.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.232 -0.918 . . . . 0.0 109.565 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.515 ' HB2' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.497 0 CA-C-O 117.936 -1.03 . . . . 0.0 109.47 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.1 mmt . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.262 0.553 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.189 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.67 179.1 6.89 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.303 -0.873 . . . . 0.0 110.018 179.746 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.844 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.5 OUTLIER -112.51 168.13 9.89 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.829 -1.17 . . . . 0.0 110.128 -178.857 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.495 ' N ' ' OE1' ' A' ' 3' ' ' GLU . . . -149.95 156.58 26.82 Favored Glycine 0 N--CA 1.486 2.026 0 N-CA-C 109.083 -1.607 . . . . 0.0 109.083 -179.557 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.451 ' HG2' ' C ' ' A' ' 4' ' ' GLY . 0.5 OUTLIER -135.37 120.8 19.2 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.257 -1.143 . . . . 0.0 110.575 -179.44 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.545 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.6 t -39.83 138.62 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 CA-C-O 122.749 1.261 . . . . 0.0 113.112 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.449 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -100.25 -27.59 13.42 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 103.608 -2.738 . . . . 0.0 103.608 172.948 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.705 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.6 p-90 178.41 145.13 0.13 Allowed 'General case' 0 N--CA 1.482 1.166 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 178.233 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.788 ' CE2' HD11 ' A' ' 41' ' ' LEU . 0.3 OUTLIER -114.39 146.38 40.65 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 120.445 -1.409 . . . . 0.0 110.391 -179.793 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.557 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 24.1 m-20 -127.88 37.46 4.18 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 107.097 -1.445 . . . . 0.0 107.097 178.119 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.5 p -38.8 -51.21 1.72 Allowed 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.229 -178.498 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -59.78 -45.76 91.29 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.365 -0.834 . . . . 0.0 110.291 -179.326 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.557 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -70.47 0.28 6.98 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.34 -0.85 . . . . 0.0 110.735 -179.001 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.497 ' O ' ' NE2' ' A' ' 29' ' ' HIS . . . 111.57 -2.97 27.73 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.61 -1.281 . . . . 0.0 113.199 177.889 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.54 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 0.3 OUTLIER 177.63 176.99 0.38 Allowed 'General case' 0 N--CA 1.499 2.019 0 CA-C-N 120.562 2.181 . . . . 0.0 111.82 -179.751 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.863 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -141.98 156.73 26.12 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 107.703 -2.159 . . . . 0.0 107.703 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.705 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.8 m-85 -110.45 139.9 45.23 Favored 'General case' 0 N--CA 1.482 1.127 0 O-C-N 119.929 -1.924 . . . . 0.0 109.82 -179.461 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.984 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.3 mt -106.54 152.8 8.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 178.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 0.0 OUTLIER -128.69 135.79 49.73 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 178.333 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.771 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.6 p -136.44 139.87 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 C-N-CA 118.213 -1.395 . . . . 0.0 111.483 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -65.38 140.37 58.64 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 115.485 -0.779 . . . . 0.0 109.424 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.92 -10.27 48.21 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.771 ' HB2' HG13 ' A' ' 20' ' ' VAL . 3.8 mm-40 -137.92 -174.12 3.7 Favored 'General case' 0 C--N 1.31 -1.117 0 O-C-N 121.184 -1.186 . . . . 0.0 108.787 179.796 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -100.56 -167.16 1.4 Allowed 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 122.077 0.942 . . . . 0.0 110.715 -178.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.599 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 0.2 OUTLIER -73.21 108.15 5.93 Favored 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.859 179.214 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 1.074 HG21 ' CZ ' ' A' ' 49' ' ' PHE . 2.5 t -71.62 116.73 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.046 0 O-C-N 120.17 -1.581 . . . . 0.0 111.074 178.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.454 ' CB ' ' HG2' ' A' ' 59' ' ' GLN . 3.8 t80 -53.46 142.53 21.82 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 177.636 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.984 ' CG1' HD12 ' A' ' 18' ' ' ILE . 0.7 OUTLIER -135.06 154.87 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 120.788 -1.195 . . . . 0.0 109.653 -178.857 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.497 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 9.5 t-160 -150.23 152.55 34.76 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -80.05 27.49 0.31 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.936 -1.102 . . . . 0.0 109.956 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.63 -43.84 2.88 Favored 'General case' 0 C--N 1.308 -1.209 0 O-C-N 120.946 -1.096 . . . . 0.0 108.661 179.759 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.637 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -95.67 -49.36 5.4 Favored 'General case' 0 N--CA 1.493 1.721 0 CA-C-O 121.92 0.867 . . . . 0.0 108.973 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.921 HD13 ' CG1' ' A' ' 63' ' ' VAL . 6.0 mm -48.88 -29.38 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.91 -0.494 . . . . 0.0 110.381 -178.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -112.57 -52.01 2.81 Favored 'General case' 0 N--CA 1.499 1.976 0 C-N-CA 118.867 -1.133 . . . . 0.0 109.854 -179.274 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 141.15 171.07 12.45 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 108.804 -1.719 . . . . 0.0 108.804 -179.146 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -52.01 107.57 0.21 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.104 -1.233 . . . . 0.0 109.704 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 155.34 156.39 7.75 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -86.08 89.02 7.69 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.986 -1.302 . . . . 0.0 109.646 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 24.2 mmtp -110.53 171.68 7.31 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.149 -0.969 . . . . 0.0 109.769 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -160.12 165.08 32.41 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.266 -0.896 . . . . 0.0 109.239 179.609 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.86 HD22 ' HB2' ' A' ' 45' ' ' GLN . 0.3 OUTLIER -151.73 -168.97 3.23 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.722 -1.236 . . . . 0.0 109.411 179.916 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -93.81 174.43 7.18 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 179.24 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.546 ' CG ' ' HA ' ' A' ' 8' ' ' TRP . 27.6 tt0 -77.98 61.49 2.58 Favored 'General case' 0 N--CA 1.503 2.177 0 O-C-N 121.269 -0.895 . . . . 0.0 112.481 -178.608 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -170.71 41.9 0.19 Allowed Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.976 -1.65 . . . . 0.0 108.976 177.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 1.015 ' HG3' HG13 ' A' ' 47' ' ' VAL . 44.6 tp60 -78.77 130.12 35.4 Favored 'General case' 0 N--CA 1.478 0.932 0 O-C-N 120.837 -1.39 . . . . 0.0 111.676 -178.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.647 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . -96.44 112.82 24.42 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 176.327 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 1.015 HG13 ' HG3' ' A' ' 45' ' ' GLN . 10.4 m -129.6 164.06 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 C-N-CA 117.881 -1.527 . . . . 0.0 111.706 -178.036 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.422 ' HA ' ' HA ' ' A' ' 3' ' ' GLU . 2.1 p -116.35 133.78 55.63 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 178.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.189 ' CE1' HD11 ' A' ' 2' ' ' LEU . 6.5 p90 -153.55 178.31 9.97 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.093 -1.004 . . . . 0.0 109.782 -179.198 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.6 93.52 4.07 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 179.419 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.958 HD11 HG23 ' A' ' 26' ' ' VAL . 14.6 mt -61.92 125.49 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.962 -1.086 . . . . 0.0 109.611 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.4 m -106.58 -176.07 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 178.571 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -124.06 113.57 18.57 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.052 -1.03 . . . . 0.0 109.569 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.36 170.91 16.5 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.786 -1.726 . . . . 0.0 108.786 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -37.83 -52.08 1.3 Allowed 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.331 -1.099 . . . . 0.0 113.386 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 11.3 mtp180 -76.65 22.38 0.18 Allowed 'General case' 0 N--CA 1.501 2.089 0 O-C-N 119.593 -1.942 . . . . 0.0 112.411 -177.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.26 179.43 31.29 Favored Glycine 0 N--CA 1.494 2.536 0 O-C-N 120.471 -1.393 . . . . 0.0 110.65 179.262 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.572 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.7 Cg_endo -69.09 152.23 72.81 Favored 'Trans proline' 0 C--N 1.32 -0.932 0 C-N-CA 122.135 1.89 . . . . 0.0 110.205 178.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.454 ' HG2' ' CB ' ' A' ' 27' ' ' PHE . 0.3 OUTLIER -166.43 149.44 7.03 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 120.959 -1.088 . . . . 0.0 111.697 -179.772 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.831 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -80.3 154.04 28.07 Favored 'General case' 0 N--CA 1.495 1.783 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 177.06 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.637 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.74 -39.53 0.79 Allowed 'General case' 0 N--CA 1.509 2.514 0 O-C-N 120.41 -1.431 . . . . 0.0 111.687 -176.642 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -118.89 52.01 1.08 Allowed 'General case' 0 C--N 1.284 -2.265 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.958 HG22 ' CB ' ' A' ' 49' ' ' PHE . 21.1 t -68.19 158.25 5.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.626 -179.14 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.474 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.2 OUTLIER -148.51 175.45 11.14 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.671 -0.812 . . . . 0.0 109.394 179.36 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.556 ' HA ' HG12 ' A' ' 47' ' ' VAL . 1.2 tttt -77.35 137.98 39.06 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.078 -1.013 . . . . 0.0 109.552 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -57.31 113.48 1.77 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.242 -0.911 . . . . 0.0 109.545 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.03 -0.986 . . . . 0.0 109.498 179.78 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.402 ' HA ' ' HG2' ' A' ' 50' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 . . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.137 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -141.15 173.48 11.45 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.28 -0.887 . . . . 0.0 110.001 179.506 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.612 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.1 OUTLIER -114.76 150.87 34.69 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.043 -1.036 . . . . 0.0 110.555 -179.053 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.418 ' HA3' HG21 ' A' ' 18' ' ' ILE . . . -129.62 169.85 20.67 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 108.912 -1.675 . . . . 0.0 108.912 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.44 ' O ' ' C ' ' A' ' 6' ' ' VAL . 5.2 ttmt -141.76 125.71 17.19 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.978 -1.307 . . . . 0.0 110.564 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.507 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.8 t -32.01 140.97 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 CA-C-O 123.333 1.54 . . . . 0.0 114.188 -179.602 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.465 ' HD3' ' O ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -108.51 -31.79 7.66 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 103.184 -2.895 . . . . 0.0 103.184 172.48 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.696 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 15.4 p-90 175.79 146.49 0.08 Allowed 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 105.9 -1.889 . . . . 0.0 105.9 177.656 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.584 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.2 OUTLIER -117.93 145.35 44.74 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.539 -1.351 . . . . 0.0 109.636 179.237 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.506 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.9 t-20 -131.85 41.26 3.29 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . 1.032 ' HB3' HD22 ' A' ' 41' ' ' LEU . 2.1 p -39.17 -45.87 1.39 Allowed 'General case' 0 C--N 1.295 -1.768 0 CA-C-O 121.445 0.641 . . . . 0.0 109.378 -179.542 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -61.96 -45.27 94.4 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.322 -0.861 . . . . 0.0 110.015 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.58 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 1.0 OUTLIER -69.9 0.2 6.25 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.361 -0.837 . . . . 0.0 109.866 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.52 ' O ' ' CD2' ' A' ' 29' ' ' HIS . . . 91.15 20.43 38.92 Favored Glycine 0 N--CA 1.488 2.121 0 O-C-N 121.174 -0.954 . . . . 0.0 111.569 179.105 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.58 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 16.6 p90 -176.87 165.27 2.44 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 119.81 1.805 . . . . 0.0 111.532 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.71 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -150.2 141.79 9.09 Favored Glycine 0 N--CA 1.497 2.725 0 N-CA-C 107.172 -2.371 . . . . 0.0 107.172 179.401 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.696 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.3 m-85 -109.12 139.13 44.44 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.088 -1.83 . . . . 0.0 110.885 -178.523 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.732 HD11 HG21 ' A' ' 47' ' ' VAL . 1.0 OUTLIER -106.63 146.9 12.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 N-CA-C 105.665 -1.976 . . . . 0.0 105.665 177.322 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 15.1 tt0 -121.07 135.13 55.26 Favored 'General case' 0 C--N 1.28 -2.439 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.009 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.508 HG13 ' HB2' ' A' ' 23' ' ' GLN . 7.5 p -138.49 140.81 38.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 C-N-CA 117.567 -1.653 . . . . 0.0 111.891 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.74 140.5 58.74 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.105 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.97 -18.86 33.21 Favored Glycine 0 N--CA 1.486 2.013 0 N-CA-C 108.29 -1.924 . . . . 0.0 108.29 -178.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.508 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.8 OUTLIER -135.95 -176.9 4.46 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 121.502 -0.999 . . . . 0.0 108.989 179.502 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -100.81 -166.0 1.27 Allowed 'General case' 0 C--N 1.298 -1.663 0 CA-C-O 121.881 0.848 . . . . 0.0 110.841 -178.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.547 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 5.9 p-10 -71.94 90.88 1.16 Allowed 'General case' 0 N--CA 1.489 1.499 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.568 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.917 HG12 HG13 ' A' ' 28' ' ' VAL . 2.3 t -50.16 125.44 3.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.107 0 O-C-N 120.711 -1.243 . . . . 0.0 111.832 178.681 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.626 ' CD2' ' CZ ' ' A' ' 17' ' ' PHE . 2.9 t80 -72.24 130.36 40.61 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 176.188 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.917 HG13 HG12 ' A' ' 26' ' ' VAL . 2.6 m -146.6 130.75 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 120.248 -1.532 . . . . 0.0 110.703 -179.056 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.55 ' NE2' ' CE2' ' A' ' 30' ' ' PHE . 9.5 t-160 -98.99 166.74 11.13 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 178.448 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.55 ' CE2' ' NE2' ' A' ' 29' ' ' HIS . 53.0 p90 -83.82 32.44 0.48 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.795 -1.191 . . . . 0.0 110.135 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.1 m -119.12 -37.6 3.18 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.981 -1.075 . . . . 0.0 109.164 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.659 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.38 -37.34 13.28 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.25 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.672 ' N ' HD12 ' A' ' 33' ' ' ILE . 1.4 mp -70.11 -4.84 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.9 tp60 -51.02 -51.34 54.04 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.537 -0.727 . . . . 0.0 109.989 -179.214 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 1.054 ' HA3' HG22 ' A' ' 64' ' ' THR . . . 48.85 -170.47 0.09 OUTLIER Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -71.23 96.18 1.37 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.181 -1.187 . . . . 0.0 109.368 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 159.15 -170.88 35.58 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.56 ' CD1' ' N ' ' A' ' 39' ' ' LYS . 28.5 t80 -83.23 155.91 23.43 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.268 -1.137 . . . . 0.0 109.472 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.56 ' N ' ' CD1' ' A' ' 38' ' ' PHE . 3.2 pttm -94.0 125.38 38.59 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.203 -0.935 . . . . 0.0 109.282 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.5 t -176.9 -170.23 0.3 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.992 -1.067 . . . . 0.0 109.62 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 1.032 HD22 ' HB3' ' A' ' 11' ' ' SER . 0.9 OUTLIER -125.85 166.58 16.61 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.34 -0.85 . . . . 0.0 109.919 -179.688 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.441 ' O ' ' HB2' ' A' ' 45' ' ' GLN . 8.7 tt0 -174.8 127.46 0.3 Allowed 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 179.647 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.463 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 9.3 tm-20 -58.34 145.63 37.38 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.163 -179.65 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.463 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 74.52 3.87 68.04 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -179.103 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.472 ' HB3' HG23 ' A' ' 6' ' ' VAL . 25.4 tt0 -57.18 109.86 0.74 Allowed 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.355 -1.085 . . . . 0.0 110.266 -179.593 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -91.98 128.55 37.87 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.732 HG21 HD11 ' A' ' 18' ' ' ILE . 35.1 m -132.39 164.33 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 120.893 -1.129 . . . . 0.0 110.311 -179.547 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -117.62 126.8 53.18 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.026 -1.046 . . . . 0.0 108.336 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.137 ' CE1' HD11 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -149.13 179.66 7.72 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.011 -1.055 . . . . 0.0 110.392 -179.642 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.402 ' HG2' ' HA ' ' A' ' 1' ' ' MET . 2.6 mt-10 -123.74 81.14 1.87 Allowed 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.815 ' CD1' ' HB2' ' A' ' 60' ' ' ALA . 15.1 mm -61.29 118.81 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 CA-C-O 122.051 0.929 . . . . 0.0 110.772 -178.543 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.556 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 17.5 m -98.42 -175.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 179.232 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.411 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 0.2 OUTLIER -123.66 116.05 22.44 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.9 -1.125 . . . . 0.0 109.64 -179.885 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.27 174.61 16.97 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.929 -1.668 . . . . 0.0 108.929 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -38.67 -52.85 1.66 Allowed 'General case' 0 N--CA 1.505 2.287 0 O-C-N 121.369 -1.077 . . . . 0.0 113.772 -178.65 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.509 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -77.84 22.56 0.27 Allowed 'General case' 0 N--CA 1.501 2.092 0 O-C-N 119.69 -1.881 . . . . 0.0 112.211 -177.983 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.95 -178.6 30.89 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.283 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.556 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -63.58 157.78 49.43 Favored 'Trans proline' 0 C--N 1.318 -1.051 0 C-N-CA 121.991 1.794 . . . . 0.0 110.188 179.12 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.535 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 1.2 mt-30 -165.07 147.44 8.03 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 120.99 -1.069 . . . . 0.0 110.575 -179.559 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.872 ' HB1' ' CG2' ' A' ' 63' ' ' VAL . . . -82.89 158.6 22.6 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 177.701 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.659 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -132.9 -47.29 0.86 Allowed 'General case' 0 N--CA 1.501 2.098 0 O-C-N 120.436 -1.415 . . . . 0.0 111.07 -177.149 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -121.27 55.24 1.08 Allowed 'General case' 0 C--N 1.288 -2.099 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 179.219 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.888 HG22 ' CB ' ' A' ' 49' ' ' PHE . 22.9 t -67.47 161.44 3.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-O 121.667 0.746 . . . . 0.0 110.111 -178.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' THR . . . . . 1.054 HG22 ' HA3' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -141.08 160.63 39.68 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 119.76 -0.776 . . . . 0.0 108.93 178.668 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.487 ' HA ' HG12 ' A' ' 47' ' ' VAL . 19.5 ptmt -88.35 139.4 30.53 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.927 -1.108 . . . . 0.0 109.857 -179.642 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 59.7 tt0 -80.39 143.22 33.67 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.21 -0.931 . . . . 0.0 109.299 179.61 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 117.931 -1.033 . . . . 0.0 109.589 -179.968 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 121.29 0.567 . . . . 0.0 109.543 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.978 HD22 ' CE1' ' A' ' 49' ' ' PHE . 0.3 OUTLIER -116.69 163.08 16.66 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.264 -0.897 . . . . 0.0 108.712 179.719 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.543 ' N ' ' HG ' ' A' ' 2' ' ' LEU . 0.2 OUTLIER -113.37 162.02 16.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.18 -0.95 . . . . 0.0 110.045 -179.438 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.22 159.17 27.43 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.384 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.407 ' O ' ' C ' ' A' ' 6' ' ' VAL . 8.0 mtpt -133.66 112.46 11.45 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.304 -1.115 . . . . 0.0 109.111 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.53 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.6 t -42.45 139.36 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 122.796 1.284 . . . . 0.0 112.555 -178.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.483 ' HG3' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -98.43 -31.4 12.02 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 103.266 -2.864 . . . . 0.0 103.266 172.91 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.706 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 21.0 p-90 178.11 143.9 0.11 Allowed 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 177.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.573 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.9 OUTLIER -119.56 140.47 50.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.73 -1.231 . . . . 0.0 109.522 179.566 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.484 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.5 t-20 -131.43 38.13 3.63 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.454 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.2 p -37.36 -49.76 1.01 Allowed 'General case' 0 N--CA 1.492 1.629 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.886 -179.395 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -61.37 -44.66 96.78 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.284 -0.885 . . . . 0.0 109.91 -179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.479 ' CE ' ' OD1' ' A' ' 10' ' ' ASN . 0.4 OUTLIER -69.21 0.08 5.33 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.371 -0.831 . . . . 0.0 110.267 -179.554 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.508 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 102.46 12.09 34.09 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 119.935 -1.126 . . . . 0.0 112.635 178.329 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.649 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.0 OUTLIER 177.03 166.02 0.53 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-N 120.444 2.122 . . . . 0.0 112.215 179.543 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.654 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -146.74 137.03 6.49 Favored Glycine 0 N--CA 1.499 2.854 0 N-CA-C 106.671 -2.572 . . . . 0.0 106.671 179.342 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.706 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.9 m-30 -106.96 139.16 41.8 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.054 -1.85 . . . . 0.0 110.763 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.805 ' CD1' HG21 ' A' ' 47' ' ' VAL . 2.5 mt -108.21 151.65 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 177.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.509 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 9.1 tt0 -127.22 133.57 50.23 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.719 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.72 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.5 p -136.38 140.06 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 C-N-CA 117.792 -1.563 . . . . 0.0 111.772 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.8 140.13 58.38 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.121 179.771 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.42 -17.17 40.37 Favored Glycine 0 N--CA 1.486 1.967 0 N-CA-C 108.469 -1.853 . . . . 0.0 108.469 -178.868 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.72 ' HB2' HG13 ' A' ' 20' ' ' VAL . 3.1 mm-40 -136.85 -174.35 3.7 Favored 'General case' 0 N--CA 1.482 1.163 0 O-C-N 121.324 -1.104 . . . . 0.0 108.652 179.604 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.89 -165.93 1.26 Allowed 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.168 0.985 . . . . 0.0 110.657 -179.025 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.572 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 8.1 p-10 -72.09 106.96 4.53 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.011 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.84 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.4 t -71.17 117.36 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 120.483 -1.386 . . . . 0.0 111.298 178.863 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.613 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 3.8 t80 -67.47 130.6 43.58 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.497 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.699 HG11 HD12 ' A' ' 18' ' ' ILE . 2.4 m -139.11 131.8 37.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 120.476 -1.39 . . . . 0.0 110.715 -179.799 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.544 ' CE1' ' CE1' ' A' ' 30' ' ' PHE . 6.7 t60 -99.92 164.25 12.1 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.567 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 46.1 p90 -82.84 40.94 0.71 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.962 -1.086 . . . . 0.0 109.814 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.506 ' HA ' ' NE2' ' A' ' 34' ' ' GLN . 94.1 p -129.92 -38.56 1.45 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.858 -1.151 . . . . 0.0 109.711 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.729 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.78 -41.43 10.11 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 179.518 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.627 ' CG2' HD11 ' A' ' 41' ' ' LEU . 1.7 mp -56.34 -17.28 4.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.709 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.506 ' NE2' ' HA ' ' A' ' 31' ' ' SER . 4.5 pt20 -87.6 -171.8 3.61 Favored 'General case' 0 N--CA 1.493 1.711 0 C-N-CA 119.123 -1.031 . . . . 0.0 109.595 -179.579 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.52 -45.8 0.04 OUTLIER Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -105.04 66.47 0.76 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.273 -1.134 . . . . 0.0 109.448 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.71 -174.7 38.07 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -74.75 97.04 3.16 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.233 -1.157 . . . . 0.0 109.616 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.427 ' HD3' ' HE3' ' A' ' 65' ' ' LYS . 0.0 OUTLIER -102.79 169.94 8.3 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.264 -0.897 . . . . 0.0 109.474 179.913 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.517 ' OG1' ' N ' ' A' ' 41' ' ' LEU . 0.5 OUTLIER -128.48 -178.02 4.41 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.24 -0.913 . . . . 0.0 109.168 179.943 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.627 HD11 ' CG2' ' A' ' 33' ' ' ILE . 4.5 mp -141.35 142.46 33.79 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.124 -0.985 . . . . 0.0 109.59 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -105.29 158.88 16.31 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.3 -0.875 . . . . 0.0 109.276 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.485 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 9.6 tm-20 -55.71 148.22 16.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.126 -0.984 . . . . 0.0 109.498 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.485 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 79.66 1.84 87.3 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 108.819 -1.712 . . . . 0.0 108.819 -179.425 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.469 ' HA ' ' OE1' ' A' ' 45' ' ' GLN . 35.7 tp60 -75.72 134.14 40.58 Favored 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.324 -1.103 . . . . 0.0 110.532 -179.502 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -93.84 127.58 39.66 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 178.823 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.805 HG21 ' CD1' ' A' ' 18' ' ' ILE . 33.4 m -116.9 157.72 17.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.886 -1.134 . . . . 0.0 109.909 179.745 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 89.7 p -117.48 122.2 43.09 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.282 -0.887 . . . . 0.0 108.787 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.978 ' CE1' HD22 ' A' ' 2' ' ' LEU . 10.4 p90 -153.97 -177.51 6.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.02 -1.05 . . . . 0.0 109.726 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -128.15 102.24 6.62 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.083 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.84 HD11 ' CG2' ' A' ' 26' ' ' VAL . 4.9 mt -62.76 144.56 14.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 120.816 -1.177 . . . . 0.0 111.126 -179.385 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.556 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.7 m -131.2 -173.18 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 179.1 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -122.25 114.68 21.15 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.786 -1.196 . . . . 0.0 109.776 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.87 172.66 16.49 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -38.66 -53.72 1.61 Allowed 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.21 -1.171 . . . . 0.0 113.006 -178.659 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.462 ' NH1' ' CG ' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -68.77 -21.24 64.36 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 119.647 -1.908 . . . . 0.0 112.778 -177.85 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 138.46 -170.84 23.73 Favored Glycine 0 N--CA 1.491 2.353 0 O-C-N 120.345 -1.472 . . . . 0.0 109.618 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.556 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.8 Cg_endo -62.26 122.88 11.51 Favored 'Trans proline' 0 C--N 1.321 -0.877 0 C-N-CA 121.803 1.668 . . . . 0.0 109.875 178.767 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.474 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 4.5 mt-30 -144.2 148.45 34.97 Favored 'General case' 0 N--CA 1.5 2.07 0 O-C-N 121.189 -0.944 . . . . 0.0 111.097 -179.024 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.661 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -80.48 166.75 20.91 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.644 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.729 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.99 -43.32 0.73 Allowed 'General case' 0 N--CA 1.507 2.391 0 O-C-N 120.286 -1.509 . . . . 0.0 112.012 -177.123 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 31.6 t30 -119.66 51.88 1.14 Allowed 'General case' 0 C--N 1.287 -2.129 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.959 HG22 ' CB ' ' A' ' 49' ' ' PHE . 17.7 t -66.91 157.31 6.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.53 -179.351 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.413 HG22 ' H ' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -143.7 176.69 9.03 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 178.534 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.427 ' HE3' ' HD3' ' A' ' 39' ' ' LYS . 0.0 OUTLIER -82.68 142.98 31.26 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.035 -1.04 . . . . 0.0 109.318 179.945 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -54.69 102.15 0.06 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.202 -0.936 . . . . 0.0 109.536 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.658 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.49 179.999 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 32.5 mtp . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.158 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.53 176.21 8.97 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.365 -0.834 . . . . 0.0 109.981 179.541 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.91 ' OE2' ' HB1' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -112.74 158.79 19.65 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.032 -1.042 . . . . 0.0 110.929 -178.102 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.446 ' HA2' ' HB ' ' A' ' 20' ' ' VAL . . . -136.55 160.36 24.76 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.644 -1.782 . . . . 0.0 108.644 179.492 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.9 mtpt -134.45 116.27 14.94 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.083 -1.245 . . . . 0.0 110.618 -179.42 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.54 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.8 t -32.9 141.17 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 CA-C-O 123.015 1.388 . . . . 0.0 113.635 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.473 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 3.0 tmtt? -104.07 -32.18 9.32 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 102.979 -2.971 . . . . 0.0 102.979 172.221 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.696 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.0 p-90 175.56 147.56 0.09 Allowed 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 177.716 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.588 ' CB ' ' HB2' ' A' ' 41' ' ' LEU . 0.6 OUTLIER -114.47 140.09 49.0 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 120.441 -1.412 . . . . 0.0 109.305 178.994 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.565 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 79.5 m-20 -122.77 46.78 2.08 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.605 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.953 ' OG ' HD22 ' A' ' 41' ' ' LEU . 0.1 OUTLIER -43.76 -35.34 1.83 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 -179.315 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -59.7 -48.86 79.99 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.467 -0.771 . . . . 0.0 110.009 179.769 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.52 ' O ' ' CE2' ' A' ' 15' ' ' PHE . 13.2 mptt -76.74 11.8 1.56 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.26 -0.9 . . . . 0.0 110.201 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.436 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 84.6 20.81 57.67 Favored Glycine 0 N--CA 1.488 2.118 0 O-C-N 121.093 -1.004 . . . . 0.0 111.661 178.751 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.52 ' CE2' ' O ' ' A' ' 13' ' ' LYS . 36.1 p90 179.6 167.05 1.15 Allowed 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 119.983 1.892 . . . . 0.0 112.031 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.548 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -142.46 149.31 21.14 Favored Glycine 0 N--CA 1.498 2.784 0 N-CA-C 106.937 -2.465 . . . . 0.0 106.937 178.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.696 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -106.26 143.58 34.18 Favored 'General case' 0 N--CA 1.484 1.269 0 CA-C-N 119.836 1.818 . . . . 0.0 110.302 -178.4 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.999 HD12 HG12 ' A' ' 28' ' ' VAL . 0.9 OUTLIER -106.61 161.49 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 178.916 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.572 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 2.9 tp10 -142.66 130.02 21.11 Favored 'General case' 0 C--N 1.29 -2.018 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 177.781 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.773 HG13 ' HB2' ' A' ' 23' ' ' GLN . 13.0 p -135.99 140.56 43.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 117.485 -1.686 . . . . 0.0 111.729 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -65.36 140.62 58.67 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.052 179.791 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.22 -12.85 48.51 Favored Glycine 0 N--CA 1.487 2.049 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -178.887 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.773 ' HB2' HG13 ' A' ' 20' ' ' VAL . 6.1 mm-40 -140.75 -176.57 4.71 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 121.345 -1.091 . . . . 0.0 108.322 179.612 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.49 -165.79 1.25 Allowed 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.18 -0.95 . . . . 0.0 110.806 -179.091 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.588 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 11.6 p-10 -72.57 129.9 39.37 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.05 179.339 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.896 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.5 t -98.55 121.4 49.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 120.802 -1.186 . . . . 0.0 110.81 178.252 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.504 ' HB2' ' HG2' ' A' ' 59' ' ' GLN . 23.0 t80 -58.11 137.28 57.08 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.079 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.999 HG12 HD12 ' A' ' 18' ' ' ILE . 1.2 m -131.14 115.65 30.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 120.781 -1.199 . . . . 0.0 110.348 -178.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.406 ' O ' HD12 ' A' ' 33' ' ' ILE . 7.8 t-160 -104.66 148.9 26.05 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.442 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.521 ' CD1' ' C ' ' A' ' 30' ' ' PHE . 0.0 OUTLIER -81.16 31.63 0.33 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.816 -1.177 . . . . 0.0 110.486 -179.68 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -125.35 -35.21 2.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.13 -0.981 . . . . 0.0 108.544 178.724 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.763 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.37 -35.68 14.26 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.817 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.942 HD11 ' HB ' ' A' ' 28' ' ' VAL . 63.0 mt -68.5 -5.66 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.473 ' O ' ' O ' ' A' ' 33' ' ' ILE . 0.0 OUTLIER -52.57 -167.07 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 CA-C-O 121.562 0.696 . . . . 0.0 110.159 -179.69 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 153.77 -169.72 32.42 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.702 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -81.36 74.24 8.36 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.059 -1.26 . . . . 0.0 109.571 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 176.22 -169.71 42.37 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -78.1 139.76 39.05 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.311 -1.111 . . . . 0.0 109.853 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.476 ' O ' ' HB ' ' A' ' 40' ' ' THR . 0.4 OUTLIER -110.29 136.12 49.97 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.334 -0.854 . . . . 0.0 109.411 179.82 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.476 ' HB ' ' O ' ' A' ' 39' ' ' LYS . 6.6 t 179.92 -170.67 0.15 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.999 -1.063 . . . . 0.0 109.897 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.953 HD22 ' OG ' ' A' ' 11' ' ' SER . 1.3 pt? -109.88 158.28 18.35 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.523 -0.735 . . . . 0.0 109.959 -179.29 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.439 ' OE1' ' N ' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -175.09 138.59 0.44 Allowed 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.491 -0.755 . . . . 0.0 109.116 179.524 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.439 ' N ' ' OE1' ' A' ' 42' ' ' GLU . 9.1 tm-20 -74.33 146.37 43.14 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.284 -0.885 . . . . 0.0 108.961 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 77.14 5.31 85.01 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 108.706 -1.757 . . . . 0.0 108.706 -178.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 47.5 tt0 -68.43 111.77 4.87 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 121.499 -1.001 . . . . 0.0 110.003 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.91 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . -91.9 124.92 36.38 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 178.866 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.726 HG21 HD11 ' A' ' 18' ' ' ILE . 28.8 m -119.66 163.9 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.879 -1.138 . . . . 0.0 110.469 -179.165 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.1 p -115.55 126.03 53.73 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.064 -1.023 . . . . 0.0 108.294 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.158 ' CE1' HD11 ' A' ' 2' ' ' LEU . 8.2 p90 -153.28 -179.41 7.7 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.043 -1.035 . . . . 0.0 109.83 -179.325 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -124.29 92.64 3.71 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.31 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.896 HD11 ' CG2' ' A' ' 26' ' ' VAL . 17.0 mt -61.49 132.79 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 CA-C-O 122.271 1.034 . . . . 0.0 110.338 -179.161 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.547 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.2 m -116.44 -174.46 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 178.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.423 ' CD ' ' N ' ' A' ' 53' ' ' GLU . 0.4 OUTLIER -123.72 114.33 19.81 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.001 -1.062 . . . . 0.0 109.331 179.79 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.72 175.57 18.65 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -37.92 -52.63 1.35 Allowed 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.499 -1.001 . . . . 0.0 113.548 -178.508 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.3 mmm180 -76.07 23.09 0.14 Allowed 'General case' 0 N--CA 1.5 2.036 0 O-C-N 119.807 -1.808 . . . . 0.0 112.137 -178.216 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.28 -174.78 35.62 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.547 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.2 Cg_endo -65.53 150.19 86.91 Favored 'Trans proline' 0 C--N 1.319 -0.997 0 C-N-CA 121.636 1.558 . . . . 0.0 109.791 178.871 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.504 ' HG2' ' HB2' ' A' ' 27' ' ' PHE . 1.4 mt-30 -165.58 150.31 8.69 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 120.97 -1.082 . . . . 0.0 111.521 -179.433 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.814 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.76 157.75 23.12 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 177.613 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.763 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.92 -41.49 0.75 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 120.52 -1.362 . . . . 0.0 111.578 -176.769 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.1 m-20 -119.9 57.18 0.93 Allowed 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 179.618 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.88 HG22 ' CB ' ' A' ' 49' ' ' PHE . 18.6 t -72.43 166.3 2.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.103 -178.629 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.534 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -148.1 176.27 10.34 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.669 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.471 ' O ' ' HG2' ' A' ' 65' ' ' LYS . 0.0 OUTLIER -85.54 133.38 34.07 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.052 -1.03 . . . . 0.0 109.672 179.916 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.491 ' HB3' ' O ' ' A' ' 46' ' ' ALA . 13.9 tp10 -82.31 84.67 7.04 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.147 -0.971 . . . . 0.0 109.607 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.452 179.975 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.171 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.61 174.18 10.77 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.257 -0.902 . . . . 0.0 110.119 179.688 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.744 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -113.24 155.62 24.75 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.207 -0.933 . . . . 0.0 110.007 -179.175 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.415 ' C ' ' HG2' ' A' ' 5' ' ' LYS . . . -133.28 161.95 24.25 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.436 ' O ' ' C ' ' A' ' 6' ' ' VAL . 4.0 mttp -130.24 115.5 17.06 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.209 -1.171 . . . . 0.0 109.887 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.537 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.4 t -36.87 140.44 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 122.869 1.319 . . . . 0.0 112.758 -179.577 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.5 tmtt? -99.41 -31.81 11.47 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 103.042 -2.947 . . . . 0.0 103.042 172.8 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.701 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 21.5 p-90 176.65 144.14 0.08 Allowed 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 177.741 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.764 ' CE1' HD22 ' A' ' 41' ' ' LEU . 0.7 OUTLIER -119.06 141.48 48.7 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.48 -1.387 . . . . 0.0 109.435 179.531 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.499 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.2 t-20 -130.93 37.72 3.75 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.45 ' C ' ' O ' ' A' ' 10' ' ' ASN . 15.3 p -37.79 -47.41 1.01 Allowed 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.493 0.663 . . . . 0.0 109.297 -179.682 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -61.12 -46.36 90.92 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.432 -0.792 . . . . 0.0 109.877 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.473 ' HB2' ' CG ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -69.26 0.49 4.84 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.403 -0.811 . . . . 0.0 110.256 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.411 ' O ' ' CB ' ' A' ' 15' ' ' PHE . . . 99.38 15.48 32.33 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 120.001 -1.095 . . . . 0.0 112.399 178.624 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.436 ' O ' ' C ' ' A' ' 10' ' ' ASN . 1.0 OUTLIER 175.53 163.09 0.3 Allowed 'General case' 0 N--CA 1.497 1.917 0 CA-C-N 120.299 2.05 . . . . 0.0 111.849 179.561 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.672 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -146.31 139.99 8.49 Favored Glycine 0 N--CA 1.498 2.832 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.701 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.4 m-85 -108.77 144.11 37.03 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.209 -1.759 . . . . 0.0 110.422 -178.646 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.724 HD12 HG21 ' A' ' 28' ' ' VAL . 0.5 OUTLIER -106.31 165.42 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 178.471 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.589 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 1.9 tt0 -141.8 127.77 19.48 Favored 'General case' 0 C--N 1.291 -1.967 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.155 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.751 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.8 p -134.2 141.47 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 C-N-CA 117.446 -1.701 . . . . 0.0 111.851 -179.463 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -63.8 140.14 58.84 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.259 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 82.21 -12.62 43.54 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 -179.118 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.751 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.1 OUTLIER -137.57 -176.33 4.37 Favored 'General case' 0 N--CA 1.484 1.247 0 O-C-N 121.303 -1.116 . . . . 0.0 108.669 179.696 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -100.29 -166.1 1.29 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.271 -0.893 . . . . 0.0 110.505 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.601 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 34.7 p-10 -71.68 122.21 20.2 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.849 179.366 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.87 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.3 t -84.76 104.46 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 120.592 -1.317 . . . . 0.0 111.687 178.733 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.62 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 2.1 t80 -55.44 135.1 50.71 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 178.244 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.724 HG21 HD12 ' A' ' 18' ' ' ILE . 2.3 m -150.19 127.26 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 118.067 -1.453 . . . . 0.0 111.641 -179.336 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.624 ' NE2' ' CE1' ' A' ' 30' ' ' PHE . 7.7 t-160 -99.32 162.12 13.22 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 178.659 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.624 ' CE1' ' NE2' ' A' ' 29' ' ' HIS . 52.6 p90 -81.26 39.34 0.51 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.498 -1.376 . . . . 0.0 110.435 -179.432 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.7 t -123.48 -46.5 2.02 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.698 -1.251 . . . . 0.0 109.564 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.741 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.0 -40.56 11.59 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.328 -0.857 . . . . 0.0 108.74 179.57 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.714 HG23 ' HB ' ' A' ' 63' ' ' VAL . 2.9 mp -81.08 1.78 2.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 CA-C-O 121.703 0.763 . . . . 0.0 109.262 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -78.67 -167.55 1.13 Allowed 'General case' 0 C--N 1.297 -1.698 0 CA-C-O 121.433 0.635 . . . . 0.0 109.961 -179.272 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.69 177.91 32.56 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -68.27 128.63 37.29 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.207 -1.172 . . . . 0.0 109.835 -179.725 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.86 169.01 28.5 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -75.02 85.16 2.29 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.305 -1.115 . . . . 0.0 109.418 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.5 mttp -104.65 -169.83 1.67 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.298 -0.876 . . . . 0.0 110.011 -179.628 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.8 t -176.41 178.95 1.26 Allowed 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.865 HD21 HG11 ' A' ' 47' ' ' VAL . 0.3 OUTLIER -118.6 118.21 31.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.896 -1.128 . . . . 0.0 109.818 -179.755 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 9.9 tt0 -94.84 151.12 19.49 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.374 -0.829 . . . . 0.0 109.051 179.541 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.437 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 8.6 tm-20 -51.85 145.88 9.08 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.148 -0.97 . . . . 0.0 109.412 -179.797 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.437 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 77.58 3.51 83.24 Favored Glycine 0 N--CA 1.487 2.076 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 -179.597 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.553 ' NE2' ' O ' ' A' ' 46' ' ' ALA . 35.9 tp60 -75.98 133.79 40.35 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.274 -1.133 . . . . 0.0 110.732 -179.457 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.553 ' O ' ' NE2' ' A' ' 45' ' ' GLN . . . -94.44 128.65 41.13 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.553 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.865 HG11 HD21 ' A' ' 41' ' ' LEU . 35.9 m -119.32 160.37 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.851 -1.155 . . . . 0.0 109.945 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 49.0 p -115.14 132.0 56.74 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 120.968 -1.083 . . . . 0.0 108.495 179.485 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.171 ' CE1' HD11 ' A' ' 2' ' ' LEU . 10.5 p90 -164.28 -176.56 4.49 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.973 -1.079 . . . . 0.0 109.988 -179.439 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.07 98.32 4.89 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.19 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.87 HD11 ' CG2' ' A' ' 26' ' ' VAL . 7.2 mt -62.67 141.3 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 120.827 -1.171 . . . . 0.0 110.873 -179.222 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.521 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 8.7 m -124.76 -175.35 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.487 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -123.08 115.26 21.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.935 -1.103 . . . . 0.0 109.772 -179.736 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.52 168.93 18.53 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 37.4 m-20 -37.84 -52.37 1.31 Allowed 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.329 -1.101 . . . . 0.0 113.634 -178.541 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.96 22.31 0.19 Allowed 'General case' 0 N--CA 1.5 2.062 0 O-C-N 119.777 -1.827 . . . . 0.0 112.414 -177.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.95 -179.39 28.72 Favored Glycine 0 N--CA 1.494 2.501 0 O-C-N 120.393 -1.442 . . . . 0.0 110.588 179.312 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.521 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.8 Cg_endo -68.77 142.23 51.88 Favored 'Trans proline' 0 C--N 1.321 -0.908 0 C-N-CA 122.225 1.95 . . . . 0.0 110.085 178.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.528 ' HG2' ' CB ' ' A' ' 27' ' ' PHE . 22.5 mt-30 -156.52 149.36 23.87 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.048 -1.032 . . . . 0.0 111.558 -179.568 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.77 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -80.41 161.63 24.86 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.481 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.741 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.92 -41.57 0.75 Allowed 'General case' 0 N--CA 1.508 2.426 0 O-C-N 120.458 -1.401 . . . . 0.0 111.972 -176.358 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.513 ' O ' ' ND2' ' A' ' 62' ' ' ASN . 0.2 OUTLIER -120.57 50.75 1.29 Allowed 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 179.91 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.958 HG22 ' CB ' ' A' ' 49' ' ' PHE . 14.9 t -68.18 171.33 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-O 121.814 0.816 . . . . 0.0 109.501 -179.532 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.578 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -153.62 172.19 17.61 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 177.908 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.3 tmtt? -83.75 129.28 34.95 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.696 -1.252 . . . . 0.0 109.379 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -87.93 135.38 33.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.302 -0.874 . . . . 0.0 109.53 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 117.925 -1.036 . . . . 0.0 109.558 -179.988 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 19.9 ttt . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.414 0.626 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.214 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -115.83 174.59 5.95 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.35 -0.844 . . . . 0.0 109.715 179.751 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.567 ' N ' HD22 ' A' ' 2' ' ' LEU . 0.4 OUTLIER -117.65 135.32 54.07 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 120.817 -1.177 . . . . 0.0 110.794 -179.263 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.415 ' C ' ' HG2' ' A' ' 5' ' ' LYS . . . -103.2 173.68 22.48 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.825 -1.71 . . . . 0.0 108.825 178.789 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.415 ' HG2' ' C ' ' A' ' 4' ' ' GLY . 3.4 mtpp -137.37 112.77 9.31 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 120.781 -1.423 . . . . 0.0 109.955 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.808 ' HB ' ' O ' ' A' ' 43' ' ' GLU . 2.5 t -47.88 131.77 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 CA-C-O 122.688 1.233 . . . . 0.0 112.645 -179.811 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 2.0 tttt -93.12 -30.39 15.28 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 103.213 -2.884 . . . . 0.0 103.213 173.496 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.718 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 25.1 p-90 175.28 146.57 0.08 Allowed 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 106.617 -1.624 . . . . 0.0 106.617 178.452 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.554 ' CB ' ' HA ' ' A' ' 42' ' ' GLU . 0.5 OUTLIER -112.45 147.27 36.85 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.724 -1.235 . . . . 0.0 108.773 178.517 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.556 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 10.8 m-20 -130.05 42.84 3.22 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.203 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.456 ' OG ' HG22 ' A' ' 40' ' ' THR . 54.1 p -40.89 -40.0 1.27 Allowed 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -179.676 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.0 mm-40 -59.86 -49.33 78.11 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.665 -0.647 . . . . 0.0 110.487 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.529 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 1.4 mptp? -74.5 6.09 4.1 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.097 -1.002 . . . . 0.0 110.038 -179.798 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.468 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 90.76 20.33 40.62 Favored Glycine 0 N--CA 1.49 2.246 0 O-C-N 121.133 -0.979 . . . . 0.0 112.066 178.582 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.516 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 39.8 p90 178.9 170.29 0.88 Allowed 'General case' 0 N--CA 1.499 1.994 0 CA-C-N 120.0 1.9 . . . . 0.0 111.762 179.467 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.572 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -145.3 152.34 24.42 Favored Glycine 0 N--CA 1.499 2.891 0 N-CA-C 106.864 -2.495 . . . . 0.0 106.864 179.192 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.718 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.6 m-85 -113.14 135.36 53.89 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 120.28 2.04 . . . . 0.0 110.216 -178.786 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.963 HD12 ' CG1' ' A' ' 28' ' ' VAL . 2.8 mt -108.61 146.37 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.37 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.546 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 27.6 tt0 -125.52 135.87 52.73 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 177.648 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.602 HG13 ' HB2' ' A' ' 23' ' ' GLN . 10.9 p -137.37 139.64 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 C-N-CA 117.675 -1.61 . . . . 0.0 111.905 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -64.17 140.39 58.86 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.088 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 84.08 -15.06 40.69 Favored Glycine 0 N--CA 1.485 1.953 0 N-CA-C 108.684 -1.767 . . . . 0.0 108.684 -178.924 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.634 ' NE2' HG21 ' A' ' 51' ' ' ILE . 0.2 OUTLIER -136.95 -174.67 3.79 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 121.299 -1.118 . . . . 0.0 108.682 179.46 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.421 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 4.5 m-20 -100.79 -166.4 1.31 Allowed 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 122.073 0.94 . . . . 0.0 110.71 -179.171 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.546 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 8.1 p-10 -72.3 101.83 2.97 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.92 179.09 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.791 HG13 ' H ' ' A' ' 60' ' ' ALA . 2.6 t -68.15 126.28 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 120.252 -1.53 . . . . 0.0 110.124 178.514 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.433 ' HB3' ' HG2' ' A' ' 59' ' ' GLN . 16.6 t80 -65.46 142.09 58.28 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 177.81 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.977 ' HB ' HD11 ' A' ' 33' ' ' ILE . 1.4 m -134.09 156.73 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.735 -1.228 . . . . 0.0 110.345 -178.598 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.524 ' CE1' ' CE2' ' A' ' 30' ' ' PHE . 16.7 t-80 -138.42 157.92 45.27 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.093 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.607 ' CE1' ' HB2' ' A' ' 38' ' ' PHE . 53.1 p90 -85.02 32.74 0.53 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.145 -0.972 . . . . 0.0 109.769 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.4 p -127.91 -35.48 2.07 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.832 -1.168 . . . . 0.0 109.773 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.755 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -93.04 -50.16 5.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.232 -0.917 . . . . 0.0 108.988 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.977 HD11 ' HB ' ' A' ' 28' ' ' VAL . 41.0 mt -53.09 -22.52 4.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-O 121.819 0.819 . . . . 0.0 109.047 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -112.24 -167.27 1.16 Allowed 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.601 -0.687 . . . . 0.0 109.968 -179.773 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -145.54 -38.04 0.06 OUTLIER Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 179.542 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.465 ' O ' ' O ' ' A' ' 37' ' ' GLY . 5.8 mt-10 -76.84 -170.01 1.47 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.256 -1.143 . . . . 0.0 109.771 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 36' ' ' GLU . . . -43.86 170.55 0.01 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 -179.799 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.607 ' HB2' ' CE1' ' A' ' 30' ' ' PHE . 50.1 p90 -74.5 118.02 16.98 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.397 -1.06 . . . . 0.0 110.124 -179.713 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 5.3 mmmt -111.09 160.38 16.94 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.258 -0.901 . . . . 0.0 109.335 179.383 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.456 HG22 ' OG ' ' A' ' 11' ' ' SER . 2.6 p -119.56 114.23 21.93 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.129 -0.982 . . . . 0.0 109.151 179.679 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -151.9 166.87 30.12 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.177 -1.577 . . . . 0.0 110.016 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.554 ' HA ' ' CB ' ' A' ' 9' ' ' PHE . 3.3 mp0 -101.29 98.85 9.18 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 178.075 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.808 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 1.1 tp10 -76.57 44.3 0.35 Allowed 'General case' 0 N--CA 1.501 2.118 0 N-CA-C 115.233 1.568 . . . . 0.0 115.233 -176.552 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.626 ' HA2' ' CG1' ' A' ' 6' ' ' VAL . . . -45.91 -14.93 0.09 OUTLIER Glycine 0 N--CA 1.505 3.239 0 CA-C-N 119.978 1.263 . . . . 0.0 110.684 177.397 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.526 ' N ' ' O ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -75.41 -177.36 3.54 Favored 'General case' 0 C--N 1.288 -2.071 0 O-C-N 121.564 -0.962 . . . . 0.0 110.033 -179.598 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.483 ' O ' ' HB2' ' A' ' 66' ' ' GLU . . . -91.83 144.67 25.26 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.826 0.822 . . . . 0.0 110.055 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 18.6 m -122.74 165.91 18.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 121.262 -0.899 . . . . 0.0 108.687 179.091 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -117.68 120.23 37.35 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.854 -1.154 . . . . 0.0 109.163 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.214 ' CE1' HD11 ' A' ' 2' ' ' LEU . 5.6 p90 -149.46 -178.17 6.27 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.165 -0.959 . . . . 0.0 109.978 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.495 ' CG ' ' O ' ' A' ' 50' ' ' GLU . 0.3 OUTLIER -126.47 95.11 4.25 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.376 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.784 HD11 ' CG2' ' A' ' 26' ' ' VAL . 11.3 mt -61.91 140.1 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 CA-C-O 122.513 1.149 . . . . 0.0 111.175 -178.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 12.0 m -124.57 -177.17 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 106.064 -1.828 . . . . 0.0 106.064 179.166 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -123.32 111.95 17.02 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 118.885 -1.126 . . . . 0.0 109.642 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -116.84 169.86 13.21 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 73.1 m-20 -38.23 -52.68 1.48 Allowed 'General case' 0 N--CA 1.504 2.268 0 O-C-N 121.302 -1.116 . . . . 0.0 113.723 -178.575 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -78.1 22.02 0.32 Allowed 'General case' 0 N--CA 1.5 2.074 0 O-C-N 119.62 -1.925 . . . . 0.0 112.524 -177.564 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.65 -178.02 24.89 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 119.17 -1.491 . . . . 0.0 110.628 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.489 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.3 Cg_endo -66.1 153.02 79.75 Favored 'Trans proline' 0 C--N 1.321 -0.905 0 C-N-CA 122.277 1.984 . . . . 0.0 110.529 179.21 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.433 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 0.2 OUTLIER -165.85 147.52 7.09 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.419 -0.8 . . . . 0.0 110.631 -179.758 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.791 ' H ' HG13 ' A' ' 26' ' ' VAL . . . -83.07 163.9 20.63 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 177.205 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.755 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.17 -44.05 0.78 Allowed 'General case' 0 N--CA 1.507 2.387 0 O-C-N 120.201 -1.562 . . . . 0.0 111.909 -176.869 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -119.77 52.11 1.13 Allowed 'General case' 0 C--N 1.287 -2.148 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.92 HG22 ' CB ' ' A' ' 49' ' ' PHE . 20.8 t -66.09 163.1 2.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-O 121.74 0.781 . . . . 0.0 110.554 -179.035 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.527 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -145.06 179.29 7.46 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 177.9 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -89.11 134.07 34.14 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.842 -1.161 . . . . 0.0 109.657 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.483 ' HB2' ' O ' ' A' ' 46' ' ' ALA . 2.7 tt0 -59.58 148.48 33.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.116 -0.99 . . . . 0.0 109.301 179.84 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.45 ' N ' ' HG2' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.401 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 76.4 mtp . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.182 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.5 172.64 12.44 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.125 -0.984 . . . . 0.0 110.301 179.806 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.62 ' N ' HD22 ' A' ' 2' ' ' LEU . 2.2 tt0 -113.74 144.68 42.56 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.303 -0.873 . . . . 0.0 110.174 -179.253 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.43 ' HA3' HG21 ' A' ' 18' ' ' ILE . . . -112.7 161.52 12.67 Favored Glycine 0 N--CA 1.483 1.811 0 N-CA-C 108.514 -1.835 . . . . 0.0 108.514 178.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.448 ' O ' ' C ' ' A' ' 6' ' ' VAL . 9.3 mttm -131.74 113.76 13.93 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.187 -1.184 . . . . 0.0 109.754 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.536 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.6 t -33.72 139.62 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 CA-C-O 122.91 1.338 . . . . 0.0 113.636 -179.675 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.461 ' HG2' ' CB ' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -103.92 -32.07 9.45 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 103.108 -2.923 . . . . 0.0 103.108 172.183 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.704 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 18.9 p-90 174.82 147.38 0.07 Allowed 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 106.315 -1.735 . . . . 0.0 106.315 177.803 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.841 ' HB3' HD13 ' A' ' 41' ' ' LEU . 0.4 OUTLIER -113.52 145.32 41.39 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 120.263 -1.523 . . . . 0.0 109.325 178.95 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.557 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 49.7 m-20 -130.11 41.84 3.36 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 178.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.454 ' HB3' HD23 ' A' ' 41' ' ' LEU . 62.0 p -40.98 -43.65 2.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.671 -0.643 . . . . 0.0 109.518 -179.16 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 60.4 mm-40 -61.62 -45.41 94.21 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.307 -0.871 . . . . 0.0 109.718 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.509 ' N ' ' CD ' ' A' ' 13' ' ' LYS . 0.2 OUTLIER -72.39 4.73 3.47 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.531 -0.731 . . . . 0.0 110.469 -179.66 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.486 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 93.34 19.88 34.23 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 120.053 -1.07 . . . . 0.0 112.236 178.372 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.513 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 0.8 OUTLIER 169.87 171.69 0.06 Allowed 'General case' 0 N--CA 1.498 1.958 0 CA-C-N 120.074 1.937 . . . . 0.0 111.641 179.401 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.848 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -143.6 151.85 23.66 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 106.889 -2.484 . . . . 0.0 106.889 178.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.704 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.6 m-85 -112.65 140.6 47.27 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 119.854 -1.968 . . . . 0.0 110.152 -178.817 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.929 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.2 mt -106.86 155.95 7.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 179.385 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.508 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 13.0 tt0 -132.31 133.15 43.71 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.797 HG13 ' HB2' ' A' ' 23' ' ' GLN . 14.8 p -132.94 141.04 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 C-N-CA 117.879 -1.528 . . . . 0.0 111.666 -179.606 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -64.52 140.39 58.86 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.4 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.57 -6.22 47.18 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.797 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -140.54 -175.57 4.32 Favored 'General case' 0 C--N 1.309 -1.159 0 O-C-N 121.08 -1.247 . . . . 0.0 108.706 179.789 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.41 -166.97 1.38 Allowed 'General case' 0 C--N 1.297 -1.705 0 CA-C-O 122.151 0.977 . . . . 0.0 110.866 -179.032 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.596 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 5.6 p-10 -71.92 113.02 8.52 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.31 179.486 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.972 HG21 ' CZ ' ' A' ' 49' ' ' PHE . 2.5 t -79.41 114.82 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 120.463 -1.398 . . . . 0.0 110.742 178.49 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.526 ' HB2' ' HG2' ' A' ' 59' ' ' GLN . 31.5 t80 -49.62 146.24 4.39 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 178.403 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.929 ' CG1' HD12 ' A' ' 18' ' ' ILE . 1.2 m -139.21 157.57 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 O-C-N 120.801 -1.187 . . . . 0.0 109.24 -179.443 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.486 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 5.5 t60 -158.42 155.15 28.1 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.406 ' N ' ' CD2' ' A' ' 29' ' ' HIS . 33.5 p90 -79.58 26.34 0.31 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.931 -1.106 . . . . 0.0 110.235 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.3 p -116.35 -47.82 2.73 Favored 'General case' 0 N--CA 1.483 1.218 0 O-C-N 120.839 -1.163 . . . . 0.0 108.909 179.686 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.711 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.51 -47.53 7.09 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.948 HD13 ' HB ' ' A' ' 63' ' ' VAL . 10.1 mm -49.56 -25.22 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.523 ' CG ' ' HB2' ' A' ' 39' ' ' LYS . 0.0 OUTLIER -111.15 -167.33 1.17 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.638 -0.664 . . . . 0.0 109.684 -179.777 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.429 ' H ' ' NE2' ' A' ' 34' ' ' GLN . . . 173.91 -45.27 0.15 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 179.826 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -105.35 74.86 1.12 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.213 -1.169 . . . . 0.0 110.264 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.441 ' O ' ' NE2' ' A' ' 34' ' ' GLN . . . 104.72 161.96 24.06 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 179.137 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -85.77 114.74 22.95 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.244 -1.151 . . . . 0.0 109.67 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.523 ' HB2' ' CG ' ' A' ' 34' ' ' GLN . 0.1 OUTLIER -98.55 -169.67 1.83 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.327 179.727 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.524 ' OG1' ' N ' ' A' ' 41' ' ' LEU . 0.5 OUTLIER -135.46 -174.79 3.73 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.241 -0.912 . . . . 0.0 109.32 -179.758 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.841 HD13 ' HB3' ' A' ' 9' ' ' PHE . 2.1 pp -110.54 159.62 17.37 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.285 -0.884 . . . . 0.0 110.626 -178.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.483 ' O ' ' HB2' ' A' ' 45' ' ' GLN . 9.3 tt0 -166.98 126.38 1.44 Allowed 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 178.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.408 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 5.5 tm-20 -48.35 146.78 2.64 Favored 'General case' 0 C--N 1.295 -1.803 0 C-N-CA 119.596 -0.841 . . . . 0.0 108.963 -179.357 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.408 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 84.52 -1.05 89.16 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 109.037 -1.625 . . . . 0.0 109.037 -179.142 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.507 ' NE2' ' HE3' ' A' ' 65' ' ' LYS . 18.7 tt0 -58.88 112.13 1.54 Allowed 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.372 -1.075 . . . . 0.0 110.039 -179.834 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -91.86 122.89 34.81 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 178.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.506 ' O ' ' HG2' ' A' ' 3' ' ' GLU . 33.3 m -117.92 162.68 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 120.819 -1.176 . . . . 0.0 111.026 -178.778 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -118.49 117.7 29.71 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.615 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.182 ' CE1' HD11 ' A' ' 2' ' ' LEU . 6.0 p90 -148.76 -177.73 5.95 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.093 -1.004 . . . . 0.0 110.008 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -128.91 96.87 4.47 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 179.268 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.867 HD11 ' CG2' ' A' ' 26' ' ' VAL . 10.7 mt -61.63 139.22 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.874 -1.141 . . . . 0.0 110.387 -179.218 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 2.7 m -127.19 -172.48 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -124.0 118.01 26.04 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.985 -1.072 . . . . 0.0 109.489 179.561 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -129.27 174.67 19.18 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.139 -1.584 . . . . 0.0 109.139 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -38.81 -52.99 1.72 Allowed 'General case' 0 N--CA 1.506 2.329 0 O-C-N 121.414 -1.051 . . . . 0.0 113.67 -178.565 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 29.0 mtp180 -77.91 22.45 0.28 Allowed 'General case' 0 N--CA 1.497 1.924 0 O-C-N 119.688 -1.883 . . . . 0.0 112.217 -177.886 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.54 -177.72 30.92 Favored Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.364 -1.398 . . . . 0.0 110.285 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.527 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -66.09 146.66 82.65 Favored 'Trans proline' 0 C--N 1.319 -0.981 0 C-N-CA 122.069 1.846 . . . . 0.0 110.065 178.948 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.526 ' HG2' ' HB2' ' A' ' 27' ' ' PHE . 0.4 OUTLIER -165.63 153.8 11.18 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.105 -0.997 . . . . 0.0 111.601 -179.35 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.771 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.12 159.45 23.36 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 177.107 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.711 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.28 -41.03 0.73 Allowed 'General case' 0 N--CA 1.508 2.432 0 O-C-N 120.288 -1.508 . . . . 0.0 111.97 -176.36 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.0 p30 -119.39 51.89 1.12 Allowed 'General case' 0 C--N 1.283 -2.294 0 N-CA-C 106.689 -1.596 . . . . 0.0 106.689 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.96 HG22 ' CB ' ' A' ' 49' ' ' PHE . 19.2 t -69.52 156.49 7.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.556 -179.13 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.436 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.9 OUTLIER -136.32 167.36 21.46 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.684 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.507 ' HE3' ' NE2' ' A' ' 45' ' ' GLN . 17.4 mttp -89.46 127.96 35.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.002 -1.061 . . . . 0.0 109.518 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -71.06 85.01 0.71 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.214 -0.929 . . . . 0.0 109.473 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.488 0 CA-C-O 118.059 -0.972 . . . . 0.0 109.546 -179.974 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.426 ' HG3' ' O ' ' A' ' 1' ' ' MET . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 . . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.004 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -117.34 173.65 6.57 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.226 -0.921 . . . . 0.0 110.313 -179.853 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.841 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.5 OUTLIER -114.07 162.84 15.96 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.057 -1.027 . . . . 0.0 109.386 -179.87 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -158.26 174.64 35.47 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -141.81 130.89 23.27 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.099 -1.236 . . . . 0.0 111.384 -179.293 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.588 ' HA ' ' HA ' ' A' ' 18' ' ' ILE . 2.8 t -37.57 138.52 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 122.82 1.295 . . . . 0.0 113.312 179.366 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.432 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -97.09 -29.29 13.7 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 102.992 -2.966 . . . . 0.0 102.992 172.452 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.7 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 19.8 p-90 178.27 145.97 0.14 Allowed 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 106.068 -1.827 . . . . 0.0 106.068 177.888 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.559 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.6 OUTLIER -120.28 142.54 48.98 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.533 -1.355 . . . . 0.0 109.848 179.767 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.508 ' OD1' ' CD ' ' A' ' 13' ' ' LYS . 0.5 OUTLIER -130.57 38.34 3.74 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 179.004 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 10' ' ' ASN . 11.1 p -39.15 -44.56 1.2 Allowed 'General case' 0 C--N 1.299 -1.595 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.068 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 47.2 mm-40 -61.43 -46.83 88.44 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.437 -0.789 . . . . 0.0 109.847 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.508 ' CD ' ' OD1' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -69.61 1.41 4.17 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.396 -0.815 . . . . 0.0 110.184 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.585 ' O ' ' CD2' ' A' ' 29' ' ' HIS . . . 99.04 12.35 43.12 Favored Glycine 0 N--CA 1.49 2.253 0 C-N-CA 120.152 -1.023 . . . . 0.0 112.325 178.505 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.462 ' HB3' ' O ' ' A' ' 14' ' ' GLY . 38.1 p90 179.95 163.75 1.09 Allowed 'General case' 0 N--CA 1.497 1.889 0 CA-C-N 120.269 2.035 . . . . 0.0 111.678 179.237 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.559 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -145.53 143.22 11.48 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 107.296 -2.322 . . . . 0.0 107.296 179.466 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.7 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.29 143.71 36.78 Favored 'General case' 0 N--CA 1.48 1.045 0 O-C-N 120.24 -1.741 . . . . 0.0 110.19 -178.67 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.014 HD12 HG21 ' A' ' 28' ' ' VAL . 0.3 OUTLIER -105.45 164.33 4.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 N-CA-C 104.985 -2.228 . . . . 0.0 104.985 177.583 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.554 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 12.1 tp10 -130.3 129.65 43.49 Favored 'General case' 0 C--N 1.285 -2.22 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 178.91 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.756 HG13 ' HB2' ' A' ' 23' ' ' GLN . 14.7 p -132.82 138.93 50.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 118.057 -1.457 . . . . 0.0 111.707 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -66.02 140.37 58.28 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.268 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.32 -8.7 45.14 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 -178.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.756 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.7 OUTLIER -138.45 -175.33 4.08 Favored 'General case' 0 N--CA 1.482 1.136 0 O-C-N 121.197 -1.178 . . . . 0.0 108.503 179.539 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.79 -166.55 1.33 Allowed 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 122.129 0.966 . . . . 0.0 110.923 -178.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.625 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.1 m-20 -72.62 113.8 10.06 Favored 'General case' 0 N--CA 1.485 1.324 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.455 178.861 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 1.005 HG21 ' CZ ' ' A' ' 49' ' ' PHE . 2.4 t -67.74 114.0 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.112 0 O-C-N 120.432 -1.417 . . . . 0.0 112.105 179.658 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.527 ' CD2' ' CZ ' ' A' ' 17' ' ' PHE . 0.6 OUTLIER -70.11 118.95 13.59 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 177.789 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.014 HG21 HD12 ' A' ' 18' ' ' ILE . 2.7 m -147.25 137.5 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 120.552 -1.343 . . . . 0.0 110.394 -179.346 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.585 ' CD2' ' O ' ' A' ' 14' ' ' GLY . 9.7 t-160 -99.19 172.97 7.03 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.384 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.548 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 48.0 p90 -82.64 35.54 0.46 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.044 -1.035 . . . . 0.0 109.758 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 10.8 t -128.15 -28.69 2.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.932 -1.105 . . . . 0.0 109.835 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.729 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.73 -47.89 7.12 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.027 -1.046 . . . . 0.0 108.236 179.293 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.66 HD11 ' HB ' ' A' ' 28' ' ' VAL . 53.5 mt -56.32 -30.37 30.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-O 122.115 0.96 . . . . 0.0 108.516 179.433 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.96 -168.29 1.3 Allowed 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -93.56 177.0 37.21 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 179.097 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -65.38 102.16 0.65 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.016 -1.285 . . . . 0.0 109.507 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 176.08 174.72 42.85 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 179.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 35.9 t80 -83.92 84.59 7.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.352 -1.087 . . . . 0.0 109.479 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -109.88 174.33 5.91 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.269 -0.894 . . . . 0.0 109.481 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.53 ' C ' HD12 ' A' ' 41' ' ' LEU . 0.2 OUTLIER -158.48 167.13 30.46 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.279 -0.888 . . . . 0.0 109.102 179.884 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.913 HD22 ' CD ' ' A' ' 45' ' ' GLN . 4.1 mp -146.97 -169.87 3.4 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.735 -1.228 . . . . 0.0 109.146 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -152.53 178.94 9.04 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.207 -0.933 . . . . 0.0 109.738 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -53.61 145.88 14.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.343 -0.848 . . . . 0.0 109.608 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 95.42 -9.5 69.32 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.076 -1.61 . . . . 0.0 109.076 -179.388 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.913 ' CD ' HD22 ' A' ' 41' ' ' LEU . 4.3 tt0 -59.72 104.31 0.27 Allowed 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.363 -1.081 . . . . 0.0 110.599 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -92.23 131.24 37.61 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 177.663 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.685 HG21 HD11 ' A' ' 18' ' ' ILE . 35.3 m -140.44 161.78 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 120.451 -1.406 . . . . 0.0 111.139 -178.77 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.482 ' HA ' ' O ' ' A' ' 2' ' ' LEU . 9.5 p -115.53 132.86 56.5 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 179.302 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.005 ' CZ ' HG21 ' A' ' 26' ' ' VAL . 7.1 p90 -154.88 -179.96 8.54 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.079 -1.013 . . . . 0.0 109.775 -179.005 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -121.16 91.39 3.51 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 178.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.921 HD11 HG23 ' A' ' 26' ' ' VAL . 17.9 mt -61.64 126.87 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.845 -1.159 . . . . 0.0 110.004 -179.478 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.557 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 10.4 m -106.09 -171.84 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 106.371 -1.714 . . . . 0.0 106.371 178.581 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.9 mp0 -122.98 114.44 20.41 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.9 -1.125 . . . . 0.0 109.824 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.57 169.07 16.58 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 34.5 m120 -38.07 -52.16 1.4 Allowed 'General case' 0 N--CA 1.504 2.232 0 O-C-N 121.325 -1.103 . . . . 0.0 113.587 -178.561 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.49 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -76.57 22.66 0.17 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 119.677 -1.89 . . . . 0.0 112.355 -178.035 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.07 -177.93 29.13 Favored Glycine 0 N--CA 1.494 2.531 0 O-C-N 120.434 -1.416 . . . . 0.0 110.232 179.565 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.557 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -65.66 150.82 86.01 Favored 'Trans proline' 0 C--N 1.32 -0.956 0 C-N-CA 122.025 1.817 . . . . 0.0 109.702 178.86 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.525 ' N ' HG23 ' A' ' 51' ' ' ILE . 29.5 mt-30 -161.11 144.03 12.69 Favored 'General case' 0 N--CA 1.5 2.043 0 O-C-N 120.991 -1.068 . . . . 0.0 111.567 -179.413 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.891 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -78.68 154.56 30.04 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 177.388 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.729 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -133.89 -41.61 0.83 Allowed 'General case' 0 N--CA 1.506 2.37 0 O-C-N 120.386 -1.446 . . . . 0.0 111.546 -176.534 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 5.6 m-20 -119.94 52.24 1.13 Allowed 'General case' 0 C--N 1.284 -2.255 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 179.618 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.92 HG22 ' CB ' ' A' ' 49' ' ' PHE . 20.5 t -67.13 163.68 2.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.969 -179.148 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.491 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.2 OUTLIER -147.29 167.88 23.17 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.37 -0.932 . . . . 0.0 108.796 178.608 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.15 144.77 48.46 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.864 -1.147 . . . . 0.0 109.66 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.45 ' OE2' ' O ' ' A' ' 66' ' ' GLU . 0.9 OUTLIER -56.78 134.3 54.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.346 -0.846 . . . . 0.0 109.522 -179.898 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.491 0 CA-C-O 117.961 -1.019 . . . . 0.0 109.414 179.922 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.6 tpt . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.189 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -134.35 175.2 9.72 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.245 -0.909 . . . . 0.0 109.867 179.595 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.714 ' O ' HD22 ' A' ' 2' ' ' LEU . 2.3 tt0 -113.77 157.08 22.72 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 120.907 -1.12 . . . . 0.0 110.332 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.425 ' C ' ' HG3' ' A' ' 5' ' ' LYS . . . -133.5 155.44 21.74 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.543 -1.823 . . . . 0.0 108.543 179.54 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.0 OUTLIER -132.2 119.07 20.36 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.284 -1.127 . . . . 0.0 110.201 -179.478 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.582 ' CG1' ' HG3' ' A' ' 43' ' ' GLU . 2.8 t -34.05 143.18 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.182 0 CA-C-O 123.086 1.422 . . . . 0.0 113.701 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.472 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 1.3 tmtm? -104.89 -30.74 9.64 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 103.585 -2.746 . . . . 0.0 103.585 172.733 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.745 ' CZ3' ' ND2' ' A' ' 10' ' ' ASN . 18.4 p-90 177.51 145.47 0.11 Allowed 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 105.728 -1.953 . . . . 0.0 105.728 178.1 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.917 ' CE1' HG21 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -113.23 148.43 35.53 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.457 -1.402 . . . . 0.0 110.655 -179.668 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.745 ' ND2' ' CZ3' ' A' ' 8' ' ' TRP . 36.6 m-20 -130.2 36.31 4.01 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.797 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.5 OUTLIER -39.48 -42.78 1.16 Allowed 'General case' 0 N--CA 1.49 1.57 0 CA-C-O 121.42 0.629 . . . . 0.0 109.556 -178.703 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -60.78 -47.37 86.62 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.344 -0.847 . . . . 0.0 110.282 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.554 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -72.94 3.88 4.84 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.178 -0.951 . . . . 0.0 110.068 -179.829 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.465 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 95.25 18.6 33.09 Favored Glycine 0 N--CA 1.49 2.279 0 O-C-N 121.184 -0.948 . . . . 0.0 112.465 178.289 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.512 ' O ' ' C ' ' A' ' 10' ' ' ASN . 37.1 p90 177.77 168.69 0.7 Allowed 'General case' 0 N--CA 1.501 2.075 0 CA-C-N 120.152 1.976 . . . . 0.0 111.644 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.871 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -146.34 154.29 25.87 Favored Glycine 0 N--CA 1.497 2.709 0 N-CA-C 107.044 -2.422 . . . . 0.0 107.044 179.133 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.706 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.5 m-85 -109.98 142.33 41.52 Favored 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 120.053 1.927 . . . . 0.0 109.621 -179.201 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.662 HD12 HG12 ' A' ' 28' ' ' VAL . 0.8 OUTLIER -106.37 163.5 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 179.295 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.578 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 0.8 OUTLIER -140.97 130.79 24.32 Favored 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.897 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.582 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 9.3 p -137.4 139.19 44.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 C-N-CA 117.743 -1.583 . . . . 0.0 111.779 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.86 141.06 58.18 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.428 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.19 -18.88 42.3 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.621 -1.792 . . . . 0.0 108.621 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.582 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 57.3 mt-30 -140.99 -173.15 3.64 Favored 'General case' 0 N--CA 1.484 1.244 0 O-C-N 121.418 -1.048 . . . . 0.0 109.162 179.671 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -98.35 -164.62 1.15 Allowed 'General case' 0 C--N 1.297 -1.688 0 CA-C-O 122.115 0.96 . . . . 0.0 110.822 -178.801 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.597 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 23.5 p-10 -70.91 125.82 27.89 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.239 179.747 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.873 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.3 t -90.49 114.48 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 120.705 -1.247 . . . . 0.0 110.808 178.348 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.438 ' C ' ' O ' ' A' ' 26' ' ' VAL . 18.8 t80 -46.06 143.13 2.41 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.292 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.917 HG21 ' CE1' ' A' ' 9' ' ' PHE . 1.0 OUTLIER -133.57 148.51 30.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 120.687 -1.258 . . . . 0.0 109.422 -179.176 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.446 ' O ' HG13 ' A' ' 33' ' ' ILE . 10.2 t-160 -151.61 146.84 26.12 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 21.8 p90 -78.8 24.21 0.31 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.018 -1.051 . . . . 0.0 110.714 -179.674 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.3 t -111.6 -45.7 3.34 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 120.637 -1.289 . . . . 0.0 109.212 179.615 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.729 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.55 -42.89 9.98 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.284 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.587 HD11 ' HA ' ' A' ' 28' ' ' VAL . 1.3 mt -73.83 -1.45 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 CA-C-O 121.496 0.665 . . . . 0.0 109.615 179.647 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.465 ' OE1' ' O ' ' A' ' 37' ' ' GLY . 0.2 OUTLIER -72.02 -167.89 0.34 Allowed 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.494 -0.754 . . . . 0.0 110.28 -178.83 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 143.51 -42.48 1.07 Allowed Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 -179.718 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -105.29 62.34 0.68 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.32 -1.106 . . . . 0.0 109.638 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.465 ' O ' ' OE1' ' A' ' 34' ' ' GLN . . . 61.79 164.29 0.31 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -82.03 90.52 6.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.099 -1.236 . . . . 0.0 109.664 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 10.5 mtpt -110.53 161.37 15.76 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.242 -0.911 . . . . 0.0 109.599 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.24 165.83 11.6 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.286 -0.884 . . . . 0.0 108.763 179.639 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.879 HD22 ' HB2' ' A' ' 45' ' ' GLN . 0.4 OUTLIER -151.91 -176.16 5.53 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.595 -1.316 . . . . 0.0 109.731 179.975 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -94.39 -174.91 3.48 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 178.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.582 ' HG3' ' CG1' ' A' ' 6' ' ' VAL . 34.8 tt0 -77.34 65.51 2.92 Favored 'General case' 0 N--CA 1.501 2.105 0 O-C-N 121.363 -0.836 . . . . 0.0 111.668 -179.155 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -162.82 35.01 0.32 Allowed Glycine 0 N--CA 1.49 2.243 0 O-C-N 120.856 -1.152 . . . . 0.0 110.427 178.525 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.879 ' HB2' HD22 ' A' ' 41' ' ' LEU . 41.7 tp60 -79.62 127.29 31.99 Favored 'General case' 0 N--CA 1.481 1.088 0 O-C-N 120.353 -1.675 . . . . 0.0 111.167 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.475 ' HB3' ' HG2' ' A' ' 66' ' ' GLU . . . -96.98 115.74 27.96 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 176.785 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.781 HG13 ' HG3' ' A' ' 45' ' ' GLN . 32.9 m -124.56 163.74 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 120.428 -1.42 . . . . 0.0 111.105 -178.755 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -116.58 129.02 55.93 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.1 -1.0 . . . . 0.0 108.517 179.591 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.189 ' CE1' HD11 ' A' ' 2' ' ' LEU . 6.3 p90 -153.75 -177.97 6.73 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.044 -1.035 . . . . 0.0 109.882 -179.466 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -126.09 93.12 3.73 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.197 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.873 HD11 ' CG2' ' A' ' 26' ' ' VAL . 13.7 mt -61.73 128.49 23.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.973 -1.079 . . . . 0.0 109.907 -179.303 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.57 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 7.5 m -109.3 -175.99 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 178.707 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.96 116.11 22.34 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.941 -1.099 . . . . 0.0 109.415 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.25 176.16 18.25 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -38.59 -52.59 1.63 Allowed 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.424 -1.044 . . . . 0.0 113.807 -178.504 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.458 ' NH1' ' CG ' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -79.42 22.27 0.45 Allowed 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.665 -1.897 . . . . 0.0 112.134 -177.706 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.56 -177.74 30.9 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.429 -1.367 . . . . 0.0 110.298 179.43 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.57 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.4 Cg_endo -66.64 153.1 79.18 Favored 'Trans proline' 0 C--N 1.32 -0.921 0 C-N-CA 121.942 1.761 . . . . 0.0 110.186 179.189 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.421 ' HG3' ' O ' ' A' ' 58' ' ' PRO . 2.4 mt-30 -166.31 147.46 6.5 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.069 -1.02 . . . . 0.0 111.278 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.767 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -80.12 155.84 27.3 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 177.239 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.729 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.66 -41.88 0.77 Allowed 'General case' 0 N--CA 1.508 2.445 0 O-C-N 120.308 -1.495 . . . . 0.0 111.695 -176.576 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -120.19 52.03 1.16 Allowed 'General case' 0 C--N 1.283 -2.292 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.952 HG22 ' CB ' ' A' ' 49' ' ' PHE . 15.2 t -67.43 167.32 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-O 121.83 0.824 . . . . 0.0 109.562 -179.501 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.586 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.3 OUTLIER -147.17 168.89 20.51 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.994 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.8 mttm -83.85 136.47 34.11 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.917 -1.114 . . . . 0.0 109.643 -179.797 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.475 ' HG2' ' HB3' ' A' ' 46' ' ' ALA . 0.1 OUTLIER -54.68 158.46 2.58 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.198 -0.939 . . . . 0.0 109.605 -179.823 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.408 179.899 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.178 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.18 172.24 13.04 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.182 -0.949 . . . . 0.0 110.082 179.504 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.595 ' O ' HD22 ' A' ' 2' ' ' LEU . 1.9 tt0 -113.95 149.71 34.86 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.165 -0.96 . . . . 0.0 110.423 -178.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.12 165.47 19.29 Favored Glycine 0 N--CA 1.486 1.969 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 179.37 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 6' ' ' VAL . 12.0 mmtt -131.4 115.16 15.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.929 -1.336 . . . . 0.0 109.742 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.553 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.2 t -36.47 139.56 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 CA-C-O 122.914 1.34 . . . . 0.0 112.873 -179.551 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.473 ' HE2' ' OE1' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -99.73 -33.23 10.67 Favored 'General case' 0 C--N 1.288 -2.105 0 N-CA-C 102.876 -3.009 . . . . 0.0 102.876 172.471 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 24.1 p-90 175.16 146.58 0.07 Allowed 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 177.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.599 ' CG ' ' HG ' ' A' ' 41' ' ' LEU . 0.4 OUTLIER -112.08 147.41 36.1 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 120.298 -1.501 . . . . 0.0 109.37 178.815 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.605 ' HB2' ' CD1' ' A' ' 15' ' ' PHE . 2.6 m-20 -126.45 41.7 3.47 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.689 -0.632 . . . . 0.0 109.363 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.48 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -39.04 -47.29 1.49 Allowed 'General case' 0 N--CA 1.493 1.712 0 CA-C-O 121.601 0.715 . . . . 0.0 109.569 -179.189 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -58.6 -50.27 74.44 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.45 -0.781 . . . . 0.0 110.939 -179.385 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.558 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -70.85 0.98 6.09 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.014 -1.054 . . . . 0.0 110.429 -179.211 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.47 25.96 24.4 Favored Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.014 -1.054 . . . . 0.0 111.797 178.505 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.605 ' CD1' ' HB2' ' A' ' 10' ' ' ASN . 4.9 p90 -178.58 172.48 1.42 Allowed 'General case' 0 N--CA 1.497 1.914 0 CA-C-N 119.836 1.818 . . . . 0.0 110.866 179.47 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.445 ' O ' ' CG2' ' A' ' 28' ' ' VAL . . . -154.48 143.94 10.59 Favored Glycine 0 N--CA 1.5 2.911 0 N-CA-C 107.104 -2.399 . . . . 0.0 107.104 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.0 m-85 -111.12 141.33 44.77 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 119.97 -1.9 . . . . 0.0 110.456 -178.465 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.651 HD11 HG21 ' A' ' 47' ' ' VAL . 0.5 OUTLIER -106.32 162.35 5.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 178.262 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.558 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 14.6 tp10 -141.7 128.47 20.45 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.473 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.744 HG13 ' HB2' ' A' ' 23' ' ' GLN . 12.4 p -135.53 141.17 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 117.3 -1.76 . . . . 0.0 112.021 -179.213 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.71 140.44 58.46 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-N 115.384 -0.825 . . . . 0.0 108.913 179.596 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.03 -16.23 43.97 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.419 -1.872 . . . . 0.0 108.419 -178.63 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.744 ' HB2' HG13 ' A' ' 20' ' ' VAL . 3.1 mm-40 -139.29 -177.11 4.77 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 179.439 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -100.9 -165.95 1.26 Allowed 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.236 -0.915 . . . . 0.0 110.912 -178.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.587 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 3.8 p30 -72.27 124.37 24.92 Favored 'General case' 0 N--CA 1.488 1.46 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.741 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.895 HG12 HG13 ' A' ' 28' ' ' VAL . 2.4 t -88.23 116.01 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 120.647 -1.283 . . . . 0.0 111.264 178.605 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.543 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 1.5 t80 -64.5 127.82 33.16 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 178.191 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.895 HG13 HG12 ' A' ' 26' ' ' VAL . 16.1 m -143.32 137.01 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.55 -1.344 . . . . 0.0 111.626 -178.787 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.519 ' CE1' ' CE1' ' A' ' 30' ' ' PHE . 42.2 t-80 -99.82 162.02 13.25 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 177.327 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.519 ' CE1' ' CE1' ' A' ' 29' ' ' HIS . 49.0 p90 -83.99 34.2 0.5 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.467 -1.396 . . . . 0.0 109.993 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.6 m -123.26 -34.27 3.15 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.034 -1.041 . . . . 0.0 108.905 179.305 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.739 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.56 -43.3 9.74 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.572 ' CD1' ' HB ' ' A' ' 28' ' ' VAL . 1.2 mp -59.39 -22.91 23.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.849 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.531 ' HG3' ' HA ' ' A' ' 39' ' ' LYS . 0.5 OUTLIER -112.18 -166.89 1.12 Allowed 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.812 -0.755 . . . . 0.0 110.796 -178.937 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 154.48 -29.52 0.69 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.782 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -99.71 119.2 37.75 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.093 -1.239 . . . . 0.0 109.971 -179.497 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.429 ' O ' ' C ' ' A' ' 38' ' ' PHE . . . 59.7 -176.36 3.27 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 179.598 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.429 ' C ' ' O ' ' A' ' 37' ' ' GLY . 0.1 OUTLIER -43.63 156.41 0.06 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.327 -1.102 . . . . 0.0 109.472 179.892 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.531 ' HA ' ' HG3' ' A' ' 34' ' ' GLN . 0.0 OUTLIER -107.89 159.43 16.53 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.154 -0.966 . . . . 0.0 109.984 -179.684 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.618 ' C ' HD13 ' A' ' 41' ' ' LEU . 5.9 t 179.3 -169.13 0.1 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.384 -0.823 . . . . 0.0 109.614 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.923 ' N ' HD13 ' A' ' 41' ' ' LEU . 0.0 OUTLIER -147.08 -174.4 4.49 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.361 -0.837 . . . . 0.0 110.223 -178.834 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.432 ' O ' ' CB ' ' A' ' 45' ' ' GLN . 1.3 mt-10 -168.75 124.75 0.95 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.541 -0.725 . . . . 0.0 109.166 179.808 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.452 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 11.9 tm-20 -55.85 145.49 24.46 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.181 -0.949 . . . . 0.0 109.471 -179.683 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.452 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 73.31 5.59 67.31 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 -179.563 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.432 ' CB ' ' O ' ' A' ' 42' ' ' GLU . 37.1 tp60 -76.24 133.78 40.02 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.269 -1.136 . . . . 0.0 110.815 -179.451 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.534 ' O ' ' CB ' ' A' ' 66' ' ' GLU . . . -94.08 123.24 37.33 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 178.593 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.651 HG21 HD11 ' A' ' 18' ' ' ILE . 35.7 m -112.59 162.03 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 120.829 -1.17 . . . . 0.0 110.405 -179.882 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.68 119.15 34.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.06 -1.025 . . . . 0.0 108.729 179.4 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.178 ' CE1' HD11 ' A' ' 2' ' ' LEU . 10.7 p90 -149.49 -177.6 5.95 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.952 -1.093 . . . . 0.0 110.023 -179.374 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -128.86 93.31 3.58 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.452 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.877 HD11 ' CG2' ' A' ' 26' ' ' VAL . 14.1 mt -61.69 132.81 27.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.931 -1.105 . . . . 0.0 109.929 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 17.0 m -113.42 -177.3 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.152 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -123.17 117.19 24.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.999 -1.063 . . . . 0.0 109.299 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.83 175.2 15.63 Favored Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.67 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -39.1 -52.1 1.87 Allowed 'General case' 0 N--CA 1.5 2.071 0 N-CA-C 114.287 1.217 . . . . 0.0 114.287 -178.484 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -93.25 21.09 6.28 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 119.416 -2.053 . . . . 0.0 113.534 -176.616 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 122.68 173.65 14.23 Favored Glycine 0 N--CA 1.495 2.593 0 C-N-CA 118.723 -1.703 . . . . 0.0 111.533 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.527 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 3.0 Cg_endo -69.07 156.51 64.94 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 C-N-CA 122.661 2.241 . . . . 0.0 110.561 179.27 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 -166.41 146.11 5.93 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.298 -0.876 . . . . 0.0 110.962 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.715 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.19 159.14 23.34 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.502 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.739 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.15 -44.53 0.71 Allowed 'General case' 0 N--CA 1.506 2.349 0 O-C-N 120.36 -1.462 . . . . 0.0 112.13 -176.171 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -119.54 51.62 1.15 Allowed 'General case' 0 C--N 1.284 -2.24 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.932 HG22 ' CB ' ' A' ' 49' ' ' PHE . 18.1 t -66.06 159.64 4.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.681 -179.431 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.489 HG22 ' H ' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -143.92 -177.86 5.64 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.846 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.489 ' H ' HG22 ' A' ' 64' ' ' THR . 0.2 OUTLIER -86.39 139.51 30.87 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.931 -1.106 . . . . 0.0 109.354 -179.961 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.534 ' CB ' ' O ' ' A' ' 46' ' ' ALA . 29.4 tp10 -60.56 115.15 3.39 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.199 -0.938 . . . . 0.0 109.572 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.475 ' HB3' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 118.038 -0.982 . . . . 0.0 109.458 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.069 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.77 174.64 10.32 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.179 -0.951 . . . . 0.0 110.264 179.75 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.84 ' CD ' ' HB1' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -112.64 165.2 12.49 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.252 -0.905 . . . . 0.0 109.937 -179.059 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 46' ' ' ALA . . . -148.05 169.68 28.76 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 20.0 mttt -134.05 116.14 15.14 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 120.919 -1.342 . . . . 0.0 110.313 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.818 HG21 ' HB3' ' A' ' 43' ' ' GLU . 2.4 t -49.06 134.98 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 CA-C-O 122.71 1.243 . . . . 0.0 112.998 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.65 -28.36 13.58 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 104.015 -2.587 . . . . 0.0 104.015 174.155 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.681 ' O ' ' CE3' ' A' ' 8' ' ' TRP . 21.6 p-90 176.16 141.88 0.07 Allowed 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 178.274 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.576 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 0.7 OUTLIER -130.02 110.57 11.75 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.537 -1.352 . . . . 0.0 110.096 -179.949 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.567 ' OD1' ' CB ' ' A' ' 13' ' ' LYS . 1.2 p30 -95.15 88.35 5.17 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-O 122.978 1.371 . . . . 0.0 109.031 179.047 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.569 ' HB2' HG22 ' A' ' 40' ' ' THR . 0.4 OUTLIER -67.65 -57.97 5.47 Favored 'General case' 0 C--N 1.29 -2.02 0 O-C-N 120.417 -1.427 . . . . 0.0 108.709 179.741 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.79 ' HG2' HG21 ' A' ' 40' ' ' THR . 13.9 mt-10 -59.7 -45.13 93.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.469 -0.77 . . . . 0.0 111.362 -179.097 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.567 ' CB ' ' OD1' ' A' ' 10' ' ' ASN . 1.4 mptt -68.68 -11.85 60.68 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.05 -1.032 . . . . 0.0 111.134 -177.885 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.514 ' N ' ' OD1' ' A' ' 10' ' ' ASN . . . 138.73 -37.79 1.75 Allowed Glycine 0 N--CA 1.496 2.636 0 C-N-CA 118.376 -1.869 . . . . 0.0 113.3 178.299 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.532 ' O ' ' ND2' ' A' ' 10' ' ' ASN . 10.9 p90 -175.85 -174.83 0.69 Allowed 'General case' 0 N--CA 1.497 1.882 0 CA-C-N 121.079 2.439 . . . . 0.0 110.424 -179.222 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.862 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -134.49 146.35 18.36 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.626 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 6.0 m-30 -107.0 136.71 46.4 Favored 'General case' 0 N--CA 1.48 1.04 0 O-C-N 120.577 -1.543 . . . . 0.0 109.419 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.961 ' CD1' HG11 ' A' ' 28' ' ' VAL . 1.0 OUTLIER -107.39 150.53 9.88 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 N-CA-C 105.85 -1.908 . . . . 0.0 105.85 178.049 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.466 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 1.0 OUTLIER -125.92 133.19 51.94 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.396 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.687 HG13 ' HB2' ' A' ' 23' ' ' GLN . 8.5 p -137.87 140.24 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 C-N-CA 117.635 -1.626 . . . . 0.0 112.221 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -65.28 140.18 58.68 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.056 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.84 -13.76 46.55 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 108.654 -1.778 . . . . 0.0 108.654 -178.73 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.687 ' HB2' HG13 ' A' ' 20' ' ' VAL . 3.6 mt-30 -138.56 -175.97 4.31 Favored 'General case' 0 N--CA 1.483 1.195 0 O-C-N 121.257 -1.143 . . . . 0.0 108.632 179.489 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.82 -165.62 1.23 Allowed 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 122.135 0.969 . . . . 0.0 110.627 -179.059 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.626 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.5 m-20 -73.0 104.85 4.24 Favored 'General case' 0 N--CA 1.486 1.355 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.223 179.477 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 1.038 HG22 ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -65.72 115.25 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 120.345 -1.472 . . . . 0.0 112.112 179.061 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.453 ' HB3' ' CD ' ' A' ' 59' ' ' GLN . 12.7 t80 -70.53 129.84 40.27 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.336 -0.852 . . . . 0.0 109.04 178.236 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.961 HG11 ' CD1' ' A' ' 18' ' ' ILE . 23.6 m -135.85 144.83 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.617 -1.302 . . . . 0.0 109.654 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.848 ' O ' HD12 ' A' ' 33' ' ' ILE . 0.5 OUTLIER -99.63 165.99 11.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.766 -1.209 . . . . 0.0 108.78 179.678 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.516 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 42.9 p90 -80.28 26.0 0.38 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.949 -1.095 . . . . 0.0 110.937 -179.398 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 43.3 p -136.68 -17.64 1.46 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.701 -1.249 . . . . 0.0 110.209 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.735 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.35 -49.6 6.07 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 120.735 -1.228 . . . . 0.0 108.79 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.848 HD12 ' O ' ' A' ' 29' ' ' HIS . 2.5 mt -55.59 -27.65 21.76 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 CA-C-O 121.933 0.873 . . . . 0.0 108.736 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -112.3 -168.09 1.27 Allowed 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.745 -0.597 . . . . 0.0 109.732 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.27 -42.65 0.03 OUTLIER Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' A' ' 37' ' ' GLY . 0.0 OUTLIER -65.7 -170.09 0.07 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.381 -1.07 . . . . 0.0 109.653 179.871 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.471 ' O ' ' O ' ' A' ' 36' ' ' GLU . . . -44.19 170.0 0.01 OUTLIER Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.584 ' O ' ' CD2' ' A' ' 38' ' ' PHE . 48.0 p90 -73.11 116.11 13.24 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.21 -1.171 . . . . 0.0 110.098 -179.625 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.679 ' HG3' HD23 ' A' ' 41' ' ' LEU . 0.5 OUTLIER -110.68 135.08 51.83 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.273 -0.892 . . . . 0.0 108.881 179.608 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.79 HG21 ' HG2' ' A' ' 12' ' ' GLU . 25.8 p -99.62 110.95 23.35 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.873 -1.142 . . . . 0.0 109.967 -179.567 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.679 HD23 ' HG3' ' A' ' 39' ' ' LYS . 0.7 OUTLIER -151.79 -179.19 7.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.419 -1.426 . . . . 0.0 109.706 179.757 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.551 ' HA ' ' HB3' ' A' ' 9' ' ' PHE . 1.8 mp0 -114.13 105.98 13.84 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.385 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.818 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.1 tp10 -76.59 45.66 0.41 Allowed 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 115.031 1.493 . . . . 0.0 115.031 -176.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.592 ' HA2' ' CG1' ' A' ' 6' ' ' VAL . . . -45.57 -15.8 0.1 OUTLIER Glycine 0 N--CA 1.507 3.385 0 CA-C-N 119.86 1.209 . . . . 0.0 110.432 177.337 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.532 ' N ' ' O ' ' A' ' 43' ' ' GLU . 0.0 OUTLIER -70.0 177.54 3.13 Favored 'General case' 0 C--N 1.289 -2.024 0 O-C-N 121.699 -0.883 . . . . 0.0 109.779 -179.844 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.84 ' HB1' ' CD ' ' A' ' 3' ' ' GLU . . . -90.68 132.54 35.73 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.679 -0.638 . . . . 0.0 109.395 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.564 HG21 ' CD1' ' A' ' 18' ' ' ILE . 29.7 m -111.3 162.8 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.18 -0.95 . . . . 0.0 110.247 -179.806 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -115.88 125.38 52.55 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.194 -0.941 . . . . 0.0 108.587 179.503 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.069 ' CE1' HD11 ' A' ' 2' ' ' LEU . 25.0 p90 -153.59 -178.35 6.96 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.019 -1.051 . . . . 0.0 110.035 -179.646 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -126.85 96.14 4.55 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 179.413 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 1.038 ' CD1' HG22 ' A' ' 26' ' ' VAL . 1.3 mm -61.09 141.39 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 122.609 1.195 . . . . 0.0 111.048 -179.393 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.544 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 2.1 m -130.65 -174.96 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 -179.558 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -124.14 116.26 22.46 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.002 -1.062 . . . . 0.0 109.623 179.627 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -129.36 173.32 19.6 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.753 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -38.04 -52.26 1.39 Allowed 'General case' 0 N--CA 1.504 2.254 0 O-C-N 121.407 -1.055 . . . . 0.0 113.426 -178.634 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 4.9 mtt180 -75.42 22.74 0.12 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 119.728 -1.858 . . . . 0.0 112.102 -178.409 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.74 -178.75 36.64 Favored Glycine 0 N--CA 1.492 2.389 0 O-C-N 120.438 -1.414 . . . . 0.0 110.124 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.544 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.4 Cg_endo -68.04 139.59 47.31 Favored 'Trans proline' 0 C--N 1.319 -1.023 0 C-N-CA 122.095 1.863 . . . . 0.0 110.069 178.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.959 ' C ' HD13 ' A' ' 51' ' ' ILE . 77.6 mt-30 -159.33 157.92 31.37 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.2 -0.938 . . . . 0.0 111.206 -179.364 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.799 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -83.99 160.56 21.0 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 177.517 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.735 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.08 -40.98 0.74 Allowed 'General case' 0 N--CA 1.508 2.433 0 O-C-N 120.294 -1.504 . . . . 0.0 111.812 -176.709 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.438 ' N ' ' OD1' ' A' ' 62' ' ' ASN . 1.6 m-20 -119.62 52.28 1.11 Allowed 'General case' 0 C--N 1.283 -2.283 0 N-CA-C 106.924 -1.509 . . . . 0.0 106.924 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.914 HG22 ' CB ' ' A' ' 49' ' ' PHE . 13.4 t -69.17 163.66 3.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.488 -179.308 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.59 HG22 ' H ' ' A' ' 65' ' ' LYS . 1.2 m -149.45 -179.08 6.8 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 178.643 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.59 ' H ' HG22 ' A' ' 64' ' ' THR . 0.4 OUTLIER -82.93 128.58 34.58 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.991 -1.068 . . . . 0.0 109.432 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 46' ' ' ALA . 0.5 OUTLIER -79.89 120.22 23.83 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.233 -0.917 . . . . 0.0 109.454 179.929 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 117.991 -1.004 . . . . 0.0 109.432 -179.964 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.6 ptt? . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.175 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -113.87 177.75 4.53 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.206 -0.934 . . . . 0.0 110.045 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.847 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -113.07 165.94 11.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.87 -1.143 . . . . 0.0 109.858 -179.07 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -151.82 156.27 26.6 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.401 ' O ' ' C ' ' A' ' 6' ' ' VAL . 2.5 ttpt -135.4 126.93 28.77 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.45 -1.03 . . . . 0.0 110.675 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.663 HG23 ' CB ' ' A' ' 45' ' ' GLN . 5.6 t -35.7 150.01 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.285 0 CA-C-O 123.453 1.597 . . . . 0.0 113.338 -179.634 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.524 ' CG ' ' HB2' ' A' ' 19' ' ' GLU . 1.0 OUTLIER -110.54 -29.21 8.16 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 103.174 -2.899 . . . . 0.0 103.174 172.247 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.711 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 15.4 p-90 178.92 144.61 0.14 Allowed 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 177.816 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.592 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 1.1 t80 -118.89 127.41 53.47 Favored 'General case' 0 N--CA 1.506 2.361 0 O-C-N 120.527 -1.358 . . . . 0.0 109.756 -178.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.554 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 72.7 m-20 -120.6 56.21 1.0 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.598 -0.689 . . . . 0.0 109.682 -179.426 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.589 ' HG ' ' HG ' ' A' ' 41' ' ' LEU . 0.0 OUTLIER -43.74 -38.11 3.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.287 -0.883 . . . . 0.0 108.861 179.933 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -61.03 -47.03 88.32 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.572 -0.705 . . . . 0.0 110.253 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.512 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -71.53 4.42 3.09 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.218 -0.926 . . . . 0.0 109.768 179.853 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.478 ' C ' ' CD2' ' A' ' 15' ' ' PHE . . . 98.53 8.0 55.13 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 120.22 -0.99 . . . . 0.0 111.712 179.045 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.478 ' CD2' ' C ' ' A' ' 14' ' ' GLY . 3.9 p90 173.88 173.78 0.16 Allowed 'General case' 0 N--CA 1.495 1.818 0 CA-C-N 120.391 2.096 . . . . 0.0 112.588 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.882 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -130.33 142.61 13.89 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 106.644 -2.582 . . . . 0.0 106.644 178.678 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.711 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 4.1 m-30 -99.0 142.27 30.7 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 120.199 -1.765 . . . . 0.0 109.001 -178.849 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.028 HD12 ' CG1' ' A' ' 28' ' ' VAL . 0.6 OUTLIER -105.64 165.88 3.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 179.746 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.586 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 14.4 tm-20 -140.96 132.34 26.75 Favored 'General case' 0 C--N 1.289 -2.063 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 178.425 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.667 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.5 p -136.1 140.87 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 118.068 -1.453 . . . . 0.0 111.641 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -64.05 140.55 58.88 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.363 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.5 -8.88 45.38 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.667 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.3 OUTLIER -139.23 -175.07 4.04 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 121.129 -1.218 . . . . 0.0 108.849 179.608 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -100.66 -166.31 1.3 Allowed 'General case' 0 C--N 1.296 -1.721 0 CA-C-O 122.112 0.958 . . . . 0.0 110.437 -179.208 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.624 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 5.1 p30 -72.12 125.12 26.48 Favored 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.689 179.177 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 1.003 HG21 ' CZ ' ' A' ' 49' ' ' PHE . 2.5 t -87.62 108.76 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 120.557 -1.339 . . . . 0.0 111.341 178.794 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.459 ' CE2' ' CE1' ' A' ' 17' ' ' PHE . 8.8 t80 -51.16 135.13 26.31 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 177.88 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.028 ' CG1' HD12 ' A' ' 18' ' ' ILE . 0.7 OUTLIER -131.74 140.8 47.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 120.48 -1.388 . . . . 0.0 109.615 -178.831 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.736 ' O ' HD12 ' A' ' 33' ' ' ILE . 36.2 t-80 -123.63 155.73 37.17 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.492 ' CE1' ' CE1' ' A' ' 29' ' ' HIS . 55.6 p90 -82.47 32.5 0.4 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.975 -1.078 . . . . 0.0 109.585 179.754 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.7 m -132.04 -33.24 1.36 Allowed 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.075 -1.016 . . . . 0.0 109.358 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.758 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.34 -40.93 11.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.154 -0.966 . . . . 0.0 108.781 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.79 HD11 ' HB ' ' A' ' 28' ' ' VAL . 3.1 mt -75.16 -0.59 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.382 -0.823 . . . . 0.0 108.878 178.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.591 ' O ' ' C ' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -30.2 -34.8 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.543 -178.876 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.984 ' HA3' HG22 ' A' ' 64' ' ' THR . . . -10.46 123.96 0.01 OUTLIER Glycine 0 N--CA 1.506 3.361 0 N-CA-C 111.591 -0.604 . . . . 0.0 111.591 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.506 ' C ' ' O ' ' A' ' 35' ' ' GLY . 0.2 OUTLIER -30.37 129.69 0.11 Allowed 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.935 -0.744 . . . . 0.0 110.919 -179.219 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 155.39 162.82 11.58 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.516 ' O ' ' CD1' ' A' ' 38' ' ' PHE . 37.2 p90 -84.96 130.95 34.55 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.018 -1.283 . . . . 0.0 109.458 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.423 ' O ' ' HB ' ' A' ' 40' ' ' THR . 0.8 OUTLIER -97.89 154.07 17.9 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -0.908 . . . . 0.0 109.505 -179.857 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.545 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 9.2 t 179.91 -176.83 0.34 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.265 -0.897 . . . . 0.0 109.327 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.589 ' HG ' ' HG ' ' A' ' 11' ' ' SER . 5.2 mp -108.25 89.3 2.95 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.162 -0.962 . . . . 0.0 109.558 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -146.31 143.92 29.46 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 179.338 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.445 ' HG3' HG12 ' A' ' 6' ' ' VAL . 28.8 tt0 -77.7 60.9 2.29 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.044 -1.035 . . . . 0.0 112.144 -178.567 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -150.69 33.56 0.98 Allowed Glycine 0 N--CA 1.494 2.566 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 178.639 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.663 ' CB ' HG23 ' A' ' 6' ' ' VAL . 3.2 tt0 -80.19 96.7 6.64 Favored 'General case' 0 C--N 1.31 -1.15 0 O-C-N 121.077 -1.249 . . . . 0.0 110.452 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -94.18 105.44 17.43 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 177.555 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.593 HG12 ' HA ' ' A' ' 65' ' ' LYS . 35.0 m -128.28 164.29 30.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 120.675 -1.266 . . . . 0.0 110.741 -178.292 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -115.36 136.4 53.13 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 179.1 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.175 ' CE1' HD11 ' A' ' 2' ' ' LEU . 7.0 p90 -156.52 -179.41 8.15 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-O 121.99 0.9 . . . . 0.0 109.522 -178.731 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 20.1 tt0 -123.18 93.45 3.96 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.049 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.908 HD11 ' CG2' ' A' ' 26' ' ' VAL . 16.9 mt -62.14 128.58 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.981 -1.074 . . . . 0.0 110.154 -179.519 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 11.4 m -108.16 -176.56 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 178.348 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.408 ' CD ' ' N ' ' A' ' 53' ' ' GLU . 2.1 pm0 -123.85 116.62 23.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.967 -1.083 . . . . 0.0 109.729 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.406 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -132.26 172.4 21.14 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.181 -1.567 . . . . 0.0 109.181 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.406 ' C ' ' O ' ' A' ' 54' ' ' GLY . 17.8 m120 -37.37 -51.88 1.1 Allowed 'General case' 0 N--CA 1.505 2.322 0 O-C-N 121.439 -1.036 . . . . 0.0 113.268 -178.639 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.87 23.34 0.1 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 119.65 -1.907 . . . . 0.0 112.14 -178.456 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.77 -177.07 38.46 Favored Glycine 0 N--CA 1.491 2.359 0 O-C-N 120.529 -1.357 . . . . 0.0 109.773 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.554 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -68.28 152.92 75.44 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 C-N-CA 121.832 1.688 . . . . 0.0 109.652 178.768 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.468 ' HG3' ' O ' ' A' ' 58' ' ' PRO . 0.8 OUTLIER -165.82 146.1 6.61 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 120.907 -1.121 . . . . 0.0 111.608 -179.557 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.809 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -78.49 155.75 29.66 Favored 'General case' 0 N--CA 1.494 1.77 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.235 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.758 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.52 -40.57 0.8 Allowed 'General case' 0 N--CA 1.508 2.475 0 O-C-N 120.557 -1.339 . . . . 0.0 111.37 -176.836 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -119.88 57.09 0.93 Allowed 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.914 HG22 ' CB ' ' A' ' 49' ' ' PHE . 19.9 t -73.14 165.61 3.0 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.184 -178.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.984 HG22 ' HA3' ' A' ' 35' ' ' GLY . 0.2 OUTLIER -149.83 157.97 43.71 Favored 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.143 178.952 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.593 ' HA ' HG12 ' A' ' 47' ' ' VAL . 4.2 tmtm? -70.25 138.07 51.34 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.821 -1.174 . . . . 0.0 109.562 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -55.4 160.56 2.27 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.27 -0.894 . . . . 0.0 109.419 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.607 -179.834 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.158 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.957 0 CA-C-O 121.063 0.458 . . . . 0.0 110.348 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.701 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -114.51 154.5 28.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.076 -1.015 . . . . 0.0 110.096 -179.552 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.24 158.0 20.27 Favored Glycine 0 N--CA 1.484 1.858 0 N-CA-C 109.064 -1.615 . . . . 0.0 109.064 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.443 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.3 mttt -130.73 115.85 17.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.446 -1.032 . . . . 0.0 110.195 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.588 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.6 t -35.42 143.52 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 CA-C-O 123.045 1.402 . . . . 0.0 112.925 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.423 ' CG ' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -102.5 -30.63 10.87 Favored 'General case' 0 C--N 1.288 -2.068 0 N-CA-C 102.996 -2.964 . . . . 0.0 102.996 171.94 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 17.9 p-90 177.31 147.5 0.13 Allowed 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 105.77 -1.937 . . . . 0.0 105.77 177.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.977 ' CE1' HG21 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -114.19 145.01 42.27 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 120.37 -1.456 . . . . 0.0 110.142 179.944 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.57 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 4.7 m-20 -131.91 32.96 4.0 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.351 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.1 OUTLIER -38.4 -46.95 1.19 Allowed 'General case' 0 N--CA 1.494 1.727 0 CA-C-O 121.486 0.66 . . . . 0.0 109.787 -178.765 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -60.15 -46.82 88.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.363 -0.836 . . . . 0.0 110.044 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.57 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -73.01 4.84 3.81 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.299 -0.876 . . . . 0.0 110.781 -179.317 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.552 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 110.71 -3.78 29.13 Favored Glycine 0 N--CA 1.494 2.545 0 C-N-CA 119.731 -1.223 . . . . 0.0 113.008 177.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.558 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 5.7 p90 176.68 174.77 0.37 Allowed 'General case' 0 N--CA 1.5 2.058 0 CA-C-N 120.614 2.207 . . . . 0.0 111.972 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.905 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -140.03 151.96 22.45 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 107.432 -2.267 . . . . 0.0 107.432 179.32 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.36 141.33 40.34 Favored 'General case' 0 N--CA 1.485 1.323 0 O-C-N 120.058 -1.848 . . . . 0.0 109.498 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.03 HD12 HG12 ' A' ' 28' ' ' VAL . 0.9 OUTLIER -107.48 160.72 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 178.656 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.549 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 4.3 tt0 -137.74 130.52 29.97 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.071 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.765 HG13 ' HB2' ' A' ' 23' ' ' GLN . 14.5 p -134.76 140.32 45.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 C-N-CA 117.855 -1.538 . . . . 0.0 111.593 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.45 140.55 58.88 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-N 115.371 -0.832 . . . . 0.0 109.15 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 81.51 -10.7 49.11 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.765 ' HB2' HG13 ' A' ' 20' ' ' VAL . 2.7 mp0 -139.42 -174.89 4.0 Favored 'General case' 0 C--N 1.308 -1.203 0 O-C-N 121.137 -1.213 . . . . 0.0 108.814 179.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.42 -165.78 1.25 Allowed 'General case' 0 C--N 1.295 -1.782 0 CA-C-O 122.005 0.907 . . . . 0.0 110.368 -179.3 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.613 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 7.5 m-20 -71.12 120.11 16.21 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 115.861 -0.608 . . . . 0.0 109.701 179.214 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.866 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.5 t -83.83 115.29 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 120.482 -1.386 . . . . 0.0 110.722 178.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.413 ' CB ' ' CD ' ' A' ' 59' ' ' GLN . 23.4 t80 -53.71 138.12 35.99 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.03 HG12 HD12 ' A' ' 18' ' ' ILE . 0.6 OUTLIER -129.27 146.48 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 O-C-N 120.712 -1.242 . . . . 0.0 109.381 -179.681 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.552 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 3.7 t60 -147.7 143.85 27.9 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.424 ' CZ ' ' NE2' ' A' ' 29' ' ' HIS . 22.6 p90 -63.85 2.79 0.45 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.043 -1.036 . . . . 0.0 111.611 -179.348 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.3 t -93.75 -51.07 5.07 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.21 -1.556 . . . . 0.0 109.574 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.745 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -93.31 -44.25 8.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.177 -0.952 . . . . 0.0 108.919 179.364 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.693 ' O ' HG22 ' A' ' 33' ' ' ILE . 1.1 mp . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.698 HG21 HD11 ' A' ' 18' ' ' ILE . 21.3 m -136.18 166.06 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 120.535 -1.353 . . . . 0.0 110.551 -179.151 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.9 t -116.66 135.39 53.82 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.09 -1.006 . . . . 0.0 108.6 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.158 ' CE1' HD11 ' A' ' 2' ' ' LEU . 7.2 p90 -164.1 -178.11 5.39 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.951 -1.093 . . . . 0.0 109.695 -179.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -127.05 94.95 4.16 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.305 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.866 HD11 ' CG2' ' A' ' 26' ' ' VAL . 12.3 mt -62.17 133.11 28.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.915 -1.116 . . . . 0.0 110.339 -179.409 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.542 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.1 m -116.04 -173.48 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 178.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -123.03 116.03 22.84 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.005 -1.059 . . . . 0.0 109.531 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.94 174.26 17.22 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -38.93 -52.67 1.77 Allowed 'General case' 0 N--CA 1.505 2.298 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -178.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 27.0 mmm180 -80.77 22.37 0.6 Allowed 'General case' 0 N--CA 1.498 1.967 0 O-C-N 119.676 -1.89 . . . . 0.0 112.247 -177.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.39 -177.7 26.14 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.278 -1.439 . . . . 0.0 110.488 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.542 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 0.9 OUTLIER -65.56 152.24 82.38 Favored 'Trans proline' 0 C--N 1.32 -0.948 0 C-N-CA 122.109 1.873 . . . . 0.0 110.426 179.114 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.413 ' CD ' ' CB ' ' A' ' 27' ' ' PHE . 0.0 OUTLIER -166.04 146.91 6.65 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.19 -0.944 . . . . 0.0 111.322 -179.653 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.794 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -79.4 159.23 27.16 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 177.174 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.745 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.67 -42.6 0.76 Allowed 'General case' 0 N--CA 1.508 2.439 0 O-C-N 120.366 -1.459 . . . . 0.0 111.886 -176.456 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -119.66 53.19 1.06 Allowed 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 1.008 HG22 ' CB ' ' A' ' 49' ' ' PHE . 25.0 t -70.85 168.77 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.887 -178.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.598 ' N ' HG12 ' A' ' 63' ' ' VAL . 1.4 m -152.69 173.84 14.74 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 178.4 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.484 ' H ' HG22 ' A' ' 64' ' ' THR . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 O-C-N 121.002 -1.061 . . . . 0.0 109.458 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.911 HD12 ' O ' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.785 0 CA-C-O 120.974 0.416 . . . . 0.0 110.214 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.861 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -112.13 168.03 9.93 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.105 -0.997 . . . . 0.0 109.553 -179.202 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.514 ' O ' ' HA ' ' A' ' 46' ' ' ALA . . . -151.78 167.9 31.08 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.379 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.5 mtpp -134.75 118.38 17.01 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.146 -1.208 . . . . 0.0 110.094 -179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.556 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.8 t -43.23 142.54 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 122.78 1.276 . . . . 0.0 112.366 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.402 ' HG3' ' OE2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -97.41 -29.65 13.38 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 103.179 -2.897 . . . . 0.0 103.179 172.587 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.702 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 21.1 p-90 177.79 144.78 0.11 Allowed 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 105.957 -1.868 . . . . 0.0 105.957 177.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.492 ' CD1' HG22 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -118.84 141.0 49.05 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.487 -1.383 . . . . 0.0 109.541 179.493 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.535 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 0.2 OUTLIER -131.5 37.78 3.65 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 179.4 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' ASN . 1.2 p -37.94 -48.49 1.17 Allowed 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.44 0.638 . . . . 0.0 109.332 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -61.9 -44.76 96.14 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.412 -0.805 . . . . 0.0 109.761 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.505 ' CB ' ' OD1' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -69.05 -0.88 6.33 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.359 -0.838 . . . . 0.0 110.132 -179.796 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.484 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 108.35 -0.44 32.95 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.874 -1.155 . . . . 0.0 112.523 178.547 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.436 ' O ' ' C ' ' A' ' 10' ' ' ASN . 6.3 p90 -179.21 169.97 1.44 Allowed 'General case' 0 N--CA 1.498 1.929 0 CA-C-N 120.456 2.128 . . . . 0.0 111.991 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.585 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -143.64 143.08 11.86 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 107.755 -2.138 . . . . 0.0 107.755 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.702 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.87 141.95 40.17 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 120.205 -1.762 . . . . 0.0 110.162 -178.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.946 HD11 HG21 ' A' ' 47' ' ' VAL . 0.9 OUTLIER -107.58 163.83 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.475 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.585 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 28.6 tt0 -139.2 130.54 26.91 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.609 HG13 ' HB2' ' A' ' 23' ' ' GLN . 9.0 p -134.39 140.66 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 C-N-CA 117.594 -1.642 . . . . 0.0 111.984 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -64.05 139.36 58.76 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.242 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.12 -13.65 43.5 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.609 ' HB2' HG13 ' A' ' 20' ' ' VAL . 1.5 mt-30 -138.0 -175.98 4.28 Favored 'General case' 0 C--N 1.308 -1.212 0 O-C-N 121.254 -1.145 . . . . 0.0 108.804 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.39 -165.89 1.26 Allowed 'General case' 0 C--N 1.295 -1.773 0 CA-C-O 121.987 0.899 . . . . 0.0 110.3 -179.429 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.627 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.6 m-20 -72.08 126.51 29.97 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.011 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 1.015 HG22 ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -91.82 118.72 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.034 0 O-C-N 120.625 -1.297 . . . . 0.0 111.125 178.539 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.481 ' CB ' ' HG2' ' A' ' 59' ' ' GLN . 4.7 t80 -65.05 134.12 53.15 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.419 -0.8 . . . . 0.0 109.256 178.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.788 HG11 ' CD1' ' A' ' 18' ' ' ILE . 2.0 m -142.27 131.95 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.674 -1.266 . . . . 0.0 111.14 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.613 ' NE2' ' CZ ' ' A' ' 30' ' ' PHE . 2.5 t-160 -115.68 132.26 56.69 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.613 ' CZ ' ' NE2' ' A' ' 29' ' ' HIS . 7.4 p90 -43.96 -22.12 0.05 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.701 -1.25 . . . . 0.0 111.128 -178.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.441 ' N ' ' O ' ' A' ' 29' ' ' HIS . 1.5 m -66.24 -42.59 88.4 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.755 -1.215 . . . . 0.0 111.218 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.808 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.57 -41.33 10.85 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.95 -1.094 . . . . 0.0 108.802 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.637 HD11 HG12 ' A' ' 28' ' ' VAL . 1.5 mp . . . . . 0 C--N 1.305 -1.349 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.56 ' HB1' ' CD ' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.486 1.374 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.946 HG21 HD11 ' A' ' 18' ' ' ILE . 35.0 m -119.29 159.68 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 120.868 -1.145 . . . . 0.0 110.281 -179.478 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -114.19 136.01 53.42 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.116 -0.99 . . . . 0.0 108.57 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.915 ' CZ ' HG21 ' A' ' 26' ' ' VAL . 19.9 p90 -163.04 -176.05 4.67 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.072 -1.018 . . . . 0.0 109.87 -179.247 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -129.07 96.6 4.38 Favored 'General case' 0 C--N 1.295 -1.771 0 O-C-N 121.542 -0.724 . . . . 0.0 109.185 179.129 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 1.015 ' CD1' HG22 ' A' ' 26' ' ' VAL . 1.5 mm -61.57 139.6 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 CA-C-O 122.452 1.12 . . . . 0.0 111.137 -179.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 3.1 m -126.72 -174.25 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -123.39 115.99 22.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.966 -1.083 . . . . 0.0 109.933 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.12 171.89 15.86 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 10.6 p-10 -39.1 -52.69 1.86 Allowed 'General case' 0 N--CA 1.505 2.309 0 O-C-N 121.283 -1.128 . . . . 0.0 113.956 -178.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 11.1 ttm180 -78.8 21.96 0.39 Allowed 'General case' 0 N--CA 1.5 2.054 0 O-C-N 119.601 -1.937 . . . . 0.0 112.224 -177.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.0 -179.27 26.07 Favored Glycine 0 N--CA 1.492 2.404 0 C-N-CA 119.339 -1.41 . . . . 0.0 110.667 179.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.527 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -66.78 150.16 83.4 Favored 'Trans proline' 0 C--N 1.321 -0.915 0 C-N-CA 122.238 1.959 . . . . 0.0 110.484 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.965 ' C ' HD13 ' A' ' 51' ' ' ILE . 2.5 mt-30 -165.71 152.69 10.09 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.245 -0.91 . . . . 0.0 111.03 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.808 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.15 161.43 22.81 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 177.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.808 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.0 -41.71 0.74 Allowed 'General case' 0 N--CA 1.51 2.526 0 O-C-N 120.273 -1.517 . . . . 0.0 111.725 -176.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 9.3 m-20 -120.1 52.28 1.14 Allowed 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.9 HG22 ' CB ' ' A' ' 49' ' ' PHE . 12.5 t -68.74 170.6 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 121.819 0.818 . . . . 0.0 109.69 -179.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.552 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -152.74 171.75 17.74 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 178.553 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.407 ' O ' ' HG2' ' A' ' 65' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.598 0 O-C-N 121.003 -1.06 . . . . 0.0 109.584 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.191 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.77 0 CA-C-O 121.082 0.467 . . . . 0.0 110.154 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.797 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.2 OUTLIER -111.82 161.56 16.22 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.169 -0.957 . . . . 0.0 110.151 -178.527 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.02 157.89 24.51 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.429 ' HD3' ' OE1' ' A' ' 3' ' ' GLU . 10.2 mmtp -130.27 114.55 15.78 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.318 -1.107 . . . . 0.0 109.645 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.553 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.4 t -41.29 140.24 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 CA-C-O 122.8 1.286 . . . . 0.0 112.443 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.01 -30.33 12.4 Favored 'General case' 0 C--N 1.289 -2.041 0 N-CA-C 103.126 -2.916 . . . . 0.0 103.126 172.579 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.697 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 17.3 p-90 176.96 146.27 0.1 Allowed 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 106.228 -1.768 . . . . 0.0 106.228 177.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.881 ' CE1' HG21 ' A' ' 28' ' ' VAL . 1.5 t80 -113.66 143.23 44.94 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 120.576 -1.327 . . . . 0.0 109.433 179.394 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.56 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 90.6 m-20 -131.24 39.01 3.59 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -39.08 -47.82 1.58 Allowed 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.436 0.636 . . . . 0.0 109.525 -179.087 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -61.8 -44.52 96.7 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.393 -0.817 . . . . 0.0 109.706 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.543 ' CG ' ' HB3' ' A' ' 10' ' ' ASN . 12.6 mmmt -70.55 2.3 4.17 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.429 -0.794 . . . . 0.0 110.45 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 113.27 -10.57 24.38 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 119.564 -1.303 . . . . 0.0 112.063 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.556 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 3.9 p90 175.32 179.1 0.15 Allowed 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.03 -1.865 . . . . 0.0 111.302 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.907 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -136.34 149.38 20.1 Favored Glycine 0 N--CA 1.498 2.803 0 N-CA-C 107.482 -2.247 . . . . 0.0 107.482 179.279 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.697 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.2 m-85 -105.31 140.68 38.07 Favored 'General case' 0 N--CA 1.484 1.252 0 O-C-N 120.272 -1.722 . . . . 0.0 109.792 -178.816 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.049 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.2 mt -106.91 162.03 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 178.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.572 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 13.2 tt0 -140.07 130.28 25.12 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 177.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.802 HG13 ' HB2' ' A' ' 23' ' ' GLN . 14.1 p -135.49 140.96 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 C-N-CA 117.526 -1.67 . . . . 0.0 111.953 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -65.33 140.67 58.7 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.123 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.71 -10.48 45.47 Favored Glycine 0 N--CA 1.486 2.011 0 N-CA-C 108.662 -1.775 . . . . 0.0 108.662 -178.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.802 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.9 OUTLIER -140.33 -177.71 5.15 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 121.323 -1.104 . . . . 0.0 108.439 179.619 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 69.7 m-20 -100.84 -166.28 1.3 Allowed 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 121.913 0.863 . . . . 0.0 110.655 -179.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.599 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 0.9 OUTLIER -72.54 126.55 30.15 Favored 'General case' 0 N--CA 1.487 1.421 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.741 179.146 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.854 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.4 t -92.84 114.74 30.19 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 120.494 -1.379 . . . . 0.0 111.059 178.479 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.454 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 11.1 t80 -56.5 135.64 54.38 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.049 ' CG1' HD12 ' A' ' 18' ' ' ILE . 0.6 OUTLIER -129.5 142.55 43.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 120.6 -1.313 . . . . 0.0 110.393 -178.118 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.809 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.8 t-160 -117.48 155.13 30.24 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.318 -0.994 . . . . 0.0 108.318 179.522 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.517 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 41.1 p90 -84.03 33.05 0.48 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.964 -1.085 . . . . 0.0 109.82 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -135.7 -31.1 0.96 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.046 -1.034 . . . . 0.0 109.732 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.747 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.13 -40.82 11.37 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.021 -1.049 . . . . 0.0 108.649 179.646 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.809 HD12 ' O ' ' A' ' 29' ' ' HIS . 2.8 mt . . . . . 0 N--CA 1.485 1.321 0 O-C-N 121.388 -0.82 . . . . 0.0 109.178 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.689 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.486 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.613 HG21 HD11 ' A' ' 18' ' ' ILE . 28.6 m -111.49 159.48 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.823 -1.173 . . . . 0.0 109.911 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.6 p -115.72 123.55 48.58 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.076 -1.015 . . . . 0.0 108.429 179.448 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.191 ' CE1' HD11 ' A' ' 2' ' ' LEU . 8.8 p90 -151.92 -178.7 6.91 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.959 -1.088 . . . . 0.0 109.905 -179.429 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -125.36 94.02 4.03 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.483 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.854 HD11 ' CG2' ' A' ' 26' ' ' VAL . 10.5 mt -60.63 140.0 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 O-C-N 120.92 -1.112 . . . . 0.0 110.032 -179.381 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.584 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.9 m -124.52 -173.01 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 106.384 -1.71 . . . . 0.0 106.384 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -122.53 110.75 15.97 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 120.877 -1.139 . . . . 0.0 109.502 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.4 171.13 16.55 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -37.95 -52.25 1.36 Allowed 'General case' 0 N--CA 1.505 2.288 0 O-C-N 121.426 -1.044 . . . . 0.0 113.571 -178.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.21 22.53 0.16 Allowed 'General case' 0 N--CA 1.5 2.049 0 O-C-N 119.66 -1.9 . . . . 0.0 112.252 -178.084 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.424 ' O ' ' HG2' ' A' ' 59' ' ' GLN . . . 97.43 -175.52 30.58 Favored Glycine 0 N--CA 1.492 2.432 0 O-C-N 120.399 -1.438 . . . . 0.0 110.266 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.584 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.3 Cg_endo -65.22 131.36 28.19 Favored 'Trans proline' 0 C--N 1.32 -0.936 0 C-N-CA 121.858 1.706 . . . . 0.0 109.839 178.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.463 ' OE1' ' O ' ' A' ' 58' ' ' PRO . 10.4 mm100 -143.25 148.15 35.95 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.93 -1.106 . . . . 0.0 111.916 -178.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.713 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.1 158.2 23.8 Favored 'General case' 0 N--CA 1.496 1.872 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 176.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.747 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.29 -42.54 0.71 Allowed 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.219 -1.551 . . . . 0.0 111.876 -176.454 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 43.1 t30 -119.76 54.3 1.02 Allowed 'General case' 0 C--N 1.285 -2.238 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.916 HG22 ' CB ' ' A' ' 49' ' ' PHE . 18.4 t -68.62 164.94 2.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.596 -179.193 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.566 HG22 ' H ' ' A' ' 65' ' ' LYS . 0.7 OUTLIER -151.3 -175.8 5.32 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 178.804 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.566 ' H ' HG22 ' A' ' 64' ' ' THR . 25.1 mmtp . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.035 -1.041 . . . . 0.0 109.653 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.026 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.776 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.91 ' OE2' ' HB1' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -113.74 153.48 28.95 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 120.931 -1.106 . . . . 0.0 109.92 -179.716 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.442 ' C ' ' HG3' ' A' ' 5' ' ' LYS . . . -136.37 169.7 23.62 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.442 ' HG3' ' C ' ' A' ' 4' ' ' GLY . 7.6 mttm -138.01 123.58 19.69 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.943 -1.327 . . . . 0.0 109.991 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.596 HG13 ' H ' ' A' ' 8' ' ' TRP . 4.5 t -47.09 143.53 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 CA-C-O 122.857 1.313 . . . . 0.0 112.221 -179.538 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.74 -28.23 13.6 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 103.282 -2.859 . . . . 0.0 103.282 172.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.713 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 23.1 p-90 177.92 145.71 0.12 Allowed 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.976 ' CE1' HG21 ' A' ' 28' ' ' VAL . 0.8 OUTLIER -112.72 148.8 33.97 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 120.528 -1.357 . . . . 0.0 109.902 179.821 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.591 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 2.2 m120 -129.25 36.87 4.11 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 178.471 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.6 p -38.74 -50.95 1.69 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.9 -0.5 . . . . 0.0 110.41 -178.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.431 ' OE2' ' O ' ' A' ' 12' ' ' GLU . 6.7 tp10 -63.96 -37.69 88.34 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.04 -1.038 . . . . 0.0 110.151 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.591 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 1.1 mptt -75.23 2.38 11.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.962 -1.086 . . . . 0.0 110.057 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.468 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 100.63 8.56 48.77 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.983 -1.103 . . . . 0.0 112.828 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.556 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 7.0 p90 177.08 172.6 0.48 Allowed 'General case' 0 N--CA 1.501 2.11 0 CA-C-N 120.213 2.007 . . . . 0.0 111.492 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.93 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -145.49 153.1 25.07 Favored Glycine 0 N--CA 1.501 3.012 0 N-CA-C 107.152 -2.379 . . . . 0.0 107.152 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.713 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.1 m-85 -112.32 139.7 47.66 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 119.72 -2.047 . . . . 0.0 110.095 -179.112 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.05 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.2 mt -107.29 162.16 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.589 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 4.4 tt0 -140.42 133.81 29.9 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.138 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.622 HG13 ' HB2' ' A' ' 23' ' ' GLN . 7.6 p -137.9 140.67 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 C-N-CA 117.936 -1.505 . . . . 0.0 111.804 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -63.92 140.6 58.89 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.302 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.86 -13.8 46.46 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.622 ' HB2' HG13 ' A' ' 20' ' ' VAL . 1.2 mt-30 -138.48 -175.48 4.14 Favored 'General case' 0 C--N 1.309 -1.166 0 O-C-N 121.326 -1.102 . . . . 0.0 108.746 179.612 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.31 -165.37 1.21 Allowed 'General case' 0 C--N 1.295 -1.783 0 CA-C-O 122.044 0.926 . . . . 0.0 110.324 -179.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.589 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 38.1 p-10 -71.34 120.69 17.28 Favored 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.833 179.393 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 1.028 HG22 ' CD1' ' A' ' 51' ' ' ILE . 2.5 t -83.26 114.06 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 120.512 -1.367 . . . . 0.0 110.523 178.428 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.434 ' CB ' ' HG2' ' A' ' 59' ' ' GLN . 3.2 t80 -54.24 140.65 32.17 Favored 'General case' 0 C--N 1.296 -1.761 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 178.511 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.05 ' CG1' HD12 ' A' ' 18' ' ' ILE . 0.6 OUTLIER -132.51 148.3 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 120.699 -1.251 . . . . 0.0 110.537 -178.583 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 24.5 t-80 -144.61 137.6 26.82 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 13.4 p90 -65.78 5.91 0.41 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.789 -1.194 . . . . 0.0 111.52 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.12 -35.57 11.84 Favored 'General case' 0 N--CA 1.484 1.267 0 O-C-N 120.345 -1.472 . . . . 0.0 108.744 179.307 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.748 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.82 -41.52 10.6 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.246 -0.909 . . . . 0.0 108.666 179.38 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.802 HD11 ' HB ' ' A' ' 28' ' ' VAL . 7.0 mt . . . . . 0 N--CA 1.49 1.534 0 C-N-CA 119.5 -0.88 . . . . 0.0 109.027 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.91 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.568 HG21 ' CD1' ' A' ' 18' ' ' ILE . 33.5 m -123.52 163.61 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 120.77 -1.206 . . . . 0.0 110.525 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.2 p -117.52 131.9 56.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.147 -0.971 . . . . 0.0 108.951 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.026 ' CE1' HD11 ' A' ' 2' ' ' LEU . 23.0 p90 -161.74 -179.3 7.12 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.865 -1.147 . . . . 0.0 109.966 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -127.5 95.45 4.25 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.668 -0.645 . . . . 0.0 109.484 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 1.028 ' CD1' HG22 ' A' ' 26' ' ' VAL . 1.2 mm -61.49 136.14 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 CA-C-O 122.469 1.128 . . . . 0.0 110.857 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.528 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 4.0 m -121.88 -175.01 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 179.364 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.73 114.58 20.13 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.977 -1.077 . . . . 0.0 109.413 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.34 172.68 18.68 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.126 -1.589 . . . . 0.0 109.126 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -37.8 -52.14 1.29 Allowed 'General case' 0 N--CA 1.504 2.252 0 O-C-N 121.426 -1.043 . . . . 0.0 113.411 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 7.2 mtm180 -75.8 22.72 0.14 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 119.609 -1.932 . . . . 0.0 112.162 -178.216 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.32 -177.05 34.65 Favored Glycine 0 N--CA 1.49 2.276 0 O-C-N 120.48 -1.388 . . . . 0.0 109.9 179.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.528 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -66.65 148.9 83.89 Favored 'Trans proline' 0 C--N 1.317 -1.088 0 C-N-CA 121.911 1.741 . . . . 0.0 109.781 178.736 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.95 ' C ' HD13 ' A' ' 51' ' ' ILE . 2.6 mt-30 -165.59 151.25 9.24 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.067 -1.021 . . . . 0.0 111.468 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.759 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -81.7 158.79 24.11 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 177.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.748 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.4 -42.45 0.7 Allowed 'General case' 0 N--CA 1.507 2.41 0 O-C-N 120.336 -1.477 . . . . 0.0 111.358 -176.788 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -119.43 61.72 0.82 Allowed 'General case' 0 C--N 1.282 -2.357 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.96 HG22 ' CB ' ' A' ' 49' ' ' PHE . 18.9 t -79.66 172.48 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.036 -178.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.57 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -153.93 171.08 19.56 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.764 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.501 0 O-C-N 120.931 -1.106 . . . . 0.0 109.407 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.089 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.822 0 CA-C-O 121.042 0.448 . . . . 0.0 110.036 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.802 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.4 OUTLIER -112.04 160.89 17.05 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.194 -0.941 . . . . 0.0 110.155 -178.994 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.23 168.32 28.36 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 6' ' ' VAL . 5.2 mttt -139.86 120.18 13.92 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.026 -1.279 . . . . 0.0 110.086 -179.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.614 HG22 ' CD1' ' A' ' 9' ' ' PHE . 3.7 t -41.55 140.51 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 CA-C-O 122.736 1.255 . . . . 0.0 112.073 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.499 ' HG3' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -98.09 -28.1 13.91 Favored 'General case' 0 C--N 1.289 -2.054 0 N-CA-C 103.536 -2.765 . . . . 0.0 103.536 173.008 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 26.1 p-90 177.55 141.74 0.09 Allowed 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 178.17 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.614 ' CD1' HG22 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -120.5 139.71 52.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.511 -1.368 . . . . 0.0 110.162 -179.893 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.52 ' ND2' ' HB2' ' A' ' 13' ' ' LYS . 2.0 t30 -132.05 32.88 3.97 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 179.245 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.457 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -37.45 -48.26 0.95 Allowed 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 121.634 0.73 . . . . 0.0 109.192 -179.404 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -59.99 -47.52 85.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.565 -0.709 . . . . 0.0 109.898 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.52 ' HB2' ' ND2' ' A' ' 10' ' ' ASN . 5.1 mptt -69.52 0.36 5.42 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.428 -0.795 . . . . 0.0 110.64 -179.409 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.438 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 109.9 4.38 29.68 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 119.67 -1.253 . . . . 0.0 113.063 178.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.466 ' O ' ' C ' ' A' ' 10' ' ' ASN . 5.0 p90 179.6 166.36 1.12 Allowed 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 120.975 2.387 . . . . 0.0 112.163 179.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.532 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -147.4 143.25 11.05 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 107.668 -2.173 . . . . 0.0 107.668 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.0 m-85 -115.07 138.95 50.29 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.196 -1.767 . . . . 0.0 110.231 -178.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.796 HD11 HG21 ' A' ' 47' ' ' VAL . 1.1 mt -106.74 152.71 8.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 177.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.556 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 1.7 tt0 -129.23 136.29 49.92 Favored 'General case' 0 C--N 1.286 -2.175 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.325 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.571 HG13 ' HB2' ' A' ' 23' ' ' GLN . 6.6 p -138.88 139.43 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 117.592 -1.643 . . . . 0.0 111.861 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -62.41 140.78 58.57 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.112 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.76 -18.15 36.44 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.51 -1.836 . . . . 0.0 108.51 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.571 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.1 OUTLIER -136.44 -175.92 4.16 Favored 'General case' 0 N--CA 1.484 1.226 0 O-C-N 121.423 -1.045 . . . . 0.0 108.334 179.336 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.91 -166.38 1.3 Allowed 'General case' 0 C--N 1.296 -1.749 0 CA-C-O 122.143 0.973 . . . . 0.0 111.014 -178.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.556 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 1.9 p-10 -73.21 102.2 3.57 Favored 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.553 178.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.885 HG13 ' H ' ' A' ' 60' ' ' ALA . 2.7 t -66.65 128.38 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 120.422 -1.424 . . . . 0.0 111.04 179.326 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.55 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 3.8 t80 -71.1 135.99 47.98 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.803 HG13 HG12 ' A' ' 26' ' ' VAL . 11.2 m -149.88 128.21 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 120.406 -1.434 . . . . 0.0 110.721 -179.574 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.634 ' NE2' ' CE2' ' A' ' 30' ' ' PHE . 10.9 t-80 -99.21 166.31 11.29 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.634 ' CE2' ' NE2' ' A' ' 29' ' ' HIS . 48.5 p90 -82.35 31.61 0.4 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.806 -1.184 . . . . 0.0 110.062 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 32.5 p -116.81 -38.2 3.49 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.976 -1.078 . . . . 0.0 109.11 179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.751 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.56 -41.92 9.96 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 108.508 179.356 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.603 ' N ' HD12 ' A' ' 33' ' ' ILE . 1.5 mp . . . . . 0 N--CA 1.486 1.344 0 O-C-N 121.535 -0.728 . . . . 0.0 109.083 179.729 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.68 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.486 1.362 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.796 HG21 HD11 ' A' ' 18' ' ' ILE . 29.9 m -135.92 162.98 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.852 -1.155 . . . . 0.0 109.851 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.3 p -116.0 137.1 52.42 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.036 -1.04 . . . . 0.0 108.442 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.089 ' CE1' HD11 ' A' ' 2' ' ' LEU . 10.4 p90 -162.43 -175.74 4.68 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.884 -1.135 . . . . 0.0 109.852 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -127.35 98.5 5.28 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.555 -0.716 . . . . 0.0 109.586 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.629 HD11 ' CG2' ' A' ' 26' ' ' VAL . 5.6 mt -61.89 143.69 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 CA-C-O 122.529 1.157 . . . . 0.0 111.309 -179.482 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.52 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 13.9 m -129.51 -176.76 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.27 116.78 23.92 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.728 -1.232 . . . . 0.0 110.369 -179.681 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -116.32 165.03 12.24 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.523 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.431 ' C ' ' O ' ' A' ' 54' ' ' GLY . 4.6 m-20 -38.31 -54.67 1.41 Allowed 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.072 -1.252 . . . . 0.0 112.914 -178.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.1 ttm180 -69.7 -21.26 63.51 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 119.564 -1.96 . . . . 0.0 113.069 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.69 179.2 25.33 Favored Glycine 0 N--CA 1.492 2.415 0 O-C-N 120.27 -1.519 . . . . 0.0 110.358 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.52 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -65.81 140.82 62.85 Favored 'Trans proline' 0 C--N 1.317 -1.094 0 C-N-CA 122.007 1.805 . . . . 0.0 110.464 179.206 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.522 ' HG2' ' CB ' ' A' ' 27' ' ' PHE . 30.3 mt-30 -154.83 151.78 29.03 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.347 -0.846 . . . . 0.0 110.71 -179.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.885 ' H ' HG13 ' A' ' 26' ' ' VAL . . . -83.83 167.76 16.76 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 177.328 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.751 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.23 -44.07 0.71 Allowed 'General case' 0 N--CA 1.503 2.22 0 O-C-N 120.289 -1.507 . . . . 0.0 111.672 -176.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.41 ' OD1' ' O ' ' A' ' 62' ' ' ASN . 21.3 p30 -120.0 52.16 1.14 Allowed 'General case' 0 C--N 1.287 -2.11 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.973 HG22 ' CB ' ' A' ' 49' ' ' PHE . 20.0 t -67.81 164.13 2.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 121.561 0.696 . . . . 0.0 109.681 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.484 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -146.24 164.29 32.76 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 178.672 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.526 ' HA ' HG12 ' A' ' 47' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.646 0 O-C-N 121.081 -1.012 . . . . 0.0 109.75 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.145 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.889 0 CA-C-O 120.8 0.333 . . . . 0.0 110.196 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.866 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.1 OUTLIER -112.66 167.27 10.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.858 -1.151 . . . . 0.0 109.651 -179.284 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -148.54 159.81 28.16 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.7 mttt -133.88 117.96 17.39 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.373 -1.075 . . . . 0.0 110.742 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.605 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.5 t -37.89 146.67 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 123.122 1.439 . . . . 0.0 113.143 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.63 -30.65 9.84 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 103.191 -2.892 . . . . 0.0 103.191 172.137 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.714 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 22.6 p-90 177.66 145.92 0.12 Allowed 'General case' 0 N--CA 1.484 1.267 0 N-CA-C 106.035 -1.839 . . . . 0.0 106.035 177.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.847 ' CE1' HG21 ' A' ' 28' ' ' VAL . 1.4 t80 -119.18 138.45 52.93 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.442 -1.411 . . . . 0.0 109.611 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.516 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.2 t-20 -133.65 36.76 3.32 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.651 ' HG ' ' HD2' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -37.21 -49.59 0.93 Allowed 'General case' 0 N--CA 1.495 1.818 0 CA-C-O 121.443 0.639 . . . . 0.0 109.541 -179.451 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -60.92 -46.22 91.53 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.475 -0.766 . . . . 0.0 109.806 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.501 ' HD2' ' N ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -69.96 1.0 4.96 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.51 -0.744 . . . . 0.0 110.453 -179.606 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.44 ' O ' ' CB ' ' A' ' 15' ' ' PHE . . . 123.35 -19.52 7.62 Favored Glycine 0 N--CA 1.491 2.355 0 C-N-CA 119.685 -1.245 . . . . 0.0 111.946 178.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.471 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 5.3 p90 173.7 178.4 0.11 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.056 -1.85 . . . . 0.0 111.456 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.954 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -135.52 145.81 17.84 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 107.884 -2.087 . . . . 0.0 107.884 179.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.714 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.7 m-30 -104.57 142.18 35.1 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 120.247 -1.737 . . . . 0.0 109.664 -179.245 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.005 HD12 HG11 ' A' ' 28' ' ' VAL . 0.5 OUTLIER -106.34 164.51 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 178.56 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.568 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 3.1 tm-20 -141.68 129.77 22.08 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.693 HG13 ' HB2' ' A' ' 23' ' ' GLN . 10.3 p -135.59 141.65 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 C-N-CA 117.695 -1.602 . . . . 0.0 112.043 -179.657 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -65.65 140.25 58.48 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-N 115.381 -0.827 . . . . 0.0 108.827 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.41 -14.01 42.96 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.693 ' HB2' HG13 ' A' ' 20' ' ' VAL . 1.6 mm100 -137.66 -177.37 4.77 Favored 'General case' 0 N--CA 1.483 1.202 0 O-C-N 121.333 -1.098 . . . . 0.0 108.407 179.538 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -100.73 -166.27 1.3 Allowed 'General case' 0 C--N 1.296 -1.748 0 CA-C-O 121.962 0.887 . . . . 0.0 110.378 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.612 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.4 m-20 -72.08 123.46 22.88 Favored 'General case' 0 N--CA 1.486 1.367 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.676 179.149 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.88 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.4 t -84.91 110.5 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.02 0 O-C-N 120.589 -1.32 . . . . 0.0 111.454 178.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -55.37 133.73 49.87 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 178.07 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.005 HG11 HD12 ' A' ' 18' ' ' ILE . 0.6 OUTLIER -132.75 137.19 54.53 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 C-N-CA 117.891 -1.524 . . . . 0.0 110.661 -178.782 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.714 ' O ' HD12 ' A' ' 33' ' ' ILE . 5.6 t-160 -109.81 159.49 17.15 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.572 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 46.1 p90 -82.67 39.86 0.64 Allowed 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.763 -1.211 . . . . 0.0 109.831 -179.674 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.1 t -137.65 -33.2 0.73 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.816 -1.178 . . . . 0.0 110.518 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.734 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -93.53 -49.91 5.67 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.961 -1.087 . . . . 0.0 109.706 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.823 HG23 ' CG1' ' A' ' 63' ' ' VAL . 1.4 mp . . . . . 0 N--CA 1.491 1.575 0 O-C-N 121.677 -0.64 . . . . 0.0 110.359 -178.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.764 HG21 HD11 ' A' ' 18' ' ' ILE . 26.2 m -124.13 163.13 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 120.627 -1.296 . . . . 0.0 110.882 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 22.7 p -115.87 137.22 52.3 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 108.5 179.362 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.145 ' CE1' HD11 ' A' ' 2' ' ' LEU . 9.4 p90 -163.66 -177.97 5.5 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.816 -1.177 . . . . 0.0 109.941 -179.257 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -127.15 93.02 3.64 Favored 'General case' 0 C--N 1.295 -1.773 0 O-C-N 121.688 -0.633 . . . . 0.0 109.475 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.88 HD11 ' CG2' ' A' ' 26' ' ' VAL . 16.3 mt -62.1 128.92 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.023 -1.048 . . . . 0.0 109.886 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 16.1 m -108.11 -176.59 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 178.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -123.32 114.66 20.49 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.012 -1.055 . . . . 0.0 109.735 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.405 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -125.89 169.04 17.86 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.591 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' A' ' 54' ' ' GLY . 22.1 m120 -37.44 -51.99 1.13 Allowed 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.227 -1.161 . . . . 0.0 113.412 -178.45 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.9 tpt180 -75.33 22.62 0.12 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 119.718 -1.864 . . . . 0.0 112.352 -178.14 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.02 -178.32 31.94 Favored Glycine 0 N--CA 1.494 2.551 0 O-C-N 120.414 -1.429 . . . . 0.0 110.269 179.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.54 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -67.91 155.01 71.4 Favored 'Trans proline' 0 C--N 1.32 -0.947 0 C-N-CA 122.005 1.803 . . . . 0.0 109.918 178.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.436 ' N ' HG23 ' A' ' 51' ' ' ILE . 0.3 OUTLIER -166.07 143.22 5.31 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.982 -1.074 . . . . 0.0 111.398 -179.693 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.775 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -78.09 157.63 29.44 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 177.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.734 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.54 -44.26 0.75 Allowed 'General case' 0 N--CA 1.507 2.395 0 O-C-N 120.498 -1.376 . . . . 0.0 111.933 -176.407 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -119.81 51.78 1.16 Allowed 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.976 HG22 ' CB ' ' A' ' 49' ' ' PHE . 21.2 t -68.03 169.2 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-O 121.693 0.758 . . . . 0.0 109.513 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.592 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -154.62 178.14 10.43 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 178.237 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.579 ' N ' ' CD ' ' A' ' 65' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.735 0 O-C-N 121.043 -1.036 . . . . 0.0 109.557 -179.712 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.192 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.808 0 CA-C-O 121.09 0.471 . . . . 0.0 110.011 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.845 ' OE2' ' HB1' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -113.92 149.03 35.8 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 121.213 -0.929 . . . . 0.0 110.389 -179.372 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.438 ' HA3' HG21 ' A' ' 18' ' ' ILE . . . -121.33 166.16 14.26 Favored Glycine 0 N--CA 1.483 1.796 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 179.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.47 ' O ' ' C ' ' A' ' 6' ' ' VAL . 2.0 mttm -140.3 119.0 12.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.922 -1.34 . . . . 0.0 109.609 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.504 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.7 t -33.5 136.67 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 CA-C-O 122.913 1.34 . . . . 0.0 113.401 -179.327 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.489 ' CG ' ' HB3' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -101.8 -31.51 10.71 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 103.149 -2.908 . . . . 0.0 103.149 172.61 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.699 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 22.8 p-90 174.25 145.25 0.05 Allowed 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 178.009 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.595 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.2 OUTLIER -114.21 147.04 39.58 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.149 -1.594 . . . . 0.0 109.952 179.333 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.544 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 80.5 m-20 -130.21 38.68 3.75 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 179.013 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' ASN . 24.7 p -40.89 -41.59 1.64 Allowed 'General case' 0 N--CA 1.488 1.47 0 CA-C-O 121.71 0.767 . . . . 0.0 109.103 -179.078 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -59.9 -48.4 81.87 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.537 -0.727 . . . . 0.0 110.414 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.567 ' N ' ' CD ' ' A' ' 13' ' ' LYS . 2.2 mptp? -73.83 4.35 5.36 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.215 -0.928 . . . . 0.0 110.125 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.414 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 92.24 23.55 26.71 Favored Glycine 0 N--CA 1.49 2.242 0 C-N-CA 120.251 -0.976 . . . . 0.0 112.144 178.549 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.496 ' O ' ' C ' ' A' ' 10' ' ' ASN . 26.7 p90 179.44 167.19 1.09 Allowed 'General case' 0 N--CA 1.501 2.076 0 CA-C-N 120.102 1.951 . . . . 0.0 111.631 179.447 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.595 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -149.0 150.89 23.09 Favored Glycine 0 N--CA 1.497 2.752 0 N-CA-C 106.995 -2.442 . . . . 0.0 106.995 179.328 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.699 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 6.1 m-85 -117.24 138.31 51.8 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 120.035 1.917 . . . . 0.0 110.235 -178.648 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.547 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.7 mt -105.47 146.55 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.809 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.56 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 9.6 pt-20 -121.01 137.02 54.85 Favored 'General case' 0 C--N 1.285 -2.229 0 C-N-CA 119.472 -0.891 . . . . 0.0 108.944 178.45 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.52 HG13 ' HB2' ' A' ' 23' ' ' GLN . 10.0 p -138.73 140.93 38.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 C-N-CA 117.822 -1.551 . . . . 0.0 111.787 179.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.87 140.49 58.28 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.391 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 87.77 -19.1 35.16 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.52 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -136.4 -175.43 4.0 Favored 'General case' 0 C--N 1.308 -1.219 0 O-C-N 121.416 -1.049 . . . . 0.0 108.693 179.406 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.61 -165.1 1.17 Allowed 'General case' 0 C--N 1.296 -1.756 0 CA-C-O 122.009 0.909 . . . . 0.0 110.588 -179.051 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.56 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 0.9 OUTLIER -71.65 93.24 1.23 Allowed 'General case' 0 N--CA 1.487 1.388 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.037 179.257 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.822 HG13 ' H ' ' A' ' 60' ' ' ALA . 2.7 t -56.27 142.4 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 120.299 -1.501 . . . . 0.0 109.952 178.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.498 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 5.0 t80 -71.69 146.3 48.3 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 176.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.859 ' HB ' HD11 ' A' ' 33' ' ' ILE . 2.0 m -142.06 113.96 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 120.332 -1.48 . . . . 0.0 110.363 -179.299 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.691 ' O ' HD12 ' A' ' 33' ' ' ILE . 7.5 t60 -99.55 148.95 23.74 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 178.296 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -79.86 32.71 0.26 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.747 -1.221 . . . . 0.0 110.163 -179.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.78 -36.93 3.34 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.963 -1.085 . . . . 0.0 108.924 179.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.706 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.36 -47.16 7.33 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 179.366 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.859 HD11 ' HB ' ' A' ' 28' ' ' VAL . 11.6 mt . . . . . 0 N--CA 1.487 1.397 0 CA-C-O 121.495 0.664 . . . . 0.0 109.44 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.845 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.486 1.374 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.5 HG21 ' CD1' ' A' ' 18' ' ' ILE . 31.3 m -122.32 165.06 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 120.704 -1.247 . . . . 0.0 110.462 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.4 p -117.01 122.55 44.53 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.192 ' CE1' HD11 ' A' ' 2' ' ' LEU . 6.3 p90 -150.85 -178.45 6.59 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 120.858 -1.151 . . . . 0.0 109.726 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -127.71 95.02 4.1 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.751 HD11 ' CG2' ' A' ' 26' ' ' VAL . 13.3 mt -62.35 136.34 25.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 CA-C-O 122.326 1.06 . . . . 0.0 110.906 -179.165 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.515 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 11.5 m -119.53 -176.61 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 179.124 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -123.48 113.66 19.05 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.01 -1.057 . . . . 0.0 109.629 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.23 171.66 16.52 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -37.99 -52.13 1.37 Allowed 'General case' 0 N--CA 1.505 2.292 0 O-C-N 121.367 -1.078 . . . . 0.0 113.735 -178.363 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.38 22.38 0.23 Allowed 'General case' 0 N--CA 1.5 2.046 0 O-C-N 119.655 -1.903 . . . . 0.0 112.247 -177.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.18 -176.97 29.67 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.451 -1.357 . . . . 0.0 110.257 179.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.515 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -66.94 153.43 77.93 Favored 'Trans proline' 0 C--N 1.32 -0.938 0 C-N-CA 121.915 1.744 . . . . 0.0 109.977 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.412 ' CD ' ' HB2' ' A' ' 27' ' ' PHE . 0.0 OUTLIER -165.65 147.04 7.17 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.207 -0.933 . . . . 0.0 111.083 -179.428 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.822 ' H ' HG13 ' A' ' 26' ' ' VAL . . . -81.04 161.7 24.09 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 177.051 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.706 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.27 -44.98 0.77 Allowed 'General case' 0 N--CA 1.508 2.441 0 O-C-N 120.155 -1.59 . . . . 0.0 111.93 -176.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -119.02 50.73 1.18 Allowed 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.953 HG22 ' CB ' ' A' ' 49' ' ' PHE . 19.9 t -64.63 157.64 4.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.76 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.409 HG22 ' H ' ' A' ' 65' ' ' LYS . 0.9 OUTLIER -142.14 173.57 11.4 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.153 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.409 ' H ' HG22 ' A' ' 64' ' ' THR . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.57 0 O-C-N 120.929 -1.107 . . . . 0.0 109.376 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.935 HD13 ' O ' ' A' ' 2' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.858 0 CA-C-O 121.467 0.651 . . . . 0.0 110.385 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.683 ' N ' HD22 ' A' ' 2' ' ' LEU . 0.1 OUTLIER -121.26 136.75 54.92 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.473 -0.767 . . . . 0.0 109.498 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -129.59 -164.19 11.35 Favored Glycine 0 N--CA 1.484 1.834 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 20.9 ttpt -151.71 135.9 16.68 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.882 -1.364 . . . . 0.0 111.048 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.555 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.3 t -42.58 140.07 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 122.865 1.317 . . . . 0.0 112.856 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.438 ' HG3' ' OE1' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -97.4 -31.13 12.53 Favored 'General case' 0 C--N 1.29 -2.011 0 N-CA-C 103.009 -2.96 . . . . 0.0 103.009 172.631 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.707 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.2 p-90 177.45 145.85 0.11 Allowed 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 177.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -113.81 146.32 40.12 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 120.591 -1.318 . . . . 0.0 109.61 179.234 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.562 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 31.4 m-20 -130.08 43.03 3.19 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 10' ' ' ASN . 53.4 p -41.33 -41.44 1.94 Allowed 'General case' 0 N--CA 1.489 1.511 0 CA-C-O 121.612 0.72 . . . . 0.0 109.077 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -59.49 -49.37 78.06 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.435 -0.791 . . . . 0.0 110.607 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.534 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -72.95 4.36 4.3 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.01 -1.056 . . . . 0.0 110.395 -179.429 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.56 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 91.46 23.91 27.62 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 120.051 -1.071 . . . . 0.0 111.933 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.473 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 11.1 p90 178.92 167.63 0.93 Allowed 'General case' 0 N--CA 1.499 1.987 0 CA-C-N 120.122 1.961 . . . . 0.0 111.815 179.306 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -146.58 144.33 12.59 Favored Glycine 0 N--CA 1.497 2.758 0 N-CA-C 107.271 -2.331 . . . . 0.0 107.271 179.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.707 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.1 m-85 -110.13 142.68 41.3 Favored 'General case' 0 N--CA 1.482 1.134 0 O-C-N 120.013 -1.874 . . . . 0.0 110.153 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.003 HD12 HG21 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -105.91 165.23 3.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 177.975 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.591 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 6.8 tt0 -133.92 130.17 37.36 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.47 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.781 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.3 p -131.95 139.11 51.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 C-N-CA 117.728 -1.589 . . . . 0.0 111.699 -179.645 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -65.4 140.7 58.66 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.266 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.2 -9.58 46.8 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.781 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -139.78 -175.43 4.21 Favored 'General case' 0 C--N 1.309 -1.158 0 O-C-N 121.125 -1.221 . . . . 0.0 108.871 179.675 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -100.48 -165.68 1.24 Allowed 'General case' 0 C--N 1.295 -1.77 0 CA-C-O 122.208 1.004 . . . . 0.0 110.583 -178.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.594 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.2 m-20 -71.04 119.95 15.9 Favored 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 115.714 -0.676 . . . . 0.0 109.74 179.353 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.861 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.2 t -78.82 114.31 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 120.674 -1.267 . . . . 0.0 111.398 178.632 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.62 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 2.0 t80 -66.26 125.03 24.3 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.38 -0.971 . . . . 0.0 108.38 178.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.003 HG21 HD12 ' A' ' 18' ' ' ILE . 2.3 m -143.99 136.82 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 120.593 -1.317 . . . . 0.0 110.26 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.629 ' NE2' ' CE1' ' A' ' 30' ' ' PHE . 35.6 t60 -98.85 166.91 11.07 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 179.273 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.629 ' CE1' ' NE2' ' A' ' 29' ' ' HIS . 42.0 p90 -83.61 38.99 0.65 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.773 -1.204 . . . . 0.0 109.424 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.5 m -132.27 -30.39 1.52 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.091 -1.006 . . . . 0.0 109.527 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.771 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.53 -42.12 10.42 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.108 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.493 ' O ' ' HA ' ' A' ' 64' ' ' THR . 17.1 mt . . . . . 0 N--CA 1.484 1.243 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.682 HG21 ' CD1' ' A' ' 18' ' ' ILE . 26.8 m -134.09 155.92 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.877 -1.139 . . . . 0.0 109.975 179.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.1 p -117.32 120.39 38.05 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.09 -1.007 . . . . 0.0 108.613 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.924 ' CB ' HG22 ' A' ' 63' ' ' VAL . 10.8 p90 -149.09 -178.45 6.39 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.056 -1.028 . . . . 0.0 109.729 -179.264 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.503 ' CG ' ' O ' ' A' ' 50' ' ' GLU . 5.1 pt-20 -127.74 96.53 4.54 Favored 'General case' 0 C--N 1.296 -1.732 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.098 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.861 HD11 ' CG2' ' A' ' 26' ' ' VAL . 10.6 mt -62.38 132.26 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.05 -1.031 . . . . 0.0 110.105 -179.427 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.538 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 6.3 m -113.63 -176.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 178.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -124.0 116.13 22.35 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.974 -1.079 . . . . 0.0 109.844 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.404 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -129.96 172.08 20.22 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 179.757 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.404 ' C ' ' O ' ' A' ' 54' ' ' GLY . 0.7 OUTLIER -37.71 -52.03 1.25 Allowed 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.378 -1.071 . . . . 0.0 113.394 -178.572 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.26 22.69 0.11 Allowed 'General case' 0 N--CA 1.501 2.12 0 O-C-N 119.717 -1.865 . . . . 0.0 112.262 -178.303 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.37 -178.28 35.43 Favored Glycine 0 N--CA 1.491 2.337 0 O-C-N 120.434 -1.416 . . . . 0.0 110.13 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.538 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.2 Cg_endo -68.81 150.91 74.26 Favored 'Trans proline' 0 C--N 1.32 -0.938 0 C-N-CA 122.046 1.831 . . . . 0.0 109.791 178.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.513 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 2.9 mt-30 -165.99 148.15 7.13 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.018 -1.051 . . . . 0.0 111.65 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.735 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -79.29 157.14 27.79 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 177.279 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.771 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.82 -42.9 0.74 Allowed 'General case' 0 N--CA 1.506 2.351 0 O-C-N 120.354 -1.466 . . . . 0.0 112.027 -176.46 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -119.13 52.17 1.08 Allowed 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.924 HG22 ' CB ' ' A' ' 49' ' ' PHE . 15.0 t -66.68 157.41 5.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.668 -179.436 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.493 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.1 OUTLIER -135.8 158.49 44.26 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 178.713 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.417 ' O ' ' HG3' ' A' ' 65' ' ' LYS . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.569 0 O-C-N 120.907 -1.121 . . . . 0.0 109.445 -179.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.189 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.961 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.844 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.5 OUTLIER -112.51 168.13 9.89 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.829 -1.17 . . . . 0.0 110.128 -178.857 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.495 ' N ' ' OE1' ' A' ' 3' ' ' GLU . . . -149.95 156.58 26.82 Favored Glycine 0 N--CA 1.486 2.026 0 N-CA-C 109.083 -1.607 . . . . 0.0 109.083 -179.557 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.451 ' HG2' ' C ' ' A' ' 4' ' ' GLY . 0.5 OUTLIER -135.37 120.8 19.2 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.257 -1.143 . . . . 0.0 110.575 -179.44 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.545 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.6 t -39.83 138.62 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 CA-C-O 122.749 1.261 . . . . 0.0 113.112 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.449 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -100.25 -27.59 13.42 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 103.608 -2.738 . . . . 0.0 103.608 172.948 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.705 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.6 p-90 178.41 145.13 0.13 Allowed 'General case' 0 N--CA 1.482 1.166 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 178.233 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.641 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.3 OUTLIER -114.39 146.38 40.65 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 120.445 -1.409 . . . . 0.0 110.391 -179.793 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.557 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 24.1 m-20 -127.88 37.46 4.18 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 107.097 -1.445 . . . . 0.0 107.097 178.119 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.5 p -38.8 -51.21 1.72 Allowed 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.229 -178.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -59.78 -45.76 91.29 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.365 -0.834 . . . . 0.0 110.291 -179.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.557 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -70.47 0.28 6.98 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.34 -0.85 . . . . 0.0 110.735 -179.001 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.497 ' O ' ' NE2' ' A' ' 29' ' ' HIS . . . 111.57 -2.97 27.73 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.61 -1.281 . . . . 0.0 113.199 177.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.54 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 0.3 OUTLIER 177.63 176.99 0.38 Allowed 'General case' 0 N--CA 1.499 2.019 0 CA-C-N 120.562 2.181 . . . . 0.0 111.82 -179.751 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.863 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -141.98 156.73 26.12 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 107.703 -2.159 . . . . 0.0 107.703 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.705 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.8 m-85 -110.45 139.9 45.23 Favored 'General case' 0 N--CA 1.482 1.127 0 O-C-N 119.929 -1.924 . . . . 0.0 109.82 -179.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.984 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.3 mt -106.54 152.8 8.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 178.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 0.0 OUTLIER -128.69 135.79 49.73 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 178.333 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.771 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.6 p -136.44 139.87 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 C-N-CA 118.213 -1.395 . . . . 0.0 111.483 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -65.38 140.37 58.64 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 115.485 -0.779 . . . . 0.0 109.424 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.92 -10.27 48.21 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.771 ' HB2' HG13 ' A' ' 20' ' ' VAL . 3.8 mm-40 -137.92 -174.12 3.7 Favored 'General case' 0 C--N 1.31 -1.117 0 O-C-N 121.184 -1.186 . . . . 0.0 108.787 179.796 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -100.56 -167.16 1.4 Allowed 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 122.077 0.942 . . . . 0.0 110.715 -178.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.599 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 0.2 OUTLIER -73.21 108.15 5.93 Favored 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.859 179.214 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 1.074 HG21 ' CZ ' ' A' ' 49' ' ' PHE . 2.5 t -71.62 116.73 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.046 0 O-C-N 120.17 -1.581 . . . . 0.0 111.074 178.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.477 ' HB2' ' NE2' ' A' ' 59' ' ' GLN . 3.8 t80 -53.46 142.53 21.82 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 177.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.984 ' CG1' HD12 ' A' ' 18' ' ' ILE . 0.7 OUTLIER -135.06 154.87 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 120.788 -1.195 . . . . 0.0 109.653 -178.857 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.497 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 9.5 t-160 -150.23 152.55 34.76 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -80.05 27.49 0.31 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.936 -1.102 . . . . 0.0 109.956 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.63 -43.84 2.88 Favored 'General case' 0 C--N 1.308 -1.209 0 O-C-N 120.946 -1.096 . . . . 0.0 108.661 179.759 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.637 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -95.67 -49.36 5.4 Favored 'General case' 0 N--CA 1.493 1.721 0 CA-C-O 121.92 0.867 . . . . 0.0 108.973 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.921 HD13 ' CG1' ' A' ' 63' ' ' VAL . 6.0 mm . . . . . 0 N--CA 1.488 1.444 0 O-C-N 121.91 -0.494 . . . . 0.0 110.381 -178.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.647 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.487 1.399 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.578 ' HB ' HG12 ' A' ' 63' ' ' VAL . 10.4 m -129.6 164.06 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 C-N-CA 117.881 -1.527 . . . . 0.0 111.706 -178.036 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.422 ' HA ' ' HA ' ' A' ' 3' ' ' GLU . 2.1 p -116.35 133.78 55.63 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 178.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.189 ' CE1' HD11 ' A' ' 2' ' ' LEU . 6.5 p90 -153.55 178.31 9.97 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.093 -1.004 . . . . 0.0 109.782 -179.198 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.6 93.52 4.07 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 179.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.958 HD11 HG23 ' A' ' 26' ' ' VAL . 14.6 mt -61.92 125.49 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.962 -1.086 . . . . 0.0 109.611 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.4 m -106.58 -176.07 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 178.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -124.06 113.57 18.57 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.052 -1.03 . . . . 0.0 109.569 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.36 170.91 16.5 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.786 -1.726 . . . . 0.0 108.786 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -37.83 -52.08 1.3 Allowed 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.331 -1.099 . . . . 0.0 113.386 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 11.3 mtp180 -76.65 22.38 0.18 Allowed 'General case' 0 N--CA 1.501 2.089 0 O-C-N 119.593 -1.942 . . . . 0.0 112.411 -177.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.26 179.43 31.29 Favored Glycine 0 N--CA 1.494 2.536 0 O-C-N 120.471 -1.393 . . . . 0.0 110.65 179.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.572 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.7 Cg_endo -69.09 152.23 72.81 Favored 'Trans proline' 0 C--N 1.32 -0.932 0 C-N-CA 122.135 1.89 . . . . 0.0 110.205 178.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.477 ' NE2' ' HB2' ' A' ' 27' ' ' PHE . 0.8 OUTLIER -166.43 149.44 7.03 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 120.959 -1.088 . . . . 0.0 111.697 -179.772 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.831 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -80.3 154.04 28.07 Favored 'General case' 0 N--CA 1.495 1.783 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 177.06 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.637 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.74 -39.53 0.79 Allowed 'General case' 0 N--CA 1.509 2.514 0 O-C-N 120.41 -1.431 . . . . 0.0 111.687 -176.642 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -118.89 52.01 1.08 Allowed 'General case' 0 C--N 1.284 -2.265 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.958 HG22 ' CB ' ' A' ' 49' ' ' PHE . 21.1 t -68.19 158.25 5.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.626 -179.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.474 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.2 OUTLIER -148.51 175.45 11.14 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.671 -0.812 . . . . 0.0 109.394 179.36 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.556 ' HA ' HG12 ' A' ' 47' ' ' VAL . 1.2 tttt . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.078 -1.013 . . . . 0.0 109.552 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.137 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.94 0 CA-C-O 121.029 0.442 . . . . 0.0 110.001 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.612 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.1 OUTLIER -114.76 150.87 34.69 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.043 -1.036 . . . . 0.0 110.555 -179.053 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.418 ' HA3' HG21 ' A' ' 18' ' ' ILE . . . -129.62 169.85 20.67 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 108.912 -1.675 . . . . 0.0 108.912 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.44 ' O ' ' C ' ' A' ' 6' ' ' VAL . 5.2 ttmt -141.76 125.71 17.19 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.978 -1.307 . . . . 0.0 110.564 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.507 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.8 t -32.01 140.97 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 CA-C-O 123.333 1.54 . . . . 0.0 114.188 -179.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.465 ' HD3' ' O ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -108.51 -31.79 7.66 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 103.184 -2.895 . . . . 0.0 103.184 172.48 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.696 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 15.4 p-90 175.79 146.49 0.08 Allowed 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 105.9 -1.889 . . . . 0.0 105.9 177.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.584 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.2 OUTLIER -117.93 145.35 44.74 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.539 -1.351 . . . . 0.0 109.636 179.237 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.506 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.9 t-20 -131.85 41.26 3.29 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 10' ' ' ASN . 2.1 p -39.17 -45.87 1.39 Allowed 'General case' 0 C--N 1.295 -1.768 0 CA-C-O 121.445 0.641 . . . . 0.0 109.378 -179.542 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -61.96 -45.27 94.4 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.322 -0.861 . . . . 0.0 110.015 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.58 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 1.0 OUTLIER -69.9 0.2 6.25 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.361 -0.837 . . . . 0.0 109.866 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.52 ' O ' ' CD2' ' A' ' 29' ' ' HIS . . . 91.15 20.43 38.92 Favored Glycine 0 N--CA 1.488 2.121 0 O-C-N 121.174 -0.954 . . . . 0.0 111.569 179.105 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.58 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 16.6 p90 -176.87 165.27 2.44 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 119.81 1.805 . . . . 0.0 111.532 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.71 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -150.2 141.79 9.09 Favored Glycine 0 N--CA 1.497 2.725 0 N-CA-C 107.172 -2.371 . . . . 0.0 107.172 179.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.696 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.3 m-85 -109.12 139.13 44.44 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.088 -1.83 . . . . 0.0 110.885 -178.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.732 HD11 HG21 ' A' ' 47' ' ' VAL . 1.0 OUTLIER -106.63 146.9 12.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 N-CA-C 105.665 -1.976 . . . . 0.0 105.665 177.322 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 15.1 tt0 -121.07 135.13 55.26 Favored 'General case' 0 C--N 1.28 -2.439 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.009 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.508 HG13 ' HB2' ' A' ' 23' ' ' GLN . 7.5 p -138.49 140.81 38.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 C-N-CA 117.567 -1.653 . . . . 0.0 111.891 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.74 140.5 58.74 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.105 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.51 ' O ' ' NE2' ' A' ' 23' ' ' GLN . . . 86.97 -18.86 33.21 Favored Glycine 0 N--CA 1.486 2.013 0 N-CA-C 108.29 -1.924 . . . . 0.0 108.29 -178.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.51 ' NE2' ' O ' ' A' ' 22' ' ' GLY . 0.1 OUTLIER -135.95 -176.9 4.46 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 121.502 -0.999 . . . . 0.0 108.989 179.502 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -100.81 -166.0 1.27 Allowed 'General case' 0 C--N 1.298 -1.663 0 CA-C-O 121.881 0.848 . . . . 0.0 110.841 -178.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.547 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 5.9 p-10 -71.94 90.88 1.16 Allowed 'General case' 0 N--CA 1.489 1.499 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.568 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.917 HG12 HG13 ' A' ' 28' ' ' VAL . 2.3 t -50.16 125.44 3.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.107 0 O-C-N 120.711 -1.243 . . . . 0.0 111.832 178.681 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.626 ' CD2' ' CZ ' ' A' ' 17' ' ' PHE . 2.9 t80 -72.24 130.36 40.61 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 176.188 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.917 HG13 HG12 ' A' ' 26' ' ' VAL . 2.6 m -146.6 130.75 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 120.248 -1.532 . . . . 0.0 110.703 -179.056 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.55 ' NE2' ' CE2' ' A' ' 30' ' ' PHE . 9.5 t-160 -98.99 166.74 11.13 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 178.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.55 ' CE2' ' NE2' ' A' ' 29' ' ' HIS . 53.0 p90 -83.82 32.44 0.48 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.795 -1.191 . . . . 0.0 110.135 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.1 m -119.12 -37.6 3.18 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.981 -1.075 . . . . 0.0 109.164 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.659 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.38 -37.34 13.28 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.25 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.672 ' N ' HD12 ' A' ' 33' ' ' ILE . 1.4 mp . . . . . 0 N--CA 1.486 1.373 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.732 HG21 HD11 ' A' ' 18' ' ' ILE . 35.1 m -132.39 164.33 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 120.893 -1.129 . . . . 0.0 110.311 -179.547 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -117.62 126.8 53.18 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.026 -1.046 . . . . 0.0 108.336 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.137 ' CE1' HD11 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -149.13 179.66 7.72 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.011 -1.055 . . . . 0.0 110.392 -179.642 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -123.74 81.14 1.87 Allowed 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.815 ' CD1' ' HB2' ' A' ' 60' ' ' ALA . 15.1 mm -61.29 118.81 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 CA-C-O 122.051 0.929 . . . . 0.0 110.772 -178.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.556 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 17.5 m -98.42 -175.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 179.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.411 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 0.2 OUTLIER -123.66 116.05 22.44 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.9 -1.125 . . . . 0.0 109.64 -179.885 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.27 174.61 16.97 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.929 -1.668 . . . . 0.0 108.929 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -38.67 -52.85 1.66 Allowed 'General case' 0 N--CA 1.505 2.287 0 O-C-N 121.369 -1.077 . . . . 0.0 113.772 -178.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.509 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -77.84 22.56 0.27 Allowed 'General case' 0 N--CA 1.501 2.092 0 O-C-N 119.69 -1.881 . . . . 0.0 112.211 -177.983 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.95 -178.6 30.89 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.283 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.556 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -63.58 157.78 49.43 Favored 'Trans proline' 0 C--N 1.318 -1.051 0 C-N-CA 121.991 1.794 . . . . 0.0 110.188 179.12 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.535 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 1.2 mt-30 -165.07 147.44 8.03 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 120.99 -1.069 . . . . 0.0 110.575 -179.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.872 ' HB1' ' CG2' ' A' ' 63' ' ' VAL . . . -82.89 158.6 22.6 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 177.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.659 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -132.9 -47.29 0.86 Allowed 'General case' 0 N--CA 1.501 2.098 0 O-C-N 120.436 -1.415 . . . . 0.0 111.07 -177.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -121.27 55.24 1.08 Allowed 'General case' 0 C--N 1.288 -2.099 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 179.219 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.888 HG22 ' CB ' ' A' ' 49' ' ' PHE . 22.9 t -67.47 161.44 3.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-O 121.667 0.746 . . . . 0.0 110.111 -178.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.494 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -141.08 160.63 39.68 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 119.76 -0.776 . . . . 0.0 108.93 178.668 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.487 ' HA ' HG12 ' A' ' 47' ' ' VAL . 19.5 ptmt . . . . . 0 N--CA 1.494 1.761 0 O-C-N 120.927 -1.108 . . . . 0.0 109.857 -179.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.978 HD22 ' CE1' ' A' ' 49' ' ' PHE . 0.3 OUTLIER . . . . . 0 N--CA 1.488 1.444 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.543 ' N ' ' HG ' ' A' ' 2' ' ' LEU . 0.2 OUTLIER -113.37 162.02 16.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.18 -0.95 . . . . 0.0 110.045 -179.438 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.22 159.17 27.43 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.384 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.407 ' O ' ' C ' ' A' ' 6' ' ' VAL . 8.0 mtpt -133.66 112.46 11.45 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.304 -1.115 . . . . 0.0 109.111 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.53 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.6 t -42.45 139.36 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 122.796 1.284 . . . . 0.0 112.555 -178.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.483 ' HG3' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -98.43 -31.4 12.02 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 103.266 -2.864 . . . . 0.0 103.266 172.91 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.706 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 21.0 p-90 178.11 143.9 0.11 Allowed 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 177.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.573 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.9 OUTLIER -119.56 140.47 50.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.73 -1.231 . . . . 0.0 109.522 179.566 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.484 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.5 t-20 -131.43 38.13 3.63 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.454 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.2 p -37.36 -49.76 1.01 Allowed 'General case' 0 N--CA 1.492 1.629 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.886 -179.395 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -61.37 -44.66 96.78 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.284 -0.885 . . . . 0.0 109.91 -179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.479 ' CE ' ' OD1' ' A' ' 10' ' ' ASN . 0.4 OUTLIER -69.21 0.08 5.33 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.371 -0.831 . . . . 0.0 110.267 -179.554 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.508 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 102.46 12.09 34.09 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 119.935 -1.126 . . . . 0.0 112.635 178.329 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.649 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.0 OUTLIER 177.03 166.02 0.53 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-N 120.444 2.122 . . . . 0.0 112.215 179.543 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.654 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -146.74 137.03 6.49 Favored Glycine 0 N--CA 1.499 2.854 0 N-CA-C 106.671 -2.572 . . . . 0.0 106.671 179.342 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.706 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.9 m-30 -106.96 139.16 41.8 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.054 -1.85 . . . . 0.0 110.763 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.805 ' CD1' HG21 ' A' ' 47' ' ' VAL . 2.5 mt -108.21 151.65 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 177.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.509 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 9.1 tt0 -127.22 133.57 50.23 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.719 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.72 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.5 p -136.38 140.06 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 C-N-CA 117.792 -1.563 . . . . 0.0 111.772 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.8 140.13 58.38 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.121 179.771 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.42 -17.17 40.37 Favored Glycine 0 N--CA 1.486 1.967 0 N-CA-C 108.469 -1.853 . . . . 0.0 108.469 -178.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.72 ' HB2' HG13 ' A' ' 20' ' ' VAL . 3.1 mm-40 -136.85 -174.35 3.7 Favored 'General case' 0 N--CA 1.482 1.163 0 O-C-N 121.324 -1.104 . . . . 0.0 108.652 179.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.89 -165.93 1.26 Allowed 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.168 0.985 . . . . 0.0 110.657 -179.025 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.572 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 8.1 p-10 -72.09 106.96 4.53 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.011 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.84 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.4 t -71.17 117.36 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 120.483 -1.386 . . . . 0.0 111.298 178.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.613 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 3.8 t80 -67.47 130.6 43.58 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.497 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.699 HG11 HD12 ' A' ' 18' ' ' ILE . 2.4 m -139.11 131.8 37.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 120.476 -1.39 . . . . 0.0 110.715 -179.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.544 ' CE1' ' CE1' ' A' ' 30' ' ' PHE . 6.7 t60 -99.92 164.25 12.1 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.567 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 46.1 p90 -82.84 40.94 0.71 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.962 -1.086 . . . . 0.0 109.814 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 94.1 p -129.92 -38.56 1.45 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.858 -1.151 . . . . 0.0 109.711 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.729 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.78 -41.43 10.11 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 179.518 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.622 HD11 HG12 ' A' ' 28' ' ' VAL . 1.7 mp . . . . . 0 C--N 1.307 -1.28 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.43 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.805 HG21 ' CD1' ' A' ' 18' ' ' ILE . 33.4 m -116.9 157.72 17.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.886 -1.134 . . . . 0.0 109.909 179.745 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 89.7 p -117.48 122.2 43.09 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.282 -0.887 . . . . 0.0 108.787 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.978 ' CE1' HD22 ' A' ' 2' ' ' LEU . 10.4 p90 -153.97 -177.51 6.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.02 -1.05 . . . . 0.0 109.726 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -128.15 102.24 6.62 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.083 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.84 HD11 ' CG2' ' A' ' 26' ' ' VAL . 4.9 mt -62.76 144.56 14.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 120.816 -1.177 . . . . 0.0 111.126 -179.385 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.556 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.7 m -131.2 -173.18 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 179.1 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -122.25 114.68 21.15 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.786 -1.196 . . . . 0.0 109.776 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.87 172.66 16.49 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -38.66 -53.72 1.61 Allowed 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.21 -1.171 . . . . 0.0 113.006 -178.659 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.462 ' NH1' ' CG ' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -68.77 -21.24 64.36 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 119.647 -1.908 . . . . 0.0 112.778 -177.85 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 138.46 -170.84 23.73 Favored Glycine 0 N--CA 1.491 2.353 0 O-C-N 120.345 -1.472 . . . . 0.0 109.618 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.556 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.8 Cg_endo -62.26 122.88 11.51 Favored 'Trans proline' 0 C--N 1.321 -0.877 0 C-N-CA 121.803 1.668 . . . . 0.0 109.875 178.767 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.474 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 4.5 mt-30 -144.2 148.45 34.97 Favored 'General case' 0 N--CA 1.5 2.07 0 O-C-N 121.189 -0.944 . . . . 0.0 111.097 -179.024 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.661 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -80.48 166.75 20.91 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.729 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.99 -43.32 0.73 Allowed 'General case' 0 N--CA 1.507 2.391 0 O-C-N 120.286 -1.509 . . . . 0.0 112.012 -177.123 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 31.6 t30 -119.66 51.88 1.14 Allowed 'General case' 0 C--N 1.287 -2.129 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.959 HG22 ' CB ' ' A' ' 49' ' ' PHE . 17.7 t -66.91 157.31 6.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.53 -179.351 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.413 HG22 ' H ' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -143.7 176.69 9.03 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 178.534 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.413 ' H ' HG22 ' A' ' 64' ' ' THR . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.035 -1.04 . . . . 0.0 109.318 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.158 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.885 0 CA-C-O 120.972 0.415 . . . . 0.0 109.981 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.91 ' OE2' ' HB1' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -112.74 158.79 19.65 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.032 -1.042 . . . . 0.0 110.929 -178.102 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.446 ' HA2' ' HB ' ' A' ' 20' ' ' VAL . . . -136.55 160.36 24.76 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.644 -1.782 . . . . 0.0 108.644 179.492 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.9 mtpt -134.45 116.27 14.94 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.083 -1.245 . . . . 0.0 110.618 -179.42 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.54 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.8 t -32.9 141.17 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 CA-C-O 123.015 1.388 . . . . 0.0 113.635 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.473 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 3.0 tmtt? -104.07 -32.18 9.32 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 102.979 -2.971 . . . . 0.0 102.979 172.221 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.696 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.0 p-90 175.56 147.56 0.09 Allowed 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 177.716 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.548 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.6 OUTLIER -114.47 140.09 49.0 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 120.441 -1.412 . . . . 0.0 109.305 178.994 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.565 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 4.9 m120 -122.77 46.78 2.08 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.1 OUTLIER -43.76 -35.34 1.83 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 -179.315 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -59.7 -48.86 79.99 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.467 -0.771 . . . . 0.0 110.009 179.769 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.52 ' O ' ' CE2' ' A' ' 15' ' ' PHE . 13.2 mptt -76.74 11.8 1.56 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.26 -0.9 . . . . 0.0 110.201 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.436 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 84.6 20.81 57.67 Favored Glycine 0 N--CA 1.488 2.118 0 O-C-N 121.093 -1.004 . . . . 0.0 111.661 178.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.52 ' CE2' ' O ' ' A' ' 13' ' ' LYS . 36.1 p90 179.6 167.05 1.15 Allowed 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 119.983 1.892 . . . . 0.0 112.031 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.548 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -142.46 149.31 21.14 Favored Glycine 0 N--CA 1.498 2.784 0 N-CA-C 106.937 -2.465 . . . . 0.0 106.937 178.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.696 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -106.26 143.58 34.18 Favored 'General case' 0 N--CA 1.484 1.269 0 CA-C-N 119.836 1.818 . . . . 0.0 110.302 -178.4 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.999 HD12 HG12 ' A' ' 28' ' ' VAL . 0.9 OUTLIER -106.61 161.49 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 178.916 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.572 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 2.9 tp10 -142.66 130.02 21.11 Favored 'General case' 0 C--N 1.29 -2.018 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 177.781 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.773 HG13 ' HB2' ' A' ' 23' ' ' GLN . 13.0 p -135.99 140.56 43.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 117.485 -1.686 . . . . 0.0 111.729 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -65.36 140.62 58.67 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.052 179.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.22 -12.85 48.51 Favored Glycine 0 N--CA 1.487 2.049 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -178.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.773 ' HB2' HG13 ' A' ' 20' ' ' VAL . 6.1 mm-40 -140.75 -176.57 4.71 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 121.345 -1.091 . . . . 0.0 108.322 179.612 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.49 -165.79 1.25 Allowed 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.18 -0.95 . . . . 0.0 110.806 -179.091 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.588 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 11.6 p-10 -72.57 129.9 39.37 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.05 179.339 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.896 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.5 t -98.55 121.4 49.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 120.802 -1.186 . . . . 0.0 110.81 178.252 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.504 ' HB2' ' HG2' ' A' ' 59' ' ' GLN . 23.0 t80 -58.11 137.28 57.08 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.079 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.999 HG12 HD12 ' A' ' 18' ' ' ILE . 1.2 m -131.14 115.65 30.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 120.781 -1.199 . . . . 0.0 110.348 -178.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.406 ' O ' HD12 ' A' ' 33' ' ' ILE . 7.8 t-160 -104.66 148.9 26.05 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.442 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.521 ' CD1' ' C ' ' A' ' 30' ' ' PHE . 0.0 OUTLIER -81.16 31.63 0.33 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.816 -1.177 . . . . 0.0 110.486 -179.68 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -125.35 -35.21 2.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.13 -0.981 . . . . 0.0 108.544 178.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.763 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.37 -35.68 14.26 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.942 HD11 ' HB ' ' A' ' 28' ' ' VAL . 63.0 mt . . . . . 0 N--CA 1.483 1.18 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.91 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.487 1.407 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.726 HG21 HD11 ' A' ' 18' ' ' ILE . 28.8 m -119.66 163.9 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.879 -1.138 . . . . 0.0 110.469 -179.165 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.1 p -115.55 126.03 53.73 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.064 -1.023 . . . . 0.0 108.294 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.158 ' CE1' HD11 ' A' ' 2' ' ' LEU . 8.2 p90 -153.28 -179.41 7.7 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.043 -1.035 . . . . 0.0 109.83 -179.325 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -124.29 92.64 3.71 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.31 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.896 HD11 ' CG2' ' A' ' 26' ' ' VAL . 17.0 mt -61.49 132.79 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 CA-C-O 122.271 1.034 . . . . 0.0 110.338 -179.161 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.547 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.2 m -116.44 -174.46 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 178.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.423 ' CD ' ' N ' ' A' ' 53' ' ' GLU . 0.4 OUTLIER -123.72 114.33 19.81 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.001 -1.062 . . . . 0.0 109.331 179.79 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.72 175.57 18.65 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -37.92 -52.63 1.35 Allowed 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.499 -1.001 . . . . 0.0 113.548 -178.508 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.3 mmm180 -76.07 23.09 0.14 Allowed 'General case' 0 N--CA 1.5 2.036 0 O-C-N 119.807 -1.808 . . . . 0.0 112.137 -178.216 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.28 -174.78 35.62 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.547 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.2 Cg_endo -65.53 150.19 86.91 Favored 'Trans proline' 0 C--N 1.319 -0.997 0 C-N-CA 121.636 1.558 . . . . 0.0 109.791 178.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.504 ' HG2' ' HB2' ' A' ' 27' ' ' PHE . 1.4 mt-30 -165.58 150.31 8.69 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 120.97 -1.082 . . . . 0.0 111.521 -179.433 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.814 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.76 157.75 23.12 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 177.613 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.763 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.92 -41.49 0.75 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 120.52 -1.362 . . . . 0.0 111.578 -176.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.1 m-20 -119.9 57.18 0.93 Allowed 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 179.618 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.88 HG22 ' CB ' ' A' ' 49' ' ' PHE . 18.6 t -72.43 166.3 2.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.103 -178.629 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.534 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -148.1 176.27 10.34 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.669 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.471 ' O ' ' HG2' ' A' ' 65' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.636 0 O-C-N 121.052 -1.03 . . . . 0.0 109.672 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.171 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.796 0 CA-C-O 121.216 0.531 . . . . 0.0 110.119 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.744 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -113.24 155.62 24.75 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.207 -0.933 . . . . 0.0 110.007 -179.175 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.415 ' C ' ' HG2' ' A' ' 5' ' ' LYS . . . -133.28 161.95 24.25 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.436 ' O ' ' C ' ' A' ' 6' ' ' VAL . 4.0 mttp -130.24 115.5 17.06 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.209 -1.171 . . . . 0.0 109.887 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.537 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.4 t -36.87 140.44 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 122.869 1.319 . . . . 0.0 112.758 -179.577 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.5 tmtt? -99.41 -31.81 11.47 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 103.042 -2.947 . . . . 0.0 103.042 172.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.701 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 21.5 p-90 176.65 144.14 0.08 Allowed 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 177.741 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.5 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.7 OUTLIER -119.06 141.48 48.7 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.48 -1.387 . . . . 0.0 109.435 179.531 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.499 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 0.1 OUTLIER -130.93 37.72 3.75 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.673 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.45 ' C ' ' O ' ' A' ' 10' ' ' ASN . 15.3 p -37.79 -47.41 1.01 Allowed 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.493 0.663 . . . . 0.0 109.297 -179.682 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -61.12 -46.36 90.92 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.432 -0.792 . . . . 0.0 109.877 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.473 ' HB2' ' CG ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -69.26 0.49 4.84 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.403 -0.811 . . . . 0.0 110.256 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.411 ' O ' ' CB ' ' A' ' 15' ' ' PHE . . . 99.38 15.48 32.33 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 120.001 -1.095 . . . . 0.0 112.399 178.624 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.436 ' O ' ' C ' ' A' ' 10' ' ' ASN . 1.0 OUTLIER 175.53 163.09 0.3 Allowed 'General case' 0 N--CA 1.497 1.917 0 CA-C-N 120.299 2.05 . . . . 0.0 111.849 179.561 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.672 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -146.31 139.99 8.49 Favored Glycine 0 N--CA 1.498 2.832 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.701 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.4 m-85 -108.77 144.11 37.03 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.209 -1.759 . . . . 0.0 110.422 -178.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.724 HD12 HG21 ' A' ' 28' ' ' VAL . 0.5 OUTLIER -106.31 165.42 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 178.471 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.589 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 1.9 tt0 -141.8 127.77 19.48 Favored 'General case' 0 C--N 1.291 -1.967 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.155 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.751 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.8 p -134.2 141.47 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 C-N-CA 117.446 -1.701 . . . . 0.0 111.851 -179.463 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -63.8 140.14 58.84 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.259 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 82.21 -12.62 43.54 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 -179.118 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.751 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -137.57 -176.33 4.37 Favored 'General case' 0 N--CA 1.484 1.247 0 O-C-N 121.303 -1.116 . . . . 0.0 108.669 179.696 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -100.29 -166.1 1.29 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.271 -0.893 . . . . 0.0 110.505 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.601 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 34.7 p-10 -71.68 122.21 20.2 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.849 179.366 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.87 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.3 t -84.76 104.46 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 120.592 -1.317 . . . . 0.0 111.687 178.733 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.62 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 2.1 t80 -55.44 135.1 50.71 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 178.244 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.724 HG21 HD12 ' A' ' 18' ' ' ILE . 2.3 m -150.19 127.26 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 118.067 -1.453 . . . . 0.0 111.641 -179.336 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.624 ' NE2' ' CE1' ' A' ' 30' ' ' PHE . 7.7 t-160 -99.32 162.12 13.22 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 178.659 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.624 ' CE1' ' NE2' ' A' ' 29' ' ' HIS . 52.6 p90 -81.26 39.34 0.51 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.498 -1.376 . . . . 0.0 110.435 -179.432 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.7 t -123.48 -46.5 2.02 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.698 -1.251 . . . . 0.0 109.564 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.741 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.0 -40.56 11.59 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.328 -0.857 . . . . 0.0 108.74 179.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.714 HG23 ' HB ' ' A' ' 63' ' ' VAL . 2.9 mp . . . . . 0 C--N 1.3 -1.581 0 CA-C-O 121.703 0.763 . . . . 0.0 109.262 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.495 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.713 HG21 HD11 ' A' ' 18' ' ' ILE . 35.9 m -119.32 160.37 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.851 -1.155 . . . . 0.0 109.945 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 49.0 p -115.14 132.0 56.74 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 120.968 -1.083 . . . . 0.0 108.495 179.485 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.171 ' CE1' HD11 ' A' ' 2' ' ' LEU . 10.5 p90 -164.28 -176.56 4.49 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.973 -1.079 . . . . 0.0 109.988 -179.439 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.07 98.32 4.89 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.19 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.87 HD11 ' CG2' ' A' ' 26' ' ' VAL . 7.2 mt -62.67 141.3 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 120.827 -1.171 . . . . 0.0 110.873 -179.222 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.521 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 8.7 m -124.76 -175.35 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.487 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -123.08 115.26 21.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.935 -1.103 . . . . 0.0 109.772 -179.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.52 168.93 18.53 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 37.4 m-20 -37.84 -52.37 1.31 Allowed 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.329 -1.101 . . . . 0.0 113.634 -178.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.96 22.31 0.19 Allowed 'General case' 0 N--CA 1.5 2.062 0 O-C-N 119.777 -1.827 . . . . 0.0 112.414 -177.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.95 -179.39 28.72 Favored Glycine 0 N--CA 1.494 2.501 0 O-C-N 120.393 -1.442 . . . . 0.0 110.588 179.312 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.521 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.8 Cg_endo -68.77 142.23 51.88 Favored 'Trans proline' 0 C--N 1.321 -0.908 0 C-N-CA 122.225 1.95 . . . . 0.0 110.085 178.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.528 ' HG2' ' CB ' ' A' ' 27' ' ' PHE . 22.5 mt-30 -156.52 149.36 23.87 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.048 -1.032 . . . . 0.0 111.558 -179.568 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.77 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -80.41 161.63 24.86 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.741 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.92 -41.57 0.75 Allowed 'General case' 0 N--CA 1.508 2.426 0 O-C-N 120.458 -1.401 . . . . 0.0 111.972 -176.358 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.432 ' OD1' ' O ' ' A' ' 62' ' ' ASN . 35.1 t-20 -120.57 50.75 1.29 Allowed 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.958 HG22 ' CB ' ' A' ' 49' ' ' PHE . 14.9 t -68.18 171.33 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-O 121.814 0.816 . . . . 0.0 109.501 -179.532 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.578 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -153.62 172.19 17.61 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 177.908 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.3 tmtt? . . . . . 0 N--CA 1.491 1.599 0 O-C-N 120.696 -1.252 . . . . 0.0 109.379 179.979 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.214 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.499 1.994 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.567 ' N ' HD22 ' A' ' 2' ' ' LEU . 0.4 OUTLIER -117.65 135.32 54.07 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 120.817 -1.177 . . . . 0.0 110.794 -179.263 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.415 ' C ' ' HG2' ' A' ' 5' ' ' LYS . . . -103.2 173.68 22.48 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.825 -1.71 . . . . 0.0 108.825 178.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.415 ' HG2' ' C ' ' A' ' 4' ' ' GLY . 3.4 mtpp -137.37 112.77 9.31 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 120.781 -1.423 . . . . 0.0 109.955 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.45 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.5 t -47.88 131.77 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 CA-C-O 122.688 1.233 . . . . 0.0 112.645 -179.811 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 2.0 tttt -93.12 -30.39 15.28 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 103.213 -2.884 . . . . 0.0 103.213 173.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.718 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 25.1 p-90 175.28 146.57 0.08 Allowed 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 106.617 -1.624 . . . . 0.0 106.617 178.452 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.522 ' CZ ' HG23 ' A' ' 28' ' ' VAL . 0.5 OUTLIER -112.45 147.27 36.85 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.724 -1.235 . . . . 0.0 108.773 178.517 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.556 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 10.8 m-20 -130.05 42.84 3.22 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.203 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 10' ' ' ASN . 54.1 p -40.89 -40.0 1.27 Allowed 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -179.676 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.0 mm-40 -59.86 -49.33 78.11 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.665 -0.647 . . . . 0.0 110.487 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.529 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 1.4 mptp? -74.5 6.09 4.1 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.097 -1.002 . . . . 0.0 110.038 -179.798 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.529 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 90.76 20.33 40.62 Favored Glycine 0 N--CA 1.49 2.246 0 O-C-N 121.133 -0.979 . . . . 0.0 112.066 178.582 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.516 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 39.8 p90 178.9 170.29 0.88 Allowed 'General case' 0 N--CA 1.499 1.994 0 CA-C-N 120.0 1.9 . . . . 0.0 111.762 179.467 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.572 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -145.3 152.34 24.42 Favored Glycine 0 N--CA 1.499 2.891 0 N-CA-C 106.864 -2.495 . . . . 0.0 106.864 179.192 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.718 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.6 m-85 -113.14 135.36 53.89 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 120.28 2.04 . . . . 0.0 110.216 -178.786 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.963 HD12 ' CG1' ' A' ' 28' ' ' VAL . 2.8 mt -108.61 146.37 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.37 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.546 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 27.6 tt0 -125.52 135.87 52.73 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 177.648 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.602 HG13 ' HB2' ' A' ' 23' ' ' GLN . 10.9 p -137.37 139.64 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 C-N-CA 117.675 -1.61 . . . . 0.0 111.905 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -64.17 140.39 58.86 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.088 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 84.08 -15.06 40.69 Favored Glycine 0 N--CA 1.485 1.953 0 N-CA-C 108.684 -1.767 . . . . 0.0 108.684 -178.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.634 ' NE2' HG21 ' A' ' 51' ' ' ILE . 0.2 OUTLIER -136.95 -174.67 3.79 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 121.299 -1.118 . . . . 0.0 108.682 179.46 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.421 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 4.5 m-20 -100.79 -166.4 1.31 Allowed 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 122.073 0.94 . . . . 0.0 110.71 -179.171 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.546 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 8.1 p-10 -72.3 101.83 2.97 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.92 179.09 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.791 HG13 ' H ' ' A' ' 60' ' ' ALA . 2.6 t -68.15 126.28 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 120.252 -1.53 . . . . 0.0 110.124 178.514 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.433 ' HB3' ' HG2' ' A' ' 59' ' ' GLN . 16.6 t80 -65.46 142.09 58.28 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 177.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.977 ' HB ' HD11 ' A' ' 33' ' ' ILE . 1.4 m -134.09 156.73 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.735 -1.228 . . . . 0.0 110.345 -178.598 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.529 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 9.1 t60 -138.42 157.92 45.27 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.093 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.453 ' CD1' ' O ' ' A' ' 30' ' ' PHE . 53.1 p90 -85.02 32.74 0.53 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.145 -0.972 . . . . 0.0 109.769 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.4 p -127.91 -35.48 2.07 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.832 -1.168 . . . . 0.0 109.773 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.755 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -93.04 -50.16 5.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.232 -0.917 . . . . 0.0 108.988 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.977 HD11 ' HB ' ' A' ' 28' ' ' VAL . 41.0 mt . . . . . 0 C--N 1.305 -1.348 0 CA-C-O 121.819 0.819 . . . . 0.0 109.047 -179.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 121.826 0.822 . . . . 0.0 110.055 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 18.6 m -122.74 165.91 18.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 121.262 -0.899 . . . . 0.0 108.687 179.091 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -117.68 120.23 37.35 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.854 -1.154 . . . . 0.0 109.163 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.214 ' CE1' HD11 ' A' ' 2' ' ' LEU . 5.6 p90 -149.46 -178.17 6.27 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.165 -0.959 . . . . 0.0 109.978 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.495 ' CG ' ' O ' ' A' ' 50' ' ' GLU . 0.3 OUTLIER -126.47 95.11 4.25 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.376 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.784 HD11 ' CG2' ' A' ' 26' ' ' VAL . 11.3 mt -61.91 140.1 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 CA-C-O 122.513 1.149 . . . . 0.0 111.175 -178.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 12.0 m -124.57 -177.17 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 106.064 -1.828 . . . . 0.0 106.064 179.166 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -123.32 111.95 17.02 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 118.885 -1.126 . . . . 0.0 109.642 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -116.84 169.86 13.21 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 73.1 m-20 -38.23 -52.68 1.48 Allowed 'General case' 0 N--CA 1.504 2.268 0 O-C-N 121.302 -1.116 . . . . 0.0 113.723 -178.575 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -78.1 22.02 0.32 Allowed 'General case' 0 N--CA 1.5 2.074 0 O-C-N 119.62 -1.925 . . . . 0.0 112.524 -177.564 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.65 -178.02 24.89 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 119.17 -1.491 . . . . 0.0 110.628 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.489 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.3 Cg_endo -66.1 153.02 79.75 Favored 'Trans proline' 0 C--N 1.321 -0.905 0 C-N-CA 122.277 1.984 . . . . 0.0 110.529 179.21 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.433 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 0.2 OUTLIER -165.85 147.52 7.09 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.419 -0.8 . . . . 0.0 110.631 -179.758 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.791 ' H ' HG13 ' A' ' 26' ' ' VAL . . . -83.07 163.9 20.63 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 177.205 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.755 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.17 -44.05 0.78 Allowed 'General case' 0 N--CA 1.507 2.387 0 O-C-N 120.201 -1.562 . . . . 0.0 111.909 -176.869 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -119.77 52.11 1.13 Allowed 'General case' 0 C--N 1.287 -2.148 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.92 HG22 ' CB ' ' A' ' 49' ' ' PHE . 20.8 t -66.09 163.1 2.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-O 121.74 0.781 . . . . 0.0 110.554 -179.035 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.527 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -145.06 179.29 7.46 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 177.9 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.493 1.714 0 O-C-N 120.842 -1.161 . . . . 0.0 109.657 -179.837 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.182 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.883 0 CA-C-O 121.304 0.573 . . . . 0.0 110.301 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.62 ' N ' HD22 ' A' ' 2' ' ' LEU . 2.2 tt0 -113.74 144.68 42.56 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.303 -0.873 . . . . 0.0 110.174 -179.253 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.43 ' HA3' HG21 ' A' ' 18' ' ' ILE . . . -112.7 161.52 12.67 Favored Glycine 0 N--CA 1.483 1.811 0 N-CA-C 108.514 -1.835 . . . . 0.0 108.514 178.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.448 ' O ' ' C ' ' A' ' 6' ' ' VAL . 9.3 mttm -131.74 113.76 13.93 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.187 -1.184 . . . . 0.0 109.754 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.536 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.6 t -33.72 139.62 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 CA-C-O 122.91 1.338 . . . . 0.0 113.636 -179.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.461 ' HG2' ' CB ' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -103.92 -32.07 9.45 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 103.108 -2.923 . . . . 0.0 103.108 172.183 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.704 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 18.9 p-90 174.82 147.38 0.07 Allowed 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 106.315 -1.735 . . . . 0.0 106.315 177.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.569 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.4 OUTLIER -113.52 145.32 41.39 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 120.263 -1.523 . . . . 0.0 109.325 178.95 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.557 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 49.7 m-20 -130.11 41.84 3.36 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 178.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.439 ' C ' ' O ' ' A' ' 10' ' ' ASN . 62.0 p -40.98 -43.65 2.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.671 -0.643 . . . . 0.0 109.518 -179.16 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 60.4 mm-40 -61.62 -45.41 94.21 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.307 -0.871 . . . . 0.0 109.718 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.509 ' N ' ' CD ' ' A' ' 13' ' ' LYS . 0.2 OUTLIER -72.39 4.73 3.47 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.531 -0.731 . . . . 0.0 110.469 -179.66 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.486 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 93.34 19.88 34.23 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 120.053 -1.07 . . . . 0.0 112.236 178.372 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.513 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 0.8 OUTLIER 169.87 171.69 0.06 Allowed 'General case' 0 N--CA 1.498 1.958 0 CA-C-N 120.074 1.937 . . . . 0.0 111.641 179.401 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.848 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -143.6 151.85 23.66 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 106.889 -2.484 . . . . 0.0 106.889 178.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.704 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.6 m-85 -112.65 140.6 47.27 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 119.854 -1.968 . . . . 0.0 110.152 -178.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.929 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.2 mt -106.86 155.95 7.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 179.385 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.508 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 13.0 tt0 -132.31 133.15 43.71 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.797 HG13 ' HB2' ' A' ' 23' ' ' GLN . 14.8 p -132.94 141.04 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 C-N-CA 117.879 -1.528 . . . . 0.0 111.666 -179.606 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -64.52 140.39 58.86 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.4 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.57 -6.22 47.18 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.797 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -140.54 -175.57 4.32 Favored 'General case' 0 C--N 1.309 -1.159 0 O-C-N 121.08 -1.247 . . . . 0.0 108.706 179.789 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.41 -166.97 1.38 Allowed 'General case' 0 C--N 1.297 -1.705 0 CA-C-O 122.151 0.977 . . . . 0.0 110.866 -179.032 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.596 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 5.6 p-10 -71.92 113.02 8.52 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.31 179.486 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.972 HG21 ' CZ ' ' A' ' 49' ' ' PHE . 2.5 t -79.41 114.82 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 120.463 -1.398 . . . . 0.0 110.742 178.49 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.526 ' HB2' ' HG2' ' A' ' 59' ' ' GLN . 31.5 t80 -49.62 146.24 4.39 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 178.403 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.929 ' CG1' HD12 ' A' ' 18' ' ' ILE . 1.2 m -139.21 157.57 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 O-C-N 120.801 -1.187 . . . . 0.0 109.24 -179.443 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.486 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 5.5 t60 -158.42 155.15 28.1 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.406 ' N ' ' CD2' ' A' ' 29' ' ' HIS . 33.5 p90 -79.58 26.34 0.31 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.931 -1.106 . . . . 0.0 110.235 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.3 p -116.35 -47.82 2.73 Favored 'General case' 0 N--CA 1.483 1.218 0 O-C-N 120.839 -1.163 . . . . 0.0 108.909 179.686 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.711 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.51 -47.53 7.09 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.948 HD13 ' HB ' ' A' ' 63' ' ' VAL . 10.1 mm . . . . . 0 N--CA 1.486 1.349 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.506 ' O ' ' HG2' ' A' ' 3' ' ' GLU . 33.3 m -117.92 162.68 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 120.819 -1.176 . . . . 0.0 111.026 -178.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -118.49 117.7 29.71 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.615 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.182 ' CE1' HD11 ' A' ' 2' ' ' LEU . 6.0 p90 -148.76 -177.73 5.95 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.093 -1.004 . . . . 0.0 110.008 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -128.91 96.87 4.47 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 179.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.867 HD11 ' CG2' ' A' ' 26' ' ' VAL . 10.7 mt -61.63 139.22 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.874 -1.141 . . . . 0.0 110.387 -179.218 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 2.7 m -127.19 -172.48 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -124.0 118.01 26.04 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.985 -1.072 . . . . 0.0 109.489 179.561 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -129.27 174.67 19.18 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.139 -1.584 . . . . 0.0 109.139 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -38.81 -52.99 1.72 Allowed 'General case' 0 N--CA 1.506 2.329 0 O-C-N 121.414 -1.051 . . . . 0.0 113.67 -178.565 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 29.0 mtp180 -77.91 22.45 0.28 Allowed 'General case' 0 N--CA 1.497 1.924 0 O-C-N 119.688 -1.883 . . . . 0.0 112.217 -177.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.54 -177.72 30.92 Favored Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.364 -1.398 . . . . 0.0 110.285 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.527 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -66.09 146.66 82.65 Favored 'Trans proline' 0 C--N 1.319 -0.981 0 C-N-CA 122.069 1.846 . . . . 0.0 110.065 178.948 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.526 ' HG2' ' HB2' ' A' ' 27' ' ' PHE . 0.4 OUTLIER -165.63 153.8 11.18 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.105 -0.997 . . . . 0.0 111.601 -179.35 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.771 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.12 159.45 23.36 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 177.107 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.711 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.28 -41.03 0.73 Allowed 'General case' 0 N--CA 1.508 2.432 0 O-C-N 120.288 -1.508 . . . . 0.0 111.97 -176.36 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.0 p30 -119.39 51.89 1.12 Allowed 'General case' 0 C--N 1.283 -2.294 0 N-CA-C 106.689 -1.596 . . . . 0.0 106.689 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.96 HG22 ' CB ' ' A' ' 49' ' ' PHE . 19.2 t -69.52 156.49 7.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.556 -179.13 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.436 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.9 OUTLIER -136.32 167.36 21.46 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.684 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 17.4 mttp . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.002 -1.061 . . . . 0.0 109.518 -179.84 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.004 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.922 0 CA-C-O 121.161 0.505 . . . . 0.0 110.313 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.841 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.5 OUTLIER -114.07 162.84 15.96 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.057 -1.027 . . . . 0.0 109.386 -179.87 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -158.26 174.64 35.47 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -141.81 130.89 23.27 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.099 -1.236 . . . . 0.0 111.384 -179.293 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.588 ' HA ' ' HA ' ' A' ' 18' ' ' ILE . 2.8 t -37.57 138.52 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 122.82 1.295 . . . . 0.0 113.312 179.366 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.432 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -97.09 -29.29 13.7 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 102.992 -2.966 . . . . 0.0 102.992 172.452 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.7 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 19.8 p-90 178.27 145.97 0.14 Allowed 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 106.068 -1.827 . . . . 0.0 106.068 177.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.559 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.6 OUTLIER -120.28 142.54 48.98 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.533 -1.355 . . . . 0.0 109.848 179.767 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.508 ' OD1' ' CD ' ' A' ' 13' ' ' LYS . 0.5 OUTLIER -130.57 38.34 3.74 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 179.004 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 10' ' ' ASN . 11.1 p -39.15 -44.56 1.2 Allowed 'General case' 0 C--N 1.299 -1.595 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.068 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 47.2 mm-40 -61.43 -46.83 88.44 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.437 -0.789 . . . . 0.0 109.847 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.508 ' CD ' ' OD1' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -69.61 1.41 4.17 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.396 -0.815 . . . . 0.0 110.184 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.585 ' O ' ' CD2' ' A' ' 29' ' ' HIS . . . 99.04 12.35 43.12 Favored Glycine 0 N--CA 1.49 2.253 0 C-N-CA 120.152 -1.023 . . . . 0.0 112.325 178.505 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.462 ' HB3' ' O ' ' A' ' 14' ' ' GLY . 38.1 p90 179.95 163.75 1.09 Allowed 'General case' 0 N--CA 1.497 1.889 0 CA-C-N 120.269 2.035 . . . . 0.0 111.678 179.237 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.559 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -145.53 143.22 11.48 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 107.296 -2.322 . . . . 0.0 107.296 179.466 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.7 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.29 143.71 36.78 Favored 'General case' 0 N--CA 1.48 1.045 0 O-C-N 120.24 -1.741 . . . . 0.0 110.19 -178.67 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.014 HD12 HG21 ' A' ' 28' ' ' VAL . 0.3 OUTLIER -105.45 164.33 4.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 N-CA-C 104.985 -2.228 . . . . 0.0 104.985 177.583 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.554 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 12.1 tp10 -130.3 129.65 43.49 Favored 'General case' 0 C--N 1.285 -2.22 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 178.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.756 HG13 ' HB2' ' A' ' 23' ' ' GLN . 14.7 p -132.82 138.93 50.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 118.057 -1.457 . . . . 0.0 111.707 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -66.02 140.37 58.28 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.268 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.32 -8.7 45.14 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 -178.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.756 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.7 OUTLIER -138.45 -175.33 4.08 Favored 'General case' 0 N--CA 1.482 1.136 0 O-C-N 121.197 -1.178 . . . . 0.0 108.503 179.539 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.79 -166.55 1.33 Allowed 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 122.129 0.966 . . . . 0.0 110.923 -178.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.625 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.1 m-20 -72.62 113.8 10.06 Favored 'General case' 0 N--CA 1.485 1.324 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.455 178.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 1.005 HG21 ' CZ ' ' A' ' 49' ' ' PHE . 2.4 t -67.74 114.0 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.112 0 O-C-N 120.432 -1.417 . . . . 0.0 112.105 179.658 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.527 ' CD2' ' CZ ' ' A' ' 17' ' ' PHE . 0.6 OUTLIER -70.11 118.95 13.59 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 177.789 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.014 HG21 HD12 ' A' ' 18' ' ' ILE . 2.7 m -147.25 137.5 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 120.552 -1.343 . . . . 0.0 110.394 -179.346 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.585 ' CD2' ' O ' ' A' ' 14' ' ' GLY . 9.7 t-160 -99.19 172.97 7.03 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.384 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.548 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 48.0 p90 -82.64 35.54 0.46 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.044 -1.035 . . . . 0.0 109.758 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 10.8 t -128.15 -28.69 2.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.932 -1.105 . . . . 0.0 109.835 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.729 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.73 -47.89 7.12 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.027 -1.046 . . . . 0.0 108.236 179.293 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.66 HD11 ' HB ' ' A' ' 28' ' ' VAL . 53.5 mt . . . . . 0 C--N 1.305 -1.337 0 CA-C-O 122.115 0.96 . . . . 0.0 108.516 179.433 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.459 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.685 HG21 HD11 ' A' ' 18' ' ' ILE . 35.3 m -140.44 161.78 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 120.451 -1.406 . . . . 0.0 111.139 -178.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.482 ' HA ' ' O ' ' A' ' 2' ' ' LEU . 9.5 p -115.53 132.86 56.5 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 179.302 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.005 ' CZ ' HG21 ' A' ' 26' ' ' VAL . 7.1 p90 -154.88 -179.96 8.54 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.079 -1.013 . . . . 0.0 109.775 -179.005 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -121.16 91.39 3.51 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 178.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.921 HD11 HG23 ' A' ' 26' ' ' VAL . 17.9 mt -61.64 126.87 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.845 -1.159 . . . . 0.0 110.004 -179.478 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.557 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 10.4 m -106.09 -171.84 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 106.371 -1.714 . . . . 0.0 106.371 178.581 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.9 mp0 -122.98 114.44 20.41 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.9 -1.125 . . . . 0.0 109.824 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.57 169.07 16.58 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 34.5 m120 -38.07 -52.16 1.4 Allowed 'General case' 0 N--CA 1.504 2.232 0 O-C-N 121.325 -1.103 . . . . 0.0 113.587 -178.561 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.49 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -76.57 22.66 0.17 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 119.677 -1.89 . . . . 0.0 112.355 -178.035 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.07 -177.93 29.13 Favored Glycine 0 N--CA 1.494 2.531 0 O-C-N 120.434 -1.416 . . . . 0.0 110.232 179.565 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.557 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -65.66 150.82 86.01 Favored 'Trans proline' 0 C--N 1.32 -0.956 0 C-N-CA 122.025 1.817 . . . . 0.0 109.702 178.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.525 ' N ' HG23 ' A' ' 51' ' ' ILE . 29.5 mt-30 -161.11 144.03 12.69 Favored 'General case' 0 N--CA 1.5 2.043 0 O-C-N 120.991 -1.068 . . . . 0.0 111.567 -179.413 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.891 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -78.68 154.56 30.04 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 177.388 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.729 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -133.89 -41.61 0.83 Allowed 'General case' 0 N--CA 1.506 2.37 0 O-C-N 120.386 -1.446 . . . . 0.0 111.546 -176.534 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 5.6 m-20 -119.94 52.24 1.13 Allowed 'General case' 0 C--N 1.284 -2.255 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 179.618 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.92 HG22 ' CB ' ' A' ' 49' ' ' PHE . 20.5 t -67.13 163.68 2.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.969 -179.148 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.491 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.2 OUTLIER -147.29 167.88 23.17 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.37 -0.932 . . . . 0.0 108.796 178.608 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.63 0 O-C-N 120.864 -1.147 . . . . 0.0 109.66 -179.77 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.189 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.952 0 CA-C-O 121.003 0.43 . . . . 0.0 109.867 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.714 ' O ' HD22 ' A' ' 2' ' ' LEU . 2.3 tt0 -113.77 157.08 22.72 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 120.907 -1.12 . . . . 0.0 110.332 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.425 ' C ' ' HG3' ' A' ' 5' ' ' LYS . . . -133.5 155.44 21.74 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.543 -1.823 . . . . 0.0 108.543 179.54 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.0 OUTLIER -132.2 119.07 20.36 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.284 -1.127 . . . . 0.0 110.201 -179.478 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.544 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.8 t -34.05 143.18 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.182 0 CA-C-O 123.086 1.422 . . . . 0.0 113.701 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.472 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 1.3 tmtm? -104.89 -30.74 9.64 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 103.585 -2.746 . . . . 0.0 103.585 172.733 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.706 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 18.4 p-90 177.51 145.47 0.11 Allowed 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 105.728 -1.953 . . . . 0.0 105.728 178.1 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.917 ' CE1' HG21 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -113.23 148.43 35.53 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.457 -1.402 . . . . 0.0 110.655 -179.668 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.595 ' OD1' ' CZ3' ' A' ' 8' ' ' TRP . 3.0 m120 -130.2 36.31 4.01 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.797 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.5 OUTLIER -39.48 -42.78 1.16 Allowed 'General case' 0 N--CA 1.49 1.57 0 CA-C-O 121.42 0.629 . . . . 0.0 109.556 -178.703 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -60.78 -47.37 86.62 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.344 -0.847 . . . . 0.0 110.282 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.554 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -72.94 3.88 4.84 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.178 -0.951 . . . . 0.0 110.068 -179.829 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.465 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 95.25 18.6 33.09 Favored Glycine 0 N--CA 1.49 2.279 0 O-C-N 121.184 -0.948 . . . . 0.0 112.465 178.289 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.512 ' O ' ' C ' ' A' ' 10' ' ' ASN . 37.1 p90 177.77 168.69 0.7 Allowed 'General case' 0 N--CA 1.501 2.075 0 CA-C-N 120.152 1.976 . . . . 0.0 111.644 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.871 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -146.34 154.29 25.87 Favored Glycine 0 N--CA 1.497 2.709 0 N-CA-C 107.044 -2.422 . . . . 0.0 107.044 179.133 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.706 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.5 m-85 -109.98 142.33 41.52 Favored 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 120.053 1.927 . . . . 0.0 109.621 -179.201 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.662 HD12 HG12 ' A' ' 28' ' ' VAL . 0.8 OUTLIER -106.37 163.5 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 179.295 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.578 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 0.8 OUTLIER -140.97 130.79 24.32 Favored 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.897 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.582 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 9.3 p -137.4 139.19 44.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 C-N-CA 117.743 -1.583 . . . . 0.0 111.779 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.86 141.06 58.18 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.428 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.19 -18.88 42.3 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.621 -1.792 . . . . 0.0 108.621 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.582 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 57.3 mt-30 -140.99 -173.15 3.64 Favored 'General case' 0 N--CA 1.484 1.244 0 O-C-N 121.418 -1.048 . . . . 0.0 109.162 179.671 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -98.35 -164.62 1.15 Allowed 'General case' 0 C--N 1.297 -1.688 0 CA-C-O 122.115 0.96 . . . . 0.0 110.822 -178.801 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.597 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 23.5 p-10 -70.91 125.82 27.89 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.239 179.747 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.873 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.3 t -90.49 114.48 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 120.705 -1.247 . . . . 0.0 110.808 178.348 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.438 ' C ' ' O ' ' A' ' 26' ' ' VAL . 18.8 t80 -46.06 143.13 2.41 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.917 HG21 ' CE1' ' A' ' 9' ' ' PHE . 1.0 OUTLIER -133.57 148.51 30.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 120.687 -1.258 . . . . 0.0 109.422 -179.176 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.446 ' O ' HG13 ' A' ' 33' ' ' ILE . 10.2 t-160 -151.61 146.84 26.12 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 21.8 p90 -78.8 24.21 0.31 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.018 -1.051 . . . . 0.0 110.714 -179.674 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.3 t -111.6 -45.7 3.34 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 120.637 -1.289 . . . . 0.0 109.212 179.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.729 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.55 -42.89 9.98 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.284 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.587 HD11 ' HA ' ' A' ' 28' ' ' VAL . 1.3 mt . . . . . 0 N--CA 1.487 1.376 0 CA-C-O 121.496 0.665 . . . . 0.0 109.615 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.408 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.491 HG21 HD11 ' A' ' 18' ' ' ILE . 32.9 m -124.56 163.74 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 120.428 -1.42 . . . . 0.0 111.105 -178.755 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -116.58 129.02 55.93 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.1 -1.0 . . . . 0.0 108.517 179.591 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.189 ' CE1' HD11 ' A' ' 2' ' ' LEU . 6.3 p90 -153.75 -177.97 6.73 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.044 -1.035 . . . . 0.0 109.882 -179.466 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -126.09 93.12 3.73 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.197 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.873 HD11 ' CG2' ' A' ' 26' ' ' VAL . 13.7 mt -61.73 128.49 23.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.973 -1.079 . . . . 0.0 109.907 -179.303 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.57 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 7.5 m -109.3 -175.99 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 178.707 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.96 116.11 22.34 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.941 -1.099 . . . . 0.0 109.415 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.25 176.16 18.25 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -38.59 -52.59 1.63 Allowed 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.424 -1.044 . . . . 0.0 113.807 -178.504 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.458 ' NH1' ' CG ' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -79.42 22.27 0.45 Allowed 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.665 -1.897 . . . . 0.0 112.134 -177.706 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.56 -177.74 30.9 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.429 -1.367 . . . . 0.0 110.298 179.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.57 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.4 Cg_endo -66.64 153.1 79.18 Favored 'Trans proline' 0 C--N 1.32 -0.921 0 C-N-CA 121.942 1.761 . . . . 0.0 110.186 179.189 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.421 ' HG3' ' O ' ' A' ' 58' ' ' PRO . 2.4 mt-30 -166.31 147.46 6.5 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.069 -1.02 . . . . 0.0 111.278 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.767 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -80.12 155.84 27.3 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 177.239 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.729 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.66 -41.88 0.77 Allowed 'General case' 0 N--CA 1.508 2.445 0 O-C-N 120.308 -1.495 . . . . 0.0 111.695 -176.576 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -120.19 52.03 1.16 Allowed 'General case' 0 C--N 1.283 -2.292 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.952 HG22 ' CB ' ' A' ' 49' ' ' PHE . 15.2 t -67.43 167.32 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-O 121.83 0.824 . . . . 0.0 109.562 -179.501 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.586 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.3 OUTLIER -147.17 168.89 20.51 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.994 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.8 mttm . . . . . 0 N--CA 1.49 1.543 0 O-C-N 120.917 -1.114 . . . . 0.0 109.643 -179.797 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.178 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.764 0 CA-C-O 121.3 0.572 . . . . 0.0 110.082 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.595 ' O ' HD22 ' A' ' 2' ' ' LEU . 1.9 tt0 -113.95 149.71 34.86 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.165 -0.96 . . . . 0.0 110.423 -178.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.12 165.47 19.29 Favored Glycine 0 N--CA 1.486 1.969 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 179.37 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 6' ' ' VAL . 12.0 mmtt -131.4 115.16 15.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.929 -1.336 . . . . 0.0 109.742 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.553 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.2 t -36.47 139.56 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 CA-C-O 122.914 1.34 . . . . 0.0 112.873 -179.551 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.473 ' HE2' ' OE1' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -99.73 -33.23 10.67 Favored 'General case' 0 C--N 1.288 -2.105 0 N-CA-C 102.876 -3.009 . . . . 0.0 102.876 172.471 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 24.1 p-90 175.16 146.58 0.07 Allowed 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 177.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -112.08 147.41 36.1 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 120.298 -1.501 . . . . 0.0 109.37 178.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.605 ' HB2' ' CD1' ' A' ' 15' ' ' PHE . 1.0 OUTLIER -126.45 41.7 3.47 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.689 -0.632 . . . . 0.0 109.363 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.48 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -39.04 -47.29 1.49 Allowed 'General case' 0 N--CA 1.493 1.712 0 CA-C-O 121.601 0.715 . . . . 0.0 109.569 -179.189 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -58.6 -50.27 74.44 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.45 -0.781 . . . . 0.0 110.939 -179.385 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.558 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -70.85 0.98 6.09 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.014 -1.054 . . . . 0.0 110.429 -179.211 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.579 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 90.47 25.96 24.4 Favored Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.014 -1.054 . . . . 0.0 111.797 178.505 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.605 ' CD1' ' HB2' ' A' ' 10' ' ' ASN . 4.9 p90 -178.58 172.48 1.42 Allowed 'General case' 0 N--CA 1.497 1.914 0 CA-C-N 119.836 1.818 . . . . 0.0 110.866 179.47 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.445 ' O ' ' CG2' ' A' ' 28' ' ' VAL . . . -154.48 143.94 10.59 Favored Glycine 0 N--CA 1.5 2.911 0 N-CA-C 107.104 -2.399 . . . . 0.0 107.104 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.0 m-85 -111.12 141.33 44.77 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 119.97 -1.9 . . . . 0.0 110.456 -178.465 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.651 HD11 HG21 ' A' ' 47' ' ' VAL . 0.5 OUTLIER -106.32 162.35 5.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 178.262 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.558 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 14.6 tp10 -141.7 128.47 20.45 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.473 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.744 HG13 ' HB2' ' A' ' 23' ' ' GLN . 12.4 p -135.53 141.17 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 117.3 -1.76 . . . . 0.0 112.021 -179.213 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.71 140.44 58.46 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-N 115.384 -0.825 . . . . 0.0 108.913 179.596 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.03 -16.23 43.97 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.419 -1.872 . . . . 0.0 108.419 -178.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.744 ' HB2' HG13 ' A' ' 20' ' ' VAL . 3.1 mm-40 -139.29 -177.11 4.77 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 179.439 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -100.9 -165.95 1.26 Allowed 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.236 -0.915 . . . . 0.0 110.912 -178.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.587 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 3.8 p30 -72.27 124.37 24.92 Favored 'General case' 0 N--CA 1.488 1.46 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.741 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.895 HG12 HG13 ' A' ' 28' ' ' VAL . 2.4 t -88.23 116.01 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 120.647 -1.283 . . . . 0.0 111.264 178.605 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.543 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 1.5 t80 -64.5 127.82 33.16 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 178.191 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.895 HG13 HG12 ' A' ' 26' ' ' VAL . 16.1 m -143.32 137.01 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.55 -1.344 . . . . 0.0 111.626 -178.787 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.579 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 4.1 t60 -99.82 162.02 13.25 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 177.327 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.455 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 49.0 p90 -83.99 34.2 0.5 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.467 -1.396 . . . . 0.0 109.993 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.6 m -123.26 -34.27 3.15 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.034 -1.041 . . . . 0.0 108.905 179.305 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.739 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.56 -43.3 9.74 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.572 ' CD1' ' HB ' ' A' ' 28' ' ' VAL . 1.2 mp . . . . . 0 C--N 1.305 -1.361 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.46 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.651 HG21 HD11 ' A' ' 18' ' ' ILE . 35.7 m -112.59 162.03 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 120.829 -1.17 . . . . 0.0 110.405 -179.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.68 119.15 34.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.06 -1.025 . . . . 0.0 108.729 179.4 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.178 ' CE1' HD11 ' A' ' 2' ' ' LEU . 10.7 p90 -149.49 -177.6 5.95 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.952 -1.093 . . . . 0.0 110.023 -179.374 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -128.86 93.31 3.58 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.452 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.877 HD11 ' CG2' ' A' ' 26' ' ' VAL . 14.1 mt -61.69 132.81 27.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.931 -1.105 . . . . 0.0 109.929 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 17.0 m -113.42 -177.3 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.152 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -123.17 117.19 24.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.999 -1.063 . . . . 0.0 109.299 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.83 175.2 15.63 Favored Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.67 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -39.1 -52.1 1.87 Allowed 'General case' 0 N--CA 1.5 2.071 0 N-CA-C 114.287 1.217 . . . . 0.0 114.287 -178.484 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -93.25 21.09 6.28 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 119.416 -2.053 . . . . 0.0 113.534 -176.616 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 122.68 173.65 14.23 Favored Glycine 0 N--CA 1.495 2.593 0 C-N-CA 118.723 -1.703 . . . . 0.0 111.533 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.527 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 3.0 Cg_endo -69.07 156.51 64.94 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 C-N-CA 122.661 2.241 . . . . 0.0 110.561 179.27 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.409 ' NE2' ' HB3' ' A' ' 27' ' ' PHE . 3.2 mt-30 -166.41 146.11 5.93 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.298 -0.876 . . . . 0.0 110.962 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.715 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.19 159.14 23.34 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.739 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.15 -44.53 0.71 Allowed 'General case' 0 N--CA 1.506 2.349 0 O-C-N 120.36 -1.462 . . . . 0.0 112.13 -176.171 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -119.54 51.62 1.15 Allowed 'General case' 0 C--N 1.284 -2.24 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.932 HG22 ' CB ' ' A' ' 49' ' ' PHE . 18.1 t -66.06 159.64 4.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.681 -179.431 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.489 HG22 ' H ' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -143.92 -177.86 5.64 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.846 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.489 ' H ' HG22 ' A' ' 64' ' ' THR . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.533 0 O-C-N 120.931 -1.106 . . . . 0.0 109.354 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.069 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.813 0 CA-C-O 121.155 0.503 . . . . 0.0 110.264 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.84 ' CD ' ' HB1' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -112.64 165.2 12.49 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.252 -0.905 . . . . 0.0 109.937 -179.059 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 46' ' ' ALA . . . -148.05 169.68 28.76 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 20.0 mttt -134.05 116.14 15.14 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 120.919 -1.342 . . . . 0.0 110.313 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.406 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.4 t -49.06 134.98 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 CA-C-O 122.71 1.243 . . . . 0.0 112.998 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.65 -28.36 13.58 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 104.015 -2.587 . . . . 0.0 104.015 174.155 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.681 ' O ' ' CE3' ' A' ' 8' ' ' TRP . 21.6 p-90 176.16 141.88 0.07 Allowed 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 178.274 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.576 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 0.7 OUTLIER -130.02 110.57 11.75 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.537 -1.352 . . . . 0.0 110.096 -179.949 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.567 ' OD1' ' CB ' ' A' ' 13' ' ' LYS . 1.2 p30 -95.15 88.35 5.17 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-O 122.978 1.371 . . . . 0.0 109.031 179.047 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.485 ' HA ' ' CE1' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -67.65 -57.97 5.47 Favored 'General case' 0 C--N 1.29 -2.02 0 O-C-N 120.417 -1.427 . . . . 0.0 108.709 179.741 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -59.7 -45.13 93.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.469 -0.77 . . . . 0.0 111.362 -179.097 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.567 ' CB ' ' OD1' ' A' ' 10' ' ' ASN . 1.4 mptt -68.68 -11.85 60.68 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.05 -1.032 . . . . 0.0 111.134 -177.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.514 ' N ' ' OD1' ' A' ' 10' ' ' ASN . . . 138.73 -37.79 1.75 Allowed Glycine 0 N--CA 1.496 2.636 0 C-N-CA 118.376 -1.869 . . . . 0.0 113.3 178.299 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.532 ' O ' ' ND2' ' A' ' 10' ' ' ASN . 10.9 p90 -175.85 -174.83 0.69 Allowed 'General case' 0 N--CA 1.497 1.882 0 CA-C-N 121.079 2.439 . . . . 0.0 110.424 -179.222 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.862 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -134.49 146.35 18.36 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.626 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 6.0 m-30 -107.0 136.71 46.4 Favored 'General case' 0 N--CA 1.48 1.04 0 O-C-N 120.577 -1.543 . . . . 0.0 109.419 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.961 ' CD1' HG11 ' A' ' 28' ' ' VAL . 1.0 OUTLIER -107.39 150.53 9.88 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 N-CA-C 105.85 -1.908 . . . . 0.0 105.85 178.049 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.466 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 1.0 OUTLIER -125.92 133.19 51.94 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.396 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.687 HG13 ' HB2' ' A' ' 23' ' ' GLN . 8.5 p -137.87 140.24 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 C-N-CA 117.635 -1.626 . . . . 0.0 112.221 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -65.28 140.18 58.68 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.056 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.84 -13.76 46.55 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 108.654 -1.778 . . . . 0.0 108.654 -178.73 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.687 ' HB2' HG13 ' A' ' 20' ' ' VAL . 3.6 mt-30 -138.56 -175.97 4.31 Favored 'General case' 0 N--CA 1.483 1.195 0 O-C-N 121.257 -1.143 . . . . 0.0 108.632 179.489 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.82 -165.62 1.23 Allowed 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 122.135 0.969 . . . . 0.0 110.627 -179.059 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.626 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.5 m-20 -73.0 104.85 4.24 Favored 'General case' 0 N--CA 1.486 1.355 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.223 179.477 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 1.038 HG22 ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -65.72 115.25 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 120.345 -1.472 . . . . 0.0 112.112 179.061 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.453 ' HB3' ' CD ' ' A' ' 59' ' ' GLN . 12.7 t80 -70.53 129.84 40.27 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.336 -0.852 . . . . 0.0 109.04 178.236 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.961 HG11 ' CD1' ' A' ' 18' ' ' ILE . 23.6 m -135.85 144.83 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.617 -1.302 . . . . 0.0 109.654 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.848 ' O ' HD12 ' A' ' 33' ' ' ILE . 0.5 OUTLIER -99.63 165.99 11.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.766 -1.209 . . . . 0.0 108.78 179.678 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.516 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 42.9 p90 -80.28 26.0 0.38 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.949 -1.095 . . . . 0.0 110.937 -179.398 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 43.3 p -136.68 -17.64 1.46 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.701 -1.249 . . . . 0.0 110.209 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.735 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.35 -49.6 6.07 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 120.735 -1.228 . . . . 0.0 108.79 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.848 HD12 ' O ' ' A' ' 29' ' ' HIS . 2.5 mt . . . . . 0 N--CA 1.487 1.401 0 CA-C-O 121.933 0.873 . . . . 0.0 108.736 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.84 ' HB1' ' CD ' ' A' ' 3' ' ' GLU . . . . . . . . 0 N--CA 1.485 1.301 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.564 HG21 ' CD1' ' A' ' 18' ' ' ILE . 29.7 m -111.3 162.8 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.18 -0.95 . . . . 0.0 110.247 -179.806 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -115.88 125.38 52.55 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.194 -0.941 . . . . 0.0 108.587 179.503 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.069 ' CE1' HD11 ' A' ' 2' ' ' LEU . 25.0 p90 -153.59 -178.35 6.96 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.019 -1.051 . . . . 0.0 110.035 -179.646 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -126.85 96.14 4.55 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 179.413 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 1.038 ' CD1' HG22 ' A' ' 26' ' ' VAL . 1.3 mm -61.09 141.39 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 122.609 1.195 . . . . 0.0 111.048 -179.393 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.544 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 2.1 m -130.65 -174.96 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 -179.558 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -124.14 116.26 22.46 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.002 -1.062 . . . . 0.0 109.623 179.627 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -129.36 173.32 19.6 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.753 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -38.04 -52.26 1.39 Allowed 'General case' 0 N--CA 1.504 2.254 0 O-C-N 121.407 -1.055 . . . . 0.0 113.426 -178.634 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 4.9 mtt180 -75.42 22.74 0.12 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 119.728 -1.858 . . . . 0.0 112.102 -178.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.74 -178.75 36.64 Favored Glycine 0 N--CA 1.492 2.389 0 O-C-N 120.438 -1.414 . . . . 0.0 110.124 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.544 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.4 Cg_endo -68.04 139.59 47.31 Favored 'Trans proline' 0 C--N 1.319 -1.023 0 C-N-CA 122.095 1.863 . . . . 0.0 110.069 178.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.959 ' C ' HD13 ' A' ' 51' ' ' ILE . 77.6 mt-30 -159.33 157.92 31.37 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.2 -0.938 . . . . 0.0 111.206 -179.364 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.799 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -83.99 160.56 21.0 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 177.517 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.735 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.08 -40.98 0.74 Allowed 'General case' 0 N--CA 1.508 2.433 0 O-C-N 120.294 -1.504 . . . . 0.0 111.812 -176.709 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.438 ' N ' ' OD1' ' A' ' 62' ' ' ASN . 1.6 m-20 -119.62 52.28 1.11 Allowed 'General case' 0 C--N 1.283 -2.283 0 N-CA-C 106.924 -1.509 . . . . 0.0 106.924 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.914 HG22 ' CB ' ' A' ' 49' ' ' PHE . 13.4 t -69.17 163.66 3.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.488 -179.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.59 HG22 ' H ' ' A' ' 65' ' ' LYS . 1.2 m -149.45 -179.08 6.8 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 178.643 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.59 ' H ' HG22 ' A' ' 64' ' ' THR . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.603 0 O-C-N 120.991 -1.068 . . . . 0.0 109.432 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 1.175 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.913 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.847 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -113.07 165.94 11.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.87 -1.143 . . . . 0.0 109.858 -179.07 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -151.82 156.27 26.6 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.401 ' O ' ' C ' ' A' ' 6' ' ' VAL . 2.5 ttpt -135.4 126.93 28.77 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.45 -1.03 . . . . 0.0 110.675 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.619 HG13 ' N ' ' A' ' 8' ' ' TRP . 5.6 t -35.7 150.01 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.285 0 CA-C-O 123.453 1.597 . . . . 0.0 113.338 -179.634 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.524 ' CG ' ' HB2' ' A' ' 19' ' ' GLU . 1.0 OUTLIER -110.54 -29.21 8.16 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 103.174 -2.899 . . . . 0.0 103.174 172.247 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.711 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 15.4 p-90 178.92 144.61 0.14 Allowed 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 177.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.592 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 1.1 t80 -118.89 127.41 53.47 Favored 'General case' 0 N--CA 1.506 2.361 0 O-C-N 120.527 -1.358 . . . . 0.0 109.756 -178.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.554 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 72.7 m-20 -120.6 56.21 1.0 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.598 -0.689 . . . . 0.0 109.682 -179.426 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -43.74 -38.11 3.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.287 -0.883 . . . . 0.0 108.861 179.933 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -61.03 -47.03 88.32 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.572 -0.705 . . . . 0.0 110.253 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.512 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -71.53 4.42 3.09 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.218 -0.926 . . . . 0.0 109.768 179.853 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.478 ' C ' ' CD2' ' A' ' 15' ' ' PHE . . . 98.53 8.0 55.13 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 120.22 -0.99 . . . . 0.0 111.712 179.045 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.478 ' CD2' ' C ' ' A' ' 14' ' ' GLY . 3.9 p90 173.88 173.78 0.16 Allowed 'General case' 0 N--CA 1.495 1.818 0 CA-C-N 120.391 2.096 . . . . 0.0 112.588 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.882 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -130.33 142.61 13.89 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 106.644 -2.582 . . . . 0.0 106.644 178.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.711 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 4.1 m-30 -99.0 142.27 30.7 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 120.199 -1.765 . . . . 0.0 109.001 -178.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.028 HD12 ' CG1' ' A' ' 28' ' ' VAL . 0.6 OUTLIER -105.64 165.88 3.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 179.746 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.586 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 14.4 tm-20 -140.96 132.34 26.75 Favored 'General case' 0 C--N 1.289 -2.063 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 178.425 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.667 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.5 p -136.1 140.87 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 118.068 -1.453 . . . . 0.0 111.641 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -64.05 140.55 58.88 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.363 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.5 -8.88 45.38 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.667 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.3 OUTLIER -139.23 -175.07 4.04 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 121.129 -1.218 . . . . 0.0 108.849 179.608 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -100.66 -166.31 1.3 Allowed 'General case' 0 C--N 1.296 -1.721 0 CA-C-O 122.112 0.958 . . . . 0.0 110.437 -179.208 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.624 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 5.1 p30 -72.12 125.12 26.48 Favored 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.689 179.177 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 1.003 HG21 ' CZ ' ' A' ' 49' ' ' PHE . 2.5 t -87.62 108.76 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 120.557 -1.339 . . . . 0.0 111.341 178.794 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.459 ' CE2' ' CE1' ' A' ' 17' ' ' PHE . 8.8 t80 -51.16 135.13 26.31 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 177.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.028 ' CG1' HD12 ' A' ' 18' ' ' ILE . 0.7 OUTLIER -131.74 140.8 47.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 120.48 -1.388 . . . . 0.0 109.615 -178.831 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.736 ' O ' HD12 ' A' ' 33' ' ' ILE . 36.2 t-80 -123.63 155.73 37.17 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.492 ' CE1' ' CE1' ' A' ' 29' ' ' HIS . 55.6 p90 -82.47 32.5 0.4 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.975 -1.078 . . . . 0.0 109.585 179.754 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.7 m -132.04 -33.24 1.36 Allowed 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.075 -1.016 . . . . 0.0 109.358 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.758 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.34 -40.93 11.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.154 -0.966 . . . . 0.0 108.781 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.79 HD11 ' HB ' ' A' ' 28' ' ' VAL . 3.1 mt . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.382 -0.823 . . . . 0.0 108.878 178.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.333 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.593 HG12 ' HA ' ' A' ' 65' ' ' LYS . 35.0 m -128.28 164.29 30.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 120.675 -1.266 . . . . 0.0 110.741 -178.292 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -115.36 136.4 53.13 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 179.1 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 1.175 ' CE1' HD11 ' A' ' 2' ' ' LEU . 7.0 p90 -156.52 -179.41 8.15 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-O 121.99 0.9 . . . . 0.0 109.522 -178.731 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 20.1 tt0 -123.18 93.45 3.96 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.049 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.908 HD11 ' CG2' ' A' ' 26' ' ' VAL . 16.9 mt -62.14 128.58 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.981 -1.074 . . . . 0.0 110.154 -179.519 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 11.4 m -108.16 -176.56 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 178.348 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.408 ' CD ' ' N ' ' A' ' 53' ' ' GLU . 2.1 pm0 -123.85 116.62 23.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.967 -1.083 . . . . 0.0 109.729 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.406 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -132.26 172.4 21.14 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.181 -1.567 . . . . 0.0 109.181 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.406 ' C ' ' O ' ' A' ' 54' ' ' GLY . 17.8 m120 -37.37 -51.88 1.1 Allowed 'General case' 0 N--CA 1.505 2.322 0 O-C-N 121.439 -1.036 . . . . 0.0 113.268 -178.639 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.87 23.34 0.1 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 119.65 -1.907 . . . . 0.0 112.14 -178.456 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.77 -177.07 38.46 Favored Glycine 0 N--CA 1.491 2.359 0 O-C-N 120.529 -1.357 . . . . 0.0 109.773 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.554 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -68.28 152.92 75.44 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 C-N-CA 121.832 1.688 . . . . 0.0 109.652 178.768 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.468 ' HG3' ' O ' ' A' ' 58' ' ' PRO . 0.8 OUTLIER -165.82 146.1 6.61 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 120.907 -1.121 . . . . 0.0 111.608 -179.557 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.809 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -78.49 155.75 29.66 Favored 'General case' 0 N--CA 1.494 1.77 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.235 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.758 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.52 -40.57 0.8 Allowed 'General case' 0 N--CA 1.508 2.475 0 O-C-N 120.557 -1.339 . . . . 0.0 111.37 -176.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -119.88 57.09 0.93 Allowed 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.914 HG22 ' CB ' ' A' ' 49' ' ' PHE . 19.9 t -73.14 165.61 3.0 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.184 -178.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.507 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -149.83 157.97 43.71 Favored 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.143 178.952 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.593 ' HA ' HG12 ' A' ' 47' ' ' VAL . 4.2 tmtm? . . . . . 0 N--CA 1.491 1.617 0 O-C-N 120.821 -1.174 . . . . 0.0 109.562 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.45 ' HG3' ' O ' ' A' ' 1' ' ' MET . 1.6 ppp? . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.213 0.53 . . . . 0.0 109.583 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.158 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -141.29 174.13 10.83 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.203 -0.935 . . . . 0.0 110.348 179.661 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.701 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -114.51 154.5 28.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.076 -1.015 . . . . 0.0 110.096 -179.552 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.24 158.0 20.27 Favored Glycine 0 N--CA 1.484 1.858 0 N-CA-C 109.064 -1.615 . . . . 0.0 109.064 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.443 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.3 mttt -130.73 115.85 17.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.446 -1.032 . . . . 0.0 110.195 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.588 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.6 t -35.42 143.52 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 CA-C-O 123.045 1.402 . . . . 0.0 112.925 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.423 ' CG ' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -102.5 -30.63 10.87 Favored 'General case' 0 C--N 1.288 -2.068 0 N-CA-C 102.996 -2.964 . . . . 0.0 102.996 171.94 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 17.9 p-90 177.31 147.5 0.13 Allowed 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 105.77 -1.937 . . . . 0.0 105.77 177.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.977 ' CE1' HG21 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -114.19 145.01 42.27 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 120.37 -1.456 . . . . 0.0 110.142 179.944 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.57 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 4.7 m-20 -131.91 32.96 4.0 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.351 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.1 OUTLIER -38.4 -46.95 1.19 Allowed 'General case' 0 N--CA 1.494 1.727 0 CA-C-O 121.486 0.66 . . . . 0.0 109.787 -178.765 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -60.15 -46.82 88.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.363 -0.836 . . . . 0.0 110.044 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.57 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -73.01 4.84 3.81 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.299 -0.876 . . . . 0.0 110.781 -179.317 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.552 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 110.71 -3.78 29.13 Favored Glycine 0 N--CA 1.494 2.545 0 C-N-CA 119.731 -1.223 . . . . 0.0 113.008 177.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.558 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 5.7 p90 176.68 174.77 0.37 Allowed 'General case' 0 N--CA 1.5 2.058 0 CA-C-N 120.614 2.207 . . . . 0.0 111.972 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.905 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -140.03 151.96 22.45 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 107.432 -2.267 . . . . 0.0 107.432 179.32 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.36 141.33 40.34 Favored 'General case' 0 N--CA 1.485 1.323 0 O-C-N 120.058 -1.848 . . . . 0.0 109.498 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.03 HD12 HG12 ' A' ' 28' ' ' VAL . 0.9 OUTLIER -107.48 160.72 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 178.656 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.549 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 4.3 tt0 -137.74 130.52 29.97 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.071 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.765 HG13 ' HB2' ' A' ' 23' ' ' GLN . 14.5 p -134.76 140.32 45.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 C-N-CA 117.855 -1.538 . . . . 0.0 111.593 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.45 140.55 58.88 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-N 115.371 -0.832 . . . . 0.0 109.15 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 81.51 -10.7 49.11 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.765 ' HB2' HG13 ' A' ' 20' ' ' VAL . 2.7 mp0 -139.42 -174.89 4.0 Favored 'General case' 0 C--N 1.308 -1.203 0 O-C-N 121.137 -1.213 . . . . 0.0 108.814 179.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.42 -165.78 1.25 Allowed 'General case' 0 C--N 1.295 -1.782 0 CA-C-O 122.005 0.907 . . . . 0.0 110.368 -179.3 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.613 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 7.5 m-20 -71.12 120.11 16.21 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 115.861 -0.608 . . . . 0.0 109.701 179.214 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.866 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.5 t -83.83 115.29 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 120.482 -1.386 . . . . 0.0 110.722 178.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.413 ' CB ' ' CD ' ' A' ' 59' ' ' GLN . 23.4 t80 -53.71 138.12 35.99 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.03 HG12 HD12 ' A' ' 18' ' ' ILE . 0.6 OUTLIER -129.27 146.48 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 O-C-N 120.712 -1.242 . . . . 0.0 109.381 -179.681 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.552 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 3.7 t60 -147.7 143.85 27.9 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.477 ' O ' ' HB3' ' A' ' 34' ' ' GLN . 22.6 p90 -63.85 2.79 0.45 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.043 -1.036 . . . . 0.0 111.611 -179.348 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.459 ' O ' ' OE1' ' A' ' 34' ' ' GLN . 23.3 t -93.75 -51.07 5.07 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.21 -1.556 . . . . 0.0 109.574 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.745 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -93.31 -44.25 8.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.177 -0.952 . . . . 0.0 108.919 179.364 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.693 ' O ' HG22 ' A' ' 33' ' ' ILE . 1.1 mp -76.09 2.14 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.501 ' O ' ' O ' ' A' ' 33' ' ' ILE . 0.6 OUTLIER -47.3 -176.25 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.532 -0.73 . . . . 0.0 110.869 -178.355 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -159.34 -169.67 22.95 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -48.17 109.61 0.25 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.161 -1.199 . . . . 0.0 109.624 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 69.56 165.54 4.68 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.856 -1.298 . . . . 0.0 109.856 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -84.8 87.3 7.31 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.192 -1.181 . . . . 0.0 109.47 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -110.26 168.02 9.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.219 -0.926 . . . . 0.0 109.382 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.431 ' C ' ' HG ' ' A' ' 41' ' ' LEU . 0.2 OUTLIER -99.43 167.31 10.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.249 -0.907 . . . . 0.0 108.607 179.698 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.538 HD22 ' CD ' ' A' ' 45' ' ' GLN . 1.1 mp -134.69 142.83 46.92 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.543 -1.348 . . . . 0.0 110.043 -179.513 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -108.81 179.94 4.04 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.537 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.465 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 9.9 tm-20 -52.67 152.66 3.59 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.267 -0.895 . . . . 0.0 109.046 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.465 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 92.82 -6.4 76.85 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 -179.211 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.58 ' OE1' ' CE1' ' A' ' 9' ' ' PHE . 36.0 tt0 -62.2 105.94 0.67 Allowed 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.307 -1.113 . . . . 0.0 110.754 -179.482 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.463 ' O ' ' HB2' ' A' ' 66' ' ' GLU . . . -92.37 135.36 34.1 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 177.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.698 HG21 HD11 ' A' ' 18' ' ' ILE . 21.3 m -136.18 166.06 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 120.535 -1.353 . . . . 0.0 110.551 -179.151 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.9 t -116.66 135.39 53.82 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.09 -1.006 . . . . 0.0 108.6 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.158 ' CE1' HD11 ' A' ' 2' ' ' LEU . 7.2 p90 -164.1 -178.11 5.39 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.951 -1.093 . . . . 0.0 109.695 -179.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -127.05 94.95 4.16 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.305 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.866 HD11 ' CG2' ' A' ' 26' ' ' VAL . 12.3 mt -62.17 133.11 28.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.915 -1.116 . . . . 0.0 110.339 -179.409 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.542 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.1 m -116.04 -173.48 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 178.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -123.03 116.03 22.84 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.005 -1.059 . . . . 0.0 109.531 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.94 174.26 17.22 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -38.93 -52.67 1.77 Allowed 'General case' 0 N--CA 1.505 2.298 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -178.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 27.0 mmm180 -80.77 22.37 0.6 Allowed 'General case' 0 N--CA 1.498 1.967 0 O-C-N 119.676 -1.89 . . . . 0.0 112.247 -177.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.39 -177.7 26.14 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.278 -1.439 . . . . 0.0 110.488 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.542 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 0.9 OUTLIER -65.56 152.24 82.38 Favored 'Trans proline' 0 C--N 1.32 -0.948 0 C-N-CA 122.109 1.873 . . . . 0.0 110.426 179.114 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.413 ' CD ' ' CB ' ' A' ' 27' ' ' PHE . 0.0 OUTLIER -166.04 146.91 6.65 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.19 -0.944 . . . . 0.0 111.322 -179.653 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.794 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -79.4 159.23 27.16 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 177.174 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.745 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.67 -42.6 0.76 Allowed 'General case' 0 N--CA 1.508 2.439 0 O-C-N 120.366 -1.459 . . . . 0.0 111.886 -176.456 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -119.66 53.19 1.06 Allowed 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 1.008 HG22 ' CB ' ' A' ' 49' ' ' PHE . 25.0 t -70.85 168.77 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.887 -178.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.598 ' N ' HG12 ' A' ' 63' ' ' VAL . 1.4 m -152.69 173.84 14.74 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 178.4 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.484 ' H ' HG22 ' A' ' 64' ' ' THR . 0.2 OUTLIER -79.68 135.7 36.61 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.002 -1.061 . . . . 0.0 109.458 -179.878 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.463 ' HB2' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -61.72 98.69 0.1 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.298 -0.876 . . . . 0.0 109.505 -179.993 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.49 179.987 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.911 HD12 ' O ' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -129.41 175.69 8.56 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.234 -0.916 . . . . 0.0 110.214 179.844 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.861 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -112.13 168.03 9.93 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.105 -0.997 . . . . 0.0 109.553 -179.202 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.514 ' O ' ' HA ' ' A' ' 46' ' ' ALA . . . -151.78 167.9 31.08 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.379 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.5 mtpp -134.75 118.38 17.01 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.146 -1.208 . . . . 0.0 110.094 -179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.556 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.8 t -43.23 142.54 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 122.78 1.276 . . . . 0.0 112.366 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.402 ' HG3' ' OE2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -97.41 -29.65 13.38 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 103.179 -2.897 . . . . 0.0 103.179 172.587 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.702 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 21.1 p-90 177.79 144.78 0.11 Allowed 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 105.957 -1.868 . . . . 0.0 105.957 177.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.731 ' CZ ' HD21 ' A' ' 41' ' ' LEU . 0.1 OUTLIER -118.84 141.0 49.05 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.487 -1.383 . . . . 0.0 109.541 179.493 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.535 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 0.2 OUTLIER -131.5 37.78 3.65 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 179.4 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' ASN . 1.2 p -37.94 -48.49 1.17 Allowed 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.44 0.638 . . . . 0.0 109.332 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -61.9 -44.76 96.14 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.412 -0.805 . . . . 0.0 109.761 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.505 ' CB ' ' OD1' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -69.05 -0.88 6.33 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.359 -0.838 . . . . 0.0 110.132 -179.796 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.484 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 108.35 -0.44 32.95 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.874 -1.155 . . . . 0.0 112.523 178.547 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.436 ' O ' ' C ' ' A' ' 10' ' ' ASN . 6.3 p90 -179.21 169.97 1.44 Allowed 'General case' 0 N--CA 1.498 1.929 0 CA-C-N 120.456 2.128 . . . . 0.0 111.991 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.585 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -143.64 143.08 11.86 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 107.755 -2.138 . . . . 0.0 107.755 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.702 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.87 141.95 40.17 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 120.205 -1.762 . . . . 0.0 110.162 -178.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.946 HD11 HG21 ' A' ' 47' ' ' VAL . 0.9 OUTLIER -107.58 163.83 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.475 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.585 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 28.6 tt0 -139.2 130.54 26.91 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.609 HG13 ' HB2' ' A' ' 23' ' ' GLN . 9.0 p -134.39 140.66 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 C-N-CA 117.594 -1.642 . . . . 0.0 111.984 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -64.05 139.36 58.76 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.242 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.12 -13.65 43.5 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.609 ' HB2' HG13 ' A' ' 20' ' ' VAL . 1.5 mt-30 -138.0 -175.98 4.28 Favored 'General case' 0 C--N 1.308 -1.212 0 O-C-N 121.254 -1.145 . . . . 0.0 108.804 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.39 -165.89 1.26 Allowed 'General case' 0 C--N 1.295 -1.773 0 CA-C-O 121.987 0.899 . . . . 0.0 110.3 -179.429 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.627 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.6 m-20 -72.08 126.51 29.97 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.011 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 1.015 HG22 ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -91.82 118.72 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.034 0 O-C-N 120.625 -1.297 . . . . 0.0 111.125 178.539 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.481 ' CB ' ' HG2' ' A' ' 59' ' ' GLN . 4.7 t80 -65.05 134.12 53.15 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.419 -0.8 . . . . 0.0 109.256 178.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.788 HG11 ' CD1' ' A' ' 18' ' ' ILE . 2.0 m -142.27 131.95 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.674 -1.266 . . . . 0.0 111.14 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.613 ' NE2' ' CZ ' ' A' ' 30' ' ' PHE . 2.5 t-160 -115.68 132.26 56.69 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.613 ' CZ ' ' NE2' ' A' ' 29' ' ' HIS . 7.4 p90 -43.96 -22.12 0.05 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 120.701 -1.25 . . . . 0.0 111.128 -178.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.465 ' O ' ' HG2' ' A' ' 34' ' ' GLN . 1.5 m -66.24 -42.59 88.4 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.755 -1.215 . . . . 0.0 111.218 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.808 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.57 -41.33 10.85 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.95 -1.094 . . . . 0.0 108.802 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.637 HD11 HG12 ' A' ' 28' ' ' VAL . 1.5 mp -57.69 -16.1 5.29 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.484 ' OE1' ' O ' ' A' ' 30' ' ' PHE . 4.7 pt20 -83.77 -174.93 5.56 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 119.306 -0.958 . . . . 0.0 109.47 -179.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 174.37 -50.23 0.14 Allowed Glycine 0 N--CA 1.489 2.216 0 N-CA-C 108.429 -1.868 . . . . 0.0 108.429 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -104.12 54.37 0.73 Allowed 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.708 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 107.43 172.13 22.2 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 108.842 -1.703 . . . . 0.0 108.842 -179.182 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 39.1 t80 -79.81 88.33 5.25 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.094 -1.239 . . . . 0.0 109.581 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 5.6 tptm -110.63 143.67 40.72 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.346 -0.846 . . . . 0.0 109.731 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.9 t -116.51 -169.92 1.72 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.29 -0.881 . . . . 0.0 108.728 179.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.731 HD21 ' CZ ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -146.88 172.49 13.59 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.13 -0.981 . . . . 0.0 109.623 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.44 ' O ' ' HB2' ' A' ' 45' ' ' GLN . 1.2 tt0 -119.6 -175.97 3.06 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.371 -0.83 . . . . 0.0 109.462 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -66.64 143.37 57.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.434 -0.791 . . . . 0.0 109.46 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.54 -8.08 80.36 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 -179.407 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.488 ' NE2' ' CB ' ' A' ' 41' ' ' LEU . 0.0 OUTLIER -77.11 126.05 30.33 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.308 -1.113 . . . . 0.0 110.508 -179.556 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.56 ' HB1' ' CD ' ' A' ' 3' ' ' GLU . . . -91.68 135.65 33.72 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.602 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.946 HG21 HD11 ' A' ' 18' ' ' ILE . 35.0 m -119.29 159.68 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 120.868 -1.145 . . . . 0.0 110.281 -179.478 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -114.19 136.01 53.42 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.116 -0.99 . . . . 0.0 108.57 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.915 ' CZ ' HG21 ' A' ' 26' ' ' VAL . 19.9 p90 -163.04 -176.05 4.67 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.072 -1.018 . . . . 0.0 109.87 -179.247 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -129.07 96.6 4.38 Favored 'General case' 0 C--N 1.295 -1.771 0 O-C-N 121.542 -0.724 . . . . 0.0 109.185 179.129 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 1.015 ' CD1' HG22 ' A' ' 26' ' ' VAL . 1.5 mm -61.57 139.6 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 CA-C-O 122.452 1.12 . . . . 0.0 111.137 -179.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 3.1 m -126.72 -174.25 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -123.39 115.99 22.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.966 -1.083 . . . . 0.0 109.933 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.12 171.89 15.86 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 10.6 p-10 -39.1 -52.69 1.86 Allowed 'General case' 0 N--CA 1.505 2.309 0 O-C-N 121.283 -1.128 . . . . 0.0 113.956 -178.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 11.1 ttm180 -78.8 21.96 0.39 Allowed 'General case' 0 N--CA 1.5 2.054 0 O-C-N 119.601 -1.937 . . . . 0.0 112.224 -177.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.0 -179.27 26.07 Favored Glycine 0 N--CA 1.492 2.404 0 C-N-CA 119.339 -1.41 . . . . 0.0 110.667 179.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.527 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -66.78 150.16 83.4 Favored 'Trans proline' 0 C--N 1.321 -0.915 0 C-N-CA 122.238 1.959 . . . . 0.0 110.484 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.965 ' C ' HD13 ' A' ' 51' ' ' ILE . 2.5 mt-30 -165.71 152.69 10.09 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.245 -0.91 . . . . 0.0 111.03 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.808 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.15 161.43 22.81 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 177.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.808 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.0 -41.71 0.74 Allowed 'General case' 0 N--CA 1.51 2.526 0 O-C-N 120.273 -1.517 . . . . 0.0 111.725 -176.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 9.3 m-20 -120.1 52.28 1.14 Allowed 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.9 HG22 ' CB ' ' A' ' 49' ' ' PHE . 12.5 t -68.74 170.6 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 121.819 0.818 . . . . 0.0 109.69 -179.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.552 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -152.74 171.75 17.74 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 178.553 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.407 ' O ' ' HG2' ' A' ' 65' ' ' LYS . 0.0 OUTLIER -89.4 132.7 34.86 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.003 -1.06 . . . . 0.0 109.584 -179.859 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -80.66 148.77 30.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.188 -0.945 . . . . 0.0 109.605 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.474 179.941 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 121.31 0.576 . . . . 0.0 109.476 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.191 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -132.29 176.23 8.59 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.168 -0.957 . . . . 0.0 110.154 179.93 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.797 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.2 OUTLIER -111.82 161.56 16.22 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.169 -0.957 . . . . 0.0 110.151 -178.527 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.02 157.89 24.51 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.429 ' HD3' ' OE1' ' A' ' 3' ' ' GLU . 10.2 mmtp -130.27 114.55 15.78 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.318 -1.107 . . . . 0.0 109.645 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.56 HG12 ' OE1' ' A' ' 43' ' ' GLU . 3.4 t -41.29 140.24 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 CA-C-O 122.8 1.286 . . . . 0.0 112.443 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.01 -30.33 12.4 Favored 'General case' 0 C--N 1.289 -2.041 0 N-CA-C 103.126 -2.916 . . . . 0.0 103.126 172.579 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.697 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 17.3 p-90 176.96 146.27 0.1 Allowed 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 106.228 -1.768 . . . . 0.0 106.228 177.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.881 ' CE1' HG21 ' A' ' 28' ' ' VAL . 1.5 t80 -113.66 143.23 44.94 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 120.576 -1.327 . . . . 0.0 109.433 179.394 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.56 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 90.6 m-20 -131.24 39.01 3.59 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -39.08 -47.82 1.58 Allowed 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.436 0.636 . . . . 0.0 109.525 -179.087 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -61.8 -44.52 96.7 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.393 -0.817 . . . . 0.0 109.706 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.543 ' CG ' ' HB3' ' A' ' 10' ' ' ASN . 12.6 mmmt -70.55 2.3 4.17 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.429 -0.794 . . . . 0.0 110.45 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 113.27 -10.57 24.38 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 119.564 -1.303 . . . . 0.0 112.063 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.556 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 3.9 p90 175.32 179.1 0.15 Allowed 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.03 -1.865 . . . . 0.0 111.302 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.907 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -136.34 149.38 20.1 Favored Glycine 0 N--CA 1.498 2.803 0 N-CA-C 107.482 -2.247 . . . . 0.0 107.482 179.279 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.697 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.2 m-85 -105.31 140.68 38.07 Favored 'General case' 0 N--CA 1.484 1.252 0 O-C-N 120.272 -1.722 . . . . 0.0 109.792 -178.816 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.049 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.2 mt -106.91 162.03 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 178.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.572 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 13.2 tt0 -140.07 130.28 25.12 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 177.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.802 HG13 ' HB2' ' A' ' 23' ' ' GLN . 14.1 p -135.49 140.96 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 C-N-CA 117.526 -1.67 . . . . 0.0 111.953 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -65.33 140.67 58.7 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.123 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.71 -10.48 45.47 Favored Glycine 0 N--CA 1.486 2.011 0 N-CA-C 108.662 -1.775 . . . . 0.0 108.662 -178.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.802 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.9 OUTLIER -140.33 -177.71 5.15 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 121.323 -1.104 . . . . 0.0 108.439 179.619 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 69.7 m-20 -100.84 -166.28 1.3 Allowed 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 121.913 0.863 . . . . 0.0 110.655 -179.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.599 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 0.9 OUTLIER -72.54 126.55 30.15 Favored 'General case' 0 N--CA 1.487 1.421 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.741 179.146 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.854 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.4 t -92.84 114.74 30.19 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 120.494 -1.379 . . . . 0.0 111.059 178.479 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.454 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 11.1 t80 -56.5 135.64 54.38 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.049 ' CG1' HD12 ' A' ' 18' ' ' ILE . 0.6 OUTLIER -129.5 142.55 43.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 120.6 -1.313 . . . . 0.0 110.393 -178.118 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.809 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.8 t-160 -117.48 155.13 30.24 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.318 -0.994 . . . . 0.0 108.318 179.522 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.517 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 41.1 p90 -84.03 33.05 0.48 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.964 -1.085 . . . . 0.0 109.82 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -135.7 -31.1 0.96 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.046 -1.034 . . . . 0.0 109.732 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.747 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.13 -40.82 11.37 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.021 -1.049 . . . . 0.0 108.649 179.646 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.809 HD12 ' O ' ' A' ' 29' ' ' HIS . 2.8 mt -73.8 -4.88 5.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 O-C-N 121.388 -0.82 . . . . 0.0 109.178 179.661 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.27 -168.5 1.32 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.474 -0.766 . . . . 0.0 109.966 -179.048 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.515 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -162.5 -169.58 26.08 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -47.99 91.6 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.274 -1.133 . . . . 0.0 109.811 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' A' ' 35' ' ' GLY . . . 151.24 154.13 6.43 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 179.536 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 27.4 t80 -86.2 81.54 8.38 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.096 -1.238 . . . . 0.0 109.629 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.68 161.01 16.18 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.095 -1.003 . . . . 0.0 109.894 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.487 ' OG1' ' N ' ' A' ' 41' ' ' LEU . 0.2 OUTLIER -138.36 179.72 6.29 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.391 -0.818 . . . . 0.0 108.984 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.487 ' N ' ' OG1' ' A' ' 40' ' ' THR . 0.1 OUTLIER -114.61 153.19 30.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.062 -1.024 . . . . 0.0 109.622 -179.959 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.403 ' O ' ' HB2' ' A' ' 45' ' ' GLN . 5.2 pt-20 -121.09 177.09 5.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.352 -0.842 . . . . 0.0 109.445 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.56 ' OE1' HG12 ' A' ' 6' ' ' VAL . 3.4 tp10 -75.16 141.52 43.65 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.237 -0.915 . . . . 0.0 108.957 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 78.29 6.99 87.95 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 -179.438 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.458 ' OE1' ' N ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -75.89 131.93 39.98 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.172 -1.193 . . . . 0.0 110.624 -179.505 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.689 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . -94.54 118.0 30.99 Favored 'General case' 0 N--CA 1.489 1.486 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.15 178.761 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.613 HG21 HD11 ' A' ' 18' ' ' ILE . 28.6 m -111.49 159.48 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.823 -1.173 . . . . 0.0 109.911 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.6 p -115.72 123.55 48.58 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.076 -1.015 . . . . 0.0 108.429 179.448 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.191 ' CE1' HD11 ' A' ' 2' ' ' LEU . 8.8 p90 -151.92 -178.7 6.91 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.959 -1.088 . . . . 0.0 109.905 -179.429 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -125.36 94.02 4.03 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.483 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.854 HD11 ' CG2' ' A' ' 26' ' ' VAL . 10.5 mt -60.63 140.0 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 O-C-N 120.92 -1.112 . . . . 0.0 110.032 -179.381 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.584 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.9 m -124.52 -173.01 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 106.384 -1.71 . . . . 0.0 106.384 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -122.53 110.75 15.97 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 120.877 -1.139 . . . . 0.0 109.502 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.4 171.13 16.55 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -37.95 -52.25 1.36 Allowed 'General case' 0 N--CA 1.505 2.288 0 O-C-N 121.426 -1.044 . . . . 0.0 113.571 -178.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.21 22.53 0.16 Allowed 'General case' 0 N--CA 1.5 2.049 0 O-C-N 119.66 -1.9 . . . . 0.0 112.252 -178.084 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.424 ' O ' ' HG2' ' A' ' 59' ' ' GLN . . . 97.43 -175.52 30.58 Favored Glycine 0 N--CA 1.492 2.432 0 O-C-N 120.399 -1.438 . . . . 0.0 110.266 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.584 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.3 Cg_endo -65.22 131.36 28.19 Favored 'Trans proline' 0 C--N 1.32 -0.936 0 C-N-CA 121.858 1.706 . . . . 0.0 109.839 178.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.463 ' OE1' ' O ' ' A' ' 58' ' ' PRO . 10.4 mm100 -143.25 148.15 35.95 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.93 -1.106 . . . . 0.0 111.916 -178.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.713 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.1 158.2 23.8 Favored 'General case' 0 N--CA 1.496 1.872 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 176.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.747 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.29 -42.54 0.71 Allowed 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.219 -1.551 . . . . 0.0 111.876 -176.454 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 43.1 t30 -119.76 54.3 1.02 Allowed 'General case' 0 C--N 1.285 -2.238 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.916 HG22 ' CB ' ' A' ' 49' ' ' PHE . 18.4 t -68.62 164.94 2.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.596 -179.193 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.566 HG22 ' H ' ' A' ' 65' ' ' LYS . 0.7 OUTLIER -151.3 -175.8 5.32 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 178.804 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.566 ' H ' HG22 ' A' ' 64' ' ' THR . 25.1 mmtp -87.74 131.05 34.62 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.035 -1.041 . . . . 0.0 109.653 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.481 ' HB2' ' O ' ' A' ' 46' ' ' ALA . 0.3 OUTLIER -76.55 110.13 10.86 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.044 -1.035 . . . . 0.0 109.773 -179.881 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.603 0 CA-C-O 117.926 -1.035 . . . . 0.0 109.361 179.876 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 121.201 0.525 . . . . 0.0 109.627 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.026 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -100.58 175.62 5.6 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.276 -0.89 . . . . 0.0 109.866 -179.961 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.91 ' OE2' ' HB1' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -113.74 153.48 28.95 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 120.931 -1.106 . . . . 0.0 109.92 -179.716 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.442 ' C ' ' HG3' ' A' ' 5' ' ' LYS . . . -136.37 169.7 23.62 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.442 ' HG3' ' C ' ' A' ' 4' ' ' GLY . 7.6 mttm -138.01 123.58 19.69 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.943 -1.327 . . . . 0.0 109.991 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.596 HG13 ' H ' ' A' ' 8' ' ' TRP . 4.5 t -47.09 143.53 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 CA-C-O 122.857 1.313 . . . . 0.0 112.221 -179.538 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.74 -28.23 13.6 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 103.282 -2.859 . . . . 0.0 103.282 172.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.713 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 23.1 p-90 177.92 145.71 0.12 Allowed 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.976 ' CE1' HG21 ' A' ' 28' ' ' VAL . 0.8 OUTLIER -112.72 148.8 33.97 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 120.528 -1.357 . . . . 0.0 109.902 179.821 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.591 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 2.2 m120 -129.25 36.87 4.11 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 178.471 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.6 p -38.74 -50.95 1.69 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.9 -0.5 . . . . 0.0 110.41 -178.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.431 ' OE2' ' O ' ' A' ' 12' ' ' GLU . 6.7 tp10 -63.96 -37.69 88.34 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.04 -1.038 . . . . 0.0 110.151 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.591 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 1.1 mptt -75.23 2.38 11.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.962 -1.086 . . . . 0.0 110.057 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.468 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 100.63 8.56 48.77 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 119.983 -1.103 . . . . 0.0 112.828 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.556 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 7.0 p90 177.08 172.6 0.48 Allowed 'General case' 0 N--CA 1.501 2.11 0 CA-C-N 120.213 2.007 . . . . 0.0 111.492 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.93 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -145.49 153.1 25.07 Favored Glycine 0 N--CA 1.501 3.012 0 N-CA-C 107.152 -2.379 . . . . 0.0 107.152 179.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.713 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.1 m-85 -112.32 139.7 47.66 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 119.72 -2.047 . . . . 0.0 110.095 -179.112 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.05 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.2 mt -107.29 162.16 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.589 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 4.4 tt0 -140.42 133.81 29.9 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.138 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.622 HG13 ' HB2' ' A' ' 23' ' ' GLN . 7.6 p -137.9 140.67 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 C-N-CA 117.936 -1.505 . . . . 0.0 111.804 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -63.92 140.6 58.89 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.302 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.86 -13.8 46.46 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.622 ' HB2' HG13 ' A' ' 20' ' ' VAL . 1.2 mt-30 -138.48 -175.48 4.14 Favored 'General case' 0 C--N 1.309 -1.166 0 O-C-N 121.326 -1.102 . . . . 0.0 108.746 179.612 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.31 -165.37 1.21 Allowed 'General case' 0 C--N 1.295 -1.783 0 CA-C-O 122.044 0.926 . . . . 0.0 110.324 -179.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.589 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 38.1 p-10 -71.34 120.69 17.28 Favored 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.833 179.393 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 1.028 HG22 ' CD1' ' A' ' 51' ' ' ILE . 2.5 t -83.26 114.06 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 120.512 -1.367 . . . . 0.0 110.523 178.428 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.434 ' CB ' ' HG2' ' A' ' 59' ' ' GLN . 3.2 t80 -54.24 140.65 32.17 Favored 'General case' 0 C--N 1.296 -1.761 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 178.511 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.05 ' CG1' HD12 ' A' ' 18' ' ' ILE . 0.6 OUTLIER -132.51 148.3 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 120.699 -1.251 . . . . 0.0 110.537 -178.583 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 24.5 t-80 -144.61 137.6 26.82 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 13.4 p90 -65.78 5.91 0.41 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.789 -1.194 . . . . 0.0 111.52 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.417 ' O ' ' CG ' ' A' ' 34' ' ' GLN . 0.4 OUTLIER -95.12 -35.57 11.84 Favored 'General case' 0 N--CA 1.484 1.267 0 O-C-N 120.345 -1.472 . . . . 0.0 108.744 179.307 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.748 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.82 -41.52 10.6 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.246 -0.909 . . . . 0.0 108.666 179.38 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.802 HD11 ' HB ' ' A' ' 28' ' ' VAL . 7.0 mt -72.73 -4.44 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 119.5 -0.88 . . . . 0.0 109.027 179.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.477 ' O ' ' O ' ' A' ' 37' ' ' GLY . 1.7 pp0? -32.7 -43.44 0.09 Allowed 'General case' 0 N--CA 1.497 1.911 0 CA-C-O 121.017 0.437 . . . . 0.0 111.169 -178.401 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.559 ' HA2' ' CG2' ' A' ' 64' ' ' THR . . . 54.11 -169.68 1.29 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -57.13 92.91 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.297 -1.119 . . . . 0.0 110.328 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 34' ' ' GLN . . . 96.51 157.25 31.3 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 110.173 -1.171 . . . . 0.0 110.173 179.115 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.574 ' O ' ' CD2' ' A' ' 38' ' ' PHE . 20.1 t80 -85.92 90.36 8.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.109 -1.23 . . . . 0.0 109.116 179.652 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.3 mtmp? -110.68 157.17 20.02 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.134 -0.979 . . . . 0.0 109.908 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.469 ' O ' ' HG ' ' A' ' 41' ' ' LEU . 0.2 OUTLIER -99.83 -179.06 4.05 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 179.202 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.861 HD22 ' NE2' ' A' ' 45' ' ' GLN . 0.5 OUTLIER -145.97 152.07 38.81 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.806 -1.184 . . . . 0.0 110.124 -179.357 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.469 ' O ' ' HB3' ' A' ' 45' ' ' GLN . 1.9 mt-10 -103.75 173.44 6.3 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.392 -0.817 . . . . 0.0 108.867 179.388 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.477 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 8.1 tm-20 -62.8 152.2 36.63 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.117 -0.989 . . . . 0.0 108.945 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.477 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 83.55 4.52 89.13 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.464 -1.455 . . . . 0.0 109.464 -179.616 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.861 ' NE2' HD22 ' A' ' 41' ' ' LEU . 0.8 OUTLIER -75.9 134.12 40.36 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.201 -1.176 . . . . 0.0 110.746 -179.316 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.91 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . -94.16 128.25 40.47 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.219 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.568 HG21 ' CD1' ' A' ' 18' ' ' ILE . 33.5 m -123.52 163.61 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 120.77 -1.206 . . . . 0.0 110.525 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.2 p -117.52 131.9 56.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.147 -0.971 . . . . 0.0 108.951 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.026 ' CE1' HD11 ' A' ' 2' ' ' LEU . 23.0 p90 -161.74 -179.3 7.12 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.865 -1.147 . . . . 0.0 109.966 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -127.5 95.45 4.25 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.668 -0.645 . . . . 0.0 109.484 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 1.028 ' CD1' HG22 ' A' ' 26' ' ' VAL . 1.2 mm -61.49 136.14 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 CA-C-O 122.469 1.128 . . . . 0.0 110.857 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.528 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 4.0 m -121.88 -175.01 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 179.364 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.73 114.58 20.13 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.977 -1.077 . . . . 0.0 109.413 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.34 172.68 18.68 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.126 -1.589 . . . . 0.0 109.126 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -37.8 -52.14 1.29 Allowed 'General case' 0 N--CA 1.504 2.252 0 O-C-N 121.426 -1.043 . . . . 0.0 113.411 -178.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 7.2 mtm180 -75.8 22.72 0.14 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 119.609 -1.932 . . . . 0.0 112.162 -178.216 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.32 -177.05 34.65 Favored Glycine 0 N--CA 1.49 2.276 0 O-C-N 120.48 -1.388 . . . . 0.0 109.9 179.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.528 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -66.65 148.9 83.89 Favored 'Trans proline' 0 C--N 1.317 -1.088 0 C-N-CA 121.911 1.741 . . . . 0.0 109.781 178.736 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.95 ' C ' HD13 ' A' ' 51' ' ' ILE . 2.6 mt-30 -165.59 151.25 9.24 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.067 -1.021 . . . . 0.0 111.468 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.759 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -81.7 158.79 24.11 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 177.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.748 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.4 -42.45 0.7 Allowed 'General case' 0 N--CA 1.507 2.41 0 O-C-N 120.336 -1.477 . . . . 0.0 111.358 -176.788 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -119.43 61.72 0.82 Allowed 'General case' 0 C--N 1.282 -2.357 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.96 HG22 ' CB ' ' A' ' 49' ' ' PHE . 18.9 t -79.66 172.48 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.036 -178.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.57 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -153.93 171.08 19.56 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.764 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.32 130.34 34.55 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.931 -1.106 . . . . 0.0 109.407 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.406 ' OE2' ' N ' ' A' ' 67' ' ' ALA . 0.7 OUTLIER -81.76 154.78 25.8 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.286 -0.884 . . . . 0.0 109.716 -179.727 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.406 ' N ' ' OE2' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.424 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.2 mtt . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 121.243 0.544 . . . . 0.0 109.634 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.089 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -119.77 175.76 5.72 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.353 -0.842 . . . . 0.0 110.036 179.841 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.802 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.4 OUTLIER -112.04 160.89 17.05 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.194 -0.941 . . . . 0.0 110.155 -178.994 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.23 168.32 28.36 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 6' ' ' VAL . 5.2 mttt -139.86 120.18 13.92 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.026 -1.279 . . . . 0.0 110.086 -179.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.614 HG22 ' CD1' ' A' ' 9' ' ' PHE . 3.7 t -41.55 140.51 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 CA-C-O 122.736 1.255 . . . . 0.0 112.073 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.499 ' HG3' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -98.09 -28.1 13.91 Favored 'General case' 0 C--N 1.289 -2.054 0 N-CA-C 103.536 -2.765 . . . . 0.0 103.536 173.008 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 26.1 p-90 177.55 141.74 0.09 Allowed 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 178.17 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.614 ' CD1' HG22 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -120.5 139.71 52.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.511 -1.368 . . . . 0.0 110.162 -179.893 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.52 ' ND2' ' HB2' ' A' ' 13' ' ' LYS . 2.0 t30 -132.05 32.88 3.97 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 179.245 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.457 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -37.45 -48.26 0.95 Allowed 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 121.634 0.73 . . . . 0.0 109.192 -179.404 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -59.99 -47.52 85.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.565 -0.709 . . . . 0.0 109.898 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.52 ' HB2' ' ND2' ' A' ' 10' ' ' ASN . 5.1 mptt -69.52 0.36 5.42 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.428 -0.795 . . . . 0.0 110.64 -179.409 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.438 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 109.9 4.38 29.68 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 119.67 -1.253 . . . . 0.0 113.063 178.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.466 ' O ' ' C ' ' A' ' 10' ' ' ASN . 5.0 p90 179.6 166.36 1.12 Allowed 'General case' 0 N--CA 1.502 2.131 0 CA-C-N 120.975 2.387 . . . . 0.0 112.163 179.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.532 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -147.4 143.25 11.05 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 107.668 -2.173 . . . . 0.0 107.668 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.0 m-85 -115.07 138.95 50.29 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.196 -1.767 . . . . 0.0 110.231 -178.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.796 HD11 HG21 ' A' ' 47' ' ' VAL . 1.1 mt -106.74 152.71 8.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 177.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.556 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 1.7 tt0 -129.23 136.29 49.92 Favored 'General case' 0 C--N 1.286 -2.175 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.325 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.571 HG13 ' HB2' ' A' ' 23' ' ' GLN . 6.6 p -138.88 139.43 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 117.592 -1.643 . . . . 0.0 111.861 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -62.41 140.78 58.57 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.112 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.76 -18.15 36.44 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.51 -1.836 . . . . 0.0 108.51 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.571 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.1 OUTLIER -136.44 -175.92 4.16 Favored 'General case' 0 N--CA 1.484 1.226 0 O-C-N 121.423 -1.045 . . . . 0.0 108.334 179.336 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.91 -166.38 1.3 Allowed 'General case' 0 C--N 1.296 -1.749 0 CA-C-O 122.143 0.973 . . . . 0.0 111.014 -178.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.556 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 1.9 p-10 -73.21 102.2 3.57 Favored 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.553 178.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.885 HG13 ' H ' ' A' ' 60' ' ' ALA . 2.7 t -66.65 128.38 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 120.422 -1.424 . . . . 0.0 111.04 179.326 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.55 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 3.8 t80 -71.1 135.99 47.98 Favored 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.803 HG13 HG12 ' A' ' 26' ' ' VAL . 11.2 m -149.88 128.21 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 120.406 -1.434 . . . . 0.0 110.721 -179.574 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.634 ' NE2' ' CE2' ' A' ' 30' ' ' PHE . 10.9 t-80 -99.21 166.31 11.29 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.634 ' CE2' ' NE2' ' A' ' 29' ' ' HIS . 48.5 p90 -82.35 31.61 0.4 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.806 -1.184 . . . . 0.0 110.062 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.49 ' O ' ' OE1' ' A' ' 34' ' ' GLN . 32.5 p -116.81 -38.2 3.49 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.976 -1.078 . . . . 0.0 109.11 179.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.751 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.56 -41.92 9.96 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 108.508 179.356 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.603 ' N ' HD12 ' A' ' 33' ' ' ILE . 1.5 mp -62.7 -11.77 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.535 -0.728 . . . . 0.0 109.083 179.729 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.49 ' OE1' ' O ' ' A' ' 31' ' ' SER . 1.1 pt20 -83.58 -175.96 6.07 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.195 -0.941 . . . . 0.0 109.663 -179.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -169.56 -48.24 0.03 OUTLIER Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -104.6 78.44 1.46 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.294 -1.121 . . . . 0.0 109.126 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.43 163.68 23.71 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.022 -1.631 . . . . 0.0 109.022 -179.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.61 ' CG ' ' O ' ' A' ' 38' ' ' PHE . 10.2 p90 -47.07 103.65 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.884 -1.362 . . . . 0.0 109.154 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.502 ' HE3' ' CE ' ' A' ' 65' ' ' LYS . 13.7 mmtt -106.15 150.64 25.64 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.198 -0.938 . . . . 0.0 109.695 -179.49 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.511 ' OG1' ' N ' ' A' ' 41' ' ' LEU . 0.6 OUTLIER -115.42 -177.68 3.2 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.542 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.594 ' HB3' ' CD2' ' A' ' 9' ' ' PHE . 2.1 tp -144.05 132.95 22.64 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.002 -1.061 . . . . 0.0 110.024 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -98.66 179.51 4.65 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.416 -0.802 . . . . 0.0 108.91 179.524 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.513 ' OE1' ' N ' ' A' ' 44' ' ' GLY . 0.0 OUTLIER -75.17 141.84 43.6 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.203 -0.936 . . . . 0.0 109.627 -179.511 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.513 ' N ' ' OE1' ' A' ' 43' ' ' GLU . . . 92.69 -7.92 76.98 Favored Glycine 0 N--CA 1.487 2.067 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.49 ' OE1' ' HG ' ' A' ' 41' ' ' LEU . 1.4 tt0 -77.07 125.16 28.86 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.218 -1.166 . . . . 0.0 110.767 -179.411 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.68 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . -92.27 146.5 23.66 Favored 'General case' 0 N--CA 1.486 1.362 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 178.391 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.796 HG21 HD11 ' A' ' 18' ' ' ILE . 29.9 m -135.92 162.98 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.852 -1.155 . . . . 0.0 109.851 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.3 p -116.0 137.1 52.42 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.036 -1.04 . . . . 0.0 108.442 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.089 ' CE1' HD11 ' A' ' 2' ' ' LEU . 10.4 p90 -162.43 -175.74 4.68 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.884 -1.135 . . . . 0.0 109.852 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -127.35 98.5 5.28 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.555 -0.716 . . . . 0.0 109.586 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.629 HD11 ' CG2' ' A' ' 26' ' ' VAL . 5.6 mt -61.89 143.69 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 CA-C-O 122.529 1.157 . . . . 0.0 111.309 -179.482 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.52 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 13.9 m -129.51 -176.76 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.27 116.78 23.92 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.728 -1.232 . . . . 0.0 110.369 -179.681 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -116.32 165.03 12.24 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.523 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.431 ' C ' ' O ' ' A' ' 54' ' ' GLY . 4.6 m-20 -38.31 -54.67 1.41 Allowed 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.072 -1.252 . . . . 0.0 112.914 -178.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.1 ttm180 -69.7 -21.26 63.51 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 119.564 -1.96 . . . . 0.0 113.069 -177.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.69 179.2 25.33 Favored Glycine 0 N--CA 1.492 2.415 0 O-C-N 120.27 -1.519 . . . . 0.0 110.358 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.52 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -65.81 140.82 62.85 Favored 'Trans proline' 0 C--N 1.317 -1.094 0 C-N-CA 122.007 1.805 . . . . 0.0 110.464 179.206 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.522 ' HG2' ' CB ' ' A' ' 27' ' ' PHE . 30.3 mt-30 -154.83 151.78 29.03 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.347 -0.846 . . . . 0.0 110.71 -179.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.885 ' H ' HG13 ' A' ' 26' ' ' VAL . . . -83.83 167.76 16.76 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 177.328 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.751 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.23 -44.07 0.71 Allowed 'General case' 0 N--CA 1.503 2.22 0 O-C-N 120.289 -1.507 . . . . 0.0 111.672 -176.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.41 ' OD1' ' O ' ' A' ' 62' ' ' ASN . 21.3 p30 -120.0 52.16 1.14 Allowed 'General case' 0 C--N 1.287 -2.11 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.973 HG22 ' CB ' ' A' ' 49' ' ' PHE . 20.0 t -67.81 164.13 2.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 121.561 0.696 . . . . 0.0 109.681 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.484 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -146.24 164.29 32.76 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 178.672 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.526 ' HA ' HG12 ' A' ' 47' ' ' VAL . 0.0 OUTLIER -79.62 140.41 37.12 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.081 -1.012 . . . . 0.0 109.75 -179.74 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.482 ' HB2' ' O ' ' A' ' 46' ' ' ALA . 1.3 mm-40 -68.23 140.18 56.05 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.216 -0.927 . . . . 0.0 109.643 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 118.06 -0.971 . . . . 0.0 109.353 179.819 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.8 tpp . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.145 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -110.2 179.19 4.17 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.223 -0.923 . . . . 0.0 110.196 -179.88 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.866 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.1 OUTLIER -112.66 167.27 10.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.858 -1.151 . . . . 0.0 109.651 -179.284 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -148.54 159.81 28.16 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.7 mttt -133.88 117.96 17.39 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.373 -1.075 . . . . 0.0 110.742 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.605 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.5 t -37.89 146.67 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 123.122 1.439 . . . . 0.0 113.143 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.63 -30.65 9.84 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 103.191 -2.892 . . . . 0.0 103.191 172.137 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.714 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 22.6 p-90 177.66 145.92 0.12 Allowed 'General case' 0 N--CA 1.484 1.267 0 N-CA-C 106.035 -1.839 . . . . 0.0 106.035 177.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.847 ' CE1' HG21 ' A' ' 28' ' ' VAL . 1.4 t80 -119.18 138.45 52.93 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.442 -1.411 . . . . 0.0 109.611 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.516 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.2 t-20 -133.65 36.76 3.32 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.651 ' HG ' ' HD2' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -37.21 -49.59 0.93 Allowed 'General case' 0 N--CA 1.495 1.818 0 CA-C-O 121.443 0.639 . . . . 0.0 109.541 -179.451 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -60.92 -46.22 91.53 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.475 -0.766 . . . . 0.0 109.806 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.501 ' HD2' ' N ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -69.96 1.0 4.96 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.51 -0.744 . . . . 0.0 110.453 -179.606 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.44 ' O ' ' CB ' ' A' ' 15' ' ' PHE . . . 123.35 -19.52 7.62 Favored Glycine 0 N--CA 1.491 2.355 0 C-N-CA 119.685 -1.245 . . . . 0.0 111.946 178.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.471 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 5.3 p90 173.7 178.4 0.11 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.056 -1.85 . . . . 0.0 111.456 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.954 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -135.52 145.81 17.84 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 107.884 -2.087 . . . . 0.0 107.884 179.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.714 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.7 m-30 -104.57 142.18 35.1 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 120.247 -1.737 . . . . 0.0 109.664 -179.245 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.005 HD12 HG11 ' A' ' 28' ' ' VAL . 0.5 OUTLIER -106.34 164.51 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 178.56 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.568 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 3.1 tm-20 -141.68 129.77 22.08 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.693 HG13 ' HB2' ' A' ' 23' ' ' GLN . 10.3 p -135.59 141.65 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 C-N-CA 117.695 -1.602 . . . . 0.0 112.043 -179.657 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -65.65 140.25 58.48 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-N 115.381 -0.827 . . . . 0.0 108.827 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.41 -14.01 42.96 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.693 ' HB2' HG13 ' A' ' 20' ' ' VAL . 1.6 mm100 -137.66 -177.37 4.77 Favored 'General case' 0 N--CA 1.483 1.202 0 O-C-N 121.333 -1.098 . . . . 0.0 108.407 179.538 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -100.73 -166.27 1.3 Allowed 'General case' 0 C--N 1.296 -1.748 0 CA-C-O 121.962 0.887 . . . . 0.0 110.378 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.612 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.4 m-20 -72.08 123.46 22.88 Favored 'General case' 0 N--CA 1.486 1.367 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.676 179.149 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.88 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.4 t -84.91 110.5 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.02 0 O-C-N 120.589 -1.32 . . . . 0.0 111.454 178.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -55.37 133.73 49.87 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 178.07 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.005 HG11 HD12 ' A' ' 18' ' ' ILE . 0.6 OUTLIER -132.75 137.19 54.53 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 C-N-CA 117.891 -1.524 . . . . 0.0 110.661 -178.782 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.714 ' O ' HD12 ' A' ' 33' ' ' ILE . 5.6 t-160 -109.81 159.49 17.15 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.572 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 46.1 p90 -82.67 39.86 0.64 Allowed 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.763 -1.211 . . . . 0.0 109.831 -179.674 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.524 ' O ' ' HG2' ' A' ' 34' ' ' GLN . 3.1 t -137.65 -33.2 0.73 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.816 -1.178 . . . . 0.0 110.518 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.734 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -93.53 -49.91 5.67 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.961 -1.087 . . . . 0.0 109.706 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.823 HG23 ' CG1' ' A' ' 63' ' ' VAL . 1.4 mp -75.93 0.53 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.677 -0.64 . . . . 0.0 110.359 -178.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.524 ' HG2' ' O ' ' A' ' 31' ' ' SER . 9.7 pt20 -77.75 -3.75 42.85 Favored 'General case' 0 C--N 1.293 -1.851 0 O-C-N 121.403 -0.81 . . . . 0.0 109.916 -179.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 47.35 -169.7 0.06 OUTLIER Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 19.4 mt-10 -50.18 130.91 23.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.35 -1.088 . . . . 0.0 109.955 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 76.12 157.84 7.49 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 179.452 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -85.6 104.35 15.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.115 -1.226 . . . . 0.0 109.033 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -109.84 157.75 18.87 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.248 -0.908 . . . . 0.0 109.867 -179.63 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.941 ' C ' HD22 ' A' ' 41' ' ' LEU . 0.2 OUTLIER -99.16 169.17 9.58 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.732 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.941 HD22 ' C ' ' A' ' 40' ' ' THR . 4.0 mm? -122.48 178.37 5.0 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.733 -1.229 . . . . 0.0 109.999 -179.285 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -156.89 -179.82 8.57 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.382 -0.824 . . . . 0.0 109.084 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 21.0 tp10 -70.65 145.51 50.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.197 -0.939 . . . . 0.0 109.056 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 84.94 -2.34 88.33 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -178.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.698 ' HG3' HD12 ' A' ' 41' ' ' LEU . 3.6 tt0 -55.9 111.66 0.99 Allowed 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.489 -1.007 . . . . 0.0 110.516 -179.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -94.43 116.25 28.57 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 177.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.764 HG21 HD11 ' A' ' 18' ' ' ILE . 26.2 m -124.13 163.13 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 120.627 -1.296 . . . . 0.0 110.882 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.444 ' HB3' ' HG2' ' A' ' 66' ' ' GLU . 22.7 p -115.87 137.22 52.3 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 108.5 179.362 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.145 ' CE1' HD11 ' A' ' 2' ' ' LEU . 9.4 p90 -163.66 -177.97 5.5 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.816 -1.177 . . . . 0.0 109.941 -179.257 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -127.15 93.02 3.64 Favored 'General case' 0 C--N 1.295 -1.773 0 O-C-N 121.688 -0.633 . . . . 0.0 109.475 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.88 HD11 ' CG2' ' A' ' 26' ' ' VAL . 16.3 mt -62.1 128.92 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.023 -1.048 . . . . 0.0 109.886 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 16.1 m -108.11 -176.59 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 178.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -123.32 114.66 20.49 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.012 -1.055 . . . . 0.0 109.735 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.405 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -125.89 169.04 17.86 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 179.591 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' A' ' 54' ' ' GLY . 22.1 m120 -37.44 -51.99 1.13 Allowed 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.227 -1.161 . . . . 0.0 113.412 -178.45 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.9 tpt180 -75.33 22.62 0.12 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 119.718 -1.864 . . . . 0.0 112.352 -178.14 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.02 -178.32 31.94 Favored Glycine 0 N--CA 1.494 2.551 0 O-C-N 120.414 -1.429 . . . . 0.0 110.269 179.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.54 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -67.91 155.01 71.4 Favored 'Trans proline' 0 C--N 1.32 -0.947 0 C-N-CA 122.005 1.803 . . . . 0.0 109.918 178.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.436 ' N ' HG23 ' A' ' 51' ' ' ILE . 0.3 OUTLIER -166.07 143.22 5.31 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.982 -1.074 . . . . 0.0 111.398 -179.693 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.775 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -78.09 157.63 29.44 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 177.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.734 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.54 -44.26 0.75 Allowed 'General case' 0 N--CA 1.507 2.395 0 O-C-N 120.498 -1.376 . . . . 0.0 111.933 -176.407 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -119.81 51.78 1.16 Allowed 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.976 HG22 ' CB ' ' A' ' 49' ' ' PHE . 21.2 t -68.03 169.2 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-O 121.693 0.758 . . . . 0.0 109.513 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.592 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -154.62 178.14 10.43 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 178.237 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.676 ' HZ3' HD11 ' A' ' 41' ' ' LEU . 0.0 OUTLIER -84.36 140.89 31.27 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.043 -1.036 . . . . 0.0 109.557 -179.712 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.622 ' O ' ' HB3' ' A' ' 67' ' ' ALA . 1.0 OUTLIER -95.22 139.94 30.84 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.31 -0.869 . . . . 0.0 109.292 179.684 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.622 ' HB3' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 118.071 -0.966 . . . . 0.0 109.383 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 121.235 0.541 . . . . 0.0 109.554 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.192 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.32 172.61 12.49 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.143 -0.973 . . . . 0.0 110.011 179.727 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.845 ' OE2' ' HB1' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -113.92 149.03 35.8 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 121.213 -0.929 . . . . 0.0 110.389 -179.372 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.438 ' HA3' HG21 ' A' ' 18' ' ' ILE . . . -121.33 166.16 14.26 Favored Glycine 0 N--CA 1.483 1.796 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 179.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.47 ' O ' ' C ' ' A' ' 6' ' ' VAL . 2.0 mttm -140.3 119.0 12.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.922 -1.34 . . . . 0.0 109.609 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.504 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.7 t -33.5 136.67 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 CA-C-O 122.913 1.34 . . . . 0.0 113.401 -179.327 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.489 ' CG ' ' HB3' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -101.8 -31.51 10.71 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 103.149 -2.908 . . . . 0.0 103.149 172.61 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.699 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 22.8 p-90 174.25 145.25 0.05 Allowed 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 178.009 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.811 ' HB3' HD13 ' A' ' 41' ' ' LEU . 0.2 OUTLIER -114.21 147.04 39.58 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.149 -1.594 . . . . 0.0 109.952 179.333 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.544 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 80.5 m-20 -130.21 38.68 3.75 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 179.013 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.565 ' HB3' HD23 ' A' ' 41' ' ' LEU . 24.7 p -40.89 -41.59 1.64 Allowed 'General case' 0 N--CA 1.488 1.47 0 CA-C-O 121.71 0.767 . . . . 0.0 109.103 -179.078 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -59.9 -48.4 81.87 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.537 -0.727 . . . . 0.0 110.414 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.567 ' N ' ' CD ' ' A' ' 13' ' ' LYS . 2.2 mptp? -73.83 4.35 5.36 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.215 -0.928 . . . . 0.0 110.125 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.414 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 92.24 23.55 26.71 Favored Glycine 0 N--CA 1.49 2.242 0 C-N-CA 120.251 -0.976 . . . . 0.0 112.144 178.549 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.496 ' O ' ' C ' ' A' ' 10' ' ' ASN . 26.7 p90 179.44 167.19 1.09 Allowed 'General case' 0 N--CA 1.501 2.076 0 CA-C-N 120.102 1.951 . . . . 0.0 111.631 179.447 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.595 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -149.0 150.89 23.09 Favored Glycine 0 N--CA 1.497 2.752 0 N-CA-C 106.995 -2.442 . . . . 0.0 106.995 179.328 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.699 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 6.1 m-85 -117.24 138.31 51.8 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 120.035 1.917 . . . . 0.0 110.235 -178.648 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.547 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.7 mt -105.47 146.55 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.809 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.56 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 9.6 pt-20 -121.01 137.02 54.85 Favored 'General case' 0 C--N 1.285 -2.229 0 C-N-CA 119.472 -0.891 . . . . 0.0 108.944 178.45 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.52 HG13 ' HB2' ' A' ' 23' ' ' GLN . 10.0 p -138.73 140.93 38.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 C-N-CA 117.822 -1.551 . . . . 0.0 111.787 179.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.87 140.49 58.28 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.391 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 87.77 -19.1 35.16 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.52 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -136.4 -175.43 4.0 Favored 'General case' 0 C--N 1.308 -1.219 0 O-C-N 121.416 -1.049 . . . . 0.0 108.693 179.406 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.61 -165.1 1.17 Allowed 'General case' 0 C--N 1.296 -1.756 0 CA-C-O 122.009 0.909 . . . . 0.0 110.588 -179.051 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.56 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 0.9 OUTLIER -71.65 93.24 1.23 Allowed 'General case' 0 N--CA 1.487 1.388 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.037 179.257 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.822 HG13 ' H ' ' A' ' 60' ' ' ALA . 2.7 t -56.27 142.4 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 120.299 -1.501 . . . . 0.0 109.952 178.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.498 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 5.0 t80 -71.69 146.3 48.3 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 176.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.859 ' HB ' HD11 ' A' ' 33' ' ' ILE . 2.0 m -142.06 113.96 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 120.332 -1.48 . . . . 0.0 110.363 -179.299 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.691 ' O ' HD12 ' A' ' 33' ' ' ILE . 7.5 t60 -99.55 148.95 23.74 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 178.296 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.431 ' O ' ' HD2' ' A' ' 39' ' ' LYS . 49.8 p90 -79.86 32.71 0.26 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.747 -1.221 . . . . 0.0 110.163 -179.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -118.78 -36.93 3.34 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.963 -1.085 . . . . 0.0 108.924 179.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.706 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.36 -47.16 7.33 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 179.366 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.859 HD11 ' HB ' ' A' ' 28' ' ' VAL . 11.6 mt -58.22 -16.22 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 CA-C-O 121.495 0.664 . . . . 0.0 109.44 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.431 ' HG2' ' HA ' ' A' ' 39' ' ' LYS . 0.0 OUTLIER -111.41 -168.84 1.36 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.59 -0.694 . . . . 0.0 109.886 -179.557 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 37' ' ' GLY . . . -152.28 -169.97 18.29 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.081 -1.607 . . . . 0.0 109.081 179.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -49.53 92.4 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.105 -1.232 . . . . 0.0 109.339 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 35' ' ' GLY . . . 166.21 -170.05 40.68 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.427 ' O ' ' CD1' ' A' ' 38' ' ' PHE . 45.2 p90 -67.06 139.66 57.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.285 -1.127 . . . . 0.0 109.582 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.431 ' HA ' ' HG2' ' A' ' 34' ' ' GLN . 24.1 mtmt -110.24 137.37 48.07 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -0.891 . . . . 0.0 109.43 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.1 t -169.35 -169.91 1.01 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.058 -1.026 . . . . 0.0 109.761 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.811 HD13 ' HB3' ' A' ' 9' ' ' PHE . 0.8 OUTLIER -119.99 179.91 4.12 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.35 -0.844 . . . . 0.0 110.247 -179.511 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.468 ' O ' ' CB ' ' A' ' 45' ' ' GLN . 0.1 OUTLIER -163.92 120.59 1.69 Allowed 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 179.246 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -62.05 140.88 58.35 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.286 -0.884 . . . . 0.0 108.975 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 69.06 16.14 70.37 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.34 -1.904 . . . . 0.0 108.34 -178.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.468 ' CB ' ' O ' ' A' ' 42' ' ' GLU . 44.7 tt0 -72.54 116.11 12.6 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.535 -0.98 . . . . 0.0 110.351 -179.342 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.845 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . -92.16 126.05 37.09 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 178.322 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.5 HG21 ' CD1' ' A' ' 18' ' ' ILE . 31.3 m -122.32 165.06 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 120.704 -1.247 . . . . 0.0 110.462 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.4 p -117.01 122.55 44.53 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.192 ' CE1' HD11 ' A' ' 2' ' ' LEU . 6.3 p90 -150.85 -178.45 6.59 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 120.858 -1.151 . . . . 0.0 109.726 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -127.71 95.02 4.1 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.751 HD11 ' CG2' ' A' ' 26' ' ' VAL . 13.3 mt -62.35 136.34 25.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 CA-C-O 122.326 1.06 . . . . 0.0 110.906 -179.165 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.515 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 11.5 m -119.53 -176.61 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 179.124 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -123.48 113.66 19.05 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.01 -1.057 . . . . 0.0 109.629 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.23 171.66 16.52 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -37.99 -52.13 1.37 Allowed 'General case' 0 N--CA 1.505 2.292 0 O-C-N 121.367 -1.078 . . . . 0.0 113.735 -178.363 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.38 22.38 0.23 Allowed 'General case' 0 N--CA 1.5 2.046 0 O-C-N 119.655 -1.903 . . . . 0.0 112.247 -177.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.18 -176.97 29.67 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.451 -1.357 . . . . 0.0 110.257 179.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.515 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -66.94 153.43 77.93 Favored 'Trans proline' 0 C--N 1.32 -0.938 0 C-N-CA 121.915 1.744 . . . . 0.0 109.977 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.412 ' CD ' ' HB2' ' A' ' 27' ' ' PHE . 0.0 OUTLIER -165.65 147.04 7.17 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.207 -0.933 . . . . 0.0 111.083 -179.428 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.822 ' H ' HG13 ' A' ' 26' ' ' VAL . . . -81.04 161.7 24.09 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 177.051 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.706 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.27 -44.98 0.77 Allowed 'General case' 0 N--CA 1.508 2.441 0 O-C-N 120.155 -1.59 . . . . 0.0 111.93 -176.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -119.02 50.73 1.18 Allowed 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.953 HG22 ' CB ' ' A' ' 49' ' ' PHE . 19.9 t -64.63 157.64 4.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.76 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.409 HG22 ' H ' ' A' ' 65' ' ' LYS . 0.9 OUTLIER -142.14 173.57 11.4 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.153 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.409 ' H ' HG22 ' A' ' 64' ' ' THR . 0.4 OUTLIER -79.3 126.0 30.22 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.929 -1.107 . . . . 0.0 109.376 -179.917 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.461 ' HG3' ' CG ' ' A' ' 3' ' ' GLU . 10.1 tm-20 -90.58 97.03 10.94 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.285 -0.884 . . . . 0.0 109.602 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.412 ' C ' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.524 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.6 mtp . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 121.24 0.543 . . . . 0.0 109.63 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.935 HD13 ' O ' ' A' ' 2' ' ' LEU . 0.0 OUTLIER -140.84 169.34 17.81 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.205 -0.935 . . . . 0.0 110.385 179.585 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.683 ' N ' HD22 ' A' ' 2' ' ' LEU . 0.1 OUTLIER -121.26 136.75 54.92 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.473 -0.767 . . . . 0.0 109.498 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -129.59 -164.19 11.35 Favored Glycine 0 N--CA 1.484 1.834 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 20.9 ttpt -151.71 135.9 16.68 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.882 -1.364 . . . . 0.0 111.048 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.555 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.3 t -42.58 140.07 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 122.865 1.317 . . . . 0.0 112.856 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.438 ' HG3' ' OE1' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -97.4 -31.13 12.53 Favored 'General case' 0 C--N 1.29 -2.011 0 N-CA-C 103.009 -2.96 . . . . 0.0 103.009 172.631 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.707 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.2 p-90 177.45 145.85 0.11 Allowed 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 177.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.991 ' CE1' HD11 ' A' ' 41' ' ' LEU . 0.7 OUTLIER -113.81 146.32 40.12 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 120.591 -1.318 . . . . 0.0 109.61 179.234 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.562 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 31.4 m-20 -130.08 43.03 3.19 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 10' ' ' ASN . 53.4 p -41.33 -41.44 1.94 Allowed 'General case' 0 N--CA 1.489 1.511 0 CA-C-O 121.612 0.72 . . . . 0.0 109.077 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -59.49 -49.37 78.06 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.435 -0.791 . . . . 0.0 110.607 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.534 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -72.95 4.36 4.3 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.01 -1.056 . . . . 0.0 110.395 -179.429 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.56 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 91.46 23.91 27.62 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 120.051 -1.071 . . . . 0.0 111.933 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.473 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 11.1 p90 178.92 167.63 0.93 Allowed 'General case' 0 N--CA 1.499 1.987 0 CA-C-N 120.122 1.961 . . . . 0.0 111.815 179.306 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -146.58 144.33 12.59 Favored Glycine 0 N--CA 1.497 2.758 0 N-CA-C 107.271 -2.331 . . . . 0.0 107.271 179.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.707 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.1 m-85 -110.13 142.68 41.3 Favored 'General case' 0 N--CA 1.482 1.134 0 O-C-N 120.013 -1.874 . . . . 0.0 110.153 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.003 HD12 HG21 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -105.91 165.23 3.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 177.975 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.591 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 6.8 tt0 -133.92 130.17 37.36 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.47 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.781 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.3 p -131.95 139.11 51.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 C-N-CA 117.728 -1.589 . . . . 0.0 111.699 -179.645 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -65.4 140.7 58.66 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.266 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.2 -9.58 46.8 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.781 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -139.78 -175.43 4.21 Favored 'General case' 0 C--N 1.309 -1.158 0 O-C-N 121.125 -1.221 . . . . 0.0 108.871 179.675 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -100.48 -165.68 1.24 Allowed 'General case' 0 C--N 1.295 -1.77 0 CA-C-O 122.208 1.004 . . . . 0.0 110.583 -178.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.594 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.2 m-20 -71.04 119.95 15.9 Favored 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 115.714 -0.676 . . . . 0.0 109.74 179.353 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.861 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.2 t -78.82 114.31 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 120.674 -1.267 . . . . 0.0 111.398 178.632 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.62 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 2.0 t80 -66.26 125.03 24.3 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.38 -0.971 . . . . 0.0 108.38 178.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.003 HG21 HD12 ' A' ' 18' ' ' ILE . 2.3 m -143.99 136.82 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 120.593 -1.317 . . . . 0.0 110.26 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.629 ' NE2' ' CE1' ' A' ' 30' ' ' PHE . 35.6 t60 -98.85 166.91 11.07 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 179.273 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.629 ' CE1' ' NE2' ' A' ' 29' ' ' HIS . 42.0 p90 -83.61 38.99 0.65 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.773 -1.204 . . . . 0.0 109.424 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.457 ' HA ' ' NE2' ' A' ' 34' ' ' GLN . 2.5 m -132.27 -30.39 1.52 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.091 -1.006 . . . . 0.0 109.527 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.771 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.53 -42.12 10.42 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.108 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.493 ' O ' ' HA ' ' A' ' 64' ' ' THR . 17.1 mt -53.63 -19.74 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.193 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.483 ' NE2' ' O ' ' A' ' 30' ' ' PHE . 2.9 pt20 -110.56 -169.59 1.49 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.33 -0.856 . . . . 0.0 109.312 179.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -154.59 -49.85 0.01 OUTLIER Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.439 ' O ' ' O ' ' A' ' 37' ' ' GLY . 1.0 OUTLIER -103.65 130.88 51.18 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.299 -1.118 . . . . 0.0 109.225 179.791 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.439 ' O ' ' O ' ' A' ' 36' ' ' GLU . . . 56.08 167.61 0.06 OUTLIER Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.154 -1.578 . . . . 0.0 109.154 -179.688 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.582 ' CG ' ' O ' ' A' ' 38' ' ' PHE . 7.0 p90 -82.14 114.72 20.85 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.065 -1.256 . . . . 0.0 109.341 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.413 ' HB2' ' CB ' ' A' ' 34' ' ' GLN . 0.0 OUTLIER -109.3 -174.4 2.5 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.086 -1.009 . . . . 0.0 109.483 -179.749 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.483 ' C ' HD23 ' A' ' 41' ' ' LEU . 0.1 OUTLIER -160.58 178.85 9.1 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.278 -0.889 . . . . 0.0 109.234 179.813 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.991 HD11 ' CE1' ' A' ' 9' ' ' PHE . 0.2 OUTLIER -145.5 168.34 20.83 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.964 -1.085 . . . . 0.0 109.511 -179.974 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.49 ' O ' ' HB2' ' A' ' 45' ' ' GLN . 0.3 OUTLIER -116.2 -179.1 3.57 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.263 -0.898 . . . . 0.0 109.193 179.833 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.521 ' OE1' HG12 ' A' ' 6' ' ' VAL . 12.4 tp10 -68.88 145.31 53.8 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.191 -0.943 . . . . 0.0 109.035 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 83.85 2.21 89.73 Favored Glycine 0 N--CA 1.486 1.998 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.493 ' NE2' ' O ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -76.21 136.97 39.72 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.153 -1.204 . . . . 0.0 110.319 -179.675 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.493 ' O ' ' NE2' ' A' ' 45' ' ' GLN . . . -93.34 140.23 29.78 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.224 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.682 HG21 ' CD1' ' A' ' 18' ' ' ILE . 26.8 m -134.09 155.92 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.877 -1.139 . . . . 0.0 109.975 179.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.1 p -117.32 120.39 38.05 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.09 -1.007 . . . . 0.0 108.613 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.924 ' CB ' HG22 ' A' ' 63' ' ' VAL . 10.8 p90 -149.09 -178.45 6.39 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.056 -1.028 . . . . 0.0 109.729 -179.264 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.503 ' CG ' ' O ' ' A' ' 50' ' ' GLU . 5.1 pt-20 -127.74 96.53 4.54 Favored 'General case' 0 C--N 1.296 -1.732 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.098 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.861 HD11 ' CG2' ' A' ' 26' ' ' VAL . 10.6 mt -62.38 132.26 28.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.05 -1.031 . . . . 0.0 110.105 -179.427 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.538 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 6.3 m -113.63 -176.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 178.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -124.0 116.13 22.35 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.974 -1.079 . . . . 0.0 109.844 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.404 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -129.96 172.08 20.22 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 179.757 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.404 ' C ' ' O ' ' A' ' 54' ' ' GLY . 0.7 OUTLIER -37.71 -52.03 1.25 Allowed 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.378 -1.071 . . . . 0.0 113.394 -178.572 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.26 22.69 0.11 Allowed 'General case' 0 N--CA 1.501 2.12 0 O-C-N 119.717 -1.865 . . . . 0.0 112.262 -178.303 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.37 -178.28 35.43 Favored Glycine 0 N--CA 1.491 2.337 0 O-C-N 120.434 -1.416 . . . . 0.0 110.13 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.538 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.2 Cg_endo -68.81 150.91 74.26 Favored 'Trans proline' 0 C--N 1.32 -0.938 0 C-N-CA 122.046 1.831 . . . . 0.0 109.791 178.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.513 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 2.9 mt-30 -165.99 148.15 7.13 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.018 -1.051 . . . . 0.0 111.65 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.735 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -79.29 157.14 27.79 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 177.279 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.771 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.82 -42.9 0.74 Allowed 'General case' 0 N--CA 1.506 2.351 0 O-C-N 120.354 -1.466 . . . . 0.0 112.027 -176.46 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -119.13 52.17 1.08 Allowed 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.924 HG22 ' CB ' ' A' ' 49' ' ' PHE . 15.0 t -66.68 157.41 5.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.668 -179.436 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.493 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.1 OUTLIER -135.8 158.49 44.26 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 178.713 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.417 ' O ' ' HG3' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -81.42 126.18 31.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.907 -1.121 . . . . 0.0 109.445 -179.883 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.515 ' O ' ' HB2' ' A' ' 67' ' ' ALA . 4.3 tt0 -88.06 138.16 31.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.232 -0.918 . . . . 0.0 109.565 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.515 ' HB2' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.497 0 CA-C-O 117.936 -1.03 . . . . 0.0 109.47 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.1 mmt . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.262 0.553 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.189 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.67 179.1 6.89 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.303 -0.873 . . . . 0.0 110.018 179.746 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.844 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.5 OUTLIER -112.51 168.13 9.89 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.829 -1.17 . . . . 0.0 110.128 -178.857 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.495 ' N ' ' OE1' ' A' ' 3' ' ' GLU . . . -149.95 156.58 26.82 Favored Glycine 0 N--CA 1.486 2.026 0 N-CA-C 109.083 -1.607 . . . . 0.0 109.083 -179.557 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.451 ' HG2' ' C ' ' A' ' 4' ' ' GLY . 0.5 OUTLIER -135.37 120.8 19.2 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.257 -1.143 . . . . 0.0 110.575 -179.44 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.545 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.6 t -39.83 138.62 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.01 0 CA-C-O 122.749 1.261 . . . . 0.0 113.112 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.449 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -100.25 -27.59 13.42 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 103.608 -2.738 . . . . 0.0 103.608 172.948 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.705 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.6 p-90 178.41 145.13 0.13 Allowed 'General case' 0 N--CA 1.482 1.166 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 178.233 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.788 ' CE2' HD11 ' A' ' 41' ' ' LEU . 0.3 OUTLIER -114.39 146.38 40.65 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 120.445 -1.409 . . . . 0.0 110.391 -179.793 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.557 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 24.1 m-20 -127.88 37.46 4.18 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 107.097 -1.445 . . . . 0.0 107.097 178.119 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.5 p -38.8 -51.21 1.72 Allowed 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.229 -178.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -59.78 -45.76 91.29 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.365 -0.834 . . . . 0.0 110.291 -179.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.557 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -70.47 0.28 6.98 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.34 -0.85 . . . . 0.0 110.735 -179.001 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.497 ' O ' ' NE2' ' A' ' 29' ' ' HIS . . . 111.57 -2.97 27.73 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.61 -1.281 . . . . 0.0 113.199 177.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.54 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 0.3 OUTLIER 177.63 176.99 0.38 Allowed 'General case' 0 N--CA 1.499 2.019 0 CA-C-N 120.562 2.181 . . . . 0.0 111.82 -179.751 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.863 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -141.98 156.73 26.12 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 107.703 -2.159 . . . . 0.0 107.703 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.705 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.8 m-85 -110.45 139.9 45.23 Favored 'General case' 0 N--CA 1.482 1.127 0 O-C-N 119.929 -1.924 . . . . 0.0 109.82 -179.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.984 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.3 mt -106.54 152.8 8.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 178.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 0.0 OUTLIER -128.69 135.79 49.73 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 178.333 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.771 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.6 p -136.44 139.87 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 C-N-CA 118.213 -1.395 . . . . 0.0 111.483 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -65.38 140.37 58.64 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 115.485 -0.779 . . . . 0.0 109.424 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.92 -10.27 48.21 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.771 ' HB2' HG13 ' A' ' 20' ' ' VAL . 3.8 mm-40 -137.92 -174.12 3.7 Favored 'General case' 0 C--N 1.31 -1.117 0 O-C-N 121.184 -1.186 . . . . 0.0 108.787 179.796 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -100.56 -167.16 1.4 Allowed 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 122.077 0.942 . . . . 0.0 110.715 -178.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.599 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 0.2 OUTLIER -73.21 108.15 5.93 Favored 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.859 179.214 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 1.074 HG21 ' CZ ' ' A' ' 49' ' ' PHE . 2.5 t -71.62 116.73 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.046 0 O-C-N 120.17 -1.581 . . . . 0.0 111.074 178.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.477 ' HB2' ' NE2' ' A' ' 59' ' ' GLN . 3.8 t80 -53.46 142.53 21.82 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 177.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.984 ' CG1' HD12 ' A' ' 18' ' ' ILE . 0.7 OUTLIER -135.06 154.87 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 120.788 -1.195 . . . . 0.0 109.653 -178.857 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.497 ' NE2' ' O ' ' A' ' 14' ' ' GLY . 9.5 t-160 -150.23 152.55 34.76 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -80.05 27.49 0.31 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.936 -1.102 . . . . 0.0 109.956 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.63 -43.84 2.88 Favored 'General case' 0 C--N 1.308 -1.209 0 O-C-N 120.946 -1.096 . . . . 0.0 108.661 179.759 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.637 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -95.67 -49.36 5.4 Favored 'General case' 0 N--CA 1.493 1.721 0 CA-C-O 121.92 0.867 . . . . 0.0 108.973 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.921 HD13 ' CG1' ' A' ' 63' ' ' VAL . 6.0 mm -48.88 -29.38 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.91 -0.494 . . . . 0.0 110.381 -178.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -112.57 -52.01 2.81 Favored 'General case' 0 N--CA 1.499 1.976 0 C-N-CA 118.867 -1.133 . . . . 0.0 109.854 -179.274 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 141.15 171.07 12.45 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 108.804 -1.719 . . . . 0.0 108.804 -179.146 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -52.01 107.57 0.21 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.104 -1.233 . . . . 0.0 109.704 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 155.34 156.39 7.75 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -86.08 89.02 7.69 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.986 -1.302 . . . . 0.0 109.646 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 24.2 mmtp -110.53 171.68 7.31 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.149 -0.969 . . . . 0.0 109.769 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -160.12 165.08 32.41 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.266 -0.896 . . . . 0.0 109.239 179.609 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.86 HD22 ' HB2' ' A' ' 45' ' ' GLN . 0.3 OUTLIER -151.73 -168.97 3.23 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.722 -1.236 . . . . 0.0 109.411 179.916 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -93.81 174.43 7.18 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 179.24 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.546 ' CG ' ' HA ' ' A' ' 8' ' ' TRP . 27.6 tt0 -77.98 61.49 2.58 Favored 'General case' 0 N--CA 1.503 2.177 0 O-C-N 121.269 -0.895 . . . . 0.0 112.481 -178.608 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -170.71 41.9 0.19 Allowed Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.976 -1.65 . . . . 0.0 108.976 177.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 1.015 ' HG3' HG13 ' A' ' 47' ' ' VAL . 7.6 tp-100 -78.77 130.12 35.4 Favored 'General case' 0 N--CA 1.478 0.932 0 O-C-N 120.837 -1.39 . . . . 0.0 111.676 -178.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.647 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . -96.44 112.82 24.42 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 176.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 1.015 HG13 ' HG3' ' A' ' 45' ' ' GLN . 10.4 m -129.6 164.06 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 C-N-CA 117.881 -1.527 . . . . 0.0 111.706 -178.036 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.422 ' HA ' ' HA ' ' A' ' 3' ' ' GLU . 2.1 p -116.35 133.78 55.63 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 178.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.189 ' CE1' HD11 ' A' ' 2' ' ' LEU . 6.5 p90 -153.55 178.31 9.97 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.093 -1.004 . . . . 0.0 109.782 -179.198 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.6 93.52 4.07 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 179.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.958 HD11 HG23 ' A' ' 26' ' ' VAL . 14.6 mt -61.92 125.49 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.962 -1.086 . . . . 0.0 109.611 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.4 m -106.58 -176.07 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 178.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -124.06 113.57 18.57 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.052 -1.03 . . . . 0.0 109.569 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.36 170.91 16.5 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.786 -1.726 . . . . 0.0 108.786 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -37.83 -52.08 1.3 Allowed 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.331 -1.099 . . . . 0.0 113.386 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 11.3 mtp180 -76.65 22.38 0.18 Allowed 'General case' 0 N--CA 1.501 2.089 0 O-C-N 119.593 -1.942 . . . . 0.0 112.411 -177.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.26 179.43 31.29 Favored Glycine 0 N--CA 1.494 2.536 0 O-C-N 120.471 -1.393 . . . . 0.0 110.65 179.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.572 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.7 Cg_endo -69.09 152.23 72.81 Favored 'Trans proline' 0 C--N 1.32 -0.932 0 C-N-CA 122.135 1.89 . . . . 0.0 110.205 178.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.477 ' NE2' ' HB2' ' A' ' 27' ' ' PHE . 0.8 OUTLIER -166.43 149.44 7.03 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 120.959 -1.088 . . . . 0.0 111.697 -179.772 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.831 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -80.3 154.04 28.07 Favored 'General case' 0 N--CA 1.495 1.783 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 177.06 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.637 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.74 -39.53 0.79 Allowed 'General case' 0 N--CA 1.509 2.514 0 O-C-N 120.41 -1.431 . . . . 0.0 111.687 -176.642 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -118.89 52.01 1.08 Allowed 'General case' 0 C--N 1.284 -2.265 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.958 HG22 ' CB ' ' A' ' 49' ' ' PHE . 21.1 t -68.19 158.25 5.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.626 -179.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.474 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.2 OUTLIER -148.51 175.45 11.14 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.671 -0.812 . . . . 0.0 109.394 179.36 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.556 ' HA ' HG12 ' A' ' 47' ' ' VAL . 1.2 tttt -77.35 137.98 39.06 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.078 -1.013 . . . . 0.0 109.552 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -57.31 113.48 1.77 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.242 -0.911 . . . . 0.0 109.545 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.03 -0.986 . . . . 0.0 109.498 179.78 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.402 ' HA ' ' HG2' ' A' ' 50' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.137 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -141.15 173.48 11.45 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.28 -0.887 . . . . 0.0 110.001 179.506 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.612 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.1 OUTLIER -114.76 150.87 34.69 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.043 -1.036 . . . . 0.0 110.555 -179.053 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.418 ' HA3' HG21 ' A' ' 18' ' ' ILE . . . -129.62 169.85 20.67 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 108.912 -1.675 . . . . 0.0 108.912 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.44 ' O ' ' C ' ' A' ' 6' ' ' VAL . 5.2 ttmt -141.76 125.71 17.19 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.978 -1.307 . . . . 0.0 110.564 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.507 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.8 t -32.01 140.97 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 CA-C-O 123.333 1.54 . . . . 0.0 114.188 -179.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.465 ' HD3' ' O ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -108.51 -31.79 7.66 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 103.184 -2.895 . . . . 0.0 103.184 172.48 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.696 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 15.4 p-90 175.79 146.49 0.08 Allowed 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 105.9 -1.889 . . . . 0.0 105.9 177.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.584 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.2 OUTLIER -117.93 145.35 44.74 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.539 -1.351 . . . . 0.0 109.636 179.237 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.506 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.9 t-20 -131.85 41.26 3.29 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 1.032 ' HB3' HD22 ' A' ' 41' ' ' LEU . 2.1 p -39.17 -45.87 1.39 Allowed 'General case' 0 C--N 1.295 -1.768 0 CA-C-O 121.445 0.641 . . . . 0.0 109.378 -179.542 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -61.96 -45.27 94.4 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.322 -0.861 . . . . 0.0 110.015 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.58 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 1.0 OUTLIER -69.9 0.2 6.25 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.361 -0.837 . . . . 0.0 109.866 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.52 ' O ' ' CD2' ' A' ' 29' ' ' HIS . . . 91.15 20.43 38.92 Favored Glycine 0 N--CA 1.488 2.121 0 O-C-N 121.174 -0.954 . . . . 0.0 111.569 179.105 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.58 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 16.6 p90 -176.87 165.27 2.44 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 119.81 1.805 . . . . 0.0 111.532 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.71 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -150.2 141.79 9.09 Favored Glycine 0 N--CA 1.497 2.725 0 N-CA-C 107.172 -2.371 . . . . 0.0 107.172 179.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.696 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.3 m-85 -109.12 139.13 44.44 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.088 -1.83 . . . . 0.0 110.885 -178.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.732 HD11 HG21 ' A' ' 47' ' ' VAL . 1.0 OUTLIER -106.63 146.9 12.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 N-CA-C 105.665 -1.976 . . . . 0.0 105.665 177.322 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 15.1 tt0 -121.07 135.13 55.26 Favored 'General case' 0 C--N 1.28 -2.439 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.009 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.508 HG13 ' HB2' ' A' ' 23' ' ' GLN . 7.5 p -138.49 140.81 38.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 C-N-CA 117.567 -1.653 . . . . 0.0 111.891 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.74 140.5 58.74 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.105 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.51 ' O ' ' NE2' ' A' ' 23' ' ' GLN . . . 86.97 -18.86 33.21 Favored Glycine 0 N--CA 1.486 2.013 0 N-CA-C 108.29 -1.924 . . . . 0.0 108.29 -178.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.51 ' NE2' ' O ' ' A' ' 22' ' ' GLY . 0.1 OUTLIER -135.95 -176.9 4.46 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 121.502 -0.999 . . . . 0.0 108.989 179.502 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -100.81 -166.0 1.27 Allowed 'General case' 0 C--N 1.298 -1.663 0 CA-C-O 121.881 0.848 . . . . 0.0 110.841 -178.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.547 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 5.9 p-10 -71.94 90.88 1.16 Allowed 'General case' 0 N--CA 1.489 1.499 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.568 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.917 HG12 HG13 ' A' ' 28' ' ' VAL . 2.3 t -50.16 125.44 3.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.107 0 O-C-N 120.711 -1.243 . . . . 0.0 111.832 178.681 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.626 ' CD2' ' CZ ' ' A' ' 17' ' ' PHE . 2.9 t80 -72.24 130.36 40.61 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 176.188 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.917 HG13 HG12 ' A' ' 26' ' ' VAL . 2.6 m -146.6 130.75 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 120.248 -1.532 . . . . 0.0 110.703 -179.056 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.55 ' NE2' ' CE2' ' A' ' 30' ' ' PHE . 9.5 t-160 -98.99 166.74 11.13 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 178.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.55 ' CE2' ' NE2' ' A' ' 29' ' ' HIS . 53.0 p90 -83.82 32.44 0.48 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.795 -1.191 . . . . 0.0 110.135 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.1 m -119.12 -37.6 3.18 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.981 -1.075 . . . . 0.0 109.164 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.659 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.38 -37.34 13.28 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.25 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.672 ' N ' HD12 ' A' ' 33' ' ' ILE . 1.4 mp -70.11 -4.84 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -51.02 -51.34 54.04 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.537 -0.727 . . . . 0.0 109.989 -179.214 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 1.054 ' HA3' HG22 ' A' ' 64' ' ' THR . . . 48.85 -170.47 0.09 OUTLIER Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -71.23 96.18 1.37 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.181 -1.187 . . . . 0.0 109.368 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 159.15 -170.88 35.58 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.56 ' CD1' ' N ' ' A' ' 39' ' ' LYS . 28.5 t80 -83.23 155.91 23.43 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.268 -1.137 . . . . 0.0 109.472 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.56 ' N ' ' CD1' ' A' ' 38' ' ' PHE . 3.2 pttm -94.0 125.38 38.59 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.203 -0.935 . . . . 0.0 109.282 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.5 t -176.9 -170.23 0.3 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.992 -1.067 . . . . 0.0 109.62 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 1.032 HD22 ' HB3' ' A' ' 11' ' ' SER . 0.9 OUTLIER -125.85 166.58 16.61 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.34 -0.85 . . . . 0.0 109.919 -179.688 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.441 ' O ' ' HB2' ' A' ' 45' ' ' GLN . 8.7 tt0 -174.8 127.46 0.3 Allowed 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 179.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.463 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 9.3 tm-20 -58.34 145.63 37.38 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.163 -179.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.463 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 74.52 3.87 68.04 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -179.103 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.472 ' HB3' HG23 ' A' ' 6' ' ' VAL . 25.4 tt0 -57.18 109.86 0.74 Allowed 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.355 -1.085 . . . . 0.0 110.266 -179.593 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -91.98 128.55 37.87 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.732 HG21 HD11 ' A' ' 18' ' ' ILE . 35.1 m -132.39 164.33 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 120.893 -1.129 . . . . 0.0 110.311 -179.547 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -117.62 126.8 53.18 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.026 -1.046 . . . . 0.0 108.336 179.36 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.137 ' CE1' HD11 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -149.13 179.66 7.72 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.011 -1.055 . . . . 0.0 110.392 -179.642 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.402 ' HG2' ' HA ' ' A' ' 1' ' ' MET . 2.6 mt-10 -123.74 81.14 1.87 Allowed 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.815 ' CD1' ' HB2' ' A' ' 60' ' ' ALA . 15.1 mm -61.29 118.81 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 CA-C-O 122.051 0.929 . . . . 0.0 110.772 -178.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.556 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 17.5 m -98.42 -175.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 179.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.411 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 0.2 OUTLIER -123.66 116.05 22.44 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.9 -1.125 . . . . 0.0 109.64 -179.885 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.27 174.61 16.97 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.929 -1.668 . . . . 0.0 108.929 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -38.67 -52.85 1.66 Allowed 'General case' 0 N--CA 1.505 2.287 0 O-C-N 121.369 -1.077 . . . . 0.0 113.772 -178.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.509 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -77.84 22.56 0.27 Allowed 'General case' 0 N--CA 1.501 2.092 0 O-C-N 119.69 -1.881 . . . . 0.0 112.211 -177.983 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.95 -178.6 30.89 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.283 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.556 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -63.58 157.78 49.43 Favored 'Trans proline' 0 C--N 1.318 -1.051 0 C-N-CA 121.991 1.794 . . . . 0.0 110.188 179.12 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.535 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 1.2 mt-30 -165.07 147.44 8.03 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 120.99 -1.069 . . . . 0.0 110.575 -179.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.872 ' HB1' ' CG2' ' A' ' 63' ' ' VAL . . . -82.89 158.6 22.6 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 177.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.659 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -132.9 -47.29 0.86 Allowed 'General case' 0 N--CA 1.501 2.098 0 O-C-N 120.436 -1.415 . . . . 0.0 111.07 -177.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -121.27 55.24 1.08 Allowed 'General case' 0 C--N 1.288 -2.099 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 179.219 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.888 HG22 ' CB ' ' A' ' 49' ' ' PHE . 22.9 t -67.47 161.44 3.8 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 CA-C-O 121.667 0.746 . . . . 0.0 110.111 -178.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 1.054 HG22 ' HA3' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -141.08 160.63 39.68 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 119.76 -0.776 . . . . 0.0 108.93 178.668 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.487 ' HA ' HG12 ' A' ' 47' ' ' VAL . 19.5 ptmt -88.35 139.4 30.53 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.927 -1.108 . . . . 0.0 109.857 -179.642 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 59.7 tt0 -80.39 143.22 33.67 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.21 -0.931 . . . . 0.0 109.299 179.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 117.931 -1.033 . . . . 0.0 109.589 -179.968 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 121.29 0.567 . . . . 0.0 109.543 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.978 HD22 ' CE1' ' A' ' 49' ' ' PHE . 0.3 OUTLIER -116.69 163.08 16.66 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.264 -0.897 . . . . 0.0 108.712 179.719 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.543 ' N ' ' HG ' ' A' ' 2' ' ' LEU . 0.2 OUTLIER -113.37 162.02 16.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.18 -0.95 . . . . 0.0 110.045 -179.438 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.22 159.17 27.43 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.384 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.407 ' O ' ' C ' ' A' ' 6' ' ' VAL . 8.0 mtpt -133.66 112.46 11.45 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.304 -1.115 . . . . 0.0 109.111 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.53 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.6 t -42.45 139.36 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 CA-C-O 122.796 1.284 . . . . 0.0 112.555 -178.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.483 ' HG3' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -98.43 -31.4 12.02 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 103.266 -2.864 . . . . 0.0 103.266 172.91 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.706 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 21.0 p-90 178.11 143.9 0.11 Allowed 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 177.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.573 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.9 OUTLIER -119.56 140.47 50.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.73 -1.231 . . . . 0.0 109.522 179.566 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.484 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 1.5 t-20 -131.43 38.13 3.63 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.454 ' C ' ' O ' ' A' ' 10' ' ' ASN . 9.2 p -37.36 -49.76 1.01 Allowed 'General case' 0 N--CA 1.492 1.629 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.886 -179.395 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -61.37 -44.66 96.78 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.284 -0.885 . . . . 0.0 109.91 -179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.479 ' CE ' ' OD1' ' A' ' 10' ' ' ASN . 0.4 OUTLIER -69.21 0.08 5.33 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.371 -0.831 . . . . 0.0 110.267 -179.554 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.508 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 102.46 12.09 34.09 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 119.935 -1.126 . . . . 0.0 112.635 178.329 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.649 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.0 OUTLIER 177.03 166.02 0.53 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-N 120.444 2.122 . . . . 0.0 112.215 179.543 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.654 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -146.74 137.03 6.49 Favored Glycine 0 N--CA 1.499 2.854 0 N-CA-C 106.671 -2.572 . . . . 0.0 106.671 179.342 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.706 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 3.9 m-30 -106.96 139.16 41.8 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.054 -1.85 . . . . 0.0 110.763 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.805 ' CD1' HG21 ' A' ' 47' ' ' VAL . 2.5 mt -108.21 151.65 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 177.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.509 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 9.1 tt0 -127.22 133.57 50.23 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.719 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.72 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.5 p -136.38 140.06 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 C-N-CA 117.792 -1.563 . . . . 0.0 111.772 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.8 140.13 58.38 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.121 179.771 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.42 -17.17 40.37 Favored Glycine 0 N--CA 1.486 1.967 0 N-CA-C 108.469 -1.853 . . . . 0.0 108.469 -178.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.72 ' HB2' HG13 ' A' ' 20' ' ' VAL . 3.1 mm-40 -136.85 -174.35 3.7 Favored 'General case' 0 N--CA 1.482 1.163 0 O-C-N 121.324 -1.104 . . . . 0.0 108.652 179.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.89 -165.93 1.26 Allowed 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.168 0.985 . . . . 0.0 110.657 -179.025 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.572 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 8.1 p-10 -72.09 106.96 4.53 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.011 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.84 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.4 t -71.17 117.36 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 120.483 -1.386 . . . . 0.0 111.298 178.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.613 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 3.8 t80 -67.47 130.6 43.58 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.497 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.699 HG11 HD12 ' A' ' 18' ' ' ILE . 2.4 m -139.11 131.8 37.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 120.476 -1.39 . . . . 0.0 110.715 -179.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.544 ' CE1' ' CE1' ' A' ' 30' ' ' PHE . 6.7 t60 -99.92 164.25 12.1 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.567 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 46.1 p90 -82.84 40.94 0.71 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.962 -1.086 . . . . 0.0 109.814 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.506 ' HA ' ' NE2' ' A' ' 34' ' ' GLN . 94.1 p -129.92 -38.56 1.45 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.858 -1.151 . . . . 0.0 109.711 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.729 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.78 -41.43 10.11 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 179.518 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.627 ' CG2' HD11 ' A' ' 41' ' ' LEU . 1.7 mp -56.34 -17.28 4.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.506 ' NE2' ' HA ' ' A' ' 31' ' ' SER . 4.5 pt20 -87.6 -171.8 3.61 Favored 'General case' 0 N--CA 1.493 1.711 0 C-N-CA 119.123 -1.031 . . . . 0.0 109.595 -179.579 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.52 -45.8 0.04 OUTLIER Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -105.04 66.47 0.76 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.273 -1.134 . . . . 0.0 109.448 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.71 -174.7 38.07 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -74.75 97.04 3.16 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.233 -1.157 . . . . 0.0 109.616 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.427 ' HD3' ' HE3' ' A' ' 65' ' ' LYS . 0.0 OUTLIER -102.79 169.94 8.3 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.264 -0.897 . . . . 0.0 109.474 179.913 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.517 ' OG1' ' N ' ' A' ' 41' ' ' LEU . 0.5 OUTLIER -128.48 -178.02 4.41 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.24 -0.913 . . . . 0.0 109.168 179.943 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.627 HD11 ' CG2' ' A' ' 33' ' ' ILE . 4.5 mp -141.35 142.46 33.79 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.124 -0.985 . . . . 0.0 109.59 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -105.29 158.88 16.31 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.3 -0.875 . . . . 0.0 109.276 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.485 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 9.6 tm-20 -55.71 148.22 16.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.126 -0.984 . . . . 0.0 109.498 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.485 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 79.66 1.84 87.3 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 108.819 -1.712 . . . . 0.0 108.819 -179.425 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.469 ' HA ' ' OE1' ' A' ' 45' ' ' GLN . 35.7 tp60 -75.72 134.14 40.58 Favored 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.324 -1.103 . . . . 0.0 110.532 -179.502 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -93.84 127.58 39.66 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 178.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.805 HG21 ' CD1' ' A' ' 18' ' ' ILE . 33.4 m -116.9 157.72 17.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.886 -1.134 . . . . 0.0 109.909 179.745 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 89.7 p -117.48 122.2 43.09 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.282 -0.887 . . . . 0.0 108.787 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.978 ' CE1' HD22 ' A' ' 2' ' ' LEU . 10.4 p90 -153.97 -177.51 6.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.02 -1.05 . . . . 0.0 109.726 -179.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -128.15 102.24 6.62 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.083 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.84 HD11 ' CG2' ' A' ' 26' ' ' VAL . 4.9 mt -62.76 144.56 14.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 120.816 -1.177 . . . . 0.0 111.126 -179.385 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.556 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.7 m -131.2 -173.18 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 179.1 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -122.25 114.68 21.15 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.786 -1.196 . . . . 0.0 109.776 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.87 172.66 16.49 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -38.66 -53.72 1.61 Allowed 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.21 -1.171 . . . . 0.0 113.006 -178.659 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.462 ' NH1' ' CG ' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -68.77 -21.24 64.36 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 119.647 -1.908 . . . . 0.0 112.778 -177.85 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 138.46 -170.84 23.73 Favored Glycine 0 N--CA 1.491 2.353 0 O-C-N 120.345 -1.472 . . . . 0.0 109.618 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.556 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.8 Cg_endo -62.26 122.88 11.51 Favored 'Trans proline' 0 C--N 1.321 -0.877 0 C-N-CA 121.803 1.668 . . . . 0.0 109.875 178.767 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.474 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 4.5 mt-30 -144.2 148.45 34.97 Favored 'General case' 0 N--CA 1.5 2.07 0 O-C-N 121.189 -0.944 . . . . 0.0 111.097 -179.024 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.661 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -80.48 166.75 20.91 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 177.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.729 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.99 -43.32 0.73 Allowed 'General case' 0 N--CA 1.507 2.391 0 O-C-N 120.286 -1.509 . . . . 0.0 112.012 -177.123 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 31.6 t30 -119.66 51.88 1.14 Allowed 'General case' 0 C--N 1.287 -2.129 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.959 HG22 ' CB ' ' A' ' 49' ' ' PHE . 17.7 t -66.91 157.31 6.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.53 -179.351 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.413 HG22 ' H ' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -143.7 176.69 9.03 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 178.534 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.427 ' HE3' ' HD3' ' A' ' 39' ' ' LYS . 0.0 OUTLIER -82.68 142.98 31.26 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.035 -1.04 . . . . 0.0 109.318 179.945 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -54.69 102.15 0.06 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.202 -0.936 . . . . 0.0 109.536 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.658 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.49 179.999 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 32.5 mtp . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.158 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.53 176.21 8.97 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.365 -0.834 . . . . 0.0 109.981 179.541 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.91 ' OE2' ' HB1' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -112.74 158.79 19.65 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.032 -1.042 . . . . 0.0 110.929 -178.102 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.446 ' HA2' ' HB ' ' A' ' 20' ' ' VAL . . . -136.55 160.36 24.76 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.644 -1.782 . . . . 0.0 108.644 179.492 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.9 mtpt -134.45 116.27 14.94 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.083 -1.245 . . . . 0.0 110.618 -179.42 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.54 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.8 t -32.9 141.17 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 CA-C-O 123.015 1.388 . . . . 0.0 113.635 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.473 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 3.0 tmtt? -104.07 -32.18 9.32 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 102.979 -2.971 . . . . 0.0 102.979 172.221 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.696 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 20.0 p-90 175.56 147.56 0.09 Allowed 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 177.716 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.588 ' CB ' ' HB2' ' A' ' 41' ' ' LEU . 0.6 OUTLIER -114.47 140.09 49.0 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 120.441 -1.412 . . . . 0.0 109.305 178.994 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.565 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 4.9 m120 -122.77 46.78 2.08 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.953 ' OG ' HD22 ' A' ' 41' ' ' LEU . 0.1 OUTLIER -43.76 -35.34 1.83 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 -179.315 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -59.7 -48.86 79.99 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.467 -0.771 . . . . 0.0 110.009 179.769 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.52 ' O ' ' CE2' ' A' ' 15' ' ' PHE . 13.2 mptt -76.74 11.8 1.56 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.26 -0.9 . . . . 0.0 110.201 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.436 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 84.6 20.81 57.67 Favored Glycine 0 N--CA 1.488 2.118 0 O-C-N 121.093 -1.004 . . . . 0.0 111.661 178.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.52 ' CE2' ' O ' ' A' ' 13' ' ' LYS . 36.1 p90 179.6 167.05 1.15 Allowed 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 119.983 1.892 . . . . 0.0 112.031 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.548 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -142.46 149.31 21.14 Favored Glycine 0 N--CA 1.498 2.784 0 N-CA-C 106.937 -2.465 . . . . 0.0 106.937 178.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.696 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -106.26 143.58 34.18 Favored 'General case' 0 N--CA 1.484 1.269 0 CA-C-N 119.836 1.818 . . . . 0.0 110.302 -178.4 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.999 HD12 HG12 ' A' ' 28' ' ' VAL . 0.9 OUTLIER -106.61 161.49 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 178.916 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.572 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 2.9 tp10 -142.66 130.02 21.11 Favored 'General case' 0 C--N 1.29 -2.018 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 177.781 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.773 HG13 ' HB2' ' A' ' 23' ' ' GLN . 13.0 p -135.99 140.56 43.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 117.485 -1.686 . . . . 0.0 111.729 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -65.36 140.62 58.67 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.052 179.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.22 -12.85 48.51 Favored Glycine 0 N--CA 1.487 2.049 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -178.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.773 ' HB2' HG13 ' A' ' 20' ' ' VAL . 6.1 mm-40 -140.75 -176.57 4.71 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 121.345 -1.091 . . . . 0.0 108.322 179.612 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.49 -165.79 1.25 Allowed 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.18 -0.95 . . . . 0.0 110.806 -179.091 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.588 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 11.6 p-10 -72.57 129.9 39.37 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.05 179.339 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.896 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.5 t -98.55 121.4 49.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 120.802 -1.186 . . . . 0.0 110.81 178.252 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.504 ' HB2' ' HG2' ' A' ' 59' ' ' GLN . 23.0 t80 -58.11 137.28 57.08 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.079 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.999 HG12 HD12 ' A' ' 18' ' ' ILE . 1.2 m -131.14 115.65 30.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 120.781 -1.199 . . . . 0.0 110.348 -178.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.406 ' O ' HD12 ' A' ' 33' ' ' ILE . 7.8 t-160 -104.66 148.9 26.05 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.442 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.521 ' CD1' ' C ' ' A' ' 30' ' ' PHE . 0.0 OUTLIER -81.16 31.63 0.33 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.816 -1.177 . . . . 0.0 110.486 -179.68 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -125.35 -35.21 2.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.13 -0.981 . . . . 0.0 108.544 178.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.763 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.37 -35.68 14.26 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.942 HD11 ' HB ' ' A' ' 28' ' ' VAL . 63.0 mt -68.5 -5.66 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.473 ' O ' ' O ' ' A' ' 33' ' ' ILE . 0.1 OUTLIER -52.57 -167.07 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 CA-C-O 121.562 0.696 . . . . 0.0 110.159 -179.69 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 153.77 -169.72 32.42 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.702 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -81.36 74.24 8.36 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.059 -1.26 . . . . 0.0 109.571 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 176.22 -169.71 42.37 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -78.1 139.76 39.05 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.311 -1.111 . . . . 0.0 109.853 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.476 ' O ' ' HB ' ' A' ' 40' ' ' THR . 0.4 OUTLIER -110.29 136.12 49.97 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.334 -0.854 . . . . 0.0 109.411 179.82 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.476 ' HB ' ' O ' ' A' ' 39' ' ' LYS . 6.6 t 179.92 -170.67 0.15 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.999 -1.063 . . . . 0.0 109.897 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.953 HD22 ' OG ' ' A' ' 11' ' ' SER . 1.3 pt? -109.88 158.28 18.35 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.523 -0.735 . . . . 0.0 109.959 -179.29 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.439 ' OE1' ' N ' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -175.09 138.59 0.44 Allowed 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.491 -0.755 . . . . 0.0 109.116 179.524 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.439 ' N ' ' OE1' ' A' ' 42' ' ' GLU . 9.1 tm-20 -74.33 146.37 43.14 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.284 -0.885 . . . . 0.0 108.961 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 77.14 5.31 85.01 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 108.706 -1.757 . . . . 0.0 108.706 -178.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 47.5 tt0 -68.43 111.77 4.87 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 121.499 -1.001 . . . . 0.0 110.003 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.91 ' HB1' ' OE2' ' A' ' 3' ' ' GLU . . . -91.9 124.92 36.38 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 178.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.726 HG21 HD11 ' A' ' 18' ' ' ILE . 28.8 m -119.66 163.9 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.879 -1.138 . . . . 0.0 110.469 -179.165 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.1 p -115.55 126.03 53.73 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.064 -1.023 . . . . 0.0 108.294 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.158 ' CE1' HD11 ' A' ' 2' ' ' LEU . 8.2 p90 -153.28 -179.41 7.7 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.043 -1.035 . . . . 0.0 109.83 -179.325 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -124.29 92.64 3.71 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.31 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.896 HD11 ' CG2' ' A' ' 26' ' ' VAL . 17.0 mt -61.49 132.79 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 CA-C-O 122.271 1.034 . . . . 0.0 110.338 -179.161 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.547 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.2 m -116.44 -174.46 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 178.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.423 ' CD ' ' N ' ' A' ' 53' ' ' GLU . 0.4 OUTLIER -123.72 114.33 19.81 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.001 -1.062 . . . . 0.0 109.331 179.79 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.72 175.57 18.65 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -37.92 -52.63 1.35 Allowed 'General case' 0 N--CA 1.507 2.393 0 O-C-N 121.499 -1.001 . . . . 0.0 113.548 -178.508 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.3 mmm180 -76.07 23.09 0.14 Allowed 'General case' 0 N--CA 1.5 2.036 0 O-C-N 119.807 -1.808 . . . . 0.0 112.137 -178.216 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.28 -174.78 35.62 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.547 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.2 Cg_endo -65.53 150.19 86.91 Favored 'Trans proline' 0 C--N 1.319 -0.997 0 C-N-CA 121.636 1.558 . . . . 0.0 109.791 178.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.504 ' HG2' ' HB2' ' A' ' 27' ' ' PHE . 1.4 mt-30 -165.58 150.31 8.69 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 120.97 -1.082 . . . . 0.0 111.521 -179.433 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.814 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.76 157.75 23.12 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 177.613 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.763 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.92 -41.49 0.75 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 120.52 -1.362 . . . . 0.0 111.578 -176.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.1 m-20 -119.9 57.18 0.93 Allowed 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 179.618 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.88 HG22 ' CB ' ' A' ' 49' ' ' PHE . 18.6 t -72.43 166.3 2.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.103 -178.629 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.534 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -148.1 176.27 10.34 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.669 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.471 ' O ' ' HG2' ' A' ' 65' ' ' LYS . 0.0 OUTLIER -85.54 133.38 34.07 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.052 -1.03 . . . . 0.0 109.672 179.916 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.491 ' HB3' ' O ' ' A' ' 46' ' ' ALA . 13.9 tp10 -82.31 84.67 7.04 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.147 -0.971 . . . . 0.0 109.607 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.452 179.975 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.171 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.61 174.18 10.77 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.257 -0.902 . . . . 0.0 110.119 179.688 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.744 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -113.24 155.62 24.75 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.207 -0.933 . . . . 0.0 110.007 -179.175 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.415 ' C ' ' HG2' ' A' ' 5' ' ' LYS . . . -133.28 161.95 24.25 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.436 ' O ' ' C ' ' A' ' 6' ' ' VAL . 4.0 mttp -130.24 115.5 17.06 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.209 -1.171 . . . . 0.0 109.887 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.537 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.4 t -36.87 140.44 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 CA-C-O 122.869 1.319 . . . . 0.0 112.758 -179.577 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.5 tmtt? -99.41 -31.81 11.47 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 103.042 -2.947 . . . . 0.0 103.042 172.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.701 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 21.5 p-90 176.65 144.14 0.08 Allowed 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 177.741 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.764 ' CE1' HD22 ' A' ' 41' ' ' LEU . 0.7 OUTLIER -119.06 141.48 48.7 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.48 -1.387 . . . . 0.0 109.435 179.531 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.499 ' HB2' ' CZ3' ' A' ' 8' ' ' TRP . 0.1 OUTLIER -130.93 37.72 3.75 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.673 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.45 ' C ' ' O ' ' A' ' 10' ' ' ASN . 15.3 p -37.79 -47.41 1.01 Allowed 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.493 0.663 . . . . 0.0 109.297 -179.682 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -61.12 -46.36 90.92 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.432 -0.792 . . . . 0.0 109.877 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.473 ' HB2' ' CG ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -69.26 0.49 4.84 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.403 -0.811 . . . . 0.0 110.256 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.411 ' O ' ' CB ' ' A' ' 15' ' ' PHE . . . 99.38 15.48 32.33 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 120.001 -1.095 . . . . 0.0 112.399 178.624 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.436 ' O ' ' C ' ' A' ' 10' ' ' ASN . 1.0 OUTLIER 175.53 163.09 0.3 Allowed 'General case' 0 N--CA 1.497 1.917 0 CA-C-N 120.299 2.05 . . . . 0.0 111.849 179.561 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.672 ' O ' HG23 ' A' ' 28' ' ' VAL . . . -146.31 139.99 8.49 Favored Glycine 0 N--CA 1.498 2.832 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.701 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.4 m-85 -108.77 144.11 37.03 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.209 -1.759 . . . . 0.0 110.422 -178.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.724 HD12 HG21 ' A' ' 28' ' ' VAL . 0.5 OUTLIER -106.31 165.42 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 178.471 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.589 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 1.9 tt0 -141.8 127.77 19.48 Favored 'General case' 0 C--N 1.291 -1.967 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.155 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.751 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.8 p -134.2 141.47 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 C-N-CA 117.446 -1.701 . . . . 0.0 111.851 -179.463 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -63.8 140.14 58.84 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.259 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 82.21 -12.62 43.54 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 -179.118 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.751 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -137.57 -176.33 4.37 Favored 'General case' 0 N--CA 1.484 1.247 0 O-C-N 121.303 -1.116 . . . . 0.0 108.669 179.696 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -100.29 -166.1 1.29 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.271 -0.893 . . . . 0.0 110.505 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.601 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 34.7 p-10 -71.68 122.21 20.2 Favored 'General case' 0 N--CA 1.488 1.441 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.849 179.366 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.87 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.3 t -84.76 104.46 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 120.592 -1.317 . . . . 0.0 111.687 178.733 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.62 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 2.1 t80 -55.44 135.1 50.71 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 178.244 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.724 HG21 HD12 ' A' ' 18' ' ' ILE . 2.3 m -150.19 127.26 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 118.067 -1.453 . . . . 0.0 111.641 -179.336 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.624 ' NE2' ' CE1' ' A' ' 30' ' ' PHE . 7.7 t-160 -99.32 162.12 13.22 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 178.659 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.624 ' CE1' ' NE2' ' A' ' 29' ' ' HIS . 52.6 p90 -81.26 39.34 0.51 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.498 -1.376 . . . . 0.0 110.435 -179.432 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.7 t -123.48 -46.5 2.02 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.698 -1.251 . . . . 0.0 109.564 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.741 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.0 -40.56 11.59 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.328 -0.857 . . . . 0.0 108.74 179.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.714 HG23 ' HB ' ' A' ' 63' ' ' VAL . 2.9 mp -81.08 1.78 2.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 CA-C-O 121.703 0.763 . . . . 0.0 109.262 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -78.67 -167.55 1.13 Allowed 'General case' 0 C--N 1.297 -1.698 0 CA-C-O 121.433 0.635 . . . . 0.0 109.961 -179.272 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -155.69 177.91 32.56 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -68.27 128.63 37.29 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.207 -1.172 . . . . 0.0 109.835 -179.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.86 169.01 28.5 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -75.02 85.16 2.29 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.305 -1.115 . . . . 0.0 109.418 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.5 mttp -104.65 -169.83 1.67 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.298 -0.876 . . . . 0.0 110.011 -179.628 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.8 t -176.41 178.95 1.26 Allowed 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.865 HD21 HG11 ' A' ' 47' ' ' VAL . 0.3 OUTLIER -118.6 118.21 31.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.896 -1.128 . . . . 0.0 109.818 -179.755 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 9.9 tt0 -94.84 151.12 19.49 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.374 -0.829 . . . . 0.0 109.051 179.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.437 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 8.6 tm-20 -51.85 145.88 9.08 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.148 -0.97 . . . . 0.0 109.412 -179.797 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.437 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 77.58 3.51 83.24 Favored Glycine 0 N--CA 1.487 2.076 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 -179.597 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.501 ' HA ' ' NE2' ' A' ' 45' ' ' GLN . 5.7 tp-100 -75.98 133.79 40.35 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.274 -1.133 . . . . 0.0 110.732 -179.457 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.404 ' O ' ' OE1' ' A' ' 45' ' ' GLN . . . -94.44 128.65 41.13 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.553 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.865 HG11 HD21 ' A' ' 41' ' ' LEU . 35.9 m -119.32 160.37 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.851 -1.155 . . . . 0.0 109.945 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 49.0 p -115.14 132.0 56.74 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 120.968 -1.083 . . . . 0.0 108.495 179.485 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.171 ' CE1' HD11 ' A' ' 2' ' ' LEU . 10.5 p90 -164.28 -176.56 4.49 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.973 -1.079 . . . . 0.0 109.988 -179.439 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.07 98.32 4.89 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.19 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.87 HD11 ' CG2' ' A' ' 26' ' ' VAL . 7.2 mt -62.67 141.3 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 120.827 -1.171 . . . . 0.0 110.873 -179.222 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.521 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 8.7 m -124.76 -175.35 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.487 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -123.08 115.26 21.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.935 -1.103 . . . . 0.0 109.772 -179.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.52 168.93 18.53 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 37.4 m-20 -37.84 -52.37 1.31 Allowed 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.329 -1.101 . . . . 0.0 113.634 -178.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.96 22.31 0.19 Allowed 'General case' 0 N--CA 1.5 2.062 0 O-C-N 119.777 -1.827 . . . . 0.0 112.414 -177.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.95 -179.39 28.72 Favored Glycine 0 N--CA 1.494 2.501 0 O-C-N 120.393 -1.442 . . . . 0.0 110.588 179.312 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.521 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 2.8 Cg_endo -68.77 142.23 51.88 Favored 'Trans proline' 0 C--N 1.321 -0.908 0 C-N-CA 122.225 1.95 . . . . 0.0 110.085 178.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.528 ' HG2' ' CB ' ' A' ' 27' ' ' PHE . 22.5 mt-30 -156.52 149.36 23.87 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.048 -1.032 . . . . 0.0 111.558 -179.568 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.77 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -80.41 161.63 24.86 Favored 'General case' 0 N--CA 1.495 1.776 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.741 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.92 -41.57 0.75 Allowed 'General case' 0 N--CA 1.508 2.426 0 O-C-N 120.458 -1.401 . . . . 0.0 111.972 -176.358 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.432 ' OD1' ' O ' ' A' ' 62' ' ' ASN . 35.1 t-20 -120.57 50.75 1.29 Allowed 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.958 HG22 ' CB ' ' A' ' 49' ' ' PHE . 14.9 t -68.18 171.33 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-O 121.814 0.816 . . . . 0.0 109.501 -179.532 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.578 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -153.62 172.19 17.61 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 177.908 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.3 tmtt? -83.75 129.28 34.95 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.696 -1.252 . . . . 0.0 109.379 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -87.93 135.38 33.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.302 -0.874 . . . . 0.0 109.53 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 117.925 -1.036 . . . . 0.0 109.558 -179.988 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 19.9 ttt . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.414 0.626 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.214 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -115.83 174.59 5.95 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.35 -0.844 . . . . 0.0 109.715 179.751 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.567 ' N ' HD22 ' A' ' 2' ' ' LEU . 0.4 OUTLIER -117.65 135.32 54.07 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 120.817 -1.177 . . . . 0.0 110.794 -179.263 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.415 ' C ' ' HG2' ' A' ' 5' ' ' LYS . . . -103.2 173.68 22.48 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.825 -1.71 . . . . 0.0 108.825 178.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.415 ' HG2' ' C ' ' A' ' 4' ' ' GLY . 3.4 mtpp -137.37 112.77 9.31 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 120.781 -1.423 . . . . 0.0 109.955 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.808 ' HB ' ' O ' ' A' ' 43' ' ' GLU . 2.5 t -47.88 131.77 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 CA-C-O 122.688 1.233 . . . . 0.0 112.645 -179.811 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 2.0 tttt -93.12 -30.39 15.28 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 103.213 -2.884 . . . . 0.0 103.213 173.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.718 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 25.1 p-90 175.28 146.57 0.08 Allowed 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 106.617 -1.624 . . . . 0.0 106.617 178.452 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.554 ' CB ' ' HA ' ' A' ' 42' ' ' GLU . 0.5 OUTLIER -112.45 147.27 36.85 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.724 -1.235 . . . . 0.0 108.773 178.517 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.556 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 10.8 m-20 -130.05 42.84 3.22 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.203 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.456 ' OG ' HG22 ' A' ' 40' ' ' THR . 54.1 p -40.89 -40.0 1.27 Allowed 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -179.676 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.0 mm-40 -59.86 -49.33 78.11 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.665 -0.647 . . . . 0.0 110.487 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.529 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 1.4 mptp? -74.5 6.09 4.1 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.097 -1.002 . . . . 0.0 110.038 -179.798 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.529 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 90.76 20.33 40.62 Favored Glycine 0 N--CA 1.49 2.246 0 O-C-N 121.133 -0.979 . . . . 0.0 112.066 178.582 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.516 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 39.8 p90 178.9 170.29 0.88 Allowed 'General case' 0 N--CA 1.499 1.994 0 CA-C-N 120.0 1.9 . . . . 0.0 111.762 179.467 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.572 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -145.3 152.34 24.42 Favored Glycine 0 N--CA 1.499 2.891 0 N-CA-C 106.864 -2.495 . . . . 0.0 106.864 179.192 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.718 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.6 m-85 -113.14 135.36 53.89 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 120.28 2.04 . . . . 0.0 110.216 -178.786 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.963 HD12 ' CG1' ' A' ' 28' ' ' VAL . 2.8 mt -108.61 146.37 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.37 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.546 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 27.6 tt0 -125.52 135.87 52.73 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 177.648 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.602 HG13 ' HB2' ' A' ' 23' ' ' GLN . 10.9 p -137.37 139.64 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 C-N-CA 117.675 -1.61 . . . . 0.0 111.905 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -64.17 140.39 58.86 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.088 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 84.08 -15.06 40.69 Favored Glycine 0 N--CA 1.485 1.953 0 N-CA-C 108.684 -1.767 . . . . 0.0 108.684 -178.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.634 ' NE2' HG21 ' A' ' 51' ' ' ILE . 0.2 OUTLIER -136.95 -174.67 3.79 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 121.299 -1.118 . . . . 0.0 108.682 179.46 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.421 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 4.5 m-20 -100.79 -166.4 1.31 Allowed 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 122.073 0.94 . . . . 0.0 110.71 -179.171 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.546 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 8.1 p-10 -72.3 101.83 2.97 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.92 179.09 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.791 HG13 ' H ' ' A' ' 60' ' ' ALA . 2.6 t -68.15 126.28 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 120.252 -1.53 . . . . 0.0 110.124 178.514 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.433 ' HB3' ' HG2' ' A' ' 59' ' ' GLN . 16.6 t80 -65.46 142.09 58.28 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 177.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.977 ' HB ' HD11 ' A' ' 33' ' ' ILE . 1.4 m -134.09 156.73 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.735 -1.228 . . . . 0.0 110.345 -178.598 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.529 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 9.1 t60 -138.42 157.92 45.27 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.093 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.607 ' CE1' ' HB2' ' A' ' 38' ' ' PHE . 53.1 p90 -85.02 32.74 0.53 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.145 -0.972 . . . . 0.0 109.769 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.4 p -127.91 -35.48 2.07 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.832 -1.168 . . . . 0.0 109.773 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.755 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -93.04 -50.16 5.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.232 -0.917 . . . . 0.0 108.988 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.977 HD11 ' HB ' ' A' ' 28' ' ' VAL . 41.0 mt -53.09 -22.52 4.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-O 121.819 0.819 . . . . 0.0 109.047 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -112.24 -167.27 1.16 Allowed 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.601 -0.687 . . . . 0.0 109.968 -179.773 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -145.54 -38.04 0.06 OUTLIER Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 179.542 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.465 ' O ' ' O ' ' A' ' 37' ' ' GLY . 5.8 mt-10 -76.84 -170.01 1.47 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.256 -1.143 . . . . 0.0 109.771 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 36' ' ' GLU . . . -43.86 170.55 0.01 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 -179.799 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.607 ' HB2' ' CE1' ' A' ' 30' ' ' PHE . 50.1 p90 -74.5 118.02 16.98 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.397 -1.06 . . . . 0.0 110.124 -179.713 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 5.3 mmmt -111.09 160.38 16.94 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.258 -0.901 . . . . 0.0 109.335 179.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.456 HG22 ' OG ' ' A' ' 11' ' ' SER . 2.6 p -119.56 114.23 21.93 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.129 -0.982 . . . . 0.0 109.151 179.679 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -151.9 166.87 30.12 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.177 -1.577 . . . . 0.0 110.016 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.554 ' HA ' ' CB ' ' A' ' 9' ' ' PHE . 3.3 mp0 -101.29 98.85 9.18 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 178.075 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.808 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 1.1 tp10 -76.57 44.3 0.35 Allowed 'General case' 0 N--CA 1.501 2.118 0 N-CA-C 115.233 1.568 . . . . 0.0 115.233 -176.552 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.626 ' HA2' ' CG1' ' A' ' 6' ' ' VAL . . . -45.91 -14.93 0.09 OUTLIER Glycine 0 N--CA 1.505 3.239 0 CA-C-N 119.978 1.263 . . . . 0.0 110.684 177.397 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.526 ' N ' ' O ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -75.41 -177.36 3.54 Favored 'General case' 0 C--N 1.288 -2.071 0 O-C-N 121.564 -0.962 . . . . 0.0 110.033 -179.598 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.483 ' O ' ' HB2' ' A' ' 66' ' ' GLU . . . -91.83 144.67 25.26 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.826 0.822 . . . . 0.0 110.055 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 3' ' ' GLU . 18.6 m -122.74 165.91 18.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 121.262 -0.899 . . . . 0.0 108.687 179.091 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -117.68 120.23 37.35 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.854 -1.154 . . . . 0.0 109.163 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.214 ' CE1' HD11 ' A' ' 2' ' ' LEU . 5.6 p90 -149.46 -178.17 6.27 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.165 -0.959 . . . . 0.0 109.978 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.495 ' CG ' ' O ' ' A' ' 50' ' ' GLU . 0.3 OUTLIER -126.47 95.11 4.25 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.376 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.784 HD11 ' CG2' ' A' ' 26' ' ' VAL . 11.3 mt -61.91 140.1 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 CA-C-O 122.513 1.149 . . . . 0.0 111.175 -178.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 12.0 m -124.57 -177.17 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 106.064 -1.828 . . . . 0.0 106.064 179.166 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -123.32 111.95 17.02 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 118.885 -1.126 . . . . 0.0 109.642 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -116.84 169.86 13.21 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 73.1 m-20 -38.23 -52.68 1.48 Allowed 'General case' 0 N--CA 1.504 2.268 0 O-C-N 121.302 -1.116 . . . . 0.0 113.723 -178.575 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -78.1 22.02 0.32 Allowed 'General case' 0 N--CA 1.5 2.074 0 O-C-N 119.62 -1.925 . . . . 0.0 112.524 -177.564 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.65 -178.02 24.89 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 119.17 -1.491 . . . . 0.0 110.628 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.489 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.3 Cg_endo -66.1 153.02 79.75 Favored 'Trans proline' 0 C--N 1.321 -0.905 0 C-N-CA 122.277 1.984 . . . . 0.0 110.529 179.21 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.433 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 0.2 OUTLIER -165.85 147.52 7.09 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.419 -0.8 . . . . 0.0 110.631 -179.758 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.791 ' H ' HG13 ' A' ' 26' ' ' VAL . . . -83.07 163.9 20.63 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 177.205 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.755 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.17 -44.05 0.78 Allowed 'General case' 0 N--CA 1.507 2.387 0 O-C-N 120.201 -1.562 . . . . 0.0 111.909 -176.869 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -119.77 52.11 1.13 Allowed 'General case' 0 C--N 1.287 -2.148 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.92 HG22 ' CB ' ' A' ' 49' ' ' PHE . 20.8 t -66.09 163.1 2.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-O 121.74 0.781 . . . . 0.0 110.554 -179.035 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.527 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -145.06 179.29 7.46 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 177.9 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -89.11 134.07 34.14 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.842 -1.161 . . . . 0.0 109.657 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.483 ' HB2' ' O ' ' A' ' 46' ' ' ALA . 2.7 tt0 -59.58 148.48 33.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.116 -0.99 . . . . 0.0 109.301 179.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.45 ' N ' ' HG2' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.401 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 76.4 mtp . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.182 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.5 172.64 12.44 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.125 -0.984 . . . . 0.0 110.301 179.806 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.62 ' N ' HD22 ' A' ' 2' ' ' LEU . 2.2 tt0 -113.74 144.68 42.56 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.303 -0.873 . . . . 0.0 110.174 -179.253 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.43 ' HA3' HG21 ' A' ' 18' ' ' ILE . . . -112.7 161.52 12.67 Favored Glycine 0 N--CA 1.483 1.811 0 N-CA-C 108.514 -1.835 . . . . 0.0 108.514 178.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.448 ' O ' ' C ' ' A' ' 6' ' ' VAL . 9.3 mttm -131.74 113.76 13.93 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.187 -1.184 . . . . 0.0 109.754 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.536 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.6 t -33.72 139.62 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 CA-C-O 122.91 1.338 . . . . 0.0 113.636 -179.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.461 ' HG2' ' CB ' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -103.92 -32.07 9.45 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 103.108 -2.923 . . . . 0.0 103.108 172.183 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.704 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 18.9 p-90 174.82 147.38 0.07 Allowed 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 106.315 -1.735 . . . . 0.0 106.315 177.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.841 ' HB3' HD13 ' A' ' 41' ' ' LEU . 0.4 OUTLIER -113.52 145.32 41.39 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 120.263 -1.523 . . . . 0.0 109.325 178.95 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.557 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 49.7 m-20 -130.11 41.84 3.36 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 178.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.454 ' HB3' HD23 ' A' ' 41' ' ' LEU . 62.0 p -40.98 -43.65 2.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.671 -0.643 . . . . 0.0 109.518 -179.16 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 60.4 mm-40 -61.62 -45.41 94.21 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.307 -0.871 . . . . 0.0 109.718 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.509 ' N ' ' CD ' ' A' ' 13' ' ' LYS . 0.2 OUTLIER -72.39 4.73 3.47 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.531 -0.731 . . . . 0.0 110.469 -179.66 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.486 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 93.34 19.88 34.23 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 120.053 -1.07 . . . . 0.0 112.236 178.372 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.513 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 0.8 OUTLIER 169.87 171.69 0.06 Allowed 'General case' 0 N--CA 1.498 1.958 0 CA-C-N 120.074 1.937 . . . . 0.0 111.641 179.401 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.848 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -143.6 151.85 23.66 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 106.889 -2.484 . . . . 0.0 106.889 178.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.704 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.6 m-85 -112.65 140.6 47.27 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 119.854 -1.968 . . . . 0.0 110.152 -178.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.929 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.2 mt -106.86 155.95 7.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 179.385 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.508 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 13.0 tt0 -132.31 133.15 43.71 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.797 HG13 ' HB2' ' A' ' 23' ' ' GLN . 14.8 p -132.94 141.04 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 C-N-CA 117.879 -1.528 . . . . 0.0 111.666 -179.606 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -64.52 140.39 58.86 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.4 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.57 -6.22 47.18 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.797 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -140.54 -175.57 4.32 Favored 'General case' 0 C--N 1.309 -1.159 0 O-C-N 121.08 -1.247 . . . . 0.0 108.706 179.789 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.41 -166.97 1.38 Allowed 'General case' 0 C--N 1.297 -1.705 0 CA-C-O 122.151 0.977 . . . . 0.0 110.866 -179.032 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.596 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 5.6 p-10 -71.92 113.02 8.52 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.31 179.486 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.972 HG21 ' CZ ' ' A' ' 49' ' ' PHE . 2.5 t -79.41 114.82 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 120.463 -1.398 . . . . 0.0 110.742 178.49 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.526 ' HB2' ' HG2' ' A' ' 59' ' ' GLN . 31.5 t80 -49.62 146.24 4.39 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 178.403 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.929 ' CG1' HD12 ' A' ' 18' ' ' ILE . 1.2 m -139.21 157.57 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 O-C-N 120.801 -1.187 . . . . 0.0 109.24 -179.443 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.486 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 5.5 t60 -158.42 155.15 28.1 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.406 ' N ' ' CD2' ' A' ' 29' ' ' HIS . 33.5 p90 -79.58 26.34 0.31 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.931 -1.106 . . . . 0.0 110.235 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.3 p -116.35 -47.82 2.73 Favored 'General case' 0 N--CA 1.483 1.218 0 O-C-N 120.839 -1.163 . . . . 0.0 108.909 179.686 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.711 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.51 -47.53 7.09 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.948 HD13 ' HB ' ' A' ' 63' ' ' VAL . 10.1 mm -49.56 -25.22 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.523 ' CG ' ' HB2' ' A' ' 39' ' ' LYS . 0.0 OUTLIER -111.15 -167.33 1.17 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.638 -0.664 . . . . 0.0 109.684 -179.777 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 173.91 -45.27 0.15 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 179.826 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -105.35 74.86 1.12 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.213 -1.169 . . . . 0.0 110.264 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.406 ' O ' ' OE1' ' A' ' 34' ' ' GLN . . . 104.72 161.96 24.06 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 179.137 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -85.77 114.74 22.95 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.244 -1.151 . . . . 0.0 109.67 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.523 ' HB2' ' CG ' ' A' ' 34' ' ' GLN . 0.1 OUTLIER -98.55 -169.67 1.83 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.327 179.727 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.524 ' OG1' ' N ' ' A' ' 41' ' ' LEU . 0.5 OUTLIER -135.46 -174.79 3.73 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.241 -0.912 . . . . 0.0 109.32 -179.758 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.841 HD13 ' HB3' ' A' ' 9' ' ' PHE . 2.1 pp -110.54 159.62 17.37 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.285 -0.884 . . . . 0.0 110.626 -178.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.483 ' O ' ' HB2' ' A' ' 45' ' ' GLN . 9.3 tt0 -166.98 126.38 1.44 Allowed 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 178.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.408 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 5.5 tm-20 -48.35 146.78 2.64 Favored 'General case' 0 C--N 1.295 -1.803 0 C-N-CA 119.596 -0.841 . . . . 0.0 108.963 -179.357 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.408 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 84.52 -1.05 89.16 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 109.037 -1.625 . . . . 0.0 109.037 -179.142 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.507 ' NE2' ' HE3' ' A' ' 65' ' ' LYS . 18.7 tt0 -58.88 112.13 1.54 Allowed 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.372 -1.075 . . . . 0.0 110.039 -179.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -91.86 122.89 34.81 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 178.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.506 ' O ' ' HG2' ' A' ' 3' ' ' GLU . 33.3 m -117.92 162.68 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 120.819 -1.176 . . . . 0.0 111.026 -178.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -118.49 117.7 29.71 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.615 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.182 ' CE1' HD11 ' A' ' 2' ' ' LEU . 6.0 p90 -148.76 -177.73 5.95 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.093 -1.004 . . . . 0.0 110.008 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -128.91 96.87 4.47 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 179.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.867 HD11 ' CG2' ' A' ' 26' ' ' VAL . 10.7 mt -61.63 139.22 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.874 -1.141 . . . . 0.0 110.387 -179.218 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 2.7 m -127.19 -172.48 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -124.0 118.01 26.04 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.985 -1.072 . . . . 0.0 109.489 179.561 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -129.27 174.67 19.18 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.139 -1.584 . . . . 0.0 109.139 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -38.81 -52.99 1.72 Allowed 'General case' 0 N--CA 1.506 2.329 0 O-C-N 121.414 -1.051 . . . . 0.0 113.67 -178.565 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 29.0 mtp180 -77.91 22.45 0.28 Allowed 'General case' 0 N--CA 1.497 1.924 0 O-C-N 119.688 -1.883 . . . . 0.0 112.217 -177.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.54 -177.72 30.92 Favored Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.364 -1.398 . . . . 0.0 110.285 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.527 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.0 OUTLIER -66.09 146.66 82.65 Favored 'Trans proline' 0 C--N 1.319 -0.981 0 C-N-CA 122.069 1.846 . . . . 0.0 110.065 178.948 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.526 ' HG2' ' HB2' ' A' ' 27' ' ' PHE . 0.4 OUTLIER -165.63 153.8 11.18 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.105 -0.997 . . . . 0.0 111.601 -179.35 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.771 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.12 159.45 23.36 Favored 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 177.107 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.711 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.28 -41.03 0.73 Allowed 'General case' 0 N--CA 1.508 2.432 0 O-C-N 120.288 -1.508 . . . . 0.0 111.97 -176.36 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.0 p30 -119.39 51.89 1.12 Allowed 'General case' 0 C--N 1.283 -2.294 0 N-CA-C 106.689 -1.596 . . . . 0.0 106.689 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.96 HG22 ' CB ' ' A' ' 49' ' ' PHE . 19.2 t -69.52 156.49 7.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.556 -179.13 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.436 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 0.9 OUTLIER -136.32 167.36 21.46 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.684 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.507 ' HE3' ' NE2' ' A' ' 45' ' ' GLN . 17.4 mttp -89.46 127.96 35.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.002 -1.061 . . . . 0.0 109.518 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -71.06 85.01 0.71 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.214 -0.929 . . . . 0.0 109.473 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.488 0 CA-C-O 118.059 -0.972 . . . . 0.0 109.546 -179.974 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.426 ' HG3' ' O ' ' A' ' 1' ' ' MET . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.004 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -117.34 173.65 6.57 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.226 -0.921 . . . . 0.0 110.313 -179.853 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.841 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.5 OUTLIER -114.07 162.84 15.96 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.057 -1.027 . . . . 0.0 109.386 -179.87 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -158.26 174.64 35.47 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -141.81 130.89 23.27 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.099 -1.236 . . . . 0.0 111.384 -179.293 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.588 ' HA ' ' HA ' ' A' ' 18' ' ' ILE . 2.8 t -37.57 138.52 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 122.82 1.295 . . . . 0.0 113.312 179.366 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.432 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 0.0 OUTLIER -97.09 -29.29 13.7 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 102.992 -2.966 . . . . 0.0 102.992 172.452 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.7 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 19.8 p-90 178.27 145.97 0.14 Allowed 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 106.068 -1.827 . . . . 0.0 106.068 177.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.559 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 0.6 OUTLIER -120.28 142.54 48.98 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.533 -1.355 . . . . 0.0 109.848 179.767 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.508 ' OD1' ' CD ' ' A' ' 13' ' ' LYS . 0.5 OUTLIER -130.57 38.34 3.74 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 179.004 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 10' ' ' ASN . 11.1 p -39.15 -44.56 1.2 Allowed 'General case' 0 C--N 1.299 -1.595 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.068 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 47.2 mm-40 -61.43 -46.83 88.44 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.437 -0.789 . . . . 0.0 109.847 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.508 ' CD ' ' OD1' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -69.61 1.41 4.17 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.396 -0.815 . . . . 0.0 110.184 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.585 ' O ' ' CD2' ' A' ' 29' ' ' HIS . . . 99.04 12.35 43.12 Favored Glycine 0 N--CA 1.49 2.253 0 C-N-CA 120.152 -1.023 . . . . 0.0 112.325 178.505 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.462 ' HB3' ' O ' ' A' ' 14' ' ' GLY . 38.1 p90 179.95 163.75 1.09 Allowed 'General case' 0 N--CA 1.497 1.889 0 CA-C-N 120.269 2.035 . . . . 0.0 111.678 179.237 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.559 ' HA3' ' CD1' ' A' ' 9' ' ' PHE . . . -145.53 143.22 11.48 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 107.296 -2.322 . . . . 0.0 107.296 179.466 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.7 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.3 m-85 -108.29 143.71 36.78 Favored 'General case' 0 N--CA 1.48 1.045 0 O-C-N 120.24 -1.741 . . . . 0.0 110.19 -178.67 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.014 HD12 HG21 ' A' ' 28' ' ' VAL . 0.3 OUTLIER -105.45 164.33 4.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 N-CA-C 104.985 -2.228 . . . . 0.0 104.985 177.583 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.554 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 12.1 tp10 -130.3 129.65 43.49 Favored 'General case' 0 C--N 1.285 -2.22 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 178.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.756 HG13 ' HB2' ' A' ' 23' ' ' GLN . 14.7 p -132.82 138.93 50.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 118.057 -1.457 . . . . 0.0 111.707 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -66.02 140.37 58.28 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.268 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.32 -8.7 45.14 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 -178.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.756 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.7 OUTLIER -138.45 -175.33 4.08 Favored 'General case' 0 N--CA 1.482 1.136 0 O-C-N 121.197 -1.178 . . . . 0.0 108.503 179.539 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.79 -166.55 1.33 Allowed 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 122.129 0.966 . . . . 0.0 110.923 -178.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.625 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 1.1 m-20 -72.62 113.8 10.06 Favored 'General case' 0 N--CA 1.485 1.324 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.455 178.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 1.005 HG21 ' CZ ' ' A' ' 49' ' ' PHE . 2.4 t -67.74 114.0 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.112 0 O-C-N 120.432 -1.417 . . . . 0.0 112.105 179.658 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.527 ' CD2' ' CZ ' ' A' ' 17' ' ' PHE . 0.6 OUTLIER -70.11 118.95 13.59 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 177.789 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.014 HG21 HD12 ' A' ' 18' ' ' ILE . 2.7 m -147.25 137.5 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 120.552 -1.343 . . . . 0.0 110.394 -179.346 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.585 ' CD2' ' O ' ' A' ' 14' ' ' GLY . 9.7 t-160 -99.19 172.97 7.03 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.384 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.548 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 48.0 p90 -82.64 35.54 0.46 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.044 -1.035 . . . . 0.0 109.758 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 10.8 t -128.15 -28.69 2.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.932 -1.105 . . . . 0.0 109.835 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.729 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.73 -47.89 7.12 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.027 -1.046 . . . . 0.0 108.236 179.293 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.66 HD11 ' HB ' ' A' ' 28' ' ' VAL . 53.5 mt -56.32 -30.37 30.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-O 122.115 0.96 . . . . 0.0 108.516 179.433 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.96 -168.29 1.3 Allowed 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -93.56 177.0 37.21 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 179.097 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -65.38 102.16 0.65 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.016 -1.285 . . . . 0.0 109.507 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 176.08 174.72 42.85 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 179.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 35.9 t80 -83.92 84.59 7.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.352 -1.087 . . . . 0.0 109.479 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -109.88 174.33 5.91 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.269 -0.894 . . . . 0.0 109.481 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.53 ' C ' HD12 ' A' ' 41' ' ' LEU . 0.2 OUTLIER -158.48 167.13 30.46 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.279 -0.888 . . . . 0.0 109.102 179.884 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.913 HD22 ' CD ' ' A' ' 45' ' ' GLN . 4.1 mp -146.97 -169.87 3.4 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.735 -1.228 . . . . 0.0 109.146 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -152.53 178.94 9.04 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.207 -0.933 . . . . 0.0 109.738 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -53.61 145.88 14.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.343 -0.848 . . . . 0.0 109.608 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 95.42 -9.5 69.32 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.076 -1.61 . . . . 0.0 109.076 -179.388 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.913 ' CD ' HD22 ' A' ' 41' ' ' LEU . 4.3 tt0 -59.72 104.31 0.27 Allowed 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.363 -1.081 . . . . 0.0 110.599 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -92.23 131.24 37.61 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 177.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.685 HG21 HD11 ' A' ' 18' ' ' ILE . 35.3 m -140.44 161.78 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 120.451 -1.406 . . . . 0.0 111.139 -178.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.482 ' HA ' ' O ' ' A' ' 2' ' ' LEU . 9.5 p -115.53 132.86 56.5 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 179.302 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.005 ' CZ ' HG21 ' A' ' 26' ' ' VAL . 7.1 p90 -154.88 -179.96 8.54 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.079 -1.013 . . . . 0.0 109.775 -179.005 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -121.16 91.39 3.51 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 178.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.921 HD11 HG23 ' A' ' 26' ' ' VAL . 17.9 mt -61.64 126.87 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.845 -1.159 . . . . 0.0 110.004 -179.478 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.557 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 10.4 m -106.09 -171.84 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 106.371 -1.714 . . . . 0.0 106.371 178.581 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.9 mp0 -122.98 114.44 20.41 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.9 -1.125 . . . . 0.0 109.824 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.57 169.07 16.58 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 34.5 m120 -38.07 -52.16 1.4 Allowed 'General case' 0 N--CA 1.504 2.232 0 O-C-N 121.325 -1.103 . . . . 0.0 113.587 -178.561 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.49 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -76.57 22.66 0.17 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 119.677 -1.89 . . . . 0.0 112.355 -178.035 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.07 -177.93 29.13 Favored Glycine 0 N--CA 1.494 2.531 0 O-C-N 120.434 -1.416 . . . . 0.0 110.232 179.565 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.557 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.1 Cg_endo -65.66 150.82 86.01 Favored 'Trans proline' 0 C--N 1.32 -0.956 0 C-N-CA 122.025 1.817 . . . . 0.0 109.702 178.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.525 ' N ' HG23 ' A' ' 51' ' ' ILE . 29.5 mt-30 -161.11 144.03 12.69 Favored 'General case' 0 N--CA 1.5 2.043 0 O-C-N 120.991 -1.068 . . . . 0.0 111.567 -179.413 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.891 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -78.68 154.56 30.04 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 177.388 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.729 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -133.89 -41.61 0.83 Allowed 'General case' 0 N--CA 1.506 2.37 0 O-C-N 120.386 -1.446 . . . . 0.0 111.546 -176.534 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 5.6 m-20 -119.94 52.24 1.13 Allowed 'General case' 0 C--N 1.284 -2.255 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 179.618 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.92 HG22 ' CB ' ' A' ' 49' ' ' PHE . 20.5 t -67.13 163.68 2.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.969 -179.148 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.491 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 0.2 OUTLIER -147.29 167.88 23.17 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.37 -0.932 . . . . 0.0 108.796 178.608 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.15 144.77 48.46 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.864 -1.147 . . . . 0.0 109.66 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.45 ' OE2' ' O ' ' A' ' 66' ' ' GLU . 0.9 OUTLIER -56.78 134.3 54.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.346 -0.846 . . . . 0.0 109.522 -179.898 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.491 0 CA-C-O 117.961 -1.019 . . . . 0.0 109.414 179.922 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.6 tpt . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.189 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -134.35 175.2 9.72 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.245 -0.909 . . . . 0.0 109.867 179.595 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.714 ' O ' HD22 ' A' ' 2' ' ' LEU . 2.3 tt0 -113.77 157.08 22.72 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 120.907 -1.12 . . . . 0.0 110.332 -178.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.425 ' C ' ' HG3' ' A' ' 5' ' ' LYS . . . -133.5 155.44 21.74 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.543 -1.823 . . . . 0.0 108.543 179.54 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.43 ' O ' ' C ' ' A' ' 6' ' ' VAL . 1.0 OUTLIER -132.2 119.07 20.36 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.284 -1.127 . . . . 0.0 110.201 -179.478 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.582 ' CG1' ' HG3' ' A' ' 43' ' ' GLU . 2.8 t -34.05 143.18 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.182 0 CA-C-O 123.086 1.422 . . . . 0.0 113.701 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.472 ' HB2' ' HB2' ' A' ' 19' ' ' GLU . 1.3 tmtm? -104.89 -30.74 9.64 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 103.585 -2.746 . . . . 0.0 103.585 172.733 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.706 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 18.4 p-90 177.51 145.47 0.11 Allowed 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 105.728 -1.953 . . . . 0.0 105.728 178.1 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.917 ' CE1' HG21 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -113.23 148.43 35.53 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.457 -1.402 . . . . 0.0 110.655 -179.668 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.595 ' OD1' ' CZ3' ' A' ' 8' ' ' TRP . 3.0 m120 -130.2 36.31 4.01 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.797 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.5 OUTLIER -39.48 -42.78 1.16 Allowed 'General case' 0 N--CA 1.49 1.57 0 CA-C-O 121.42 0.629 . . . . 0.0 109.556 -178.703 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -60.78 -47.37 86.62 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.344 -0.847 . . . . 0.0 110.282 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.554 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -72.94 3.88 4.84 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.178 -0.951 . . . . 0.0 110.068 -179.829 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.465 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 95.25 18.6 33.09 Favored Glycine 0 N--CA 1.49 2.279 0 O-C-N 121.184 -0.948 . . . . 0.0 112.465 178.289 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.512 ' O ' ' C ' ' A' ' 10' ' ' ASN . 37.1 p90 177.77 168.69 0.7 Allowed 'General case' 0 N--CA 1.501 2.075 0 CA-C-N 120.152 1.976 . . . . 0.0 111.644 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.871 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -146.34 154.29 25.87 Favored Glycine 0 N--CA 1.497 2.709 0 N-CA-C 107.044 -2.422 . . . . 0.0 107.044 179.133 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.706 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 3.5 m-85 -109.98 142.33 41.52 Favored 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 120.053 1.927 . . . . 0.0 109.621 -179.201 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.662 HD12 HG12 ' A' ' 28' ' ' VAL . 0.8 OUTLIER -106.37 163.5 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 179.295 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.578 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 0.8 OUTLIER -140.97 130.79 24.32 Favored 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 177.897 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.582 ' CG1' ' HB2' ' A' ' 23' ' ' GLN . 9.3 p -137.4 139.19 44.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 C-N-CA 117.743 -1.583 . . . . 0.0 111.779 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.86 141.06 58.18 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.428 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.19 -18.88 42.3 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.621 -1.792 . . . . 0.0 108.621 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.582 ' HB2' ' CG1' ' A' ' 20' ' ' VAL . 57.3 mt-30 -140.99 -173.15 3.64 Favored 'General case' 0 N--CA 1.484 1.244 0 O-C-N 121.418 -1.048 . . . . 0.0 109.162 179.671 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -98.35 -164.62 1.15 Allowed 'General case' 0 C--N 1.297 -1.688 0 CA-C-O 122.115 0.96 . . . . 0.0 110.822 -178.801 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.597 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 23.5 p-10 -70.91 125.82 27.89 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.239 179.747 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.873 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.3 t -90.49 114.48 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 120.705 -1.247 . . . . 0.0 110.808 178.348 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.438 ' C ' ' O ' ' A' ' 26' ' ' VAL . 18.8 t80 -46.06 143.13 2.41 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.917 HG21 ' CE1' ' A' ' 9' ' ' PHE . 1.0 OUTLIER -133.57 148.51 30.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 120.687 -1.258 . . . . 0.0 109.422 -179.176 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.446 ' O ' HG13 ' A' ' 33' ' ' ILE . 10.2 t-160 -151.61 146.84 26.12 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 21.8 p90 -78.8 24.21 0.31 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.018 -1.051 . . . . 0.0 110.714 -179.674 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.3 t -111.6 -45.7 3.34 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 120.637 -1.289 . . . . 0.0 109.212 179.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.729 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.55 -42.89 9.98 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.284 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.587 HD11 ' HA ' ' A' ' 28' ' ' VAL . 1.3 mt -73.83 -1.45 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 CA-C-O 121.496 0.665 . . . . 0.0 109.615 179.647 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.465 ' OE1' ' O ' ' A' ' 37' ' ' GLY . 0.2 OUTLIER -72.02 -167.89 0.34 Allowed 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.494 -0.754 . . . . 0.0 110.28 -178.83 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 143.51 -42.48 1.07 Allowed Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 -179.718 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -105.29 62.34 0.68 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.32 -1.106 . . . . 0.0 109.638 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.465 ' O ' ' OE1' ' A' ' 34' ' ' GLN . . . 61.79 164.29 0.31 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -82.03 90.52 6.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.099 -1.236 . . . . 0.0 109.664 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 10.5 mtpt -110.53 161.37 15.76 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.242 -0.911 . . . . 0.0 109.599 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.24 165.83 11.6 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.286 -0.884 . . . . 0.0 108.763 179.639 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.879 HD22 ' HB2' ' A' ' 45' ' ' GLN . 0.4 OUTLIER -151.91 -176.16 5.53 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.595 -1.316 . . . . 0.0 109.731 179.975 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -94.39 -174.91 3.48 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 178.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.582 ' HG3' ' CG1' ' A' ' 6' ' ' VAL . 34.8 tt0 -77.34 65.51 2.92 Favored 'General case' 0 N--CA 1.501 2.105 0 O-C-N 121.363 -0.836 . . . . 0.0 111.668 -179.155 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -162.82 35.01 0.32 Allowed Glycine 0 N--CA 1.49 2.243 0 O-C-N 120.856 -1.152 . . . . 0.0 110.427 178.525 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.879 ' HB2' HD22 ' A' ' 41' ' ' LEU . 41.7 tp60 -79.62 127.29 31.99 Favored 'General case' 0 N--CA 1.481 1.088 0 O-C-N 120.353 -1.675 . . . . 0.0 111.167 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.475 ' HB3' ' HG2' ' A' ' 66' ' ' GLU . . . -96.98 115.74 27.96 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 176.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.781 HG13 ' HG3' ' A' ' 45' ' ' GLN . 32.9 m -124.56 163.74 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 120.428 -1.42 . . . . 0.0 111.105 -178.755 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -116.58 129.02 55.93 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.1 -1.0 . . . . 0.0 108.517 179.591 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.189 ' CE1' HD11 ' A' ' 2' ' ' LEU . 6.3 p90 -153.75 -177.97 6.73 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.044 -1.035 . . . . 0.0 109.882 -179.466 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -126.09 93.12 3.73 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.197 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.873 HD11 ' CG2' ' A' ' 26' ' ' VAL . 13.7 mt -61.73 128.49 23.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.973 -1.079 . . . . 0.0 109.907 -179.303 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.57 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 7.5 m -109.3 -175.99 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 178.707 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.96 116.11 22.34 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.941 -1.099 . . . . 0.0 109.415 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.25 176.16 18.25 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -38.59 -52.59 1.63 Allowed 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.424 -1.044 . . . . 0.0 113.807 -178.504 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.458 ' NH1' ' CG ' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -79.42 22.27 0.45 Allowed 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.665 -1.897 . . . . 0.0 112.134 -177.706 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.56 -177.74 30.9 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.429 -1.367 . . . . 0.0 110.298 179.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.57 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.4 Cg_endo -66.64 153.1 79.18 Favored 'Trans proline' 0 C--N 1.32 -0.921 0 C-N-CA 121.942 1.761 . . . . 0.0 110.186 179.189 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.421 ' HG3' ' O ' ' A' ' 58' ' ' PRO . 2.4 mt-30 -166.31 147.46 6.5 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.069 -1.02 . . . . 0.0 111.278 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.767 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -80.12 155.84 27.3 Favored 'General case' 0 N--CA 1.497 1.877 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 177.239 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.729 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.66 -41.88 0.77 Allowed 'General case' 0 N--CA 1.508 2.445 0 O-C-N 120.308 -1.495 . . . . 0.0 111.695 -176.576 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -120.19 52.03 1.16 Allowed 'General case' 0 C--N 1.283 -2.292 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.952 HG22 ' CB ' ' A' ' 49' ' ' PHE . 15.2 t -67.43 167.32 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-O 121.83 0.824 . . . . 0.0 109.562 -179.501 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.586 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.3 OUTLIER -147.17 168.89 20.51 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.994 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.8 mttm -83.85 136.47 34.11 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.917 -1.114 . . . . 0.0 109.643 -179.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.475 ' HG2' ' HB3' ' A' ' 46' ' ' ALA . 0.1 OUTLIER -54.68 158.46 2.58 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.198 -0.939 . . . . 0.0 109.605 -179.823 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.408 179.899 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.178 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.18 172.24 13.04 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.182 -0.949 . . . . 0.0 110.082 179.504 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.595 ' O ' HD22 ' A' ' 2' ' ' LEU . 1.9 tt0 -113.95 149.71 34.86 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.165 -0.96 . . . . 0.0 110.423 -178.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.12 165.47 19.29 Favored Glycine 0 N--CA 1.486 1.969 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 179.37 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.438 ' O ' ' C ' ' A' ' 6' ' ' VAL . 12.0 mmtt -131.4 115.16 15.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.929 -1.336 . . . . 0.0 109.742 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.553 HG13 ' N ' ' A' ' 8' ' ' TRP . 3.2 t -36.47 139.56 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 CA-C-O 122.914 1.34 . . . . 0.0 112.873 -179.551 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.473 ' HE2' ' OE1' ' A' ' 19' ' ' GLU . 0.1 OUTLIER -99.73 -33.23 10.67 Favored 'General case' 0 C--N 1.288 -2.105 0 N-CA-C 102.876 -3.009 . . . . 0.0 102.876 172.471 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.703 ' CH2' ' CD1' ' A' ' 17' ' ' PHE . 24.1 p-90 175.16 146.58 0.07 Allowed 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 177.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.599 ' CG ' ' HG ' ' A' ' 41' ' ' LEU . 0.4 OUTLIER -112.08 147.41 36.1 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 120.298 -1.501 . . . . 0.0 109.37 178.815 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.605 ' HB2' ' CD1' ' A' ' 15' ' ' PHE . 1.0 OUTLIER -126.45 41.7 3.47 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.689 -0.632 . . . . 0.0 109.363 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.48 ' C ' ' O ' ' A' ' 10' ' ' ASN . 0.3 OUTLIER -39.04 -47.29 1.49 Allowed 'General case' 0 N--CA 1.493 1.712 0 CA-C-O 121.601 0.715 . . . . 0.0 109.569 -179.189 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -58.6 -50.27 74.44 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.45 -0.781 . . . . 0.0 110.939 -179.385 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.558 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -70.85 0.98 6.09 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.014 -1.054 . . . . 0.0 110.429 -179.211 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.579 ' O ' ' CE1' ' A' ' 29' ' ' HIS . . . 90.47 25.96 24.4 Favored Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.014 -1.054 . . . . 0.0 111.797 178.505 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.605 ' CD1' ' HB2' ' A' ' 10' ' ' ASN . 4.9 p90 -178.58 172.48 1.42 Allowed 'General case' 0 N--CA 1.497 1.914 0 CA-C-N 119.836 1.818 . . . . 0.0 110.866 179.47 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.445 ' O ' ' CG2' ' A' ' 28' ' ' VAL . . . -154.48 143.94 10.59 Favored Glycine 0 N--CA 1.5 2.911 0 N-CA-C 107.104 -2.399 . . . . 0.0 107.104 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.703 ' CD1' ' CH2' ' A' ' 8' ' ' TRP . 4.0 m-85 -111.12 141.33 44.77 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 119.97 -1.9 . . . . 0.0 110.456 -178.465 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.651 HD11 HG21 ' A' ' 47' ' ' VAL . 0.5 OUTLIER -106.32 162.35 5.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 178.262 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.558 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 14.6 tp10 -141.7 128.47 20.45 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.473 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.744 HG13 ' HB2' ' A' ' 23' ' ' GLN . 12.4 p -135.53 141.17 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 C-N-CA 117.3 -1.76 . . . . 0.0 112.021 -179.213 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.71 140.44 58.46 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-N 115.384 -0.825 . . . . 0.0 108.913 179.596 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.03 -16.23 43.97 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.419 -1.872 . . . . 0.0 108.419 -178.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.744 ' HB2' HG13 ' A' ' 20' ' ' VAL . 3.1 mm-40 -139.29 -177.11 4.77 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 179.439 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -100.9 -165.95 1.26 Allowed 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.236 -0.915 . . . . 0.0 110.912 -178.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.587 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 3.8 p30 -72.27 124.37 24.92 Favored 'General case' 0 N--CA 1.488 1.46 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.741 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.895 HG12 HG13 ' A' ' 28' ' ' VAL . 2.4 t -88.23 116.01 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 120.647 -1.283 . . . . 0.0 111.264 178.605 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.543 ' CE2' ' CZ ' ' A' ' 17' ' ' PHE . 1.5 t80 -64.5 127.82 33.16 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 178.191 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.895 HG13 HG12 ' A' ' 26' ' ' VAL . 16.1 m -143.32 137.01 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.55 -1.344 . . . . 0.0 111.626 -178.787 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.579 ' CE1' ' O ' ' A' ' 14' ' ' GLY . 4.1 t60 -99.82 162.02 13.25 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 177.327 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.455 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 49.0 p90 -83.99 34.2 0.5 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.467 -1.396 . . . . 0.0 109.993 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.6 m -123.26 -34.27 3.15 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.034 -1.041 . . . . 0.0 108.905 179.305 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.739 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.56 -43.3 9.74 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.572 ' CD1' ' HB ' ' A' ' 28' ' ' VAL . 1.2 mp -59.39 -22.91 23.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.849 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.531 ' HG3' ' HA ' ' A' ' 39' ' ' LYS . 0.5 OUTLIER -112.18 -166.89 1.12 Allowed 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.812 -0.755 . . . . 0.0 110.796 -178.937 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 154.48 -29.52 0.69 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -99.71 119.2 37.75 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.093 -1.239 . . . . 0.0 109.971 -179.497 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.429 ' O ' ' C ' ' A' ' 38' ' ' PHE . . . 59.7 -176.36 3.27 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 179.598 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.429 ' C ' ' O ' ' A' ' 37' ' ' GLY . 0.1 OUTLIER -43.63 156.41 0.06 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.327 -1.102 . . . . 0.0 109.472 179.892 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.531 ' HA ' ' HG3' ' A' ' 34' ' ' GLN . 0.0 OUTLIER -107.89 159.43 16.53 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.154 -0.966 . . . . 0.0 109.984 -179.684 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.618 ' C ' HD13 ' A' ' 41' ' ' LEU . 5.9 t 179.3 -169.13 0.1 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.384 -0.823 . . . . 0.0 109.614 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.923 ' N ' HD13 ' A' ' 41' ' ' LEU . 0.0 OUTLIER -147.08 -174.4 4.49 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.361 -0.837 . . . . 0.0 110.223 -178.834 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.432 ' O ' ' CB ' ' A' ' 45' ' ' GLN . 1.3 mt-10 -168.75 124.75 0.95 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.541 -0.725 . . . . 0.0 109.166 179.808 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.452 ' CD ' ' N ' ' A' ' 44' ' ' GLY . 11.9 tm-20 -55.85 145.49 24.46 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.181 -0.949 . . . . 0.0 109.471 -179.683 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.452 ' N ' ' CD ' ' A' ' 43' ' ' GLU . . . 73.31 5.59 67.31 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 -179.563 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.432 ' CB ' ' O ' ' A' ' 42' ' ' GLU . 6.6 tp-100 -76.24 133.78 40.02 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.269 -1.136 . . . . 0.0 110.815 -179.451 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.534 ' O ' ' CB ' ' A' ' 66' ' ' GLU . . . -94.08 123.24 37.33 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 178.593 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.651 HG21 HD11 ' A' ' 18' ' ' ILE . 35.7 m -112.59 162.03 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 120.829 -1.17 . . . . 0.0 110.405 -179.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.68 119.15 34.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.06 -1.025 . . . . 0.0 108.729 179.4 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.178 ' CE1' HD11 ' A' ' 2' ' ' LEU . 10.7 p90 -149.49 -177.6 5.95 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.952 -1.093 . . . . 0.0 110.023 -179.374 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -128.86 93.31 3.58 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 179.452 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.877 HD11 ' CG2' ' A' ' 26' ' ' VAL . 14.1 mt -61.69 132.81 27.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.931 -1.105 . . . . 0.0 109.929 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 17.0 m -113.42 -177.3 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.152 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -123.17 117.19 24.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.999 -1.063 . . . . 0.0 109.299 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.83 175.2 15.63 Favored Glycine 0 N--CA 1.485 1.922 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.67 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -39.1 -52.1 1.87 Allowed 'General case' 0 N--CA 1.5 2.071 0 N-CA-C 114.287 1.217 . . . . 0.0 114.287 -178.484 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -93.25 21.09 6.28 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 119.416 -2.053 . . . . 0.0 113.534 -176.616 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 122.68 173.65 14.23 Favored Glycine 0 N--CA 1.495 2.593 0 C-N-CA 118.723 -1.703 . . . . 0.0 111.533 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.527 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 3.0 Cg_endo -69.07 156.51 64.94 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 C-N-CA 122.661 2.241 . . . . 0.0 110.561 179.27 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.409 ' NE2' ' HB3' ' A' ' 27' ' ' PHE . 3.2 mt-30 -166.41 146.11 5.93 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.298 -0.876 . . . . 0.0 110.962 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.715 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -82.19 159.14 23.34 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 177.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.739 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.15 -44.53 0.71 Allowed 'General case' 0 N--CA 1.506 2.349 0 O-C-N 120.36 -1.462 . . . . 0.0 112.13 -176.171 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -119.54 51.62 1.15 Allowed 'General case' 0 C--N 1.284 -2.24 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.932 HG22 ' CB ' ' A' ' 49' ' ' PHE . 18.1 t -66.06 159.64 4.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.681 -179.431 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.489 HG22 ' H ' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -143.92 -177.86 5.64 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.846 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.489 ' H ' HG22 ' A' ' 64' ' ' THR . 0.2 OUTLIER -86.39 139.51 30.87 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.931 -1.106 . . . . 0.0 109.354 -179.961 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.534 ' CB ' ' O ' ' A' ' 46' ' ' ALA . 29.4 tp10 -60.56 115.15 3.39 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.199 -0.938 . . . . 0.0 109.572 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.475 ' HB3' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 118.038 -0.982 . . . . 0.0 109.458 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.069 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.77 174.64 10.32 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.179 -0.951 . . . . 0.0 110.264 179.75 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.84 ' CD ' ' HB1' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -112.64 165.2 12.49 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.252 -0.905 . . . . 0.0 109.937 -179.059 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 46' ' ' ALA . . . -148.05 169.68 28.76 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 20.0 mttt -134.05 116.14 15.14 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 120.919 -1.342 . . . . 0.0 110.313 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.818 HG21 ' HB3' ' A' ' 43' ' ' GLU . 2.4 t -49.06 134.98 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 CA-C-O 122.71 1.243 . . . . 0.0 112.998 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.65 -28.36 13.58 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 104.015 -2.587 . . . . 0.0 104.015 174.155 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.681 ' O ' ' CE3' ' A' ' 8' ' ' TRP . 21.6 p-90 176.16 141.88 0.07 Allowed 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 178.274 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.576 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 0.7 OUTLIER -130.02 110.57 11.75 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.537 -1.352 . . . . 0.0 110.096 -179.949 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.567 ' OD1' ' CB ' ' A' ' 13' ' ' LYS . 1.2 p30 -95.15 88.35 5.17 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-O 122.978 1.371 . . . . 0.0 109.031 179.047 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.569 ' HB2' HG22 ' A' ' 40' ' ' THR . 0.4 OUTLIER -67.65 -57.97 5.47 Favored 'General case' 0 C--N 1.29 -2.02 0 O-C-N 120.417 -1.427 . . . . 0.0 108.709 179.741 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.79 ' HG2' HG21 ' A' ' 40' ' ' THR . 13.9 mt-10 -59.7 -45.13 93.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.469 -0.77 . . . . 0.0 111.362 -179.097 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.567 ' CB ' ' OD1' ' A' ' 10' ' ' ASN . 1.4 mptt -68.68 -11.85 60.68 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.05 -1.032 . . . . 0.0 111.134 -177.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.514 ' N ' ' OD1' ' A' ' 10' ' ' ASN . . . 138.73 -37.79 1.75 Allowed Glycine 0 N--CA 1.496 2.636 0 C-N-CA 118.376 -1.869 . . . . 0.0 113.3 178.299 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.532 ' O ' ' ND2' ' A' ' 10' ' ' ASN . 10.9 p90 -175.85 -174.83 0.69 Allowed 'General case' 0 N--CA 1.497 1.882 0 CA-C-N 121.079 2.439 . . . . 0.0 110.424 -179.222 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.862 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -134.49 146.35 18.36 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.626 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 6.0 m-30 -107.0 136.71 46.4 Favored 'General case' 0 N--CA 1.48 1.04 0 O-C-N 120.577 -1.543 . . . . 0.0 109.419 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.961 ' CD1' HG11 ' A' ' 28' ' ' VAL . 1.0 OUTLIER -107.39 150.53 9.88 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 N-CA-C 105.85 -1.908 . . . . 0.0 105.85 178.049 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.466 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 1.0 OUTLIER -125.92 133.19 51.94 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.396 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.687 HG13 ' HB2' ' A' ' 23' ' ' GLN . 8.5 p -137.87 140.24 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 C-N-CA 117.635 -1.626 . . . . 0.0 112.221 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -65.28 140.18 58.68 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-N 115.233 -0.894 . . . . 0.0 109.056 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.84 -13.76 46.55 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 108.654 -1.778 . . . . 0.0 108.654 -178.73 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.687 ' HB2' HG13 ' A' ' 20' ' ' VAL . 3.6 mt-30 -138.56 -175.97 4.31 Favored 'General case' 0 N--CA 1.483 1.195 0 O-C-N 121.257 -1.143 . . . . 0.0 108.632 179.489 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.82 -165.62 1.23 Allowed 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 122.135 0.969 . . . . 0.0 110.627 -179.059 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.626 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.5 m-20 -73.0 104.85 4.24 Favored 'General case' 0 N--CA 1.486 1.355 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.223 179.477 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 1.038 HG22 ' CD1' ' A' ' 51' ' ' ILE . 2.4 t -65.72 115.25 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 120.345 -1.472 . . . . 0.0 112.112 179.061 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.453 ' HB3' ' CD ' ' A' ' 59' ' ' GLN . 12.7 t80 -70.53 129.84 40.27 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.336 -0.852 . . . . 0.0 109.04 178.236 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.961 HG11 ' CD1' ' A' ' 18' ' ' ILE . 23.6 m -135.85 144.83 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.617 -1.302 . . . . 0.0 109.654 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.848 ' O ' HD12 ' A' ' 33' ' ' ILE . 0.5 OUTLIER -99.63 165.99 11.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.766 -1.209 . . . . 0.0 108.78 179.678 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.516 ' O ' ' CD2' ' A' ' 30' ' ' PHE . 42.9 p90 -80.28 26.0 0.38 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.949 -1.095 . . . . 0.0 110.937 -179.398 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 43.3 p -136.68 -17.64 1.46 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.701 -1.249 . . . . 0.0 110.209 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.735 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -92.35 -49.6 6.07 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 120.735 -1.228 . . . . 0.0 108.79 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.848 HD12 ' O ' ' A' ' 29' ' ' HIS . 2.5 mt -55.59 -27.65 21.76 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 CA-C-O 121.933 0.873 . . . . 0.0 108.736 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -112.3 -168.09 1.27 Allowed 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.745 -0.597 . . . . 0.0 109.732 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -149.27 -42.65 0.03 OUTLIER Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' A' ' 37' ' ' GLY . 0.0 OUTLIER -65.7 -170.09 0.07 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.381 -1.07 . . . . 0.0 109.653 179.871 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.471 ' O ' ' O ' ' A' ' 36' ' ' GLU . . . -44.19 170.0 0.01 OUTLIER Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.584 ' O ' ' CD2' ' A' ' 38' ' ' PHE . 48.0 p90 -73.11 116.11 13.24 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.21 -1.171 . . . . 0.0 110.098 -179.625 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.679 ' HG3' HD23 ' A' ' 41' ' ' LEU . 0.5 OUTLIER -110.68 135.08 51.83 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.273 -0.892 . . . . 0.0 108.881 179.608 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.79 HG21 ' HG2' ' A' ' 12' ' ' GLU . 25.8 p -99.62 110.95 23.35 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.873 -1.142 . . . . 0.0 109.967 -179.567 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.679 HD23 ' HG3' ' A' ' 39' ' ' LYS . 0.7 OUTLIER -151.79 -179.19 7.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.419 -1.426 . . . . 0.0 109.706 179.757 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.551 ' HA ' ' HB3' ' A' ' 9' ' ' PHE . 1.8 mp0 -114.13 105.98 13.84 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.385 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.818 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.1 tp10 -76.59 45.66 0.41 Allowed 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 115.031 1.493 . . . . 0.0 115.031 -176.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.592 ' HA2' ' CG1' ' A' ' 6' ' ' VAL . . . -45.57 -15.8 0.1 OUTLIER Glycine 0 N--CA 1.507 3.385 0 CA-C-N 119.86 1.209 . . . . 0.0 110.432 177.337 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.532 ' N ' ' O ' ' A' ' 43' ' ' GLU . 0.0 OUTLIER -70.0 177.54 3.13 Favored 'General case' 0 C--N 1.289 -2.024 0 O-C-N 121.699 -0.883 . . . . 0.0 109.779 -179.844 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.84 ' HB1' ' CD ' ' A' ' 3' ' ' GLU . . . -90.68 132.54 35.73 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.679 -0.638 . . . . 0.0 109.395 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.564 HG21 ' CD1' ' A' ' 18' ' ' ILE . 29.7 m -111.3 162.8 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.18 -0.95 . . . . 0.0 110.247 -179.806 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -115.88 125.38 52.55 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.194 -0.941 . . . . 0.0 108.587 179.503 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.069 ' CE1' HD11 ' A' ' 2' ' ' LEU . 25.0 p90 -153.59 -178.35 6.96 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.019 -1.051 . . . . 0.0 110.035 -179.646 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -126.85 96.14 4.55 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 179.413 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 1.038 ' CD1' HG22 ' A' ' 26' ' ' VAL . 1.3 mm -61.09 141.39 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 122.609 1.195 . . . . 0.0 111.048 -179.393 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.544 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 2.1 m -130.65 -174.96 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 -179.558 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -124.14 116.26 22.46 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.002 -1.062 . . . . 0.0 109.623 179.627 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -129.36 173.32 19.6 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.753 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -38.04 -52.26 1.39 Allowed 'General case' 0 N--CA 1.504 2.254 0 O-C-N 121.407 -1.055 . . . . 0.0 113.426 -178.634 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 4.9 mtt180 -75.42 22.74 0.12 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 119.728 -1.858 . . . . 0.0 112.102 -178.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.74 -178.75 36.64 Favored Glycine 0 N--CA 1.492 2.389 0 O-C-N 120.438 -1.414 . . . . 0.0 110.124 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.544 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.4 Cg_endo -68.04 139.59 47.31 Favored 'Trans proline' 0 C--N 1.319 -1.023 0 C-N-CA 122.095 1.863 . . . . 0.0 110.069 178.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.959 ' C ' HD13 ' A' ' 51' ' ' ILE . 77.6 mt-30 -159.33 157.92 31.37 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.2 -0.938 . . . . 0.0 111.206 -179.364 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.799 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -83.99 160.56 21.0 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 177.517 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.735 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -135.08 -40.98 0.74 Allowed 'General case' 0 N--CA 1.508 2.433 0 O-C-N 120.294 -1.504 . . . . 0.0 111.812 -176.709 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.438 ' N ' ' OD1' ' A' ' 62' ' ' ASN . 1.6 m-20 -119.62 52.28 1.11 Allowed 'General case' 0 C--N 1.283 -2.283 0 N-CA-C 106.924 -1.509 . . . . 0.0 106.924 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.914 HG22 ' CB ' ' A' ' 49' ' ' PHE . 13.4 t -69.17 163.66 3.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.488 -179.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.59 HG22 ' H ' ' A' ' 65' ' ' LYS . 1.2 m -149.45 -179.08 6.8 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 178.643 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.59 ' H ' HG22 ' A' ' 64' ' ' THR . 0.4 OUTLIER -82.93 128.58 34.58 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.991 -1.068 . . . . 0.0 109.432 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 46' ' ' ALA . 0.5 OUTLIER -79.89 120.22 23.83 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.233 -0.917 . . . . 0.0 109.454 179.929 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 117.991 -1.004 . . . . 0.0 109.432 -179.964 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.6 ptt? . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.175 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -113.87 177.75 4.53 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.206 -0.934 . . . . 0.0 110.045 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.847 ' O ' HD22 ' A' ' 2' ' ' LEU . 0.3 OUTLIER -113.07 165.94 11.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.87 -1.143 . . . . 0.0 109.858 -179.07 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -151.82 156.27 26.6 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.401 ' O ' ' C ' ' A' ' 6' ' ' VAL . 2.5 ttpt -135.4 126.93 28.77 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.45 -1.03 . . . . 0.0 110.675 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.663 HG23 ' CB ' ' A' ' 45' ' ' GLN . 5.6 t -35.7 150.01 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.285 0 CA-C-O 123.453 1.597 . . . . 0.0 113.338 -179.634 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.524 ' CG ' ' HB2' ' A' ' 19' ' ' GLU . 1.0 OUTLIER -110.54 -29.21 8.16 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 103.174 -2.899 . . . . 0.0 103.174 172.247 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.711 ' CZ2' ' CG ' ' A' ' 17' ' ' PHE . 15.4 p-90 178.92 144.61 0.14 Allowed 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 177.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.592 ' CD1' ' HA3' ' A' ' 16' ' ' GLY . 1.1 t80 -118.89 127.41 53.47 Favored 'General case' 0 N--CA 1.506 2.361 0 O-C-N 120.527 -1.358 . . . . 0.0 109.756 -178.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.554 ' CG ' ' CZ3' ' A' ' 8' ' ' TRP . 72.7 m-20 -120.6 56.21 1.0 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.598 -0.689 . . . . 0.0 109.682 -179.426 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.589 ' HG ' ' HG ' ' A' ' 41' ' ' LEU . 0.0 OUTLIER -43.74 -38.11 3.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.287 -0.883 . . . . 0.0 108.861 179.933 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -61.03 -47.03 88.32 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.572 -0.705 . . . . 0.0 110.253 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.512 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 0.0 OUTLIER -71.53 4.42 3.09 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.218 -0.926 . . . . 0.0 109.768 179.853 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.478 ' C ' ' CD2' ' A' ' 15' ' ' PHE . . . 98.53 8.0 55.13 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 120.22 -0.99 . . . . 0.0 111.712 179.045 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.478 ' CD2' ' C ' ' A' ' 14' ' ' GLY . 3.9 p90 173.88 173.78 0.16 Allowed 'General case' 0 N--CA 1.495 1.818 0 CA-C-N 120.391 2.096 . . . . 0.0 112.588 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.882 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -130.33 142.61 13.89 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 106.644 -2.582 . . . . 0.0 106.644 178.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.711 ' CG ' ' CZ2' ' A' ' 8' ' ' TRP . 4.1 m-30 -99.0 142.27 30.7 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 120.199 -1.765 . . . . 0.0 109.001 -178.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.028 HD12 ' CG1' ' A' ' 28' ' ' VAL . 0.6 OUTLIER -105.64 165.88 3.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 179.746 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.586 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 14.4 tm-20 -140.96 132.34 26.75 Favored 'General case' 0 C--N 1.289 -2.063 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 178.425 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.667 HG13 ' HB2' ' A' ' 23' ' ' GLN . 11.5 p -136.1 140.87 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 118.068 -1.453 . . . . 0.0 111.641 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -64.05 140.55 58.88 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.363 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.5 -8.88 45.38 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.667 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.3 OUTLIER -139.23 -175.07 4.04 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 121.129 -1.218 . . . . 0.0 108.849 179.608 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -100.66 -166.31 1.3 Allowed 'General case' 0 C--N 1.296 -1.721 0 CA-C-O 122.112 0.958 . . . . 0.0 110.437 -179.208 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.624 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 5.1 p30 -72.12 125.12 26.48 Favored 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.689 179.177 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 1.003 HG21 ' CZ ' ' A' ' 49' ' ' PHE . 2.5 t -87.62 108.76 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 120.557 -1.339 . . . . 0.0 111.341 178.794 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.459 ' CE2' ' CE1' ' A' ' 17' ' ' PHE . 8.8 t80 -51.16 135.13 26.31 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 177.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.028 ' CG1' HD12 ' A' ' 18' ' ' ILE . 0.7 OUTLIER -131.74 140.8 47.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 120.48 -1.388 . . . . 0.0 109.615 -178.831 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.736 ' O ' HD12 ' A' ' 33' ' ' ILE . 36.2 t-80 -123.63 155.73 37.17 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.492 ' CE1' ' CE1' ' A' ' 29' ' ' HIS . 55.6 p90 -82.47 32.5 0.4 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.975 -1.078 . . . . 0.0 109.585 179.754 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.7 m -132.04 -33.24 1.36 Allowed 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.075 -1.016 . . . . 0.0 109.358 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.758 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.34 -40.93 11.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.154 -0.966 . . . . 0.0 108.781 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.79 HD11 ' HB ' ' A' ' 28' ' ' VAL . 3.1 mt -75.16 -0.59 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.382 -0.823 . . . . 0.0 108.878 178.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.591 ' O ' ' C ' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -30.2 -34.8 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.543 -178.876 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.984 ' HA3' HG22 ' A' ' 64' ' ' THR . . . -10.46 123.96 0.01 OUTLIER Glycine 0 N--CA 1.506 3.361 0 N-CA-C 111.591 -0.604 . . . . 0.0 111.591 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.506 ' C ' ' O ' ' A' ' 35' ' ' GLY . 0.2 OUTLIER -30.37 129.69 0.11 Allowed 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.935 -0.744 . . . . 0.0 110.919 -179.219 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 155.39 162.82 11.58 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.516 ' O ' ' CD1' ' A' ' 38' ' ' PHE . 37.2 p90 -84.96 130.95 34.55 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.018 -1.283 . . . . 0.0 109.458 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.423 ' O ' ' HB ' ' A' ' 40' ' ' THR . 0.8 OUTLIER -97.89 154.07 17.9 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -0.908 . . . . 0.0 109.505 -179.857 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.545 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 9.2 t 179.91 -176.83 0.34 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.265 -0.897 . . . . 0.0 109.327 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.589 ' HG ' ' HG ' ' A' ' 11' ' ' SER . 5.2 mp -108.25 89.3 2.95 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.162 -0.962 . . . . 0.0 109.558 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -146.31 143.92 29.46 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 179.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.445 ' HG3' HG12 ' A' ' 6' ' ' VAL . 28.8 tt0 -77.7 60.9 2.29 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.044 -1.035 . . . . 0.0 112.144 -178.567 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -150.69 33.56 0.98 Allowed Glycine 0 N--CA 1.494 2.566 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 178.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.663 ' CB ' HG23 ' A' ' 6' ' ' VAL . 3.2 tt0 -80.19 96.7 6.64 Favored 'General case' 0 C--N 1.31 -1.15 0 O-C-N 121.077 -1.249 . . . . 0.0 110.452 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -94.18 105.44 17.43 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 177.555 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.593 HG12 ' HA ' ' A' ' 65' ' ' LYS . 35.0 m -128.28 164.29 30.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 120.675 -1.266 . . . . 0.0 110.741 -178.292 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -115.36 136.4 53.13 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 179.1 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.175 ' CE1' HD11 ' A' ' 2' ' ' LEU . 7.0 p90 -156.52 -179.41 8.15 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-O 121.99 0.9 . . . . 0.0 109.522 -178.731 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 20.1 tt0 -123.18 93.45 3.96 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.049 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.908 HD11 ' CG2' ' A' ' 26' ' ' VAL . 16.9 mt -62.14 128.58 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.981 -1.074 . . . . 0.0 110.154 -179.519 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 11.4 m -108.16 -176.56 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 178.348 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.408 ' CD ' ' N ' ' A' ' 53' ' ' GLU . 2.1 pm0 -123.85 116.62 23.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.967 -1.083 . . . . 0.0 109.729 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.406 ' O ' ' C ' ' A' ' 55' ' ' ASN . . . -132.26 172.4 21.14 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.181 -1.567 . . . . 0.0 109.181 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.406 ' C ' ' O ' ' A' ' 54' ' ' GLY . 17.8 m120 -37.37 -51.88 1.1 Allowed 'General case' 0 N--CA 1.505 2.322 0 O-C-N 121.439 -1.036 . . . . 0.0 113.268 -178.639 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.87 23.34 0.1 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 119.65 -1.907 . . . . 0.0 112.14 -178.456 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.77 -177.07 38.46 Favored Glycine 0 N--CA 1.491 2.359 0 O-C-N 120.529 -1.357 . . . . 0.0 109.773 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.554 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.9 Cg_endo -68.28 152.92 75.44 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 C-N-CA 121.832 1.688 . . . . 0.0 109.652 178.768 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.468 ' HG3' ' O ' ' A' ' 58' ' ' PRO . 0.8 OUTLIER -165.82 146.1 6.61 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 120.907 -1.121 . . . . 0.0 111.608 -179.557 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.809 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -78.49 155.75 29.66 Favored 'General case' 0 N--CA 1.494 1.77 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.235 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.758 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.52 -40.57 0.8 Allowed 'General case' 0 N--CA 1.508 2.475 0 O-C-N 120.557 -1.339 . . . . 0.0 111.37 -176.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -119.88 57.09 0.93 Allowed 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.914 HG22 ' CB ' ' A' ' 49' ' ' PHE . 19.9 t -73.14 165.61 3.0 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.184 -178.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.984 HG22 ' HA3' ' A' ' 35' ' ' GLY . 0.2 OUTLIER -149.83 157.97 43.71 Favored 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.143 178.952 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.593 ' HA ' HG12 ' A' ' 47' ' ' VAL . 4.2 tmtm? -70.25 138.07 51.34 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.821 -1.174 . . . . 0.0 109.562 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -55.4 160.56 2.27 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.27 -0.894 . . . . 0.0 109.419 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.607 -179.834 . . . . . . . . 0 0 . 1 stop_ save_